FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Thompson-Peer, KL Bai, JH Hu, ZT Kaplan, JM AF Thompson-Peer, Katherine L. Bai, Jihong Hu, Zhitao Kaplan, Joshua M. TI HBL-1 Patterns Synaptic Remodeling in C-elegans SO NEURON LA English DT Article ID NEMATODE CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; TRANSCRIPTION FACTORS; NEUROMUSCULAR-JUNCTION; COUP-TFI; IN-VIVO; NEURONAL DEVELOPMENT; DEVELOPMENTAL TIME; NUCLEAR RECEPTORS; MICRORNA TARGET AB During development, circuits are refined by the dynamic addition and removal of synapses; however, little is known about the molecular mechanisms that dictate where and when synaptic refinement occurs. Here we describe transcriptional mechanisms that pattern remodeling of C. elegans neuromuscular junctions (NMJs). The embryonic GABAergic DD motor neurons remodel their synapses, whereas the later born VD neurons do not. This specificity is mediated by differential expression of a transcription factor (HBL-1), which is expressed in DD neurons but is repressed in VDs by UNC-55/COUP-TF. DD remodeling is delayed in hbl-1 mutants whereas precocious remodeling is observed in mutants lacking the microRNA mir-84, which inhibits hbl-1 expression. Mutations increasing and decreasing circuit activity cause corresponding changes in hbl-1 expression, and corresponding shifts in the timing of DD plasticity. Thus, convergent regulation of hbl-1 expression defines a genetic mechanism that patterns activity-dependent synaptic remodeling across cell types and across developmental time. C1 [Thompson-Peer, Katherine L.; Bai, Jihong; Hu, Zhitao; Kaplan, Joshua M.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Thompson-Peer, Katherine L.; Bai, Jihong; Hu, Zhitao; Kaplan, Joshua M.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA. RP Kaplan, JM (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. EM kaplan@molbio.mgh.harvard.edu OI Thompson-Peer, Katherine/0000-0002-4200-3870 FU NIH National Center for Research Resources [NCRR]; Jane Coffin Childs Memorial Fund for Medical Research; National Institutes of Health [NS32196, K99MH085039]; National Science Foundation FX We thank members of the Kaplan lab for helpful discussions and comments; the Caenorhabditis Genetics Center (that is funded by the NIH National Center for Research Resources [NCRR]), G. Hayes, and S. Russell for strains; and the Wellcome Trust Sanger Institute for the hbl-1 cosmid. This work was supported by a graduate research fellowship from National Science Foundation (K.T.-P.), a postdoctoral fellowship from the Jane Coffin Childs Memorial Fund for Medical Research (J.B.), and grants from the National Institutes of Health to J.M.K. (NS32196) and J.B. (K99MH085039). K.T.-P. is an Albert J. Ryan Foundation fellow. NR 65 TC 16 Z9 18 U1 0 U2 7 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0896-6273 J9 NEURON JI Neuron PD FEB 9 PY 2012 VL 73 IS 3 BP 453 EP 465 DI 10.1016/j.neuron.2011.11.025 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 890JJ UT WOS:000300140600008 PM 22325199 ER PT J AU Srihasam, K Mandeville, JB Morocz, IA Sullivan, KJ Livingstone, MS AF Srihasam, Krishna Mandeville, Joseph B. Morocz, Istvan A. Sullivan, Kevin J. Livingstone, Margaret S. TI Behavioral and Anatomical Consequences of Early versus Late Symbol Training in Macaques SO NEURON LA English DT Article ID HUMAN EXTRASTRIATE CORTEX; SURFACE-BASED ANALYSIS; MONKEY VISUAL-CORTEX; FUSIFORM FACE AREA; WORD FORM AREA; OBJECT RECOGNITION; TEMPORAL CORTEX; CEREBRAL-CORTEX; CONTRAST AGENT; PERCEPTION AB Distinct brain regions, reproducible from one person to the next, are specialized for processing different kinds of human expertise, such as face recognition and reading. Here, we explore the relationship between age of learning, learning ability, and specialized brain structures. Specifically, we ask whether the existence of reproducible cortical domains necessarily means that certain abilities are innate, or innately easily learned, or whether reproducible domains can be formed, or refined, by interactions between genetic programs and common early experience. Functional MRI showed that intensive early, but not late, experience caused the formation of category-selective regions in macaque temporal lobe for stimuli never naturally encountered by monkeys. And behaviorally, early training produced more fluent processing of these stimuli than the same training in adults. One explanation for these results is that in higher cortical areas, as in early sensory areas, experience drives functional clustering and functional clustering determines how that information is processed. C1 [Srihasam, Krishna; Sullivan, Kevin J.; Livingstone, Margaret S.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA. [Mandeville, Joseph B.] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Morocz, Istvan A.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02114 USA. RP Livingstone, MS (reprint author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA. EM mlivingstone@hms.harvard.edu FU NIH [EY16187] FX This work was supported by NIH grant EY16187. We thank Wim Vanduffel for much help developing scanning technology, Tristram Savage for monkey training, and Winrich Freiwald, Doris Tsao, and Heather Sternshein for advice and comments. NR 65 TC 32 Z9 32 U1 0 U2 4 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0896-6273 J9 NEURON JI Neuron PD FEB 9 PY 2012 VL 73 IS 3 BP 608 EP 619 DI 10.1016/j.neuron.2011.12.022 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 890JJ UT WOS:000300140600019 PM 22325210 ER PT J AU Baselga, J Campone, M Piccart, M Burris, HA Rugo, HS Sahmoud, T Noguchi, S Gnant, M Pritchard, KI Lebrun, F Beck, JT Ito, Y Yardley, D Deleu, I Perez, A Bachelot, T Vittori, L Xu, ZY Mukhopadhyay, P Lebwohl, D Hortobagyi, GN AF Baselga, Jose Campone, Mario Piccart, Martine Burris, Howard A., III Rugo, Hope S. Sahmoud, Tarek Noguchi, Shinzaburo Gnant, Michael Pritchard, Kathleen I. Lebrun, Fabienne Beck, J. Thaddeus Ito, Yoshinori Yardley, Denise Deleu, Ines Perez, Alejandra Bachelot, Thomas Vittori, Luc Xu, Zhiying Mukhopadhyay, Pabak Lebwohl, David Hortobagyi, Gabriel N. TI Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID FIRST-LINE THERAPY; AROMATASE INHIBITORS; PHASE-III; WOMEN; TRIAL; TAMOXIFEN; ANASTROZOLE; LETROZOLE; SUPERIOR; EFFICACY AB Background Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies, the mTOR inhibitor everolimus added to endocrine therapy showed antitumor activity. Methods In this phase 3, randomized trial, we compared everolimus and exemestane versus exemestane and placebo (randomly assigned in a 2:1 ratio) in 724 patients with hormone-receptor-positive advanced breast cancer who had recurrence or progression while receiving previous therapy with a nonsteroidal aromatase inhibitor in the adjuvant setting or to treat advanced disease (or both). The primary end point was progression-free survival. Secondary end points included survival, response rate, and safety. A preplanned interim analysis was performed by an independent data and safety monitoring committee after 359 progression-free survival events were observed. Results Baseline characteristics were well balanced between the two study groups. The median age was 62 years, 56% had visceral involvement, and 84% had hormone-sensitive disease. Previous therapy included letrozole or anastrozole (100%), tamoxifen (48%), fulvestrant (16%), and chemotherapy (68%). The most common grade 3 or 4 adverse events were stomatitis (8% in the everolimus-plus-exemestane group vs. 1% in the placebo-plus-exemestane group), anemia (6% vs. <1%), dyspnea (4% vs. 1%), hyperglycemia (4% vs. <1%), fatigue (4% vs. 1%), and pneumonitis (3% vs. 0%). At the interim analysis, median progression-free survival was 6.9 months with everolimus plus exemestane and 2.8 months with placebo plus exemestane, according to assessments by local investigators (hazard ratio for progression or death, 0.43; 95% confidence interval [CI], 0.35 to 0.54; P<0.001). Median progression-free survival was 10.6 months and 4.1 months, respectively, according to central assessment (hazard ratio, 0.36; 95% CI, 0.27 to 0.47; P<0.001). Conclusions Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromatase inhibitors. (Funded by Novartis; BOLERO-2 ClinicalTrials.gov number, NCT00863655.) C1 [Baselga, Jose] Harvard Univ, Div Hematol Oncol, Ctr Canc, Massachusetts Gen Hosp,Sch Med, Boston, MA 02114 USA. [Campone, Mario] Inst Cancerol Ouest Rene Gauducheau, St Herblain, France. [Piccart, Martine; Lebrun, Fabienne] Inst Jules Bordet, B-1000 Brussels, Belgium. [Burris, Howard A., III; Yardley, Denise] Sarah Cannon Res Inst, Nashville, TN USA. [Rugo, Hope S.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Sahmoud, Tarek; Xu, Zhiying] Novartis, E Hanover, NJ USA. [Noguchi, Shinzaburo] Osaka Univ, Dept Breast & Endocrine Surg, Osaka, Japan. [Gnant, Michael] Med Univ Vienna, Dept Surg, Ctr Comprehens Canc, Vienna, Austria. [Pritchard, Kathleen I.] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada. [Pritchard, Kathleen I.] Univ Toronto, Toronto, ON, Canada. [Beck, J. Thaddeus] Highlands Oncol Grp, Fayetteville, AR USA. [Ito, Yoshinori] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan. [Deleu, Ines] AZ Nikolass, Ctr Oncol, St Niklaas, Belgium. [Perez, Alejandra] Mem Canc Inst, Hollywood, FL USA. [Bachelot, Thomas] Ctr Leon Berard, F-69373 Lyon, France. [Vittori, Luc] Novartis Pharmaceut, Basel, Switzerland. [Hortobagyi, Gabriel N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. RP Baselga, J (reprint author), Harvard Univ, Div Hematol Oncol, Ctr Canc, Massachusetts Gen Hosp,Sch Med, 55 Fruit St,Lawrence House 108, Boston, MA 02114 USA. EM jbaselga@partners.org OI Gnant, Michael/0000-0003-1002-2118 FU Novartis FX Supported by Novartis, including funding for medical editorial assistance with the manuscript. NR 25 TC 946 Z9 999 U1 11 U2 82 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 9 PY 2012 VL 366 IS 6 BP 520 EP 529 DI 10.1056/NEJMoa1109653 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 888GH UT WOS:000299991300008 PM 22149876 ER PT J AU Donohue, JM Morden, NE Gellad, WF Bynum, JP Zhou, WP Hanlon, JT Skinner, J AF Donohue, Julie M. Morden, Nancy E. Gellad, Walid F. Bynum, Julie P. Zhou, Weiping Hanlon, Joseph T. Skinner, Jonathan TI Sources of Regional Variation in Medicare Part D Drug Spending SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID HEALTH-CARE; GEOGRAPHIC-VARIATION; POTENTIAL SAVINGS; GENERIC DRUGS; BENEFIT; RISK; HYPERTENSION; METAANALYSIS; INHIBITORS; DISEASE AB Background Sources of regional variation in spending for prescription drugs under Medicare Part D are poorly understood, and such variation may reflect differences in health status, use of effective treatments, or selection of branded drugs over lower-cost generics. Methods We analyzed 2008 Medicare data for 4.7 million beneficiaries for prescription-drug use and expenditures overall and in three drug categories: angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs), 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), and selective serotonin-reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Differences in per capita expenditures across hospital-referral regions (HRRs) were decomposed into annual prescription volume and cost per prescription. The ratio of prescriptions filled as branded drugs to all prescriptions filled was calculated. We adjusted all measures for demographic, socioeconomic, and health-status differences. Results Mean adjusted per capita pharmaceutical spending ranged from $2,413 in the lowest to $3,008 in the highest quintile of HRRs. Most (75.9%) of that difference was attributable to the cost per prescription ($53 vs. $63). Regional differences in cost per prescription explained 87.5% of expenditure variation for ACE inhibitors and ARBs and 56.3% for statins but only 36.1% for SSRIs and SNRIs. The ratio of branded-drug to total prescriptions, which correlated highly with cost per prescription, ranged across HRRs from 0.24 to 0.45 overall and from 0.24 to 0.55 for ACE inhibitors and ARBs, 0.29 to 0.60 for statins, and 0.15 to 0.51 for SSRIs and SNRIs. Conclusions Regional variation in Medicare Part D spending results largely from differences in the cost of drugs selected rather than prescription volume. A reduction in branded-drug use in some regions through modification of Part D plan benefits might lower costs without reducing quality of care. (Funded by the National Institute on Aging and others.) C1 [Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA. [Gellad, Walid F.] Univ Pittsburgh, Dept Med Gen Internal Med, Pittsburgh, PA 15261 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Med Geriatr Pharm & Therapeut & Biomed Infor, Pittsburgh, PA 15261 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15261 USA. [Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Gellad, Walid F.] RAND, Pittsburgh, PA USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Morden, Nancy E.; Bynum, Julie P.; Zhou, Weiping; Skinner, Jonathan] Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA. [Morden, Nancy E.; Skinner, Jonathan] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA. [Skinner, Jonathan] Dartmouth Coll, Dept Econ, Hanover, NH 03755 USA. RP Donohue, JM (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,Crabtree Hall A613, Pittsburgh, PA 15261 USA. EM jdonohue@pitt.edu OI Donohue, Julie/0000-0003-2418-6017 FU National Institute on Aging [P01AG019783, AG-07-001, P30AG024827, T32 AG021885, K07AG033174, K23AG028947, R01AG034056, U01 AG012553, R56AG027017]; Agency for Healthcare Research and Quality [R01HS017695, R01HS018721, K12 HS019461]; National Institute of Nursing Research [R01 NR010135]; National Institute of Mental Health [R34 MH082682]; Robert Wood Johnson Foundation [059491]; Veterans Affairs Health Services Research and Development Service [IIR-06-062, CDA 09-207]; National Institute on Aging and others FX Supported by grants from the National Institute on Aging (P01AG019783, AG-07-001, P30AG024827, T32 AG021885, K07AG033174, K23AG028947, R01AG034056, U01 AG012553, and R56AG027017), the Agency for Healthcare Research and Quality (R01HS017695, R01HS018721, and K12 HS019461), the National Institute of Nursing Research (R01 NR010135), the National Institute of Mental Health (R34 MH082682), the Robert Wood Johnson Foundation (059491), and the Veterans Affairs Health Services Research and Development Service (IIR-06-062 and CDA 09-207).; Funded by the National Institute on Aging and others. NR 39 TC 34 Z9 34 U1 0 U2 7 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 9 PY 2012 VL 366 IS 6 BP 530 EP 538 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 888GH UT WOS:000299991300009 PM 22316446 ER PT J AU Stone, JH Zen, Y Deshpande, V AF Stone, John H. Zen, Yoh Deshpande, Vikram TI MECHANISMS OF DISEASE IgG4-Related Disease SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Review ID IMMUNOGLOBULIN G4-ASSOCIATED CHOLANGITIS; ENDEMIC PEMPHIGUS FOLIACEUS; REGULATORY T-CELLS; SERUM IGG4 LEVELS; FAB-ARM EXCHANGE; AUTOIMMUNE PANCREATITIS; SYSTEMIC-DISEASE; SCLEROSING DISEASE; TUBULOINTERSTITIAL NEPHRITIS; LYMPHOPLASMACYTIC AORTITIS C1 [Stone, John H.] Massachusetts Gen Hosp, Rheumatol Unit, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA. [Deshpande, Vikram] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Stone, John H.; Deshpande, Vikram] Harvard Univ, Sch Med, Boston, MA USA. [Zen, Yoh] Kings Coll Hosp London, Inst Liver Studies, London, England. RP Stone, JH (reprint author), Massachusetts Gen Hosp, Rheumatol Unit, Dept Med, Div Rheumatol Allergy & Immunol, 55 Fruit St,Yawkey 2C, Boston, MA 02114 USA. EM jhstone@partners.org NR 89 TC 635 Z9 691 U1 9 U2 72 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 9 PY 2012 VL 366 IS 6 BP 539 EP 551 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 888GH UT WOS:000299991300010 PM 22316447 ER PT J AU Rhee, EP Scott, JA Dighe, AS AF Rhee, Eugene P. Scott, James A. Dighe, Anand S. TI Case 4-2012: A 37-Year-Old Man with Muscle Pain, Weakness, and Weight Loss SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID THYROTOXIC PERIODIC PARALYSIS; THYROID-HORMONE TREATMENT; HYPOKALEMIA; POTASSIUM; HYPERTHYROIDISM; DISORDERS; MUTATIONS C1 [Rhee, Eugene P.] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA. [Scott, James A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Dighe, Anand S.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Rhee, Eugene P.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Scott, James A.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Dighe, Anand S.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Rhee, EP (reprint author), Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA. NR 32 TC 3 Z9 4 U1 0 U2 7 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 9 PY 2012 VL 366 IS 6 BP 553 EP 560 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 888GH UT WOS:000299991300012 PM 22316449 ER PT J AU Brent, GA AF Brent, Gregory A. TI The Debate over Thyroid-Function Screening in Pregnancy SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID DYSFUNCTION; MANAGEMENT; WOMEN C1 [Brent, Gregory A.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. RP Brent, GA (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. NR 11 TC 19 Z9 21 U1 1 U2 4 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 9 PY 2012 VL 366 IS 6 BP 562 EP 563 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 888GH UT WOS:000299991300013 PM 22316450 ER PT J AU Zaman, MS Shahryari, V Deng, GR Thamminana, S Saini, S Majid, S Chang, I Hirata, H Ueno, K Yamamura, S Singh, K Tanaka, Y Tabatabai, ZL Dahiya, R AF Zaman, Mohd Saif Shahryari, Varahram Deng, Guoren Thamminana, Sobha Saini, Sharonjot Majid, Shahana Chang, Inik Hirata, Hiroshi Ueno, Koji Yamamura, Soichiro Singh, Kamaldeep Tanaka, Yuichiro Tabatabai, Z. Laura Dahiya, Rajvir TI Up-Regulation of MicroRNA-21 Correlates with Lower Kidney Cancer Survival SO PLOS ONE LA English DT Article ID RENAL-CELL CARCINOMA; HUMAN BREAST-CANCER; GENE-EXPRESSION; APOPTOSIS; P53; P21(WAF1/CIP1/SDI1); TRANSCRIPTION; PROTEIN; P21; CDK AB Background: MicroRNA-21 is up-regulated in a variety of cancers like, breast, colorectal, lung, head and neck etc. However, the regulation of miR-21 in renal cell carcinoma (RCC) has not yet been studied systematically. Methods and Results: We measured miR-21 levels in 54 pairs of kidney cancers and their normal matched tissues by real-time PCR. The expression level of miR-21 was correlated with 5 year survival and the pathological stage. Functional studies were done after inhibiting miR-21 in RCC cell lines. We studied in vitro and in vivo effects of the chemo preventive agent genistein on miR-21 expression. In 48 cases (90%), miR-21 was increased. All patients with low miR-21 expression survived 5 years, while with high miR-21 expression, only 50% survived. Higher expression of miR-21 is associated with an increase in the stage of renal cancer. Functional studies after inhibiting miRNA-21 in RCC cell lines show cell cycle arrest, induction of apoptosis and reduced invasive and migratory capabilities. Western blot analysis showed an increase in the expression of p21 and p38 MAP kinase genes and a reduction in cyclin E2. Genistein inhibited the expression of miR-21 in A-498 cells and in the tumors formed after injecting genistein treated A-498 cells in nude mice besides inhibiting tumor formation. Conclusions: The current study shows a clear correlation between miR-21 expression and clinical characteristics of renal cancer. Thus we believe that miR-21 can be used as a tumor marker and its inhibition may prove to be useful in controlling cancers with up-regulated miR-21. C1 [Zaman, Mohd Saif] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Zaman, MS (reprint author), San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA. EM rdahiya@urology.ucsf.edu FU Veterans Association; National Institutes of Health [RO1CA130860] FX This study was supported by the Veterans Association Merit Review, Veterans Association Research Enhancement Award Program and National Institutes of Health Grant RO1CA130860 (to the principal investigator, Dr. R. Dahiya). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 59 Z9 61 U1 1 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 8 PY 2012 VL 7 IS 2 AR e31060 DI 10.1371/journal.pone.0031060 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 924ZP UT WOS:000302730100036 PM 22347428 ER PT J AU Davidson, SM Vander Heiden, MG AF Davidson, Shawn M. Vander Heiden, Matthew G. TI METabolic Adaptations in the Tumor MYCroenvironment SO CELL METABOLISM LA English DT Editorial Material ID GLUTAMINE-METABOLISM; MYC; ADENOCARCINOMAS; INACTIVATION; GLYCOLYSIS; REGRESSION; CANCER C1 [Davidson, Shawn M.; Vander Heiden, Matthew G.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. [Vander Heiden, Matthew G.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Vander Heiden, MG (reprint author), MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM mvh@mit.edu NR 10 TC 4 Z9 4 U1 0 U2 6 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1550-4131 J9 CELL METAB JI Cell Metab. PD FEB 8 PY 2012 VL 15 IS 2 BP 131 EP 133 DI 10.1016/j.cmet.2012.01.005 PG 3 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA 895FM UT WOS:000300481600002 PM 22326214 ER PT J AU Swirski, FK Nahrendorf, M Libby, P AF Swirski, Flip K. Nahrendorf, Matthias Libby, Peter TI The Ins and Outs of Inflammatory Cells in Atheromata SO CELL METABOLISM LA English DT Editorial Material ID MONOCYTE-DERIVED CELLS; ATHEROSCLEROTIC PLAQUES; MACROPHAGES; EMIGRATION; REGRESSION; PROMOTES C1 [Libby, Peter] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA. [Swirski, Flip K.; Nahrendorf, Matthias] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. RP Libby, P (reprint author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA. EM plibby@rics.bwh.harvard.edu FU NHLBI NIH HHS [R01 HL095612] NR 10 TC 11 Z9 11 U1 0 U2 2 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1550-4131 J9 CELL METAB JI Cell Metab. PD FEB 8 PY 2012 VL 15 IS 2 BP 135 EP 136 DI 10.1016/j.cmet.2012.01.012 PG 2 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA 895FM UT WOS:000300481600004 PM 22326216 ER PT J AU Gupta, RK Mepani, RJ Kleiner, S Lo, JC Khandekar, MJ Cohen, P Frontini, A Bhowmick, DC Ye, L Cinti, S Spiegelman, BM AF Gupta, Rana K. Mepani, Rina J. Kleiner, Sandra Lo, James C. Khandekar, Melin J. Cohen, Paul Frontini, Andrea Bhowmick, Diti Chatterjee Ye, Li Cinti, Saverio Spiegelman, Bruce M. TI Zfp423 Expression Identifies Committed Preadipocytes and Localizes to Adipose Endothelial and Perivascular Cells SO CELL METABOLISM LA English DT Article ID ADIPOCYTE PRECURSOR CELLS; PPAR-GAMMA; PROGENITOR CELLS; SKELETAL-MUSCLE; GENE-EXPRESSION; STROMAL CELLS; STEM-CELLS; IN-VITRO; TRANSCRIPTIONAL CONTROL; OLIGONUCLEOTIDE ARRAYS AB Progress has been made in elucidating the cell-surface phenotype of primary adipose progenitors; however, specific functional markers and distinct molecular signatures of fat depot-specific preadipocytes have remained elusive. In this study, we label committed murine adipose progenitors through expression of GFP from the genetic locus for Zfp423, a gene controlling preadipocyte determination. Selection of GFP-expressing fibroblasts from either subcutaneous or visceral adipose-derived stromal vascular cultures isolates stably committed preadipocytes that undergo robust adipogenesis. Immunohistochemistry for Zfp423-driven GFP expression in vivo confirms a perivascular origin of preadipocytes within both white and brown adipose tissues. Interestingly, a small subset of capillary endothelial cells within white and brown fat also express this marker, suggesting a contribution of specialized endothelial cells to the adipose lineage. Zfp423(GFP) mice represent a simple tool for the specific localization and isolation of molecularly defined preadipocytes from distinct adipose tissue depots. C1 [Gupta, Rana K.; Mepani, Rina J.; Kleiner, Sandra; Lo, James C.; Khandekar, Melin J.; Cohen, Paul; Bhowmick, Diti Chatterjee; Ye, Li; Spiegelman, Bruce M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Gupta, Rana K.; Mepani, Rina J.; Kleiner, Sandra; Lo, James C.; Khandekar, Melin J.; Cohen, Paul; Bhowmick, Diti Chatterjee; Ye, Li; Spiegelman, Bruce M.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. [Frontini, Andrea; Cinti, Saverio] Univ Politecn Marche, Elect Microscopy Unit, Azienda Osped Riuniti, Dept Expt & Clin Med, I-60020 Ancona, Italy. RP Spiegelman, BM (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM bruce_spiegelman@dfci.harvard.edu FU National Institutes of Health (NIH) [KO1 DK090120-02, T32 HL007604, DK31405]; Universita Politecnica delle Marche FX The authors are grateful to J. Lawitts (Beth Israel Deaconess Medical Center Transgenic Core) for derivation of BAC transgenic mice, S. White (Beth Israel Deaconess Medical Center Histology Core) for cryosectioning and histology services, E. Fox (Dana-Farber Cancer Institute Microarray Core) for Affymetrix gene chip analysis, M. Curry (Dana-Farber Cancer Institute Flow cytometry Core) for assistance with FACS analysis, and L. Cameron (Dana-Farber Cancer Institute Microscopy Core) for assistance with confocal microscopy. R.K.G is supported by National Institutes of Health (NIH) grant KO1 DK090120-02, J.C.L. and P.C. are supported by NIH grant T32 HL007604, and the research described in this study was supported by the NIH grant DK31405 to B.M.S. and by funding from Universita Politecnica delle Marche to S.C. NR 72 TC 133 Z9 135 U1 1 U2 19 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1550-4131 J9 CELL METAB JI Cell Metab. PD FEB 8 PY 2012 VL 15 IS 2 BP 230 EP 239 DI 10.1016/j.cmet.2012.01.010 PG 10 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA 895FM UT WOS:000300481600013 PM 22326224 ER PT J AU Katayama, R Shaw, AT Khan, TM Mino-Kenudson, M Solomon, BJ Halmos, B Jessop, NA Wain, JC Yeo, AT Benes, C Drew, L Saeh, JC Crosby, K Sequist, LV Iafrate, AJ Engelman, JA AF Katayama, Ryohei Shaw, Alice T. Khan, Tahsin M. Mino-Kenudson, Mari Solomon, Benjamin J. Halmos, Balazs Jessop, Nicholas A. Wain, John C. Yeo, Alan Tien Benes, Cyril Drew, Lisa Saeh, Jamal Carlos Crosby, Katherine Sequist, Lecia V. Iafrate, A. John Engelman, Jeffrey A. TI Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Article ID ANAPLASTIC LYMPHOMA KINASE; EML4-ALK FUSION GENE; ACTIVATING MUTATIONS; MET AMPLIFICATION; GEFITINIB RESISTANCE; INHIBITORS; EGFR; MUTANT; RECEPTOR; BIM AB Most anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancers (NSCLCs) are highly responsive to treatment with ALK tyrosine kinase inhibitors (TKIs). However, patients with these cancers invariably relapse, typically within 1 year, because of the development of drug resistance. Herein, we report findings from a series of lung cancer patients (n = 18) with acquired resistance to the ALK TKI crizotinib. In about one-fourth of patients, we identified a diverse array of secondary mutations distributed throughout the ALK TK domain, including new resistance mutations located in the solvent-exposed region of the adenosine triphosphate-binding pocket, as well as amplification of the ALK fusion gene. Next-generation ALK inhibitors, developed to overcome crizotinib resistance, had differing potencies against specific resistance mutations. In addition to secondary ALK mutations and ALK gene amplification, we also identified aberrant activation of other kinases including marked amplification of KIT and increased autophosphorylation of epidermal growth factor receptor in drug-resistant tumors from patients. In a subset of patients, we found evidence of multiple resistance mechanisms developing simultaneously. These results highlight the unique features of TKI resistance in ALK-positive NSCLCs and provide the rationale for pursuing combinatorial therapeutics that are tailored to the precise resistance mechanisms identified in patients who relapse on crizotinib treatment. C1 [Katayama, Ryohei; Shaw, Alice T.; Khan, Tahsin M.; Jessop, Nicholas A.; Wain, John C.; Yeo, Alan Tien; Benes, Cyril; Sequist, Lecia V.; Engelman, Jeffrey A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02129 USA. [Katayama, Ryohei; Shaw, Alice T.; Mino-Kenudson, Mari; Benes, Cyril; Sequist, Lecia V.; Iafrate, A. John; Engelman, Jeffrey A.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Shaw, Alice T.; Khan, Tahsin M.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. [Mino-Kenudson, Mari; Iafrate, A. John] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Solomon, Benjamin J.] Peter MacCallum Canc Ctr, Melbourne, Vic 3002, Australia. [Halmos, Balazs] Columbia Univ, Med Ctr, New York, NY 10032 USA. [Wain, John C.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. [Drew, Lisa; Saeh, Jamal Carlos] AstraZeneca R&D Boston, Waltham, MA 02451 USA. [Crosby, Katherine] Cell Signaling Technol Inc, Danvers, MA 01923 USA. RP Engelman, JA (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02129 USA. EM jengelman@partners.org RI Mendez, Pedro /J-8955-2016 OI Mendez, Pedro /0000-0001-6713-7907 FU V Foundation for Cancer Research Translational; NIH [CA120060-01, R01CA137008, R01CA140594, 1U01CA141457-01]; National Cancer Institute (NCI) [P50CA090578]; Dana-Farber/Harvard Cancer Center; American Association for Cancer Research; American Cancer Society [RSG-06-102-01-CCE]; Ellison Foundation; American Lung Association; Sig Adler Lung Cancer Research Fund; MGH Thoracic Oncology Fund; Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science, and Technology of Japan; Uniting Against Lung Cancer; Uniting Against Lung Cancer: New England and the Marjorie E. Korff Fund; NCI [R21CA156000] FX We thank T. Della Pelle at Massachusetts General Hospital (MGH) for help with the phospho-EGFR immunohistochemistry and E. Code, A. Wu, and S. Throner (Cancer Research, AstraZeneca R&D Boston) for help with the in vitro kinase assay experiments. Funding: This study was supported in part by a V Foundation for Cancer Research Translational Grant (J.A.E. and A. T. S.), NIH K08 grant CA120060-01 (J.A.E.), R01CA137008 (J.A.E.), R01CA140594 (J.A.E.), 1U01CA141457-01 (J.A.E.), National Cancer Institute (NCI) Lung SPORE P50CA090578 (J.A.E.), the Dana-Farber/Harvard Cancer Center, the American Association for Cancer Research (J.A.E.), American Cancer Society RSG-06-102-01-CCE (J.A.E.), the Ellison Foundation Scholar (J.A.E.), the American Lung Association (J.A.E.), Be a Part of the Solution philanthropy, friends and family of Ed and Judy Shanley, the Sig Adler Lung Cancer Research Fund, the MGH Thoracic Oncology Fund, and a Japan Society for the Promotion of Science Postdoctoral Fellowship for Research Abroad from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (R. K.). A. T. S. is the Charles W. and Jennifer C. Johnson Koch Institute Clinical Investigator. L. V. S. is supported by grants from Uniting Against Lung Cancer, sponsored by Uniting Against Lung Cancer: New England and the Marjorie E. Korff Fund, and from the NCI (R21CA156000). Author contributions: R. K. designed the experiments, performed cell line and in vitro studies, and wrote the manuscript. A. T. S. identified patients and obtained repeat biopsy samples, designed and supervised the experiments, and wrote the manuscript. T. M. K. performed cell line and in vitro studies. M.M.-K. performed and analyzed immunohistochemistry and pathology of all repeat biopsy samples. B.J.S., B. H., and L. V. S. identified patients and obtained repeat biopsy samples. N.A.J. organized specimen collection and genetic testing. J.C.W. performed biopsies on patients. A.T.Y. assisted R. K. in DNA sequence analysis. C. B. helped design experiments. L. D. and J.C.S. performed in vitro kinase assays and performed computational modeling. K. C. performed immunohistochemistry. A.J.I. supervised nucleic acid extraction and FISH testing. J.A.E. designed and supervised the experiments and wrote the manuscript. Competing interests: J.A.E. is a paid consultant for Ariad and Novartis; A.J.I. is a paid consultant for Pfizer and Abbott; A. T. S. is a paid consultant for Pfizer, Ariad, Chugai, and Novartis; B.J.S. has served on the advisory boards for Pfizer and Novartis. The other authors declare that they have no competing interests. NR 46 TC 395 Z9 412 U1 4 U2 34 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 EI 1946-6242 J9 SCI TRANSL MED JI Sci. Transl. Med. PD FEB 8 PY 2012 VL 4 IS 120 AR 120ra17 DI 10.1126/scitranslmed.3003316 PG 12 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 891NJ UT WOS:000300223600005 PM 22277784 ER PT J AU Choi, SH Wales, TE Nam, Y O'Donovan, DJ Sliz, P Engen, JR Blacklow, SC AF Choi, Sung Hee Wales, Thomas E. Nam, Yunsun O'Donovan, Daniel J. Sliz, Piotr Engen, John R. Blacklow, Stephen C. TI Conformational Locking upon Cooperative Assembly of Notch Transcription Complexes SO STRUCTURE LA English DT Article ID ACUTE LYMPHOBLASTIC-LEUKEMIA; SQUAMOUS-CELL CARCINOMA; HYDROGEN-EXCHANGE; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; ACTIVATION COMPLEX; ANKYRIN DOMAIN; LOW-RESOLUTION; PATHWAY; CSL AB The Notch intracellular domain (NICD) forms a transcriptional activation complex with the DNA-binding factor CSL and a transcriptional co-activator of the Mastermind family (MAML). The "RAM" region of NICD recruits Notch to CSL, facilitating the binding of MAML at the interface between the ankyrin (ANK) repeat domain of NICD and CSL. Here, we report the X-ray structure of a human MAML1/RAM/ANK/CSL/DNA complex, and probe changes in component dynamics upon stepwise assembly of a MAML1/NICD/CSL complex using HX-MS. Association of CSL with NICD exerts remarkably little effect on the exchange kinetics of the ANK domain, whereas MAML1 binding greatly retards the exchange kinetics of ANK repeats 2-3. These exchange patterns identify critical features contributing to the cooperative assembly of Notch transcription complexes (NTCs), highlight the importance of MAML recruitment in rigidifying the ANK domain and stabilizing its interface with CSL, and rationalize the requirement for MAML1 in driving cooperative dimerization of NTCs on paired-site DNA. C1 [Choi, Sung Hee; Blacklow, Stephen C.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Wales, Thomas E.; Engen, John R.] Northeastern Univ, Dept Chem & Chem Biol, Barnett Inst Chem & Biol Anal, Boston, MA 02115 USA. [Nam, Yunsun; O'Donovan, Daniel J.; Sliz, Piotr; Blacklow, Stephen C.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Nam, Yunsun; O'Donovan, Daniel J.; Sliz, Piotr] Childrens Hosp, Lab Mol Med, Boston, MA 02115 USA. [Blacklow, Stephen C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. RP Blacklow, SC (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. EM sblacklow@rics.bwh.harvard.edu OI Sliz, Piotr/0000-0002-6522-0835 FU NIH [R01 CA092433, P01 CA119070, R01 GM086507]; NSF [RCN 0639193]; Waters Corporation; Leukemia and Lymphoma Society Special Center of Research FX We thank Jon Aster, Kelly Arnett, and Wendy Gordon for helpful discussions and critical reading of the manuscript. We also thank two anonymous reviewers for their thoughtful comments and suggestions for revision. This work was supported by NIH grants R01 CA092433, P01 CA119070, R01 GM086507, NSF grant RCN 0639193, a research collaboration with the Waters Corporation, and a Leukemia and Lymphoma Society Special Center of Research. This is contribution 988 from the Barnett Institute. NR 46 TC 22 Z9 22 U1 0 U2 14 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0969-2126 J9 STRUCTURE JI Structure PD FEB 8 PY 2012 VL 20 IS 2 BP 340 EP 349 DI 10.1016/j.str.2011.12.011 PG 10 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 893WI UT WOS:000300388000017 PM 22325781 ER PT J AU Carnes, M AF Carnes, Molly TI What Would Patsy Mink Think? SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID PREJUDICE; CLIMATE; WOMEN; GAP C1 [Carnes, Molly] Univ Wisconsin Madison, Dept Med, Madison, WI 53706 USA. [Carnes, Molly] Univ Wisconsin Madison, Dept Psychiat, Madison, WI 53706 USA. [Carnes, Molly] Univ Wisconsin Madison, Dept Ind & Syst Engn, Madison, WI USA. [Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Carnes, M (reprint author), Univ Wisconsin Madison, Dept Med, Madison, WI 53706 USA. EM mlcarnes@wisc.edu NR 11 TC 2 Z9 2 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 8 PY 2012 VL 307 IS 6 BP 571 EP 572 DI 10.1001/jama.2012.79 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 888GT UT WOS:000299992500020 PM 22318277 ER PT J AU Raut, CP Boucher, Y Duda, DG Morgan, JA Quek, R Ancukiewicz, M Landenranta, J Eder, JP Demetri, GD Jain, RK AF Raut, Chandrajit P. Boucher, Yves Duda, Dan G. Morgan, Jeffrey A. Quek, Richard Ancukiewicz, Marek Landenranta, Johanna Eder, J. Paul Demetri, George D. Jain, Rakesh K. TI Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948) SO PLOS ONE LA English DT Article ID HUMAN-MELANOMA XENOGRAFTS; SOLID TUMORS; ANTIANGIOGENIC THERAPY; RAF/MEK/ERK PATHWAY; DRUG PENETRATION; HYPERTENSION; VASCULATURE; TARGETS; GROWTH; CANCER AB Purpose: Sorafenib is a multi-targeted tyrosine kinase inhibitor with therapeutic efficacy in several malignancies. Sorafenib may exert its anti-neoplastic effect in part by altering vascular permeability and reducing intra-tumoral interstitial hypertension. As correlative science with a phase II study in patients with advanced soft-tissue sarcomas (STS), we evaluated the impact of this agent on intra-tumor interstitial fluid pressure (IFP), serum circulating biomarkers, and vascular density. Patients and Methods: Patients with advanced STS with measurable disease and at least one superficial lesion amenable to biopsy received sorafenib 400 mg twice daily. Intratumoral IFP and plasma and circulating cell biomarkers were measured before and after 1-2 months of sorafenib administration. Results were analyzed in the context of the primary clinical endpoint of time-to-progression (TTP). Results: In 15 patients accrued, the median TTP was 45 days (range 14-228). Intra-tumoral IFP measurements obtained in 6 patients at baseline showed a direct correlation with tumor size. Two patients with stable disease at two months had post-sorafenib IFP evaluations and demonstrated a decline in IFP and vascular density. Sorafenib significantly increased plasma VEGF, PlGF, and SDF1 alpha and decreased sVEGFR-2 levels. Increased plasma SDF1 alpha and decreased sVEGFR-2 levels on day 28 correlated with disease progression. Conclusions: Pretreatment intra-tumoral IFP correlated with tumor size and decreased in two evaluable patients with SD on sorafenib. Sorafenib also induced changes in circulating biomarkers consistent with expected VEGF pathway blockade, despite the lack of more striking clinical activity in this small series. C1 [Raut, Chandrajit P.] Harvard Univ, Sch Med, Dept Surg, Brigham & Womens Hosp, Boston, MA 02115 USA. [Raut, Chandrajit P.; Morgan, Jeffrey A.; Quek, Richard; Eder, J. Paul; Demetri, George D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Boucher, Yves; Duda, Dan G.; Ancukiewicz, Marek; Landenranta, Johanna; Jain, Rakesh K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Morgan, Jeffrey A.; Quek, Richard; Eder, J. Paul; Demetri, George D.] Harvard Univ, Sch Med, Dept Med Oncol, Brigham & Womens Hosp, Boston, MA 02115 USA. RP Raut, CP (reprint author), Harvard Univ, Sch Med, Dept Surg, Brigham & Womens Hosp, Boston, MA 02115 USA. EM craut@partners.org FU National Institutes of Health [P01CA80124, R01CA115767]; Federal Share Proton Beam Income; Novartis; Pfizer; Ariad; Johnson Johnson; Bristol-Myers Squib; Infinity Pharmaceuticals; Daiichi-Sankyo; Dyax; AstraZeneca; MedImmune; [U01CA062490] FX This work was partially supported by the National Institutes of Health grants P01CA80124, R01CA115767 and Federal Share Proton Beam Income (RKJ) and U01CA062490 (JPE). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.; Chandrajit P. Raut is a Novartis - Honorarium. Johanna Lahdenranta has an employment/leadership position at Merrimack Pharmaceuticals. J. Paul Eder is currently employed at AstraZeneca PLC. George D. Demetri is a Consultant for Novartis, Pfizer, Ariad, Johnson & Johnson, Genentech, Infinity Pharmaceuticals, ZioPharm, Alnylam, Idera, Momenta Pharma, EMD-Serono, Glaxo Smith Kline, Amgen, Daiichi-Sankyo, ArQule, Enzon, Millenium/Takeda, PamGene (no compensation), Plexxikon, N-of-One (no compensation), Champions Biotechnology, and Kolltan Pharmaceuticals; on the Scientific Advisory Board of ZioPharm, PamGene, Plexxikon, N-of-One, Kolltan Pharmaceuticals (chair); on the Medical Advisory Board at Kolltan Pharmaceuticals (chair); an Honorarium at Novartis and Pfizer; provides research support (to Dana-Farber Cancer Institute for clinical trial) at Novartis, Pfizer, Ariad, Johnson & Johnson, Bristol-Myers Squib, Infinity Pharmaceuticals, and Daiichi-Sankyo; and has equity (minor stake, non-public) at PamGene, Plexxikon, N-of-One, Champions Biotechnology, and Kolltan Pharmaceuticals. Rakesh K. Jain has a Consultant/advisory role at Millenium, Dyax, AstraZeneca, Regeneron, Astellas-Fibrogen, MorphoSys AG, Genzyme, SynDevRx, and Noxxon; is Honoraria at Pfizer and Genzyme (honoraria for lecture); provides research funding/contracted research at Dyax, AstraZeneca and MedImmune; and has ownership interest in SynDevRx. There are no patents or products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. Yves Boucher, Dan G. Duda, Jeffrey A. Morgan, Richard Quek and Marek Ancukiewicz declare no competing interest. NR 41 TC 23 Z9 24 U1 3 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 7 PY 2012 VL 7 IS 2 AR e26331 DI 10.1371/journal.pone.0026331 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 917MF UT WOS:000302180600003 PM 22347360 ER PT J AU Kostis, WJ Cheng, JQ Dobrzynski, JM Cabrera, J Kostis, JB AF Kostis, William J. Cheng, Jerry Q. Dobrzynski, Jeanne M. Cabrera, Javier Kostis, John B. TI Meta-Analysis of Statin Effects in Women Versus Men SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE cardiovascular disease; LDL; lipids; statins; women ID CORONARY-HEART-DISEASE; PRIMARY PREVENTION; CARDIOVASCULAR-DISEASE; RANDOMIZED-TRIALS; LDL CHOLESTEROL; EFFICACY; GENDER; ROSUVASTATIN; JUPITER; THERAPY AB Objectives The aim of this study was to evaluate the effect of statins in decreasing cardiovascular events in women and men. Background Published data reviews have suggested that statins might not be as effective in women as in men in decreasing cardiovascular events. Methods Published data searches and contacts with investigators identified 18 randomized clinical trials of statins with sex-specific outcomes (N = 141,235, 40,275 women, 21,468 cardiovascular events). Odds ratios (ORs) and 95% confidence intervals (CIs) for cardiovascular events were calculated for women and men separately with random effects meta-analyses. Results The cardiovascular event rate was lower among those randomized to statin intervention than in those randomized to control (low-dose statin in 4 studies, placebo in 11 studies, usual care in 3 studies) and similar in women and men (OR: 0.81, 95% CI: 0.75 to 0.89; p < 0.0001, and OR: 0.77, 95% CI: 0.71 to 0.83, p < 0.0001, respectively). The benefit of statins was statistically significant in both sexes, regardless of the type of control, baseline risk, or type of endpoint and in both primary and secondary prevention. All-cause mortality was also lower with statin therapy both in women and men without significant interaction by sex (p for interaction = 0.4457). Conclusions Statin therapy is associated with significant decreases in cardiovascular events and in all-cause mortality in women and men. Statin therapy should be used in appropriate patients without regard to sex. (J Am Coll Cardiol 2012;59:572-82) (C) 2012 by the American College of Cardiology Foundation C1 [Kostis, William J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Cheng, Jerry Q.] Columbia Univ, Dept Stat, New York, NY USA. [Cheng, Jerry Q.; Dobrzynski, Jeanne M.; Cabrera, Javier; Kostis, John B.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08903 USA. [Cheng, Jerry Q.; Dobrzynski, Jeanne M.; Cabrera, Javier; Kostis, John B.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Cardiovasc Inst, New Brunswick, NJ USA. [Cabrera, Javier] Rutgers State Univ, Dept Stat, Piscataway, NJ USA. RP Kostis, WJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St,GRB-800, Boston, MA 02114 USA. EM wkostis@partners.org FU Robert Wood Johnson Foundation FX This study was supported in part by the Robert Wood Johnson Foundation. All authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 29 TC 112 Z9 116 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD FEB 7 PY 2012 VL 59 IS 6 BP 572 EP 582 DI 10.1016/j.jacc.2011.09.067 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 891DK UT WOS:000300196500004 PM 22300691 ER PT J AU Baldwin, LM Trivers, KF Matthews, B Andrilla, CHA Miller, JW Berry, DL Lishner, DM Goff, BA AF Baldwin, Laura-Mae Trivers, Katrina F. Matthews, Barbara Andrilla, C. Holly A. Miller, Jacqueline W. Berry, Donna L. Lishner, Denise M. Goff, Barbara A. TI Vignette-Based Study of Ovarian Cancer Screening: Do US Physicians Report Adhering to Evidence-Based Recommendations? SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID PRIMARY-CARE PHYSICIANS; UNITED-STATES; RISK WOMEN; TRANSVAGINAL ULTRASOUND; RANDOMIZED-TRIAL; NATIONAL-SURVEY; SUSCEPTIBILITY; QUALITY; POPULATION; SERVICES AB Background: No professional society or group recommends routine ovarian cancer screening, yet physicians' enthusiasm for several cancer screening tests before benefit has been proven suggests that some women may be exposed to potential harms. Objective: To provide nationally representative estimates of physicians' reported nonadherence to recommendations against ovarian cancer screening. Design: Cross-sectional survey of physicians offering women's primary care. The 12-page questionnaire contained a woman's annual examination vignette and questions about offers or orders for transvaginal ultrasonography (TVU) and cancer antigen 125 (CA-125). Setting: United States. Participants: 3200 physicians randomly sampled equally from the 2008 American Medical Association Physician Masterfile lists of family physicians, general internists, and obstetrician-gynecologists; 61.7% responded. After exclusions, 1088 respondents were included; their responses were weighted to represent the specialty distribution of practicing U. S. physicians nationally. Measurements: Reported nonadherence to screening recommendations (defined as sometimes or almost always ordering screening TVU or CA-125 or both). Results: Twenty-eight percent (95% CI, 24.5% to 32.9%) of physicians reported nonadherence to screening recommendations for women at low risk for ovarian cancer; 65.4% (CI, 61.1% to 69.4%) did so for women at medium risk for ovarian cancer. Six percent (CI, 4.4% to 8.9%) reported routinely ordering or offering ovarian cancer screening for low-risk women, as did 24.0% (CI, 20.5% to 28.0%) for medium-risk women (P <= 0.001). Thirty-three percent believed TVU or CA-125 was an effective screening test. In adjusted analysis, actual and physician-perceived patient risk, patient request for ovarian cancer screening, and physician belief that TVU or CA-125 was an effective screening test were the strongest predictors of physician-reported nonadherence to published recommendations. Limitation: The results are limited by their reliance on survey methods; there may be respondent-nonrespondent bias. Conclusion: One in 3 physicians believed that ovarian cancer screening was effective, despite evidence to the contrary. Substantial proportions of physicians reported routinely offering or ordering ovarian cancer screening, thereby exposing women to the documented risks of these tests. C1 [Baldwin, Laura-Mae] Univ Washington, Dept Family Med, Seattle, WA 98195 USA. Ctr Dis Control & Prevent, Atlanta, GA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RP Baldwin, LM (reprint author), Univ Washington, Dept Family Med, Box 354982, Seattle, WA 98195 USA. EM lmb@uw.edu FU Centers for Disease Control and Prevention through the University of Washington Health Promotion Research Centers [U48DP001911]; Centers for Disease Control and Prevention through the Alliance for Reducing Cancer, Northwest; Centers for Disease Control and Prevention [U48DP001911]; National Cancer Institute FX Grant Support: By the Centers for Disease Control and Prevention through the University of Washington Health Promotion Research Centers Cooperative Agreement U48DP001911 and through the Alliance for Reducing Cancer, Northwest, funded by both the Centers for Disease Control and Prevention (grant U48DP001911; V. Taylor, primary investigator) and the National Cancer Institute. NR 58 TC 25 Z9 26 U1 0 U2 3 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 7 PY 2012 VL 156 IS 3 BP 182 EP U46 DI 10.7326/0003-4819-156-3-201202070-00006 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA 887XD UT WOS:000299964200002 PM 22312138 ER PT J AU Mack, JW Cronin, A Taback, N Huskamp, HA Keating, NL Malin, JL Earle, CC Weeks, JC AF Mack, Jennifer W. Cronin, Angel Taback, Nathan Huskamp, Haiden A. Keating, Nancy L. Malin, Jennifer L. Earle, Craig C. Weeks, Jane C. TI End-of-Life Care Discussions Among Patients With Advanced Cancer A Cohort Study SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID METASTATIC COLORECTAL-CANCER; OUTCOMES RESEARCH; PALLIATIVE CARE; MENTAL-HEALTH; ILL PATIENTS; LUNG-CANCER; DEATH; SURVEILLANCE; CHEMOTHERAPY; SURVIVAL AB Background: National guidelines recommend that physicians discuss end-of-life (EOL) care planning with patients with cancer whose life expectancy is less than 1 year. Objective: To evaluate the incidence of EOL care discussions for patients with stage IV lung or colorectal cancer and where, when, and with whom these discussions take place. Design: Prospective cohort study of patients diagnosed with lung or colorectal cancer from 2003 to 2005. Setting: Participants lived in Northern California, Los Angeles County, North Carolina, Iowa, or Alabama or received care in 1 of 5 large HMOs or 1 of 15 Veterans Health Administration sites. Patients: 2155 patients with stage IV lung or colorectal cancer. Measurements: End-of-life care discussions reported in patient and surrogate interviews or documented in medical records through 15 months after diagnosis. Results: 73% of patients had EOL care discussions identified by at least 1 source. Among the 1470 patients who died during follow-up, 87% had EOL care discussions, compared with 41% of the 685 patients who were alive at the end of follow-up. Of the 1081 first EOL care discussions documented in records, 55% occurred in the hospital. Oncologists documented EOL care discussions with only 27% of their patients. Among 959 patients with documented EOL care discussions who died during follow-up, discussions took place a median of 33 days before death. Limitations: The depth and quality of EOL care discussions was not evaluated. Much of the information about discussions came from surrogates of patients who died before baseline interviews could be obtained. Conclusion: Although most patients with stage IV lung or colorectal cancer discuss EOL care planning with physicians before death, many discussions occur during acute hospital care, with providers other than oncologists, and late in the course of illness. C1 [Mack, Jennifer W.] Harvard Univ, Dana Farber Canc Inst, Childrens Hosp, Sch Med, Boston, MA 02215 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. Ontario Inst Canc Res, Toronto, ON, Canada. RP Mack, JW (reprint author), Harvard Univ, Dana Farber Canc Inst, Childrens Hosp, Sch Med, 450 Brookline Ave, Boston, MA 02215 USA. EM jennifer_mack@dfci.harvard.edu FU National Cancer Institute (NCI) [U01 CA093344, U01 CA093332, U01 CA093324, U01 CA093348, U01 CA093329, U01 CA093339, U01 CA093326]; Department of Veterans Affairs [CRS 02-164]; American Cancer Society; National Palliative Care Research Center FX The work of the CanCORS Consortium was supported by grants from the National Cancer Institute (NCI) to the Statistical Coordinating Center (U01 CA093344) and the NCI-supported Primary Data Collection and Research Centers (grant U01 CA093332 to the Dana-Farber Cancer Institute/Cancer Research Network, grant U01 CA093324 to Harvard Medical School/Northern California Cancer Center, grant U01 CA093348 to RAND/University of California, Los Angeles, grant U01 CA093329 to the University of Alabama at Birmingham, grant U01 CA093339 to the University of Iowa, grant U01 CA093326 to University of North Carolina) and by grant CRS 02-164 from the Department of Veterans Affairs to the Durham Veterans Affairs Medical Center. Dr. Mack was funded by an American Cancer Society Mentored Research Scholar Grant and by the National Palliative Care Research Center. NR 32 TC 98 Z9 99 U1 2 U2 21 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 7 PY 2012 VL 156 IS 3 BP 204 EP U65 DI 10.7326/0003-4819-156-3-201202070-00008 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 887XD UT WOS:000299964200004 PM 22312140 ER PT J AU Qaseem, A Humphrey, LL Sweet, DE Starkey, M Shekelle, P AF Qaseem, Amir Humphrey, Linda L. Sweet, Donna E. Starkey, Melissa Shekelle, Paul CA Clinical Guidelines Comm Amer Coll TI Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID DIPEPTIDYL PEPTIDASE-4 INHIBITOR; FIXED-DOSE COMBINATION; RANDOMIZED CONTROLLED-TRIAL; IMPROVED GLYCEMIC CONTROL; SULFONYLUREA PLUS METFORMIN; CONGESTIVE-HEART-FAILURE; ALL-CAUSE MORTALITY; DOUBLE-BLIND; RETROSPECTIVE COHORT; INSULIN SENSITIVITY AB Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the comparative effectiveness and safety of type 2 diabetes medications. Methods: This guideline is based on a systematic evidence review evaluating literature published on this topic from 1966 through April 2010 that was identified by using MEDLINE (updated through December 2010), EMBASE, and the Cochrane Central Register of Controlled Trials. Searches were limited to English-language publications. The clinical outcomes evaluated for this guideline included all-cause mortality, cardiovascular morbidity and mortality, cerebrovascular morbidity, neuropathy, nephropathy, and retinopathy. This guideline grades the evidence and recommendations by using the American College of Physicians clinical practice guidelines grading system. Recommendation 1: ACP recommends that clinicians add oral pharmacologic therapy in patients diagnosed with type 2 diabetes when lifestyle modifications, including diet, exercise, and weight loss, have failed to adequately improve hyperglycemia (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians prescribe monotherapy with metformin for initial pharmacologic therapy to treat most patients with type 2 diabetes (Grade: strong recommendation; high-quality evidence). Recommendation 3: ACP recommends that clinicians add a second agent to metformin to treat patients with persistent hyperglycemia when lifestyle modifications and monotherapy with metformin fail to control hyperglycemia (Grade: strong recommendation; high-quality evidence). C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Univ Kansas, Sch Med, Wichita, KS 67214 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA. EM aqaseem@acponline.org FU ACP FX Financial support for the development of this guideline comes exclusively from the ACP operating budget. NR 134 TC 123 Z9 127 U1 2 U2 18 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 7 PY 2012 VL 156 IS 3 BP 218 EP U92 DI 10.7326/0003-4819-156-3-201202070-00011 PG 19 WC Medicine, General & Internal SC General & Internal Medicine GA 887XD UT WOS:000299964200006 PM 22312141 ER PT J AU Kerlikowske, K Hubbard, R AF Kerlikowske, Karla Hubbard, Rebecca TI Comparative Effectiveness of Digital Versus Film-Screen Mammography RESPONSE SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 [Kerlikowske, Karla] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Hubbard, Rebecca] Grp Hlth Res Inst, Seattle, WA 98101 USA. RP Kerlikowske, K (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. NR 4 TC 0 Z9 0 U1 1 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 7 PY 2012 VL 156 IS 3 BP 251 EP 251 DI 10.7326/0003-4819-156-3-201202070-00024 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 887XD UT WOS:000299964200018 ER PT J AU Chen, W Unkelbach, J Trofimov, A Madden, T Kooy, H Bortfeld, T Craft, D AF Chen, Wei Unkelbach, Jan Trofimov, Alexei Madden, Thomas Kooy, Hanne Bortfeld, Thomas Craft, David TI Including robustness in multi-criteria optimization for intensity-modulated proton therapy SO PHYSICS IN MEDICINE AND BIOLOGY LA English DT Article ID TREATMENT UNCERTAINTIES; RANGE UNCERTAINTIES; RADIOTHERAPY; SENSITIVITY; ALGORITHM; PLAN AB We present a method to include robustness in a multi-criteria optimization (MCO) framework for intensity-modulated proton therapy (IMPT). The approach allows one to simultaneously explore the trade-off between different objectives as well as the trade-off between robustness and nominal plan quality. In MCO, a database of plans each emphasizing different treatment planning objectives, is pre-computed to approximate the Pareto surface. An IMPT treatment plan that strikes the best balance between the different objectives can be selected by navigating on the Pareto surface. In our approach, robustness is integrated into MCO by adding robustified objectives and constraints to the MCO problem. Uncertainties (or errors) of the robust problem are modeled by pre-calculated dose-influence matrices for a nominal scenario and a number of pre-defined error scenarios (shifted patient positions, proton beam undershoot and overshoot). Objectives and constraints can be defined for the nominal scenario, thus characterizing nominal plan quality. A robustified objective represents the worst objective function value that can be realized for any of the error scenarios and thus provides a measure of plan robustness. The optimization method is based on a linear projection solver and is capable of handling large problem sizes resulting from a fine dose grid resolution, many scenarios, and a large number of proton pencil beams. A base-of-skull case is used to demonstrate the robust optimization method. It is demonstrated that the robust optimization method reduces the sensitivity of the treatment plan to setup and range errors to a degree that is not achieved by a safety margin approach. A chordoma case is analyzed in more detail to demonstrate the involved trade-offs between target underdose and brainstem sparing as well as robustness and nominal plan quality. The latter illustrates the advantage of MCO in the context of robust planning. For all cases examined, the robust optimization for each Pareto optimal plan takes less than 5 min on a standard computer, making a computationally friendly interface possible to the planner. In conclusion, the uncertainty pertinent to the IMPT procedure can be reduced during treatment planning by optimizing plans that emphasize different treatment objectives, including robustness, and then interactively seeking for a most-preferred one from the solution Pareto surface. C1 [Chen, Wei] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Chen, W (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. EM chen.wei@mgh.harvard.edu FU NCI [P01 CA21239, R01 CA1039040-1A1] FX The authors thank Wei Liu and Xiaodong Zhang from the MD Anderson Cancer Center for valuable discussions and providing the base-of-skull case. This work was supported in part by NCI grant P01 CA21239 Proton Radiation Therapy Research and NCI grant R01 CA1039040-1A1 Multi-criteria IMRT Optimization. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. NR 25 TC 53 Z9 53 U1 0 U2 7 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 0031-9155 J9 PHYS MED BIOL JI Phys. Med. Biol. PD FEB 7 PY 2012 VL 57 IS 3 BP 591 EP 608 DI 10.1088/0031-9155/57/3/591 PG 18 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Radiology, Nuclear Medicine & Medical Imaging GA 882DP UT WOS:000299542000004 PM 22222720 ER PT J AU Normandin, MD Koeppe, RA Morris, ED AF Normandin, M. D. Koeppe, R. A. Morris, E. D. TI Selection of weighting factors for quantification of PET radioligand binding using simplified reference tissue models with noisy input functions SO PHYSICS IN MEDICINE AND BIOLOGY LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; REFERENCE REGION MODEL; LIGAND-RECEPTOR MODEL; PARAMETER-ESTIMATION; DYNAMIC PET; HUMAN BRAIN; COMPARTMENTAL ANALYSIS; COMPUTED-TOMOGRAPHY; LINEAR-REGRESSION; KINETIC-ANALYSIS AB Input function noise contributes to model-predicted values and should be accounted for during parameter estimation. This problem has been examined in the context of PET data analysis using a noisy image-derived arterial input function. Huesman and Mazoyer (1987 Phys. Med. Biol 32 1569-79) incorporated the effect of error in the measured input function into the objective function and observed a subsequent improvement in the accuracy of parameters estimated from a kinetic model of cardiac blood flow. Such a treatment has not been applied to the reference region models commonly used to analyze dynamic positron emission tomography data with receptor-ligand tracers. Here, we propose a strategy for selection of weighting factors that accounts for noise in the reference region input function and test the method on two common formulations of the simplified reference tissue model (SRTM). We present a simulation study which demonstrates that the proposed weighting approach improves the accuracy of estimated binding potential at high noise levels and when the reference tissue and target regions of interest are of comparable size. In the second simulation experiment, we show that using a small, homogeneous reference tissue with our weighting technique may have advantages over input functions derived from a larger (and thus less noisy), heterogeneous region with conventional weighting. A comparative analysis of clinical [C-11] flumazenil data found a small but significant increase in estimated binding potential when using the proposed weighting method, consistent with the finding of reduced negative bias in our simulation study. The weighting strategy described here accounts for noise in the reference region input function and may improve the performance of the SRTM in applications where data are noisy and the reference region is relatively small. This technique may offer similar benefits to other models using reference region inputs, particularly those derived from the SRTM. C1 [Normandin, M. D.; Morris, E. D.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA. [Normandin, M. D.; Morris, E. D.] Indiana Univ Sch Med, Dept Radiol, Indianapolis, IN USA. [Koeppe, R. A.] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA. [Morris, E. D.] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA. RP Normandin, MD (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA. EM normandin@pet.mgh.harvard.edu RI Normandin, Marc/C-6728-2015 OI Normandin, Marc/0000-0003-1645-523X FU Society of Nuclear Medicine; NIH [R21 AA015077] FX The authors acknowledge the support of the Society of Nuclear Medicine Student Fellowship Award to M D Normandin and NIH grant R21 AA015077 to E D Morris. NR 47 TC 3 Z9 3 U1 0 U2 4 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 0031-9155 J9 PHYS MED BIOL JI Phys. Med. Biol. PD FEB 7 PY 2012 VL 57 IS 3 BP 609 EP 629 DI 10.1088/0031-9155/57/3/609 PG 21 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Radiology, Nuclear Medicine & Medical Imaging GA 882DP UT WOS:000299542000005 PM 22241524 ER PT J AU Jaber, N Dou, ZX Chen, JS Catanzaro, J Jiang, YP Ballou, LM Selinger, E Ouyang, XS Lin, RZ Zhang, JH Zong, WX AF Jaber, Nadia Dou, Zhixun Chen, Juei-Suei Catanzaro, Joseph Jiang, Ya-Ping Ballou, Lisa M. Selinger, Elzbieta Ouyang, Xiaosen Lin, Richard Z. Zhang, Jianhua Zong, Wei-Xing TI Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE LC3; SQSTM1/p62; 3-MA; epidermal growth factor receptor; transferrin ID PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASES; EARLY ENDOSOMES; SELF-DIGESTION; METABOLISM; PATHWAY; HVPS34; CANCER; MICE; ACTIVATION AB A critical regulator of autophagy is the Class III PI3K Vps34 (also called PIK3C3). Although Vps34 is known to play an essential role in autophagy in yeast, its role in mammals remains elusive. To elucidate the physiological function of Vps34 and to determine its precise role in autophagy, we have generated Vps34(f/f) mice, in which expression of Cre recombinase results in a deletion of exon 4 of Vps34 and a frame shift causing a deletion of 755 of the 887 amino acids of Vps34. Acute ablation of Vps34 in MEFs upon adenoviral Cre infection results in a diminishment of localized generation of phosphatidylinositol 3-phosphate and blockade of both endocytic and autophagic degradation. Starvation-induced autophagosome formation is blocked in both Vps34-null MEFs and liver. Liver-specific Albumin-Cre; Vps34(f/f) mice developed hepatomegaly and hepatic steatosis, and impaired protein turnover. Ablation of Vps34 in the heart of muscle creatine kinase-Cre; Vps34(f/f) mice led to cardiomegaly and decreased contractility. In addition, while amino acid-stimulated mTOR activation was suppressed in the absence of Vps34, the steady-state level of mTOR signaling was not affected in Vps34-null MEFs, liver, or cardiomyocytes. Taken together, our results indicate that Vps34 plays an essential role in regulating functional autophagy and is indispensable for normal liver and heart function. C1 [Zhang, Jianhua] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. [Jaber, Nadia; Dou, Zhixun; Chen, Juei-Suei; Catanzaro, Joseph; Zong, Wei-Xing] SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA. [Jiang, Ya-Ping; Selinger, Elzbieta; Lin, Richard Z.] SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA. [Ballou, Lisa M.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA. [Lin, Richard Z.] Northport VA Med Ctr, Northport, NY 11768 USA. [Zhang, Jianhua] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. RP Zhang, JH (reprint author), Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. EM zhanja@uab.edu; wzong@notes.cc.sunysb.edu RI Lin, Richard/J-1754-2014; OI Lin, Richard/0000-0002-3473-7276; Zhang, Jianhua/0000-0002-2128-9574 FU National Institute of Health [CA129536, DK62722, CA136754, NS064090]; Susan Komen for the Cure [KG081538]; Department of Veterans Affairs; Carol Baldwin Breast Cancer Research Foundation FX We thank Drs. Deborah Brown, Noboru Mizushima, Zhenyu Yue, Qing Zhong, and Hong Chen for reagents and insightful suggestions; Namratha Sheshadri, Shengnan Liu, and Debjani Pal for technical assistance; and Susan van Horn and Edward Philips for assistance on EM. Work was supported by National Institute of Health Grants CA129536 (to W.-X.Z.), DK62722, CA136754 (to R.Z.L.), and NS064090 (to J.Z.), Susan Komen for the Cure Grant KG081538 (to W.-X.Z.), Department of Veterans Affairs merit awards (to R.Z.L. and J.Z.), and the Carol Baldwin Breast Cancer Research Foundation (to W.-X.Z.). NR 42 TC 130 Z9 140 U1 3 U2 30 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD FEB 7 PY 2012 VL 109 IS 6 BP 2003 EP 2008 DI 10.1073/pnas.1112848109 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 887KC UT WOS:000299925000045 PM 22308354 ER PT J AU Newton, TF De la Garza, R Brown, G Kosten, TR Mahoney, JJ Haile, CN AF Newton, Thomas F. De la Garza, Richard, II Brown, Gregory Kosten, Thomas R. Mahoney, James J., III Haile, Colin N. TI Noradrenergic alpha(1) Receptor Antagonist Treatment Attenuates Positive Subjective Effects of Cocaine in Humans: A Randomized Trial SO PLOS ONE LA English DT Article ID ABUSE LIABILITY; RHESUS-MONKEYS; D-AMPHETAMINE; LOCOMOTOR; REINSTATEMENT; DOXAZOSIN; DOPAMINE; PRAZOSIN; AGONIST; NOREPINEPHRINE AB Background: Preclinical research implicates dopaminergic and noradrenergic mechanisms in mediating the reinforcing effects of drugs of abuse, including cocaine. The objective of this study was to evaluate the impact of treatment with the noradrenergic alpha(1) receptor antagonist doxazosin on the positive subjective effects of cocaine. Methods: Thirteen non-treatment seeking, cocaine-dependent volunteers completed this single-site, randomized, placebo-controlled, within-subjects study. In one study phase volunteers received placebo and in the other they received doxazosin, with the order counterbalanced across participants. Study medication was masked by over-encapsulating doxazosin tablets and matched placebo lactose served as the control. Study medication treatment was initiated at 1 mg doxazosin or equivalent number of placebo capsules PO/day and increased every three days by 1 mg. After receiving 4 mg doxazosin or equivalent number of placebo capsules participants received masked doses of 20 and 40 mg cocaine IV in that order with placebo saline randomly interspersed to maintain the blind. Results: Doxazosin treatment was well tolerated and doxazosin alone produced minimal changes in heart rate and blood pressure. During treatment with placebo, cocaine produced dose-dependent increases in subjective effect ratings of "high'', "stimulated'', "like cocaine'', "desire cocaine'', "any drug effect'', and "likely to use cocaine if had access'' (p<.001). Doxazosin treatment significantly attenuated the effects of 20 mg cocaine on ratings of "stimulated'', "like cocaine'', and "likely to use cocaine if had access'' (p<.05). There were trends for doxazosin to reduce ratings of "stimulated'', "desire cocaine'', and "likely to use cocaine if had access'' (p<.10). Conclusions: Medications that block noradrenergic alpha(1) receptors, such as doxazosin, may be useful as treatments for cocaine dependence, and should be evaluated further. C1 [Newton, Thomas F.; De la Garza, Richard, II; Brown, Gregory; Kosten, Thomas R.; Mahoney, James J., III; Haile, Colin N.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Newton, TF (reprint author), Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. EM tnewton@bcm.edu RI De La Garza, Richard/B-2489-2014; Mahoney, James/I-2753-2014; OI De La Garza, Richard/0000-0003-1943-4469; Mahoney, James/0000-0003-0824-1776; Haile, Colin/0000-0001-8293-7291; newton, thomas/0000-0002-3198-5901; Brown, Grant/0000-0002-9002-5003 FU National Institutes of Health [P50 DA18197, M01 RR00188] FX This study was supported by grants from the National Institutes of Health, P50 DA18197 and M01 RR00188. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 31 TC 21 Z9 22 U1 1 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 3 PY 2012 VL 7 IS 2 AR e30854 DI 10.1371/journal.pone.0030854 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 917LO UT WOS:000302178400017 PM 22319592 ER PT J AU Das, F Ghosh-Choudhury, N Dey, N Mandal, CC Mahimainathan, L Kasinath, BS Abboud, HE Choudhury, GG AF Das, Falguni Ghosh-Choudhury, Nandini Dey, Nirmalya Mandal, Chandi Charan Mahimainathan, Lenin Kasinath, Balakuntalam S. Abboud, Hanna E. Choudhury, Goutam Ghosh TI Unrestrained Mammalian Target of Rapamycin Complexes 1 and 2 Increase Expression of Phosphatase and Tensin Homolog Deleted on Chromosome 10 to Regulate Phosphorylation of Akt Kinase SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID TUMOR-SUPPRESSOR GENE; TUBEROUS-SCLEROSIS; SIGNALING PATHWAY; S6 KINASE; INSULIN-RESISTANCE; BINDING PARTNER; MTOR COMPLEX; ACTIVATION; PTEN; TSC2 AB Tuberous sclerosis complex 2 (TSC2) and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) function to block growth factor-induced mammalian target of rapamycin (mTOR) signaling and are mutated in autosomal dominant hamartoma syndromes. mTOR binds to a spectrum of common and different proteins to form TOR complex 1 (TORC1) and TORC2, which regulate cell growth, division, and metabolism. TSC2 deficiency induces constitutive activation of mTOR, leading to a state of insulin resistance due to a negative feedback regulation, resulting in reduced Akt phosphorylation. We have recently described an alternative mechanism showing that in TSC2 deficiency, enhanced PTEN expression contributes to reduced Akt phosphorylation. To explore the mechanism of PTEN regulation, we used rapamycin and constitutively active mTOR to show that TORC1 increases the expression of PTEN mRNA and protein. We found that in TSC2(-/-) mouse embryonic fibroblasts expression of a kinase-dead mutant of mTOR, which inhibits both TORC1 and TORC2, decreases the expression of PTEN via transcriptional mechanism. Furthermore, kinase-deadm TOR increased and decreased phosphorylation of Akt at catalytic loop site Thr-308 and hydrophobic motif site Ser-473, respectively. Moreover, inhibition of deregulated TORC1 in TSC2-null mouse embryonic fibroblasts or in 293 cells by down-regulation of raptor decreased the levels of the transcription factor Hif1 alpha and blocked PTEN expression, resulting in enhanced phosphorylation of Akt at Thr-308 and Ser-473. Finally, knockdown of rictor or mSin1 attenuated the expression of Hif1 alpha, which decreased transcription of PTEN. These results unravel a previously unrecognized cell-autonomous function of TORC1 and TORC2 in the up-regulation of PTEN, which prevents phosphorylation of Akt and may shield against the development of malignancy in TSC patients. C1 [Das, Falguni; Dey, Nirmalya; Mahimainathan, Lenin; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini; Mandal, Chandi Charan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini; Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Vet Affairs Res, San Antonio, TX 78229 USA. RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu OI /0000-0001-5077-3552 FU National Institutes of Health [RO1 DK50190, RO1 AR 52425, RO1 DK 077295, RC2A 036613]; Veterans Affairs Merit Review; Cancer Therapy and Research Center, San Antonio; Veterans Affairs Senior Research Career Scientist Award; Juvenile Diabetes Research Foundation [1-2008-185] FX This work was supported, in whole or in part, by National Institutes of Health Grants RO1 DK50190 (to G. G. C.), RO1 AR 52425 (to N. G. C.). This work was also supported by Veterans Affairs Merit Review grant (to G. G. C.).; Supported by Veterans Affairs Merit Review grants and a Ronald P. Williams Orthopedic Oncology Developmental Research Award from Cancer Therapy and Research Center, San Antonio.; Supported by NIH RO1 DK 077295, RC2A 036613, and Veterans Affairs Research Service grant.; Recipient of a Veterans Affairs Senior Research Career Scientist Award and supported by Regular Research Grant 1-2008-185 from the Juvenile Diabetes Research Foundation. To whom correspondence should be addressed: Dept. of Medicine, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX 78229. E-mail: choudhuryg@uthscsa.edu. NR 65 TC 20 Z9 20 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 3 PY 2012 VL 287 IS 6 BP 3808 EP 3822 DI 10.1074/jbc.M111.246397 PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 894EX UT WOS:000300410900018 PM 22184110 ER PT J AU Kang, H Davis-Dusenbery, BN Nguyen, PH Lal, A Lieberman, J Van Aelst, L Lagna, G Hata, A AF Kang, Hara Davis-Dusenbery, Brandi N. Nguyen, Peter H. Lal, Ashish Lieberman, Judy Van Aelst, Linda Lagna, Giorgio Hata, Akiko TI Bone Morphogenetic Protein 4 Promotes Vascular Smooth Muscle Contractility by Activating MicroRNA-21 (miR-21), which Down-regulates Expression of Family of Dedicator of Cytokinesis (DOCK) Proteins SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID TUMOR-SUPPRESSOR GENE; CANCER CELLS; TARGETS; GROWTH; PROLIFERATION; INVASION; IDENTIFICATION; RECOGNITION; METASTASIS; MATURATION AB The bone morphogenetic protein 4 (BMP4) signaling pathway plays a critical role in the promotion and maintenance of the contractile phenotype in vascular smooth muscle cell (vSMC). Misexpression or inactivating mutations of the BMP receptor gene can lead to dedifferentiation of vSMC characterized by increased migration and proliferation that is linked to vascular proliferative disorders. Previously we demonstrated that vSMCs increase microRNA-21 (miR-21) biogenesis upon BMP4 treatment, which induces contractile gene expression by targeting programmed cell death 4 (PDCD4). To identify novel targets of miR-21 that are critical for induction of the contractile phenotype by BMP4, biotinylated miR-21 was expressed in vSMCs followed by an affinity purification of mRNAs associated with miR-21. Nearly all members of the dedicator of cytokinesis (DOCK) 180-related protein superfamily were identified as targets of miR-21. Down-regulation of DOCK4, -5, and -7 by miR-21 inhibited cell migration and promoted cytoskeletal organization by modulating an activity of small GTPase. Thus, this study uncovers a regulatory mechanism of the vSMC phenotype by the BMP4-miR-21 axis through DOCK family proteins. C1 [Kang, Hara; Lagna, Giorgio; Hata, Akiko] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA. [Kang, Hara; Davis-Dusenbery, Brandi N.; Nguyen, Peter H.; Lagna, Giorgio; Hata, Akiko] Tufts Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA. [Lal, Ashish; Lieberman, Judy] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. [Lal, Ashish; Lieberman, Judy] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Lal, Ashish] NCI, Genet Branch, NIH, Bethesda, MD 20889 USA. [Van Aelst, Linda] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA. [Hata, Akiko] Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA. RP Hata, A (reprint author), Univ Calif San Francisco, Cardiovasc Res Inst, 555 Mission Bay Blvd, San Francisco, CA 94158 USA. EM akiko.hata@ucsf.edu RI Davis-Dusenbery, Brandi/N-2798-2013; Lieberman, Judy/A-2717-2015 OI Davis-Dusenbery, Brandi/0000-0001-7811-8613; FU National Institutes of Health [HD042149, HL093154, HL082854]; American Heart Association [0940095N]; LeDucq Foundation FX This work was supported, in whole or in part, by National Institutes of Health Grants HD042149, HL093154, and HL082854 (to A. H.). This work was also supported by American Heart Association Grant 0940095N and a LeDucq Foundation transatlantic network grant (to A. H.). NR 50 TC 47 Z9 51 U1 1 U2 8 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 3 PY 2012 VL 287 IS 6 BP 3976 EP 3986 DI 10.1074/jbc.M111.303156 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 894EX UT WOS:000300410900032 PM 22158624 ER PT J AU Lee, J Kim, HR Quinley, C Kim, J Gonzalez-Navajas, J Xavier, R Raz, E AF Lee, Jongdae Kim, Hye Ri Quinley, Christine Kim, Joanna Gonzalez-Navajas, Jose Xavier, Ramnik Raz, Eyal TI Autophagy Suppresses Interleukin-1 beta (IL-1 beta) Signaling by Activation of p62 Degradation via Lysosomal and Proteasomal Pathways SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID TRANSCRIPTION FACTOR NRF2; NF-KAPPA-B; CROHNS-DISEASE; IMPAIRED AUTOPHAGY; GENE ATG16L1; ASSOCIATION; P62/SQSTM1; CULLIN3; CELLS; KEAP1 AB ATG16L1 is an essential component of the autophagasome. The T300A allele of ATG16L1 is associated with the increased susceptibility to Crohn disease. In this study, we identified a novel function of ATG16L1, which suppresses signaling of the pro-inflammatory cytokine IL-1 beta. Deletion of ATG16L1 in mouse embryonic fibroblasts significantly amplifies IL-1 beta signal transduction cascades. This amplification is due to elevated p62 levels in ATG16L1-deficient cells. We found that ATG16L1 regulates p62 levels via both autolysosomal and proteasomal pathways. For proteasomal degradation, we found that Cullin-3 (Cul-3) is a E3 ubiquitin ligase of p62 and that ATG16L1 is essential for neddylation of Cul-3, a step required for Cul-3 activation. Taken together our data indicate that loss-of-function of ATG16L1 results in a hyper-responsiveness to the IL-1 beta signaling because of the increased p62 level. C1 [Lee, Jongdae; Kim, Hye Ri; Quinley, Christine; Kim, Joanna; Gonzalez-Navajas, Jose; Raz, Eyal] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA. [Xavier, Ramnik] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Xavier, Ramnik] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. RP Lee, J (reprint author), 9500 Gilman Dr, La Jolla, CA 92093 USA. EM j142lee@ucsd.edu; eraz@ucsd.edu OI Gonzalez-Navajas, Jose Manuel/0000-0002-1591-939X FU National Institutes of Health [A1068685, A1095623, DK35108, DK080506]; CCFA FX This work was supported by National Institutes of Health Grants A1068685, A1095623, DK35108, and DK080506, and a grant from CCFA. NR 25 TC 37 Z9 38 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 3 PY 2012 VL 287 IS 6 BP 4033 EP 4040 DI 10.1074/jbc.M111.280065 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 894EX UT WOS:000300410900037 PM 22167182 ER PT J AU Dutchak, PA Katafuchi, T Bookout, AL Choi, JH Yu, RT Mangelsdorf, DJ Kliewer, SA AF Dutchak, Paul A. Katafuchi, Takeshi Bookout, Angie L. Choi, Jang Hyun Yu, Ruth T. Mangelsdorf, David J. Kliewer, Steven A. TI Fibroblast Growth Factor-21 Regulates PPAR gamma Activity and the Antidiabetic Actions of Thiazolidinediones SO CELL LA English DT Article ID ACTIVATED-RECEPTOR-GAMMA; INCREASES ENERGY-EXPENDITURE; INSULIN SENSITIVITY; BETA-KLOTHO; ADIPOCYTE DIFFERENTIATION; METABOLIC-ACTIVITY; 3T3 FIBROBLASTS; HEPATIC FGF21; C/EBP-ALPHA; EXPRESSION AB Fibroblast growth factor-21 (FGF21) is a circulating hepatokine that beneficially affects carbohydrate and lipid metabolism. Here, we report that FGF21 is also an inducible, fed-state autocrine factor in adipose tissue that functions in a feed-forward loop to regulate the activity of peroxisome proliferator-activated receptor gamma (PPAR gamma), a master transcriptional regulator of adipogenesis. FGF21 knockout (KO) mice display defects in PPARg signaling including decreased body fat and attenuation of PPAR gamma-dependent gene expression. Moreover, FGF21-KO mice are refractory to both the beneficial insulin-sensitizing effects and the detrimental weight gain and edema side effects of the PPAR gamma agonist rosiglitazone. This loss of function in FGF21-KO mice is coincident with a marked increase in the sumoylation of PPAR gamma, which reduces its transcriptional activity. Adding back FGF21 prevents sumoylation and restores PPAR gamma activity. Collectively, these results reveal FGF21 as a key mediator of the physiologic and pharmacologic actions of PPAR gamma. C1 [Katafuchi, Takeshi; Bookout, Angie L.; Mangelsdorf, David J.; Kliewer, Steven A.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA. [Dutchak, Paul A.; Kliewer, Steven A.] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA. [Bookout, Angie L.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Hypothalam Res, Dallas, TX 75390 USA. [Mangelsdorf, David J.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA. [Choi, Jang Hyun] Harvard Univ, Sch Med, Div Metab & Chron Dis, Dept Canc Biol,Dana Farber Canc Inst, Boston, MA 02115 USA. [Choi, Jang Hyun] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. [Yu, Ruth T.] Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA. RP Mangelsdorf, DJ (reprint author), Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA. EM davo.mango@utsouthwestern.edu; steven.kliewer@utsouthwestern.edu RI Choi, Jang Hyun/B-3055-2012 FU Howard Hughes Medical Institute; NIH [RL1GM084436, R56DK089600, U19DK62434, GM007062]; Robert A. Welch Foundation [I-1275, I-1558]; Leona M. and Harry B. Helmsley Charitable Trust FX We thank Drs. Regina Goetz and Moosa Mohammadi for recombinant FGF21 protein, Dr. James Richardson for histopathology expertise, and members of the D.J.M./S.A.K. laboratory for discussion. This research was supported by the Howard Hughes Medical Institute (to D.J.M.), NIH Grants RL1GM084436 and R56DK089600 (to D.J.M. and S.A.K.), U19DK62434 (to D.J.M.), and GM007062 (to A.L.B.), the Robert A. Welch Foundation (I-1275 to D.J.M. and I-1558 to S.A.K.), and the Leona M. and Harry B. Helmsley Charitable Trust (to R.T.Y.). NR 56 TC 213 Z9 222 U1 4 U2 45 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 J9 CELL JI Cell PD FEB 3 PY 2012 VL 148 IS 3 BP 556 EP 567 DI 10.1016/j.cell.2011.11.062 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 891NX UT WOS:000300225000022 PM 22304921 ER PT J AU He, AB Ma, Q Cao, JJ von Gise, A Zhou, PZ Xie, HF Zhang, B Hsing, M Christodoulou, DC Cahan, P Daley, GQ Kong, SW Orkin, SH Seidman, CE Seidman, JG Pu, WT AF He, Aibin Ma, Qing Cao, Jingjing von Gise, Alexander Zhou, Pingzhu Xie, Huafeng Zhang, Bing Hsing, Michael Christodoulou, Danos C. Cahan, Patrick Daley, George Q. Kong, Sek Won Orkin, Stuart H. Seidman, Christine E. Seidman, Jonathan G. Pu, William T. TI Polycomb Repressive Complex 2 Regulates Normal Development of the Mouse Heart SO CIRCULATION RESEARCH LA English DT Article DE heart development; epigenomics; transcriptional regulation ID GENE-EXPRESSION; STEM-CELLS; PROTEIN; DIFFERENTIATION; METHYLATION; DISEASE; EZH2; MORPHOGENESIS; SUPPRESSION; GENOME AB Rationale: Epigenetic marks are crucial for organogenesis, but their role in heart development is poorly understood. Polycomb repressive complex 2 (PRC2) trimethylates histone H3 at lysine 27, which establishes H3K27me3 repressive epigenetic marks that promote tissue-specific differentiation by silencing ectopic gene programs. Objective: We studied the function of PRC2 in murine heart development using a tissue-restricted conditional inactivation strategy. Methods and Results: Inactivation of the PRC2 subunit Ezh2 by Nkx2-5(Cre) (Ezh2(NK)) caused lethal congenital heart malformations, namely, compact myocardial hypoplasia, hypertrabeculation, and ventricular septal defect. Candidate and genome-wide RNA expression profiling and chromatin immunoprecipitation analyses of Ezh2(NK) heart identified genes directly repressed by EZH2. Among these were the potent cell cycle inhibitors Ink4a/b (inhibitors of cyclin-dependent kinase 4 A and B), the upregulation of which was associated with decreased cardiomyocyte proliferation in Ezh2(NK). EZH2-repressed genes were enriched for transcriptional regulators of noncardiomyocyte expression programs such as Pax6, Isl1, and Six1. EZH2 was also required for proper spatiotemporal regulation of cardiac gene expression, because Hcn4, Mlc2a, and Bmp10 were inappropriately upregulated in ventricular RNA. PRC2 was also required later in heart development, as indicated by cardiomyocyte-restricted TNT-Cre inactivation of the PRC2 subunit Eed. However, Ezh2 inactivation by TNT-Cre did not cause an overt phenotype, likely because of functional redundancy with Ezh1. Thus, early Ezh2 inactivation by Nk2-5(Cre) caused later disruption of cardiomyocyte gene expression and heart development. Conclusions: Our study reveals a previously undescribed role of EZH2 in regulating heart formation and shows that perturbation of the epigenetic landscape early in cardiogenesis has sustained disruptive effects at later developmental stages. (Circ Res. 2012;110:406-415.) C1 [He, Aibin; Ma, Qing; Cao, Jingjing; von Gise, Alexander; Zhou, Pingzhu; Zhang, Bing; Hsing, Michael; Kong, Sek Won; Pu, William T.] Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA. [Xie, Huafeng; Orkin, Stuart H.] Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Kong, Sek Won] Childrens Hosp, Dept Med, Div Hlth Sci & Technol, Childrens Hosp Informat Program,Harvard MIT, Boston, MA 02115 USA. [Christodoulou, Danos C.; Seidman, Christine E.; Seidman, Jonathan G.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Cahan, Patrick; Daley, George Q.; Orkin, Stuart H.; Pu, William T.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Daley, George Q.; Orkin, Stuart H.; Seidman, Christine E.] Howard Hughes Med Inst, Boston, MA 02115 USA. RP Pu, WT (reprint author), Enders 1254,300 Longwood Ave, Boston, MA 02115 USA. EM wpu@enders.tch.harvard.edu RI Zhou, Pingzhu/J-2809-2014; OI Cahan, Patrick/0000-0003-3652-2540 FU National Institutes of Health [U01HL098166, R01HL095712]; American Heart Association [10POST4290028] FX This work was supported by funding from the National Institutes of Health (W.T.P., U01HL098166 and R01HL095712) and the American Heart Association (A.H., postdoctoral fellowship 10POST4290028), and by charitable donations from Edward Marram, Karen Carpenter, and Gail Federici Smith. NR 41 TC 64 Z9 67 U1 1 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7330 EI 1524-4571 J9 CIRC RES JI Circ.Res. PD FEB 3 PY 2012 VL 110 IS 3 BP 406 EP U102 DI 10.1161/CIRCRESAHA.111.252205 PG 19 WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Hematology GA 891PT UT WOS:000300229800009 PM 22158708 ER PT J AU Rauch, PJ Chudnovskiy, A Robbins, CS Weber, GF Etzrodt, M Hilgendorf, I Tiglao, E Figueiredo, JL Iwamoto, Y Theurl, I Gorbatov, R Waring, MT Chicoine, AT Mouded, M Pittet, MJ Nahrendorf, M Weissleder, R Swirski, FK AF Rauch, Philipp J. Chudnovskiy, Aleksey Robbins, Clinton S. Weber, Georg F. Etzrodt, Martin Hilgendorf, Ingo Tiglao, Elizabeth Figueiredo, Jose-Luiz Iwamoto, Yoshiko Theurl, Igor Gorbatov, Rostic Waring, Michael T. Chicoine, Adam T. Mouded, Majd Pittet, Mikael J. Nahrendorf, Matthias Weissleder, Ralph Swirski, Filip K. TI Innate Response Activator B Cells Protect Against Microbial Sepsis SO SCIENCE LA English DT Article ID COLONY-STIMULATING FACTOR; MARGINAL-ZONE; SURVIVAL; MICE; AUTOIMMUNITY; LYMPHOCYTES; CLEARANCE; ENDOTOXIN; SUBSETS; MODELS AB Recognition and clearance of a bacterial infection are fundamental properties of innate immunity. Here, we describe an effector B cell population that protects against microbial sepsis. Innate response activator (IRA) B cells are phenotypically and functionally distinct, develop and diverge from B1a B cells, depend on pattern-recognition receptors, and produce granulocyte-macrophage colony-stimulating factor. Specific deletion of IRA B cell activity impairs bacterial clearance, elicits a cytokine storm, and precipitates septic shock. These observations enrich our understanding of innate immunity, position IRA B cells as gatekeepers of bacterial infection, and identify new treatment avenues for infectious diseases. C1 [Rauch, Philipp J.; Chudnovskiy, Aleksey; Robbins, Clinton S.; Weber, Georg F.; Etzrodt, Martin; Hilgendorf, Ingo; Tiglao, Elizabeth; Figueiredo, Jose-Luiz; Iwamoto, Yoshiko; Theurl, Igor; Gorbatov, Rostic; Pittet, Mikael J.; Nahrendorf, Matthias; Weissleder, Ralph; Swirski, Filip K.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Rauch, Philipp J.; Chudnovskiy, Aleksey; Robbins, Clinton S.; Weber, Georg F.; Etzrodt, Martin; Hilgendorf, Ingo; Tiglao, Elizabeth; Figueiredo, Jose-Luiz; Iwamoto, Yoshiko; Theurl, Igor; Gorbatov, Rostic; Waring, Michael T.; Chicoine, Adam T.; Pittet, Mikael J.; Nahrendorf, Matthias; Weissleder, Ralph; Swirski, Filip K.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA. [Theurl, Igor] Massachusetts Gen Hosp, Program Membrane Biol, Boston, MA 02114 USA. [Theurl, Igor] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA. [Waring, Michael T.; Chicoine, Adam T.] Massachusetts Gen Hosp, Ragon Inst Imaging Core, Boston, MA 02114 USA. [Mouded, Majd] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Sch Med, Pittsburgh, PA 15213 USA. [Hilgendorf, Ingo] Univ Hosp Freiburg, Dept Cardiol, D-79106 Freiburg, Germany. [Theurl, Igor] Univ Innsbruck Hosp, Dept Gen Internal Med Clin Immunol & Infect Dis, A-6020 Innsbruck, Austria. RP Robbins, CS (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. EM robbins.clinton@mgh.harvard.edu; fswirski@mgh.harvard.edu RI Etzrodt, Martin/P-3325-2015 OI Etzrodt, Martin/0000-0003-1928-3904 FU NIH [1R01HL095612, U01 HL080731, P50 CA86355, R24 CA69246, P01-A154904]; Boehringer Ingelheim Fonds; American Heart Association; MGH Executive Committee on Research (ECOR); German Research Foundation; Max Kade Foundation FX This work was supported in part by NIH grants 1R01HL095612 (to F. K. S.), as well as U01 HL080731, P50 CA86355, R24 CA69246, and P01-A154904 (to R. W.). P.J.R. was supported by the Boehringer Ingelheim Fonds; C. S. R. was supported by an American Heart Association postdoctoral fellowship and the MGH Executive Committee on Research (ECOR) Postdoctoral Award; G. F. W. and I. H. were supported by the German Research Foundation; and I. T. was supported by the Max Kade Foundation. We thank K. Rajewsky, D. Scadden, A. Luster, and K. Otipoby (Harvard Medical School) for helpful discussions and critical reading of the manuscript and M. Greene for secretarial assistance. The data reported in this paper are tabulated in the main paper and in the supporting online material. MIAME (minimum information about a microarray experiment)-compliant expression data have been deposited under the accession no. GSE32372. NR 27 TC 145 Z9 147 U1 4 U2 38 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD FEB 3 PY 2012 VL 335 IS 6068 BP 597 EP 601 DI 10.1126/science.1215173 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 885HI UT WOS:000299769200047 PM 22245738 ER PT J AU Jansen, AJG Josefsson, EC Rumjantseva, V Liu, QP Falet, H Bergmeier, W Cifuni, SM Sackstein, R von Andrian, UH Wagner, DD Hartwig, JH Hoffmeister, KM AF Jansen, A. J. Gerard Josefsson, Emma C. Rumjantseva, Viktoria Liu, Qiyong Peter Falet, Herve Bergmeier, Wolfgang Cifuni, Stephen M. Sackstein, Robert von Andrian, Ulrich H. Wagner, Denisa D. Hartwig, John H. Hoffmeister, Karin M. TI Desialylation accelerates platelet clearance after refrigeration and initiates GPIb alpha metalloproteinase-mediated cleavage in mice SO BLOOD LA English DT Article ID CHILLED BLOOD-PLATELETS; GLYCOPROTEIN-IB-ALPHA; GPVI DOWN-REGULATION; SIALIC-ACID; IN-VIVO; MULTIENZYME COMPLEX; HEMOSTATIC FUNCTION; IX-V; FAMILY; PHAGOCYTOSIS AB When refrigerated platelets are rewarmed, they secrete active sialidases, including the lysosomal sialidase Neu1, and express surface Neu3 that remove sialic acid from platelet von Willebrand factor receptor (VWFR), specifically the GPIb alpha subunit. The recovery and circulation of refrigerated platelets is greatly improved by storage in the presence of inhibitors of sialidases. Desialylated VWFR is also a target for metalloproteinases (MPs), because GPIb alpha and GPV are cleaved from the surface of refrigerated platelets. Receptor shedding is inhibited by the MP inhibitor GM6001 and does not occur in Adam17(Delta Zn/Delta Zn) platelets expressing inactive ADAM17. Critically, desialylation in the absence of MP-mediated receptor shedding is sufficient to cause the rapid clearance of platelets from circulation. Desialylation of platelet VWFR therefore triggers platelet clearance and primes GPIb alpha and GPV for MP-dependent cleavage. (Blood. 2012;119(5): 1263-1273) C1 [Jansen, A. J. Gerard; Josefsson, Emma C.; Rumjantseva, Viktoria; Liu, Qiyong Peter; Falet, Herve; Hartwig, John H.; Hoffmeister, Karin M.] Harvard Univ, Translat Med Div, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Liu, Qiyong Peter] Velico Med Inc, Beverly, MA USA. [Bergmeier, Wolfgang; Cifuni, Stephen M.; von Andrian, Ulrich H.; Wagner, Denisa D.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. [Cifuni, Stephen M.] Harvard Univ, Sch Med, Program Cellular & Mol Med, Childrens Hosp Boston, Boston, MA 02115 USA. [Bergmeier, Wolfgang; von Andrian, Ulrich H.; Wagner, Denisa D.] Harvard Univ, Sch Med, Div Immunol, Dept Microbiol & Immunobiol, Boston, MA 02115 USA. [Sackstein, Robert] Harvard Univ, Dept Dermatol, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. RP Hoffmeister, KM (reprint author), Harvard Univ, Translat Med Div, Brigham & Womens Hosp, Sch Med, 1 Blackfan Cir,Karp 6th Fl, Boston, MA 02115 USA. EM khoffmeister@rics.bwh.harvard.edu RI von Andrian, Ulrich/A-5775-2008 FU National Institutes of Health [PO1 HL056949, HL089224, PO1 HL107146, HL094596]; Pew Scholars Award; Stichting Vrieden van de Bloedtransfusie and Stichting De Drie Lichten; Gothenburg University FX This work was supported by the National Institutes of Health (grant PO1 HL056949, J.H.H. and K.M.H.; grants HL089224 and PO1 HL107146, K.M.H.; and grant HL094596, W.B.); The Pew Scholars Award (K.M.H.); Stichting Vrieden van de Bloedtransfusie and Stichting De Drie Lichten (A.J.G.J.); and Gothenburg University's Jubileumsfond Stipend (E.C.J.). NR 36 TC 46 Z9 50 U1 1 U2 7 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD FEB 2 PY 2012 VL 119 IS 5 BP 1263 EP 1273 DI 10.1182/blood-2011-05-355628 PG 11 WC Hematology SC Hematology GA 894AW UT WOS:000300400300027 PM 22101895 ER PT J AU Crasta, K Ganem, NJ Dagher, R Lantermann, AB Ivanova, EV Pan, YF Nezi, L Protopopov, A Chowdhury, D Pellman, D AF Crasta, Karen Ganem, Neil J. Dagher, Regina Lantermann, Alexandra B. Ivanova, Elena V. Pan, Yunfeng Nezi, Luigi Protopopov, Alexei Chowdhury, Dipanjan Pellman, David TI DNA breaks and chromosome pulverization from errors in mitosis SO NATURE LA English DT Article ID KINETOCHORE-MICROTUBULE ATTACHMENT; TUMOR-SUPPRESSOR; NUCLEAR-PORE; CANCER-CELLS; REPLICATION; INSTABILITY; ANEUPLOIDY; DAMAGE; TUMORIGENESIS; COMPLEX AB The involvement of whole-chromosome aneuploidy in tumorigenesis is the subject of debate, in large part because of the lack of insight into underlying mechanisms. Here we identify a mechanism by which errors in mitotic chromosome segregation generate DNA breaks via the formation of structures called micronuclei. Whole-chromosome-containing micronuclei form when mitotic errors produce lagging chromosomes. We tracked the fate of newly generated micronuclei and found that they undergo defective and asynchronous DNA replication, resulting in DNA damage and often extensive fragmentation of the chromosome in the micronucleus. Micronuclei can persist in cells over several generations but the chromosome in the micronucleus can also be distributed to daughter nuclei. Thus, chromosome segregation errors potentially lead to mutations and chromosome rearrangements that can integrate into the genome. Pulverization of chromosomes in micronuclei may also be one explanation for 'chromothripsis' in cancer and developmental disorders, where isolated chromosomes or chromosome arms undergo massive local DNA breakage and rearrangement. C1 [Crasta, Karen; Ganem, Neil J.; Dagher, Regina; Lantermann, Alexandra B.; Nezi, Luigi; Pellman, David] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Crasta, Karen; Ganem, Neil J.; Dagher, Regina; Pellman, David] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. [Crasta, Karen; Ganem, Neil J.; Dagher, Regina; Pellman, David] Howard Hughes Med Inst, Boston, MA 02115 USA. [Ivanova, Elena V.; Protopopov, Alexei] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA. [Pan, Yunfeng; Chowdhury, Dipanjan] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. RP Pellman, D (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave, Boston, MA 02115 USA. EM david_pellman@dfci.harvard.edu RI Crasta, Karen/F-8752-2015 FU Howard Hughes Medical Institute; NIH [GM083299, 1R01CA142698-01] FX We thank A. D'Andrea, M. E. McLaughlin, T. A. Rapoport, J. Walters and Pellman laboratory members for discussions and/or comments on the manuscript; L. Cameron for advice and help on microscopy; H. Li for irradiation of cells; M. Nitta and M. Hennessy for preliminary experiments; and V. Larionov, B. Stillman, J. Ellenberg, I. Mattaj, A. Miyawaki and T. Kuroda for reagents. D. P. was supported by the Howard Hughes Medical Institute and the NIH (GM083299); K. C. was a fellow of A*STAR Singapore; N.J.G. was a fellow of the Leukemia and Lymphoma Society; Y.P. and D. C. were funded by the NIH (1R01CA142698-01). NR 50 TC 316 Z9 321 U1 16 U2 47 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD FEB 2 PY 2012 VL 482 IS 7383 BP 53 EP U70 DI 10.1038/nature10802 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 884RN UT WOS:000299726000033 PM 22258507 ER PT J AU Ludvigsson, J Krisky, D Casas, R Battelino, T Castano, L Greening, J Kordonouri, O Otonkoski, T Pozzilli, P Robert, JJ Veeze, HJ Palmer, J AF Ludvigsson, Johnny Krisky, David Casas, Rosaura Battelino, Tadej Castano, Luis Greening, James Kordonouri, Olga Otonkoski, Timo Pozzilli, Paolo Robert, Jean-Jacques Veeze, Henk J. Palmer, Jerry TI GAD65 Antigen Therapy in Recently Diagnosed Type 1 Diabetes Mellitus SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID BETA-CELL FUNCTION; DOUBLE-BLIND TRIAL; PROTEIN PEPTIDE DIAPEP277; LONG-TERM COMPLICATIONS; RECENT-ONSET; INSULIN-SECRETION; C-PEPTIDE; KETOACIDOSIS; CHILDREN; RECOMMENDATIONS AB Background The 65-kD isoform of glutamic acid decarboxylase (GAD65) is a major autoantigen in type 1 diabetes. We hypothesized that alum-formulated GAD65 (GAD-alum) can preserve beta-cell function in patients with recent-onset type 1 diabetes. Methods We studied 334 patients, 10 to 20 years of age, with type 1 diabetes, fasting C-peptide levels of more than 0.3 ng per milliliter (0.1 nmol per liter), and detectable serum GAD65 autoantibodies. Within 3 months after diagnosis, patients were randomly assigned to receive one of three study treatments: four doses of GAD-alum, two doses of GAD-alum followed by two doses of placebo, or four doses of placebo. The primary outcome was the change in the stimulated serum C-peptide level (after a mixed-meal tolerance test) between the baseline visit and the 15-month visit. Secondary outcomes included the glycated hemoglobin level, mean daily insulin dose, rate of hypoglycemia, and fasting and maximum stimulated C-peptide levels. Results The stimulated C-peptide level declined to a similar degree in all study groups, and the primary outcome at 15 months did not differ significantly between the combined active-drug groups and the placebo group (P=0.10). The use of GAD-alum as compared with placebo did not affect the insulin dose, glycated hemoglobin level, or hypoglycemia rate. Adverse events were infrequent and mild in the three groups, with no significant differences. Conclusions Treatment with GAD-alum did not significantly reduce the loss of stimulated C peptide or improve clinical outcomes over a 15-month period. (Funded by Diamyd Medical and the Swedish Child Diabetes Foundation; ClinicalTrials.gov number, NCT00723411.) C1 [Ludvigsson, Johnny] Linkoping Univ, Dept Clin & Expt Med, Div Pediat, S-58185 Linkoping, Sweden. [Krisky, David] Diamyd Med, Pittsburgh, PA USA. [Battelino, Tadej] Univ Med Ctr Univ Childrens Hosp, Fac Med, Ljubljana, Slovenia. [Castano, Luis] Hosp Cruces Univ Basque Country, Baracaldo, Bizkaia, Spain. [Greening, James] Leicester Royal Infirm, Dept Paediat, Leicester, Leics, England. [Kordonouri, Olga] Kinderkrankenhaus Bult, Diabet Ctr Children & Adolescents, Hannover, Germany. [Otonkoski, Timo] Univ Helsinki, Childrens Hosp, Helsinki, Finland. [Otonkoski, Timo] Helsinki Univ Cent Hosp, Helsinki, Finland. [Pozzilli, Paolo] Univ Campus Biomed, Rome, Italy. [Robert, Jean-Jacques] Univ Paris 05, Hop Necker Enfants Malades, Paris, France. [Veeze, Henk J.] Stichting Diabeter, Rotterdam, Netherlands. [Palmer, Jerry] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [Palmer, Jerry] Univ Washington, Seattle, WA 98195 USA. RP Ludvigsson, J (reprint author), Linkoping Univ, Dept Clin & Expt Med, Div Pediat, S-58185 Linkoping, Sweden. EM johnny.ludvigsson@liu.se RI Rica, Itxaso /E-7645-2012; , Ivan/D-6804-2012 OI , Ivan/0000-0002-3108-058X FU Diamyd Medical; Swedish Child Diabetes Foundation (Barndiabetesfonden) FX Supported by Diamyd Medical and the Swedish Child Diabetes Foundation (Barndiabetesfonden). NR 36 TC 121 Z9 129 U1 4 U2 40 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 2 PY 2012 VL 366 IS 5 BP 433 EP 442 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 884QX UT WOS:000299724400008 PM 22296077 ER PT J AU John, S Chung, RT AF John, Savio Chung, Raymond T. TI Early Liver Transplantation for Severe Alcoholic Hepatitis SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [John, Savio; Chung, Raymond T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP John, S (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM sjohn5@partners.org NR 0 TC 1 Z9 1 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 2 PY 2012 VL 366 IS 5 BP 478 EP 478 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 884QX UT WOS:000299724400024 PM 22296090 ER PT J AU Lysy, PA Weir, GC Bonner-Weir, S AF Lysy, Philippe A. Weir, Gordon C. Bonner-Weir, Susan TI Concise Review: Pancreas Regeneration: Recent Advances and Perspectives SO STEM CELLS TRANSLATIONAL MEDICINE LA English DT Review DE Diabetes; Pancreas; Progenitor cells; Transplantation; Cellular therapy ID EMBRYONIC STEM-CELLS; GLUCAGON-LIKE PEPTIDE-1; EPITHELIAL-MESENCHYMAL TRANSITION; INSULIN-PRODUCING CELLS; ADULT-MOUSE PANCREAS; ISLET-LIKE CLUSTERS; DIABETIC NOD MICE; BETA-CELL; IN-VITRO; PORCINE ISLETS AB The replacement of functional pancreatic beta-cells is seen as an attractive potential therapy for diabetes, because diabetes results from an inadequate beta-cell mass. Inducing replication of the remaining beta-cells and new islet formation from progenitors within the pancreas (neogenesis) are the most direct ways to increase the beta-cell mass. Stimulation of both replication and neogenesis have been reported in rodents, but their clinical significance must still be shown. Because human islet transplantation is limited by the scarcity of donors and graft failure within a few years, efforts have recently concentrated on the use of stem cells to replace the deficient beta-cells. Currently, embryonic stem cells and induced pluripotent stem cells achieve high levels of beta-cell differentiation, but their clinical use is still hampered by ethical issues and/or the risk of developing tumors after transplantation. Pancreatic epithelial cells (duct, acinar, or alpha-cells) represent an appealing alternative to stem cells because they demonstrate beta-cell differentiation capacities. Yet translation of such capacity to human cells after significant in vitro expansion has yet to be achieved. Besides providing new beta-cells, cell therapy also has to address the question on how to protect the transplanted cells from destruction by the immune system via either allo- or autoimmunity. Encouraging developments have been made in encapsulation and immunomodulation techniques, but many challenges still remain. Herein, we discuss recent advances in the search for beta-cell replacement therapies, current strategies for circumventing the immune system, and mandatory steps for new techniques to be translated from bench to clinics. STEM CELLS TRANSLATIONAL MEDICINE 2012;1:150-159 C1 [Lysy, Philippe A.; Weir, Gordon C.; Bonner-Weir, Susan] Harvard Univ, Joslin Diabet Ctr, Sch Med, Harvard Stem Cell Inst, Boston, MA 02215 USA. RP Weir, GC (reprint author), Harvard Univ, Joslin Diabet Ctr, Sch Med, Harvard Stem Cell Inst, 1 Joslin Pl, Boston, MA 02215 USA. EM gordon.weir@joslin.harvard.edu OI Bonner-Weir, Susan/0000-0003-4682-0656 FU NIDDK NIH HHS [P30 DK036836] NR 150 TC 40 Z9 40 U1 1 U2 27 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 2157-6564 J9 STEM CELL TRANSL MED JI Stem Cells Transl. Med. PD FEB PY 2012 VL 1 IS 2 BP 150 EP 159 DI 10.5966/sctm.2011-0025 PG 10 WC Cell & Tissue Engineering SC Cell Biology GA 057NX UT WOS:000312571400013 PM 23197762 ER PT J AU Tasan, M Drabkin, HJ Beaver, JE Chua, HN Dunham, J Tian, WD Blake, JA Roth, FP AF Tasan, Murat Drabkin, Harold J. Beaver, John E. Chua, Hon Nian Dunham, Julie Tian, Weidong Blake, Judith A. Roth, Frederick P. TI A Resource of Quantitative Functional Annotation for Homo sapiens Genes SO G3-GENES GENOMES GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; FUNCTION PREDICTION; SACCHAROMYCES-CEREVISIAE; DISEASE GENES; MUS-MUSCULUS; NETWORK; PROTEIN; MODEL; YEAST; SUSCEPTIBILITY AB The body of human genomic and proteomic evidence continues to grow at ever-increasing rates, while annotation efforts struggle to keep pace. A surprisingly small fraction of human genes have clear, documented associations with specific functions, and new functions continue to be found for characterized genes. Here we assembled an integrated collection of diverse genomic and proteomic data for 21,341 human genes and make quantitative associations of each to 4333 Gene Ontology terms. We combined guilt-by-profiling and guilt-by-association approaches to exploit features unique to the data types. Performance was evaluated by cross-validation, prospective validation, and by manual evaluation with the biological literature. Functional-linkage networks were also constructed, and their utility was demonstrated by identifying candidate genes related to a glioma FLN using a seed network from genome-wide association studies. Our annotations are presented-alongside existing validated annotations-in a publicly accessible and searchable web interface. C1 [Tasan, Murat; Chua, Hon Nian; Dunham, Julie; Roth, Frederick P.] Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON M5S 3E1, Canada. [Tasan, Murat; Beaver, John E.; Chua, Hon Nian; Roth, Frederick P.] Harvard Univ, Dept Biol Chem & Mol Pharmacol, Sch Med, Boston, MA 02115 USA. [Drabkin, Harold J.; Blake, Judith A.] Jackson Lab, Mouse Genome Informat, Bar Harbor, ME 04609 USA. [Tian, Weidong] Fudan Univ, Sch Life Sci, Inst Biostat, Shanghai 200433, Peoples R China. [Roth, Frederick P.] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA. [Roth, Frederick P.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. RP Roth, FP (reprint author), Univ Toronto, Donnelly Ctr, 160 Coll St,Room 1010, Toronto, ON M5S 3E1, Canada. EM fritz.roth@utoronto.ca RI Roth, Frederick/H-6308-2011; OI Roth, Frederick/0000-0002-6628-649X FU U.S. National Institutes of Health (NIH) [HG003224, HG004233, HG001715, HL107440, MH087394]; NIH [DK071507, HG002273, F32 HG004098]; A*STAR Foundation; Canada Excellence Research Chairs Program; Canadian Institute for Advanced Research FX We thank Research Computing groups at Harvard Medical School and Mt. Sinai Hospital for computational resources and support. This work was supported by U.S. National Institutes of Health (NIH) grants HG003224, HG004233, HG001715, HL107440, and MH087394 (supporting F. P. R.), by NIH DK071507 (supporting W. T.), by NIH HG002273 (supporting J.A.B. and H.J.D.), by NIH F32 HG004098 (supporting M. T.), by the A*STAR Foundation (supporting H.N.C.), and by the Canada Excellence Research Chairs Program. F. P. R. also acknowledges support by a Fellowship from the Canadian Institute for Advanced Research. NR 49 TC 4 Z9 4 U1 0 U2 5 PU GENETICS SOC AM PI BETHESDA PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA SN 2160-1836 J9 G3-GENES GENOM GENET JI G3-Genes Genomes Genet. PD FEB 1 PY 2012 VL 2 IS 2 BP 223 EP 233 DI 10.1534/g3.111.000828 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA 055JE UT WOS:000312411000010 PM 22384401 ER PT J AU Donington, JS Blasberg, JD AF Donington, Jessica S. Blasberg, Justin D. TI Management of Early Stage Non-Small Cell Lung Cancer in High-Risk Patients SO THORACIC SURGERY CLINICS LA English DT Article DE Non-small cell lung cancer; Sublobar resection; Stereotactic body radiotherapy; Radiofrequency ablation ID BODY RADIATION-THERAPY; PERCUTANEOUS RADIOFREQUENCY ABLATION; PROSPECTIVE PHASE-II; SUBLOBAR RESECTION; WEDGE RESECTION; SEGMENTAL RESECTION; PULMONARY-FUNCTION; STEREOTACTIC RADIOTHERAPY; ANATOMIC SEGMENTECTOMY; CONFORMAL RADIOTHERAPY AB The preferred treatment of stage I non small cell lung cancer (NSCLC) is anatomic resection with systematic mediastinal lymph node evaluation. However, 20% of patients with operable lung cancer are not candidates for this type of resection. Recent advancements in radiology-guided technologies have expanded the treatment options for high-risk patients with early-stage NSCLC. There has simultaneously been resurgence in interest and refinement of indications and techniques for sublobar resection in this population. While these treatments appear to have decreased pen-procedural morbidity and mortality, their oncologic efficacy compared to that of lobectomy remains to be determined. C1 [Donington, Jessica S.] NYU, Sch Med, Dept Cardiothorac Surg, New York, NY 10016 USA. [Blasberg, Justin D.] Massachusetts Gen Hosp, Dept Cardiothorac Surg, Boston, MA 02114 USA. RP Donington, JS (reprint author), NYU, Sch Med, Dept Cardiothorac Surg, 530 1st Ave,Suite 9V, New York, NY 10016 USA. EM jessica.donington@nyumc.org NR 83 TC 5 Z9 5 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1547-4127 J9 THORAC SURG CLIN JI Thorac. Surg. Clin. PD FEB PY 2012 VL 22 IS 1 BP 55 EP + DI 10.1016/j.thorsurg.2011.08.018 PG 12 WC Respiratory System; Surgery SC Respiratory System; Surgery GA 047TE UT WOS:000311863600008 PM 22108689 ER PT J AU Walling, A Weeks, J Kahn, K Tisnado, D Keating, N Dy, S Hopkins, J Arora, N Pantoja, P Malin, J AF Walling, Anne Weeks, Jane Kahn, Katherine Tisnado, Diana Keating, Nancy Dy, Sydney Hopkins, Johns Arora, Neeraj Pantoja, Philip Malin, Jennifer TI Unmet Need for Symptom Management in a Newly Diagnosed Population of Lung and Colorectal Cancer Patients SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Walling, Anne] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Weeks, Jane] Dana Farber Canc Inst, Boston, MA 02115 USA. [Tisnado, Diana] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Keating, Nancy] Harvard Univ, Sch Med, Boston, MA USA. [Dy, Sydney; Hopkins, Johns; Arora, Neeraj] NCI, Bethesda, MD 20892 USA. [Pantoja, Philip] US Dept Vet Affairs, North Hills, CA USA. [Malin, Jennifer] VA Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 377 EP 378 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900091 ER PT J AU Beaucaire, M Zabicki, K Yao, K Czechura, T Martz, B Goldschmidt, RA Barrera, E Winchester, DP Winchester, DJ AF Beaucaire, M. Zabicki, K. Yao, K. Czechura, T. Martz, B. Goldschmidt, R. A. Barrera, E., Jr. Winchester, D. P. Winchester, D. J. TI Outcome of Lobular Neoplasia with Surgical Excision or Observation SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Beaucaire, M.; Yao, K.; Czechura, T.; Martz, B.; Goldschmidt, R. A.; Barrera, E., Jr.; Winchester, D. P.; Winchester, D. J.] NorthShore Univ HealthSyst, Evanston, IL USA. [Zabicki, K.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S63 EP S63 PG 1 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700168 ER PT J AU Buckley, JM Brachtel, EF Yagi, Y Fernandez, LJ Tang, R Aftreth, OP Michaelson, JS Coopey, SB Specht, MC Gadd, MA Hughes, KS Koerner, FC Smith, BL AF Buckley, J. M. Brachtel, E. F. Yagi, Y. Fernandez, L. J. Tang, R. Aftreth, O. P. Michaelson, J. S. Coopey, S. B. Specht, M. C. Gadd, M. A. Hughes, K. S. Koerner, F. C. Smith, B. L. TI Three-dimensional Geometry of Breast Tumors: Implications for Lumpectomy Technique SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Buckley, J. M.; Brachtel, E. F.; Yagi, Y.; Fernandez, L. J.; Tang, R.; Aftreth, O. P.; Michaelson, J. S.; Coopey, S. B.; Specht, M. C.; Gadd, M. A.; Hughes, K. S.; Koerner, F. C.; Smith, B. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S85 EP S85 PG 1 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700236 ER PT J AU Chung, H Fragomeni, RS Cusack, J AF Chung, H. Fragomeni, R. Salas Cusack, J. TI Inhibition of Nuclear Proteins Export using a Novel CRM1 Inhibitor Increases the Apoptotic Response to SN38 in Colon Cancer SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Chung, H.; Fragomeni, R. Salas; Cusack, J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Surg Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S102 EP S102 PG 1 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700289 ER PT J AU Colombo, C Ronellenfitsch, U Zhong, Y Rutkowski, P Raut, CP Hohenberger, P Gronchi, A AF Colombo, C. Ronellenfitsch, U. Zhong, Y. Rutkowski, P. Raut, C. P. Hohenberger, P. Gronchi, A. TI Clinical, Pathological and Surgical Characteristics of Duodenal Gastrointestinal Stromal Tumor and Their Influence on Survival: A Multi-centre Study SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Colombo, C.; Gronchi, A.] Natl Tumor Inst, Milan, Italy. [Ronellenfitsch, U.; Hohenberger, P.] Univ Med Ctr Mannheim, Mannheim, Germany. [Zhong, Y.; Raut, C. P.] Dana Farber Harvard Canc Ctr, Boston, MA USA. [Rutkowski, P.] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland. [Rutkowski, P.] Inst Oncol, Warsaw, Poland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S28 EP S29 PG 2 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700067 ER PT J AU Girgis, M Lin, WY Hou, S Rochefort, M Shen, C Tomlinson, JS AF Girgis, M. Lin, W. Y. Hou, S. Rochefort, M. Shen, C. Tomlinson, J. S. TI MicroPET Evaluation of In Vivo Biorthogonal Click Chemistry Reaction between a Radiolabeled Tetrazine Probe and TCO-modified Nanoparticles SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Girgis, M.; Tomlinson, J. S.] Univ Calif Los Angeles, Div Surg Oncol, Los Angeles, CA USA. [Rochefort, M.] VA Greater Los Angeles, Dept Surg, Los Angeles, CA USA. [Lin, W. Y.; Hou, S.; Shen, C.] Univ Calif Los Angeles, Crump Mol Imaging Inst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S18 EP S19 PG 2 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700040 ER PT J AU Gold, JS Al Natour, RH Saund, MS Yoon, CH Sharma, AM Huang, Q Boosalis, VA Whang, EE AF Gold, J. S. Al Natour, R. H. Saund, M. S. Yoon, C. H. Sharma, A. M. Huang, Q. Boosalis, V. A. Whang, E. E. TI Population-based Outcome of Stages IA-IIA Resected Gastric Adenocarcinoma: Who Should Get Adjuvant Treatment? SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Gold, J. S.; Al Natour, R. H.; Sharma, A. M.; Huang, Q.; Boosalis, V. A.; Whang, E. E.] VA Boston Healthcare Syst, W Roxbury, MA USA. [Saund, M. S.; Yoon, C. H.] Brigham & Womens Hosp, Boston, MA 02115 USA. RI Gold, Jason/O-5112-2014 OI Gold, Jason/0000-0002-2925-4755 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S9 EP S9 PG 1 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700012 ER PT J AU Greenup, RA Bardia, A Buckley, J Camp, MS Gadd, MA Hughes, K Coopey, SB Niemierko, A Isakoff, SJ Taghian, AG Specht, MC Smith, BL AF Greenup, R. A. Bardia, A. Buckley, J. Camp, M. S. Gadd, M. A. Hughes, K. Coopey, S. B. Niemierko, A. Isakoff, S. J. Taghian, A. G. Specht, M. C. Smith, B. L. TI Clinical Utility and Effectiveness of Neoadjuvant Chemotherapy for Young Women with Breast Cancer SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Greenup, R. A.; Bardia, A.; Buckley, J.; Camp, M. S.; Gadd, M. A.; Hughes, K.; Coopey, S. B.; Niemierko, A.; Isakoff, S. J.; Taghian, A. G.; Specht, M. C.; Smith, B. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S58 EP S58 PG 1 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700151 ER PT J AU Hatzaras, I Sotiropoulos, G Schulick, R Alexandrescu, S Pulitano, C Clary, B Zhu, A Paul, A Popescu, I Marques, H Barroso, E Aldrighetti, L Choti, M Turley, R Ferrone, C Bauer, T Walters, D Gamblin, T Nguyen, K Hubert, C Gigot, J Meyer, S Mentha, G Pawlik, TM AF Hatzaras, I. Sotiropoulos, G. Schulick, R. Alexandrescu, S. Pulitano, C. Clary, B. Zhu, A. Paul, A. Popescu, I. Marques, H. Barroso, E. Aldrighetti, L. Choti, M. Turley, R. Ferrone, C. Bauer, T. Walters, D. Gamblin, T. Nguyen, K. Hubert, C. Gigot, J. Meyer, S. Mentha, G. Pawlik, T. M. TI Patterns of Recurrence after Resection of Intrahepatic Cholangiocarcinoma: Results from 449 Patients SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Hatzaras, I.; Schulick, R.; Choti, M.; Pawlik, T. M.] Johns Hopkins Univ, Baltimore, MD USA. [Sotiropoulos, G.; Paul, A.] Univ Hosp Essen, Essen, Germany. [Alexandrescu, S.; Popescu, I.] Inst Digest Dis & Liver Transplantat Fundeni, Bucharest, Romania. [Marques, H.; Barroso, E.] Curry Cabral Hosp, Lisbon, Portugal. [Pulitano, C.; Aldrighetti, L.] Univ Milan, Osped San Raffaele, I-20127 Milan, Italy. [Clary, B.; Turley, R.] Duke Med Ctr, Durham, NC USA. [Zhu, A.; Ferrone, C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bauer, T.; Walters, D.] Univ Virginia, Charlottesville, VA USA. [Gamblin, T.; Nguyen, K.] Univ Pittsburgh, Pittsburgh, PA USA. [Hubert, C.; Gigot, J.] Clin Univ St Luc, B-1200 Brussels, Belgium. [Meyer, S.; Mentha, G.] Hop Univ Geneve, Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 6 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S33 EP S34 PG 2 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700082 ER PT J AU Hong, NJL Nielsen, GP Hornicek, FJ Raskin, KA Springfield, D Yoon, SS Rosenberg, AE Chen, YL DeLaney, TF Szymonifka, J Mullen, JT AF Hong, N. J. Look Nielsen, G. P. Hornicek, F. J. Raskin, K. A. Springfield, D. Yoon, S. S. Rosenberg, A. E. Chen, Y. L. DeLaney, T. F. Szymonifka, J. Mullen, J. T. TI Prognostic Factors and Outcomes of Patients with Myxofibrosarcoma SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Hong, N. J. Look; Nielsen, G. P.; Hornicek, F. J.; Raskin, K. A.; Springfield, D.; Yoon, S. S.; Rosenberg, A. E.; Chen, Y. L.; DeLaney, T. F.; Szymonifka, J.; Mullen, J. T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S146 EP S146 PG 1 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700435 ER PT J AU Merkow, RP Kmiecik, TE Bentrem, DJ Chow, WB Cohen, ME Hall, BL Ko, CY Bilimoria, KY AF Merkow, R. P. Kmiecik, T. E. Bentrem, D. J. Chow, W. B. Cohen, M. E. Hall, B. L. Ko, C. Y. Bilimoria, K. Y. TI Do Cancer-specific Variables Improve Risk-adjusted Hospital Quality Comparisons? SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Merkow, R. P.; Kmiecik, T. E.; Bentrem, D. J.; Bilimoria, K. Y.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Chow, W. B.; Ko, C. Y.] Univ Calif Los Angeles, Los Angeles, CA USA. [Chow, W. B.; Ko, C. Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Cohen, M. E.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Hall, B. L.] Washington Univ, St Louis, MO USA. [Hall, B. L.] Barnes Jewish Hosp, St Louis, MO 63110 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S6 EP S6 PG 1 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700002 ER PT J AU Meyers, MO Shi, Q Resnick, MB Lyle, S Goldar-Najafi, A Clancy, T Gill, S Haince, J Fradet, Y Sargent, DJ AF Meyers, M. O. Shi, Q. Resnick, M. B. Lyle, S. Goldar-Najafi, A. Clancy, T. Gill, S. Haince, J. Fradet, Y. Sargent, D. J. TI Evaluation of the Prognostic Value of Guanylyl Cyclase C (GCC) Lymph Node (LN) Classification in Patients with Stage II Colon Cancer: A Pooled Analysis SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Meyers, M. O.] Univ N Carolina, Sch Med, Div Surg Oncol, Chapel Hill, NC USA. [Shi, Q.; Sargent, D. J.] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA. [Gill, S.] Univ British Columbia, BC Canc Agcy, Div Med Oncol, Vancouver, BC V5Z 1M9, Canada. [Resnick, M. B.] Brown Univ, Alpert Medial Sch, Providence, RI 02912 USA. [Resnick, M. B.] Rhode Isl Hosp, Providence, RI USA. [Goldar-Najafi, A.] Lahey Clin Fdn, Gordon Canc Ctr, Dept Pathol, Burlington, MA USA. [Clancy, T.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Clancy, T.] Dana Farber Canc Inst, Div Surg Oncol, Boston, MA 02115 USA. [Haince, J.; Fradet, Y.] DiagnoCure Inc, Quebec City, PQ, Canada. [Lyle, S.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S97 EP S98 PG 2 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700275 ER PT J AU Rochefort, MM Girgis, MD Knowles, S Bergara, F Olafsen, T Tomlinson, JS AF Rochefort, M. M. Girgis, M. D. Knowles, S. Bergara, F. Olafsen, T. Tomlinson, J. S. TI An Engineered Chimeric, Fc Mutated, Anti-CA19-9 scFv-Fc for Imaging Pancreas Cancer SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Rochefort, M. M.; Girgis, M. D.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Knowles, S.; Bergara, F.; Olafsen, T.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Crump Insitute Mol Imaging, Los Angeles, CA 90024 USA. [Tomlinson, J. S.] Vet Affairs Greater Los Angeles, Dept Surg, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S44 EP S44 PG 1 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700111 ER PT J AU Santamaria-Barria, JA Boland, GM Yeap, BY Nardi, V Dias-Santagata, D Cusack, JC AF Santamaria-Barria, J. A. Boland, G. M. Yeap, B. Y. Nardi, V. Dias-Santagata, D. Cusack, J. C., Jr. TI Merkel Cell Carcinoma: 30-Year Experience from a Single Institution SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Santamaria-Barria, J. A.; Boland, G. M.; Cusack, J. C., Jr.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp,Div Surg Oncol, Boston, MA 02115 USA. [Yeap, B. Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA. [Nardi, V.; Dias-Santagata, D.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S25 EP S26 PG 2 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700058 ER PT J AU Specht, M Miller, C Horick, N Skolny, M O'Toole, J Smith, BL Taghian, A AF Specht, M. Miller, C. Horick, N. Skolny, M. O'Toole, J. Smith, B. L. Taghian, A. TI Does Neoadjuvant Chemotherapy Reduce the Risk of Lymphedema in Patients with Node Positive Breast Cancer? SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Specht, M.; Miller, C.; Horick, N.; Skolny, M.; O'Toole, J.; Smith, B. L.; Taghian, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S91 EP S91 PG 1 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700252 ER PT J AU Valero, MG Camp, MS Opara, N Benabou, K Cutone, L Dominici, L Golshan, M AF Valero, M. G. Camp, M. S. Opara, N. Benabou, K. Cutone, L. Dominici, L. Golshan, M. TI Intraoperative Digital Specimen Mammography Decreases Operative Time SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Valero, M. G.; Camp, M. S.; Dominici, L.; Golshan, M.] MGH Brigham, Breast Surg, Boston, MA USA. [Opara, N.; Benabou, K.; Cutone, L.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S71 EP S72 PG 2 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700195 ER PT J AU Yeo, H Patil, S Paty, P Guillem, J Weiser, M Nash, G Schrag, D Temple, L AF Yeo, H. Patil, S. Paty, P. Guillem, J. Weiser, M. Nash, G. Schrag, D. Temple, L. TI Understanding Bowel Dysfunction after Sphincter-preserving Surgery: Results from a Prospective Study SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Yeo, H.; Patil, S.; Paty, P.; Guillem, J.; Weiser, M.; Nash, G.; Temple, L.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Schrag, D.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S22 EP S23 PG 2 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700050 ER PT J AU Yuan, CC Matthews, AGW Jin, Y Chen, CF Chapman, BA Ohsumi, TK Glass, KC Kutateladze, TG Borowsky, ML Struhl, K Oettinger, MA AF Yuan, Chih-Chi Matthews, Adam G. W. Jin, Yi Chen, Chang Feng Chapman, Brad A. Ohsumi, Toshiro K. Glass, Karen C. Kutateladze, Tatiana G. Borowsky, Mark L. Struhl, Kevin Oettinger, Marjorie A. TI Histone H3R2 Symmetric Dimethylation and Histone H3K4 Trimethylation Are Tightly Correlated in Eukaryotic Genomes SO CELL REPORTS LA English DT Article ID V(D)J RECOMBINATION; CHROMATIN IMMUNOPRECIPITATION; PRE-B; METHYLATION; LYSINE-4; H2B; PHOSPHORYLATION; UBIQUITINATION; ACETYLATION; RAG2 AB The preferential in vitro interaction of the PHD finger of RAG2, a subunit of the V(D)J recombinase, with histone H3 tails simultaneously trimethylated at lysine 4 and symmetrically dimethylated at arginine 2 (H3R2me2sK4me3) predicted the existence of the previously unknown histone modification H3R2me2s. Here, we report the in vivo identification of H3R2me2s. Consistent with the binding specificity of the RAG2 PHD finger, high levels of H3R2me2sK4me3 are found at antigen receptor gene segments ready for rearrangement. However, this double modification is muchmoregeneral; it is conserved throughout eukaryotic evolution. In mouse, H3R2me2s is tightly correlated with H3K4me3 at active promoters throughout the genome. Mutational analysis in S. cerevisiae reveals that deposition of H3R2me2s requires the same Set1 complex that deposits H3K4me3. Our work suggests that H3R2me2sK4me3, not simply H3K4me3 alone, is the mark of active promoters and that factors that recognize H3K4me3 will have their binding modulated by their preference for H3R2me2s. C1 [Yuan, Chih-Chi; Matthews, Adam G. W.; Chen, Chang Feng; Chapman, Brad A.; Ohsumi, Toshiro K.; Borowsky, Mark L.; Oettinger, Marjorie A.] Harvard Univ, Sch Med, Dept Mol Biol, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Yuan, Chih-Chi; Matthews, Adam G. W.; Chen, Chang Feng; Chapman, Brad A.; Ohsumi, Toshiro K.; Borowsky, Mark L.; Oettinger, Marjorie A.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA. [Jin, Yi; Struhl, Kevin] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Glass, Karen C.; Kutateladze, Tatiana G.] Univ Colorado Denver, Dept Pharmacol, Aurora, CO 80045 USA. RP Oettinger, MA (reprint author), Harvard Univ, Sch Med, Dept Mol Biol, Massachusetts Gen Hosp, Boston, MA 02114 USA. EM oettinger@frodo.mgh.harvard.edu RI Jin, Yi/I-7234-2012; OI Chapman, Brad/0000-0002-3026-1856; Glass, Karen/0000-0002-2761-733X FU National Institutes of Health (NIH) [GM048026, DK082711, AI083510, CA113472, GM30186]; Damon Runyon Cancer Research Foundation [DRG-1994-08]; NIH National Research Service Award Postdoctoral Fellowship FX We would like to thank Yu-Hui Chen for assistance with statistical analysis, Sandhya Pulivarthy for assistance with shRNA experiments, Mark Parthun and Fred Winston for mutant yeast strains, Zarmik Moqtaderi for assisting in the generation of yeast nuclear extracts, Jose Antao for Drosophila S2 cells, and Mike Blower for Xenopus heart tissue. This work was supported by National Institutes of Health (NIH) grants GM048026 (M.A.O.), DK082711 (M.A.O.), AI083510 (M.A.O.), CA113472 (T. G. K.), and GM30186 (K. S.). A. G. W. M. was a Damon Runyon Fellow supported by the Damon Runyon Cancer Research Foundation (DRG-1994-08). K. C. G. was supported by an NIH National Research Service Award Postdoctoral Fellowship. NR 31 TC 31 Z9 32 U1 0 U2 4 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2211-1247 J9 CELL REPORTS JI Cell Reports PD FEB PY 2012 VL 1 IS 2 BP 83 EP 90 DI 10.1016/j.celrep.2011.12.008 PG 8 WC Cell Biology SC Cell Biology GA 019AV UT WOS:000309710200001 PM 22720264 ER PT J AU Kaab, S Crawford, DC Sinner, MF Behr, ER Kannankeril, PJ Wilde, AAM Bezzina, CR Schulze-Bahr, E Guicheney, P Bishopric, NH Myerburg, RJ Schott, JJ Pfeufer, A Beckmann, BM Martens, E Zhang, TF Stallmeyer, B Zumhagen, S Denjoy, I Bardai, A Van Gelder, IC Jamshidi, Y Dalageorgou, C Marshall, V Jeffery, S Shakir, S Camm, AJ Steinbeck, G Perz, S Lichtner, P Meitinger, T Peters, A Wichmann, HE Ingram, C Bradford, Y Carter, S Norris, K Ritchie, MD George, AL Roden, DM AF Kaeaeb, Stefan Crawford, Dana C. Sinner, Moritz F. Behr, Elijah R. Kannankeril, Prince J. Wilde, Arthur A. M. Bezzina, Connie R. Schulze-Bahr, Eric Guicheney, Pascale Bishopric, Nanette H. Myerburg, Robert J. Schott, Jean-Jacques Pfeufer, Arne Beckmann, Britt-Maria Martens, Eimo Zhang, Taifang Stallmeyer, Birgit Zumhagen, Sven Denjoy, Isabelle Bardai, Abdennasser Van Gelder, Isabelle C. Jamshidi, Yalda Dalageorgou, Chrysoula Marshall, Vanessa Jeffery, Steve Shakir, Saad Camm, A. John Steinbeck, Gerhard Perz, Siegfried Lichtner, Peter Meitinger, Thomas Peters, Annette Wichmann, H. -Erich Ingram, Christiana Bradford, Yuki Carter, Shannon Norris, Kris Ritchie, Marylyn D. George, Alfred L., Jr. Roden, Dan M. TI A Large Candidate Gene Survey Identifies the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE candidate genes; death, sudden; SNP; torsade de pointes; adverse drug events ID LONG-QT SYNDROME; REDUCED REPOLARIZATION RESERVE; MULTILOCUS GENOTYPE DATA; INTERVAL DURATION; CARDIOVASCULAR DRUGS; COMMON VARIANTS; HUMAN GENOME; I-KS; POPULATION; PROLONGATION AB Background-Drug-induced long-QT syndrome (diLQTS) is an adverse drug effect that has an important impact on drug use, development, and regulation. We tested the hypothesis that common variants in key genes controlling cardiac electric properties modify the risk of diLQTS. Methods and Results-In a case-control setting, we included 176 patients of European descent from North America and Europe with diLQTS, defined as documented torsades de pointes during treatment with a QT-prolonging drug. Control samples were obtained from 207 patients of European ancestry who displayed <50 ms QT lengthening during initiation of therapy with a QT-prolonging drug and 837 control subjects from the population-based KORA study. Subjects were successfully genotyped at 1424 single-nucleotide polymorphisms (SNPs) in 18 candidate genes including 1386 SNPs tagging common haplotype blocks and 38 nonsynonymous ion channel gene SNPs. For validation, we used a set of cases (n=57) and population-based control subjects of European descent. The SNP KCNE1 D85N (rs1805128), known to modulate an important potassium current in the heart, predicted diLQTS with an odds ratio of 9.0 (95% confidence interval, 3.5-22.9). The variant allele was present in 8.6% of cases, 2.9% of drug-exposed control subjects, and 1.8% of population control subjects. In the validation cohort, the variant allele was present in 3.5% of cases and in 1.4% of control subjects. Conclusions-This high-density candidate SNP approach identified a key potassium channel susceptibility allele that may be associated with the rare adverse drug reaction torsades de pointes. (Circ Cardiovasc Genet. 2012;5:91-99.) C1 [Kaeaeb, Stefan; Sinner, Moritz F.; Beckmann, Britt-Maria; Martens, Eimo; Steinbeck, Gerhard] Univ Munich, Dept Med 1, Univ Hosp Munich, D-81366 Munich, Germany. [Kaeaeb, Stefan; Meitinger, Thomas; Peters, Annette] Munich Heart Alliance, Munich, Germany. [Crawford, Dana C.; Ingram, Christiana; Carter, Shannon; Norris, Kris] Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37212 USA. [Crawford, Dana C.; Bradford, Yuki] Vanderbilt Univ, Sch Med, Ctr Human Genet Res, Nashville, TN 37212 USA. [Kannankeril, Prince J.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA. [Sinner, Moritz F.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Behr, Elijah R.; Dalageorgou, Chrysoula; Jeffery, Steve; Camm, A. John] St Georgess Univ London, London, England. [Wilde, Arthur A. M.; Bezzina, Connie R.; Bardai, Abdennasser] Univ Amsterdam, Acad Med Ctr, Dept Clin & Expt Cardiol, Heart Failure Res Ctr, NL-1105 AZ Amsterdam, Netherlands. [Schulze-Bahr, Eric; Stallmeyer, Birgit; Zumhagen, Sven] Univ Hosp Munster, Inst Genet Heart Dis, Munster, Germany. [Schulze-Bahr, Eric; Stallmeyer, Birgit; Zumhagen, Sven] Univ Hosp Munster, Dept Cardiol & Angiol, Munster, Germany. [Guicheney, Pascale; Denjoy, Isabelle] Univ Paris 06, INSERM, UMRS 956, Paris, France. [Bishopric, Nanette H.; Myerburg, Robert J.] Univ Miami, Miller Sch Med, Dept Med, Div Cardiol, Miami, FL 33136 USA. [Bishopric, Nanette H.] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA. [Bishopric, Nanette H.] Univ Miami, Miller Sch Med, Hussmann Inst Human Genom, Miami, FL 33136 USA. [Myerburg, Robert J.] Univ Miami, Miller Sch Med, Dept Physiol, Miami, FL 33136 USA. [Schott, Jean-Jacques] INSERM, UMR915, Inst Thorax, Nantes, France. [Schott, Jean-Jacques] Univ Nantes, CHU Nantes, CNRS, ERL3147, Nantes, France. [Lichtner, Peter; Meitinger, Thomas; Peters, Annette] Helmholtz Zentrum Munchen, Inst Human Genet, Neuherberg, Germany. [Peters, Annette] Inst Med Genet, EURAC Res, Bolzano, Italy. [Meitinger, Thomas; Peters, Annette] Tech Univ Munich, Inst Human Genet, Munich, Germany. [Denjoy, Isabelle] Lariboisiere Hosp, AP HP, Ctr Reference Malad Cardiaques Hereditaires, Paris, France. [Van Gelder, Isabelle C.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9713 AV Groningen, Netherlands. [Jamshidi, Yalda] St Georges Univ London, Human Genet Res Ctr, London, England. [Marshall, Vanessa; Shakir, Saad] Drug Safety Res Unit, Southampton, Hants, England. [Perz, Siegfried] Helmholtz Zentrum Munchen, Inst Biol & Med Imaging, Neuherberg, Germany. [Wichmann, H. -Erich] Helmholtz Zentrum Munchen, Inst Epidemiol 1, Neuherberg, Germany. [Peters, Annette] Helmholtz Zentrum Munchen, Inst Epidemiol 2, Neuherberg, Germany. [Wichmann, H. -Erich] Univ Munich, Univ Hosp Grosshadern, IBE Chair Epidemiol, Munich, Germany. [Wichmann, H. -Erich] Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany. [Ritchie, Marylyn D.] Penn State Univ, Ctr Syst Genom, Dept Biochem & Mol Biol, University Pk, PA 16802 USA. [George, Alfred L., Jr.; Roden, Dan M.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA. RP Kaab, S (reprint author), Univ Munich, Dept Med 1, Univ Hosp Munich, Campus Grosshadern, D-81366 Munich, Germany. EM skaab@med.lmu.de; dan.roden@Vanderbilt.edu RI Pfeufer, Arne/B-6634-2013; Ritchie, Marylyn/C-1114-2012; Crawford, Dana/C-1054-2012; Schott, jean-Jacques/F-8842-2013; Meitinger, Thomas/O-1318-2015; Peters, Annette/A-6117-2011; OI Jamshidi, Yalda/0000-0003-0151-6482 FU Pharmacogenetics Research Network; Fondation Leducq [05 CVD 01]; Bundesministerium fur Bildung und Forschung (BMBF) [01GS0838]; LMU Excellence Initiative; Munich Center of Health Sciences (MC Health) as part of LMUinnovativ; Helmholtz Zentrum Munchen; German Research Center for Environmental Health; German Federal Ministry of Education and Research; State of Bavaria; British Heart Foundation [SP/02/001]; German Heart Foundation; National Heart, Lung, and Blood Institute; Medtronic; GE; Zoll; Servier; Novartis; BMs; Pfizer; Gilead Sciences; [U01HL65962] FX This study was supported by U01HL65962, the Pharmacogenomics of Arrhythmia Therapy site of the Pharmacogenetics Research Network, and by a grant from the Fondation Leducq (Trans-Atlantic Network of Excellence "Alliance Against Sudden Cardiac Death," 05 CVD 01). Additional support was provided from Bundesministerium fur Bildung und Forschung (BMBF) in the context of the German National Genome Research Network NGFNplus 01GS0838, the LMU Excellence Initiative, and within the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ. The KORA research platform and the MONICA Augsburg studies were initiated and financed by the Helmholtz Zentrum Munchen, German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research and by the State of Bavaria. Additional support for the collection and genotyping of the Miami cohort was provided by the Florida Heart Research Institute. The DARE study was funded by the British Heart Foundation under special project grant SP/02/001. Dr Sinner is supported by the German Heart Foundation.; Dr Wilde is a member of the scientific advisory board of Transgenomics (formerly PGxHealth). Dr Myerburg reports consultancy for Sanofi-Aventis, GSK, and Boston Scientific. He reports various expert testimonies not related to the present study. He was paid for lectures by Sanofi-Aventis and Boston Scientific. Travel and accommodations have been paid by Sanofi-Aventis. He is chair of DSMB of a multicenter study co-supported by the National Heart, Lung, and Blood Institute and Medtronic, GE, and Zoll. Dr Camm has acted as a consultant for Sanofi, Servier, Daiichi, Boehringer Ingelheim, Bayer, Novartis, Gilead, and Menarini. He is a member of DSMB for studies funded by Servier, Novartis, BMs, and Pfizer. Dr George reports additional funding to his institution by Gilead Sciences to study proprietary compounds but unrelated to the present study. Together with Dr Roden, he holds US Letters Patent No. 6 458 542, issued October 1, 2002, for "Method of Screening for Susceptibility to Drug-Induced Cardiac Arrhythmia." Dr Roden in addition reports consultancy for Merck, Novartis, Dai-Ichi, Astellas, Avanir, Pfizer, ARCA, and Vitae Pharm. NR 46 TC 51 Z9 52 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1942-3268 J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD FEB PY 2012 VL 5 IS 1 BP 91 EP 99 DI 10.1161/CIRCGENETICS.111.960930 PG 9 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA 021KQ UT WOS:000309884100016 PM 22100668 ER PT J AU Thanassoulis, G Peloso, GM Pencina, MJ Hoffmann, U Fox, CS Cupples, LA Levy, D D'Agostino, RB Hwang, SJ O'Donnell, CJ AF Thanassoulis, George Peloso, Gina M. Pencina, Michael J. Hoffmann, Udo Fox, Caroline S. Cupples, L. Adrienne Levy, Daniel D'Agostino, Ralph B., Sr. Hwang, Shih-Jen O'Donnell, Christopher J. TI A Genetic Risk Score Is Associated With Incident Cardiovascular Disease and Coronary Artery Calcium The Framingham Heart Study SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE genetics; single nucleotide polymorphisms; cardiovascular disease; coronary heart disease; risk prediction; reclassification ID GENOME-WIDE ASSOCIATION; SINGLE NUCLEOTIDE POLYMORPHISMS; MIDDLE-AGED ADULTS; MYOCARDIAL-INFARCTION; ATHEROSCLEROSIS RISK; COMPUTED-TOMOGRAPHY; CHROMOSOME 9P21.3; AMERICAN-COLLEGE; COMPLEX DISEASES; TASK-FORCE AB Background-Limited data exist regarding the use of a genetic risk score (GRS) for predicting risk of incident cardiovascular disease (CVD) in US-based samples. Methods and Results-By using findings from recent genome-wide association studies, we constructed GRSs composed of 13 genetic variants associated with myocardial infarction or other manifestations of coronary heart disease (CHD) and 102 genetic variants associated with CHD or its major risk factors. We also updated the 13 single-nucleotide polymorphism (SNP) GRSs with 16 SNPs recently discovered by genome-wide association studies. We estimated the association, discrimination, and risk reclassification of each GRS for incident cardiovascular events and prevalent coronary artery calcium (CAC). In analyses adjusted for age, sex, CVD risk factors, and parental history of CVD, the 13 SNP GRSs were significantly associated with incident hard CHD (hazard ratio, 1.07; 95% CI, 1.00-1.15; P=0.04), CVD (hazard ratio per allele, 1.05; 95% CI, 1.01-1.09; P=0.03), and high CAC (defined as >75th age-and sex-specific percentile; odds ratio per allele, 1.18; 95% CI, 1.11-1.26; P=3.4 x 10(-7)). The GRS did not improve discrimination for incident CHD or CVD but led to modest improvements in risk reclassification. However, significant improvements in discrimination and risk reclassification were observed for the prediction of high CAC. The addition of 16 newly discovered SNPs to the 13 SNP GRSs did not significantly modify these results. Conclusions-A GRS composed of 13 SNPs associated with coronary disease is an independent predictor of cardiovascular events and of high CAC, modestly improves risk reclassification for incident CHD, and significantly improves discrimination for high CAC. The addition of recently discovered SNPs did not significantly improve the performance of this GRS. (Circ Cardiovasc Genet. 2012; 5:113-121.) C1 [Thanassoulis, George; Peloso, Gina M.; Pencina, Michael J.; Fox, Caroline S.; Cupples, L. Adrienne; Levy, Daniel; D'Agostino, Ralph B., Sr.; Hwang, Shih-Jen; O'Donnell, Christopher J.] NHLBI, NIH, Framingham Heart Study, Framingham, MA 01702 USA. [Thanassoulis, George] McGill Univ, Ctr Hlth, Div Cardiol & Clin Epidemiol, Montreal, PQ, Canada. [Thanassoulis, George] Boston Univ, Sch Med, Boston, MA 02118 USA. [Pencina, Michael J.; D'Agostino, Ralph B., Sr.] Boston Univ, Dept Math, Boston, MA 02215 USA. [Fox, Caroline S.; Levy, Daniel; Hwang, Shih-Jen; O'Donnell, Christopher J.] NHLBI, Ctr Populat Studies, Div Intramural Res, Bethesda, MD 20892 USA. [Hoffmann, Udo; O'Donnell, Christopher J.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Hoffmann, Udo] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol, Boston, MA 02115 USA. [Hoffmann, Udo; Fox, Caroline S.; O'Donnell, Christopher J.] Harvard Univ, Sch Med, Boston, MA USA. RP O'Donnell, CJ (reprint author), NHLBI, NIH, Framingham Heart Study, 73 Mt Wayte Ave 2, Framingham, MA 01702 USA. EM odonnellc@nhlbi.nih.gov OI Cupples, L. Adrienne/0000-0003-0273-7965 FU National Heart, Lung, and Blood Institute of National Institutes of Health; Boston University School of Medicine; National Heart, Lung, and Blood Institute [N01-HC-25195]; Affymetrix, Inc [N02-HL-6-4278]; Canadian Institute of Health Research; Fonds de Recherche en Sante du Quebec FX From the Framingham Heart Study of the National Heart, Lung, and Blood Institute of the National Institutes of Health and Boston University School of Medicine. This work was supported by the National Heart, Lung, and Blood Institute's Framingham Heart Study (contract N01-HC-25195). Part of this work was also supported by the National Heart, Lung, and Blood Institute's contract with Affymetrix, Inc, for genotyping services (contract N02-HL-6-4278). Analyses are based in part on the efforts and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource project. Dr Thanassoulis is supported by a Research Fellowship from the Canadian Institute of Health Research and the Fonds de Recherche en Sante du Quebec. NR 55 TC 87 Z9 91 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1942-325X J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD FEB PY 2012 VL 5 IS 1 BP 113 EP 121 DI 10.1161/CIRCGENETICS.111.961342 PG 9 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA 021KQ UT WOS:000309884100018 PM 22235037 ER PT J AU Alschuler, KN Otis, JD AF Alschuler, K. N. Otis, J. D. TI Coping strategies and beliefs about pain in veterans with comorbid chronic pain and significant levels of posttraumatic stress disorder symptoms SO EUROPEAN JOURNAL OF PAIN LA English DT Article ID ANXIETY SENSITIVITY; EMOTIONAL DISTRESS; MUTUAL MAINTENANCE; OIF/OEF VETERANS; US VETERANS; PTSD; QUESTIONNAIRE; AVOIDANCE; IMPACT; FEAR AB Objectives: The purpose of this study was to assess differences in beliefs about pain and coping strategies employed in veterans with comorbid chronic pain and posttraumatic stress disorder (PTSD), compared to veterans with chronic pain alone. It was hypothesized that veterans with comorbid chronic pain and significant levels of PTSD symptomatology would report higher levels of maladaptive coping strategies and beliefs about pain when compared to veterans with pain alone. Methods: Data were obtained from 194 veterans who completed self-report questionnaires as part of their participation in a Psychology Pain Management Program at a northeastern Department of Veterans Affairs healthcare facility. Results: Analyses indicated that 47.4% of the sample scored above the clinical cutoff for PTSD symptomatology on the PTSD Checklist - Military Version (PCL-M). A Multivariate Analysis of Covariance (MANCOVA) was conducted with age and pain intensity as covariates. In support of the hypothesis, veterans with comorbid chronic pain and significant levels of PTSD symptomatology endorsed significantly higher levels of maladaptive coping strategies and beliefs about pain (greater catastrophizing and emotional impact on pain; less control over pain) when compared to veterans with chronic pain alone. Discussion: The results of this study suggest potential explanations for the previously observed negative effect of PTSD on chronic pain. Moreover, the results suggest specific targets for intervention with patients who have comorbid pain and PTSD. C1 [Alschuler, K. N.] Univ Washington, Dept Rehabil Med, Sch Med, Seattle, WA 98195 USA. [Otis, J. D.] VA Boston Healthcare Syst, Boston, MA USA. [Otis, J. D.] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Alschuler, KN (reprint author), Univ Washington, Dept Rehabil Med, Sch Med, Box 356490,1959 NE Pacific St, Seattle, WA 98195 USA. EM kalschul@uw.edu RI Schueter, nicos/A-3625-2014; OI Otis, John/0000-0002-5441-7421 FU Department of Veterans Affairs, Veterans Health Administration, Rehabilitation, Research and Development Service (RR&D), VA Merit Review Grant [C3322R]; Research Service of the VA Boston Healthcare System FX This work was supported by a Department of Veterans Affairs, Veterans Health Administration, Rehabilitation, Research and Development Service (RR&D), VA Merit Review Grant (C3322R) and by the Research Service of the VA Boston Healthcare System. NR 42 TC 14 Z9 14 U1 3 U2 8 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1090-3801 J9 EUR J PAIN JI Eur. J. Pain PD FEB PY 2012 VL 16 IS 2 BP 312 EP 319 DI 10.1016/j.ejpain.2011.06.010 PG 8 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 980NU UT WOS:000306900900016 PM 22323383 ER PT J AU Reisinger, HS Hunt, SC Burgo-Black, AL Agarwal, MA AF Reisinger, Heather Schacht Hunt, Stephen C. Burgo-Black, A. Lucile Agarwal, Madhulika A. TI A Population Approach to Mitigating the Long-Term Health Effects of Combat Deployments SO PREVENTING CHRONIC DISEASE LA English DT Article ID TRAUMATIC BRAIN-INJURY; RISK-FACTORS; VETERANS; IRAQ; CARE; AFGHANISTAN; WAR; POLYTRAUMA; SOLDIERS; SYSTEM AB A major focus of the mission of the US Department of Veterans Affairs (VA) is to respond to the needs of military personnel returning from war. Given the broad spectrum of the potential effects of combat deployment on the health and well being of service members, VA is increasingly oriented toward comprehensive postcombat support, health promotion, disease prevention, and proactive approaches to caring for combat veterans. This article briefly summarizes the health care needs of service members returning from Afghanistan and Iraq, describes VA's approaches to addressing their needs, and outlines VA's evolving vision for how to apply principles of population health management to ensure prompt and effective response to the postdeployment needs of veterans returning from future conflicts. At the heart of postcombat care will be population-based approaches oriented to health recovery using interdisciplinary, team-based platforms. C1 [Hunt, Stephen C.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Hunt, Stephen C.] Univ Washington, Sch Med, Seattle, WA USA. [Burgo-Black, A. Lucile] VA Connecticut Healthcare Syst, New Haven, CT USA. [Burgo-Black, A. Lucile] Yale Univ, Sch Med, New Haven, CT USA. [Agarwal, Madhulika A.] Off Hlth Policy & Serv, Dept Vet Affairs, Washington, DC USA. RP Reisinger, HS (reprint author), Iowa City VA Healthcare Syst, CADRE, 601 Hwy 6 W, Iowa City, IA 52246 USA. EM heather.reisinger@va.gov FU VA career development award [CD1 08-013-1] FX We thank our interdisciplinary team, Margaret Hammond, Ira Katz, Linda Kinsinger, Larry Mole, Joel Scholten, and Terry Walters, who reviewed this manuscript and provided important feedback. Dr. Reisinger acknowledges the support of her VA career development award (CD1 08-013-1), which focuses on VA outreach to OEF/OIF/OND service members and their families. NR 23 TC 2 Z9 2 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD FEB PY 2012 VL 9 AR 110116 DI 10.5888/pcd9.110116 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 977HC UT WOS:000306646300007 ER PT J AU Lyssiotis, CA Anastasiou, D Locasale, JW Vander Heiden, MG Christofk, HR Cantley, LC AF Lyssiotis, Costas A. Anastasiou, Dimitrios Locasale, Jason W. Vander Heiden, Matthew G. Christofk, Heather R. Cantley, Lewis C. TI Cellular Control Mechanisms that Regulate Pyruvate Kinase M2 Activity and Promote Cancer Growth SO BIOMEDICAL RESEARCH-INDIA LA English DT Article DE Glycolysis; Anabolic Glucose Metabolism; Alternative Splicing; Reactive Oxygen Species ID TUMOR-GROWTH; ALLOSTERIC REGULATION; OXIDATIVE STRESS; BINDING PROTEIN; CELLS; ISOFORM; METABOLISM; ENZYMES; FLUX C1 [Lyssiotis, Costas A.; Anastasiou, Dimitrios; Locasale, Jason W.; Cantley, Lewis C.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA. [Lyssiotis, Costas A.; Anastasiou, Dimitrios; Locasale, Jason W.; Cantley, Lewis C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA. [Vander Heiden, Matthew G.] MIT, Dept Biol, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. [Vander Heiden, Matthew G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Christofk, Heather R.] Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. RP Lyssiotis, CA (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA. RI Cantley, Lewis/D-1800-2014 OI Cantley, Lewis/0000-0002-1298-7653 FU Damon Runyon Cancer Research Foundation; Burroughs Wellcome Fund; Smith Family; National Institute of Health Grant [GM56203] FX CAL is the Amgen fellow of the Damon Runyon Cancer Research Foundation; HK and MVH are funded by Rachleff Innovator awards from the Damon Runyon Cancer Research Foundation; MVH is also supported by grants from the Burroughs Wellcome Fund and the Smith Family; and LCC is supported by a National Institute of Health Grant (GM56203). NR 33 TC 3 Z9 3 U1 1 U2 5 PU SCIENTIFIC PUBLISHERS INDIA PI ALIGARH PA 87-GREATER AZAD ENCLAVE, P O QUARSI, ALIGARH, 00000, INDIA SN 0970-938X J9 BIOMED RES-INDIA JI Biomed. Res.-India PD FEB PY 2012 VL 23 SI SI BP 213 EP 217 PG 5 WC Engineering, Biomedical; Medicine, Research & Experimental SC Engineering; Research & Experimental Medicine GA 967DH UT WOS:000305886100025 ER PT J AU Patti, JA AF Patti, John A. TI Is Quality Good Enough? SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material C1 Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Patti, JA (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,FND 202, Boston, MA 02114 USA. EM jpatti@partners.org NR 2 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD FEB PY 2012 VL 9 IS 2 BP 88 EP 88 DI 10.1016/j.jacr.2011.12.032 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 961FK UT WOS:000305449400001 PM 22305690 ER PT J AU Krishnaraj, A Weinreb, JC Ellenbogen, PH Patti, JA Hillman, BJ AF Krishnaraj, Arun Weinreb, Jeffrey C. Ellenbogen, Paul H. Patti, John A. Hillman, Bruce J. TI Impact of Generational Differences on the Future of Radiology: Proceedings of the 11th Annual ACR Forum SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE ACR Forum; generational differences; gender issues; work-life issues; leadership and participation AB The 2011 ACR Forum focused on the impact of generational differences on the future of radiology, seeking to inform ACR leadership and members on how best to address the influence of the new integrated workforce on the specialty of radiology and on individual practices. C1 [Krishnaraj, Arun; Patti, John A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Weinreb, Jeffrey C.] Yale Univ, New Haven, CT USA. [Ellenbogen, Paul H.] Presbyterian Med Ctr, Dallas, TX USA. [Hillman, Bruce J.] Univ Virginia, Charlottesville, VA USA. RP Krishnaraj, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 55 Fruit St, Boston, MA 02114 USA. EM akrishnarai@partners.org NR 12 TC 7 Z9 7 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD FEB PY 2012 VL 9 IS 2 BP 104 EP 107 DI 10.1016/j.jacr.2011.08.019 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 961FK UT WOS:000305449400008 PM 22305696 ER PT J AU Giuliano, AJ Li, HJ Mesholam-Gately, RI Sorenson, SM Woodberry, KA Seidman, LJ AF Giuliano, Anthony J. Li, Huijun Mesholam-Gately, Raquelle I. Sorenson, Shannon M. Woodberry, Kristen A. Seidman, Larry J. TI Neurocognition in the Psychosis Risk Syndrome: A Quantitative and Qualitative Review SO CURRENT PHARMACEUTICAL DESIGN LA English DT Review DE Schizophrenia; psychosis; prodrome; clinical high risk; neurocognition; meta-analysis ID ULTRA-HIGH-RISK; CLINICAL HIGH-RISK; RANDOMIZED CONTROLLED-TRIAL; FOLLOW-UP; NEUROPSYCHOLOGICAL DEFICITS; SCHIZOPHRENIA PRODROME; 1ST-EPISODE PSYCHOSIS; NEUROMOTOR PRECURSORS; COGNITIVE DEFICITS; WORKING-MEMORY AB Cognitive dysfunction is a hallmark feature of schizophrenia and is evident across all phases of the illness. While prior meta-analyses have elucidated the level and pattern of cognitive deficits in the premorbid and post-onset periods of psychosis, no meta-analyses of studies of the putative prodromal period have been published. Our primary aim is to provide a meta-analysis of neurocognitive findings from 14 studies of psychosis risk syndrome (PRS) individuals published through February 2011, and compare the resulting profile with that synthesized by meta-analyses from other periods of the disorder. Meta-analysis of 1215 PRS individuals with a mean age of 19.2 (+/- 3.3) and 851 healthy control subjects yielded small-to-medium impairments across nine of 10 neurocognitive domains (Cohen's d = -0.26 to -0.67). Seven studies reported on PRS individuals who later developed psychosis (n = 175) and their baseline performance level generally yielded moderate-to-large ESs (d = -0.35 to -0.84). Mild cognitive deficits are reliably and broadly present in PRS individuals, falling at a level that is intermediate between healthy individuals and those diagnosed with schizophrenia, and at a level that is comparable to those at familial ("genetic") risk and with premorbid data. Moreover, baseline neurocognition in PRS individuals who converted to psychosis showed more severe deficits than non-converters in nearly all domains. However, considerable heterogeneity of ESs across studies in many domains underscores variability in phenotypic expression and/or measurement sensitivity, and a critical need for improved reporting of sample characteristics to support moderator variable analyses. C1 [Seidman, Larry J.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Mental Hlth Ctr,Publ Psychiat Div,B, Boston, MA 02115 USA. [Li, Huijun] Florida A&M Univ, Dept Psychol, Tallahassee, FL 32307 USA. [Sorenson, Shannon M.] Univ Massachusetts, Dept Psychol, Boston, MA 02125 USA. [Seidman, Larry J.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Seidman, LJ (reprint author), Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Mental Hlth Ctr,Publ Psychiat Div,B, 75 Fenwood Rd, Boston, MA 02115 USA. EM lseidman@bidmc.harvard.edu FU NIMH [U01 MH081928, P50MH080272, 3P50MH080272-03S2, SCDMH82101008006] FX This research was supported, in part, by NIMH Grants U01 MH081928 (L. Seidman), P50MH080272 (R. McCarley, L. Seidman), 3P50MH080272-03S2 (R. McCarley, H. Li) and SCDMH82101008006 (L. Seidman). NR 121 TC 90 Z9 92 U1 6 U2 22 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1381-6128 J9 CURR PHARM DESIGN JI Curr. Pharm. Design PD FEB PY 2012 VL 18 IS 4 BP 399 EP 415 PG 17 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 945ZA UT WOS:000304315500009 PM 22239571 ER PT J AU Psaros, C Pajolek, H Park, ER AF Psaros, Christina Pajolek, Hannah Park, Elyse R. TI The role of negative affect management in postpartum relapse to smoking SO ARCHIVES OF WOMENS MENTAL HEALTH LA English DT Article DE Smoking; Postpartum relapse; Negative affect; Mood management ID DEPRESSION; PREGNANCY; CESSATION; ANXIETY; PREVENTION; PREDICTORS; NICOTINE; SYMPTOMS; WOMEN AB The aim of this study was to explore the role of affect management in postpartum relapse to smoking. Between January and October 2005, 65 women who smoked prior to pregnancy but not during the last month of pregnancy were recruited from Brigham and Women's Hospital in Boston, MA, and followed for 24 weeks. Surveys administered at baseline, 2, 6, 12, and 24 weeks postpartum assessed smoking status and symptoms of depression (Beck Depression Inventory, BDI) and anxiety (Beck Anxiety Inventory, BAI). Qualitative interviews were conducted when women relapsed or achieved an elevated BDI or BAI score. Elevated BDI or BAI scores did not predict relapse, suggesting that symptoms that make women vulnerable to relapse may not be fully captured by these instruments. Women described feelings of anger or frustration as part of the relapse experience. Women with elevated BDI or BAI scores who did not relapse were more likely to normalize their mood symptoms as part of the postpartum experience and described more adaptive and active coping strategies. Interventions designed to prevent postpartum relapse to smoking may need to target a broader range of negative affect and mood management strategies to increase the likelihood of efficacy. C1 [Pajolek, Hannah; Park, Elyse R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Psaros, Christina; Park, Elyse R.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. EM cpsaros@partners.org FU Robert Wood Johnson Smoke Free Families Initiative; American Cancer Society [MRSG-005-05-CPPB] FX This project was funded by grants from the Robert Wood Johnson Smoke Free Families Initiative and the American Cancer Society's Mentored Research Scholar Award (MRSG-005-05-CPPB) to support Dr. Park's work. We would like to thank the obstetric nursing staff at Brigham and Women's Hospital for helping us access study participants. The authors also wish to thank Kristin Perry for interviewing participants and Jennifer Pandiscio and Kaile Ross for their assistance with preparing the data for this paper. The authors also wish to thank the participants of this study for sharing their postpartum experiences. NR 27 TC 6 Z9 6 U1 3 U2 9 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 1434-1816 J9 ARCH WOMEN MENT HLTH JI Arch. Womens Ment. Health PD FEB PY 2012 VL 15 IS 1 BP 15 EP 20 DI 10.1007/s00737-011-0250-2 PG 6 WC Psychiatry SC Psychiatry GA 944AE UT WOS:000304169500002 PM 22194083 ER PT J AU Anselmetti, GC Manca, A Montemurro, F Hirsch, J Chiara, G Grignani, G Schianca, FC Capaldi, A Scalabrini, DR Sardo, E Debernardi, F Iussich, G Regge, D AF Anselmetti, Giovanni Carlo Manca, Antonio Montemurro, Filippo Hirsch, Joshua Chiara, Gabriele Grignani, Giovanni Schianca, Fabrizio Carnevale Capaldi, Antonio Scalabrini, Delia Rota Sardo, Elena Debernardi, Felicino Iussich, Gabriella Regge, Daniele TI Percutaneous Vertebroplasty in Multiple Myeloma: Prospective Long-Term Follow-Up in 106 Consecutive Patients SO CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article DE Vertebroplasty; Myeloma; Pain treatment; Interventional radiology; Quality of Life ID VERTEBRAL COMPRESSION FRACTURES; ZOLEDRONIC ACID; SKELETAL COMPLICATIONS; FAT-EMBOLISM; CHRONIC PAIN; KYPHOPLASTY; METASTASES; EFFICACY; THERAPY; CANCER AB Purpose Percutaneous vertebroplasty (PV) is a minimally invasive procedure involving the injection of bone cement within a collapsed vertebral body. Although this procedure was demonstrated to be effective in osteoporosis and metastases, few studies have been reported in cases of multiple myeloma (MM). We prospectively evaluated the safety and efficacy of PV in the treatment of vertebral compression fractures (VCFs) resulting from MM. Materials and Methods PV was performed in 106 consecutive MM patients who had back pain due to VCFs, the treatment of which had failed conservative therapies. Follow-up (28.2 +/- 12.1 months) was evaluated at 7 and 15 days as well as at 1, 3, 6, 12, 18, and every 6 months after PV. Visual analog scale (VAS) pain score, opioid use, external brace support, and Oswestry Disability Index (ODI) score were recorded. Results The median pretreatment VAS score of 9 (range 4-10) significantly (P < 0.001) decreased to 1 (range 0-9) after PV. Median pre-ODI values of 82% (range 36-89%) significantly improved to 7% (range 0-82%) (P < 0.001). Differences in pretreatment and posttreatment use of analgesic drug were statistically significant (P < 0.001). The majority of patients (70 of 81; 86%) did not use an external brace after PV (P < 0.001). Conclusion PV is a safe, effective, and long-lasting procedure for the treatment of vertebral compression pain resulting from MM. C1 [Anselmetti, Giovanni Carlo; Manca, Antonio; Chiara, Gabriele; Iussich, Gabriella] Inst Canc Res & Treatment, Intervent Radiol Unit, I-10060 Turin, Italy. [Hirsch, Joshua] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Montemurro, Filippo; Grignani, Giovanni; Schianca, Fabrizio Carnevale; Capaldi, Antonio; Scalabrini, Delia Rota] Inst Canc Res & Treatment, Oncol Unit, I-10060 Turin, Italy. [Sardo, Elena; Debernardi, Felicino] Inst Canc Res & Treatment, Anesthesiol Unit, I-10060 Turin, Italy. [Regge, Daniele] Inst Canc Res & Treatment, Radiol Unit, I-10060 Turin, Italy. RP Anselmetti, GC (reprint author), Inst Canc Res & Treatment, Intervent Radiol Unit, I-10060 Turin, Italy. EM giovanni.anselmetti@ircc.it; anto.manca@gmail.com; filippo.montemurro@ircc.it; jahirschmd@yahoo.com; chiaragabriele@gmail.com; giovanni.grignani@ircc.it; fabrizio.carnevale@ircc.it; antonio.capaldi@ircc.it; delia.rotascalabrini@ircc.it; elena.sardo@ircc.it; felicino.debernardi@ircc.it; gabriellaiussich@yahoo.com; daniele.regge@ircc.it OI Manca, Antonio/0000-0002-8193-5208 NR 31 TC 13 Z9 15 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0174-1551 J9 CARDIOVASC INTER RAD JI Cardiovasc. Interv. Radiol. PD FEB PY 2012 VL 35 IS 1 BP 139 EP 145 DI 10.1007/s00270-011-0111-4 PG 7 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 943XV UT WOS:000304161900016 PM 21305282 ER PT J AU Mullins, RJ Camargo, CA AF Mullins, Raymond James Camargo, Carlos A., Jr. TI Latitude, Sunlight, Vitamin D, and Childhood Food Allergy/Anaphylaxis SO CURRENT ALLERGY AND ASTHMA REPORTS LA English DT Review DE Food allergy; Anaphylaxis; Children; Sunlight; Vitamin D; Pathogenesis; Latitude ID 25-HYDROXYVITAMIN D LEVELS; UNITED-STATES; D SUPPLEMENTATION; ATOPIC-DERMATITIS; D INSUFFICIENCY; D DEFICIENCY; ULTRAVIOLET-RADIATION; REGIONAL-VARIATION; ALLERGIC RHINITIS; US POPULATION AB Vitamin D is widely known for its role in bone metabolism, but this sterol hormone also has important immunomodulatory properties. Vitamin D is produced by the conversion of D3 in the skin following UVB exposure, or after ingestion of D2 or D3. At the extremes of latitude, there is insufficient UVB intensity in the autumn and winter months for adequate synthesis of vitamin D to occur. Growing evidence implicates vitamin D deficiency in early life in the pathogenesis of nonskeletal disorders (e. g., type 1 diabetes and multiple sclerosis) and, more recently, atopic disorders. Several studies have reported higher rates of food allergy/anaphylaxis or proxy measures at higher absolute latitudes. Although causality remains to be determined, these studies suggest a possible role for sunlight and/or vitamin D in the pathogenesis of food allergy/anaphylaxis. C1 [Mullins, Raymond James] Australian Natl Univ, Sch Med, Canberra, ACT 0200, Australia. [Mullins, Raymond James] Univ Canberra, Fac Hlth, Canberra, ACT 2601, Australia. [Mullins, Raymond James] John James Med Ctr, Deakin, ACT 2600, Australia. [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA USA. [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA. [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA. RP Mullins, RJ (reprint author), Australian Natl Univ, Sch Med, GPO Box 4, Canberra, ACT 0200, Australia. EM rmullins@allergycapital.com.au; ccamargo@partners.org OI Mullins, Raymond/0000-0002-0267-1591 FU Commonwealth Serum Laboratories Australia; Alphapharm Australia; Abbott Nutrition Australia; Ilhan Food Allergy Foundation; Dey Pharma; Sanofi-Aventis FX Dr. Mullins has received unrestricted investigator-initiated grants from Commonwealth Serum Laboratories Australia and Alphapharm Australia, Abbott Nutrition Australia, and the Ilhan Food Allergy Foundation.; Dr. Camargo has received investigator-initiated research grants from and served as a consultant for Dey Pharma and Sanofi-Aventis. Study sponsors had no input into the contents of this article. NR 86 TC 16 Z9 16 U1 0 U2 10 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1529-7322 EI 1534-6315 J9 CURR ALLERGY ASTHM R JI Curr. Allergy Asthma Rep. PD FEB PY 2012 VL 12 IS 1 BP 64 EP 71 DI 10.1007/s11882-011-0230-7 PG 8 WC Allergy; Immunology SC Allergy; Immunology GA 939JL UT WOS:000303805800009 PM 22006065 ER PT J AU Tian, ZR Sharma, A Nozari, A Subramaniam, R Lundstedt, T Sharma, HS AF Tian, Z. Ryan Sharma, Aruna Nozari, Ala Subramaniam, Raman Lundstedt, Torbjorn Sharma, Hari Shanker TI Nanowired Drug Delivery to Enhance Neuroprotection in Spinal Cord Injury SO CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS LA English DT Article DE Nanowired drug delivery; spinal cord injury; blood-spinal cord barrier; spinal cord edema; TiO2 nanowires; silica nanowires; neuronal injury; stem cells; functional recovery; astrocytes; myelin; ultrastructure; nanoparticles ID CENTRAL-NERVOUS-SYSTEM; TITANIUM-DIOXIDE NANOPARTICLES; ANTIOXIDANT COMPOUND H-290/51; SEROTONIN SYNTHESIS INHIBITOR; FINE PARTICULATE MATTER; PARTICLE-SIZE; IN-VIVO; ELECTRON-MICROSCOPY; TISSUE DISTRIBUTION; SURFACE-PROPERTIES AB Spinal cord injury (SCI) is a serious clinical situation for which no suitable drug therapy exists. SCI often results in paraplegia or quadriplegia and, apart from the personal trauma leads to huge costs to society for rehabilitation or day-to-day life support. Sensory motor dysfunction following SCI is mainly a consequence of the slowly progressing cord pathology after primary injury that worsens over tine. Thus, almost all sensory and motor nerve control and pathways passing through spinal cord and reflexes are compromised in SCI patients. As a result their peripheral nervous system, autonomic nervous function and central nervous system regulations are adversely affected. Experiments carried out in our laboratory show that various therapeutic agents, if given within 10 to 30 minutes after primary SCI could correct morphological changes to a certain extent. In these rat models of SCI reduction in cord pathology, e.g., blood-spinal cord barrier (BSCB) breakdown, edema formation and cell injury by the neuroprotective agents that also limited sensory motor dysfunction and improved functional behavior. However, these drugs if given beyond 30 minutes after SCI showed a markedly reduced neuroprotective efficacy. Thus, new strategies are needed to enhance neuroprotection in SCI to prevent structural and functional changes over longer periods of time. To that end our laboratory has initiated a series of investigations in which nanowired delivery of various neurotherapeutic agents are applied after different time periods of SCI, that resulted in a much better outcome than with the parent compounds under identical conditions. The superior neuroprotective activity of nanowired compound delivery could be due to a reduced metabolism of active compounds in the central nervous system (CNS) or by sustained release of the drug for longer times. In addition, nanowired drugs may penetrate the CNS faster and could reach widespread areas once entering the spinal cord. Thus, nanowired drug delivery to treat SCI may have potential therapeutic value. These aspects of nanowired drug delivery to enhance neuroprotection in SCI are discussed in this review based on our own investigations. C1 [Sharma, Aruna; Sharma, Hari Shanker] Uppsala Univ, Univ Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden. [Tian, Z. Ryan; Subramaniam, Raman] Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA. [Nozari, Ala] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Lundstedt, Torbjorn] AcurePharma AB, Uppsala, Sweden. [Lundstedt, Torbjorn] Uppsala Univ, Div Organ Chem, Dept Med Chem, SE-75185 Uppsala, Sweden. RP Sharma, HS (reprint author), Uppsala Univ, Univ Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden. EM Sharma@surgsci.uu.se RI Sharma, Hari/G-4508-2016; Tian, Z. Ryan /R-6671-2016 OI Tian, Z. Ryan /0000-0002-5644-8483 FU Air Force Office of Scientific Research (London), Air Force Material Command, USAF [FA8655-05-1-3065]; Swedish Medical Research Council [2710]; Astra-Zeneca, Molndal, Sweden; Alexander von Humboldt Foundation, Germany; IPSEN Medical, France; University Grants Commission, New Delhi, India; Indian Council of Medical Research, New Delhi, India FX This investigation was partially supported by the Air Force Office of Scientific Research (London), Air Force Material Command, USAF, under grant number FA8655-05-1-3065. The U.S. Government is authorized to reproduce and distribute reprints for Government purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the Air Force Office of Scientific Research or the U.S. Government. We express sincere gratitude to several laboratories where a part of the work was done or some data recorded and evaluated. Financial support Swedish Medical Research Council (Grant Nr. 2710, HSS); Astra-Zeneca, Molndal, Sweden (HSS), Alexander von Humboldt Foundation, Germany (HSS); IPSEN Medical, France (HSS); and University Grants Commission, New Delhi, India (HSS); Indian Council of Medical Research, New Delhi, India (HSS) is gratefully acknowledged. The authors have no conflict of interest with any financial agencies mentioned above. NR 103 TC 12 Z9 13 U1 0 U2 10 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1871-5273 J9 CNS NEUROL DISORD-DR JI CNS Neurol. Disord.-Drug Targets PD FEB PY 2012 VL 11 IS 1 BP 86 EP 95 PG 10 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 934MW UT WOS:000303449400010 PM 22385571 ER PT J AU Pakdaman, MN Herrmann, BS Curtin, HD Van Beek-King, J Lee, DJ AF Pakdaman, Michael N. Herrmann, Barbara S. Curtin, Hugh D. Van Beek-King, Jessica Lee, Daniel J. TI Cochlear Implantation in Children with Anomalous Cochleovestibular Anatomy: A Systematic Review SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Review DE cochlear implant; cochlea; anatomic anomaly; cochleovestibular anomaly; cochlear implantation; Mondini; dysplasia; enlarged vestibular aqueduct; incomplete partition; deformity; cochlear anomaly; systematic review; review ID INNER-EAR MALFORMATIONS; VESTIBULAR AQUEDUCT SYNDROME; COMPUTED-TOMOGRAPHY; MALFORMED COCHLEA; AUDIOLOGICAL PERFORMANCE; CONGENITAL-MALFORMATIONS; MONDINI DYSPLASIA; HEARING-LOSS; FOLLOW-UP; CLASSIFICATION AB Objective. To determine the influence of inner ear dysplasia on both surgical and audiologic outcomes following pediatric cochlear implant (CI) surgery. Data Sources. MEDLINE (1982-2009) and data from Massachusetts Eye and Ear Infirmary. Review Methods. A systematic review of the literature was performed. Variables assessed included age at implantation, duration of CI use, radiologic and operative findings, and speech perception outcome data. Results. The initial search yielded 1326 articles. Including data from our own study, twenty-two fulfilled criteria for inclusion, representing 311 patients. Data for bilateral implants were recorded only for the first implant. Data on simultaneous bilateral implants were not recorded. The most common anomaly seen was large vestibular aqueduct (89/311 or 29%). When comparing patients with mild-moderate or severe dysplasia, rates of cerebrospinal fluid gusher were 31% versus 35% (odds ratio [OR] = 0.50), anomalous facial nerve anatomy was seen in 11% versus 51% (OR = 0.15), and postoperative speech perception abilities were found in 84% versus 54% (OR = 1.93), respectively. A large heterogeneity was found among studies regarding all outcome measures. Conclusion. Although we found that severe inner ear dysplasia was associated with increased surgical difficulty and lower speech perception, the lack of uniformity in published clinical data limited the strength of these results. Standardization of surgical and radiologic reporting as well as more consistent speech perception testing is needed to better determine the association between anomalous cochleovestibular anatomy and clinical outcomes. C1 [Lee, Daniel J.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Pakdaman, Michael N.] Univ Texas Houston, Sch Med, Dept Otorhinolaryngol, Houston, TX USA. [Herrmann, Barbara S.] Massachusetts Eye & Ear Infirm, Dept Audiol, Boston, MA 02114 USA. [Herrmann, Barbara S.; Lee, Daniel J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Curtin, Hugh D.] Massachusetts Eye & Ear Infirm, Dept Radiol, Boston, MA 02114 USA. [Van Beek-King, Jessica] Georgia Hlth Sci Univ, Dept Otolaryngol Head & Neck Surg, Augusta, GA USA. RP Lee, DJ (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM daniel_lee@meei.harvard.edu NR 61 TC 15 Z9 17 U1 0 U2 14 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2012 VL 146 IS 2 BP 180 EP 190 DI 10.1177/0194599811429244 PG 11 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 935SR UT WOS:000303541300001 PM 22140206 ER PT J AU Lee, LN Bhattacharyya, N AF Lee, Linda N. Bhattacharyya, Neil TI Contemporary Trends in Procedural Volume for Adult Facial Trauma, 1996-2006 SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE facial fractures; otolaryngology residency; facial trauma; zygomaticomaxillary fracture; mandible fracture; nasal fracture ID CHANGING FACE; SURGERY AB Objectives. To determine how rates of operative facial fractures may have changed between 1996 and 2006 and to determine the potential impact of such change on otolaryngology residency surgical key indicator cases. Study Design. Historical cohort study. Setting. Academic medical center. Subjects and Methods. The National Hospital Discharge Survey (NHDS) and National Survey of Ambulatory Surgery (NSAS) 1996 and 2006 cases were reviewed, extracting all cases of adult nasal, malar/zygomatic, maxillary, and mandibular fracture reductions in inpatient and outpatient settings, respectively. Procedure rates for each facial fracture were tabulated and compared between 1996 and 2006. Results. Overall in 1996, there were an estimated 113,041 +/- 3740 operative facial fracture repairs performed. Among the 3 key indicator fracture repairs most relevant to otolaryngologists, there were 15,810 +/- 2143 open nasal fracture reductions, 9360 +/- 1742 open zygomaticomaxillary (ZMC) fracture reductions, and 20,214 +/- 2585 open mandibular fracture repairs. Overall in 2006, there were 120,463 +/- 7554 total facial fracture procedures, with 11,613 +/- 2846 open nasal fracture reductions, 10,216 +/- 2881 open ZMC fracture reductions, and 17,965 +/- 3171 open mandibular repairs. Comparing cohorts, there was no significant change in number of open nasal, ZMC, or mandibular fracture repairs (P = .24, P = .58, P = .80, respectively). Conclusion. Facial fracture procedure rates have remained largely stable over the past 10 years. These data have implications for otolaryngology training programs and could help guide resident education in facial trauma. C1 [Lee, Linda N.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otolaryngol,Dept Otol & Laryngol, Boston, MA 02114 USA. [Bhattacharyya, Neil] Brigham & Womens Hosp, Div Otolaryngol, Boston, MA 02115 USA. RP Lee, LN (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otolaryngol,Dept Otol & Laryngol, 243 Charles St, Boston, MA 02114 USA. EM linda_lee@meei.harvard.edu NR 8 TC 5 Z9 5 U1 0 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2012 VL 146 IS 2 BP 226 EP 229 DI 10.1177/0194599811427825 PG 4 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 935SR UT WOS:000303541300009 PM 22063732 ER PT J AU Pakdaman, MN Herrmann, BS Curtin, HD Van Beek-King, J Lee, DJ AF Pakdaman, Michael N. Herrmann, Barbara S. Curtin, Hugh D. Van Beek-King, Jessica Lee, Daniel J. TI Cochlear Implantation in Children with Anomalous Cochleovestibular Anatomy SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE cochleovestibular; cochlear implant; anomaly; malformation; dysplasia; cochlear; pediatric; retrospective review; mondini; cochleovestibular AB Our aim was to determine the influence of inner-ear anomalies on surgical difficulty and postoperative audiologic outcomes among pediatric cochlear implant (CI) recipients at our institution. We reviewed medical and audiologic records from 78 consecutive pediatric CI cases between 1985 and June 2009. Thirty patients had high-resolution temporal bone computed tomography imaging available for retrospective interpretation. Seven of these 30 patients (23%) had cochleovestibular dysplasia. Fifty percent of patients with severe dysplasia had a cerebrospinal fluid gusher intraoperatively, compared with 13% of patients with no dysplasia. Of patients with available audiologic outcome data, 17 of 26 patients with normal/mild/moderate dysplasia were able to complete CNC testing, whereas neither of the 2 patients with severe dysplasia could complete the open set test. Our experience suggests that surgical difficulty and audiologic outcomes in pediatric CI recipients may be affected by the presence and severity of a cochleovestibular anomaly. C1 [Lee, Daniel J.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Pakdaman, Michael N.] Univ Texas Houston, Sch Med, Dept Otorhinolaryngol, Houston, TX USA. [Herrmann, Barbara S.] Massachusetts Eye & Ear Infirm, Dept Audiol, Boston, MA 02114 USA. [Herrmann, Barbara S.; Lee, Daniel J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Curtin, Hugh D.] Massachusetts Eye & Ear Infirm, Dept Radiol, Boston, MA 02114 USA. [Van Beek-King, Jessica] Georgia Hlth Sci Univ, Dept Otolaryngol Head & Neck Surg, Augusta, GA USA. RP Lee, DJ (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM daniel_lee@meei.harvard.edu NR 5 TC 2 Z9 2 U1 0 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2012 VL 146 IS 2 BP 295 EP 297 DI 10.1177/0194599811427379 PG 3 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 935SR UT WOS:000303541300021 PM 22114309 ER PT J AU Maturo, S Hill, C Bunting, G Ballif, C Maurer, R Hartnick, C AF Maturo, Steve Hill, Courtney Bunting, Glenn Ballif, Cathy Maurer, Rie Hartnick, Christopher TI Pediatric Laryngeal Diadochokinetic Rates: Establishing a Normative Database SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE diadochokinetic; DDK; pediatric voice; pediatric speech ID ORAL DIADOCHOKINESIS; SPEECH; CHILDREN; ADOLESCENTS; ACCURACY AB Objective. Laryngeal diadochokinetic (L-DDK) rate is a measure of laryngeal neural integrity. The objectives for this study included the following: (1) establish the first comprehensive pediatric normative database for L-DDK rates (DDK) using the Voice Evaluation Suite, a computerized voice analysis program; and (2) analyze normal L-DDK rates for age and gender differences. Study Design. Cross-sectional study with planned data collection. Setting. Outpatient pediatric otolaryngology clinic. Subjects and Methods. Three hundred seven children aged 4 to 18 with normal voices. L-DDK rates were collected during a 6-month period. Main outcome measures included age, gender, and L-DDK rates. Results. Three hundred seven children (151 girls and 156 boys) were evaluated. There was no statistically significant difference between the overall mean L-DDK rate of boys (2.69 syllables/s) compared to girls (2.55 syllables/s; P > .05). Further analysis of all individual age groups did not reveal any statistical significance between boys and girls. There was a statistically significant difference among children aged 4 to 11 compared to those 12 to 18 years old. Among boys aged 4 to 11, the mean rate was 2.49 syllables per second, whereas among 12- to 18-year-olds, the rate was 2.95 syllables per second (P < .01). The mean rate was 2.40 syllables per second among girls aged 4 to 11 and 2.74 syllables per second for those aged 12 to 18 (P < .01). Conclusion. This is the largest normative pediatric L-DDK analysis in the English literature. The findings suggest that neurolaryngeal development approaches adult maturation at the beginning of the teenage years. These data have the potential application for objective measurement of neurolaryngeal coordination in children with neurologic impairment and also in children who have undergone nerve reinnervation procedures. C1 [Maturo, Steve] Wilford Hall USAF Med Ctr, San Antonio Uniformed Serv Hlth Educ Consortium, Dept Otolaryngol Head & Neck Surg, Lackland AFB, TX 78236 USA. [Hill, Courtney; Hartnick, Christopher] Harvard Univ, Sch Med, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. [Bunting, Glenn; Ballif, Cathy] Massachusetts Eye & Ear Infirm, Voice & Speech Lab, Boston, MA 02114 USA. [Maurer, Rie] Brigham & Womens Hosp, Ctr Clin Invest, Boston, MA 02115 USA. [Maurer, Rie] Harvard Clin & Translat Sci Ctr, Boston, MA USA. RP Maturo, S (reprint author), Wilford Hall USAF Med Ctr, San Antonio Uniformed Serv Hlth Educ Consortium, Dept Otolaryngol Head & Neck Surg, Lackland AFB, TX 78236 USA. EM Stephen.maturo@sbcglobal.net NR 16 TC 1 Z9 1 U1 2 U2 7 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2012 VL 146 IS 2 BP 302 EP 306 DI 10.1177/0194599811426259 PG 5 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 935SR UT WOS:000303541300023 PM 22027868 ER PT J AU Lin, HW Roberts, DS Kay, J Stankovic, KM AF Lin, Harrison W. Roberts, Daniel S. Kay, Jonathan Stankovic, Konstantina M. TI Sensorineural Hearing Loss following Imatinib (Gleevec) Administration SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE imatinib; hearing loss; ototoxicity; nephrogenic systemic fibrosis C1 [Lin, Harrison W.; Roberts, Daniel S.; Stankovic, Konstantina M.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Lin, Harrison W.; Roberts, Daniel S.; Stankovic, Konstantina M.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Kay, Jonathan] Univ Massachusetts, Sch Med, Dept Med, Div Rheumatol, Worcester, MA USA. RP Stankovic, KM (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM konstantina_stankovic@meei.harvard.edu OI Kay, Jonathan/0000-0002-8970-4260 FU Massachusetts Life Sciences Center; NIH-NIDCD [K08DC010419]; Shore Fellowship at Harvard Medical School FX K.M.S. is supported by grants from NIH-NIDCD K08DC010419, Massachusetts Life Sciences Center, and the Shore Fellowship at Harvard Medical School. NR 5 TC 1 Z9 1 U1 0 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2012 VL 146 IS 2 BP 335 EP 337 DI 10.1177/0194599811415008 PG 3 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 935SR UT WOS:000303541300031 PM 21753034 ER PT J AU Barnes, CM Prox, D Christison-Lagay, EA Le, HD Short, S Cassiola, F Panigrahy, D Chaponis, D Butterfield, C Nehra, D Fallon, EM Kieran, M Folkman, J Puder, M AF Barnes, Carmen M. Prox, Daniela Christison-Lagay, Emily A. Le, Hau D. Short, Sarah Cassiola, Flavia Panigrahy, Dipak Chaponis, Deviney Butterfield, Catherine Nehra, Deepika Fallon, Erica M. Kieran, Mark Folkman, Judah Puder, Mark TI Inhibition of neuroblastoma cell proliferation with omega-3 fatty acids and treatment of a murine model of human neuroblastoma using a diet enriched with omega-3 fatty acids in combination with sunitinib SO PEDIATRIC RESEARCH LA English DT Article ID COLON-CANCER CELLS; DOCOSAHEXAENOIC ACID; FATTY-ACIDS; TUMOR ANGIOGENESIS; LIVER-DISEASE; FISH-OIL; SH-SY5Y; GROWTH; CYCLOOXYGENASE-2; DIFFERENTIATION AB INTRODUCTION: We investigated the use of dietary omega-3 (omega-3) polyunsaturated fatty acids (PUFAs) in the treatment of neuroblastoma both as a sole agent and in combination with sunitinib, a broad-spectrum tyrosine kinase receptor inhibitor. RESULTS: Substitution of all dietary fat with menhaden oil (omega-3 PUFA rich) resulted in a 40-70% inhibition of tumor growth and a statistically significant difference in the levels of several PUFAs (18: 2 omega-6, 20: 4 omega-6, 22: 4 omega-6, 20: 5 omega-3) as compared with a control diet. Furthermore, tumors from animals on the omega-3 fatty acid (FA)-enriched diet had an elevated triene/tetraene ratio suggestive of a change in local eicosanoid metabolism in these tissues similar to that seen with essential fatty acid deficiency. The omega-3 FA-enriched diet also decreased tumor-associated inflammatory cells and induced mitochondrial changes suggestive of mitochondrial damage. Combination treatment with sunitinib resulted in further reduction in tumor proliferation and microvessel density. DISCUSSION: These findings suggest a potential role for omega-3 PUFAs in the combination treatment of neuroblastoma. METHODS: We used a murine model of orthotopic and subcutaneous human neuroblastoma and diets that differ in the FA content to define the optimal dietary omega-3/omega-6 (omega-6) FA ratio required for the inhibition of these tumors. C1 [Christison-Lagay, Emily A.; Le, Hau D.; Nehra, Deepika; Fallon, Erica M.; Puder, Mark] Harvard Univ, Sch Med, Dept Surg, Childrens Hosp Boston, Boston, MA 02115 USA. [Barnes, Carmen M.; Prox, Daniela; Short, Sarah; Cassiola, Flavia; Panigrahy, Dipak; Chaponis, Deviney; Butterfield, Catherine; Folkman, Judah] Harvard Univ, Sch Med, Childrens Hosp Boston, Vasc Biol Program, Boston, MA USA. [Kieran, Mark] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. RP Puder, M (reprint author), Harvard Univ, Sch Med, Dept Surg, Childrens Hosp Boston, Boston, MA 02115 USA. EM mark.puder@childrens.harvard.edu OI Kieran, Mark/0000-0003-2184-7692 FU Saint Baldrick's Foundation; Circle of Friends; Children's Hospital Surgical Foundation; Vascular Biology Program; Joshua Ryan Rappaport Fellowship FX This work was supported by Saint Baldrick's Foundation (C. M. B., E. A. C.), Circle of Friends (C. M. B., F. C., D. P.), the Children's Hospital Surgical Foundation (E. A. C., H. D. L., D.N., E. M. F., J.F., M. P.), the Vascular Biology Program (C. M. B., D. P., H. D. L, S. S., F. C., D. P., D. C., C. B., D.N., E. M. F., M. K., J.F., M. P.), and the Joshua Ryan Rappaport Fellowship (H.D.L.). NR 30 TC 5 Z9 5 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0031-3998 J9 PEDIATR RES JI Pediatr. Res. PD FEB PY 2012 VL 71 IS 2 BP 168 EP 178 DI 10.1038/pr.2011.28 PG 11 WC Pediatrics SC Pediatrics GA 934OZ UT WOS:000303455000007 PM 22258128 ER PT J AU Hussain, M Corn, P Michaelson, D Hammers, H Alumkal, J Ryan, C Bruce, J Moran, S Mortimer, P Lee, SY George, D AF Hussain, M. Corn, P. Michaelson, D. Hammers, H. Alumkal, J. Ryan, C. Bruce, J. Moran, S. Mortimer, P. Lee, S. Y. George, D. TI Activity and safety of the investigational agent orteronel (ortl, TAK-700) in men with nonmetastatic castration-resistant prostate cancer (CRPC) and rising prostate-specific antigen (PSA): Results of a phase 2 study SO EUROPEAN UROLOGY SUPPLEMENTS LA English DT Meeting Abstract C1 [Hussain, M.] Univ Michigan, Dept Internal Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Corn, P.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA. [Michaelson, D.] Massachusetts Gen Hosp, Ctr Canc, Dept Genitourinary Canc, Boston, MA USA. [Hammers, H.] Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD USA. [Alumkal, J.] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97201 USA. [Ryan, C.] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Med, San Francisco, CA USA. [Bruce, J.] Univ Wisconsin, Dept Med, Carbone Canc Ctr, Madison, WI 53706 USA. [Moran, S.] Millennium Pharmaceut Inc, Dept Oncol Clin Res, Cambridge, MA USA. [Mortimer, P.] Takeda Global Res & Dev Ctr Europe Ltd, Dept Clin Sci, London, England. [Lee, S. Y.] Millennium Pharmaceut Inc, Dept Biostat, Cambridge, England. [George, D.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27706 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9056 J9 EUR UROL SUPPL JI Eur. Urol. Suppl. PD FEB PY 2012 VL 11 IS 1 BP E124 EP U511 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 928RP UT WOS:000303001300175 ER PT J AU Niu, Y Ge, RB Wang, ZW Olumi, AF AF Niu, Y. Ge, R. B. Wang, Z. W. Olumi, A. F. TI Finasteride: Promoter or repressor of initiated prostate epithelial cells? SO EUROPEAN UROLOGY SUPPLEMENTS LA English DT Meeting Abstract C1 [Niu, Y.] Capital Med Univ, Beijing Chaoyang Hosp, Dept Urol, Beijing, Peoples R China. [Ge, R. B.; Wang, Z. W.; Olumi, A. F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Urol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9056 J9 EUR UROL SUPPL JI Eur. Urol. Suppl. PD FEB PY 2012 VL 11 IS 1 BP E932 EP U958 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 928RP UT WOS:000303001301471 ER PT J AU Niu, YN Wang, ZW Ge, RB Olumi, AF AF Niu, Y. N. Wang, Z. W. Ge, R. B. Olumi, A. F. TI The intriguing role of fibroblast in finasteride's function on prostate cancer cells SO EUROPEAN UROLOGY SUPPLEMENTS LA English DT Meeting Abstract C1 [Niu, Y. N.] Capital Med Univ, Beijing Chaoyang Hosp, Dept Urol, Beijing, Peoples R China. [Wang, Z. W.; Ge, R. B.; Olumi, A. F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Urol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9056 J9 EUR UROL SUPPL JI Eur. Urol. Suppl. PD FEB PY 2012 VL 11 IS 1 BP E933 EP U960 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 928RP UT WOS:000303001301472 ER PT J AU Small, EJ Higano, CS Kantoff, PW Whitmore, JB Frohlich, MW Petrylak, DP AF Small, E. J. Higano, C. S. Kantoff, P. W. Whitmore, J. B. Frohlich, M. W. Petrylak, D. P. TI Time to disease-related pain (TDRP) following sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Integrated results from three randomized phase 3 trials SO EUROPEAN UROLOGY SUPPLEMENTS LA English DT Meeting Abstract C1 [Small, E. J.] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Med & Urol, San Francisco, CA USA. [Higano, C. S.] Univ Washington, Sch Med, Dept Oncol & Urol, Seattle, WA USA. [Kantoff, P. W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol Solid Tumor Oncol, Boston, MA 02115 USA. [Whitmore, J. B.] Dendreon Corp, Dept Biometr, Seattle, WA USA. [Frohlich, M. W.] Dendreon Corp, Dept Clin Affairs, Seattle, WA USA. [Petrylak, D. P.] Columbia Univ, Dept Med, Med Ctr, Div Oncol, New York, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9056 J9 EUR UROL SUPPL JI Eur. Urol. Suppl. PD FEB PY 2012 VL 11 IS 1 BP E123 EP U509 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 928RP UT WOS:000303001300174 ER PT J AU Tinzl, MV Chen, B Chen, S Abrahamsson, PA Dizeyi, N AF Tinzl, M., V Chen, B. Chen, S. Abrahamsson, P. A. Dizeyi, N. TI Androgen receptor expression is induced by docetaxel in prostate cancer cells SO EUROPEAN UROLOGY SUPPLEMENTS LA English DT Meeting Abstract C1 [Tinzl, M., V; Chen, B.; Abrahamsson, P. A.; Dizeyi, N.] Lund Univ, Dept Clin Sci, Urol Res Unit, Malmo, Sweden. [Chen, S.] Harvard Univ, Sch Med, BIDMC, Dept Hematol Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9056 J9 EUR UROL SUPPL JI Eur. Urol. Suppl. PD FEB PY 2012 VL 11 IS 1 BP E934 EP U962 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 928RP UT WOS:000303001301473 ER PT J AU Percy, AG Jacobus, SJ Kaplan, JR Kim, SB Wagner, AA AF Percy, A. G. Jacobus, S. J. Kaplan, J. R. Kim, S. B. Wagner, A. A. TI Patient-reported health-related quality of life outcomes following cytoreductive nephrectomy SO EUROPEAN UROLOGY SUPPLEMENTS LA English DT Meeting Abstract C1 [Percy, A. G.; Kaplan, J. R.; Kim, S. B.; Wagner, A. A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg,Div Urol, Boston, MA 02215 USA. [Jacobus, S. J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9056 J9 EUR UROL SUPPL JI Eur. Urol. Suppl. PD FEB PY 2012 VL 11 IS 1 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 928RP UT WOS:000303001300136 ER PT J AU Anstey, DE Heyworth, BE Price, MD Gill, TJ AF Anstey, D. Edmund Heyworth, Benton E. Price, Mark D. Gill, Thomas J. TI Effect of Timing of ACL Reconstruction in Surgery and Development of Meniscal and Chondral Lesions SO PHYSICIAN AND SPORTSMEDICINE LA English DT Article DE anterior cruciate ligament; anterior cruciate ligament reconstruction; meniscal tears; cartilage lesions; timing of surgery ID ANTERIOR CRUCIATE LIGAMENT; DEFICIENT KNEE; POSTERIOR MOTION; TEARS; INJURY; OSTEOARTHRITIS; RISK AB Purpose: To investigate whether a delay in the timing of surgery of > 6 months compared with performing the surgery <= 6 months after the anterior cruciate ligament (ACL) injury leads to an increased risk of injuries or degenerative changes in the ACL-deficient knee. Methods: Patients who underwent primary ACL reconstruction at an academic tertiary care center, and had preoperative magnetic resonance imaging (MRI) performed within 2 months of the time of the ACL injury were included. The prevalence of degenerative changes at the time of surgery was assessed and related to the timing of ACL surgery, with "early reconstruction" defined as a surgery performed <= 6 months and "delayed reconstruction" defined as surgery performed > 6 months after ACL injury. "New" meniscal tears were defined as lesions detected at the time of surgery that were not detected by MM. Results: Of 195 patients who were selected based on inclusion criteria, 171 patients underwent surgery <= 6 months after their ACL injury, and 24 patients underwent surgery > 6 months after their ACL injury. The prevalence of new medial meniscal tears in the early reconstruction group was 4.1%, while in the delayed reconstruction group, the prevalence was 16.7% (P = 0.012). Conclusion: A delay in the timing of ACL reconstruction from <= 6 months to > 6 months following injury is associated with a significant increase in the prevalence of medial meniscal tears (P= 0.012), with a relative risk of 4.07 (CI, 1.29-12.88). C1 [Anstey, D. Edmund] Massachusetts Gen Hosp, Sports Med Serv, Div Sports Med, Dept Orthoped Surg, Boston, MA 02114 USA. [Heyworth, Benton E.] Childrens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA. [Price, Mark D.] Univ Massachusetts, Sch Med, Mem Med Ctr, Dept Orthoped Surg,Div Sports Med, Worcester, MA USA. RP Anstey, DE (reprint author), Massachusetts Gen Hosp, Sports Med Serv, Div Sports Med, Dept Orthoped Surg, 175 Cambridge St,4th Floor, Boston, MA 02114 USA. EM david_anstey@hms.harvard.edu NR 25 TC 12 Z9 12 U1 0 U2 5 PU JTE MULTIMEDIA PI BERWYN PA 1235 WESTLAKES DR, STE 220, BERWYN, PA 19312 USA SN 0091-3847 J9 PHYSICIAN SPORTSMED JI Physician Sportsmed. PD FEB PY 2012 VL 40 IS 1 BP 36 EP 40 DI 10.3810/psm.2012.02.1949 PG 5 WC Primary Health Care; Orthopedics; Sport Sciences SC General & Internal Medicine; Orthopedics; Sport Sciences GA 934CO UT WOS:000303419500011 PM 22508249 ER PT J AU Freehill, MT Shi, LL Tompson, JD Warner, JJP AF Freehill, Michael T. Shi, Lewis L. Tompson, Jeffrey D. Warner, Jon J. P. TI Suprascapular Neuropathy: Diagnosis and Management SO PHYSICIAN AND SPORTSMEDICINE LA English DT Article DE shoulder; suprascapular nerve; ganglion cyst; compression; rotator cuff ID ROTATOR-CUFF TEARS; PARSONAGE-TURNER-SYNDROME; SHOULDER GANGLION CYST; NERVE ENTRAPMENT; SPINOGLENOID NOTCH; VOLLEYBALL PLAYERS; LABRAL TEARS; ARTHROSCOPIC DECOMPRESSION; PAINFUL SHOULDER; MR ARTHROGRAPHY AB Although historically considered a diagnosis of exclusion, suprascapular neuropathy may be more common than once believed, as more recent reports are describing the condition as a cause of substantial pain and weakness in patients with and without concomitant shoulder pathology. The etiology is traction or compression of the suprascapular nerve. This can result from a space-occupying lesion, such as a ganglion cyst, or a traction injury as a result of repetitive overhead activities. More recent studies have cited cases of traction injuries occurring with retraction of a large rotator cuff tear. Atrophy of the infraspinatus and/or supraspinatus rotator cuff muscles with resultant weakness in forward flexion and/or external rotation of the shoulder on physical examination may be demonstrated. Magnetic resonance imaging (MRI) is the preferred modality to assess atrophy of the rotator cuff muscles as well as assess potential causes of suprascapular nerve compression. Electromyography and nerve conduction velocity studies remain the gold standard for confirmation of the diagnosis of suprascapular neuropathy; however, nerve pain may occur even in the setting of a negative electromyography. Initial management is usually nonoperative, consisting of activity modification, physical therapy, and nonsteroidal anti-inflammatory drugs. Surgical intervention is considered for patients with nerve compression by an external source or for symptoms refractory to conservative measures. Decompression of the suprascapular nerve may be accomplished through an open approach, although arthroscopic surgical approaches have become more common in the past several years. C1 [Freehill, Michael T.] Massachusetts Gen Hosp, Harvard Shoulder Serv, Yawkey Ctr 3G, Boston, MA 02114 USA. RP Freehill, MT (reprint author), Massachusetts Gen Hosp, Harvard Shoulder Serv, Yawkey Ctr 3G, 55 Fruit St, Boston, MA 02114 USA. EM jwarner@partners.org NR 95 TC 6 Z9 7 U1 2 U2 9 PU JTE MULTIMEDIA PI BERWYN PA 1235 WESTLAKES DR, STE 220, BERWYN, PA 19312 USA SN 0091-3847 J9 PHYSICIAN SPORTSMED JI Physician Sportsmed. PD FEB PY 2012 VL 40 IS 1 BP 72 EP 83 DI 10.3810/psm.2012.02.1953 PG 12 WC Primary Health Care; Orthopedics; Sport Sciences SC General & Internal Medicine; Orthopedics; Sport Sciences GA 934CO UT WOS:000303419500015 PM 22508253 ER PT J AU Fukumura, D AF Fukumura, Dai TI Exploiting and taming abnormal tumor microvasculature and microenvironment SO CELLULAR ONCOLOGY LA English DT Meeting Abstract CT Joint Meeting of the European Workshop on Cytogenetics and Molecular Genetics of Solid Tumours/Conference of the International-Society-for-Cellular-Oncology (ISCO) CY MAR 04-08, 2012 CL Palma, SPAIN SP Int Soc Cellular Oncol (ISCO) C1 [Fukumura, Dai] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Edwin L Steele Lab,Dept Radiat Oncol, Boston, MA USA. EM dai@steele.mgh.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 2211-3428 J9 CELL ONCOL JI Cell. Oncol. PD FEB PY 2012 VL 35 SU 1 BP S12 EP S13 PG 2 WC Oncology; Cell Biology; Pathology SC Oncology; Cell Biology; Pathology GA 927ZE UT WOS:000302948400023 ER PT J AU Ueno, H Ferrari, G Hattori, T Saban, DR Katikireddy, KR Chauhan, SK Dana, R AF Ueno, Hiroki Ferrari, Giulio Hattori, Takaaki Saban, Daniel R. Katikireddy, Kishore R. Chauhan, Sunil K. Dana, Reza TI Dependence of Corneal Stem/Progenitor Cells on Ocular Surface Innervation SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID SIDE-POPULATION CELLS; EPITHELIAL STEM-CELLS; NERVE GROWTH-FACTOR; P-DERIVED PEPTIDE; NEUROTROPHIC KERATOPATHY; AMNIOTIC MEMBRANE; DIABETES-MELLITUS; HUMAN LIMBAL; ADULT-MOUSE; DYE EFFLUX AB PURPOSE. Neurotrophic keratopathy (NK) is a corneal degeneration associated with corneal nerve dysfunction. It can cause corneal epithelial defects, stromal thinning, and perforation. However, it is not clear if and to which extent epithelial stem cells are affected in NK. The purpose of this study was to identify the relationship between corneolimbal epithelial progenitor/stem cells and sensory nerves using a denervated mouse model of NK. METHODS. NK was induced in mice by electrocoagulation of the ophthalmic branch of the trigeminal nerve. The absence of corneal nerves was confirmed with beta-III tubulin immunostaining and blink reflex test after 7 days. ATP-binding cassette subfamily G member 2 (ABCG2), p63, and hairy enhancer of split 1 (Hes1) were chosen as corneolimbal stem/progenitor cell markers and assessed in denervated mice versus controls by immunofluorescent microscopy and real-time PCR. In addition, corneolimbal stem/progenitor cells were detected as side population cells using flow cytometry, and colony-forming efficiency assay was performed to assess their function. RESULTS. ABCG2, p63, and Hes1 immunostaining were significantly decreased in denervated eyes after 7 days. Similarly, the expression levels of ABCG2, p63, K15, Hes1, and N-cadherin transcripts were also significantly decreased in denervated eyes. Stem/progenitor cells measured as side population from NK mice were decreased by approximately 75% compared with normals. In addition, the authors found a significant (P = 0.038) reduction in colony-forming efficiency of stem/progenitor cells harvested from denervated eyes. CONCLUSIONS. Corneolimbal stem/progenitor cells are significantly reduced after depletion of sensory nerves. The data suggest a critical role of innervation in maintaining stem cells and/or the stem cell niche. (Invest Ophthalmol Vis Sci. 2012; 53: 867-872) DOI: 10.1167/iovs.11-8438 C1 [Ueno, Hiroki; Hattori, Takaaki; Saban, Daniel R.; Katikireddy, Kishore R.; Chauhan, Sunil K.; Dana, Reza] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA. [Ueno, Hiroki; Hattori, Takaaki; Saban, Daniel R.; Katikireddy, Kishore R.; Chauhan, Sunil K.; Dana, Reza] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA USA. [Ferrari, Giulio] IRCCS, Bietti Eye Fdn, Rome, Italy. RP Dana, R (reprint author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA. EM reza.dana@schepens.harvard.edu RI ferrari, giulio/J-9260-2016 OI ferrari, giulio/0000-0001-6474-9908 FU NIH/NEI [K24 EY019098, R01-EY-20889] FX Supported by NIH/NEI Grants K24 EY019098 and R01-EY-20889. NR 43 TC 33 Z9 34 U1 2 U2 14 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD FEB PY 2012 VL 53 IS 2 BP 867 EP 872 DI 10.1167/iovs.11-8438 PG 6 WC Ophthalmology SC Ophthalmology GA 925VA UT WOS:000302788600045 PM 22232434 ER PT J AU Sapozhnikova, V Willsey, B Asmis, R Wang, TY Jenkins, JT Mancuso, J Ma, LL Kuranov, R Milner, TE Johnston, K Feldman, MD AF Sapozhnikova, Veronika Willsey, Brian Asmis, Reto Wang, Tianyi Jenkins, James Travis Mancuso, Jacob Ma, Li Leo Kuranov, Roman Milner, Thomas E. Johnston, Keith Feldman, Marc D. TI Use of near-infrared luminescent gold nanoclusters for detection of macrophages SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE nanoparticles; imaging; luminescence spectroscopy; biophotonics ID QUANTUM DOTS; NANOPARTICLES; FLUORESCENCE; SILICA; CANCER; MOUSE; CELLS AB We determined the effect of aggregation and coating thickness of gold on the luminescence of nanoparticles engulfed by macrophages and in gelatin phantoms. Thin gold-coated iron oxide nanoclusters (nanoroses) have been developed to target macrophages to provide contrast enhancement for near-infrared optical imaging applications. We compare the brightness of nanoroses luminescent emissions in response to 635 nm laser excitation to other nanoparticles including nanoshells, nanorods, and Cy5 conjugated iron oxide nanoparticles. Luminescent properties of all these nanoparticles were investigated in monomeric and aggregated form in gelatin phantoms and primary macrophage cell cultures using confocal microscopy. Aggregation of the gold nanoparticles increased luminescence emission and correlated with increased surface mass of gold per nanoparticle (nanoshells 37 +/- 14.30 x 10(-3) brightness with 1.23 x 10(-4) wt of gold (g)/nanoparticle versus original nanorose 1.45 +/- 0.37 x 10(-3) with 2.10 x 10(-16) wt of gold/nanoparticle, p < 0.05). Nanoshells showed greater luminescent intensity than original nanoroses or Cy5 conjugated iron oxide nanoparticles when compared as nanoparticles per macrophage (38 +/- 10 versus 11 +/- 2.8 versus 17 +/- 6.5, p < 0.05, respectively, ANOVA), but showed relatively poor macrophage uptake (1025 +/- 128 versus 7549 +/- 236 versus 96, 000 nanoparticles/cell, p < 0.05, student t-test nanoshel Is versus nanoroses). Enhancement of gold fluorescent emissions by nanoparticles can be achieved by reducing the thickness of the gold coating, by clustering the gold on the surface of the nanoparticles (nanoshells), and by clustering the gold nanoparticles themselves. (C) 2012 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.JBO.17.2.026006] C1 [Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX 78229 USA. [Willsey, Brian; Ma, Li Leo; Johnston, Keith] Univ Texas Austin, Dept Chem Engn, Austin, TX 78712 USA. [Sapozhnikova, Veronika] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Asmis, Reto] Univ Texas Hlth Sci Ctr San Antonio, Dept Clin Lab Sci, San Antonio, TX 78229 USA. [Asmis, Reto] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Wang, Tianyi] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Kuranov, Roman] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Milner, Thomas E.] Univ Texas Austin, Inst Cellular & Mol Biol, Dept Biomed Engn, Austin, TX 78712 USA. RP Feldman, MD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Room 5-642,7703 Floyd Curl Dr, San Antonio, TX 78248 USA. EM feldmanm@uthscsa.edu OI Ma, Li/0000-0002-0959-5616 FU UTHSCSA; NIH-NCI [P30 CA54174]; NIH-NIA [P01AG19316]; Veterans Administration; NIH NRSA [HL07446] FX The authors would like to thank Hunter Barbara for assistance with TEM imaging and cell culture processing. Confocal images were generated in the Core Optical Imaging Facility, which is supported by UTHSCSA, NIH-NCI P30 CA54174 (CTRC at UTHSCSA) and NIH-NIA P01AG19316. The current study was supported by Veterans Administration Merit Grant, and NIH NRSA Grant #HL07446. NR 29 TC 4 Z9 4 U1 3 U2 43 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD FEB PY 2012 VL 17 IS 2 AR 026006 DI 10.1117/1.JBO.17.2.026006 PG 12 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 929AM UT WOS:000303033600022 PM 22463038 ER PT J AU Wirth, D Snuderl, M Sheth, S Kwon, CS Frosch, MP Curry, W Yaroslavsky, AN AF Wirth, Dennis Snuderl, Matija Sheth, Sameer Kwon, Churl-Su Frosch, Matthew P. Curry, William Yaroslavsky, Anna N. TI Identifying brain neoplasms using dye-enhanced multimodal confocal imaging SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE brain cancers; multimodal confocal; fluorescence; reflectance ID METHYLENE-BLUE; RADIOTHERAPY; RESECTION; CANCER; TUMORS AB Brain tumors cause significant morbidity and mortality even when benign. Completeness of resection of brain tumors improves quality of life and survival; however, that is often difficult to accomplish. The goal of this study was to evaluate the feasibility of using multimodal confocal imaging for intraoperative detection of brain neoplasms. We have imaged different types of benign and malignant, primary and metastatic brain tumors. We correlated optical images with histopathology and evaluated the possibility of interpreting confocal images in a manner similar to pathology. Surgical specimens were briefly stained in 0.05 mg/ml aqueous solution of methylene blue (MB) and imaged using a multimodal confocal microscope. Reflectance and fluorescence signals of MB were excited at 642 nm. Fluorescence emission of MB was registered between 670 and 710 nm. After imaging, tissues were processed for hematoxylin and eosin (H&E) histopathology. The results of comparison demonstrate good correlation between fluorescence images and histopathology. Reflectance images provide information about morphology and vascularity of the specimens, complementary to that provided by fluorescence images. Multimodal confocal imaging has the potential to aid in the intraoperative detection of microscopic deposits of brain neoplasms. The application of this technique may improve completeness of resection and increase patient survival. (c) 2012 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/ 1.JBO.17.2.026012] C1 [Wirth, Dennis; Yaroslavsky, Anna N.] Univ Massachusetts, Dept Phys & Appl Phys, Lowell, MA 01854 USA. [Snuderl, Matija; Frosch, Matthew P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA. [Sheth, Sameer; Kwon, Churl-Su; Curry, William] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA 02114 USA. [Yaroslavsky, Anna N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Yaroslavsky, AN (reprint author), Univ Massachusetts, Dept Phys & Appl Phys, 1 Univ Ave, Lowell, MA 01854 USA. EM yaroslav@helix.mgh.harvard.edu OI Snuderl, Matija/0000-0003-0752-0917 FU Massachusetts General Hospital Cancer Center; University of Massachusetts at Lowell FX We gratefully acknowledge Irina Tabatadze for processing histopathology and Polina Ogas for help with sample transportation. Funding was provided by the Massachusetts General Hospital Cancer Center and a seed grant from the University of Massachusetts at Lowell. NR 24 TC 8 Z9 8 U1 0 U2 6 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD FEB PY 2012 VL 17 IS 2 AR 026012 DI 10.1117/1.JBO.17.2.026012 PG 7 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 929AM UT WOS:000303033600028 PM 22463044 ER PT J AU Li, Y Iglehart, JD Richardson, AL Wang, ZC AF Li, Yang Iglehart, J. Dirk Richardson, Andrea L. Wang, Zhigang Charles TI The amplified cancer gene LAPTM4B promotes tumor growth and tolerance to stress through the induction of autophagy SO AUTOPHAGY LA English DT Editorial Material DE LAPTM4b; breast cancer; autophagy; lysosome-mediated death; metabolic stress AB Autophagy is a fundamental salvage pathway that encapsulates damaged cellular components and delivers them to the lysosome for degradation and recycling. This pathway usually conducts a protective cellular response to nutrient deprivation and various stresses. Tumor cells live with metabolic stress and use autophagy for their survival during tumor progression and metastasis. Genomic instability in tumor cells may result in amplification of crucial gene(s) for autophagy and upregulate the autophagic pathway. We demonstrate that a cancer-associated gene, LAPTM4B, plays an important role in lysosomal functions and is critical for autophagic maturation. Its amplification and overexpression promote autophagy, which renders tumor cells resistant to metabolic and genotoxic stress and results in more rapid tumor growth. C1 [Li, Yang; Iglehart, J. Dirk; Richardson, Andrea L.; Wang, Zhigang Charles] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Iglehart, J. Dirk; Richardson, Andrea L.; Wang, Zhigang Charles] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. RP Richardson, AL (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM arichardson@partners.org; zhigang_wang@dfci.harvard.edu NR 0 TC 13 Z9 15 U1 0 U2 4 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1554-8627 J9 AUTOPHAGY JI Autophagy PD FEB PY 2012 VL 8 IS 2 BP 273 EP 274 DI 10.4161/auto.8.2.18941 PG 2 WC Cell Biology SC Cell Biology GA 920PY UT WOS:000302420100014 PM 22301992 ER PT J AU Ebrahimi-Fakhari, D McLean, PJ Unni, VK AF Ebrahimi-Fakhari, Darius McLean, Pamela J. Unni, Vivek K. TI Alpha-synuclein's degradation in vivo Opening a new (cranial) window on the roles of degradation pathways in Parkinson disease SO AUTOPHAGY LA English DT Editorial Material DE neurodegeneration; Parkinson disease; Lewy bodies; alpha-synuclein; degradation; autophagy; lysosome; proteasome; in vivo; multiphoton imaging AB Progressive accumulation of alpha-synuclein is key to the pathology of many neurodegenerative diseases, including Parkinson disease and dementia with Lewy bodies. Increased intracellular levels of alpha-synuclein may be caused by enhanced expression or alterations in protein degradation pathways. Here we review our recent study showing that the ubiquitin-proteasome system and the autophagy-lysosomal pathway are differentially involved in alpha-synuclein's degradation in vivo. We discuss the key findings obtained with our novel in vivo approach and also present a model for the progression of protein aggregation and dysfunctional degradation in Parkinson disease. C1 [Ebrahimi-Fakhari, Darius; McLean, Pamela J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis,Dept Neurol, Charlestown, MA 02129 USA. [Ebrahimi-Fakhari, Darius] Univ Heidelberg, Inst Anat & Cell Biol, Heidelberg, Germany. [Unni, Vivek K.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Unni, Vivek K.] Oregon Hlth & Sci Univ, Parkinson Ctr Oregon, Portland, OR 97201 USA. [Unni, Vivek K.] Oregon Hlth & Sci Univ, Jungers Ctr Neurosci Res, Portland, OR 97201 USA. RP McLean, PJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis,Dept Neurol, Charlestown, MA 02129 USA. EM pmclean@partners.org; unni@ohsu.edu OI Ebrahimi-Fakhari, Darius/0000-0002-0026-4714 FU NINDS NIH HHS [K08 NS069625] NR 0 TC 25 Z9 26 U1 0 U2 3 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1554-8627 J9 AUTOPHAGY JI Autophagy PD FEB PY 2012 VL 8 IS 2 BP 281 EP 283 DI 10.4161/auto.8.2.18938 PG 3 WC Cell Biology SC Cell Biology GA 920PY UT WOS:000302420100017 PM 22301995 ER PT J AU Gollan, JK Fava, M Kurian, B Wisniewski, SR Rush, AJ Daly, E Miyahara, S Trivedi, MH AF Gollan, Jackie K. Fava, Maurizio Kurian, Benji Wisniewski, Stephen R. Rush, A. John Daly, Ella Miyahara, Sachiko Trivedi, Madhukar H. TI What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression? SO DEPRESSION AND ANXIETY LA English DT Article DE anxiety; change; depression; SSRI; outcome ID STAR-ASTERISK-D; SEQUENCED TREATMENT ALTERNATIVES; SEROTONIN REUPTAKE INHIBITORS; MEASUREMENT-BASED CARE; DIAGNOSTIC SCREENING QUESTIONNAIRE; REPORT QIDS-SR; MAJOR DEPRESSION; ANXIOUS DEPRESSION; RELIEVE DEPRESSION; TRICYCLIC ANTIDEPRESSANTS AB Selective Serotonin Reuptake Inhibitor (SSRI) pharmacotherapy for depression. Method: Adult outpatients with nonpsychotic major depressive disorder were enrolled in an 8-week acute phase SSRI treatment trial at 15 clinical sites across the United States. Worsening anxiety was defined as a greater than 2-point increase on the Beck Anxiety Inventory (BAI) between baseline and Week 2. New onset of anxiety symptoms was ascribed when the BAI baseline rating was 0 and the Week 2 value was greater or equal to 2 points on the BAI. Results: Overall, after 2 weeks of treatment, 48.8% (98 of 201 participants) reported improvement in anxiety symptoms, 36.3% (73 of 201) reported minimal symptom change, and 14.9% (30 of 201) reported worsening of anxiety symptoms. No association was found between change in anxiety symptoms within the first 2 weeks and change in depressive symptoms or remission at the end of 8 weeks of treatment. For participants with clinically meaningful anxiety symptoms at baseline, however, worsening of anxiety during the first 2 weeks of treatment was associated with worsening depressive symptoms by 8 weeks (P = .054). Conclusions: The trajectory of anxiety symptom change early in SSRI treatment is an important indicator of eventual outcome for outpatients with major depression and baseline anxiety symptoms. Depression and Anxiety 29:94-101, 2012. (C) 2011 Wiley Periodicals, Inc. C1 [Gollan, Jackie K.] Northwestern Univ, Feinberg Sch Med, Asher Ctr Study & Treatment Depress Disorders, Stress & Depress Lab,Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Fava, Maurizio] Massachusetts Gen Hosp, Clin Psychopharmacol Unit, Boston, MA 02114 USA. [Kurian, Benji; Daly, Ella; Trivedi, Madhukar H.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Wisniewski, Stephen R.] Univ Pittsburgh, Grad Sch Publ Hlth, Epidemiol Data Ctr, Pittsburgh, PA USA. [Rush, A. John] Duke Natl Univ Singapore, Singapore, Singapore. [Miyahara, Sachiko] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Gollan, JK (reprint author), Northwestern Univ, Feinberg Sch Med, Asher Ctr Study & Treatment Depress Disorders, Stress & Depress Lab,Dept Psychiat & Behav Sci, 446 E Ontario St,Suite 7-100, Chicago, IL 60611 USA. EM j-gollan@northwestern.edu OI Wisniewski, Stephen/0000-0002-3877-9860; Rush, Augustus/0000-0003-2004-2382 FU National Institute of Mental Health [N01MH90003]; National Alliance for Research in Schizophrenia and Depression; Educational Foundation of America; American Foundation of Suicide Prevention; Northwestern Memorial Hospital Women's Board; Evergreen Invitational Committee; Brain Research Foundation; Abbott Laboratories; Abdi Brahim; Alkermes; Aspect Medical Systems; AstraZeneca; Bayer AG; Biovail Pharmaceuticals; BrainCells; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Cephalon, Inc.; Compellis; Cypress Pharmaceuticals; DOV Pharmaceuticals; Eli Lilly; EPIX Pharmaceuticals; Fabre-Kramer Pharmaceuticals; Forest Pharmaceuticals; GlaxoSmithKline; Grunenthal GmbH; Janssen Pharmaceutica; Jazz Pharmaceuticals; J & J Pharmaceuticals; Knoll Pharmaceutical Company; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Lundbeck; MedAvante; Neuronetics; Novartis; Nutrition 21; Organon; PamLab; Pfizer Inc.; PharmaStar; Pharmavite; Roche; Sanofi-Synthelabo; Sepracor; Solvay Pharmaceuticals; Somaxon; Somerset Pharmaceuticals; Wyeth-Ayerst Laboratories; Targacept, Inc.; Advanced Neuromodulation Systems; Best Practice Project Management; Bristol-Myers Squibb; Cyberonics; Gerson Lehman Group; Merck; Ono Pharmaceutical; Organon USA; Personality Disorder Research Corp.; Robert Wood Johnson Foundation; Stanley Foundation; Urban Institute; Agency for Healthcare Research and Quality; National Institute on Drug Abuse; Targacept FX The NIMH approved of the design of the overall study and reviewed its conduct, but performed no role in the collection, management, and interpretation of the data analyzed in this manuscript, nor in the preparation, review, or approval of the manuscript. We express our thanks to the SAMS investigators and staff for their work in running this complex study. Also, we acknowledge the editorial support of Jon Kilner, MS, MA (Pittsburgh, PA). Dr. Gollan has received research support from National Institute of Mental Health; National Alliance for Research in Schizophrenia and Depression; Educational Foundation of America, American Foundation of Suicide Prevention, Northwestern Memorial Hospital Women's Board, Evergreen Invitational Committee, Brain Research Foundation. Dr. Fava has received research support from, served in advisory capacity to, or received speakers honoraria from Abbott Laboratories, Abdi Brahim; Alkermes, Aspect Medical Systems, AstraZeneca, Bayer AG, Biovail Pharmaceuticals, BrainCells, Boehringer-Ingelheim, Bristol-Myers Squibb Company; Cephalon, Inc.; Compellis, Cypress Pharmaceuticals, DOV Pharmaceuticals, Eli Lilly; EPIX Pharmaceuticals, Fabre-Kramer Pharmaceuticals; Forest Pharmaceuticals; GlaxoSmithKline; Grunenthal GmbH; Janssen Pharmaceutica; Jazz Pharmaceuticals; J & J Pharmaceuticals; Knoll Pharmaceutical Company; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Lundbeck, MedAvante; Neuronetics; Novartis; Nutrition 21, Organon, PamLab, Pfizer Inc.; PharmaStar; Pharmavite; Roche; Sanofi-Synthelabo, Sepracor, Solvay Pharmaceuticals; Somaxon; Somerset Pharmaceuticals; Wyeth-Ayerst Laboratories. Dr. Kurian has received research grant support from Targacept, Inc. Dr. Rush has received research support from, served in advisory capacity to, or received speakers honoraria from Advanced Neuromodulation Systems; AstraZeneca; Best Practice Project Management; Bristol-Myers Squibb; Cyberonics; Eli Lilly; Forest Pharmaceuticals; Gerson Lehman Group; GlaxoSmithKline; Jazz Pharmaceuticals; Merck; NIMH; Neuronetics; Ono Pharmaceutical; Organon USA; PamLab; Personality Disorder Research Corp.; Pfizer Inc.; Robert Wood Johnson Foundation; Stanley Foundation; Urban Institute; and Wyeth-Ayerst Laboratories. Dr. Trivedi has received research support from the Agency for Healthcare Research and Quality, National Institute of Mental Health, National Institute on Drug Abuse, and Targacept. This project was funded by the National Institute of Mental Health under Contract N01MH90003 to UT Southwestern Medical Center at Dallas (P. I.: M. Trivedi). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. NR 45 TC 10 Z9 11 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PD FEB PY 2012 VL 29 IS 2 BP 94 EP 101 DI 10.1002/da.20917 PG 8 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 923KO UT WOS:000302618400003 PM 22147631 ER PT J AU Davis, LL Pilkinton, P Wisniewski, SR Trivedi, MH Gaynes, BN Howland, RH Zisook, S Balasubramani, G Fava, M Rush, AJ AF Davis, Lori L. Pilkinton, Patricia Wisniewski, Stephen R. Trivedi, Madhukar H. Gaynes, Bradley N. Howland, Robert H. Zisook, Sidney Balasubramani, G. K. Fava, Maurizio Rush, A. John TI EFFECT OF CONCURRENT SUBSTANCE USE DISORDER ON THE EFFECTIVENESS OF SINGLE AND COMBINATION ANTIDEPRESSANT MEDICATIONS FOR THE TREATMENT OF MAJOR DEPRESSION: AN EXPLORATORY ANALYSIS OF A SINGLE-BLIND RANDOMIZED TRIAL SO DEPRESSION AND ANXIETY LA English DT Article DE major depressive disorder; substance use disorder; dual diagnosis; combination antidepressants; treatment outcome ID STAR-ASTERISK-D; MEASUREMENT-BASED CARE; DIAGNOSTIC SCREENING QUESTIONNAIRE; SEQUENCED TREATMENT ALTERNATIVES; ALCOHOL-USE DISORDERS; PSYCHIATRIC-DISORDERS; SELF-REPORT; CLINICAL-FEATURES; ABUSE DEPENDENCE; QUICK INVENTORY AB Background: The co-occurrence of substance use disorder (SUD) and major depressive disorder (MDD) is common and is often thought to impair response to antidepressant therapy. These patients are often excluded from clinical trials, resulting in a significant knowledge gap regarding optimal pharmacotherapy for the treatment of MDD with concurrent SUD. Methods: In the Combining Medications to Enhance Depression Outcomes study, 665 adult outpatients with chronic and/or recurrent MDD were prospectively treated with either escitalopram monotherapy (escitalopram and placebo) or an antidepressant combination (venalfaxine-XR and mirtazapine or escitalopram and bupropion-SR). Participants with MDD and concurrent SUD (13.1%) were compared to those without SUD (86.9%) on sociodemographic and clinical characteristics at baseline and treatment response at 12- and 28-week endpoints. Results: The participants with MDD and SUD were more likely to be male and have current suicidal thoughts/plans, and had a greater lifetime severity and number of suicide attempts, and a higher number of concurrent Axis I disorders, particularly concurrent anxiety disorders. There were no significant differences between the MDD with or without SUD groups in terms of dose, time in treatment, response or remission at week 12 and 28. Furthermore, no significant differences in response or remission rates were noted between groups on the basis of the presence or absence of SUD and treatment assignment. Conclusions: Although significant baseline sociodemographic and clinical differences exist, patients with MDD and concurrent SUD are as likely to respond and remit to a single or combination antidepressant treatment as those presenting without SUD. Depression and Anxiety 29:111-122, 2012. (C) 2012 Wiley Periodicals, Inc. C1 [Davis, Lori L.; Pilkinton, Patricia] VA Med Ctr, Tuscaloosa, AL USA. [Davis, Lori L.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Wisniewski, Stephen R.; Balasubramani, G. K.] Univ Pittsburgh, Epidemiol Data Ctr, Pittsburgh, PA USA. [Wisniewski, Stephen R.; Howland, Robert H.] Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Pittsburgh, PA 15213 USA. [Trivedi, Madhukar H.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Gaynes, Bradley N.] Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC USA. [Zisook, Sidney] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Zisook, Sidney] VA Healthcare Syst, San Diego, CA USA. [Fava, Maurizio] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. [Rush, A. John] Duke NUS Grad Med Sch Singapore, Singapore, Singapore. RP Davis, LL (reprint author), VA Med Ctr 151, 3701 Loop Rd E, Tuscaloosa, AL 35404 USA. EM lori.davis@med.va.gov RI Howland, Robert/K-6937-2015; OI Howland, Robert/0000-0002-6533-6010; Wisniewski, Stephen/0000-0002-3877-9860; Gaynes, Bradley/0000-0002-8283-5030; Rush, Augustus/0000-0003-2004-2382; Goundappa K, Balasubramani/0000-0001-7221-1825 FU National Institute of Mental Health, National Institutes of Health [N01MH90003] FX This project has been funded with Federal funds from the National Institute of Mental Health, National Institutes of Health, under Contract N01MH90003 to the University of Texas Southwestern Medical Center at Dallas. NR 56 TC 6 Z9 6 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PD FEB PY 2012 VL 29 IS 2 BP 111 EP 122 DI 10.1002/da.20918 PG 12 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 923KO UT WOS:000302618400005 PM 22495941 ER PT J AU Hinton, DE Kredlow, MA Bui, E Pollack, MH Hofmann, SG AF Hinton, Devon E. Kredlow, Maria A. Bui, Eric Pollack, Mark H. Hofmann, Stefan G. TI Treatment change of somatic symptoms and cultural syndromes among Cambodian refugees with PTSD SO DEPRESSION AND ANXIETY LA English DT Article DE Cambodia; cultural syndromes; culture; PTSD; somatization ID TREATMENT-RESISTANT PTSD; FOCUSED PANIC-ATTACKS; CATASTROPHIC COGNITIONS; DISTRESS; FLASHBACKS; SURVIVORS; IDIOM; MODEL AB Background: There is only one previously published study of treatment change across initial pharmacological treatment for a minority or refugee group with posttraumatic stress disorder (PTSD). That study found that certain somatic symptoms among Southeast Asian populations did not improve across treatment. This article assesses in a culturally sensitive way symptom change through time of Cambodian patients presenting for pharmacotherapy treatment of PTSD. Methods: Fifty-six Cambodian refugees with PTSD and no previous psychiatric treatment were assessed at baseline and then at 3 and 6 months after initiating pharmacotherapy. The measures included the PTSD Checklist; the Cambodian Somatic Symptom and Syndrome Inventory (SSI) to assess culturally salient somatic symptoms and cultural syndromes; and the Short Form-12 Health Survey to assess self-perceived functioning. Results: Across treatment, large effect sizes were seen on all measures (Cohen's d = 1.1-1.4). The SF-12 change score was more highly correlated to the SSI change score (r = .82) than to the PTSD change score (r = .61). Significant change only occurred from baseline to 3 months. Conclusions: Pharmacological treatment for traumatized Cambodian refugees with PTSD seems to lead to improvement not only in PTSD symptoms, but also in culturally salient somatic symptoms and cultural syndromes. Culturally sensitive assessment and treatment should ideally include the assessment of culturally salient somatic symptoms and cultural syndromes. (C) 2011 Wiley Periodicals, Inc. Depression and Anxiety 29:147-154, 2012. C1 [Hinton, Devon E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Hinton, Devon E.; Kredlow, Maria A.; Bui, Eric; Pollack, Mark H.] Harvard Univ, Sch Med, Boston, MA USA. [Hinton, Devon E.] Arbour Counseling Serv, Lowell, MA USA. [Hinton, Devon E.; Hofmann, Stefan G.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Bui, Eric] Univ Toulouse 3, Lab Stress Traumat, F-31062 Toulouse, France. RP Hinton, DE (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 15 Parkman St,WACC 812, Boston, MA 02114 USA. EM devon_hinton@hms.harvard.edu RI Hofmann, Stefan/B-8769-2014; Bui, Eric/J-8347-2015 OI Hofmann, Stefan/0000-0002-3548-9681; Bui, Eric/0000-0002-1413-6473 NR 28 TC 10 Z9 10 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PD FEB PY 2012 VL 29 IS 2 BP 148 EP 155 DI 10.1002/da.20905 PG 8 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 923KO UT WOS:000302618400009 ER PT J AU Villemagne, VL Klunk, WE Mathis, CA Rowe, CC Brooks, DJ Hyman, BT Ikonomovic, MD Ishii, K Jack, CR Jagust, WJ Johnson, KA Koeppe, RA Lowe, VJ Masters, CL Montine, TJ Morris, JC Nordberg, A Petersen, RC Reiman, EM Selkoe, DJ Sperling, RA Van Laere, K Weiner, MW Drzezga, A AF Villemagne, Victor L. Klunk, William E. Mathis, Chester A. Rowe, Christopher C. Brooks, David J. Hyman, Bradley T. Ikonomovic, Milos D. Ishii, Kenji Jack, Clifford R. Jagust, William J. Johnson, Keith A. Koeppe, Robert A. Lowe, Val J. Masters, Colin L. Montine, Thomas J. Morris, John C. Nordberg, Agneta Petersen, Ronald C. Reiman, Eric M. Selkoe, Dennis J. Sperling, Reisa A. Van Laere, Koen Weiner, Michael W. Drzezga, Alexander TI A beta Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING LA English DT Editorial Material ID PITTSBURGH COMPOUND-B; POSITRON-EMISSION-TOMOGRAPHY; MILD COGNITIVE IMPAIRMENT; CEREBRAL AMYLOID ANGIOPATHY; C-11-PIB PET; NEUROPATHOLOGIC ASSESSMENT; LEWY BODIES; MOUSE MODEL; HUMAN BRAIN; PIB-PET C1 [Drzezga, Alexander] Tech Univ Munich, Dept Nucl Med, Munich, Germany. [Villemagne, Victor L.; Rowe, Christopher C.] Austin Hlth, Dept Nucl Med, Heidelberg, Vic, Australia. [Villemagne, Victor L.; Rowe, Christopher C.] Austin Hlth, Ctr PET, Heidelberg, Vic, Australia. [Klunk, William E.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Mathis, Chester A.] Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA USA. [Brooks, David J.] Univ London Imperial Coll Sci Technol & Med, Dept Med, London SW7 2AZ, England. [Brooks, David J.] GE Healthcare, Med Diagnost, Amersham, Bucks, England. [Johnson, Keith A.; Selkoe, Dennis J.; Sperling, Reisa A.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Ishii, Kenji] Tokyo Metropolitan Inst Gerontol, Positron Med Ctr Clin, Itabashi Ku, Tokyo, Japan. [Jack, Clifford R.; Lowe, Val J.] Mayo Clin, Dept Radiol, Rochester, MN USA. [Jagust, William J.] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Johnson, Keith A.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Koeppe, Robert A.] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA. [Masters, Colin L.] Univ Melbourne, Mental Hlth Res Inst, Parkville, Vic 3052, Australia. [Montine, Thomas J.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Morris, John C.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA. [Nordberg, Agneta] Karolinska Univ Hosp, Dept Neurobiol Care Sci & Soc, Karolinska Inst, Stockholm, Sweden. [Petersen, Ronald C.] Mayo Clin, Dept Neurol, Coll Med, Rochester, MN USA. [Reiman, Eric M.] Univ Arizona, Banner Alzheimers Inst, Phoenix, AZ USA. [Van Laere, Koen] Katholieke Univ Leuven Hosp, Div Nucl Med, Louvain, Belgium. [Weiner, Michael W.] Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Drzezga, A (reprint author), Tech Univ Munich, Dept Nucl Med, Munich, Germany. EM villemagne@petnm.unimelb.edu.au; klunkwe@upmc.edu; mathisca@upmc.edu; christopher.rowe@austin.org.au; david.brooks@csc.mrc.ac.uk; bhyman@partners.org; ikonomovicmd@upmc.edu; ishii@pet.tmig.or.jp; jack.clifford@mayo.edu; jagust@berkeley.edu; kajohnson@partners.org; koeppe@umich.edu; vlowe@mayo.edu; c.masters@unimelb.edu.au; tmontine@uw.edu; morrisj@abraxas.wustl.edu; agneta.k.nordberg@ki.se; peter8@mayo.edu; eric.reiman@bannerhealth.com; dselkoe@rics.bwh.harvard.edu; reisa@rics.bwh.harvard.edu; koen.vanlaere@uzleuven.be; michael.weiner@ucsf.edu; a.drzezga@lrz.tu-muenchen.de RI Jack, Clifford/F-2508-2010; IBL, A/C-8408-2013; OI Jack, Clifford/0000-0001-7916-622X; Klunk, William/0000-0001-5512-0251 FU Medical Research Council [MC_U120036861]; NIA NIH HHS [P30 AG019610, R01 AG006173] NR 90 TC 22 Z9 23 U1 0 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1619-7070 J9 EUR J NUCL MED MOL I JI Eur. J. Nucl. Med. Mol. Imaging PD FEB PY 2012 VL 39 IS 2 BP 209 EP 219 DI 10.1007/s00259-011-2045-0 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 918YC UT WOS:000302286600002 PM 22218879 ER PT J AU Kaye, SB Lubinski, J Matulonis, U Ang, JE Gourley, C Karlan, BY Amnon, A Bell-McGuinn, KM Chen, LM Friedlander, M Safra, T Vergote, I Wickens, M Lowe, ES Carmichael, J Kaufman, B AF Kaye, Stan B. Lubinski, Jan Matulonis, Ursula Ang, Joo Ern Gourley, Charlie Karlan, Beth Y. Amnon, Amit Bell-McGuinn, Katherine M. Chen, Lee-May Friedlander, Michael Safra, Tamar Vergote, Ignace Wickens, Mark Lowe, Elizabeth S. Carmichael, James Kaufman, Bella TI Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID HOMOLOGY-DIRECTED REPAIR; DNA-REPAIR; POLY(ADP-RIBOSE) POLYMERASE; GENETIC INSTABILITY; SOLID TUMORS; GUIDELINES; CARCINOMA; EVALUATE; CARRIERS; BREAKS AB Purpose Olaparib (AZD2281), an orally active poly (ADP-ribose) polymerase inhibitor that induces synthetic lethality in BRCA1- or BRCA2-deficient cells, has shown promising clinical efficacy in nonrandomized phase II trials in patients with ovarian cancer with BRCA1 or BRCA2 deficiency. We assessed the comparative efficacy and safety of olaparib and pegylated liposomal doxorubicin (PLD) in this patient population. Patients and Methods In this multicenter, open-label, randomized, phase II study, patients with ovarian cancer that recurred within 12 months of prior platinum therapy and with confirmed germline BRCA1 or BRCA2 mutations were enrolled. Patients were assigned in a 1: 1: 1 ratio to olaparib 200 mg twice per day or 400 mg twice per day continuously or PLD 50 mg/m(2) intravenously every 28 days. The primary efficacy end point was Response Evaluation Criteria in Solid Tumors (RECIST) -assessed progression-free survival (PFS). Secondary end points included objective response rate (ORR) and safety. Results Ninety-seven patients were randomly assigned. Median PFS was 6.5 months (95% CI, 5.5 to 10.1 months), 8.8 months (95% CI, 5.4 to 9.2 months), and 7.1 months (95% CI, 3.7 to 10.7 months) for the olaparib 200 mg, olaparib 400 mg, and PLD groups, respectively. There was no statistically significant difference in PFS (hazard ratio, 0.88; 95% CI, 0.51 to 1.56; P = .66) for combined olaparib doses versus PLD. RECIST-assessed ORRs were 25%, 31%, and 18% for olaparib 200 mg, olaparib 400 mg, and PLD, respectively; differences were not statistically significant. Tolerability of both treatments was as expected based on previous trials. Conclusion The efficacy of olaparib was consistent with previous studies. However, the efficacy of PLD was greater than expected. Olaparib 400 mg twice per day is a suitable dose to explore in further studies in this patient population. J Clin Oncol 30: 372-379. (C) 2011 by American Society of Clinical Oncology C1 [Kaye, Stan B.; Ang, Joo Ern] Royal Marsden Natl Hlth Serv Fdn Trust, Sutton SM2 5PT, Surrey, England. [Kaye, Stan B.; Ang, Joo Ern] Inst Canc Res, Sutton SM2 5PT, Surrey, England. [Gourley, Charlie] Canc Res UK, Edinburgh, Midlothian, Scotland. [Gourley, Charlie] Univ Edinburgh, Canc Res Ctr, Edinburgh, Midlothian, Scotland. [Wickens, Mark; Carmichael, James] AstraZeneca, Macclesfield, Cheshire, England. [Lubinski, Jan] Int Hereditary Canc Ctr, Szczecin, Poland. [Matulonis, Ursula] Dana Farber Canc Inst, Boston, MA 02115 USA. [Karlan, Beth Y.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Chen, Lee-May] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Bell-McGuinn, Katherine M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Lowe, Elizabeth S.] AstraZeneca, Wilmington, DE USA. [Amnon, Amit] Rambam Med Ctr, Haifa, Israel. [Amnon, Amit] Technion Israel Inst Technol, Haifa, Israel. [Safra, Tamar] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Inst Oncol, IL-69978 Tel Aviv, Israel. [Kaufman, Bella] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel. [Friedlander, Michael] Prince Wales Canc Ctr, Sydney, NSW, Australia. [Vergote, Ignace] Univ Hosp Leuven, Louvain, Belgium. RP Kaye, SB (reprint author), Royal Marsden Natl Hlth Serv Fdn Trust, Sycamore House,Downs Rd, Sutton SM2 5PT, Surrey, England. EM stan.kaye@rmh.nhs.uk RI friedlander, michael/G-3490-2013 OI friedlander, michael/0000-0002-6488-0604 FU AstraZeneca; Cancer Research UK; Department of Health, through Experimental Cancer Medicine Centre; Department of Health, through Biomedical Research Centre FX Supported by AstraZeneca. S. B. K. is supported by Cancer Research UK and the Department of Health, through Experimental Cancer Medicine Centre and Biomedical Research Centre grants to the Royal Marsden Hospital and Institute of Cancer Research. NR 25 TC 178 Z9 183 U1 2 U2 22 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 1 PY 2012 VL 30 IS 4 BP 372 EP 379 DI 10.1200/JCO.2011.36.9215 PG 8 WC Oncology SC Oncology GA 923LN UT WOS:000302620900015 PM 22203755 ER PT J AU Greer, JA Pirl, WF Jackson, VA Muzikansky, A Lennes, IT Heist, RS Gallagher, ER Temel, JS AF Greer, Joseph A. Pirl, William F. Jackson, Vicki A. Muzikansky, Alona Lennes, Inga T. Heist, Rebecca S. Gallagher, Emily R. Temel, Jennifer S. TI Effect of Early Palliative Care on Chemotherapy Use and End-of-Life Care in Patients With Metastatic Non-Small-Cell Lung Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID PHASE-III TRIAL; HOSPICE; PERSPECTIVES; FAMILIES; OUTCOMES; QUALITY; AGGRESSIVENESS; CONSULTATION; PREFERENCES; DOCETAXEL AB Purpose Prior research shows that introducing palliative care soon after diagnosis for patients with metastatic non-small-cell lung cancer (NSCLC) is associated with improvements in quality of life, mood, and survival. We sought to investigate whether early palliative care also affects the frequency and timing of chemotherapy use and hospice care for these patients. Patients and Methods This secondary analysis is based on a randomized controlled trial of 151 patients with newly diagnosed metastatic NSCLC presenting to an outpatient clinic at a tertiary cancer center from June 2006 to July 2009. Participants received either early palliative care integrated with standard oncology care or standard oncology care alone. By 18-month follow-up, 133 participants (88.1%) had died. Outcome measures included: first, number and types of chemotherapy regimens, and second, frequency and timing of chemotherapy administration and hospice referral. Results The overall number of chemotherapy regimens did not differ significantly by study group. However, compared with those in the standard care group, participants receiving early palliative care had half the odds of receiving chemotherapy within 60 days of death (odds ratio, 0.47; 95% CI, 0.23 to 0.99; P = .05), a longer interval between the last dose of intravenous chemotherapy and death (median, 64.00 days [range, 3 to 406 days] v 40.50 days [range, 6 to 287 days]; P = .02), and higher enrollment in hospice care for longer than 1 week (60.0% [36 of 60 patients] v 33.3% [21 of 63 patients]; P = .004). Conclusion Although patients with metastatic NSCLC received similar numbers of chemotherapy regimens in the sample, early palliative care optimized the timing of final chemotherapy administration and transition to hospice services, key measures of quality end-of-life care. J Clin Oncol 30: 394-400. (C) 2011 by American Society of Clinical Oncology C1 [Greer, Joseph A.] Massachusetts Gen Hosp, Ctr Canc, Ctr Psychiat Oncol & Behav Sci, Boston, MA 02114 USA. RP Greer, JA (reprint author), Massachusetts Gen Hosp, Ctr Canc, Ctr Psychiat Oncol & Behav Sci, Yawkey Bldg,Suite 9A,55 Fruit St, Boston, MA 02114 USA. EM jgreer2@partners.org FU American Society of Clinical Oncology FX Supported in part by an American Society of Clinical Oncology Career Development Award (J.S.T.) and gifts from the Joanne Hill Monahan Cancer Fund and Golf Fights Cancer. NR 32 TC 148 Z9 150 U1 2 U2 30 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 1 PY 2012 VL 30 IS 4 BP 394 EP 400 DI 10.1200/JCO.2011.35.7996 PG 7 WC Oncology SC Oncology GA 923LN UT WOS:000302620900018 PM 22203758 ER PT J AU Sperduto, PW Kased, N Roberge, D Xu, ZY Shanley, R Luo, XH Sneed, PK Chao, ST Weil, RJ Suh, J Bhatt, A Jensen, AW Brown, PD Shih, HA Kirkpatrick, J Gaspar, LE Fiveash, JB Chiang, V Knisely, JPS Sperduto, CM Lin, N Mehta, M AF Sperduto, Paul W. Kased, Norbert Roberge, David Xu, Zhiyuan Shanley, Ryan Luo, Xianghua Sneed, Penny K. Chao, Samuel T. Weil, Robert J. Suh, John Bhatt, Amit Jensen, Ashley W. Brown, Paul D. Shih, Helen A. Kirkpatrick, John Gaspar, Laurie E. Fiveash, John B. Chiang, Veronica Knisely, Jonathan P. S. Sperduto, Christina Maria Lin, Nancy Mehta, Minesh TI Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID PARTITIONING ANALYSIS RPA; RANDOMIZED PHASE-III; RADIATION; CLASSIFICATION; VALIDATION; CANCER; TRIAL; INDEX AB Purpose Our group has previously published the Graded Prognostic Assessment (GPA), a prognostic index for patients with brain metastases. Updates have been published with refinements to create diagnosis-specific Graded Prognostic Assessment indices. The purpose of this report is to present the updated diagnosis-specific GPA indices in a single, unified, user-friendly report to allow ease of access and use by treating physicians. Methods A multi-institutional retrospective (1985 to 2007) database of 3,940 patients with newly diagnosed brain metastases underwent univariate and multivariate analyses of prognostic factors associated with outcomes by primary site and treatment. Significant prognostic factors were used to define the diagnosis-specific GPA prognostic indices. A GPA of 4.0 correlates with the best prognosis, whereas a GPA of 0.0 corresponds with the worst prognosis. Results Significant prognostic factors varied by diagnosis. For lung cancer, prognostic factors were Karnofsky performance score, age, presence of extracranial metastases, and number of brain metastases, confirming the original Lung-GPA. For melanoma and renal cell cancer, prognostic factors were Karnofsky performance score and the number of brain metastases. For breast cancer, prognostic factors were tumor subtype, Karnofsky performance score, and age. For GI cancer, the only prognostic factor was the Karnofsky performance score. The median survival times by GPA score and diagnosis were determined. Conclusion Prognostic factors for patients with brain metastases vary by diagnosis, and for each diagnosis, a robust separation into different GPA scores was discerned, implying considerable heterogeneity in outcome, even within a single tumor type. In summary, these indices and related worksheet provide an accurate and facile diagnosis-specific tool to estimate survival, potentially select appropriate treatment, and stratify clinical trials for patients with brain metastases. J Clin Oncol 30: 419-425. (C) 2011 by American Society of Clinical Oncology C1 [Shanley, Ryan; Luo, Xianghua] Univ Minnesota, Minneapolis, MN USA. [Jensen, Ashley W.; Brown, Paul D.] Mayo Clin, Rochester, MN USA. [Kased, Norbert; Sneed, Penny K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Xu, Zhiyuan; Chao, Samuel T.; Weil, Robert J.; Suh, John] Cleveland Clin, Cleveland, OH 44106 USA. [Bhatt, Amit] Univ Wisconsin, Madison, WI USA. [Shih, Helen A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. [Lin, Nancy] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kirkpatrick, John] Duke Univ, Med Ctr, Durham, NC USA. [Gaspar, Laurie E.] Univ Colorado, Sch Med, Aurora, CO USA. [Fiveash, John B.] Univ Alabama, Med Ctr Birmingham, Birmingham, AL USA. [Chiang, Veronica] Yale Univ, Sch Med, New Haven, CT USA. [Chiang, Veronica] Yale Canc Ctr, New Haven, CT USA. [Knisely, Jonathan P. S.] Hofstra Univ, Sch Med, Manhasset, NY USA. [Knisely, Jonathan P. S.] N Shore Long Isl Jewish Hlth Syst, Manhasset, NY USA. [Sperduto, Christina Maria] Dartmouth Coll, Hanover, NH 03755 USA. [Mehta, Minesh] Northwestern Univ, Chicago, IL 60611 USA. [Roberge, David] McGill Univ, Ctr Hlth, Montreal, PQ, Canada. RP Sperduto, PW (reprint author), 560 S Maple St,Ste 10, Waconia, MN 55387 USA. EM psperduto@mropa.com RI Xu, Zhiyuan/J-8698-2013; OI Kirkpatrick, John/0000-0002-4019-0350; mehta, minesh/0000-0002-4812-5713 FU US Department of Defense [W81XWH-062-0033]; National Institutes of Health [P30-CA77598]; Varian Medical Systems; Genentech; GlaxoSmithKline; Boehringer Ingelheim; Geron FX Supported in part by Grant No. W81XWH-062-0033 from the US Department of Defense Breast Cancer Research Program (R.J.W.) and by National Institutes of Health Grant No. P30-CA77598 using the services of the Biostatistics and Bioinformatics Core, Masonic Cancer Center, University of Minnesota shared resource.; Research Funding: John Kirkpatrick, Varian Medical Systems; Nancy Lin, Genentech, GlaxoSmithKline, Boehringer Ingelheim, Geron NR 18 TC 287 Z9 293 U1 0 U2 13 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 1 PY 2012 VL 30 IS 4 BP 419 EP 425 DI 10.1200/JCO.2011.38.0527 PG 7 WC Oncology SC Oncology GA 923LN UT WOS:000302620900022 PM 22203767 ER PT J AU Anderson, KC AF Anderson, Kenneth C. TI The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID PROTEASOME INHIBITOR PS-341; LENALIDOMIDE PLUS DEXAMETHASONE; MARROW-TRANSPLANTATION THERAPY; DEPENDENT KINASE INHIBITOR; OVERCOMES DRUG-RESISTANCE; IN-VIVO CYTOTOXICITY; BONE-MARROW; COMBINATION THERAPY; ANTITUMOR-ACTIVITY; INITIAL TREATMENT AB Multiple myeloma (MM) is a remarkable example of rapid bench-to-bedside translation in new drug development. The proteasome inhibitor bortezomib and immunomodulatory drug lenalidomide targeted MM cells in the bone marrow (BM) microenvironment to overcome conventional drug resistance in laboratory and animal models and were rapidly translated into clinical trials demonstrating their efficacy in patients with relapsed and then newly diagnosed MM, with a doubling of the median survival as a direct result. The future is even brighter. First, immune-based therapies are being developed (eg, elotuzumab monoclonal antibody [MoAb]; CD138DM immunotoxin; MM cell-dendritic cell vaccines; CD138, CS-1, and XBP-1 peptide vaccines; anti-17 MoAb; and other treatments to overcome causes of immune dysfunction). Second, promising next-generation agents target the MM cell in its microenvironment (eg, deubiquitinating enzyme inhibitors; chymotryptic [carfilzomib, Onyx 0912, MLN 9708] and broader [NPI-0052] proteasome inhibitors; immunoproteasome inhibitors; and pomalidamide). Moreover, agents targeting bone biology (eg, zoledronic acid, anti-DKK-1 MoAb, anti-B-cell activating factor MoAb and bortezomib, Btk inhibitor) show promise not only in preserving bone integrity but also against MM. Third, rationally based combination therapies, including bortezomib with Akt, mammalian target of rapamycin, or histone deacetylase inhibitors, are active even in bortezomib-refractory MM. Finally, genomics is currently being used in the definition of MM heterogeneity, new target discovery, and development of personalized therapy. Myeloma therefore represents a paradigm for targeting the tumor in its microenvironment, which has already markedly improved patient outcome in MM and has great potential in other hematologic malignancies and solid tumors as well. C1 Harvard Univ, Sch Med, Jerome Lipper Multiple Myeloma Ctr, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Anderson, KC (reprint author), Harvard Univ, Sch Med, Jerome Lipper Multiple Myeloma Ctr, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA. EM kenneth_anderson@dfci.harvard.edu FU National Institute of Health [RO1-50947, PO-1 78,378, P50-100707] FX Supported by National Institute of Health Grants No. RO1-50947, PO-1 78,378, and P50-100707. K. C. A. is an American Cancer Society Clinical Research Professor. NR 73 TC 56 Z9 58 U1 0 U2 9 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 1 PY 2012 VL 30 IS 4 BP 445 EP 452 DI 10.1200/JCO.2011.37.8919 PG 8 WC Oncology SC Oncology GA 923LN UT WOS:000302620900026 PM 22215754 ER PT J AU Si, L Xu, XW Kong, Y Flaherty, KT Chi, ZH Cui, CL Sheng, XA Li, SM Dai, J Yu, WW Guo, J AF Si, Lu Xu, Xiaowei Kong, Yan Flaherty, Keith T. Chi, Zhihong Cui, Chuanliang Sheng, Xinan Li, Siming Dai, Jie Yu, Weiwei Guo, Jun TI Major Response to Everolimus in Melanoma With Acquired Imatinib Resistance SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID GASTROINTESTINAL STROMAL TUMORS; METASTATIC MELANOMA; PHASE-II; KIT; CANCER; MTOR; MANAGEMENT; TRIALS; GENE C1 [Si, Lu; Kong, Yan; Chi, Zhihong; Cui, Chuanliang; Sheng, Xinan; Li, Siming; Dai, Jie; Yu, Weiwei; Guo, Jun] Peking Univ, Canc Hosp & Inst, Beijing 100871, Peoples R China. [Xu, Xiaowei] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Flaherty, Keith T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. RP Si, L (reprint author), Peking Univ, Canc Hosp & Inst, Beijing 100871, Peoples R China. FU Program for New Century Excellent Talents in University [985-2-085-113]; Program for Beijing Medical Disciplines Leaders [2011-2-25]; National Natural Science Foundation of China [30973483, 81172796, 81102068]; Program for Beijing Science Topics [Z111107058811101] FX Supported by Grants No. 985-2-085-113 from the Program for New Century Excellent Talents in University; No. 2011-2-25 from the Program for Beijing Medical Disciplines Leaders; No. 30973483, No. 81172796, and No. 81102068 from the National Natural Science Foundation of China; and No. Z111107058811101 from the Program for Beijing Science Topics. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. NR 23 TC 11 Z9 14 U1 2 U2 8 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 1 PY 2012 VL 30 IS 4 BP E37 EP E40 DI 10.1200/JCO.2011.37.9644 PG 4 WC Oncology SC Oncology GA 923LN UT WOS:000302620900001 PM 22162580 ER PT J AU Drummond, IA AF Drummond, Iain A. TI Cilia functions in development SO CURRENT OPINION IN CELL BIOLOGY LA English DT Article ID LEFT-RIGHT ASYMMETRY; INTRAFLAGELLAR TRANSPORT PROTEINS; SONIC HEDGEHOG; GLI PROTEINS; MEMBRANE-PROTEIN; EPITHELIAL-CELLS; MOTILE CILIA; NODAL CILIA; MOUSE; FLOW AB Recent advances in developmental genetics and human disease gene cloning have highlighted the essential roles played by cilia in developmental cell fate decisions, left-right asymmetry, and the pathology of human congenital disorders. Hedgehog signaling in sensory cilia illustrates the importance of trafficking receptors to the cilia membrane (Patched and Smoothened) and the concept of cilia 'gatekeepers' that restrict entry and egress of cilia proteins (Suppressor of fused: Gli complexes). Cilia-driven fluid flow in the embryonic node highlights the role of motile cilia in both generation and detection of mechanical signals in development. In this brief review I select examples of recent studies that have clarified and consolidated our understanding of the role of cilia in development. C1 [Drummond, Iain A.] Massachusetts Gen Hosp, Div Nephrol, Charlestown, MA 02129 USA. [Drummond, Iain A.] Harvard Univ, Sch Med, Dept Genet, Charlestown, MA 02129 USA. RP Drummond, IA (reprint author), Massachusetts Gen Hosp, Div Nephrol, 149,13th St, Charlestown, MA 02129 USA. EM idrummond@partners.org FU National Institututes of Health [DK053093] FX The author gratefully acknowledges the contributions of Narendra Pathak and Danica Rili for editorial suggestions. This work was funded by the National Institututes of Health grant number DK053093 to IAD. NR 72 TC 48 Z9 48 U1 2 U2 12 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0955-0674 J9 CURR OPIN CELL BIOL JI Curr. Opin. Cell Biol. PD FEB PY 2012 VL 24 IS 1 BP 24 EP 30 DI 10.1016/j.ceb.2011.12.007 PG 7 WC Cell Biology SC Cell Biology GA 917VO UT WOS:000302206900004 PM 22226236 ER PT J AU Springer, TA Dustin, ML AF Springer, Timothy A. Dustin, Michael L. TI Integrin inside-out signaling and the immunological synapse SO CURRENT OPINION IN CELL BIOLOGY LA English DT Article ID T-CELL-ACTIVATION; STRUCTURAL BASIS; DENDRITIC CELLS; EXTENDED CONFORMATIONS; ADHESION RECEPTORS; CYTOPLASMIC DOMAIN; CRYSTAL-STRUCTURE; AFFINITY STATE; HYBRID DOMAIN; CONTACT AREA AB Integrins dynamically equilibrate between three conformational states on cell surfaces. A bent conformation has a closed headpiece. Two extended conformations contain either a closed or an open headpiece. Headpiece opening involves hybrid domain swing-out and a 70 angstrom separation at the integrin knees, which is conveyed by allostery from the hybrid-proximal end of the beta I domain to a 3 angstrom rearrangement of the ligand-binding site at the opposite end of the beta I domain. Both bent-closed and extended-closed integrins have low affinity, whereas extended-open integrin affinity is 10(3) to 10(4) higher. lntegrin-mediated adhesion requires the extended-open conformation, which in physiological contexts is stabilized by post-ligand binding events. Integrins thus discriminate between substrate-bound and soluble ligands. Analysis of LFA-1-ICAM-1 interactions in the immunological synapse suggests that bond lifetimes are on the order of seconds, which is consistent with high affinity interactions subjected to cytoskeletal forces that increase the dissociation rate. LFA-1 beta I domain antagonists abrogate function in the immunological synapse, further supporting a critical role for high affinity LFA-1. C1 [Springer, Timothy A.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Immune Dis Inst, Boston, MA 02115 USA. [Dustin, Michael L.] NYU, Sch Med, Dept Pathol, Program Mol Pathogenesis,Skirball Inst Biomol Med, New York, NY 10016 USA. [Springer, Timothy A.] Childrens Hosp, Boston, MA 02115 USA. RP Springer, TA (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Immune Dis Inst, Boston, MA 02115 USA. EM springer_lab@idi.harvard.edu OI Dustin, Michael/0000-0003-4983-6389 FU NCI NIH HHS [R37 CA031798, R37 CA031798-32] NR 53 TC 118 Z9 122 U1 0 U2 26 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0955-0674 J9 CURR OPIN CELL BIOL JI Curr. Opin. Cell Biol. PD FEB PY 2012 VL 24 IS 1 BP 107 EP 115 DI 10.1016/j.ceb.2011.10.004 PG 9 WC Cell Biology SC Cell Biology GA 917VO UT WOS:000302206900015 PM 22129583 ER PT J AU Zhu, ZZ Hou, LF Bollati, V Tarantini, L Marinelli, B Cantone, L Yang, AS Vokonas, P Lissowska, J Fustinoni, S Pesatori, AC Bonzini, M Apostoli, P Costa, G Bertazzi, PA Chow, WH Schwartz, J Baccarelli, A AF Zhu, Zhong-Zheng Hou, Lifang Bollati, Valentina Tarantini, Letizia Marinelli, Barbara Cantone, Laura Yang, Allen S. Vokonas, Pantel Lissowska, Jolanta Fustinoni, Silvia Pesatori, Angela C. Bonzini, Matteo Apostoli, Pietro Costa, Giovanni Bertazzi, Pier Alberto Chow, Wong-Ho Schwartz, Joel Baccarelli, Andrea TI Predictors of global methylation levels in blood DNA of healthy subjects: a combined analysis SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article DE Blood; DNA methylation; epigenetics; meta-analysis; repetitive elements ID SQUAMOUS-CELL CARCINOMA; LINE-1 HYPOMETHYLATION; MICROSATELLITE INSTABILITY; NECK-CANCER; LIFE-STYLE; ALU; EXPOSURE; ALCOHOL; DISEASE; GENOME AB Background Estimates of global DNA methylation from repetitive DNA elements, such as Alu and LINE-1, have been increasingly used in epidemiological investigations because of their relative low-cost, high-throughput and quantitative results. Nevertheless, determinants of these methylation measures in healthy individuals are still largely unknown. The aim of this study was to examine whether age, gender, smoking habits, alcohol drinking and body mass index (BMI) are associated with Alu or LINE-1 methylation levels in blood leucocyte DNA of healthy individuals. Methods Individual data from five studies including a total of 1465 healthy subjects were combined. DNA methylation was quantified by PCR-pyrosequencing. Results Age [beta = -0.011% of 5-methyl-cytosine (% 5mC)/year, 95% confidence interval (CI) -0.020 to -0.001% 5mC/year] and alcohol drinking (beta = -0.214, 95% CI -0.415 to -0.013) were inversely associated with Alu methylation. Compared with females, males had lower Alu methylation (beta = -0.385, 95% CI -0.665 to -0.104) and higher LINE-1 methylation (-0.796, 95% CI 0.261 to 1.330). No associations were found with smoking or BMI. Percent neutrophils and lymphocytes in blood counts exhibited a positive (beta=0.036, 95% CI 0.010 to 0.061) and negative (beta = -0.038, 95% CI -0.065 to -0.012) association with LINE-1 methylation, respectively. Conclusions Global methylation measures in blood DNA vary in relation with certain host and lifestyle characteristics, including age, gender, alcohol drinking and white blood cell counts. These findings need to be considered in designing epidemiological investigations aimed at identifying associations between DNA methylation and health outcomes. C1 [Zhu, Zhong-Zheng; Bollati, Valentina; Tarantini, Letizia; Marinelli, Barbara; Cantone, Laura; Fustinoni, Silvia; Pesatori, Angela C.; Costa, Giovanni; Bertazzi, Pier Alberto; Baccarelli, Andrea] Univ Milan, Ctr Mol & Genet Epidemiol, Dept Environm & Occupat Hlth, I-20122 Milan, Italy. [Zhu, Zhong-Zheng; Bollati, Valentina; Tarantini, Letizia; Marinelli, Barbara; Cantone, Laura; Fustinoni, Silvia; Pesatori, Angela C.; Costa, Giovanni; Bertazzi, Pier Alberto; Baccarelli, Andrea] IRCCS Maggiore Policlin Hosp, Mangiagalli & Regina Elena Fdn, Milan, Italy. [Zhu, Zhong-Zheng] 113 Hosp Peoples Liberat Army, Dept Oncol, Ningbo, Zhejiang, Peoples R China. [Hou, Lifang] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA. [Hou, Lifang] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA. [Yang, Allen S.] Univ So Calif, Div Hematol, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA USA. [Vokonas, Pantel] Boston Univ, Sch Med, VA Boston Healthcare Syst, Dept Med, Boston, MA 02118 USA. [Lissowska, Jolanta] M Sklodowska Curie Mem Canc Ctr, Dept Canc Epidemiol & Prevent, Warsaw, Poland. [Lissowska, Jolanta] Inst Oncol, Warsaw, Poland. [Bonzini, Matteo] Univ Insubria, Dept Clin & Biol Sci, Varese, Italy. [Apostoli, Pietro] Univ Brescia, Dept Expt & Appl Med Occupat Med & Ind Hyg, Brescia, Italy. [Chow, Wong-Ho] NCI, Div Canc Epidemiol & Genet, NIH, DHHS, Rockville, MD USA. [Schwartz, Joel; Baccarelli, Andrea] Harvard Univ, Sch Publ Hlth, Exposure Epidemiol & Risk Program, Dept Environm Hlth, Boston, MA 02115 USA. RP Baccarelli, A (reprint author), Univ Milan, Ctr Mol & Genet Epidemiol, Dept Environm & Occupat Hlth, Via San Barnaba 8, I-20122 Milan, Italy. EM andrea.baccarelli@unimi.it RI Fustinoni, Silvia/I-8773-2012; Bonzini, Matteo/K-7540-2016; bertazzi, pietro alberto/D-5039-2017; OI Fustinoni, Silvia/0000-0002-0287-7338; Bonzini, Matteo/0000-0002-6405-7554; bertazzi, pietro alberto/0000-0003-3475-2449; Baccarelli, Andrea/0000-0002-3436-0640; Lissowska, Jolanta/0000-0003-2695-5799; pesatori, angela/0000-0002-0261-3252; Cantone, Laura/0000-0003-3660-129X; Bollati, Valentina/0000-0002-0370-9598 FU National Institute of Environmental Health Sciences [ES015172-01]; Environmental Protection Agency [R83241601, R827353]; Cooperative Studies Program/Epidemiology Research and Information Center of the U. S. Department of Veterans Affairs; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC); Intramural Research Program (Division of Cancer Epidemiology and Genetics, NCI) of the National Institutes of Health; Diane Belfer Program for Human Microbial Diversity; National Institutes of Health [R01GM63270]; Italian Association for Cancer Research (AIRC) [(2008-10) [6016]]; Cariplo Foundation [2007-5469]; Italian Ministry of Scientific Research (MIUR) [PRIN-20072S2HT8]; Milan University FX Study 1: National Institute of Environmental Health Sciences [ES015172-01] and Environmental Protection Agency [R83241601, R827353]. The VA Normative Aging Study is supported by the Cooperative Studies Program/Epidemiology Research and Information Center of the U. S. Department of Veterans Affairs and is a component of the Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC). Study 2: Intramural Research Program (Division of Cancer Epidemiology and Genetics, NCI) of the National Institutes of Health, Diane Belfer Program for Human Microbial Diversity and the National Institutes of Health [R01GM63270]. Study 3: Italian Association for Cancer Research (AIRC) (2008-10) [6016]. Study 4: Cariplo Foundation [2007-5469] and Italian Ministry of Scientific Research (MIUR) [PRIN-20072S2HT8]. Study 5: Milan University intramural funding. NR 62 TC 101 Z9 104 U1 2 U2 23 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD FEB PY 2012 VL 41 IS 1 BP 126 EP 139 DI 10.1093/ije/dyq154 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 915LH UT WOS:000302026800017 PM 20846947 ER PT J AU Cheung, OS Bar, M AF Cheung, Olivia S. Bar, Moshe TI Visual prediction and perceptual expertise SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Review DE Expectation; Anticipation; Learning; Perception; Memory; Top-down processing ID FUSIFORM FACE AREA; HUMAN EXTRASTRIATE CORTEX; TOP-DOWN FACILITATION; REAL-WORLD SCENES; FUNCTIONAL NEUROANATOMY; ORBITOFRONTAL CORTEX; OBJECT RECOGNITION; CONTEXTUAL ASSOCIATIONS; MUSICAL NOTATION; PROACTIVE BRAIN AB Making accurate predictions about what may happen in the environment requires analogies between perceptual input and associations in memory. These elements of predictions are based on cortical representations, but little is known about how these processes can be enhanced by experience and training. On the other hand, studies on perceptual expertise have revealed that the acquisition of expertise leads to strengthened associative processing among features or objects, suggesting that predictions and expertise may be tightly connected. Here we review the behavioral and neural findings regarding the mechanisms involving prediction and expert processing, and highlight important possible overlaps between them. Future investigation should examine the relations among perception, memory and prediction skills as a function of expertise. The knowledge gained by this line of research will have implications for visual cognition research, and will advance our understanding of how the human brain can improve its ability to predict by learning from experience. (C) 2011 Elsevier B.V. All rights reserved. C1 [Cheung, Olivia S.; Bar, Moshe] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Cheung, OS (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, 149 13th St,Room 2301, Charlestown, MA 02129 USA. EM olivia@nmr.mgh.harvard.edu FU NEI-NIH [1R01EY019477-01]; NSF [BCS-0842947]; DARPA [N10AP20036] FX This work was supported by NEI-NIH grant 1R01EY019477-01, NSF grant BCS-0842947, and DARPA grant N10AP20036. We thank Daryl Fougnie, Eiran Vadim Harel and Tomer Livne for helpful comments on the manuscript. NR 133 TC 10 Z9 10 U1 6 U2 36 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD FEB PY 2012 VL 83 IS 2 SI SI BP 156 EP 163 DI 10.1016/j.ijpsycho.2011.11.002 PG 8 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 921ZW UT WOS:000302517600005 PM 22123523 ER PT J AU Ford, JM Mathalon, DH AF Ford, Judith M. Mathalon, Daniel H. TI Anticipating the future: Automatic prediction failures in schizophrenia SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Review DE Schizophrenia; Efference copy; Corollary discharge; Context; ERPs ID COROLLARY DISCHARGE DYSFUNCTION; PRIMATE AUDITORY-CORTEX; CORTICAL RESPONSIVENESS; STIMULUS SEQUENCE; SPEECH PRODUCTION; EFFERENCE COPY; P300; RESPONSES; DEFICITS; SYMPTOMS AB People with schizophrenia often misperceive sensations and misinterpret experiences, perhaps contributing to psychotic symptoms. These misperceptions and misinterpretations might result from an inability to make valid predictions about expected sensations and experiences. Healthy normal people take advantage of neural mechanisms that allow them to make predictions unconsciously, facilitating processing of expected sensations and distinguishing the expected from the unexpected. In this paper, we focus on two types of automatic, unconscious mechanisms that allow us to predict our perceptions. The first involves predictions made via innate mechanisms basic to all species in the animal kingdom - the efference copy and corollary discharge mechanisms. They accompany our voluntary movements and allow us to suppress sensations resulting from our actions. We study this during talking, and show that auditory cortical response to the speech sounds during talking is reduced compared to when they are played back. This suppression is reduced in schizophrenia, suggesting a failure to predict the sensations resulting from talking. The second mechanism involves implicitly learning what to expect from the current context of events. We study this by observing the brain's response to an unexpected repetition of an event, when a change would have been predicted. That patients have a reduced response suggests they failed to predict that it was time for a change. Both types of predictions should happen automatically and effortlessly, allowing for economic processing of expected events and orientation to unexpected ones. These prediction failures characterize the diagnosis of schizophrenia rather than reflecting specific symptoms. Published by Elsevier B.V. C1 [Ford, Judith M.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. RP Ford, JM (reprint author), San Francisco VA Med Ctr, Psychiat Serv, 116D,4150 Clement St, San Francisco, CA 94121 USA. EM Judith.ford@yale.edu OI Mathalon, Daniel/0000-0001-6090-4974 FU NIMH [R01, K02]; VA (Merit Review); NARSAD FX This work was supported by grants from NIMH (R01, K02) and the VA (Merit Review), which were administered by the Northern California Institute for Research and Education, and with resources of the Veterans Affairs Medical Center, San Francisco, California. This work was also supported by NARSAD. NR 85 TC 33 Z9 34 U1 2 U2 24 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD FEB PY 2012 VL 83 IS 2 SI SI BP 232 EP 239 DI 10.1016/j.ijpsycho.2011.09.004 PG 8 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 921ZW UT WOS:000302517600013 PM 21959054 ER PT J AU Ben Barnes, J Dickstein, BD Maguen, S Neria, Y Litz, BT AF Ben Barnes, J. Dickstein, Benjamin D. Maguen, Shira Neria, Yuval Litz, Brett T. TI The distinctiveness of prolonged grief and posttraumatic stress disorder in adults bereaved by the attacks of September 11th SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Prolonged Grief Disorder; Posttraumatic stress disorder; Bereavement; Trauma ID CONFIRMATORY FACTOR-ANALYSIS; COMPLICATED GRIEF; TRAUMATIC GRIEF; DEPRESSION; ANXIETY; REPLICATION AB Background: Prolonged Grief Disorder (PGD) is a new diagnosis proposed for inclusion in the DSM-V. Although some studies have shown the distinctiveness of PGD and posttraumatic stress disorder (PTSD), this relationship has yet to be tested within a context of sudden, violent loss. Method: We conducted an exploratory factor analysis (EFA) using self-report data collected from a sample of 587 bereaved adults who lost friends and relatives in the attacks of September 11th. Participants completed a 9-item PGD screening measure and the 17-item PTSD Checklist. Results: A five factor solution representing two distinct constructs emerged from our analysis. Although two PGD items loaded onto factors containing PTSD symptoms, these items assessed non-specific symptomatology (i.e., generalized negative affect). Thus, overall, our results support the distinctiveness of PGD and PTSD within a context of sudden, violent loss. Limitations: Data were collected using self-report. The representativeness of our sample is uncertain. Conclusions: These findings provide a stringent test of construct validity and suggest that PGD warrants inclusion in the diagnostic nosology. Adding PGD to the DSM-V will help clinicians better assess and treat psychopathology resulting from grief. (C) 2011 Elsevier B.V. All rights reserved. C1 [Ben Barnes, J.; Dickstein, Benjamin D.; Litz, Brett T.] VA Boston Healthcare Syst, Boston, MA 02130 USA. [Dickstein, Benjamin D.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Maguen, Shira] San Francisco VA Med Ctr, San Francisco, CA USA. [Neria, Yuval] Columbia Univ, Dept Psychiat, Med Ctr, New York, NY USA. [Litz, Brett T.] Boston Univ, Sch Med, Boston, MA 02215 USA. [Dickstein, Benjamin D.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Maguen, Shira] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. RP Ben Barnes, J (reprint author), VA Boston Healthcare Syst, 116-B4,150 S Huntington Ave, Boston, MA 02130 USA. EM Ben.Barnes@va.gov FU New York Times Neediest Fund; Spunk Fund Inc. FX This work was partially supported by funding from the New York Times Neediest Fund and Spunk Fund Inc. to Dr. Yuval Neria. NR 25 TC 0 Z9 0 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD FEB PY 2012 VL 136 IS 3 BP 366 EP 369 DI 10.1016/j.jad.2011.11.022 PG 4 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915AT UT WOS:000301996000020 ER PT J AU Desseilles, M Perroud, N Guillaume, S Jaussent, I Genty, C Malafosse, A Courtet, P AF Desseilles, Martin Perroud, Nader Guillaume, Sebastien Jaussent, Isabelle Genty, Catherine Malafosse, Alain Courtet, Philippe TI Is it valid to measure suicidal ideation by depression rating scales? SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Suicidal ideation; Suicide; Depression; Beck Depression Inventory; Hamilton Depression Rating Scale for Depression; Scale for Suicide Ideation ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; RISK-FACTORS; DSM-IV; ANTIDEPRESSANT TREATMENT; PSYCHIATRIC OUTPATIENTS; GENETIC PREDICTORS; DISORDER; GENDEP; PREVALENCE; HAMILTON AB Objective: To date, most researchers rely on suicidal items of scales primarily designed to measure depression severity to capture suicidal ideation (SI). This study aims at investigating how well the suicide item of the clinician rated Hamilton Scale for Depression (HAM-D) and principal factors derived from this scale correlate with SI scores derived from a well validated measure of SI: the Beck's scale for SI (SSI). Method: 281 suicide attempters consecutively hospitalized between 2007 and 2009 were assessed by using the SSI, the HAM-D and the self-report Beck Depression Inventory (BDI). Principal Component Analysis (PCA) was computed to extract main factors. Correlations between these factors, BDI's and HAM-D's suicide items and the SSI scores were then computed. Results: Three components were derived from the PCA. Factor 2 showed a major loading for the HAM-D suicide item. Both the HAM-D suicide item and Factor 2 positively correlated with the SSI total score (both p<0.00001). Moreover, the BDI suicide item highly correlated with the Factor 2 (p<0.001) and the SSI total score (p<0.00001). Finally, the HAM-D suicide item correlated significantly with the number of suicide attempts (p=0.0001) and the age at the first attempt (p=0.002). Limitations: Our sample was heterogeneous and. future studies should refine the taxonomy of the suicidal behavior in specific sub-populations. The study design was cross-sectional and replication in a prospective study is needed. Conclusion: These findings suggest that the use of a single suicide item or a dimensional factor derived from a depression scale might be a valid approach to assess the suicidal ideations. Moreover, the results suggest that clinician rated scales as well as self-report questionnaires are equally valid to do so. (C) 2011 Elsevier B.V. All rights reserved. C1 [Desseilles, Martin] Univ Liege, Cyclotron Res Ctr, B-4000 Liege, Belgium. [Desseilles, Martin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat,Depress Clin & Res Program, Boston, MA USA. [Desseilles, Martin] Univ Geneva, Dept Neurosci, Lab Neurol & Imaging Cognit, CH-1211 Geneva 4, Switzerland. [Perroud, Nader; Malafosse, Alain] Univ Geneva, Sch Med, Dept Psychiat, CH-1211 Geneva 4, Switzerland. [Guillaume, Sebastien; Jaussent, Isabelle; Genty, Catherine; Courtet, Philippe] Univ Montpellier I, F-34006 Montpellier, France. [Guillaume, Sebastien; Jaussent, Isabelle; Genty, Catherine; Courtet, Philippe] INSERM, U888, Montpellier, France. [Guillaume, Sebastien; Jaussent, Isabelle; Genty, Catherine; Courtet, Philippe] Dept Emergency Psychiat, Montpellier, France. [Malafosse, Alain] Univ Hosp Geneva, Dept Med Genet & Labs, Div Med Genet, Psychiat Genet Unit, Geneva, Switzerland. RP Desseilles, M (reprint author), Univ Liege, Cyclotron Res Ctr, B30,8 Allee 6 Aout, B-4000 Liege, Belgium. EM m.desseilles@ulg.ac.be OI guillaume, sebastien/0000-0002-6769-9982 FU FNRS-FRS (National Funds for Scientific Research of Belgium); Institut National de la sante et de la Recherche Medicale (INSERM); CHU of Montpellier [PHRC UF 7653]; Agence Nationale de la Recherche FX Funding for this study was provided by a FNRS-FRS (National Funds for Scientific Research of Belgium) grant to MD. This research also was supported by grants from Institut National de la sante et de la Recherche Medicale (INSERM), the CHU of Montpellier (PHRC UF 7653) and Agence Nationale de la Recherche (NEURO 2007-GENESIS). Additional supports come from the Jean and Madeleine Vachoux foundation. Those sponsors had no further role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 41 TC 55 Z9 56 U1 1 U2 12 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD FEB PY 2012 VL 136 IS 3 BP 398 EP 404 DI 10.1016/j.jad.2011.11.013 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915AT UT WOS:000301996000026 PM 22154567 ER PT J AU Ribeiro, JD Pease, JL Gutierrez, PM Silva, C Bernert, RA Rudd, MD Joiner, TE AF Ribeiro, Jessica D. Pease, James L. Gutierrez, Peter M. Silva, Caroline Bernert, Rebecca A. Rudd, M. David Joiner, Thomas E., Jr. TI Sleep problems outperform depression and hopelessness as cross-sectional and longitudinal predictors of suicidal ideation and behavior in young adults in the military SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Sleep; Insomnia; Suicide; Suicidal ideation; Depression; Hopelessness ID MENTAL-HEALTH PROBLEMS; MAJOR DEPRESSION; COMPLETED SUICIDE; MODIFIED SCALE; RISK-FACTORS; MCMI-III; DISORDER; INSOMNIA; DISTURBANCE; NIGHTMARES AB Background: Sleep problems appear to represent an underappreciated and important warning sign and risk factor for suicidal behaviors. Given past research indicating that disturbed sleep may confer such risk independent of depressed mood, in the present report we compared self-reported insomnia symptoms to several more traditional, well-established suicide risk factors: depression severity, hopelessness, PTSD diagnosis, as well as anxiety, drug abuse, and alcohol abuse symptoms. Methods: Using multiple regression, we examined the cross-sectional and longitudinal relationships between insomnia symptoms and suicidal ideation and behavior, controlling for depressive symptom severity, hopelessness, PTSD diagnosis, anxiety symptoms, and drug and alcohol abuse symptoms in a sample of military personnel (N = 311). Results: In support of a priori hypotheses, self-reported insomnia symptoms were crosssectionally associated with suicidal ideation, even after accounting for symptoms of depression, hopelessness. PTSD diagnosis, anxiety symptoms and drug and alcohol abuse. Self-reported insomnia symptoms also predicted suicide attempts prospectively at one-month follow up at the level of a non-significant trend, when controlling for baseline self-reported insomnia symptoms, depression, hopelessness, FTSD diagnosis and anxiety, drug and alcohol abuse symptoms. Insomnia symptoms were unique predictors of suicide attempt longitudinally when only baseline self-reported insomnia symptoms, depressive symptoms and hopelessness were controlled. Limitations: The assessment of insomnia symptoms consisted of only three self-report items. Findings may not generalize outside of populations at severe suicide risk. Conclusions: These findings suggest that insomnia symptoms may be an important target for suicide risk assessment and the treatment development of interventions to prevent suicide. (C) 2011 Elsevier B.V. All rights reserved. C1 [Ribeiro, Jessica D.; Silva, Caroline; Joiner, Thomas E., Jr.] Florida State Univ, Tallahassee, FL 32306 USA. [Pease, James L.; Gutierrez, Peter M.] Denver VA Med Ctr, VA VISN MIRECC 19, Denver, CO USA. [Bernert, Rebecca A.] Stanford Univ, Stanford, CA 94305 USA. [Rudd, M. David] Univ Utah, Salt Lake City, UT 84112 USA. RP Joiner, TE (reprint author), Florida State Univ, Tallahassee, FL 32306 USA. EM joiner@psy.fsu.edu OI Silva, Caroline/0000-0002-7477-1495 FU Department of Defense FX This research was supported, in part, by grants awarded to the Denver VA Medical Center and to Florida State University by the Department of Defense. The Department of Defense had no further role in the study design: in the collection, analysis, and interpretation of data: in the writing of the report; and in the decision to submit the paper for publication. The views and opinions expressed do not represent those of the Department of Veterans Affairs, the Department of Defense, or the United States Government. NR 86 TC 66 Z9 70 U1 1 U2 23 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD FEB PY 2012 VL 136 IS 3 BP 743 EP 750 DI 10.1016/j.jad.2011.09.049 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915AT UT WOS:000301996000071 PM 22032872 ER PT J AU Joshi, G Petty, C Wozniak, J Faraone, SV Doyle, R Georgiopoulos, A Hammerness, P Walls, S Glaeser, B Brethel, K Yorks, D Biederman, J AF Joshi, Gagan Petty, Carter Wozniak, Janet Faraone, Stephen V. Doyle, Robert Georgiopoulos, Anna Hammerness, Paul Walls, Sarah Glaeser, Breanna Brethel, Kristin Yorks, Dayna Biederman, Joseph TI A prospective open-label trial of quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Bipolar disorder; Children; Quetiapine ID RATING-SCALE; DOUBLE-BLIND; II DEPRESSION; ADOLESCENTS; MANIA; RISPERIDONE; OLANZAPINE; COMORBIDITY; RELIABILITY; DIVALPROEX AB Background: Although bipolar disorder frequently onsets in the preschool years, treatment studies to guide management of these highly dysfunctional children are limited. This study evaluates the response to quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder (BSD). Method: Two eight-week, prospective, open-label trials utilizing identical methodology to assess the effectiveness and tolerability of quetiapine monotherapy in the treatment of BSD in preschool (age 4-6 years) and school age children (age 6-15 years). Results: Forty-nine children (30 preschool and 19 school age) with BSD (Young Mania Rating Scale [YMRS] at entry: 34.5 +/- 5.5 and 30 +/- 6.5 respectively) were enrolled and 34 (20 preschool and 14 school age) completed the trial. Quetiapine was titrated to a mean endpoint dose of 175.8 +/- 63.8 mg/day in preschool and 248.7 +/- 153.1 mg/day in school age children. At endpoint, treatment with quetiapine was associated with similar and statistically significant improvement in mean YMRS scores in preschool (- 14.5 +/- 11.5, p<0.001) and school age (- 13 +/- 9.8, p<0.001) children. Quetiapine was generally well tolerated with treatment limiting adverse-events observed in 3/30 preschool and 1/19 school age children. Quetiapine monotherapy in preschool and school age children was associated with significant weight gain (+ 3.1 +/- 1.8 and + 7.4 +/- 7.7 lb respectively, p<0.001) and with clinically insignificant changes in vital signs. Limitations: As an uncontrolled study, the assessments were not blind to treatment and the effects of treatment cannot be separated from time. Conclusions: Open-label quetiapine treatment was beneficial for the treatment of BSD in preschool and school age children. Further controlled trials are warranted. (C) 2011 Published by Elsevier B.V. C1 [Joshi, Gagan; Petty, Carter; Wozniak, Janet; Doyle, Robert; Georgiopoulos, Anna; Hammerness, Paul; Walls, Sarah; Glaeser, Breanna; Brethel, Kristin; Yorks, Dayna; Biederman, Joseph] Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, Boston, MA 02114 USA. [Joshi, Gagan; Petty, Carter; Wozniak, Janet; Doyle, Robert; Georgiopoulos, Anna; Hammerness, Paul; Biederman, Joseph] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Syracuse, NY USA. RP Joshi, G (reprint author), Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, 55 Fruit St,Warren 705, Boston, MA 02114 USA. EM Joshi.Gagan@mgh.harvard.edu OI Brethel-Haurwitz, Kristin/0000-0003-0429-4598; Faraone, Stephen/0000-0002-9217-3982 FU Pediatric Psychopharmacology Council; Susan G. Berk Endowed Fund for Juvenile Bipolar Disorder; Norma Fine Pediatric Psychopharmacology Fellowship Fund; Astra Zeneca; Ethel DuPont Warren Fellowship; American Academy of Child and Adolescent Psychiatry; National Institute of Mental Health; McNeil Pediatrics (SynerMed Communications); Bristol Myers Squibb; Glaxo Smith Kline; Shire Pharmaceutical; Johnson & Johnson Pharmaceutical; Pfizer Pharmaceutical; Merck Pharmaceutical; Cephlon Pharmaceutical; McNeil Pharmaceutical; Eli-Lily Pharmaceutical; Abbott Pharmaceutical; Novartis Pharmaceutical; Organon Pharmaceutical; Otsuka Pharmaceutical; Takeda Pharmaceutical; New River Pharmaceutical; McNeil; Lilly; Boehringer-Ingelheim; GlaxoSmithKline; UCB (Schwarz) Pharma; Sepracor; National Institutes of Health (NIH); Janssen; Novartis; Pfizer; Eli Lilly; McNeil Pediatrics; American Academy of Child and Adolescent Psychiatry (AACAP); Elaine Schlosser Lewis Fund; American Academy of Family Physicians/-Minnesota Academy of Family Physicians; Mayo Foundation; US Department of Health and Human Services; Bristol Myers Squibb Research Institute; Cephalon; Eli-Lilly Co.; Elminda; Johnson & Johnson Pharmaceutical Research and Development LLC; McNeil Consumer and Specialty Pharmaceuticals; Novartis Pharmaceuticals Corporation; Ortho-McNeil Janssen Scientific Affairs LLC; Shire Development/Shire Pharmaceuticals; NIH-NIMH; NIH-NIDA; NARSAD; Stanley Foundation; Harvard Medical School/-Massachusetts General Hospital; CME; Abbott; Forest; Shire; Elminda Ltd; Johnson Johnson; Merck; New River; Organon; Takeda; Reed Medical Education; MGH Psychiatry Academy; Elminda Pharmaceutical; Janssen Pharmaceutical; Next Wave Pharmaceutical; Fundacion Dr.Manuel Camelo A.C.; Fundacion Areces, Medice Pharmaceuticals; Spanish Child Psychiatry Association; Alza; AstraZeneca; Celltech; Eli Lilly and Co.; Esai; Glaxo; Gliatech; NIDA; NICHD; Noven; Neurosearch; Otsuka; Pharmacia; Prechter Foundation; UCB Pharma, Inc.; Wyeth FX This study was funded by the Pediatric Psychopharmacology Council Fund, the Susan G. Berk Endowed Fund for Juvenile Bipolar Disorder, the Norma Fine Pediatric Psychopharmacology Fellowship Fund, and by a small grant from Astra Zeneca to support eye exams during the study.; 1. Ethel DuPont Warren Fellowship Award 2005-6; 2. Pilot Research Award from the American Academy of Child and Adolescent Psychiatry 2005; 3. National Institute of Mental Health (Reviewer and member of the NIMH Editorial Board); 4. McNeil Pediatrics (CME sponsored by SynerMed Communications); 5. Bristol Myers Squibb (Site PI for Multi-centered Trial); 6. Glaxo Smith Kline (Site PI for Multi-centered Trial); 7. Shire (Member of national advisory board); 8. Subinvestigator for clinical trials sponsored by Shire, Johnson & Johnson, Pfizer, Merck, Cephlon, McNeil, Eli-Lily, Abbott, Novartis, Bristol Myers Squibb, Organon, Otsuka, Takeda, & New River Pharmaceuticals.; Dr. Wozniak is the author of the book, "Is Your Child Bipolar" published May 2008, Bantam Books. She has been a speaker for McNeil, Primedia/MGH Psychiatry Academy, on the Advisory Board for Pfizer and Shire and received research support from NIMH, McNeil, Shire and Lilly. Her spouse John Winkelman MD, PhD has been on the Speakers Bureau for Boehringer-Ingelheim, Cephalon, GlaxoSmithKline, King, Sanofi-Aventis, Sepracor, Takeda, on the Advisory Board for Axon Labs, Boehringer-Ingelheim, GlaxoSmithKline, Jazz Pharmaceuticals, Novartis, Neurogen, Novadel Pharma, Pfizer, UCB (Schwarz) Pharma, Sepracor, Takeda and received research support from Boehringer-Ingelheim, GlaxoSmithKline, UCB (Schwarz) Pharma, Sepracor.; In the past year, Dr. Faraone received consulting fees and was on Advisory Boards for Shire Development and received research support from Shire and the National Institutes of Health (NIH). In previous years, he received consulting fees or was on Advisory Boards or participated in continuing medical education programs sponsored by: Shire, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. In previous years he received research support from Eli Lilly, Shire, Pfizer and the NIH. Dr. Faraone receives royalties from a book published by Guilford Press: Straight Talk about Your Child's Mental Health.; Dr. Georgiopoulos received an unrestricted educational grant for a 2005 book from GlaxoSmithKline; the book was published by Lippincott, Williams & Wilkins. She received an honorarium for a Continuing Medical Education presentation from Pri-Med/Physicians Academy for Clinical and Management Excellence, supported by an educational grant from McNeil Pediatrics, administered by Ortho-McNeil Janssen Scientific Affairs (2009). She received an honorarium for CME presentations from the Harvard Program in Refugee Trauma (2006). She received travel expense reimbursement from the Cystic Fibrosis Foundation for presentation at the North American Cystic Fibrosis Conference (2007). She currently has research funding from the American Academy of Child and Adolescent Psychiatry (AACAP) Pilot Research Awards for Attention Disorders for Junior Faculty and Child and Adolescent Psychiatry Residents supported by the Elaine Schlosser Lewis Fund. Her completed research has been funded by the American Academy of Family Physicians/-Minnesota Academy of Family Physicians, the Mayo Foundation, and the US Department of Health and Human Services. She has participated as Sub-Investigator or Co-Investigator on research studies funded by the following: Bristol Myers Squibb Research Institute, Cephalon, Eli-Lilly & Co., Elminda, GlaxoSmithKline, Johnson & Johnson Pharmaceutical Research and Development LLC, McNeil Consumer and Specialty Pharmaceuticals, Novartis Pharmaceuticals Corporation, Ortho-McNeil Janssen Scientific Affairs LLC, Shire Development/Shire Pharmaceuticals; as well as NIH-NIMH, NIH-NIDA, NARSAD, the Stanley Foundation, and Harvard Medical School/-Massachusetts General Hospital. She holds an appointment as a Staff Fellow (Medical Officer), Center for Devices and Radiological Health. US Food and Drug Administration, for work unrelated to this manuscript.; In the past 2 years. Dr. Hammerness has received research funds or participated in CME activities/professional talks supported by the following pharmaceutical companies: Abbott, Eli Lilly, Forest, McNeil, Shire. Dr. Hammerness has also received research funds from Elminda Ltd and has participated in speaker training and served on the advisory board for Shire. In the past 2 years, Dr. Hammemess has participated, as an investigator, in research studies funded by the following pharmaceutical companies: Abbott, Bristol Myers Squibb, Cephalon, Eli Lilly, Glaxo-SmithKline, Johnson & Johnson, McNeil, Merck, New River, Organon, Pfizer, Shire, Takeda. Dr. Hammerness has also received honoraria from Reed Medical Education (a logistics collaborator for the MGH Psychiatry Academy). Commercial entities supporting the MGH Psychiatry Academy are listed on the Academy's website, www.mghcme.org.; Dr. Joseph Biederman is currently receiving research support from the following sources: Elminda, Janssen, McNeil, Next Wave Pharmaceuticals, and Shire. In 2011, Dr. Joseph Biederman gave a single unpaid talk for Juste Pharmaceutical Spain, and received honoraria from the MGH Psychiatry Academy for a tuition-funded CME course. In 2010, Dr. Joseph Biederman received a speaker's fee from Fundacion Dr.Manuel Camelo A.C., provided single consultations for Shionogi Pharma Inc. and Cipher Pharmaceuticals Inc., and received honoraria from the MGH Psychiatry Academy for a tuition-funded CME course. In 2009, Dr. Joseph Biederman received a speakers fee from the following sources: Fundacion Areces, Medice Pharmaceuticals and the Spanish Child Psychiatry Association. In previous years, Dr. Joseph Biederman received research support, consultation fees, or speakers fees for/from the following additional sources: Abbott, Alza, AstraZeneca, Bristol Myers Squibb, Celltech, Cephalon, Eli Lilly and Co., Esai, Forest, Glaxo, Gliatech, Janssen, McNeil, Merck, NARSAD, NIDA, New River, NICHD, NIMH, Novartis, Noven, Neurosearch, Organon, Otsuka, Pfizer, Pharmacia, The Prechter Foundation, Shire, The Stanley Foundation, UCB Pharma, Inc. and Wyeth. NR 33 TC 10 Z9 10 U1 5 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD FEB PY 2012 VL 136 IS 3 BP 1143 EP 1153 DI 10.1016/j.jad.2011.09.042 PG 11 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915AT UT WOS:000301996000128 PM 22035648 ER PT J AU Leiderman, EA Lolich, M Vazquez, GH Baldessarini, RJ AF Leiderman, Eduardo A. Lolich, Maria Vazquez, Gustavo H. Baldessarini, Ross J. TI Depression: Point-prevalence and sociodemographic correlates in a Buenos Aires community sample SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Argentina; Community survey; Depression; Risk factors ID LATE-LIFE DEPRESSION; GENDER-DIFFERENCES; PSYCHOMETRIC PROPERTIES; EPIDEMIOLOGIC FINDINGS; GENERAL-POPULATION; SEX-DIFFERENCES; SOCIAL SUPPORT; LATIN-AMERICA; DSM-III; SYMPTOMS AB Background: Since the current epidemiology of depression is not well documented in Latin America, we conducted a community-based survey study in Argentina. Methods: The Beck Depression Inventory (BDI) and a general health questionnaire were completed by 1335 adult participants, representing most of the neighborhoods of Buenos Aires. Results: Prevalence of high total BDI scores (>= 13) indicating probable current clinically significant depression was 20.0% (women: 20.6%; men: 19.6%). Probable depression was associated with being unmarried and older, less educated, reporting recent stressors and significant medical illness. Limitations: Sampling was cross-sectional and by convenience; probable depression was not verified by clinical assessment. Conclusions: Within methodological limits, probable current clinically significant depression was highly prevalent in an urban community sample in Argentina, at rates and with risk factors similar to those found in other world regions. (C) 2011 Elsevier B.V. All rights reserved. C1 [Leiderman, Eduardo A.; Vazquez, Gustavo H.] Univ Palermo, Fac Social Sci, Buenos Aires, DF, Argentina. [Leiderman, Eduardo A.; Lolich, Maria; Vazquez, Gustavo H.] Univ Palermo, Dept Neurosci, Buenos Aires, DF, Argentina. [Vazquez, Gustavo H.; Baldessarini, Ross J.] Massachusetts Gen Hosp, McLean Div, Int Consortium Mood & Psychot Disorders, Belmont, MA USA. [Baldessarini, Ross J.] Harvard Univ, Sch Med, Dept Psychiat, McLean Div,Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Leiderman, EA (reprint author), Univ Palermo, Fac Ciencias Sociales, CABA, RA-1259 Mario Bravo, Argentina. EM edule@psi.uba.ar FU Bruce J. Anderson Foundation; McLean Private Donors Research Fund FX This project was supported, in part, by a grant from the Bruce J. Anderson Foundation and by the McLean Private Donors Research Fund (to RJB).The Bruce J. Anderson Foundation and the Mc Lean Private Donors Research Fund had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 50 TC 2 Z9 2 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD FEB PY 2012 VL 136 IS 3 BP 1154 EP 1158 DI 10.1016/j.jad.2011.09.032 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915AT UT WOS:000301996000129 PM 22036799 ER PT J AU Levkovitz, Y Alpert, JE Brintz, CE Mischoulon, D Papakostas, GI AF Levkovitz, Yechiel Alpert, Jonathan E. Brintz, Carrie E. Mischoulon, David Papakostas, George I. TI Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE S-adenosylmethionine; Major depression; Cognitive function; One-carbon cycle ID ADENOSYL-L-METHIONINE; ALZHEIMERS-DISEASE; MUSCARINIC RECEPTORS; RISK-FACTORS; NICOTINAMIDE; DEFICITS; RATS AB Background: Major depressive disorder (MDD) is often accompanied by significant cognitive impairment, and there are limited interventions specific to this particular symptom. S-adenosyl methionine (SAMe), a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism, is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MOD. Methods: This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD. Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MOD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment. Results: There was a greater improvement in the ability to recall information (p = 0.04) and a trend toward statistical significance for greater improvement in word-finding (p = 0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance. Conclusion: These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication. (C) 2011 Published by Elsevier B.V. C1 [Levkovitz, Yechiel; Alpert, Jonathan E.; Brintz, Carrie E.; Mischoulon, David; Papakostas, George I.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. RP Levkovitz, Y (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Depress Clin & Res Program, 50 Staniford St,Suite 401, Boston, MA 02114 USA. EM ylevkovich@partners.org OI Alpert, Jonathan/0000-0002-4332-908X NR 31 TC 17 Z9 18 U1 2 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD FEB PY 2012 VL 136 IS 3 BP 1174 EP 1178 DI 10.1016/j.jad.2011.04.059 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915AT UT WOS:000301996000132 PM 21911258 ER PT J AU Baron, R Hesse, E AF Baron, Roland Hesse, Eric TI Update on Bone Anabolics in Osteoporosis Treatment: Rationale, Current Status, and Perspectives SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID PARATHYROID-HORMONE 1-34; SENSING RECEPTOR ANTAGONIST; FRIZZLED-RELATED PROTEIN-1; MINERAL DENSITY; POSTMENOPAUSAL OSTEOPOROSIS; OSTEOCLAST DIFFERENTIATION; SCLEROSTIN ANTIBODY; IN-VIVO; OVARIECTOMIZED RATS; BETA-CATENIN AB Osteoporosis is defined as low bone mineral density associated with skeletal fractures secondary to minimal or no trauma, most often involving the spine, the hip, and the forearm. The decrease in bone mineral density is the consequence of an unbalanced bone remodeling process, with higher bone resorption than bone formation. Osteoporosis affects predominantly postmenopausal women, but also older men. This chronic disease represents a considerable medical and socioeconomic burden for modern societies. The therapeutic options for the treatment of osteoporosis have so far comprised mostly antiresorptive drugs, in particular bisphosphonates and more recently denosumab, but also calcitonin and, for women, estrogens or selective estrogen receptor modulators. These drugs have limitations, however, in particular the fact that they lead to a low turnover state where bone formation decreases with the decrease in bone-remodeling activity. In this review, we discuss the alternative class of osteoporosis drugs, i.e. bone anabolics, their biology, and the perspectives they offer for our therapeutic armamentarium. We focus on the two main osteoanabolic pathways identified as of today: PTH, the only anabolic drug currently on the market; and activation of canonical Wnt signaling through inhibition of the endogenous inhibitors sclerostin and dickkopf1. Each approach is based on a different molecular mechanism, but most recent evidence suggests that these two pathways may actually converge, at least in part. Whereas recombinant human PTH treatment is being revisited with different formulations and attempts to regulate endogenous PTH secretion via the calcium-sensing receptor, antibodies to sclerostin and dickkopf1 are currently in clinical trials and may prove to be even more efficient at increasing bone mass, possibly independent of bone turnover. Each of these anabolic approaches has its own limitations and safety issues, but the prospects of effective anabolic therapy for osteoporosis are indeed bright. (J Clin Endocrinol Metab 97: 311-325, 2012) C1 Harvard Univ, Sch Med, Dept Med, Endocrine Unit,Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Dept Oral Med Infect & Immun, Sch Dent Med, Boston, MA 02115 USA. RP Baron, R (reprint author), Harvard Univ, Sch Med, 188 Longwood Ave,REB 310, Boston, MA 02115 USA. EM roland_baron@hsdm.harvard.edu FU National Institutes of Health (National Institute of Arthritis and Musculoskeletal and Skin Diseases and National Institute of Dental and Craniofacial Research) FX Roland Baron acknowledges the support of National Institutes of Health (National Institute of Arthritis and Musculoskeletal and Skin Diseases and National Institute of Dental and Craniofacial Research). NR 102 TC 118 Z9 129 U1 3 U2 41 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD FEB PY 2012 VL 97 IS 2 BP 311 EP 325 DI 10.1210/jc.2011-2332 PG 15 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 904VP UT WOS:000301226800022 PM 22238383 ER PT J AU Barbesino, G Sluss, PM Caturegli, P AF Barbesino, Giuseppe Sluss, Patrick M. Caturegli, Patrizio TI Central Hypothyroidism in a Patient with Pituitary Autoimmunity: Evidence for TSH-Independent Thyroid Hormone Synthesis SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID THYROTROPIN; DYSFUNCTION; MUTATION; ADULTS; TUMORS; CELLS; GENE AB Context: Acquired central hypothyroidism is rare, especially when isolated, and is typically associated with detectable, although biologically inactive, serum TSH. Objective: We describe a 56-yr-old woman with profound central hypothyroidism and partial central hypoadrenalism, in the absence of other endocrine abnormalities. In contrast to most cases of central hypothyroidism, serum TSH remained undetectable for 9 months before the initiation of thyroid hormone and hydrocortisone treatment. A test for pituitary autoantibody was moderately positive. Serum free T-4, serum T-3, and neck radioiodine uptake were low but detectable. The thyroid and pituitary glands appeared morphologically normal on neck ultrasound and head magnetic resonance imaging, respectively. Settings: The study was conducted in a tertiary academic medical center. Conclusions: This case illustrates the variable clinical presentation of pituitary autoimmunity. The persistence of low but detectable thyroid hormone levels and radioiodine neck uptake in the absence of TSH suggests that significant TSH-independent thyroid hormone synthesis may occur in the normal thyroid. (J Clin Endocrinol Metab 97:345-350, 2012) C1 [Barbesino, Giuseppe] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Thyroid Unit, Boston, MA 02114 USA. [Barbesino, Giuseppe] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Sluss, Patrick M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Clin Pathol Core Labs, Boston, MA 02114 USA. [Caturegli, Patrizio] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD USA. RP Barbesino, G (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Thyroid Unit, Wang ACC 730S,55 Fruit St, Boston, MA 02114 USA. EM gbarbesino@partners.org FU National Institutes of Health [DK 08035] FX This work was supported in part by National Institutes of Health Grant DK 08035 (to P.C.). NR 21 TC 5 Z9 5 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD FEB PY 2012 VL 97 IS 2 BP 345 EP 350 DI 10.1210/jc.2011-1591 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 904VP UT WOS:000301226800026 PM 22090265 ER PT J AU Johannsson, G Nilsson, AG Bergthorsdottir, R Burman, P Dahlqvist, P Ekman, B Engstrom, BE Olsson, T Ragnarsson, O Ryberg, M Wahlberg, J Biller, BMK Monson, JP Stewart, PM Lennernas, H Skrtic, S AF Johannsson, G. Nilsson, A. G. Bergthorsdottir, R. Burman, P. Dahlqvist, P. Ekman, B. Engstrom, B. E. Olsson, T. Ragnarsson, O. Ryberg, M. Wahlberg, J. Biller, B. M. K. Monson, J. P. Stewart, P. M. Lennernas, H. Skrtic, S. TI Improved Cortisol Exposure-Time Profile and Outcome in Patients with Adrenal Insufficiency: A Prospective Randomized Trial of a Novel Hydrocortisone Dual-Release Formulation SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID GLUCOCORTICOID REPLACEMENT THERAPY; SUBJECTIVE HEALTH-STATUS; ADDISONS-DISEASE; PREMATURE MORTALITY; CARDIOVASCULAR-DISEASE; CUSHINGS-SYNDROME; HYPOPITUITARISM; IMPACT; AXIS; TERM AB Context: Patients with treated adrenal insufficiency (AI) have increased morbidity and mortality rate. Our goal was to improve outcome by developing a once-daily (OD) oral hydrocortisone dual-release tablet with a more physiological exposure-time cortisol profile. Objective: The aim was to compare pharmacokinetics and metabolic outcome between OD and the same daily dose of thrice-daily (TID) dose of conventional hydrocortisone tablets. Design and Setting: We conducted an open, randomized, two-period, 12-wk crossover multicenter trial with a 24-wk extension at five university hospital centers. Patients: The trial enrolled 64 adults with primary AI; 11 had concomitant diabetes mellitus (DM). Intervention: The same daily dose of hydrocortisone was administered as OD dual-release or TID. Main Outcome Measure: We evaluated cortisol pharmacokinetics. Results: Compared with conventional TID, OD provided a sustained serum cortisol profile 0-4 h after the morning intake and reduced the late afternoon and the 24-h cortisol exposure. The mean weight (difference = -0.7kg, P = 0.005), systolic blood pressure(difference = -5.5 mm Hg, P = 0.0001) and diastolic blood pressure (difference: -2.3 mm Hg; P = 0.03), and glycated hemoglobin (absolute difference = -0.1%, P = 0.0006) were all reduced after OD compared with TID at 12 wk. Compared with TID, a reduction in glycated hemoglobin by 0.6% was observed in patients with concomitant DM during OD (P = 0.004). Conclusion: The OD dual-release tablet provided a more circadian-based serum cortisol profile. Reduced body weight, reduced blood pressure, and improved glucose metabolism were observed during OD treatment. In particular, glucose metabolism improved in patients with concomitant DM. (J Clin Endocrinol Metab 97:473-481, 2012) C1 [Johannsson, G.; Nilsson, A. G.; Bergthorsdottir, R.; Ragnarsson, O.] Univ Gothenburg, Sahlgrenska Acad, Dept Endocrinol, SE-41345 Gothenburg, Sweden. [Skrtic, S.] Univ Gothenburg, Sahlgrenska Acad, Dept Clin Pharmacol, SE-41345 Gothenburg, Sweden. [Burman, P.] Skanes Univ Hosp Malmo, Dept Endocrinol, SE-20502 Malmo, Sweden. [Dahlqvist, P.; Olsson, T.; Ryberg, M.] Umea Univ, Dept Publ Hlth & Clin Med, SE-90187 Umea, Sweden. [Ekman, B.; Wahlberg, J.] Linkoping Univ, Fac Hlth Sci, Dept Med & Hlth Sci, Div Cardiovasc Med, SE-58183 Linkoping, Sweden. [Engstrom, B. E.] Uppsala Univ, Dept Endocrinol Diabet & Metab, Univ Hosp, SE-75185 Uppsala, Sweden. [Lennernas, H.] Uppsala Univ, Dept Pharm, SE-75185 Uppsala, Sweden. [Biller, B. M. K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroendocrine Clin Ctr, Boston, MA 02114 USA. [Monson, J. P.] Queen Mary Univ London, St Bartholomews Hosp, Ctr Clin Endocrinol, London EC1A 7BE, England. [Stewart, P. M.] Univ Birmingham, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England. RP Johannsson, G (reprint author), Sahlgrens Univ Hosp, Dept Endocrinol, Grona Straket 8, SE-41345 Gothenburg, Sweden. EM Gudmundur.Johannsson@gu.se OI Olsson, Tommy/0000-0001-7768-1076; Eden Engstrom, Britt/0000-0003-4514-5193; Ekman, Bertil/0000-0001-8732-7361; Skrtic, Stanko/0000-0002-1950-5418; Ragnarsson, Oskar/0000-0003-0204-9492 FU DuoCort Pharma AB; Swedish Foundation of Strategic Research FX DuoCort Pharma AB financially supported the trial. G.J. received a mobility grant from the Swedish Foundation of Strategic Research. NR 30 TC 86 Z9 88 U1 0 U2 3 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD FEB PY 2012 VL 97 IS 2 BP 473 EP 481 DI 10.1210/jc.2011-1926 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 904VP UT WOS:000301226800043 PM 22112807 ER PT J AU Magnusson, M Jujic, A Hedblad, B Engstrom, G Persson, M Struck, J Morgenthaler, NG Nilsson, P Newton-Cheh, C Wang, TJ Melander, O AF Magnusson, Martin Jujic, Amra Hedblad, Bo Engstrom, Gunnar Persson, Margaretha Struck, Joachim Morgenthaler, Nils G. Nilsson, Peter Newton-Cheh, Christopher Wang, Thomas J. Melander, Olle TI Low Plasma Level of Atrial Natriuretic Peptide Predicts Development of Diabetes: The Prospective Malmo Diet and Cancer Study SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID LEFT-VENTRICULAR DYSFUNCTION; METABOLIC SYNDROME; INSULIN-RESISTANCE; ANGIOTENSIN-II; CARDIOVASCULAR EVENTS; HYPERTENSIVE PATIENTS; ADIPOSE-TISSUE; RISK-FACTORS; RECEPTOR; PROATRIAL AB Context: The cardiac natriuretic peptides are involved in blood pressure regulation, and large cross-sectional studies have shown lower plasma levels of N-terminal pro-natriuretic peptide levels [N-terminal atrial natriuretic peptide (N-ANP) and N-terminal brain natriuretic peptide (N-BNP)] in patients with insulin resistance, obesity, and diabetes. Objective: In this study, we prospectively tested whether plasma levels of mid-regional ANP (MRANP) and N-BNP predict new-onset diabetes and long-term glucose progression. Design, Setting, and Patients: MR-ANP and N-BNP were measured in 1828 nondiabetic individuals of the Malmo Diet and Cancer cohort (mean age 60 yr; 61% women) who subsequently underwent a follow-up exam including an oral glucose tolerance test after a median follow-up time of 16 yr. Logistic regression was used to adjust for covariates. Results: During follow-up, 301 subjects developed new-onset diabetes. After full multivariate adjustment, MR-ANP was significantly inversely associated with incident diabetes (OR = 0.85; 95% CI = 0.73-0.99; P = 0.034) but not N-BNP (OR = 0.92; 95% CI = 0.80-1.06; P = 0.262). In fully adjusted linear regression models, the progression of fasting glucose during follow-up was significantly inversely related to baseline levels of MR-ANP (P = 0.004) but not N-BNP (P = 0.129). Quartile analyses revealed that the overall association was mainly accounted for by excess risk of incident diabetes in subjects belonging to the lowest quartile of MR-ANP. After full adjustment, the odds ratio for incident diabetes in the bottom compared with the top quartile of MR-ANP was 1.65 (OR = 1.08-2.51, P = 0.019) and 1.43 (OR = 1.04-1.96, P = 0.027) compared with all other subjects. Conclusion: Low plasma levels of MR-ANP predict development of future diabetes and glucose progression over time, suggesting a causal role of ANP deficiency in diabetes development. (J Clin Endocrinol Metab 97: 638-645, 2012) C1 [Magnusson, Martin] Lund Univ, Dept Cardiol, Skane Univ Hosp, SE-20502 Malmo, Sweden. [Magnusson, Martin; Hedblad, Bo; Engstrom, Gunnar; Persson, Margaretha; Nilsson, Peter; Melander, Olle] Lund Univ, Skane Univ Hosp, Dept Clin Sci, SE-20502 Malmo, Sweden. [Hedblad, Bo; Nilsson, Peter; Melander, Olle] Lund Univ, Skane Univ Hosp, Ctr Emergency Med, SE-20502 Malmo, Sweden. [Jujic, Amra] Malmo Univ, Dept Biomed Lab Sci, SE-20502 Malmo, Sweden. [Newton-Cheh, Christopher; Wang, Thomas J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02114 USA. [Newton-Cheh, Christopher] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA 02114 USA. [Newton-Cheh, Christopher; Wang, Thomas J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Newton-Cheh, Christopher] Broad Inst Harvard & Massachusetts Inst Technol, Program Med & Populat Genet, Cambridge, MA 02142 USA. [Struck, Joachim; Morgenthaler, Nils G.] Thermo Fisher Sci, D-16761 Hennigsdorf, Germany. RP Magnusson, M (reprint author), Lund Univ, Dept Cardiol, Skane Univ Hosp, Ent 35,Floor 2, SE-20502 Malmo, Sweden. EM martin.magnusson@med.lu.se OI Engstrom, Gunnar/0000-0002-8618-9152; Magnusson, Martin/0000-0003-1710-5936 FU Swedish Medical Research Council [K2009-64X-20129-04-3, 2007-2533, 2010-2917]; Swedish Heart and Lung Foundation; Medical Faculty of Lund University; Skane University Hospital; Albert Pahlsson Research Foundation; Crafoord Foundation; Ernhold Lundstroms Research Foundation; Region Skane; Hulda and Conrad Mossfelt Foundation; King Gustaf V and Queen Victoria Foundation; Lennart Hanssons Memorial Fund; Knut and Alice Wallenberg Foundation; Marianne and Marcus Wallenberg Foundation; National Institutes of Health (NIH) [HL080025, HL098283, R01-HL-086875, R01-HL-083197, R01-DK-081572]; Doris Duke Charitable Foundation; Burroughs Wellcome Fund; American Heart Association FX This work was supported by grants from the Swedish Medical Research Council (to O.M., Grant K2009-64X-20129-04-3 and PN Grant 2007-2533, 2010-2917), the Swedish Heart and Lung Foundation (to O.M.), the Medical Faculty of Lund University (to O.M.), Skane University Hospital (to O.M. and M.M.), the Albert Pahlsson Research Foundation (to O.M.), the Crafoord Foundation (to O.M.), the Ernhold Lundstroms Research Foundation (to O.M. and M.M.), the Region Skane to O.M. and M.M.), the Hulda and Conrad Mossfelt Foundation (to O.M. and M.M.), the King Gustaf V and Queen Victoria Foundation (to O.M.), the Lennart Hanssons Memorial Fund (to O.M.), Knut and Alice Wallenberg Foundation and the Marianne and Marcus Wallenberg Foundation (to O.M. and M.M.). C.N.-C. was supported by National Institutes of Health (NIH) Grants HL080025 and HL098283, a Doris Duke Charitable Foundation Clinical Scientist Development Award, and a Burroughs Wellcome Fund Career Award for Medical Scientists. T.J.W. was supported by NIH Grants R01-HL-086875, R01-HL-083197, and R01-DK-081572 and a grant from the American Heart Association. NR 37 TC 56 Z9 60 U1 0 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD FEB PY 2012 VL 97 IS 2 BP 638 EP 645 DI 10.1210/jc.2011-2425 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 904VP UT WOS:000301226800062 PM 22112816 ER PT J AU Wong, HK Shimizu, A Kirkpatrick, ND Garkavtsev, I Chan, AW di Tomaso, E Klagsbrun, M Jain, RK AF Wong, Hon-Kit Shimizu, Akio Kirkpatrick, Nathaniel D. Garkavtsev, Igor Chan, Annie W. di Tomaso, Emmanuelle Klagsbrun, Michael Jain, Rakesh K. TI Merlin/NF2 Regulates Angiogenesis in Schwannomas through a Rac1/Semaphorin 3F-Dependent Mechanism SO NEOPLASIA LA English DT Article ID GROWTH-CONE COLLAPSE; THROMBOSPONDIN-1 PROMOTES ANGIOGENESIS; ENDOTHELIAL-CELLS; TUMOR ANGIOGENESIS; SEMAPHORIN 3F; UP-REGULATION; EXPRESSION; RAC1; ACTIVATION; INHIBITION AB Neurofibromatosis type 2 (NF2) is an autosomal-dominant multiple neoplasia syndrome that results from mutations in the NF2 tumor suppressor gene. Patients with NF2 develop hallmark schwannomas that require surgery or radiation, both of which have significant adverse effects. Recent studies have indicated that the tumor microenvironment-in particular, tumor blood vessels-of schwannomas may be an important therapeutic target. Furthermore, although much has been done to understand how merlin, the NF2 gene product, functions as a tumor suppressor gene in schwannoma cells, the functional role of merlin in the tumor microenvironment and the mechanism(s) by which merlin regulates angiogenesis to support schwannoma growth is largely unexplored. Here we report that the expression of semaphorin 3F (SEMA3F) was specifically downregulated in schwannoma cells lacking merlin/NF2. When we reintroduced SEMA3F in schwannoma cells, we observed normalized tumor blood vessels, reduced tumor burden, and extended survival in nude mice bearing merlin-deficient brain tumors. Next, using chemical inhibitors and gene knockdown with RNA interference, we found that merlin regulated expression of SEMA3F through Rho GTPase family member Rac1. This study shows that, in addition to the tumor-suppressing activity of merlin, it also functions to maintain physiological angiogenesis in the nervous system by regulating antiangiogenic factors such as SEMA3F. Restoring the relative balance of proangiogenic and antiangiogenic factors, such as increases in SEMA3F, in schwannoma microenvironment may represent a novel strategy to alleviate the clinical symptoms of NF2-related schwannomas. C1 [Wong, Hon-Kit; Shimizu, Akio; Kirkpatrick, Nathaniel D.; Garkavtsev, Igor; Chan, Annie W.; di Tomaso, Emmanuelle; Klagsbrun, Michael; Jain, Rakesh K.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Wong, Hon-Kit; Kirkpatrick, Nathaniel D.; Garkavtsev, Igor; Chan, Annie W.; di Tomaso, Emmanuelle; Jain, Rakesh K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Steele Lab Tumor Biol, Boston, MA 02114 USA. [Shimizu, Akio; Klagsbrun, Michael] Childrens Hosp, Dept Surg, Boston, MA 02115 USA. [Shimizu, Akio; Klagsbrun, Michael] Childrens Hosp, Dept Pathol, Boston, MA 02115 USA. RP Jain, RK (reprint author), Harvard Univ, Sch Med, 100 Blossom St,Cox 7, Boston, MA 02114 USA. EM jain@steele.mgh.harvard.edu RI Wong, Hon-Kit/G-3944-2014 OI Wong, Hon-Kit/0000-0003-0049-8454 FU National Institutes of Health [P01-CA80124, CA37392, CA45548]; Federal Share/National Cancer Institute; Claflin Award; Flight Attendant Medical Research Institute FX This work was supported in parts by grants from the National Institutes of Health (P01-CA80124 to R.K.J. and CA37392 and CA45548 to M. K.), Federal Share/National Cancer Institute Proton Beam Program Income Grant (to R.K.J.), the Claflin Award (to E.d.T.), and the Flight Attendant Medical Research Institute (A.W.C.). The authors have no conflicts of interest to declare. NR 44 TC 18 Z9 19 U1 0 U2 3 PU NEOPLASIA PRESS PI ANN ARBOR PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648 USA SN 1522-8002 J9 NEOPLASIA JI Neoplasia PD FEB PY 2012 VL 14 IS 2 BP 84 EP 94 DI 10.1593/neo.111600 PG 11 WC Oncology SC Oncology GA 922HP UT WOS:000302538300001 PM 22431917 ER PT J AU Seok, J Xu, WH Jiang, H Davis, RW Xiao, WZ AF Seok, Junhee Xu, Weihong Jiang, Hui Davis, Ronald W. Xiao, Wenzhong TI Knowledge-Based Reconstruction of mRNA Transcripts with Short Sequencing Reads for Transcriptome Research SO PLOS ONE LA English DT Article ID HUMAN GENOME; SEQ DATA; EXPRESSION; ASSEMBLER; DATABASE; CODE; DNA AB While most transcriptome analyses in high-throughput clinical studies focus on gene level expression, the existence of alternative isoforms of gene transcripts is a major source of the diversity in the biological functionalities of the human genome. It is, therefore, essential to annotate isoforms of gene transcripts for genome-wide transcriptome studies. Recently developed mRNA sequencing technology presents an unprecedented opportunity to discover new forms of transcripts, and at the same time brings bioinformatic challenges due to its short read length and incomplete coverage for the transcripts. In this work, we proposed a computational approach to reconstruct new mRNA transcripts from short sequencing reads with reference information of known transcripts in existing databases. The prior knowledge helped to define exon boundaries and fill in the transcript regions not covered by sequencing data. This approach was demonstrated using a deep sequencing data set of human muscle tissue with transcript annotations in RefSeq as prior knowledge. We identified 2,973 junctions, 7,471 exons, and 7,571 transcripts not previously annotated in RefSeq. 73% of these new transcripts found supports from UCSC Known Genes, Ensembl or EST transcript annotations. In addition, the reconstructed transcripts were much longer than those from de novo approaches that assume no prior knowledge. These previously un-annotated transcripts can be integrated with known transcript annotations to improve both the design of microarrays and the follow-up analyses of isoform expression. The overall results demonstrated that incorporating transcript annotations from genomic databases significantly helps the reconstruction of novel transcripts from short sequencing reads for transcriptome research. C1 [Seok, Junhee; Xu, Weihong; Davis, Ronald W.] Stanford Genome Technol Ctr, Palo Alto, CA USA. [Seok, Junhee] Stanford Univ, Dept Stat, Stanford, CA 94305 USA. [Jiang, Hui] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA. [Xiao, Wenzhong] Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Seok, J (reprint author), Stanford Genome Technol Ctr, Palo Alto, CA USA. EM wxiao1@parnters.org RI Jiang, Hui/N-7083-2013; OI xiao, wenzhong/0000-0003-4944-6380 FU National Institutes of Health [PO1-HG00205, U54-GM62119] FX This study was supported by grants from National Institutes of Health (PO1-HG00205, U54-GM62119). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 31 TC 5 Z9 5 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 1 PY 2012 VL 7 IS 2 AR e31440 DI 10.1371/journal.pone.0031440 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 914UG UT WOS:000301977500037 PM 22312447 ER PT J AU Abbott, AL Adelman, MA Alexandrov, AV Barnett, HJM Beard, J Bell, P Bjorck, M Blacker, D Buckley, CJ Cambria, RP Comerota, AJ Connolly, ES Davies, AH Eckstein, HH Faruqi, R Fraedrich, G Gloviczki, P Hankey, GJ Harbaugh, RE Heldenberg, E Kittner, SJ Kleinig, TJ Mikhailidis, DP Moore, WS Naylor, R Nicolaides, A Paraskevas, KI Pelz, DM Prichard, JW Purdie, G Ricco, JB Riles, T Rothwell, P Sandercock, P Sillesen, H Spence, JD Spinelli, F Tan, A Thapar, A Veith, FJ Zhou, W AF Abbott, Anne L. Adelman, Mark A. Alexandrov, Andrei V. Barnett, Henry J. M. Beard, Jonathan Bell, Peter Bjorck, Martin Blacker, David Buckley, Clifford J. Cambria, Richard P. Comerota, Anthony J. Connolly, E. Sander Davies, Alun H. Eckstein, Hans-Henning Faruqi, Rishad Fraedrich, Gustav Gloviczki, Peter Hankey, Graeme J. Harbaugh, Robert E. Heldenberg, Eitan Kittner, Steven J. Kleinig, Timothy J. Mikhailidis, Dimitri P. Moore, Wesley S. Naylor, Ross Nicolaides, Andrew Paraskevas, Kosmas I. Pelz, David M. Prichard, James W. Purdie, Grant Ricco, Jean-Baptiste Riles, Thomas Rothwell, Peter Sandercock, Peter Sillesen, Henrik Spence, J. David Spinelli, Francesco Tan, Aaron Thapar, Ankur Veith, Frank J. Zhou, Wei TI Why the United States Center for Medicare and Medicaid Services should not extend reimbursement indications for carotid artery angioplasty/stenting SO VASCULAR LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; STROKE PREVENTION; ENDARTERECTOMY; STENOSIS; RISK; REVASCULARIZATION; PROFESSIONALS; GUIDELINES; THERAPY; DISEASE C1 [Abbott, Anne L.] Baker IDI Heart & Diabet Inst, Melbourne, Vic 3004, Australia. [Abbott, Anne L.] Florey Neurosci Inst, Melbourne, Vic, Australia. [Adelman, Mark A.] NYU, Langone Med Ctr, New York, NY 10016 USA. [Alexandrov, Andrei V.] Univ Alabama Hosp & Clin, Comprehens Stroke Ctr, Birmingham, AL 35249 USA. [Barnett, Henry J. M.] Univ Western Ontario, Robarts Res Inst, Toronto, ON N6A 5K8, Canada. [Beard, Jonathan] No Gen Hosp, Sheffield Vasc Inst, Sheffield S5 7AU, S Yorkshire, England. [Bell, Peter] Univ Leicester, Leicester, Leics, England. [Bell, Peter] Univ Leicester Hosp, Leicester, Leics, England. [Bjorck, Martin] Uppsala Univ, Dept Surg Sci, Vasc Surg Sect, SE-75186 Uppsala, Sweden. [Blacker, David] Sir Charles Gairdner Hosp, Dept Neurol, Nedlands, WA 6009, Australia. [Cambria, Richard P.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Cambria, Richard P.] Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, Boston, MA 02114 USA. [Comerota, Anthony J.] Toledo Hosp, Jobst Vasc Inst, Toledo, OH 43606 USA. [Connolly, E. Sander] Columbia Univ, Dept Neurol Surg, New York, NY 10032 USA. [Davies, Alun H.] Charing Cross Hosp, Imperial Coll Sch Med, Fac Med, London W6 8RF, England. [Eckstein, Hans-Henning] Tech Univ Munich, Klinikum Rechts Isar, Dept Vasc & Endovasc Surg, D-8000 Munich, Germany. [Faruqi, Rishad] Stanford Univ, Dept Surg, Stanford, CA 94305 USA. [Faruqi, Rishad] Kaiser Permanente Med Ctr, Dept Vasc & Endovasc Surg, Santa Clara, CA USA. [Fraedrich, Gustav] Med Univ, Dept Vasc Surg, A-6020 Innsbruck, Austria. [Gloviczki, Peter] Mayo Clin, Div Vasc & Endovasc Surg, Rochester, MN 55905 USA. [Hankey, Graeme J.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6000, Australia. [Harbaugh, Robert E.] Penn State Univ, MS Hershey Med Ctr, Penn State Inst Neurosci, Hershey, PA 17033 USA. [Harbaugh, Robert E.] Penn State Univ, MS Hershey Med Ctr, Dept Neurosurg, Hershey, PA 17033 USA. [Harbaugh, Robert E.] Penn State Univ, MS Hershey Med Ctr, Dept Engn Sci & Mech, Hershey, PA 17033 USA. [Heldenberg, Eitan] Assaf Harofeh Med Ctr, Vasc Lab, IL-70300 Zerifin, Israel. [Heldenberg, Eitan] Assaf Harofeh Med Ctr, Outpatient Clin, IL-70300 Zerifin, Israel. [Heldenberg, Eitan] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel. [Kittner, Steven J.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Kleinig, Timothy J.] Univ Adelaide, Adelaide, SA, Australia. [Kleinig, Timothy J.; Tan, Aaron] Lyell McEwin Hosp, Adelaide, SA, Australia. [Mikhailidis, Dimitri P.] UCL, Sch Med, Dept Clin Biochem, Vasc Dis Prevent Clin, London NW3 2QG, England. [Moore, Wesley S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Vasc Surg, Los Angeles, CA 90095 USA. [Naylor, Ross] Leicester Royal Infirm, Leicester LE2 7LX, Leics, England. [Nicolaides, Andrew] Univ London Imperial Coll Sci Technol & Med, Vasc Diagnost Ctr, London, England. [Paraskevas, Kosmas I.] Klinikum Nurnberg Sud, Dept Vasc & Endovasc Surg, D-90471 Nurnberg, Germany. [Pelz, David M.] Univ Western Ontario, Dept Med Imaging, London, ON N6A 3K7, Canada. [Pelz, David M.] Univ Western Ontario, Dept Clin Neurol Sci, London, ON N6A 3K7, Canada. [Pelz, David M.] Univ Western Ontario, Univ Hosp, London Hlth Sci Ctr, Neuroradiol Sect,Dept Diagnost Radiol, London, ON N6A 5A5, Canada. [Prichard, James W.] Yale Univ, Sch Med, New Haven, CT USA. [Purdie, Grant] QEH Specialist Ctr, Woodville, SA 5011, Australia. [Purdie, Grant] Queen Elizabeth Hosp, SMVS Neurol, Adelaide, SA, Australia. [Ricco, Jean-Baptiste] Univ Poitiers, Vasc Surg Serv, Poitiers, France. [Riles, Thomas] NYU, Sch Med, Dept Surg, New York, NY 10016 USA. [Rothwell, Peter] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci Clin Neurol, Oxford OX3 9DU, England. [Sandercock, Peter] Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland. [Sillesen, Henrik] Univ Copenhagen, Rigshosp, Dept Vasc Surg, DK-2100 Copenhagen, Denmark. [Spence, J. David] Robarts Res Inst, Stroke Prevent & Atherosclerosis Res Ctr, London, ON N6G 2V2, Canada. [Spence, J. David] Univ Western Ontario, London, ON N6A 3K7, Canada. [Spinelli, Francesco] Univ Messina, Dept Cardiovasc & Thorac Sci, I-98121 Messina, Italy. [Veith, Frank J.] Case Western Reserve Univ, Cleveland Clin, Cleveland, OH 44106 USA. [Veith, Frank J.] Case Western Reserve Univ, Lerner Sch Med, Cleveland, OH 44106 USA. [Zhou, Wei] Palo Alto VA Hlth Care Syst, Div Vasc & Endovasc Surg, Vasc Sect, Stanford, CA USA. RP Abbott, AL (reprint author), Baker IDI Heart & Diabet Inst, 75 Commercial Rd, Melbourne, Vic 3004, Australia. EM Anne.L.Abbott@gmail.com; Mark.Adelman@nyumc.org; avalexandrov@att.net; hjmb@bell.net; j.d.beard@btinternet.com; peterrfbell@googlemail.com; martin@bjorck.pp.se; David.Blacker@health.wa.gov.au; Clifford.Buckley@VA.GOV; RCAMBRIA@PARTNERS.ORG; anthony.comerotamd@promedica.org; esc5@columbia.edu; a.h.davies@imperial.ac.uk; HHEckstein@web.de; Rishad.Faruqi@kp.org; gustav.fraedrich@i-med.ac.at; gloviczki.peter@mayo.edu; gjhankey@cyllene.uwa.edu.au; rharbaugh@psu.edu; eitanh@asaf.health.gov.il; skittner@umaryland.edu; tkleinig@hotmail.com; MIKHAILIDIS@aol.com; WMoore@mednet.ucla.edu; ross.naylor@uhl-tr.nhs.uk; anicolaides1@gmail.com; paraskevask@hotmail.com; Pelz@uwo.ca; james.prichard@yale.edu; Grant.Purdie@health.sa.gov.au; jeanbaptistericco@gmail.com; Thomas.Riles@nyumc.org; peter.rothwell@clneuro.ox.ac.uk; Peter.sandercock@ed.ac.uk; sillesen@mac.com; dspence@robarts.ca; f.spinelli@mac.com; Aaron.Tan@health.sa.gov.au; a.thapar09@imperial.ac.uk; fjvmd@msn.com; weizhou@stanford.edu RI Mikhailidis, Dimitri/A-1869-2013; Abbott, Anne/G-6604-2013; Bjorck, Martin/A-4104-2008; Hankey, Graeme /H-4968-2014; Spence, J. David/K-6396-2013; OI Sandercock, Peter/0000-0001-8484-0135; Spinelli, Francesco/0000-0001-6527-1993; Hankey, Graeme /0000-0002-6044-7328; Spence, J. David/0000-0001-7478-1098; Alexandrov, Andrei V/0000-0001-8871-1023; Adelman, Mark/0000-0001-9276-6131; Eckstein, Hans-Henning/0000-0002-0743-1642 NR 57 TC 0 Z9 0 U1 0 U2 3 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1708-5381 J9 VASCULAR JI Vascular PD FEB PY 2012 VL 20 IS 1 BP 1 EP 7 DI 10.1258/vasc.2011.201102 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 919OJ UT WOS:000302337400002 PM 22271806 ER PT J AU Brenner, GJ Kueppenbender, K Mao, JR Spike, J AF Brenner, Gary J. Kueppenbender, Karsten Mao, Jianren Spike, Jeffrey TI Ethical Challenges and Interventional Pain Medicine SO CURRENT PAIN AND HEADACHE REPORTS LA English DT Editorial Material DE Professionalism; Medical ethics; Anesthesia ethics; Fee-for-service medicine; Interventional pain practice; Evidence-based medicine; Ethical principles ID SPINAL-CORD STIMULATION; NERVE FIELD STIMULATION; BACK SURGERY SYNDROME; NEUROPATHIC PAIN; PHYSICIANS; CARE; MANAGEMENT; CRISIS; TRIAL C1 [Brenner, Gary J.; Mao, Jianren] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Ctr Pain Med, Wang Ambulatory Care Ctr, Boston, MA 02114 USA. [Kueppenbender, Karsten] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Spike, Jeffrey] Univ Texas Hlth Sci Ctr Houston, McGovern Ctr Humanities & Eth, Houston, TX USA. RP Brenner, GJ (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Ctr Pain Med, Wang Ambulatory Care Ctr, Suite 340,15 Parkman St, Boston, MA 02114 USA. EM gjbrenner@partners.org NR 28 TC 1 Z9 1 U1 0 U2 4 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1531-3433 J9 CURR PAIN HEADACHE R JI Curr. Pain Headache Rep. PD FEB PY 2012 VL 16 IS 1 BP 1 EP 8 DI 10.1007/s11916-011-0242-y PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 914TZ UT WOS:000301976800001 PM 22160519 ER PT J AU Rathmell, JP Manion, SC AF Rathmell, James P. Manion, Smith C. TI The Role of Image Guidance in Improving the Safety of Pain Treatment SO CURRENT PAIN AND HEADACHE REPORTS LA English DT Review DE Chronic pain; Pain treatment; Fluoroscopy; Computed tomography; Ultrasound; Patient safety; Imaging; MRI; Nerve blocks; Spinal cord injury; Anesthesia ID EPIDURAL STEROID INJECTIONS; LOW-BACK-PAIN; GUIDED REGIONAL ANESTHESIA; TRANSFORAMINAL INJECTION; PLEXUS BLOCK; ULTRASOUND; SOCIETY; INJURY AB The use of fluoroscopy, computed tomography, and, most recently, ultrasound in the pain clinic all have advanced rapidly, yet there is scant evidence that this improves the safety or efficacy of pain treatment. In this manuscript, the available evidence about the usefulness of diagnostic imaging and image guidance in planning and delivering pain treatment is critically reviewed. The use of image guidance has become a routine and integral component of pain treatment; however, there is insufficient scientific evidence to judge whether this has improved safety. The logical appeal is overwhelming, to the point that it is now unlikely that scientific comparisons of most techniques with and without radiographic guidance will ever be conducted. This analysis can serve to guide future investigators who set out to understand how to apply new imaging techniques, and in the process, how to rigorously evaluate their usefulness. C1 [Rathmell, James P.; Manion, Smith C.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Manion, Smith C.] Harvard Univ, Sch Med, Boston, MA USA. RP Rathmell, JP (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St,GRB 444, Boston, MA 02114 USA. EM rathmell.james@mgh.harvard.edu NR 31 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1531-3433 EI 1534-3081 J9 CURR PAIN HEADACHE R JI Curr. Pain Headache Rep. PD FEB PY 2012 VL 16 IS 1 BP 9 EP 18 DI 10.1007/s11916-011-0241-z PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 914TZ UT WOS:000301976800002 PM 22125112 ER PT J AU Tannous, Z AF Tannous, Zeina TI Introduction SO LASERS IN SURGERY AND MEDICINE LA English DT Editorial Material C1 [Tannous, Zeina] Lebanese Amer Univ, Rizk Hosp, Univ Med Ctr, Dept Dermatol, Beirut, Lebanon. [Tannous, Zeina] Harvard Univ, Sch Med, Dept Dermatol, Wellman Ctr Photomed,Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Tannous, Z (reprint author), Lebanese Amer Univ, Rizk Hosp, Univ Med Ctr, Dept Dermatol, Beirut, Lebanon. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2012 VL 44 IS 2 BP 91 EP 92 DI 10.1002/lsm.22008 PG 2 WC Dermatology; Surgery SC Dermatology; Surgery GA 897WN UT WOS:000300691200002 PM 22334293 ER PT J AU Stankiewicz, K Chuang, G Avram, M AF Stankiewicz, Kelly Chuang, Gary Avram, Mathew TI Lentigines, laser, and melanoma: A case series and discussion SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE lentigo maligna; melanoma; melanoma in situ; lentigo; lentigines; treatment; laser ID YTTRIUM-ALUMINUM-GARNET; Q-SWITCHED RUBY; MALIGNA MELANOMA; ALEXANDRITE LASERS; SOLAR LENTIGINES; PIGMENTED MACULE; STAGED EXCISION; IN-VITRO; EXPRESSION; OUTCOMES AB Solar lentigines are considered one of the earliest signs of photoaging and are an extremely common cosmetic complaint. Successful removal of these lesions can be achieved with laser and non-laser light sources, and is one of the most frequently performed cosmetic procedures in laser centers. Distinguishing a benign lentigo from other pigmented lesions can sometimes be challenging, even for a trained dermatologist. We report a series of three patients who presented to our laser center within 2 months of one another for cosmetic removal of pigmented lesions that were found to be melanoma. One patient was referred by another dermatologist, one by a physician family member, and the other presented on his own. These cases highlight the need for careful evaluation of pigmented lesions prior to laser treatment, regardless of the source of the referral. In this article, we will review the diagnostic and treatment differences between lentigines and their malignant counterparts, and examine the role of laser in both. Lasers Surg. Med. 44:112116, 2012. (c) 2012 Wiley Periodicals, Inc. C1 [Stankiewicz, Kelly; Chuang, Gary; Avram, Mathew] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dermatol Laser & Cosmet Ctr, Boston, MA 02114 USA. RP Avram, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dermatol Laser & Cosmet Ctr, 50 Staniford St,Suite 250, Boston, MA 02114 USA. EM mavram@partners.org NR 33 TC 3 Z9 3 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2012 VL 44 IS 2 BP 112 EP 116 DI 10.1002/lsm.21148 PG 5 WC Dermatology; Surgery SC Dermatology; Surgery GA 897WN UT WOS:000300691200006 PM 22334294 ER PT J AU Shek, SY Chan, NPY Chan, HH AF Shek, Samantha Y. Chan, Nicola P. Y. Chan, Henry H. TI Non-invasive cryolipolysis for body contouring in Chineseua first commercial experience SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE cryolipolysis; fat reduction; non-invasive body contouring; multiple treatments ID FOCUSED ULTRASOUND; LIPOSUCTION; EFFICACY AB Background The objective of the study is to determine the clinical efficacy and patient satisfaction of a novel cryolipolysis device (Zeltiq (R)) for body contouring in Chinese after a single treatment and after 2 treatments at a commercial setting. Materials and Methods: Two groups of patients were recruited for this procedure at their own cost. Group A, 21 subjects, received a single treatment and group B, 12 subjects, received 2 treatments, average 3 months apart using the Zeltiq Breeze System(1). The thickness of fat at the treatment site was measured by a caliper and the data were collected at baseline and 2 months posttreatment. Standardized clinical photos were also taken at baseline and follow-up visits. Subjective assessment was carried out in the form of a questionnaire. Any adverse effects were documented. Statistical analyses were performed on the data to compare the efficacy after a single treatment and after 2 treatments. Results: The first group of subjects, received a single treatment, showed that there was a significant improvement (P < 0.0001). The second group of subjects showed that the improvement was significant after 1 and 2 treatments when compared to the baseline. The extent of improvement after the second treatment however, was not as dramatic as the first treatment. Conclusion: Non-invasive cryolipolysis is effective for body contouring in Chinese. It is shown to have a further improvement with subsequent treatment sessions but of a lesser extent. The second treatment was statistically significant for abdomen, though not for love handles. Lasers Surg. Med. 44: 125-130, 2012. (C) 2011 Wiley Periodicals, Inc. C1 [Shek, Samantha Y.; Chan, Nicola P. Y.; Chan, Henry H.] Univ Hong Kong, Dept Med, Div Dermatol, Hong Kong, Hong Kong, Peoples R China. [Chan, Henry H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. RP Chan, HH (reprint author), Dermatol & Laser Ctr, 13-F Club Lusitano,16 Ice House St, Hong Kong, Hong Kong, Peoples R China. EM hhlchan@hkucc.hku.hk RI Yeung, Chi Keung/L-4795-2013; Chan, Henry Hin Lee/L-2267-2013 NR 18 TC 20 Z9 20 U1 1 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2012 VL 44 IS 2 BP 125 EP 130 DI 10.1002/lsm.21145 PG 6 WC Dermatology; Surgery SC Dermatology; Surgery GA 897WN UT WOS:000300691200008 PM 22334296 ER PT J AU Sakamoto, FH AF Sakamoto, Fernanda H. TI Introduction SO LASERS IN SURGERY AND MEDICINE LA English DT Editorial Material C1 Harvard Univ, Sch Med, Dept Dermatol, Wellman Ctr Photomed,Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Sakamoto, FH (reprint author), Harvard Univ, Sch Med, Dept Dermatol, Wellman Ctr Photomed,Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2012 VL 44 IS 2 BP 143 EP 143 DI 10.1002/lsm.22009 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 897WN UT WOS:000300691200010 PM 22334297 ER PT J AU Rubin, IK Farinelli, WA Doukas, A Anderson, RR AF Rubin, Iris K. Farinelli, William A. Doukas, Apostolos Anderson, R. Rox TI Optimal wavelengths for vein-selective photothermolysis SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE laser; port-wine stain; selective photothermolysis; vein; venous lesion ID PORT-WINE STAINS; PULSED-DYE-LASER; IN-VIVO; BIRTHMARKS; VESSELS; NM AB Background and Objective Oxyhemoglobin (HbO2) has been regarded as the primary target chromophore for selective photothermolysis of vascular malformations. In theory, venous lesions might be better treated with wavelengths preferentially absorbed by deoxyhemoglobin (Hb). Study Design/Materials and Methods: Wavelength-dependent fluence thresholds for photocoagulation of whole human blood were determined in glass capillary samples with measured oxygen saturation levels. Pulsed dye lasers at 585, 590, 595, 600, 633 nm, a 694 nm ruby laser, a 755 nm alexandrite laser, and a 1,064 nm Nd:Yag laser were used, all with 1.5-3 milliseconds pulse width and similar exposure spot size. Results: Selectivity (a lower fluence threshold) for venous blood was maximal at 694 nm, and significant at 595, 600, 633, and 755 nm. At 633 nm, a wavelength with strong relative absorption by metHb, selectivity for venous blood was much less than expected. The Nd: YAG laser at 1,064 nm showed significant selectivity for arterial blood. Conclusion: Preferential photocoagulation of venous blood is possible at wavelengths with a high Hb/HbO(2) absorption coefficient ratio. Laser-induced metHb may also affect wavelength-dependent selective photothermolysis. Venular malformations such as port wine stains could potentially be treated more selectively with similar to 630-780 nm sources. Nd: YAG laser pulses at 1,064 nm tend to affect arterial more than venous blood. Lasers Surg. Med. 44: 152-157, 2012. (C) 2012 Wiley Periodicals, Inc. C1 [Rubin, Iris K.] Dermatol Ctr, Bethesda, MD 20817 USA. [Rubin, Iris K.] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Farinelli, William A.; Doukas, Apostolos; Anderson, R. Rox] Massachusetts Gen Hosp Dermatol, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Rubin, IK (reprint author), Dermatol Ctr, 6410 Rockledge Dr,Suite 201, Bethesda, MD 20817 USA. EM irisrubin@gmail.com NR 19 TC 14 Z9 17 U1 1 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2012 VL 44 IS 2 BP 152 EP 157 DI 10.1002/lsm.21161 PG 6 WC Dermatology; Surgery SC Dermatology; Surgery GA 897WN UT WOS:000300691200011 PM 22241659 ER PT J AU Yang, PG Yao, M DeMartelaere, SL Redmond, RW Kochevar, IE AF Yang, Penggao Yao, Min DeMartelaere, Sheri L. Redmond, Robert W. Kochevar, Irene E. TI Light-activated sutureless closure of wounds in thin skin SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE eyelid; incision; laceration; laser welding; photochemical tissue bonding; Rose Bengal; wound healing; wound closure ID BLEPHAROPLASTY COMPLICATIONS; HAIRLESS MOUSE; INCISIONS AB Background and Objectives Closing lacerations in thin eyelid and periorbital skin is time consuming and requires high skill for optimal results. In this study we evaluate the outcomes after single layer closure of wounds in thin skin with a sutureless, light-activated photochemical technique called PTB. Study Design/Materials and Methods: Dorsal skin of the SKH-1 hairless mouse was used as a model for eyelid skin. Incisions (1.2 cm) were treated with 0.1% Rose Bengal dye followed by exposure to 532 nm radiation (25, 50, or 100 J/cm(2); 0.25 W/cm(2)) for PTB. Other incisions were sutured (five 10-0 monofilament), exposed only to 532 nm (100 J/cm(2)), or not treated. Outcomes were immediate seal strength (pressure causing leakage through incision of saline infused under wound), skin strength at 1, 3, and 7 days (measured by tensiometry), inflammatory infiltrate at 1, 3, and 7 days (histological assessment), and procedure time. Results: The immediate seal strength, as measured by leak pressure, was equivalent for all PTB fluences and for sutures (27-32 mmHg); these pressures were significantly greater than for the controls (untreated incisions or laser only treatment; P < 0.001). The ultimate strength of PTB-sealed incisions was greater than the controls at day 1 (P < 0.05) and day 3 (P < 0.025) and all groups were equivalent at day 7. Sutures produced greater inflammatory infiltrate at day 1 than observed in other groups (P 0.019). The average procedure time for sutured closure (311 seconds) was longer than for the PTB group treated with 25 J/cm(2) (160 seconds) but shorter than the group treated with 100 J/cm(2) (460 seconds). Conclusion: PTB produces an immediate seal of incisions in thin, delicate skin that heals well, is more rapid than suturing, does not require painful suture removal and is easy to apply. Lasers Surg. Med. 44: 163-167, 2012. (C) 2011 Wiley Periodicals, Inc. C1 [Yang, Penggao; Yao, Min; Redmond, Robert W.; Kochevar, Irene E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. [Yang, Penggao; Yao, Min] 3 Peoples Hosp, Dept Burns & Plast Surg, Shanghai 201900, Peoples R China. [Yao, Min] Shanghai Jiao Tong Univ, Sch Med, Inst Traumat Med, Shanghai 201900, Peoples R China. [DeMartelaere, Sheri L.] San Antonio Mil Med Ctr, Ophthalmol Serv, San Antonio, TX USA. RP Kochevar, IE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, 50 Blossom St, Boston, MA 02114 USA. EM kochevar@helix.mgh.harvard.edu FU Department of the Army [W81XWH-09-2-0050]; Air Force Office of Scientific Research [FA9550-10-1-0537] FX Contract grant sponsor: Department of the Army; Grant number: W81XWH-09-2-0050; Contract grant sponsor: Air Force Office of Scientific Research; Grant number: FA9550-10-1-0537. NR 10 TC 11 Z9 14 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0196-8092 EI 1096-9101 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2012 VL 44 IS 2 BP 163 EP 167 DI 10.1002/lsm.21137 PG 5 WC Dermatology; Surgery SC Dermatology; Surgery GA 897WN UT WOS:000300691200013 PM 22170339 ER PT J AU Sakamoto, FH Doukas, AG Farinelli, WA Tannous, Z Shinn, M Benson, S Williams, GP Gubeli, JF Dylla, HF Anderson, RR AF Sakamoto, Fernanda H. Doukas, Apostolos G. Farinelli, William A. Tannous, Zeina Shinn, Michelle Benson, Steve Williams, Gwyn P. Gubeli, Joseph F., III Dylla, H. Frederick Anderson, R. Rox TI Selective photothermolysis to target sebaceous glands: Theoretical estimation of parameters and preliminary results using a free electron laser SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE acne; free electron laser; in vitro; light; laser; therapy; spectroscopy; near infrared; Monte Carlo method ID PULSED-DYE-LASER; FACIAL ACNE-VULGARIS; RANDOMIZED CONTROLLED-TRIAL; DIODE-LASER; TISSUES; PREVALENCE; SKIN AB Background and Objectives The success of permanent laser hair removal suggests that selective photothermolysis (SP) of sebaceous glands, another part of hair follicles, may also have merit. About 30% of sebum consists of fats with copious CH2 bond content. SP was studied in vitro, using free electron laser (FEL) pulses at an infrared CH2 vibrational absorption wavelength band. Methods: Absorption spectra of natural and artificially prepared sebum were measured from 200 to 3,000 nm, to determine wavelengths potentially able to target sebaceous glands. The Jefferson National Accelerator superconducting FEL was used to measure photothermal excitation of aqueous gels, artificial sebum, pig skin, human scalp, and forehead skin (sebaceous sites). In vitro skin samples were exposed to FEL pulses from 1,620 to 1,720 nm, spot diameter 7-9.5 mm with exposure through a cold 48C sapphire window in contact with the skin. Exposed and control tissue samples were stained using H& E, and nitroblue tetrazolium chloride staining (NBTC) was used to detect thermal denaturation. Results: Natural and artificial sebum both had absorption peaks near 1,210, 1,728, 1,760, 2,306 and 2,346 nm. Laser-induced heating of artificial sebum was approximately twice that of water at 1,710 and 1,720 nm, and about 1.5 x higher in human sebaceous glands than in water. Thermal camera imaging showed transient focal heating near sebaceous hair follicles. Histologically, skin samples exposed to similar to 1,700 nm, similar to 100-125 milliseconds pulses showed evidence of selective thermal damage to sebaceous glands. Sebaceous glands were positive for NBTC staining, without evidence of selective loss in samples exposed to the laser. Epidermis was undamaged in all samples. Conclusions: SP of sebaceous glands appears to be feasible. Potentially, optical pulses at similar to 1,720 or similar to 1,210 nm delivered with large beam diameter and appropriate skin cooling in approximately 0.1 seconds may provide an alternative treatment for acne. Lasers Surg. Med. 44: 175-183, 2012. (C) 2011 Wiley Periodicals, Inc. C1 [Sakamoto, Fernanda H.; Doukas, Apostolos G.; Farinelli, William A.; Tannous, Zeina; Anderson, R. Rox] Massachusetts Gen Hosp, Dept Dermatol, Wellman Ctr Photomed, Boston, MA 02114 USA. [Sakamoto, Fernanda H.; Doukas, Apostolos G.; Farinelli, William A.; Tannous, Zeina; Anderson, R. Rox] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02114 USA. [Tannous, Zeina] Lebanese Amer Univ, Rizk Hosp, Univ Med Ctr, Dept Dermatol, Beirut, Lebanon. [Shinn, Michelle; Benson, Steve; Williams, Gwyn P.; Gubeli, Joseph F., III] Thomas Jefferson Natl Accelerator Facil, Newport News, VA 23606 USA. [Dylla, H. Frederick] Amer Inst Phys, College Pk, MD 20740 USA. RP Anderson, RR (reprint author), 55 Fruit St,BHX 630, Boston, MA 02114 USA. EM rranderson@partners.org FU Medical Free Electron Laser Research Program; AFOSR, US Department of Defense [FA 9550-04-1-0079]; Office of Naval Research; Commonwealth of Virginia FX Contract grant sponsor: Medical Free Electron Laser Research Program; Contract grant sponsor: AFOSR, US Department of Defense; Contract grant number: FA 9550-04-1-0079; Contract grant sponsor: Office of Naval Research; Contract grant sponsor: Commonwealth of Virginia. NR 30 TC 17 Z9 18 U1 0 U2 12 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD FEB PY 2012 VL 44 IS 2 BP 175 EP 183 DI 10.1002/lsm.21132 PG 9 WC Dermatology; Surgery SC Dermatology; Surgery GA 897WN UT WOS:000300691200015 PM 22170298 ER PT J AU Craft, D McQuaid, D Wala, J Chen, W Salari, E Bortfeld, T AF Craft, David McQuaid, Dualta Wala, Jeremiah Chen, Wei Salari, Ehsan Bortfeld, Thomas TI Multicriteria VMAT optimization SO MEDICAL PHYSICS LA English DT Article DE VMAT; optimization; convex; multi-criteria; pareto optimal ID MODULATED ARC THERAPY; PLAN QUALITY; MULTILEAF COLLIMATORS; RADIOTHERAPY; IMRT; DELIVERY; TOMOTHERAPY AB Purpose: To make the planning of volumetric modulated arc therapy (VMAT) faster and to explore the tradeoffs between planning objectives and delivery efficiency. Methods: A convex multicriteria dose optimization problem is solved for an angular grid of 180 equi-spaced beams. This allows the planner to navigate the ideal dose distribution Pareto surface and select a plan of desired target coverage versus organ at risk sparing. The selected plan is then made VMAT deliverable by a fluence map merging and sequencing algorithm, which combines neighboring fluence maps based on a similarity score and then delivers the merged maps together, simplifying delivery. Successive merges are made as long as the dose distribution quality is maintained. The complete algorithm is called VMERGE. Results: VMERGE is applied to three cases: a prostate, a pancreas, and a brain. In each case, the selected Pareto-optimal plan is matched almost exactly with the VMAT merging routine, resulting in a high quality plan delivered with a single arc in less than 5 min on average. Conclusions: VMERGE offers significant improvements over existing VMAT algorithms. The first is the multicriteria planning aspect, which greatly speeds up planning time and allows the user to select the plan, which represents the most desirable compromise between target coverage and organ at risk sparing. The second is the user-chosen epsilon-optimality guarantee of the final VMAT plan. Finally, the user can explore the tradeoff between delivery time and plan quality, which is a fundamental aspect of VMAT that cannot be easily investigated with current commercial planning systems. (C) 2012 American Association of Physicists in Medicine. [DOI: 10.1118/1.3675601] C1 [Craft, David; Wala, Jeremiah; Chen, Wei; Salari, Ehsan; Bortfeld, Thomas] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [McQuaid, Dualta] Inst Canc Res, Joint Dept Phys, London SM2 5PT, England. [McQuaid, Dualta] Royal Marsden NHSFT, London SM2 5PT, England. [Craft, David; Wala, Jeremiah; Chen, Wei; Salari, Ehsan; Bortfeld, Thomas] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Craft, D (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. EM dcraft@partners.org FU National Cancer Institute [R01CA103904] FX The project described was supported by Award No. R01CA103904 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. Thanks to Brian Winey for providing the brain case. NR 33 TC 34 Z9 37 U1 0 U2 6 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD FEB PY 2012 VL 39 IS 2 BP 686 EP 696 DI 10.1118/1.3675601 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 891KN UT WOS:000300215800014 PM 22320778 ER PT J AU Li, XH Zhang, D Liu, B AF Li, Xinhua Zhang, Da Liu, Bob TI Estimation of the weighted CTDI infinity for multislice CT examinations SO MEDICAL PHYSICS LA English DT Article DE CT; dose index; CTDI; efficiency; equilibrium dose ID CONE-BEAM CT; DOSE INDEX; DOSIMETRY; PROFILES AB Purpose: The aim of this study was to examine the variations of CT dose index (CTDI) efficiencies, epsilon(CTDI100) = CTDI100/CTDI infinity, with bowtie filters and CT scanner types. Methods: This was an extension of our previous study [Li, Zhang, and Liu, Phys. Med. Biol. 56, 5789-5803 (2011)]. A validated Monte Carlo program was used to calculate epsilon(CTDI100) on a Siemens Somatom Definition scanner. The epsilon(CTDI100) dependencies on tube voltages and beam widths were tested in previous studies. The influences of different bowtie filters and CT scanner types were examined in this work. The authors tested the variations of epsilon(CTDI100) with bowtie filters on the Siemens Definition scanner. The authors also analyzed the published CTDI measurements of four independent studies on five scanners of four models from three manufacturers. Results: On the Siemens Definition scanner, the difference in epsilon(CTDIW) between using the head and body bowtie filters was 2.5% (maximum) in the CT scans of the 32-cm phantom, and 1.7% (maximum) in the CT scans of the 16-cm phantom. Compared with CTDIW, the weighted CTDI infinity increased by 30.5% (on average) in the 32-cm phantom, and by 20.0% (on average) in the 16-cm phantom. These results were approximately the same for 80-140 kV and 1-40 mm beam widths (4.2% maximum deviation). The differences in epsilon(CTDI100) between the simulations and the direct measurements of four previous studies were 1.3%-5.0% at the center/periphery of the 16-cm/32-cm phantom (on average). Conclusions: Compared with CTDIvol, the equilibrium dose for large scan lengths is 30.5% higher in the 32-cm phantom, and is 20.0% higher in the 16-cm phantom. The relative increases are practically independent of tube voltages (80-140 kV), beam widths (up to 4 cm), and the CT scanners covered in this study. (C) 2012 American Association of Physicists in Medicine. [DOI: 10.11181.3678990] C1 [Li, Xinhua; Zhang, Da; Liu, Bob] Massachusetts Gen Hosp, Dept Radiol, Div Diagnost Imaging Phys, Boston, MA 02114 USA. RP Liu, B (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Diagnost Imaging Phys, Boston, MA 02114 USA. EM bliu7@bics.bwh.harvard.edu FU Enterprise Research IS group at Partners Healthcare FX The authors would like to acknowledge A. Schaller of Siemens Medical Solutions for providing design parameters of the Siemens Somatom Definition CT scanner. This work used the High Performance Clusters of the Partners Cooperation for Monte Carlo calculations, and the authors thank the Enterprise Research IS group at Partners Healthcare for their in-depth support. NR 11 TC 10 Z9 10 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD FEB PY 2012 VL 39 IS 2 BP 901 EP 905 DI 10.1118/1.3678990 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 891KN UT WOS:000300215800035 PM 22320799 ER PT J AU Horvath, GA Eichler, F Poskitt, K Stockler-Ipsiroglu, S AF Horvath, Gabriella Ana Eichler, Florian Poskitt, Ken Stockler-Ipsiroglu, Sylvia TI Failure of Repeated Cyclophosphamide Pulse Therapy in Childhood Cerebral X-Linked Adrenoleukodystrophy SO NEUROPEDIATRICS LA English DT Article DE adrenoleukodystrophy; immunosuppression; cyclophosphamide ID MULTIPLE-SCLEROSIS; IMMUNOSUPPRESSION; PROGRESSION; CELLS AB Childhood cerebral X-linked adrenoleukodystrophy (ALD) remains one of the most devastating neurological diseases of childhood. Cardinal features are inflammatory cerebral demyelination that coincides with an advancing zone of gadolinium enhancement on brain MRI. Therapeutic options, including the role of antiinflammatory therapy, are limited and poorly understood. We report the failure of repeated cyclophosphamide pulse therapy to halt the clinical progression or alter the gadolinium accumulation in two cases of childhood cerebral ALD. C1 [Horvath, Gabriella Ana] British Columbia Childrens Hosp, Dept Biochem Dis, Vancouver, BC V6H 3V4, Canada. [Eichler, Florian] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Poskitt, Ken] British Columbia Childrens Hosp, Dept Radiol, Vancouver, BC V6H 3V4, Canada. [Stockler-Ipsiroglu, Sylvia] British Columbia Childrens Hosp, Dept Pediat, Vancouver, BC V6H 3V4, Canada. RP Horvath, GA (reprint author), British Columbia Childrens Hosp, Dept Biochem Dis, Rm K3-207,4480 Oak St, Vancouver, BC V6H 3V4, Canada. EM ghorvath@cw.bc.ca OI Horvath, Gabriella/0000-0003-2573-2489 NR 12 TC 1 Z9 2 U1 1 U2 2 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0174-304X J9 NEUROPEDIATRICS JI Neuropediatrics PD FEB PY 2012 VL 43 IS 1 BP 48 EP 52 DI 10.1055/s-0032-1307455 PG 5 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA 916TT UT WOS:000302126800008 PM 22430161 ER PT J AU Muller, GA Quaas, M Schumann, M Krause, E Padi, M Fischer, M Litovchick, L DeCaprio, JA Engeland, K AF Mueller, Gerd A. Quaas, Marianne Schuemann, Michael Krause, Eberhard Padi, Megha Fischer, Martin Litovchick, Larisa DeCaprio, James A. Engeland, Kurt TI The CHR promoter element controls cell cycle-dependent gene transcription and binds the DREAM and MMB complexes SO NUCLEIC ACIDS RESEARCH LA English DT Article ID B-MYB TRANSCRIPTION; HOMOLOGY REGION CHR; E2F SITE; REGULATED REPRESSION; COREPRESSOR ELEMENT; HISTONE DEACETYLASE; CDC2 PROMOTER; G(2)/M GENES; TARGET GENES; CCAAT-BOXES AB Cell cycle-dependent gene expression is often controlled on the transcriptional level. Genes like cyclin B, CDC2 and CDC25C are regulated by cell cycle-dependent element (CDE) and cell cycle genes homology region (CHR) promoter elements mainly through repression in G(0)/G(1). It had been suggested that E2F4 binding to CDE sites is central to transcriptional regulation. However, some promoters are only controlled by a CHR. We identify the DREAM complex binding to the CHR of mouse and human cyclin B2 promoters in G(0). Association of DREAM and cell cycle-dependent regulation is abrogated when the CHR is mutated. Although E2f4 is part of the complex, a CDE is not essential but can enhance binding of DREAM. We show that the CHR element is not only necessary for repression of gene transcription in G(0)/G(1), but also for activation in S, G(2) and M phases. In proliferating cells, the B-myb-containing MMB complex binds the CHR of both promoters independently of the CDE. Bioinformatic analyses identify many genes which contain conserved CHR elements in promoters binding the DREAM complex. With Ube2c as an example from that screen, we show that inverse CHR sites are functional promoter elements that can bind DREAM and MMB. Our findings indicate that the CHR is central to DREAM/MMB-dependent transcriptional control during the cell cycle. C1 [Mueller, Gerd A.; Quaas, Marianne; Fischer, Martin; Engeland, Kurt] Univ Leipzig, Sch Med, D-04103 Leipzig, Germany. [Schuemann, Michael; Krause, Eberhard] Leibniz Inst Mol Pharmacol, D-13125 Berlin, Germany. [Padi, Megha] Harvard Univ, Sch Med, Dept Biostat & Computat Biol, Dana Farber Canc Inst, Boston, MA 02115 USA. [Padi, Megha] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Litovchick, Larisa; DeCaprio, James A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Litovchick, Larisa; DeCaprio, James A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. RP Engeland, K (reprint author), Univ Leipzig, Sch Med, Semmelweisstr 14, D-04103 Leipzig, Germany. EM engeland@medizin.uni-leipzig.de RI Fischer, Martin/I-4825-2014; OI Fischer, Martin/0000-0002-3429-1876; Engeland, Kurt/0000-0003-3525-0440; Muller, Gerd A./0000-0002-4967-2487 FU Public Health Service [P01CA050661, RO1CA93804, R01CA63113]; DOD [W81XWH-08-1-0048]; Bundesministerium fur Bildung und Forschung (BMBF) through Interdisciplinary Center for Clinical Research (IZKF) at the University of Leipzig; Deutsche Forschungsgemeinschaft (DFG) [SPP 314, EN 218/6-1, 6-2]; Oxford University Press FX Public Health Service grants (P01CA050661, RO1CA93804, and R01CA63113 to J.A.D.); DOD New Investigator Award (W81XWH-08-1-0048 to L.L.). Bundesministerium fur Bildung und Forschung (BMBF) through grants by the Interdisciplinary Center for Clinical Research (IZKF) at the University of Leipzig and the Deutsche Forschungsgemeinschaft (DFG) through grants (SPP 314, EN 218/6-1 and 6-2 to K.E.). Funding for open access charge: Waived by Oxford University Press. NR 58 TC 29 Z9 29 U1 0 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 EI 1362-4962 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD FEB PY 2012 VL 40 IS 4 BP 1561 EP 1578 DI 10.1093/nar/gkr793 PG 18 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 902UY UT WOS:000301069400021 PM 22064854 ER PT J AU Meghani, SH Byun, E Gallagher, RM AF Meghani, Salimah H. Byun, Eeeseung Gallagher, Rollin M. TI Time to Take Stock: A Meta-Analysis and Systematic Review of Analgesic Treatment Disparities for Pain in the United States SO PAIN MEDICINE LA English DT Review DE Pain; DisparitiesuEthnic; DisparitiesuRacial; Pain Management; Pain Treatment; Opioids; Analgesics; The Joint Commission; United States ID LOW-BACK INJURIES; EMERGENCY-DEPARTMENT PATIENTS; ACUTE ABDOMINAL-PAIN; LONG-BONE FRACTURES; ETHNIC DISPARITIES; RACIAL-DIFFERENCES; AFRICAN-AMERICANS; PRIMARY-CARE; POSTOPERATIVE PAIN; EPIDURAL ANALGESIA AB Background. The recent Institute of Medicine Report assessing the state of pain care in the United States acknowledged the lack of consistent data to describe the nature and magnitude of unrelieved pain and identify subpopulations with disproportionate burdens. Objectives. We synthesized 20 years of cumulative evidence on racial/ethnic disparities in analgesic treatment for pain in the United States. Evidence was examined for the 1) magnitude of association between race/ethnicity and analgesic treatment; 2) subgroups at an increased risk; and 3) the effect of moderators ( pain type, setting, study quality, and data collection period) on this association. Methods. United States studies with at least one explicit aim or analysis comparing analgesic treatment for pain between Whites and a minority group were included ( SciVerse Scopus database, 19892011). Results. Blacks/African Americans experienced both a higher number and magnitude of disparities than any other group in the analyses. Opioid treatment disparities were ameliorated for Hispanics/ Latinos for " traumatic/surgical" pain ( P = 0.293) but remained for " non- traumatic/nonsurgical" pain ( odds ratio [OR] = 0.70, 95% confidence interval [CI] = 0.64- 0.77, P = 0.000). For Blacks/African Americans, opioid prescription disparities were present for both types of pain and were starker for " non- traumatic/nonsurgical" pain ( OR = 0.66, 95% CI = 0.59- 0.75, P = 0.000). In subanalyses, opioid treatment disparities for Blacks/African Americans remained consistent across pain types, settings, study quality, and data collection periods. Conclusion. Our study quantifies the magnitude of analgesic treatment disparities in subgroups of minorities. The size of the difference was sufficiently large to raise not only normative but quality and safety concerns. The treatment gap does not appear to be closing with time or existing policy initiatives. A concerted strategy is needed to reduce pain care disparities within the larger quality of care initiatives. C1 [Meghani, Salimah H.; Byun, Eeeseung] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Gallagher, Rollin M.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Meghani, SH (reprint author), Univ Penn, NewCourtland Ctr Transit & Hlth, Dept Biobehav Hlth Sci, Claire M Fagin Hall,418 Curie Blvd,Room 337, Philadelphia, PA 19104 USA. EM meghanis@nursing.upenn.edu FU Pricara, Unit of Ortho-McNeil, Inc. FX This work was supported by an unrestricted educational grant to the Philadelphia Research and Education Foundation, Philadelphia VA Medical Center, from Pricara, Unit of Ortho-McNeil, Inc. administered by Ortho-McNeil Janssen Scientific Affairs. NR 80 TC 33 Z9 33 U1 3 U2 9 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD FEB PY 2012 VL 13 IS 2 BP 150 EP 174 DI 10.1111/j.1526-4637.2011.01310.x PG 25 WC Medicine, General & Internal SC General & Internal Medicine GA 897YZ UT WOS:000300700900003 PM 22239747 ER PT J AU Shega, JW Andrew, M Hemmerich, J Cagney, KA Ersek, M Weiner, DK Dale, W AF Shega, Joseph W. Andrew, Melissa Hemmerich, Josh Cagney, Kathleen A. Ersek, Mary Weiner, Debra K. Dale, William TI The Relationship of Pain and Cognitive Impairment with Social VulnerabilityuAn Analysis of the Canadian Study of Health and Aging SO PAIN MEDICINE LA English DT Article DE Chronic Pain; Cognitively Impaired; Social ID OLDER-ADULTS; PREVALENCE; DEMENTIA; PEOPLE; OSTEOARTHRITIS; INTEGRATION; POPULATION; DECLINE; COHORT; SCALE AB Objective. The objective of this study was to delineate the relationship between noncancer pain and cognitive impairment with social vulnerability. Design. The study was designed as a crosssectional analysis of the Canadian Study of Health and Aging, 1996 wave. Setting. Community-dwelling older adults in Canada. Subjects. 3,776 study participants. Outcome Measures. Pain was categorized as no or very mild pain vs moderate or severe pain. Cognitive impairment was dichotomized from the Modified Mini-Mental State Examination (0-100) to no (> 77) or impairment (77 or <). Social vulnerability (outcome) was operationalized as the accumulation of 39 possible self-report variables related to social circumstance, scores range from 0 to 1, where higher scores indicate greater vulnerability. Additional covariates included demographics, depressed mood, comorbidity, and functional impairment. Bivariate and multivariate relationships between pain and cognitive impairment with social vulnerability were assessed using t-tests and linear regression, respectively. Results. Of 5,703 respondents, 1,927 were missing a component of the social vulnerability index and of these nine were missing a pain response, leaving 3,767 (66.1%) of the original sample. A total of 2,435 (64.6%) reported no/ mild pain and 3,435 (91.2%) were cognitively intact. The mean (standard deviation) social vulnerability index was 9.97 (3.62) with scores ranging from 1.12 to 26.85. Moderate or severe pain 0.44 (95% confidence interval [ CI] 0.21, 0.66, P < 0.01) and cognitive impairment 0.49 (95% CI 0.13, 0.86, P < 0.01) were independently associated with social vulnerability, but the interaction term was not statistically significant, 0.40 (95% CI - 0.32,1.14, P = 0.27). Conclusion. Pain and cognitive impairment are independently associated with social vulnerability. Improvements in pain management might mitigate social vulnerability in a growing number of older adults with either or both conditions. C1 [Shega, Joseph W.; Hemmerich, Josh; Dale, William] Univ Chicago, Sect Geriatr & Palliat Med, Chicago, IL 60637 USA. [Dale, William] Univ Chicago, Sect Hematol Oncol, Chicago, IL 60637 USA. [Cagney, Kathleen A.] Univ Chicago, Dept Hlth Studies & Sociol, Chicago, IL 60637 USA. [Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Weiner, Debra K.] Univ Pittsburgh, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Andrew, Melissa] Dalhousie Univ, Div Geriatr Med, Halifax, NS, Canada. RP Shega, JW (reprint author), Sect Geriatr & Palliat Med MC 6098, 5841 S Maryland Ave, Chicago, IL 60637 USA. EM jshega@gmail.com FU National Health Research Development Program [6606-3954-MC[S]]; National Institute on Aging [K23AG029815]; Canadian Institutes of Health Research [MOP-62823]; QEII Research Foundation FX All the data reported here were gathered using public funding from the National Health Research Development Program, which administrated a grant from the Seniors' Independence Research program (6606-3954-MC[S]). Funding for these analyses came from a career development award from the National Institute on Aging K23AG029815 and from the Canadian Institutes of Health Research through an operating grant (MOP-62823). Additional support came from the Dalhousie Medical Research Foundation (career support to KR as Kathryn Allen Weldon Professor of Alzheimer Research) and the Fountain Innovation Fund of the QEII Research Foundation. Funding agencies had no role in the design and conduct of the study; data collection, management, analysis, and interpretation of the data; and preparation, review or approval of the manuscript. NR 28 TC 4 Z9 4 U1 0 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD FEB PY 2012 VL 13 IS 2 BP 190 EP 197 DI 10.1111/j.1526-4637.2011.01309.x PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 897YZ UT WOS:000300700900006 PM 22239723 ER PT J AU Scott, SA Patel, M Martis, S Lubitz, SA van der Zee, S Yoo, C Edelmann, L Halperin, JL Desnick, RJ AF Scott, Stuart A. Patel, Manishkumar Martis, Suparna Lubitz, Steven A. van der Zee, Sarina Yoo, Chang Edelmann, Lisa Halperin, Jonathan L. Desnick, Robert J. TI Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU SO PHARMACOGENOMICS LA English DT Article DE CALU; CNV; copy number variation; CYP2C9; CYP4F2; GGCX; pharmacogenetics; VKORC1; warfarin ID MAINTENANCE DOSE REQUIREMENT; COMMON GENETIC-VARIANTS; HUMAN GENOME; AFRICAN-AMERICANS; MULTIETHNIC POPULATION; STRUCTURAL VARIATION; PHARMACOGENETICS; POLYMORPHISM; ASSOCIATION; DELETION AB Aim: To determine if copy number variants contribute to warfarin dose requirements, we investigated CYP2C9, VKORC1, CYP4F2, GGCX and CALU for deletions and duplications in a multiethnic patient population treated with therapeutic doses of warfarin. Patients & methods: DNA samples from 178 patients were subjected to copy number analyses by multiplex ligation-dependent probe amplification or quantitative PCR assays. Additionally, the CYP2C9 exon 8 insertion/deletion polymorphism (rs71668942) was examined among the patient cohort and 1750 additional multiethnic healthy individuals. Results: All patients carried two copies of CYP2C9 by multiplex ligation-dependent probe amplification and no exon 8 deletion carriers were detected. Similarly, quantitative PCR assays for VKORC1, CYP4F2, GGCX and CALU identified two copies in all populations. Conclusion: These data indicate that copy number variants in the principal genes involved in warfarin dose variability (CYP2C9, VKORC1), including genes with lesser effect (CYP4F2, GGCX), and those that may be more relevant among certain racial groups (CALU), are rare in multiethnic populations, including African Americans. C1 [Scott, Stuart A.; Patel, Manishkumar; Martis, Suparna; Edelmann, Lisa; Desnick, Robert J.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA. [Lubitz, Steven A.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. [Lubitz, Steven A.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [van der Zee, Sarina; Halperin, Jonathan L.] Mt Sinai Sch Med, Zena & Michael Wiener Cardiovasc Inst, New York, NY USA. [Yoo, Chang] Elmhurst Hosp Ctr, Dept Ambulatory Care, Queens, NY USA. RP Scott, SA (reprint author), Mt Sinai Sch Med, Dept Genet & Genom Sci, Box 1497,1428 Madison Ave, New York, NY 10029 USA. EM stuart.scott@mssm.edu FU NIH [KL2 RR029885] FX This research was supported in part by grant KL2 RR029885 (SAS) from the NIH. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. NR 67 TC 5 Z9 6 U1 1 U2 2 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1462-2416 J9 PHARMACOGENOMICS JI Pharmacogenomics PD FEB PY 2012 VL 13 IS 3 BP 297 EP 307 DI 10.2217/PGS.11.156 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 913OE UT WOS:000301886500015 PM 22188360 ER PT J AU Lagares, D Busnadiego, O Garcia-Fernandez, R Kapoor, M Liu, S Carter, D Abraham, D Shi-Wen, X Carreira, P Fontaine, B Shea, B Tager, A Leask, A Lamas, S Rodriguez-Pascual, F AF Lagares, D. Busnadiego, O. Garcia-Fernandez, R. Kapoor, M. Liu, S. Carter, D. Abraham, D. Shi-Wen, X. Carreira, P. Fontaine, B. Shea, B. Tager, A. Leask, A. Lamas, S. Rodriguez-Pascual, F. TI INHIBITION OF FOCAL ADHESION KINASE PREVENTS EXPERIMENTAL LUNG FIBROSIS AND MYOFIBROBLAST FORMATION SO RHEUMATOLOGY LA English DT Meeting Abstract CT 2nd Systemic Sclerosis World Congress CY FEB 02-04, 2012 CL Madrid, SPAIN C1 [Lagares, D.; Busnadiego, O.; Lamas, S.; Rodriguez-Pascual, F.] CSIC, Ctr Biol Mol Severo Ochoa, Madrid, Spain. [Lagares, D.; Busnadiego, O.; Lamas, S.; Rodriguez-Pascual, F.] CSIC, Lab Mixto, Madrid, Spain. [Garcia-Fernandez, R.] Univ Complutense Madrid, Madrid, Spain. [Kapoor, M.; Liu, S.; Leask, A.] Univ Western Ontario, Schulich Sch Med & Dent, London, ON, Canada. [Carter, D.] London Reg Genom Ctr, London, ON, Canada. [Abraham, D.; Shi-Wen, X.] UCL, London, England. [Carreira, P.] Hosp Univ 12 Octubre, Madrid, Spain. [Fontaine, B.; Shea, B.; Tager, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-0324 J9 RHEUMATOLOGY JI RHEUMATOLOGY PD FEB PY 2012 VL 51 SU 2 BP 13 EP 14 PG 2 WC Rheumatology SC Rheumatology GA 914TC UT WOS:000301974300031 ER PT J AU Linnman, C Zeidan, MA Pitman, RK Milad, MR AF Linnman, Clas Zeidan, Mohamed A. Pitman, Roger K. Milad, Mohammed R. TI Resting cerebral metabolism correlates with skin conductance and functional brain activation during fear conditioning SO BIOLOGICAL PSYCHOLOGY LA English DT Article DE PET; fMRI; Fear conditioning; Glucose metabolism; Electrodermal activity ID POSTTRAUMATIC-STRESS-DISORDER; VENTROMEDIAL PREFRONTAL CORTEX; ANTERIOR CINGULATE CORTEX; ANXIETY DISORDERS; PERIAQUEDUCTAL GRAY; EXTINCTION MEMORY; DEFAULT MODE; AMYGDALA; RESPONSES; HUMANS AB We investigated whether resting brain metabolism can be used to predict autonomic and neuronal responses during fear conditioning in 20 healthy humans. Regional cerebral metabolic rate for glucose was measured via positron emission tomography at rest. During conditioning, autonomic responses were measured via skin conductance, and blood oxygen level dependent signal was measured via functional magnetic resonance imaging. Resting dorsal anterior cingulate metabolism positively predicted differentially conditioned skin conductance responses. Midbrain and insula resting metabolism negatively predicted midbrain and insula functional reactivity, while dorsal anterior cingulate resting metabolism positively predicted midbrain functional reactivity. We conclude that resting metabolism in limbic areas can predict some aspects of psychophysiological and neuronal reactivity during fear learning. (C) 2011 Elsevier B.V. All rights reserved. C1 [Linnman, Clas] Harvard Univ, Dept Psychiat, Sch Med, Charlestown, MA USA. Massachusetts Gen Hosp, Charlestown, MA USA. RP Linnman, C (reprint author), Harvard Univ, Dept Psychiat, Sch Med, Charlestown, MA USA. EM linnman@nmr.mgh.harvard.edu OI Linnman, Clas/0000-0001-8449-894X FU Institute of Mental Health [1R01MH081975-01] FX This work was supported by Institute of Mental Health grant 1R01MH081975-01 (MGH subcontract) to M.R.M. NR 56 TC 10 Z9 10 U1 3 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0301-0511 J9 BIOL PSYCHOL JI Biol. Psychol. PD FEB PY 2012 VL 89 IS 2 BP 450 EP 459 DI 10.1016/j.biopsycho.2011.12.012 PG 10 WC Psychology, Biological; Behavioral Sciences; Psychology; Psychology, Experimental SC Psychology; Behavioral Sciences GA 909JI UT WOS:000301560400021 PM 22207247 ER PT J AU Mathews, CA Perez, VB Delucchi, KL Mathalon, DH AF Mathews, Carol A. Perez, Veronica B. Delucchi, Kevin L. Mathalon, Daniel H. TI Error-related negativity in individuals with obsessive-compulsive symptoms: Toward an understanding of hoarding behaviors SO BIOLOGICAL PSYCHOLOGY LA English DT Article DE Error monitoring; ERN; Obsessive-compulsive disorder (OCD); Hoarding symptoms ID BRAIN ACTIVITY; ANTERIOR CINGULATE; RESPONSE CONFLICT; DECISION-MAKING; ERP COMPONENTS; NEURAL SYSTEM; DISORDER; PERFORMANCE; TASK; FMRI AB The error-related negativity (ERN), an event-related potential component elicited by error responses in cognitive tasks, has been shown to be abnormal in most, but not all, studies of obsessive-compulsive disorder or obsessive-compulsive symptoms (OCD/S); these inconsistencies may be due to task selection, symptom subtype, or both. We used meta-analysis to further characterize the ERN in OCD/S, and pooled data across studies to examine the ERN in OCD/S with hoarding. We found an enhanced ERN in OCD/S relative to controls, as well as heterogeneity across tasks. When stratified, OCD/S showed a significantly enhanced ERN only in response conflict tasks. However, OCD/S + hoarding showed a marginally larger ERN than OCD/S-hoarding, but only for probabilistic learning tasks. These results suggest that abnormal ERN in OCD/S is task-dependent, and that OCD/S + hoarding show different ERN activity from OCD/S - hoarding perhaps suggesting different pathophysiological mechanisms of error monitoring. (C) 2012 Elsevier B.V. All rights reserved. C1 [Mathews, Carol A.; Perez, Veronica B.; Delucchi, Kevin L.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Perez, Veronica B.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Delucchi, Kevin L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Mathews, CA (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. EM cmathews@lppi.ucsf.edu OI Mathalon, Daniel/0000-0001-6090-4974; Delucchi, Kevin/0000-0003-2195-9627 FU NIMH NIH HHS [R01 MH058262, T32 MH089920, T32 MH089920-01] NR 71 TC 24 Z9 24 U1 4 U2 12 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0301-0511 J9 BIOL PSYCHOL JI Biol. Psychol. PD FEB PY 2012 VL 89 IS 2 BP 487 EP 494 DI 10.1016/j.biopsycho.2011.12.018 PG 8 WC Psychology, Biological; Behavioral Sciences; Psychology; Psychology, Experimental SC Psychology; Behavioral Sciences GA 909JI UT WOS:000301560400025 PM 22227169 ER PT J AU Rodman, AM Milad, MR Deckersbach, T Im, J Chou, TN Dougherty, DD AF Rodman, Alexandra M. Milad, Mohammed R. Deckersbach, Thilo Im, Jamie Chou, Tina Dougherty, Darin D. TI Neuroimaging contributions to novel surgical treatments for intractable obsessive-compulsive disorder SO EXPERT REVIEW OF NEUROTHERAPEUTICS LA English DT Review DE deep brain stimulation; functional neurosurgery; neuroimaging; neurotherapeutics; obsessive-compulsive disorder; pathophysiology; predictor studies ID DEEP BRAIN-STIMULATION; VOXEL-BASED MORPHOMETRY; VENTROMEDIAL PREFRONTAL CORTEX; POSITRON-EMISSION-TOMOGRAPHY; TERM-FOLLOW-UP; ELECTRICAL-STIMULATION; ORBITOFRONTAL CORTEX; SYMPTOM PROVOCATION; ANTERIOR CINGULATE; TREATMENT RESPONSE AB Research in predictor studies has largely been limited to disorders such as obsessive-compulsive disorder (OCD), as it has a fairly well-established pathophysiology in the literature, and patients with OCD are more likely to receive neurotherapeutic treatment. As neurosurgical procedures are often invasive and involve standard risks associated with neurosurgery, along with a high cost, there is a major impetus to distinguish potential responders to treatment using neuroimaging techniques. This could not only assist in patient selection and improve response rates, but could also potentially be implemented to tailor a treatment avenue to an individual patient. Here we review studies that elucidate the pathophysiology of OCD, illustrate modern neurosurgical treatments and investigate predictive correlates of treatment outcome. C1 [Rodman, Alexandra M.; Milad, Mohammed R.; Deckersbach, Thilo; Im, Jamie; Chou, Tina; Dougherty, Darin D.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. [Milad, Mohammed R.; Deckersbach, Thilo; Dougherty, Darin D.] Harvard Univ, Sch Med, Boston, MA USA. RP Dougherty, DD (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. EM ddougherty@partners.org FU Medtronic; Cyberonics; Northstar FX D Dougherty has received funding from Medtronic (research and consulting/ honoraria), Northstar (research), and Cyberonics (research). T Deckersbach has participated in research funded by Medtronic, Cyberonics, and Northstar. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 78 TC 5 Z9 5 U1 3 U2 12 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7175 J9 EXPERT REV NEUROTHER JI Expert Rev. Neurother. PD FEB PY 2012 VL 12 IS 2 BP 219 EP 227 DI 10.1586/ERN.11.189 PG 9 WC Clinical Neurology; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 900BF UT WOS:000300860900018 PM 22288677 ER PT J AU Abbott, AL Adelman, MA Alexandrov, AV Barnett, HJM Beard, J Bell, P Bjorck, M Blacker, D Buckley, CJ Cambria, RP Comerota, AJ Connolly, ES Davies, AH Eckstein, HH Faruqi, R Fraedrich, G Gloviczki, P Hankey, GJ Harbaugh, RE Heldenberg, E Kittner, SJ Kleinig, TJ Mikhailidis, DP Moore, WS Naylor, R Nicolaides, A Paraskevas, KI Pelz, DM Prichard, JW Purdie, G Ricco, JB Riles, T Rothwell, P Sandercock, P Sillesen, H Spence, JD Spinelli, F Tan, A Thapar, A Veith, FJ Zhou, W AF Abbott, A. L. Adelman, M. A. Alexandrov, A. V. Barnett, H. J. M. Beard, J. Bell, P. Bjorck, M. Blacker, D. Buckley, C. J. Cambria, R. P. Comerota, A. J. Connolly, E. Sander Davies, A. H. Eckstein, H. -H. Faruqi, R. Fraedrich, G. Gloviczki, P. Hankey, G. J. Harbaugh, R. E. Heldenberg, E. Kittner, S. J. Kleinig, T. J. Mikhailidis, D. P. Moore, W. S. Naylor, R. Nicolaides, A. Paraskevas, K. I. Pelz, D. M. Prichard, J. W. Purdie, G. Ricco, J. -B. Riles, T. Rothwell, P. Sandercock, P. Sillesen, H. Spence, J. D. Spinelli, F. Tan, A. Thapar, A. Veith, F. J. Zhou, Wei TI Why the United States Center for Medicare and Medicaid Services (CMS) should not extend reimbursement indications for carotid artery angioplasty/stenting SO INTERNATIONAL ANGIOLOGY LA English DT Letter ID RANDOMIZED CONTROLLED-TRIAL; STROKE PREVENTION; ENDARTERECTOMY; STENOSIS; RISK; REVASCULARIZATION; PROFESSIONALS; GUIDELINES; THERAPY C1 [Abbott, A. L.] Baker IDI Heart & Diabet Inst, Melbourne, Vic 3004, Australia. [Abbott, A. L.] Florey Neurosci Inst, Melbourne, Vic, Australia. [Adelman, M. A.] NYU, Langone Med Ctr, New York, NY USA. [Alexandrov, A. V.] Univ Alabama Hosp & Clin, Birmingham, AL USA. [Barnett, H. J. M.] Univ Western Ontario, Robarts Res Inst, Toronto, ON, Canada. [Beard, J.] No Gen Hosp, Sheffield Vasc Inst, Sheffield S5 7AU, S Yorkshire, England. [Bell, P.] Univ Leicester, Leicester, Leics, England. [Bell, P.] Univ Leicester Hosp, Leicester, Leics, England. [Bjorck, M.] Uppsala Univ, Uppsala, Sweden. [Blacker, D.] Sir Charles Gairdner Hosp, Nedlands, WA 6009, Australia. [Cambria, R. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cambria, R. P.] Harvard Univ, Sch Med, Boston, MA USA. [Comerota, A. J.] Toledo Hosp, Jobst Vasc Inst, Toledo, OH USA. [Connolly, E. Sander] Columbia Univ, New York, NY USA. [Davies, A. H.] Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Sch Med, London, England. [Eckstein, H. -H.] Tech Univ Munich, Munich, Germany. [Eckstein, H. -H.] Tech Univ Munich, Klinikum Rechts Isar, D-8000 Munich, Germany. [Faruqi, R.] Stanford Univ, Kaiser Permanente Med Ctr, Stanford, CA 94305 USA. [Fraedrich, G.] Med Univ, Innsbruck, Austria. [Gloviczki, P.] Mayo Clin, Rochester, MN USA. [Hankey, G. J.] Univ Western Australia, Perth, WA 6009, Australia. [Hankey, G. J.] Royal Perth Hosp, Perth, WA, Australia. [Harbaugh, R. E.] Penn State Univ, Penn State Inst Neurosci, Hershey, PA USA. [Heldenberg, E.] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel. [Kittner, S. J.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Kleinig, T. J.] Univ Adelaide, Royal Adelaide Hosp, Adelaide, SA, Australia. [Kleinig, T. J.] Univ Adelaide, Lyell McEwin Hosp, Adelaide, SA, Australia. [Mikhailidis, D. P.] UCL, Sch Med, London W1N 8AA, England. [Moore, W. S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naylor, R.] Leicester Royal Infirm, Leicester, Leics, England. [Nicolaides, A.] Univ London Imperial Coll Sci Technol & Med, London, England. [Paraskevas, K. I.] Klinikum Nurnberg Sud, Nurnberg, Germany. [Spence, J. D.] Univ Western Ontario, Robarts Res Inst, London, ON, Canada. [Prichard, J. W.] Yale Univ, Sch Med, New Haven, CT USA. [Purdie, G.; Tan, A.] Queen Elizabeth Hosp, Adelaide, SA, Australia. [Ricco, J. -B.] Univ Poitiers, Vasc Surg Serv, Poitiers, France. [Riles, T.] New York Univ Sch Med, New York, NY USA. [Rothwell, P.] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England. [Sandercock, P.] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland. [Sillesen, H.] Univ Copenhagen, Copenhagen, Denmark. [Spinelli, F.] Univ Messina, Messina, Italy. [Tan, A.] Lyell McEwin Hosp, Adelaide, SA, Australia. [Veith, F. J.] Univ Hlth Sci, Case Western Reserve Univ, NYU, Sch Med,Cleveland Clin,Lerner Sch Med,Edward Hebe, New York, NY USA. [Zhou, Wei] Stanford Univ, Palo Alto VA Hlth Care Syst, Stanford, CA 94305 USA. RP Abbott, AL (reprint author), Baker IDI Heart & Diabet Inst, 75 Commercial Rd, Melbourne, Vic 3004, Australia. EM mark.adelman@nyumc.org; avalexandrov@att.net; hjmb@bell.net; j.d.beard@btinternet.com; peterrfbell@googlemail.com; martin@bjorck.pp.se; david.blacker@health.wa.gov.au; clifford.buckley@va.gov; rcambria@partners.org; anthony.comerotamd@promedica.org; esc5@columbia.edu; a.h.davies@imperial.ac.uk; hheckstein@web.de; rishad.faruqi@kp.org; gustav.fraedrich@i-med.ac.at; gloviczki.peter@mayo.edu; gjhankey@cyllene.uwa.edu; rharbaugh@psu.edu; eitanh@asaf.health.gov.il; skittner@umaryland.edu; tkleinig@hotmail.com; MIKHAILIDIS@aol.com; wmoore@mednet.ucla.edu; ross.naylor@uhl-tr.nhs.uk; anicolaides1@gmail.com; paraskevask@hotmail.com; pelz@uwo.ca; james.prichard@yale.edu; grant.purdie@health.sa.gov.au; jeanbaptistericco@gmail.com; Thomas.Riles@nyumc.org; peter.rothwell@clneuro.ox.ac.uk; Peter.sandercock@ed.ac.uk; sillesen@mac.com; dspence@robarts.ca; f.spinelli@mac.com; aaron.tan@health.sa.gov.au; a.thapar09@imperial.ac.uk; fjvmd@msn.corn; weizhou@stanford.edu RI Mikhailidis, Dimitri/A-1869-2013; Abbott, Anne/G-6604-2013; Hankey, Graeme /H-4968-2014; Spence, J. David/K-6396-2013; OI Hankey, Graeme /0000-0002-6044-7328; Spence, J. David/0000-0001-7478-1098; Alexandrov, Andrei V/0000-0001-8871-1023 NR 56 TC 1 Z9 1 U1 0 U2 3 PU EDIZIONI MINERVA MEDICA PI TURIN PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY SN 0392-9590 J9 INT ANGIOL JI Int. Angiol. PD FEB PY 2012 VL 31 IS 1 BP 85 EP 90 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 912TG UT WOS:000301822400012 PM 22330629 ER PT J AU Weissman, JS Hasnain-Wynia, R Weinick, RM Kang, R Vogeli, C Iezzoni, L Landrum, MB AF Weissman, Joel S. Hasnain-Wynia, Romana Weinick, Robin M. Kang, Raymond Vogeli, Christine Iezzoni, Lisa Landrum, Mary Beth TI Pay-For-Performance Programs to Reduce Racial/Ethnic Disparities: What Might Different Designs Achieve? SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Racial/ethnic differences in health care; pay for performance ID QUALITY-OF-CARE; HEALTH-CARE; RACIAL DISPARITIES; MINORITY PATIENTS; HOSPITALS; EQUITY AB Pay-for-performance (P4P) programs may have unintended effects on racial/ethnic disparities. We used patient-level quality scores from the Hospital Quality Alliance and ranked hospitals by overall quality and by racial/ethnic disparities. We then modeled the effects of different P4P designs on national disparity scores. The models using overall quality to rank hospitals resulted in modest reductions in national disparity scores, although these were smaller than the reductions that were found from programs using disparities to rank hospitals. These results suggest that many hospitals treat Whites and minorities equitably. Nevertheless, in order to maximize both improvements in quality and reductions in national disparities, P4P programs should consider an approach that considers both overall quality and reductions in disparities when setting incentives. C1 [Weissman, Joel S.; Vogeli, Christine; Iezzoni, Lisa] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Hlth Policy, Boston, MA USA. [Weissman, Joel S.; Vogeli, Christine; Iezzoni, Lisa] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Weissman, Joel S.; Landrum, Mary Beth] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Weissman, Joel S.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Hasnain-Wynia, Romana] Northwestern Univ, Dept Med, Div Gen Internal Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Hasnain-Wynia, Romana; Kang, Raymond] Northwestern Univ, Ctr Healthcare Equ, Inst Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA. [Weinick, Robin M.] RAND Corp, Arlington, VA USA. RP Weissman, JS (reprint author), Brigham & Womens Hosp, Ctr Surg & Publ Hlth, 1 Brigham Circle,1620 Tremont St,4-020, Boston, MA 02120 USA. EM jweissman@partners.org NR 32 TC 7 Z9 7 U1 0 U2 3 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD FEB PY 2012 VL 23 IS 1 BP 144 EP 160 PG 17 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 900TN UT WOS:000300913200012 PM 22643468 ER PT J AU Freemantle, N Richardson, M Wood, J Ray, D Khosla, S Shahian, D Roche, WR Stephens, I Keogh, B Pagano, D AF Freemantle, N. Richardson, M. Wood, J. Ray, D. Khosla, S. Shahian, D. Roche, W. R. Stephens, I. Keogh, B. Pagano, D. TI Weekend hospitalization and additional risk of death: An analysis of inpatient data SO JOURNAL OF THE ROYAL SOCIETY OF MEDICINE LA English DT Article ID MORTALITY; ADMISSION; MODEL; CARE AB Objective To assess whether weekend admissions to hospital and/or already being an inpatient on weekend days were associated with any additional mortality risk. Design Retrospective observational survivorship study. We analysed all admissions to the English National Health Service (NHS) during the financial year 2009/10, following up all patients for 30 days after admission and accounting for risk of death associated with diagnosis, co-morbidities, admission history, age, sex, ethnicity, deprivation, seasonality, day of admission and hospital trust, including day of death as a time dependent covariate. The principal analysis was based on time to in-hospital death. Participants National Health Service Hospitals in England. Main Outcome Measures 30 day mortality (in or out of hospital). Results There were 14,217,640 admissions included in the principal analysis, with 187,337 in-hospital deaths reported within 30 days of admission. Admission on weekend days was associated with a considerable increase in risk of subsequent death compared with admission on weekdays, hazard ratio for Sunday versus Wednesday 1.16 (95% Cl 1.14 to 1.18; P<.0001), and for Saturday versus Wednesday 1.11 (95% Cl 1.09 to 1.13; P<.0001). Hospital stays on weekend days were associated with a lower risk of death than midweek days, hazard ratio for being in hospital on Sunday versus Wednesday 0.92 (95% Cl 0.91 to 0.94; P<.0001), and for Saturday versus Wednesday 0.95(95% Cl 0.93 to 0.96; P<.0001). Similar findings were observed on a smaller US data set. Conclusions Admission at the weekend is associated with increased risk of subsequent death within 30 days of admission. The likelihood of death actually occurring is less on a weekend day than on a mid-week day. C1 [Khosla, S.; Pagano, D.] Univ Hosp Birmingham Fdn Trust, Queen Elizabeth Hosp, Qual & Outcomes Res Unit, Birmingham B15 2TH, W Midlands, England. [Freemantle, N.] UCL, Dept Primary Care & Populat Hlth, London NW3 2PF, England. [Richardson, M.] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham B15 2SP, W Midlands, England. [Wood, J.] Univ E Anglia, Dept Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England. [Shahian, D.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Shahian, D.] Massachusetts Gen Hosp, Ctr Qual & Safety, Boston, MA 02114 USA. [Roche, W. R.] Univ Southampton, Horley RH6 7DE, Surrey, England. [Roche, W. R.] NHS S England, Horley RH6 7DE, Surrey, England. [Stephens, I.] Solut Publ Hlth, Oxford OX4 2GX, England. [Keogh, B.] Dept Hlth, London SW1A 2NS, England. [Pagano, D.] Univ Birmingham, Sch Clin & Expt Med, Birmingham B15 2TT, W Midlands, England. RP Pagano, D (reprint author), Univ Hosp Birmingham Fdn Trust, Queen Elizabeth Hosp, Qual & Outcomes Res Unit, Birmingham B15 2TH, W Midlands, England. EM domenico.pagano@uhb.nhs.uk OI Freemantle, Nick/0000-0001-5807-5740 FU Quality and Outcomes Research Unit, University Hospital Birmingham, UK FX The authors would like to acknowledge the Quality and Outcomes Research Unit, University Hospital Birmingham, UK, who supported this study NR 13 TC 85 Z9 87 U1 0 U2 7 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 0141-0768 J9 J ROY SOC MED JI J. R. Soc. Med. PD FEB PY 2012 VL 105 IS 2 BP 74 EP 84 DI 10.1258/jrsm.2012.120009 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 912SN UT WOS:000301820300009 PM 22307037 ER PT J AU Mok, GSP Yu, JH Du, Y Wang, YC Tsui, BMW AF Mok, Greta S. P. Yu, Jianhua Du, Yong Wang, Yuchuan Tsui, Benjamin M. W. TI Evaluation of a Multi-pinhole Collimator for Imaging Small Animals with Different Sizes SO MOLECULAR IMAGING AND BIOLOGY LA English DT Article DE Small animal imaging; SPECT; Single pinhole; Multi-pinhole; Multiplexing ID EMISSION COMPUTED-TOMOGRAPHY; ULTRA-HIGH-RESOLUTION; SPECT SYSTEM; ADAPTIVE SPECT; SIMULATION; RECONSTRUCTION; PERFORMANCE; GEOMETRIES; DESIGN; DEVICE AB Purpose: Our goal was to evaluate a multi-pinhole (MPH) collimator which allows changing configurations for mouse imaging and rat imaging. Procedures: The collimator length can be adjusted from 5 cm for rat imaging to a maximum of 8 cm for mouse imaging. Projections of mouse-and rat-size phantoms were simulated with collimator length of 8 cm, and the rat-size phantom was additionally simulated with collimator length of 5 cm. Bias and noise were assessed in the reconstructed images. Three physical phantoms were used to evaluate the axial sampling and resolutions for one-, four-, and five-pinhole single photon emission computed tomography (SPECT). Images of three different-sized rodents were also acquired. Results: Simulations showed that for rat imaging, shorter collimator length provided an improved bias-noise trade-off compared to that of longer collimator length. Axial distortions were significantly reduced for MPH compared to single pinhole imaging. The smallest rods visible for mouse imaging and rat imaging were 1 and 1.6 mm, respectively, and their corresponding absolute sensitivities were 3.47% and 2.02% at the center field-of-view for 5-pinhole imaging. The count ratios were 1: 3.78: 4.42, respectively, for one-, four-, and five-pinhole for same acquisition time. Good image quality was observed in real animal studies. Conclusions: This collimator allows flexible single pinhole and MPH SPECT imaging for rodents, achieving high resolution and detection efficiency with minimal image artifacts. C1 [Mok, Greta S. P.] Univ Macau, Fac Sci & Technol, Dept Elect & Elect Engn, Taipa, Peoples R China. [Yu, Jianhua; Du, Yong; Tsui, Benjamin M. W.] Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Div Med Imaging Phys, Baltimore, MD 21287 USA. [Wang, Yuchuan] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Mok, GSP (reprint author), Univ Macau, Fac Sci & Technol, Dept Elect & Elect Engn, Taipa, Peoples R China. EM gretamok@umac.mo OI Wang, Yuchuan/0000-0001-5111-6562 FU NIH [EB1558, CA92871]; Gamma Medica, Inc. FX The authors would like to thank Dr. Kathleen Gabrielson from the Department of Molecular and Comparative Pathobiology at the Johns Hopkins Medical Institutions for providing the doxorubicin rat model, Mr. Gilbert Green and Mr. James Fox from the Small Animal Imaging Resource Program at the Johns Hopkins Medical Institutions for assisting the experimental preparations. This work was supported in parts by NIH Grants EB1558 and CA92871.; The authors declare that Dr. Benjamin M. W. Tsui is the co-licensor of software package and the recipient of research contract to Gamma Medica, Inc. Dr. Yuchuan Wang is the co-licensor of software package to Gamma Medica, Inc. NR 32 TC 7 Z9 7 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1536-1632 J9 MOL IMAGING BIOL JI Mol. Imaging. Biol. PD FEB PY 2012 VL 14 IS 1 BP 60 EP 69 DI 10.1007/s11307-011-0472-8 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 909SE UT WOS:000301583900009 PM 21318421 ER PT J AU Pukkila-Worley, R Ausubel, FM AF Pukkila-Worley, Read Ausubel, Frederick M. TI Immune defense mechanisms in the Caenorhabditis elegans intestinal epithelium SO CURRENT OPINION IN IMMUNOLOGY LA English DT Review ID INNATE IMMUNITY; C. ELEGANS; PATHOGEN INTERACTIONS; SIGNALING PATHWAY; LIFE-SPAN; PROTEIN; MODEL; INFECTION; HOST; SYSTEM AB Intestinal epithelial cells provide an essential line of defense for Caernohabditis elegans against ingested pathogens. Because nematodes consume microorganisms as their food source, there has presumably been selection pressure to evolve and maintain immune defense mechanisms within the intestinal epithelium. Here we review recent advances that further define the immune signaling network within these cells and suggest mechanisms used by the nematode to monitor for infection. In reviewing studies of pathogenesis that use this simple model system, we hope to illustrate some of the basic principles of epithelial immunity that may also be of relevance in higher order hosts. C1 [Pukkila-Worley, Read] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA. [Ausubel, Frederick M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Genet,Dept Mol Biol, Boston, MA 02114 USA. RP Pukkila-Worley, R (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA. EM rpukkilaworley@partners.org; ausubel@molbio.mgh.harvard.edu FU Irvington Institute of the Cancer Research Institute; National Institutes of Health [AI081747, AI044220, AI064332, AI085581, AI076372, AI083214, DK040561] FX We are grateful to Emily Troemel for providing us with the image used in Figure 1 and to our many colleagues that allowed us to cite their unpublished results. We thank Dennis Kim, Emily Troemel, Christine Kocks, and Lynda Stuart for their comments on the manuscript. The authors' research has been supported by the Irvington Institute Fellowship Program of the Cancer Research Institute (to RPW) and by the following grants from the National Institutes of Health: K08 award AI081747 (to RPW), P01 award AI044220 (to FMA), R01 award AI064332 (to FMA), R01 award AI085581 (to FMA), R01 award AI076372 (to FMA), P01 award AI083214 (to FMA), and P30 award DK040561 (to FMA). NR 67 TC 46 Z9 47 U1 2 U2 25 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0952-7915 J9 CURR OPIN IMMUNOL JI Curr. Opin. Immunol. PD FEB PY 2012 VL 24 IS 1 BP 3 EP 9 DI 10.1016/j.coi.2011.10.004 PG 7 WC Immunology SC Immunology GA 909JN UT WOS:000301560900002 PM 22236697 ER PT J AU Schulze, MSED Wucherpfennig, KW AF Schulze, Monika-Sarah E. D. Wucherpfennig, Kai W. TI The mechanism of HLA-DM induced peptide exchange in the MHC class II antigen presentation pathway SO CURRENT OPINION IN IMMUNOLOGY LA English DT Review ID INVARIANT CHAIN PEPTIDES; DR MOLECULES; CRYSTAL-STRUCTURE; CUTTING EDGE; B-CELLS; COMPLEX; BINDING; DISSOCIATION; ASSOCIATION; EPITOPES AB HLA-DM serves a critical function in the loading and editing of peptides on MHC class II (MHCII) molecules. Recent data showed that the interaction cycle between MHCII molecules and HLA-DM is dependent on the occupancy state of the peptide binding groove. Empty MHCII molecules form stable complexes with HLA-DM, which are disrupted by binding of high-affinity peptide. Interestingly, MHCII molecules with fully engaged peptides cannot interact with HLA-DM, and prior dissociation of the peptide N-terminus from the groove is required for HLA-DM binding. There are significant similarities to the peptide loading process for MHC class I molecules, even though it is executed by a distinct set of proteins in a different cellular compartment. C1 [Schulze, Monika-Sarah E. D.; Wucherpfennig, Kai W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Schulze, Monika-Sarah E. D.] Free Univ Berlin, Fachbereich Biol, D-14195 Berlin, Germany. [Wucherpfennig, Kai W.] Harvard Univ, Sch Med, Program Immunol, Boston, MA USA. [Wucherpfennig, Kai W.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. RP Wucherpfennig, KW (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA. EM kai_wucherpfennig@dfci.harvard.edu FU National Institutes of Health [R01 NS044914, PO1 AI045757] FX We thank Anne-Kathrin Anders and Melissa J. Call for their contributions to some of the work discussed here. This work was supported by the National Institutes of Health (R01 NS044914 and PO1 AI045757 to K.W.W.). NR 50 TC 25 Z9 26 U1 0 U2 14 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0952-7915 J9 CURR OPIN IMMUNOL JI Curr. Opin. Immunol. PD FEB PY 2012 VL 24 IS 1 BP 105 EP 111 DI 10.1016/j.coi.2011.11.004 PG 7 WC Immunology SC Immunology GA 909JN UT WOS:000301560900016 PM 22138314 ER PT J AU Bouchard, C Magill, JC Nikonovskiy, V Byl, M Murphy, BA Kaban, LB Troulis, MJ AF Bouchard, C. Magill, J. C. Nikonovskiy, V. Byl, M. Murphy, B. A. Kaban, L. B. Troulis, M. J. TI Osteomark: a surgical navigation system for oral and maxillofacial surgery SO INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article DE surgical navigation; marking tool; endoscopic surgery; mandible ID INVASIVE ORTHOGNATHIC SURGERY; INTRAOPERATIVE NAVIGATION AB The purpose of this project was to test a surgical navigation tool designed to help execute a surgical treatment plan. It consists of an electromagnetically tracked pencil that is used to mark bone intraoperatively. The device was tested on a precision block, an ex vivo pig mandible and during performance of six endoscopic vertical ramus osteotomies on pig cadavers. The difference between actual pencil position and that displayed by the computer was measured three times each at ten 2 mm holes on the block (n = 30 observations) and on the ex vivo mandible (n = 11 measurements). Errors between planned and actual osteotomy locations for the cadaver procedures were measured. The mean distance between known and displayed locations was 1.55 +/- 0.72 mm on the precision block and 2.10 +/- 0.88 mm on the pig mandible. The error measured marking the same point on the block multiple (n = 5) times was 0.58 +/- 0.37 mm. The mean error on the simulated osteotomies was 2.35 +/- 1.35 mm. Osteomark was simple to use and permitted localisation of holes and osteotomies with acceptable accuracy. In the future, the device and algorithms will be revised to further decrease error and the system will be tested on live animals. C1 [Bouchard, C.; Magill, J. C.; Nikonovskiy, V.; Byl, M.; Murphy, B. A.; Kaban, L. B.; Troulis, M. J.] Harvard Univ, Sch Dent Med, Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02115 USA. RP Bouchard, C (reprint author), Hop Enfants Jesus, Dept Oral & Maxillofacial Surg, 1401 18E Rue, Quebec City, PQ G1J 1Z4, Canada. EM carlbouch@hotmail.com FU AO/Synthes/MGH; Hanson Foundation (Boston, MA); MGH Department of OMFS; National Institute of Dental & Craniofacial Research [R43DE019322] FX This work was supported in part by the AO/Synthes/MGH Fellowship in Pediatric Oral and Maxillofacial Surgery; the Hanson Foundation (Boston, MA); the MGH Department of OMFS Education and Research Fund and by Award Number R43DE019322 from the National Institute of Dental & Craniofacial Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Dental & Craniofacial Research or the National Institutes of Health. NR 18 TC 12 Z9 12 U1 0 U2 4 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0901-5027 J9 INT J ORAL MAX SURG JI Int. J. Oral Maxillofac. Surg. PD FEB PY 2012 VL 41 IS 2 BP 265 EP 270 DI 10.1016/j.ijom.2011.10.017 PG 6 WC Dentistry, Oral Surgery & Medicine; Surgery SC Dentistry, Oral Surgery & Medicine; Surgery GA 908ER UT WOS:000301473700024 PM 22103996 ER PT J AU Cheung, JS Wang, EF Zhang, XA Mandeville, E Lo, EH Sorensen, AG Sun, PZ AF Cheung, Jerry S. Wang, Enfeng Zhang, XiaoAn Mandeville, Emiri Lo, Eng H. Sorensen, A. Gregory Sun, Phillip Zhe TI Fast radio-frequency enforced steady state (FRESS) spin echo MRI for quantitative T-2 mapping: minimizing the apparent repetition time (TR) dependence for fast T-2 measurement SO NMR IN BIOMEDICINE LA English DT Article DE MRI; spin echo; stroke; T-2 ID NORMAL BRAIN MATURATION; RELAXATION-TIMES; MULTIPLE-SCLEROSIS; BLOOD-FLOW; T2; RELAXOMETRY; ERRORS; RAT AB Transverse relaxation time (T-2) is a basic but very informative MRI parameter, widely used in imaging to examine a host of diseases, including multiple sclerosis, stroke, and tumor. However, short repetition time (TR) is often used to minimize scan time, which may introduce non-negligible errors in T-2 measurement. Specifically, due to the use of refocusing pulse, the steady state magnetization depends not only on TR but also on the TE. Hence, if the TE dependence is not properly accounted for, it may be mistaken as T-2-induced signal attenuation, leading to non-negligible T-2 underestimation. Our study proposed a fast radio-frequency enforced steady state (FRESS) spin echo (SE) MRI sequence, which saturates the magnetization after the echo and ensures a TE-independent steady state. The proposed FRESS-SE MRI was evaluated with numerical simulation, implemented with echo planar imaging readout, and validated by both phantom and in vivo experiments. In summary, FRESS-SE T-2 MRI technique was developed for fast and accurate T-2 imaging, suitable for in vivo applications. Copyright (C) 2011 John Wiley & Sons, Ltd. C1 [Cheung, Jerry S.; Wang, Enfeng; Sorensen, A. Gregory; Sun, Phillip Zhe] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Cheung, Jerry S.; Wang, Enfeng; Mandeville, Emiri; Lo, Eng H.; Sorensen, A. Gregory; Sun, Phillip Zhe] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Wang, Enfeng; Zhang, XiaoAn] Zhengzhou Univ, Affiliated Hosp 3, Dept Radiol, Zhengzhou, Peoples R China. [Mandeville, Emiri; Lo, Eng H.] Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Radiol & Neurol, Charlestown, MA 02129 USA. RP Sun, PZ (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Rm 2301,149 13th St, Charlestown, MA 02129 USA. EM pzhesun@nmr.mgh.harvard.edu FU AHA/SDG [0835384N]; NIH/NIBIB [1K01EB009771-01]; [NIH/1R21NS061119]; [NIH/NCRR-P41RR14075]; [NSFC/30900365]; [BNSF/7092038] FX This study was supported in part by grants from AHA/SDG 0835384N, NIH/NIBIB 1K01EB009771-01, NIH/1R21NS061119, NIH/NCRR-P41RR14075, NSFC/30900365 and BNSF/7092038. The authors would like to thank Dr Kenneth Kwong and Dr Timothy Reese for stimulating discussions, and Ms Nichole Eusemann for editorial assistance. NR 33 TC 7 Z9 7 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0952-3480 J9 NMR BIOMED JI NMR Biomed. PD FEB PY 2012 VL 25 IS 2 BP 189 EP 194 DI 10.1002/nbm.1729 PG 6 WC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy SC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy GA 909WP UT WOS:000301597300001 PM 21755552 ER PT J AU Andronesi, OC Gagoski, BA Adalsteinsson, E Sorensen, AG AF Andronesi, Ovidiu C. Gagoski, Borjan A. Adalsteinsson, Elfar Sorensen, A. Gregory TI Correlation chemical shift imaging with low-power adiabatic pulses and constant-density spiral trajectories SO NMR IN BIOMEDICINE LA English DT Article DE Correlation Chemical Shift Imaging (CCSI); Correlation Spectroscopy (COSY); Total Correlation Spectroscopy (TOCSY); Localized Adiabatic Selective Refocusing (LASER); Gradient Offset Independent Adiabatic (GOIA); Spiral Spectroscopic Imaging; Brain; Glioblastoma Multiforme (GBM) ID MULTIDIMENSIONAL NMR-SPECTRA; IN-VIVO; HUMAN-BRAIN; MAGNETIC-RESONANCE; RAT-BRAIN; MR SPECTROSCOPY; 2-DIMENSIONAL SPECTROSCOPY; CT-PRESS; 3 T; RECONSTRUCTION AB In this work we introduce the concept of correlation chemical shift imaging (CCSI). Novel CCSI pulse sequences are demonstrated on clinical scanners for two-dimensional Correlation Spectroscopy (COSY) and Total Correlation Spectroscopy (TOCSY) imaging experiments. To date there has been limited progress reported towards a feasible and robust multivoxel 2D COSY. Localized 2D TOCSY imaging is shown for the first time in this work. Excitation with adiabatic GOIA-W(16,4) pulses (Gradient Offset Independent Adiabaticity Wurst modulation) provides minimal chemical shift displacement error, reduced lipid contamination from subcutaneous fat, uniform optimal flip angles, and efficient mixing for coupled spins, while enabling short repetition times due to low power requirements. Constant-density spiral readout trajectories are used to acquire simultaneously two spatial dimensions and f(2) frequency dimension in (k(x),k(y),t(2)) space in order to speed up data collection, while f(1) frequency dimension is encoded by consecutive time increments of t(1) in (k(x),k(y),t(1),t(2)) space. The efficient spiral sampling of the k-space enables the acquisition of a single-slice 2D COSY dataset with an 8 x 8 matrix in 8: 32 min on 3 T clinical scanners, which makes it feasible for in vivo studies on human subjects. Here we present the first results obtained on phantoms, human volunteers and patients with brain tumors. The patient data obtained by us represent the first clinical demonstration of a feasible and robust multivoxel 2D COSY. Compared to the 2D J-resolved method, 2D COSY and TOCSY provide increased spectral dispersion which scales up with increasing main magnetic field strength and may have improved ability to unambiguously identify overlapping metabolites. It is expected that the new developments presented in this work will facilitate in vivo application of 2D chemical shift correlation MRS in basic science and clinical studies. Copyright (C) 2011 John Wiley & Sons, Ltd. C1 [Andronesi, Ovidiu C.; Sorensen, A. Gregory] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging,Dept Radiol, Boston, MA 02129 USA. [Gagoski, Borjan A.; Adalsteinsson, Elfar] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA. [Adalsteinsson, Elfar] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Andronesi, OC (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, 149 13th St,Suite 2301, Boston, MA 02129 USA. EM ovidiu@nmr.mgh.harvard.edu FU NIH [R01 1200-206456, R01 EB007942]; Siemens-MIT Alliance FX Funding from the NIH grants R01 1200-206456 (G. S.), and R01 EB007942, Siemens-MIT Alliance (E. A.). Discussions with Michael Hamm from Siemens Healthcare USA are gratefully acknowledged. NR 66 TC 9 Z9 9 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0952-3480 J9 NMR BIOMED JI NMR Biomed. PD FEB PY 2012 VL 25 IS 2 BP 195 EP 209 DI 10.1002/nbm.1730 PG 15 WC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy SC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy GA 909WP UT WOS:000301597300002 PM 21774010 ER PT J AU Shelton, L Becerra, L Borsook, D AF Shelton, L. Becerra, L. Borsook, D. TI Unmasking the mysteries of the habenula in pain and analgesia SO PROGRESS IN NEUROBIOLOGY LA English DT Review DE Habenula; Pain; Imaging; fMRI; Analgesia ID VENTRAL TEGMENTAL AREA; MU-OPIOID RECEPTOR; CEREBRAL GLUCOSE-UTILIZATION; CENTRAL-NERVOUS-SYSTEM; DORSAL RAPHE NUCLEUS; C-FOS EXPRESSION; LATERAL HABENULA; PERIAQUEDUCTAL GRAY; RAT-BRAIN; DOPAMINE NEURONS AB The habenula is a small bilateral structure in the posterior-medial aspect of the dorsal thalamus that has been implicated in a remarkably wide range of behaviors including olfaction, ingestion, mating, endocrine and reward function, pain and analgesia. Afferent connections from forebrain structures send inputs to the lateral and medial habenula where efferents are mainly projected to brainstem regions that include well-known pain modulatory regions such as the periaqueductal gray and raphe nuclei. A convergence of preclinical data implicates the region in multiple behaviors that may be considered part of the pain experience including a putative role in pain modulation, affective, and motivational processes. The habenula seems to play a role as an evaluator, acting as a major point of convergence where external stimuli is received, evaluated, and redirected for motivation of appropriate behavioral response. Here, we review the role of the habenula in pain and analgesia, consider its potential role in chronic pain, and review more recent clinical and functional imaging data of the habenula from animals and humans. Even through the habenula is a small brain structure, advances in structural and functional imaging in humans should allow for further advancement of our understanding of its role in pain and analgesia. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Borsook, D.] Harvard Univ, Sch Med, Childrens Hosp Boston, Pain Grp, Cambridge, MA 02138 USA. [Shelton, L.; Becerra, L.; Borsook, D.] Harvard Univ, Sch Med, Ctr Pain & Brain, Cambridge, MA 02138 USA. [Becerra, L.; Borsook, D.] Harvard Univ, Sch Med, McLean Hosp, Cambridge, MA 02138 USA. [Becerra, L.; Borsook, D.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. RP Borsook, D (reprint author), Harvard Univ, Sch Med, Childrens Hosp Boston, Pain Grp, Cambridge, MA 02138 USA. EM david.borsook@childrens.harvard.edu FU NIH [1R01NS065051]; K24 Mentoring grant [5K24NS64050] FX This work was supported by a grant from NIH (1R01NS065051) and a K24 Mentoring grant (5K24NS64050). NR 150 TC 24 Z9 26 U1 2 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0301-0082 J9 PROG NEUROBIOL JI Prog. Neurobiol. PD FEB PY 2012 VL 96 IS 2 BP 208 EP 219 DI 10.1016/j.pneurobio.2012.01.004 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 910GE UT WOS:000301624400004 PM 22270045 ER PT J AU Egloff, AM Davis, AG Shuai, Y Land, S Pilewski, JM Luketich, JD Landreneau, R Miller, YE Grandis, JR Siegfried, JM AF Egloff, Ann Marie Davis, Autumn Gaither Shuai, Yongli Land, Stephanie Pilewski, Joseph M. Luketich, James D. Landreneau, Rodney Miller, York E. Grandis, Jennifer R. Siegfried, Jill M. TI Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study SO RESPIRATORY RESEARCH LA English DT Article DE Gastrin-releasing peptide receptor; lung cancer risk; case-control study; surrogate tissue ID BOMBESIN-LIKE PEPTIDES; AUTOCRINE GROWTH; GENE-EXPRESSION; MESSENGER-RNA; CELLS; RISK; CARCINOMA; SMOKERS; SMOKING; WOMEN AB Background: Normal bronchial tissue expression of GRPR, which encodes the gastrin-releasing peptide receptor, has been previously reported by us to be associated with lung cancer risk in 78 subjects, especially in females. We sought to define the contribution of GRPR expression in bronchial epithelia to lung cancer risk in a larger case-control study where adjustments could be made for tobacco exposure and sex. Methods: We evaluated GRPR mRNA levels in histologically normal bronchial epithelial cells from 224 lung cancer patients and 107 surgical cancer-free controls. Associations with lung cancer were tested using logistic regression models. Results: Bronchial GRPR expression was significantly associated with lung cancer (OR = 4.76; 95% CI = 2.32- 9.77) in a multivariable logistic regression (MLR) model adjusted for age, sex, smoking status and pulmonary function. MLR analysis stratified by smoking status indicated that ORs were higher in never and former smokers (OR = 7.74; 95% CI = 2.96-20.25) compared to active smokers (OR = 1.69; 95% CI = 0.46-6.33). GRPR expression did not differ by subject sex, and lung cancer risk associated with GRPR expression was not modified by sex. Conclusions: GRPR expression in non-cancerous bronchial epithelium was significantly associated with the presence of lung cancer in never and former smokers. The association in never and former smokers was found in males and females. Association with lung cancer did not differ by sex in any smoking group. C1 [Egloff, Ann Marie; Grandis, Jennifer R.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA. [Davis, Autumn Gaither; Grandis, Jennifer R.; Siegfried, Jill M.] Univ Pittsburgh, Dept Med Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA. [Shuai, Yongli; Land, Stephanie; Landreneau, Rodney] Univ Pittsburgh, Inst Canc, Dept Biostat, Pittsburgh, PA 15260 USA. [Pilewski, Joseph M.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. [Luketich, James D.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA. [Miller, York E.] Univ Colorado, Denver Vet Affairs Med Ctr, Dept Med, Denver, CO 80202 USA. RP Egloff, AM (reprint author), Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA. EM egloffam@upmc.edu FU SPORE in Lung Cancer [P50-CA090440]; SPORE in Lung Cancer at the Univerity of Colorado [P50-CA058187, K07-CA137140] FX Support:; P50-CA090440 SPORE in Lung Cancer (JMS); P50-CA058187 (SPORE in Lung Cancer at the Univerity of Colorado (YEM) K07-CA137140 (AME) NR 24 TC 4 Z9 4 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-993X J9 RESP RES JI Respir. Res. PD FEB 1 PY 2012 VL 13 AR 9 DI 10.1186/1465-9921-13-9 PG 9 WC Respiratory System SC Respiratory System GA 911KV UT WOS:000301716600002 PM 22296774 ER PT J AU Rodriguez-Jimenez, R Bagney, A Garcia-Navarro, C Aparicio, AI Lopez-Anton, R Moreno-Ortega, M Jimenez-Arriero, MA Santos, JL Lobo, A Kern, RS Green, MF Nuechterlein, KH Palomo, T AF Rodriguez-Jimenez, R. Bagney, A. Garcia-Navarro, C. Aparicio, A. I. Lopez-Anton, R. Moreno-Ortega, M. Jimenez-Arriero, M. A. Santos, J. L. Lobo, A. Kern, R. S. Green, M. F. Nuechterlein, K. H. Palomo, T. TI The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and standardization in Spain SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Cognition; MATRICS; MCCB ID MINI-MENTAL STATE; SOCIAL COGNITION; NEUROCOGNITIVE DEFICITS; INDIVIDUAL-DIFFERENCES; MEMORY PERFORMANCE; SEX-DIFFERENCES; LIFE-SPAN; SCHIZOPHRENIA; NEUROSCIENCE; EMOTION AB The MATRICS Consensus Cognitive Battery (MCCB), developed by the National Institute of Mental Health (NIMH) Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative, has been recommended as the standard battery for clinical trials of cognition-enhancing interventions for schizophrenia. Normative data for the MCCB has been previously obtained in the U.S. Extrapolation of these normative data to different countries may be problematic due to the translation of the different tests, as well as potential cultural influences. We present the process of obtaining normative data for the MCCB in Spain with administration of the battery to a general community standardization sample. In addition, we examine the influence of age, gender, and educational level on test performance. The MCCB was administered to a total sample of 210 healthy volunteers, at three Spanish sites. For each site, recruitment of the sample was stratified according to age, gender, and educational level. Our findings indicate significant age, gender, and education effects on the normative data for the MCCB in Spain, which are comparable to those effects described for the original standardized English version in the U.S. The fact that the normative data are comparable, and that the variables age, gender, and education have a similar influence on performance, supports the robustness of the MCCB for use in different countries. (C) 2011 Elsevier B.V. All rights reserved. C1 [Rodriguez-Jimenez, R.; Bagney, A.; Garcia-Navarro, C.; Moreno-Ortega, M.; Jimenez-Arriero, M. A.; Palomo, T.] Hosp 12 Octubre, Dept Psychiat, Inst Invest, E-28041 Madrid, Spain. [Rodriguez-Jimenez, R.; Bagney, A.; Garcia-Navarro, C.; Lopez-Anton, R.; Jimenez-Arriero, M. A.; Lobo, A.; Palomo, T.] Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain. [Aparicio, A. I.; Santos, J. L.] Hosp Virgen La Luz, Dept Psychiat, Cuenca, Spain. [Lobo, A.] Hosp Clin Univ, Dept Psychiat, Zaragoza, Spain. [Lobo, A.] Univ Zaragoza, Zaragoza, Spain. [Kern, R. S.; Green, M. F.; Nuechterlein, K. H.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Kern, R. S.; Green, M. F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Nuechterlein, K. H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. RP Rodriguez-Jimenez, R (reprint author), Hosp 12 Octubre, Dept Psychiat, Inst Invest, E-28041 Madrid, Spain. EM roberto.rodriguez.jimenez@gmail.com OI Lobo, Antonio/0000-0002-9098-655X; Garcia-Navarro, Cristina/0000-0002-4427-579X FU Fondo de Investigaciones Sanitarias, FIS [PI080514]; Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM) of the Instituto de Salud Carlos III FX This research was supported in part by grant PI080514 (Fondo de Investigaciones Sanitarias, FIS) and by the Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM) of the Instituto de Salud Carlos III.; Although not related to this work, Dr. Nuechterlein has consulted for Endo Pharmaceuticals, Johnson and Johnson, Merck, and Wyeth and has an investigator-initiated research grant from Ortho-McNeil Janssen Scientific Affairs.; Dr. Kern receives financial compensation for his role as officer for the non-profit organization, MATRICS Assessment, Inc. NR 51 TC 21 Z9 21 U1 1 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD FEB PY 2012 VL 134 IS 2-3 BP 279 EP 284 DI 10.1016/j.schres.2011.11.026 PG 6 WC Psychiatry SC Psychiatry GA 900FE UT WOS:000300871200026 PM 22192501 ER PT J AU Milanovic, SM Vangel, MG AF Milanovic, Snezana M. Vangel, Mark G. TI Medial prefrontal cortical activation during working memory differentiates schizophrenia and bipolar psychotic patients: A pilot fMRI study Response SO SCHIZOPHRENIA RESEARCH LA English DT Letter C1 [Milanovic, Snezana M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA. [Milanovic, Snezana M.; Vangel, Mark G.] Harvard Univ, Athinoula A Martinos Ctr Biomed Imaging, Sch Med, Dept Radiol,MGH, Charlestown, MA 02129 USA. RP Milanovic, SM (reprint author), Harvard Univ, Athinoula A Martinos Ctr Biomed Imaging, Sch Med, Dept Radiol,MGH, Bldg 149,2nd Floor,Room 2603,13th St, Charlestown, MA 02129 USA. EM smilanovic@partners.org NR 7 TC 1 Z9 1 U1 1 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD FEB PY 2012 VL 134 IS 2-3 BP 294 EP 295 DI 10.1016/j.schres.2011.10.007 PG 2 WC Psychiatry SC Psychiatry GA 900FE UT WOS:000300871200031 PM 22067289 ER PT J AU Rainville, J Childs, LA Pena, EB Suri, P Limke, JC Jouve, C Hunter, DJ AF Rainville, James Childs, Lisa A. Pena, Enrique B. Suri, Pradeep Limke, Janet C. Jouve, Cristin Hunter, David J. TI Quantification of walking ability in subjects with neurogenic claudication from lumbar spinal stenosis-a comparative study SO SPINE JOURNAL LA English DT Article DE Lumbar spinal stenosis; Neurogenic claudication; Walking capacity; Treadmill; Responsiveness ID LOW-BACK-PAIN; COMPUTED-TOMOGRAPHY FINDINGS; OSWESTRY DISABILITY INDEX; FUNCTIONAL STATUS; TREADMILL TEST; NONOPERATIVE TREATMENT; SURGICAL-TREATMENT; NO CORRELATION; OLDER-ADULTS; TRIAL AB BACKGROUND CONTEXT: Walking limitations caused by neurogenic claudication (NC) are typically assessed with self-reported measures, although objective evaluation of walking using motorized treadmill test (MTT) or self-paced walking test (SPWT) has periodically appeared in the lumbar spinal stenosis (LSS) literature. PURPOSE: This study compared the validity and responsiveness of MTT and SPWT for assessing walking ability before and after common treatments for NC. STUDY DESIGN: Prospective observational cohort study. PATIENT SAMPLE: Fifty adults were recruited from an urban spine center if they had LSS and substantial walking limitations from NC and were scheduled to undergo surgery (20%) or conservative treatment (80%). OUTCOME MEASURES: Walking times, distances, and speeds along with the characteristics of NC symptoms were recorded for MTT and SPWT. Self-reported measures included back and leg pain intensity assessed with 0 to 10 numeric pain scales, disability assessed with Oswestry Disability Index, walking ability assessed with estimated walking times and distances, and NC symptoms assessed with the subscales from the Spinal Stenosis Questionnaires. METHODS: Motorized treadmill test used a level track, and SPWT was conducted in a rectangular hallway. Walking speeds were self-selected, and test end points were NC, fatigue, or completion of the 30-minute test protocol. Results from MTT and SPWT were compared with each other and self-reported measures. Internal responsiveness was assessed by comparing changes in the initial results with the posttreatment results and external responsiveness by comparing walking test results that improved with those that did not improve by self-reported criteria. RESULTS: Mean age of the participants was 68 years, and 58% were male. Neurogenic claudication included leg pain (88%) and buttock(s) pain (12%). Five participants could not safely perform MTT. Walking speeds were faster and distances were greater with SPWT, although the results from both tests correlated with each other and self-reported measures. Of the participants, 72% reported improvement after treatment, which was confirmed by significant mean differences in self-reported measures. Motorized treadmill test results did not demonstrate internal responsiveness to change in clinical status after treatment but SPWT results did, with increased mean walking times (6 minutes) and distances (387 m). When responsiveness was assessed against external criterion, both SPWT and MTT demonstrated substantial divergence with self-reported changes in clinical status and alternative outcome measures. CONCLUSIONS: Both MTT and SPWT can quantify walking abilities in NC. As outcome tools, SPWT demonstrated better internal responsiveness than MTT, but neither test demonstrated adequate external responsiveness. Neither test should be considered as a meaningful substitution for disease-specific measures of function. (C) 2012 Elsevier Inc. All rights reserved. C1 [Rainville, James; Childs, Lisa A.; Suri, Pradeep; Limke, Janet C.; Jouve, Cristin] New England Baptist Hosp, Spine Ctr, Boston, MA 02120 USA. [Rainville, James; Suri, Pradeep; Limke, Janet C.; Jouve, Cristin] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA 02114 USA. [Pena, Enrique B.] Seton Spine & Scoliosis Ctr, Austin, TX 78731 USA. [Suri, Pradeep] VA Boston Healthcare Syst, Dept Phys Med & Rehabil, Boston, MA 02130 USA. [Suri, Pradeep] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA. [Hunter, David J.] Univ Sydney, Dept Med, Royal N Shore Hosp E25, Sydney, NSW 2006, Australia. RP Rainville, J (reprint author), New England Baptist Hosp, Spine Ctr, 125 Parker Hill Ave, Boston, MA 02120 USA. EM jrainvil@caregroup.harvard.edu RI Hunter, David/A-4622-2010 OI Hunter, David/0000-0003-3197-752X FU DonJoy; National Institutes of Health [K12 HD 01097]; AF; ACR; Michael Wall Charitable Foundation; Rehabilitation Medicine Scientist Training K12 Program FX JR: Nothing to disclose. LAC: Nothing to disclose. EBP: Nothing to disclose. PS: Nothing to disclose. JCL: Nothing to disclose. CJ: Nothing to disclose. DJH: Royalties: DonJoy (B); Consulting: NicOx (B); Board of Directors: OARSI (Nonfinancial); Research Support (Staff/Materials): Chief of research (A); Grants: NIH, AF, ACR (F).; This study was supported by an unrestricted gift from the Michael Wall Charitable Foundation. Dr Suri is supported by the Rehabilitation Medicine Scientist Training K12 Program and the National Institutes of Health (K12 HD 01097). NR 47 TC 17 Z9 17 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1529-9430 J9 SPINE J JI Spine Journal PD FEB PY 2012 VL 12 IS 2 BP 101 EP 109 DI 10.1016/j.spinee.2011.12.006 PG 9 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 906ML UT WOS:000301349200003 PM 22209240 ER PT J AU Robertson, PA Tsitsopoulos, PP Voronov, LI Havey, RM Patwardhan, AG AF Robertson, Peter A. Tsitsopoulos, Parmenion P. Voronov, Leonard I. Havey, Robert M. Patwardhan, Avinash G. TI Biomechanical investigation of a novel integrated device for intra-articular stabilization of the C1-C2 (atlantoaxial) joint SO SPINE JOURNAL LA English DT Article DE Atlantoaxial; Biomechanics; Fusion device; Stabilization ID TRANSARTICULAR SCREW FIXATION; LATERAL MASS SCREW; INTERLAMINAR CLAMPS; POLYAXIAL SCREW; TECHNICAL NOTE; FUSION; ARTHRODESIS; COMPLEX; PLATE; SUBLUXATION AB BACKGROUND CONTEXT: The anatomy of the atlantoaxial joint makes stabilization at this level challenging. Current techniques that use transarticular screw fixation (Magerl) or segmental screw fixation (Harms) give dramatically improved stability but risk damage to the vertebral artery. A novel integrated device was designed and developed to obtain intra-articular stabilization via primary interference fixation within the C1-C2 lateral mass articulation. PURPOSE: To assess the atlantoaxial stability achieved with a novel integrated device when compared with the intact, destabilized, and stabilized state using the Harms technique. STUDY DESIGN: A biomechanical study of implants in human cadaveric cervical spines. METHODS: Six human cadaveric specimens were used. Biomechanical testing was performed with moment control in flexion-extension, lateral bending, and axial rotation. Range of motion (ROM) was measured in the intact state, after both destabilization by creation of a Type II odontoid peg fracture and sequential stabilization using the integrated device and the Harms technique. RESULTS: Mean flexion-extension ROM of the intact specimens at C1-C2 was 14.1 degrees +/- 62.9 degrees. Destabilization increased the ROM to 31.6 degrees +/- 4.6 degrees. Instrumentation with the Harms technique reduced flexion-extension motion to 4.0 degrees +/- 1.4 degrees (p<.01). The integrated device reduced flexion-extension motion to 3.6 degrees +/- 1.8 degrees (p<.01). In lateral bending, the respective mean angular motions were 1.8 degrees +/- 1.1 degrees, 14.1 degrees +/- 5.8 degrees, 1.4 degrees +/- 0.7 degrees, and 0.4 degrees +/- 0.3 degrees for the intact destabilized Harms technique and integrated device. For axial rotation, the respective mean values were 67.3 degrees +/- 13.8 degrees, 74.2 degrees +/- 16.1 degrees, 1.4 degrees +/- 0.7 degrees and 0.9 degrees +/- 0.7 degrees. Both the Harms technique and integrated device significantly reduced motion compared with the destabilized spine in flexion-extension, lateral bending, and axial rotation (p<.05). Direct comparison of the Harms technique and the integrated device revealed no significant difference (p>.10). CONCLUSIONS: The integrated device resulted in interference fixation at the C1-C2 lateral mass joints with comparable stability to the Harms technique. Perceived advantages with the integrated device include avoidance of fixation below the C2 lateral mass where the vertebral artery is susceptible to injury, and access to the C1 screw entry point through the blade of the integrated device avoiding extended dissection superior to the C2 nerve root and its surrounding venous plexus. (C) 2012 Elsevier Inc. All rights reserved. C1 [Robertson, Peter A.] Mercy Specialist Ctr, Orthopaed Clin, Auckland 1023, New Zealand. [Tsitsopoulos, Parmenion P.; Voronov, Leonard I.; Havey, Robert M.; Patwardhan, Avinash G.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Musculoskeletal Biomech Lab, Hines, IL 60141 USA. [Tsitsopoulos, Parmenion P.; Voronov, Leonard I.; Havey, Robert M.; Patwardhan, Avinash G.] Loyola Univ Chicago, Dept Orthopaed Surg & Rehabil, Maywood, IL 60153 USA. RP Robertson, PA (reprint author), Mercy Specialist Ctr, Orthopaed Clin, 100 Mt Rd, Auckland 1023, New Zealand. EM p.a.robertson@xtra.co.nz FU Medtronic; Back Institute, Auckland, New Zealand; Ortho Kinematics; Axiomed; Spinal Kinetics; Simpirica; Synthes FX PAR: Consulting: Medtronic (F), Johnson and Johnson DePuy (B); Speaking/Teaching Arrangements: Medtronic (Financial); Trips/Travel: Medtronic (Financial); Board of Directors: The Back Institute, Auckland, New Zealand (Financial); Scientific Advisory Board: Medtronic (Financial); Grants: Medtronic (C, Paid directly to institution/employer). PPT: Nothing to disclose. LIV: Nothing to disclose. RMH: Nothing to disclose. AGP: Stock Ownership: Spinal Kinetics (10,000 shares); Consulting: Alphatec (B), Aesculap (B); Speaking/Teaching Arrangements: Aesculap (B); Trips/Travel: Spinal Kinetics (B), Aesculap (A); Scientific Advisory Board: Ortho Kinematics (Financial), Axiomed (Financial), Spinal Kinetics (Financial); Research Support (Staff/Materials): Simpirica (E, Paid directly to institution/employer); Grants: Synthes (E, Paid directly to istitution/employer). NR 42 TC 5 Z9 7 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1529-9430 J9 SPINE J JI Spine Journal PD FEB PY 2012 VL 12 IS 2 BP 136 EP 142 DI 10.1016/j.spinee.2012.01.004 PG 7 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 906ML UT WOS:000301349200009 PM 22341395 ER PT J AU Ting, SA Sullivan, AF Miller, I Espinola, JA Allen, MH Camargo, CA Boudreaux, ED AF Ting, Sarah A. Sullivan, Ashley F. Miller, Ivan Espinola, Janice A. Allen, Michael H. Camargo, Carlos A., Jr. Boudreaux, Edwin D. CA Emergency Dept Safety Assessment F TI Multicenter Study of Predictors of Suicide Screening in Emergency Departments SO ACADEMIC EMERGENCY MEDICINE LA English DT Article ID IDEATION; POPULATION AB Objectives: The objective was to provide estimates and predictors of screening for suicide in emergency departments (EDs). Methods: Eight geographically diverse U. S. EDs each performed chart reviews of 100 randomly selected patients, ages 18 years or older, with visits in October 2009. Trained chart abstractors collected information on patient demographics, presentation, discharge diagnosis, suicide screening, and other mental health indicators. Univariate logistic regression was used to determine factors associated with suicide screening. Results: The cohort of 800 patients had a median age of 41 years (interquartile range = 27 to 53 years) with 57% female, 16% Hispanic, 58% white, 23% black or African American, and 10% other race. Suicide screenings were documented for 39 patients (4.9%; 95% confidence interval [CI] = 3.4% to 6.4%). Of those screened, 23 (2.9% of total sample; 95% CI = 1.7% to 4.0%) were positive for suicidal ideation or behavior. Approximately 90% of those screened had documented complaints of a psychiatric nature at triage. About one-third had either documentation of alcohol abuse (33%) or intentional illegal or prescription drug misuse (36%). Conclusions: The presence of known psychiatric problems and substance use had the strongest associations with suicide screening, yet even patients presenting with these indicators were not screened for suicide. Understanding factors that currently influence suicide screening in the ED will guide the design and implementation of improved suicide screening protocols and related interventions. C1 [Boudreaux, Edwin D.] Univ Massachusetts, Sch Med, Dept Emergency Med, Worcester, MA 01605 USA. [Boudreaux, Edwin D.] Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01655 USA. [Boudreaux, Edwin D.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA. [Ting, Sarah A.; Sullivan, Ashley F.; Espinola, Janice A.; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Miller, Ivan] Butler Hosp, Providence, RI 02906 USA. [Allen, Michael H.] Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA. RP Boudreaux, ED (reprint author), Univ Massachusetts, Sch Med, Dept Emergency Med, Worcester, MA 01605 USA. EM edwin.boudreaux@umassmed.edu RI Allen, Michael/A-8776-2011; OI Boudreaux, Edwin/0000-0002-3223-6371 FU National Institute of Mental Health [U01MH088278] FX This project was supported by Award Number U01MH088278 from the National Institute of Mental Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. NR 10 TC 14 Z9 14 U1 1 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1069-6563 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD FEB PY 2012 VL 19 IS 2 BP 239 EP 243 DI 10.1111/j.1553-2712.2011.01272.x PG 5 WC Emergency Medicine SC Emergency Medicine GA 888ZY UT WOS:000300044500021 PM 22288721 ER PT J AU Garcia-Romero, MT Werth, VP AF Teresa Garcia-Romero, Maria Werth, Victoria P. TI Randomized Controlled Trials Needed for Bullous Pemphigoid Interventions SO ARCHIVES OF DERMATOLOGY LA English DT Editorial Material ID PREDNISOLONE METASULFOBENZOATE; TOPICAL CORTICOSTEROIDS; PLASMA-EXCHANGE; AZATHIOPRINE; METHYLPREDNISOLONE C1 [Teresa Garcia-Romero, Maria; Werth, Victoria P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Teresa Garcia-Romero, Maria; Werth, Victoria P.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. [Teresa Garcia-Romero, Maria] Hosp Gen Dr Manuel Gea Gonzalez, Dept Dermatol, Mexico City, DF, Mexico. RP Werth, VP (reprint author), Perelman Ctr Adv Med, Dept Dermatol, Ste 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU NIAMS NIH HHS [K24 AR002207] NR 13 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD FEB PY 2012 VL 148 IS 2 BP 243 EP 246 PG 4 WC Dermatology SC Dermatology GA 895WF UT WOS:000300526700018 PM 22351828 ER PT J AU Lyall, K Pauls, DL Spiegelman, D Ascherio, A Santangelo, SL AF Lyall, Kristen Pauls, David L. Spiegelman, Donna Ascherio, Alberto Santangelo, Susan L. TI Pregnancy complications and obstetric suboptimality in association with autism spectrum disorders in children of the nurses' health study II SO AUTISM RESEARCH LA English DT Article DE autism spectrum disorders; gestational diabetes; obstetric complications; pregnancy complications ID PERINATAL RISK-FACTORS; ASPERGER-SYNDROME; INFANTILE-AUTISM; AUTOIMMUNE-DISEASES; BIRTH COMPLICATIONS; NEONATAL FACTORS; POPULATION; PSYCHOPATHOLOGY; CHILDHOOD; HISTORY AB The authors examined pregnancy and obstetric complications in association with autism spectrum disorders (ASD) in children of participants from the Nurses' Health Study II, a prospective national cohort with information collected through biennial mailed questionnaires since 1989. Logistic regression was used to obtain crude and adjusted odds ratios for ASD, and by diagnostic subgroup. Seven hundred and ninety-three cases were reported among 66,445 pregnancies. Pregnancy complications and obstetric suboptimality factors were assessed by maternal report of occurrence in first birth and, in secondary analyses, in any birth. Complications and a suboptimality score were significantly associated with having a child with ASD (OR 1.49, 95% CI 1.26, 1.77, P<0.0001 for pregnancy complications in first birth and 2.76, 95% CI 2.04, 3.74, P<0.0001 comparing individuals with four or more obstetric suboptimality factors in first birth to those with none; results similar when assessed in any birth). In particular, gestational diabetes was associated with a significantly increased risk of ASD in results of primary and sensitivity analyses (OR in primary analysis = 1.76, 95% CI 1.34, 2.32, P<0.0001); suboptimal parity and suboptimal age-at-first-birth were also individual factors associated with ASD. Associations were similar by diagnostic subgroup, suggesting autism, Asperger syndrome, and other Pervasive Developmental Disorders are all associated with pregnancy complications. Consistent with previous research, the general class of pregnancy complications was associated with ASD as a whole. Additional work will be required to more fully assess the role of gestational diabetes. Autism Res 2012,5:2130. (c) 2011 International Society for Autism Research, Wiley Periodicals, Inc. C1 [Lyall, Kristen; Ascherio, Alberto] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Lyall, Kristen; Pauls, David L.; Spiegelman, Donna; Ascherio, Alberto; Santangelo, Susan L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Spiegelman, Donna] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Pauls, David L.; Santangelo, Susan L.] Harvard Univ, Sch Publ Hlth, Dept Psychiat, Boston, MA 02115 USA. [Pauls, David L.; Santangelo, Susan L.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Boston, MA 02114 USA. [Ascherio, Alberto] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Ascherio, Alberto] Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA. RP Lyall, K (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 655 Huntington Ave, Boston, MA 02115 USA. EM klyall@hsph.harvard.edu FU NHS II; NIH [R01-CA50385]; Autism Speaks [1788, 2210]; United States Department of Defense (DOD) and Army Medical Research and Material Command (USAMRMC) [A-14917] FX The authors would like to thank the participants of the NHS II, as well as the funding organizations for their support. Funding organizations have reviewed and approved the design and conduct of the overall NHS II, but were not involved in the collection, management, analysis, or interpretation of the data; nor were they involved in the preparation, review, or approval of this manuscript.; Grant sponsor: NIH; Grant number: R01-CA50385; Grant sponsor: Autism Speaks; Grant numbers: 1788; 2210; Grant sponsor: United States Department of Defense (DOD) and Army Medical Research and Material Command (USAMRMC); Grant number: A-14917. NR 38 TC 24 Z9 24 U1 5 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1939-3792 J9 AUTISM RES JI Autism Res. PD FEB PY 2012 VL 5 IS 1 BP 21 EP 30 DI 10.1002/aur.228 PG 10 WC Behavioral Sciences; Psychology, Developmental SC Behavioral Sciences; Psychology GA 900FG UT WOS:000300871400004 PM 21972225 ER PT J AU McDermott, S O'Connor, OJ Cronin, CG Blake, MA AF McDermott, S. O'Connor, O. J. Cronin, C. G. Blake, M. A. TI Radiological evaluation of adrenal incidentalomas - Current methods and future prospects SO BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article DE adrenal gland; computed tomography; MRI; PET; MIBG ID DUAL-ENERGY CT; APPARENT DIFFUSION-COEFFICIENT; POSITRON-EMISSION-TOMOGRAPHY; CONTRAST-ENHANCED CT; CHEMICAL-SHIFT MRI; HISTOGRAM ANALYSIS; INITIAL-EXPERIENCE; F-18-FDG PET/CT; UNENHANCED CT; I-131 METAIODOBENZYLGUANIDINE AB Incidental adrenal lesions are very common. Computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) all have a role to play in characterizing adrenal lesions. The purpose of this review is to discuss the rationale behind both established and emerging imaging techniques. We also discuss how to follow up incidentally found lesions. (C) 2011 Elsevier Ltd. All rights reserved. C1 [McDermott, S.; O'Connor, O. J.; Cronin, C. G.; Blake, M. A.] Massachusetts Gen Hosp, Dept Abdominal Imaging & Intervent Radiol, Boston, MA 02114 USA. RP McDermott, S (reprint author), Massachusetts Gen Hosp, Dept Abdominal Imaging & Intervent Radiol, White Bldg Room 270,55 Fruit St, Boston, MA 02114 USA. EM mcdermottshaunagh@gmail.com FU Springer Verlag FX Shaunagh McDermott, Owen O'Connor and Carmel Cronin have no disclosures. Michael Blake discloses that he has received book royalties from Springer Verlag for editing the book "Adrenal Imaging". NR 88 TC 12 Z9 14 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1521-690X J9 BEST PRACT RES CL EN JI Best Pract. Res. Clin. Endoc. Metab. PD FEB PY 2012 VL 26 IS 1 BP 21 EP 33 DI 10.1016/j.beem.2011.07.005 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 901JN UT WOS:000300963300004 PM 22305450 ER PT J AU Crowell, AL Ryapolova-Webb, ES Ostrem, JL Galifianakis, NB Shimamoto, S Lim, DA Starr, PA AF Crowell, Andrea L. Ryapolova-Webb, Elena S. Ostrem, Jill L. Galifianakis, Nicholas B. Shimamoto, Shoichi Lim, Daniel A. Starr, Philip A. TI Oscillations in sensorimotor cortex in movement disorders: an electrocorticography study SO BRAIN LA English DT Article DE Parkinson's disease; dystonia; essential tremor; electrocorticography; primary motor cortex ID EVENT-RELATED DESYNCHRONIZATION; SELF-PACED MOVEMENT; PARKINSONS-DISEASE; SUBTHALAMIC NUCLEUS; GLOBUS-PALLIDUS; MOTOR CORTEX; BETA OSCILLATIONS; CERVICAL DYSTONIA; NEURONAL-ACTIVITY; SPECTRAL-ANALYSIS AB Movement disorders of basal ganglia origin may arise from abnormalities in synchronized oscillatory activity in a network that includes the basal ganglia, thalamus and motor cortices. In humans, much has been learned from the study of basal ganglia local field potentials recorded from temporarily externalized deep brain stimulator electrodes. These studies have led to the theory that Parkinson's disease has characteristic alterations in the beta frequency band (13-30 Hz) in the basal ganglia-thalamocortical network. However, different disorders have rarely been compared using recordings in the same structure under the same behavioural conditions, limiting straightforward assessment of current hypotheses. To address this, we utilized subdural electrocorticography to study cortical oscillations in the three most common movement disorders: Parkinson's disease, primary dystonia and essential tremor. We recorded local field potentials from the arm area of primary motor and sensory cortices in 31 subjects using strip electrodes placed temporarily during routine surgery for deep brain stimulator placement. We show that: (i) primary motor cortex broadband gamma power is increased in Parkinson's disease compared with the other conditions, both at rest and during a movement task; (ii) primary motor cortex high beta (20-30 Hz) power is increased in Parkinson's disease during the 'stop' phase of a movement task; (iii) the alpha-beta peaks in the motor and sensory cortical power spectra occur at higher frequencies in Parkinson's disease than in the other two disorders; and (iv) patients with dystonia have impaired movement-related beta band desynchronization in primary motor and sensory cortices. The findings support the emerging hypothesis that disease states reflect abnormalities in synchronized oscillatory activity. This is the first study of sensorimotor cortex local field potentials in the three most common movement disorders. C1 [Crowell, Andrea L.] Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA 30322 USA. [Ryapolova-Webb, Elena S.; Lim, Daniel A.; Starr, Philip A.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA. [Ostrem, Jill L.; Galifianakis, Nicholas B.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Galifianakis, Nicholas B.; Lim, Daniel A.; Starr, Philip A.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Care Ctr, San Francisco, CA USA. [Shimamoto, Shoichi] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. RP Starr, PA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 533 Parnassus Ave,U-125, San Francisco, CA 94143 USA. EM starrp@neurosurg.ucsf.edu OI Lim, Daniel/0000-0001-7221-3425 FU National Institutes of Health [R01NS069779]; Dystonia Medical Research Foundation; Doris Duke Clinical Research Fellowship FX National Institutes of Health (R01NS069779 to P. A. S.); Dystonia Medical Research Foundation (to P. A. S.); and Doris Duke Clinical Research Fellowship (to A.L.C.). NR 55 TC 47 Z9 47 U1 0 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD FEB PY 2012 VL 135 BP 615 EP 630 DI 10.1093/brain/awr332 PN 2 PG 16 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 895GZ UT WOS:000300485600032 PM 22252995 ER PT J AU Johnson, N Shapiro, GI AF Johnson, Neil Shapiro, Geoffrey I. TI Chemotherapy-induced p53-dependent and -independent DNA damage responses are enhanced by poly(ADP-ribose) polymerase (PARP) inhibition in BRCA-proficient cancer cells SO CELL CYCLE LA English DT News Item ID REPAIR C1 [Johnson, Neil] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. RP Johnson, N (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM geoffrey_shapiro@dfci.harvard.edu NR 9 TC 0 Z9 1 U1 0 U2 1 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1538-4101 J9 CELL CYCLE JI Cell Cycle PD FEB 1 PY 2012 VL 11 IS 3 BP 432 EP 433 DI 10.4161/cc.11.3.19167 PG 2 WC Cell Biology SC Cell Biology GA 890MG UT WOS:000300148200007 PM 22262190 ER PT J AU Yamada, HY Yao, YX Wang, XX Zhang, YT Huang, Y Dai, W Rao, CV AF Yamada, Hiroshi Y. Yao, Yixin Wang, Xiaoxing Zhang, Yuting Huang, Ying Dai, Wei Rao, Chinthalapally V. TI Haploinsufficiency of SGO1 results in deregulated centrosome dynamics, enhanced chromosomal instability and colon tumorigenesis SO CELL CYCLE LA English DT Article DE SGO1; mouse genetics; chromosomal instability; centrosome; colon cancer ID SISTER-CHROMATID COHESION; PROTEIN PHOSPHATASE 2A; ABERRANT CRYPT FOCI; COLORECTAL-CANCER; GENOMIC INSTABILITY; TUMOR-SUPPRESSOR; STEM-CELLS; MEIOSIS I; SHUGOSHIN; P53 AB Chromosome instability (CIN) is found in 85% of colorectal cancers. Defects in mitotic processes are implicated in high CIN and may be critical events in colorectal tumorigenesis. Shugoshin-1 (SGO1) aids in the maintenance of chromosome cohesion and prevents premature chromosome separation and CIN. In addition, integrity of the centrosome may be compromised due to the deficiency of Cohesin and Sgo1 through the disengagement of centrioles. We report here the generation and characterization of SGO1-mutant mice and show that haploinsufficiency of SGO1 leads to enhanced colonic tumorigenesis. Complete disruption of SGO1 results in embryonic lethality, whereas SGO1(+/-) mice are viable and fertile. Haploinsufficiency of SGO1 results in genomic instability manifested as missegregation of chromosomes and formation of extra centrosomal foci in both murine embryonic fibroblasts and adult bone marrow cells. Enhanced CIN observed in SGO1-deficient mice resulted in an increase in formation of aberrant crypt foci (ACF) and accelerated development of tumors after exposure to azoxymethane (AOM), a colon carcinogen. Together, these results suggest that haploinsufficiency of SGO1 causes enhanced CIN, colonic preneoplastic lesions and tumorigenesis in mice. SGO1 is essential for the suppression of CIN and tumor formation. C1 [Yao, Yixin; Huang, Ying; Dai, Wei] NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY USA. [Yamada, Hiroshi Y.; Zhang, Yuting; Rao, Chinthalapally V.] Univ Oklahoma, Hlth Sci Ctr, Ctr Chemoprevent & Canc Drug Dev, Dept Med,Med Oncol Sect,PCS Oklahoma Canc Ctr, Oklahoma City, OK USA. [Wang, Xiaoxing] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Dai, W (reprint author), NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY USA. EM wei.dai@nyumc.org; cv-rao@ouhsc.edu OI Dai, Wei/0000-0003-0169-8327 FU US Public Service [CA090658, CA102947]; HIEHS [ES000260, ES010344]; Kerley-Cade chair Research endowment (OUHSC) FX This study was supported in part by a US Public Service Award to W.D. (CA090658), and in part by HIEHS center fund and Superfund grants (ES000260 and ES010344). This work is also supported in part by US Public Service Award (CA102947) and Kerley-Cade chair Research endowment (OUHSC) to C.V.R. NR 66 TC 25 Z9 25 U1 0 U2 7 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1538-4101 J9 CELL CYCLE JI Cell Cycle PD FEB 1 PY 2012 VL 11 IS 3 BP 479 EP 488 DI 10.4161/cc.11.3.18994 PG 10 WC Cell Biology SC Cell Biology GA 890MG UT WOS:000300148200019 PM 22262168 ER PT J AU Sakamoto, M Perry, W Hilsabeck, RC Barakat, F Hassanein, T AF Sakamoto, Maiko Perry, William Hilsabeck, Robin C. Barakat, Fatma Hassanein, Tarek TI Assessment and Usefulness of Clinical Scales for Semiquantification of Overt Hepatic Encephalopathy SO CLINICS IN LIVER DISEASE LA English DT Article DE Overt hepatic encephalopathy; Clinical scales; Neuropsychological tests; Neurophysiologic tests; Hepatic encephalopathy assessment; HESA; WHC; Cirrhosis ID CRITICAL FLICKER FREQUENCY; PORTAL-SYSTEMIC ENCEPHALOPATHY; CONTINUOUS REACTION-TIMES; INHIBITORY CONTROL TEST; LIVER-TRANSPLANTATION; COGNITIVE IMPAIRMENT; SCORING ALGORITHM; BISPECTRAL INDEX; CIRRHOSIS; DIAGNOSIS AB Hepatic encephalopathy (HE) represents the effects of liver dysfunction on the brain. When HE is clinically obvious (eg, confusion, poor judgment, personality change), it is termed overt HE. The severity of HE is measured by different methods. Assessing the severity of HE is important for determining patient prognosis and effectiveness of therapy. This article discusses the different methods for grading HE, including clinical rating scales, neuropsychological tests, and neurophysiologic measures. C1 [Barakat, Fatma; Hassanein, Tarek] So Calif Liver Ctr, Coronado, CA 92118 USA. [Sakamoto, Maiko; Perry, William] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Hilsabeck, Robin C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Hilsabeck, Robin C.] S Texas Vet Hlth Care Syst, Neuropsychol Postdoctoral Residency Program, San Antonio, TX 78229 USA. RP Hassanein, T (reprint author), So Calif Liver Ctr, 230 Prospect Pl,Suite 220, Coronado, CA 92118 USA. EM thassanein@livercenters.com NR 62 TC 2 Z9 2 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1089-3261 J9 CLIN LIVER DIS JI Clin. Liver Dis. PD FEB PY 2012 VL 16 IS 1 BP 27 EP + DI 10.1016/j.cld.2011.12.005 PG 17 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 903YJ UT WOS:000301159000004 PM 22321463 ER PT J AU Killeen, LA Teti, DM AF Killeen, Lauren A. Teti, Douglas M. TI Mothers' frontal EEG asymmetry in response to infant emotion states and mother-infant emotional availability, emotional experience, and internalizing symptoms SO DEVELOPMENT AND PSYCHOPATHOLOGY LA English DT Article ID BRAIN ELECTRICAL-ACTIVITY; INDIVIDUAL-DIFFERENCES; BEHAVIOR PROBLEMS; DEVELOPMENTAL PSYCHOPATHOLOGY; EXTERNALIZING BEHAVIOR; BIOLOGICAL SUBSTRATE; CHILDRENS ADJUSTMENT; INTERACTION PATTERNS; MATERNAL DEPRESSION; AFFECTIVE-DISORDERS AB This study examined the links between mothers' frontal EEG asymmetry at rest and during videos of their 5- to 8-month-old infants expressing three emotion states (joy, anger/distress, and neutral interest), mother infant emotional availability (EA) in the home, mothers' depressive and anxious symptoms, and mothers' emotional experience in response to infant emotion cues. Greater relative right frontal activity at rest was associated with greater maternal anxiety, but was unrelated to EA or mother-reported emotional experience in response to infant emotion cues. A shift toward greater relative right frontal activation in response to infant emotional stimuli was associated with lower maternal anxiety, greater mother infant EA, and mothers' experience of sadness, concern, irritability, and the absence of joy in response to seeing their own infant in distress. These findings suggest that mothers' in the moment empathetic responding to their infant's emotions, indexed by a shift in frontal EEG asymmetry in response to infant emotional displays, is related to mother infant EA in the home. Implications for conceptualizing parenting risk are discussed. C1 [Killeen, Lauren A.; Teti, Douglas M.] Penn State Univ, University Pk, PA 16802 USA. RP Killeen, LA (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 151 Merrimac St,Suite 500, Boston, MA 02114 USA. EM lkilleen@partners.org NR 86 TC 15 Z9 16 U1 10 U2 18 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0954-5794 J9 DEV PSYCHOPATHOL JI Dev. Psychopathol. PD FEB PY 2012 VL 24 IS 1 BP 9 EP 21 DI 10.1017/S0954579411000629 PG 13 WC Psychology, Developmental SC Psychology GA 892EX UT WOS:000300270600002 PM 22292990 ER PT J AU Braunwald, E AF Braunwald, Eugene TI Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials SO EUROPEAN HEART JOURNAL LA English DT Editorial Material ID ACUTE CORONARY SYNDROMES; STATIN THERAPY; CARDIOVASCULAR RISK; VASCULAR EVENTS; DISEASE; CHOLESTEROL; INFLAMMATION; PRAVASTATIN; PREVENTION; PREDICTION C1 [Braunwald, Eugene] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA. [Braunwald, Eugene] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Braunwald, E (reprint author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA. EM ebraunwald@partners.org NR 19 TC 33 Z9 33 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X J9 EUR HEART J JI Eur. Heart J. PD FEB PY 2012 VL 33 IS 4 BP 430 EP 432 DI 10.1093/eurheartj/ehr310 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 895PL UT WOS:000300508500008 PM 21896564 ER PT J AU Saggar, R Lewis, GD Systrom, DM Champion, HC Naeije, R Saggar, R AF Saggar, R. Lewis, G. D. Systrom, D. M. Champion, H. C. Naeije, R. Saggar, R. TI Pulmonary vascular responses to exercise: a haemodynamic observation SO EUROPEAN RESPIRATORY JOURNAL LA English DT Editorial Material ID HEALTHY OLD MEN; ARTERIAL-HYPERTENSION; HEART-FAILURE; SYSTEMIC-SCLEROSIS; SITTING POSITION; STROKE VOLUME; PRESSURE; REST; CIRCULATION; DISEASE C1 [Saggar, R.] St Joseph Hosp & Med Ctr, Heart Lung Inst, Phoenix, AZ 85013 USA. [Lewis, G. D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol,Dept Med, Boston, MA USA. [Systrom, D. M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Pulm,Dept Med, Boston, MA USA. [Champion, H. C.] Univ Pittsburg Med Ctr, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA. [Saggar, R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. [Naeije, R.] Free Univ Brussels, Dept Physiol, Brussels, Belgium. RP Saggar, R (reprint author), St Joseph Hosp & Med Ctr, Heart Lung Inst, 500 W Thomas Rd,Ste 500, Phoenix, AZ 85013 USA. EM rajeev.saggar@chw.edu; rajeev.saggar@chw.edu FU NHLBI NIH HHS [K23 HL091106] NR 34 TC 15 Z9 15 U1 0 U2 3 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 J9 EUR RESPIR J JI Eur. Resp. J. PD FEB PY 2012 VL 39 IS 2 BP 231 EP 234 DI 10.1183/09031936.00166211 PG 4 WC Respiratory System SC Respiratory System GA 894FB UT WOS:000300411400001 PM 22298608 ER PT J AU Girard, N Sima, CS Jackman, DM Sequist, LV Chen, H Yang, JCH Ji, H Waltman, B Rosell, R Taron, M Zakowski, MF Ladanyi, M Riely, G Pao, W AF Girard, N. Sima, C. S. Jackman, D. M. Sequist, L. V. Chen, H. Yang, J. C-H. Ji, H. Waltman, B. Rosell, R. Taron, M. Zakowski, M. F. Ladanyi, M. Riely, G. Pao, W. TI Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma SO EUROPEAN RESPIRATORY JOURNAL LA English DT Article DE Adenocarcinoma; epidermal growth factor receptor mutations; lung cancer; nomogram; prediction score; tyrosine kinase inhibitor ID FACTOR-RECEPTOR MUTATIONS; SOMATIC MUTATIONS; NEVER-SMOKERS; CANCER; GEFITINIB; GENE; CHEMOTHERAPY; SUBTYPES AB Epidermal growth factor receptor (EGFR) tumour genotyping is crucial to guide treatment decisions regarding the use of EGFR tyrosine kinase inhibitors in nonsmall cell lung cancer (NSCLC). However, some patients may not be able to obtain tumour testing, either because tissue is limited and/or tests are not routinely offered. Here, we aimed to build a model-based nomogram to allow for prediction of the presence of EGFR mutations in NSCLC. We retrospectively collected clinical and pathological data on 3,006 patients with NSCLC who had their tumours genotyped for EGFR mutations at five institutions worldwide. Variables of interest were integrated in a multivariate logistic regression model. In the 2,392 non-Asian patients with lung adenocarcinomas, the most important predictors of harbouring EGFR mutation were: lower tobacco smoking exposure (OR 0.41, 95% CI 0.37-0.46), longer time interval between smoking cessation and diagnosis (OR 2.19, 95% CI 1.71-2.80), advanced stage (OR 1.58, 95% CI 1.18-2.13), and papillary (OR 4.57, 95% CI 3.14-6.66) or bronchioloalveolar (OR 2.84, 95% CI 1.98-4.06) histologically predominant subtype. A nomogram was established and showed excellent discriminating accuracy: the concordance index on an independent validation dataset was 0.84. As clinical practices transition to incorporating genotyping as part of routine care, this nomogram could be highly useful to predict the presence of EGFR mutations in lung adenocarcinoma in non-Asian patients when mutational profiling is not available or possible. C1 [Girard, N.; Pao, W.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA. [Sima, C. S.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. [Zakowski, M. F.; Ladanyi, M.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA. [Riely, G.; Pao, W.] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, New York, NY 10021 USA. [Jackman, D. M.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA. [Sequist, L. V.; Waltman, B.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. [Chen, H.] Fudan Univ, Canc Hosp, Dept Thorac Surg, Shanghai 200433, Peoples R China. [Ji, H.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai, Peoples R China. [Yang, J. C-H.] Natl Taiwan Univ, Coll Med, Grad Inst Oncol, Taipei 10764, Taiwan. [Rosell, R.; Taron, M.] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain. RP Girard, N (reprint author), Hop Louis Pradel, Serv Pneumol U80, 28 Ave Doyen Lepine, F-69677 Bron, France. EM nicolas.girard@chu-lyon.fr OI Yang, James Chih-Hsin/0000-0002-5586-5138 NR 29 TC 33 Z9 36 U1 1 U2 3 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 EI 1399-3003 J9 EUR RESPIR J JI Eur. Resp. J. PD FEB PY 2012 VL 39 IS 2 BP 366 EP 372 DI 10.1183/09031936.00010111 PG 7 WC Respiratory System SC Respiratory System GA 894FB UT WOS:000300411400020 PM 21778168 ER PT J AU Marcos, PJ Restrepo, MI Verea, H AF Marcos, P. J. Restrepo, M. I. Verea, H. TI Supported home-care schemes: the key to increasing outpatient care? SO EUROPEAN RESPIRATORY JOURNAL LA English DT Letter ID COMMUNITY-ACQUIRED PNEUMONIA C1 [Marcos, P. J.] Complejo Hosp Univ A Coruna, Serv Neumol, Dept Pulm Dis, La Coruna 15006, Spain. [Restrepo, M. I.] Univ Texas Hlth Sci Ctr San Antonio, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX 78229 USA. [Restrepo, M. I.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. [Restrepo, M. I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA. [Restrepo, M. I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hosp Med, San Antonio, TX 78229 USA. RP Marcos, PJ (reprint author), Complejo Hosp Univ A Coruna, Serv Neumol, Dept Pulm Dis, La Coruna 15006, Spain. EM pedro.jorge.marcos.rodriguez@sergas.es RI Restrepo, Marcos/H-4442-2014; Marcos, Pedro J/K-9965-2015 OI Marcos, Pedro J/0000-0001-9600-3537 FU NHLBI NIH HHS [K23 HL096054, K23HL096054] NR 3 TC 0 Z9 0 U1 0 U2 0 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 J9 EUR RESPIR J JI Eur. Resp. J. PD FEB PY 2012 VL 39 IS 2 BP 509 EP 509 DI 10.1183/09031936.00166811 PG 1 WC Respiratory System SC Respiratory System GA 894FB UT WOS:000300411400044 PM 22298621 ER PT J AU Iezzoni, LI Rao, SR DesRoches, CM Vogeli, C Campbell, EG AF Iezzoni, Lisa I. Rao, Sowmya R. DesRoches, Catherine M. Vogeli, Christine Campbell, Eric G. TI Survey Shows That At Least Some Physicians Are Not Always Open Or Honest With Patients SO HEALTH AFFAIRS LA English DT Article ID PRIMARY-CARE PHYSICIANS; NATIONAL-SURVEY; MEDICAL ERROR; COMMUNICATION; HEALTH; HOPE; PROFESSIONALISM; MILLENNIUM; MANAGEMENT; DISCLOSURE AB The Charter on Medical Professionalism, endorsed by more than 100 professional groups worldwide and the US Accreditation Council for Graduate Medical Education, requires openness and honesty in physicians' communication with patients. We present data from a 2009 survey of 1,891 practicing physicians nationwide assessing how widely physicians endorse and follow these principles in communicating with patients. The vast majority of physicians completely agreed that physicians should fully inform patients about the risks and benefits of interventions and should never disclose confidential information to unauthorized persons. Overall, approximately one-third of physicians did not completely agree with disclosing serious medical errors to patients, almost one-fifth did not completely agree that physicians should never tell a patient something untrue, and nearly two-fifths did not completely agree that they should disclose their financial relationships with drug and device companies to patients. Just over one-tenth said they had told patients something untrue in the previous year. Our findings raise concerns that some patients might not receive complete and accurate information from their physicians, and doubts about whether patient-centered care is broadly possible without more widespread physician endorsement of the core communication principles of openness and honesty with patients. C1 [Iezzoni, Lisa I.; Campbell, Eric G.] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Iezzoni, Lisa I.; Vogeli, Christine] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Rao, Sowmya R.] Univ Massachusetts, Sch Med, Quantitat Hlth Sci Dept, Worcester, MA USA. [DesRoches, Catherine M.] Math Policy Res, Cambridge, MA USA. RP Iezzoni, LI (reprint author), Harvard Univ, Sch Med, Boston, MA 02215 USA. FU Institute on Medicine at Columbia University FX External financial support was provided by the Institute on Medicine as a Profession at Columbia University. NR 44 TC 25 Z9 25 U1 2 U2 10 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD FEB PY 2012 VL 31 IS 2 BP 383 EP 391 DI 10.1377/hlthaff.2010.1137 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 894GE UT WOS:000300414300018 PM 22323169 ER PT J AU Gellad, WF Donohue, JM Zhao, XH Zhang, YT Banthin, JS AF Gellad, Walid F. Donohue, Julie M. Zhao, Xinhua Zhang, Yuting Banthin, Jessica S. TI The Financial Burden From Prescription Drugs Has Declined Recently For The Nonelderly, Although It Is Still High For Many SO HEALTH AFFAIRS LA English DT Article ID MEDICAID PRIOR-AUTHORIZATION; EXPENDITURE PANEL SURVEY; HEALTH-CARE; TRENDS AB Prescription drug spending and pharmacy benefit design have changed greatly over the past decade. However, little is known about the financial impact these changes have had on consumers. We examined ten years of nationally representative data from the Medical Expenditure Panel Survey and describe trends in two measures of financial burden for prescription drugs: out-of-pocket drug costs as a function of family income and the proportion of all out-of-pocket health care expenses accounted for by drugs. We found that although the percentage of people with high financial burden for prescription drugs increased from 1999 to 2003, it decreased from 2003 to 2007, with a slight increase in 2008. The decline is evidence of the success of strategies to lower drug costs for consumers, including the increased use of generic drugs. However, the financial burden is still high among some groups, notably those with public insurance and those with low incomes. For example, one in four nonelderly people devote more than half of their total out-of-pocket health care spending to prescription drugs. These trends suggest that the affordability of prescription drugs under the future insurance exchanges will need to be monitored, as will efforts by states to increase prescription drug copayments under Medicaid or otherwise restrict drug use to reduce public spending. C1 [Gellad, Walid F.] Univ Pittsburgh, Sch Med, Pittsburgh Vet Affairs VA Med Ctr, Pittsburgh, PA 15260 USA. [Gellad, Walid F.] Univ Pittsburgh, Sch Med, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Gellad, Walid F.] RAND, Pittsburgh, PA USA. [Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA. [Zhao, Xinhua] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Banthin, Jessica S.] Congress Budget Off, Div Hlth & Human Resources, Washington, DC USA. RP Gellad, WF (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh Vet Affairs VA Med Ctr, Pittsburgh, PA 15260 USA. EM wfg3@pitt.edu OI Donohue, Julie/0000-0003-2418-6017 FU Veterans Affairs Health Services [CDA 09-207]; RAND-University of Pittsburgh Health Institute; Clinical and Translational Science Institute (CTSI); National Center for Research Resources, National Institutes of Health (NIH) [UL1 RR024153]; NIH Roadmap for Medical Research; Agency for Healthcare Research and Quality and National Institute of Mental Health [AHRQ 1R01HS017695, 1R34 MH082682, P30 MH090333]; National Institute of Mental Health [RC1 MH088510]; Agency for Healthcare Research and Quality [R01 HS018657] FX The results of this study were presented at the AcademyHealth Annual Research Meeting in Seattle, Washington, June 13, 2011. The study was supported in part by a Veterans Affairs Health Services Research and Development Career Development Award (CDA 09-207) to Walid Gellad, as well as by the RAND-University of Pittsburgh Health Institute and the Clinical and Translational Science Institute (CTSI) Translating Research into Practice Program. The CTSI is made possible by Grant No. UL1 RR024153 to the University of Pittsburgh from the National Center for Research Resources, a component of the National Institutes of Health (NIH), and by the NIH Roadmap for Medical Research. Julie Donohue was supported by Agency for Healthcare Research and Quality and National Institute of Mental Health grants (Nos. AHRQ 1R01HS017695, 1R34 MH082682, and P30 MH090333). Yuting Zhang was supported by National Institute of Mental Health Grant No. RC1 MH088510 and Agency for Healthcare Research and Quality Grant No. R01 HS018657. This study was conducted while Jessica Banthin was employed by the Agency for Healthcare Research and Quality. This work represents the opinions of the authors alone and does not necessarily represent the views of the Department of Veterans Affairs, the Agency for Healthcare Research and Quality, the Congressional Budget Office, or the US government. NR 28 TC 13 Z9 13 U1 1 U2 4 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD FEB PY 2012 VL 31 IS 2 BP 408 EP 416 DI 10.1377/hlthaff.2011.0469 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 894GE UT WOS:000300414300021 PM 22323172 ER PT J AU Berkowitz, RS AF Berkowitz, Ross S. TI Gynecologic Cancer Preface SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Editorial Material C1 [Berkowitz, Ross S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA. [Berkowitz, Ross S.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Berkowitz, RS (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. EM Ross_Berkowitz@dfci.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD FEB PY 2012 VL 26 IS 1 BP XI EP XII DI 10.1016/j.hoc.2011.12.001 PG 2 WC Oncology; Hematology SC Oncology; Hematology GA 895AC UT WOS:000300467600001 PM 22244669 ER PT J AU Echelman, D Feldman, S AF Echelman, Daniel Feldman, Sarah TI Management of Cervical Precancers: A Global Perspective SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Cervical dysplasia; Cervical cancer; Screening; Human papilloma virus ID RANDOMIZED CONTROLLED-TRIAL; HUMAN-PAPILLOMAVIRUS DNA; LOW-RESOURCE SETTINGS; SCREEN-AND-TREAT; CANCER PREVENTION; HPV INFECTION; DEVELOPING-COUNTRIES; COST-EFFECTIVENESS; INTRAEPITHELIAL NEOPLASIA; CONVENTIONAL CYTOLOGY AB The incidence and mortality of cervical cancer have decreased dramatically over the past 70 years in well-developed countries through successful screening programs using cytologic examination, followed by evaluation and treatment of high-grade precancers of the cervix. In less-well-developed countries, cervical cancer incidence and mortality remain high. However, moving forward, a combination of the human papillomavirus (HPV) vaccine, new HPV screening capability, and simple see-and-treat techniques may help to decrease the cervical cancer burden in these countries. C1 [Feldman, Sarah] Harvard Univ, Dana Farber Canc Inst, Brigham & Womens Hosp, Div Gynecol Oncol,Med Sch, Boston, MA 02115 USA. [Echelman, Daniel] Dana Farber Canc Inst, Womens Canc Program, Boston, MA 02115 USA. RP Feldman, S (reprint author), Harvard Univ, Dana Farber Canc Inst, Brigham & Womens Hosp, Div Gynecol Oncol,Med Sch, 75 Francis St, Boston, MA 02115 USA. EM sfeldman@partners.org NR 76 TC 7 Z9 9 U1 1 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD FEB PY 2012 VL 26 IS 1 BP 31 EP + DI 10.1016/j.hoc.2011.11.005 PG 15 WC Oncology; Hematology SC Oncology; Hematology GA 895AC UT WOS:000300467600004 PM 22244660 ER PT J AU Schorge, JO Eisenhauer, EE Chi, DS AF Schorge, John O. Eisenhauer, Eric E. Chi, Dennis S. TI Current Surgical Management of Ovarian Cancer SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Ovarian cancer; Primary debulking surgery; Interval debulking surgery; Secondary debulking surgery ID PRIMARY CYTOREDUCTIVE SURGERY; RECURRENT EPITHELIAL OVARIAN; MALIGNANT POTENTIAL TUMORS; GYNECOLOGIC-ONCOLOGY-GROUP; RANDOMIZED PHASE-III; STAGE-I OVARIAN; NEOADJUVANT CHEMOTHERAPY; UPDATED SERIES; ADJUVANT CHEMOTHERAPY; PROGNOSTIC-FACTORS AB Surgical management of ovarian cancer requires excellent judgment and mastery of a wide array of procedures. Involvement of a gynecologic oncologist improves outcomes. Staging of apparent stage I disease is important. Minimally invasive techniques provide advantages. Primary debulking surgery provides the best long-term survival of any strategy in advanced ovarian cancer. Aggressive surgical paradigms have the greatest success. Further cytoreductive surgery may be appropriate. Most relapsed patients require management of bowel obstruction at some point. Palliative intervention can enhance quality of life. Surgical correction may extend survival. For end-stage patients with progressive disease, the treating gynecologic oncologist must manage expectations. C1 [Schorge, John O.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Eisenhauer, Eric E.] Ohio State Univ, Columbus, OH 43210 USA. [Chi, Dennis S.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA. RP Schorge, JO (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM jschorge@partners.org NR 78 TC 11 Z9 12 U1 0 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD FEB PY 2012 VL 26 IS 1 BP 93 EP + DI 10.1016/j.hoc.2011.10.004 PG 18 WC Oncology; Hematology SC Oncology; Hematology GA 895AC UT WOS:000300467600008 PM 22244664 ER PT J AU Goldstein, DP Berkowitz, RS AF Goldstein, Donald Peter Berkowitz, Ross S. TI Current Management of Gestational Trophoblastic Neoplasia SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Gestational trophoblastic neoplasia; Invasive mole; Choriocarcinoma; Human chorionic gonadotropin ID WEEKLY INTRAMUSCULAR METHOTREXATE; HUMAN CHORIONIC-GONADOTROPIN; GYNECOLOGIC-ONCOLOGY-GROUP; RETROSPECTIVE COHORT SURVEY; COMPLETE MOLAR PREGNANCY; CENTRAL-NERVOUS-SYSTEM; EMA-CO CHEMOTHERAPY; DOSE ACTINOMYCIN-D; OF-THE-LITERATURE; HYDATIDIFORM MOLE AB Gestational trophoblastic neoplasms are malignant lesions that arise from placental villous and extravillous trophoblast. Four clinicopathologic conditions make up this entity: invasive mole (IM), choriocarcinoma (CCA), placental-site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (El I). IM and CCA, which make up the majority of these tumors, are highly responsive to chemotherapy with an overall cure rate exceeding 90%, making it usually possible to achieve cure while preserving reproductive function. PSTT and ETT, which rarely occur, are relatively resistant to chemotherapy, making surgery the primary treatment modality, chemotherapy being used only when the disease has metastasized. C1 [Goldstein, Donald Peter] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Div Gynecol Oncol,New England Trophoblast Dis Ctr, Boston, MA 02115 USA. [Berkowitz, Ross S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA. [Berkowitz, Ross S.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Goldstein, DP (reprint author), Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Div Gynecol Oncol,New England Trophoblast Dis Ctr, 75 Francis St, Boston, MA 02115 USA. EM dgoldstein@partners.org NR 126 TC 29 Z9 38 U1 2 U2 17 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD FEB PY 2012 VL 26 IS 1 BP 111 EP + DI 10.1016/j.hoc.2011.10.007 PG 23 WC Oncology; Hematology SC Oncology; Hematology GA 895AC UT WOS:000300467600009 PM 22244665 ER PT J AU Horowitz, N Matulonis, UA AF Horowitz, Neil Matulonis, Ursula A. TI New Biologic Agents for the Treatment of Gynecologic Cancers SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Ovarian cancer; Endornetrial cancer; Cervical cancer; Antiangiogenesis inhibitors; Poly-ADP-ribose polymerase inhibitors; Phosphoinositide 3-kinase inhibitors ID GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; PRIMARY PERITONEAL CARCINOMA; RECURRENT EPITHELIAL OVARIAN; PLATINUM-RESISTANT OVARIAN; SQUAMOUS-CELL-CARCINOMA; GENE COPY NUMBER; METASTATIC ENDOMETRIAL CANCER; ONCOLOGY-GROUP; OPEN-LABEL AB Improved understanding of the molecular basis of gynecologic cancers in addition to the availability of faster and less expensive technologies for genetic analysis of cancers has led to the exciting field of targeted biologic agents in ovarian, endometrial, cervical, and vulvar cancer. These agents include antiangiogenic therapies, poly (ADP-ribose) polymerase inhibitors, phosphoinositide 3-kinase pathway inhibitors, notch inhibitors, and epidermal growth factor receptor inhibitors. This article provides an update on the state of targeted therapy testing in gynecologic cancers. C1 [Matulonis, Ursula A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Horowitz, Neil] Brigham & Womens Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, Boston, MA 02115 USA. RP Matulonis, UA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA. EM Ursula_matulonis@dfci.harvard.edu FU Genentech FX Ursula Matulonis has participated in advisory boards for Clovis Pharmaceuticals, Boehringer Ingelheim, Sanofi-Aventis, and Merck and serves on the Clinical Advisory Board for Pathway Therapeutics. Neil Horowtiz has received research support from Genentech. NR 99 TC 1 Z9 1 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD FEB PY 2012 VL 26 IS 1 BP 133 EP + DI 10.1016/j.hoc.2011.11.002 PG 25 WC Oncology; Hematology SC Oncology; Hematology GA 895AC UT WOS:000300467600010 PM 22244666 ER PT J AU Carter, J Penson, R Barakat, R Wenzel, L AF Carter, Jeanne Penson, Richard Barakat, Richard Wenzel, Lani TI Contemporary Quality of Life Issues Affecting Gynecologic Cancer Survivors SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Quality of life; Sexual function; Chemotherapy toxicities ID ADVANCED OVARIAN-CANCER; PHASE-III TRIAL; FERTILITY-PRESERVING TREATMENT; ADVANCED CERVICAL-CANCER; LYMPH-NODE DISSECTION; LONG-TERM SURVIVORS; ATYPICAL ENDOMETRIAL HYPERPLASIA; PATIENT-PHYSICIAN COMMUNICATION; RADICAL ABDOMINAL TRACHELECTOMY; RANDOMIZED CONTROLLED-TRIAL AB Regardless of cancer origin or age of onset, the disease and its treatment can produce short- and long-term sequelae (ie, sexual dysfunction, infertility, or lymphedema) that adversely affect quality of life (QOL). This article outlines the primary contemporary issues or concerns that may affect QOL and offers strategies to offset or mitigate QOL disruption. These contemporary issues are identified within the domains of sexual functioning, reproductive issues, lymphedema, and the contribution of health-related QOL in influential gynecologic cancer clinical trials. C1 [Wenzel, Lani] Univ Calif Irvine, Dept Med & Publ Hlth, Irvine, CA 92697 USA. [Carter, Jeanne; Barakat, Richard] Mem Sloan Kettering Canc Ctr, Gynecol Serv, Dept Surg, New York, NY 10065 USA. [Penson, Richard] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Wenzel, L (reprint author), Univ Calif Irvine, Dept Med & Publ Hlth, 839 Hlth Sci Court,Sprague Hall,Suite 212, Irvine, CA 92697 USA. EM lwenzel@uci.edu FU NCI NIH HHS [P30 CA062203] NR 217 TC 9 Z9 10 U1 4 U2 14 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD FEB PY 2012 VL 26 IS 1 BP 169 EP + DI 10.1016/j.hoc.2011.11.001 PG 27 WC Oncology; Hematology SC Oncology; Hematology GA 895AC UT WOS:000300467600012 PM 22244668 ER PT J AU Masilamani, M Commins, S Shreffler, W AF Masilamani, Madhan Commins, Scott Shreffler, Wayne TI Determinants of Food Allergy SO IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA LA English DT Article DE Food allergy; Allergen; Plant food allergens; Animal food allergens; Peanut; Soy; Cross-reactive carbohydrate determinants; Alpha-gal ID REACTIVE CARBOHYDRATE DETERMINANTS; CORE ALPHA-1,3-LINKED FUCOSE; SOYBEAN-SENSITIVE PATIENTS; SIMULATED GASTRIC FLUID; ALPHA-GAL EPITOPE; COWS MILK ALLERGY; SOY ALLERGY; IN-VITRO; IGE ANTIBODIES; BETA-CONGLYCININ AB Food allergy is an emerging epidemic in the United States and the Western world. The determination of factors that make certain foods allergenic is still not clearly understood. Only a tiny fraction of thousands of proteins and other molecules is responsible for inducing food allergy. In this review, the authors present 3 examples of food allergies with disparate clinical presentations: peanut, soy, and mammalian meat. The potential relationships between allergen structure and function, emphasizing the importance of cross-reactive determinants, immunoglobulin E antibodies to the oligosaccharides, and the immune responses induced in humans are discussed. C1 [Shreffler, Wayne] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Disorders, Boston, MA 02114 USA. [Masilamani, Madhan] Mt Sinai Sch Med, Div Allergy & Immunol, Dept Pediat, Jaffe Food Allergy Inst, New York, NY 10029 USA. [Masilamani, Madhan] Mt Sinai Sch Med, Inst Immunol, New York, NY 10029 USA. [Commins, Scott] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA. RP Shreffler, W (reprint author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Disorders, 55 Fruit St,CPZS 557, Boston, MA 02114 USA. EM wshreffler@partners.org OI Masilamani, Madhan/0000-0001-8181-8848 FU Jaffe Food Allergy Institute; NIH FX The Jaffe Food Allergy Institute (M.M.), NIH (S.C., W.S.). NR 134 TC 14 Z9 15 U1 3 U2 25 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8561 J9 IMMUNOL ALLERGY CLIN JI Immunol. Allerg. Clin. North Am. PD FEB PY 2012 VL 32 IS 1 BP 11 EP + DI 10.1016/j.iac.2011.12.003 PG 24 WC Allergy; Immunology SC Allergy; Immunology GA 894ZY UT WOS:000300467200004 PM 22244230 ER PT J AU Nadeau, KC Kohli, A Iyengar, S DeKruyff, RH Umetsu, DT AF Nadeau, Kari C. Kohli, Arunima Iyengar, Shuba DeKruyff, Rosemarie H. Umetsu, Dale T. TI Oral Immunotherapy and Anti-IgE Antibody-Adjunctive Treatment for Food Allergy SO IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA LA English DT Article DE Food allergy; Immunotherapy; Anti-IgE antibody/omalizumab; Desensitization ID COWS MILK ALLERGY; ADD-ON THERAPY; TOLERANCE INDUCTION; LEUKOTRIENE RELEASE; PEANUT ALLERGY; SKIN-TESTS; OMALIZUMAB; CHILDREN; RHINITIS; ASTHMA AB One of the most promising therapies for food allergy is oral immunotherapy (OIT), in which small amounts of allergen are administered in increasing amounts, with the immediate goal of desensitization and the long-term goal of tolerance. However, safety and standardization concerns prevent its widespread use, and a subgroup of patients may experience severe allergic reactions. These concerns might be addressed by another promising therapy involving anti-IgE monoclonal antibodies (mAb), which can reduce allergic reactions associated with food administration. A recent pilot study combining anti-IgE mAb with OIT suggests that anti-IgE mAb might improve the safety, rapidity, and efficacy of OIT. C1 [DeKruyff, Rosemarie H.; Umetsu, Dale T.] Harvard Univ, Karp Labs, Childrens Hosp, Div Immunol,Sch Med, Boston, MA 02115 USA. [Nadeau, Kari C.] Stanford Univ, Div Immunol & Allergy, Stanford Food Allergy Program, Stanford, CA 94305 USA. [Kohli, Arunima] Stanford Univ, Div Immunol & Allergy, Dept Pediat, Stanford, CA 94305 USA. [Iyengar, Shuba] Massachusetts Gen Hosp, Div Pulm Med, Boston, MA 02114 USA. RP Umetsu, DT (reprint author), Harvard Univ, Karp Labs, Childrens Hosp, Div Immunol,Sch Med, 1 Blackfan Circle, Boston, MA 02115 USA. EM dale.umetsu@childrens.harvard.edu NR 58 TC 34 Z9 35 U1 1 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8561 J9 IMMUNOL ALLERGY CLIN JI Immunol. Allerg. Clin. North Am. PD FEB PY 2012 VL 32 IS 1 BP 111 EP + DI 10.1016/j.iac.2011.11.004 PG 24 WC Allergy; Immunology SC Allergy; Immunology GA 894ZY UT WOS:000300467200010 PM 22244236 ER PT J AU Elmariah, S Jang, IK AF Elmariah, Sammy Jang, Ik-Kyung TI Acute Stent Thrombosis: Technical Complication or Inadequate Antithrombotic Therapy? An Optical Coherence Tomography Study SO JACC-CARDIOVASCULAR INTERVENTIONS LA English DT Editorial Material ID PERCUTANEOUS CORONARY INTERVENTION; TRIAGE STRATEGY TRIAL; ACUTE CATHETERIZATION C1 [Elmariah, Sammy; Jang, Ik-Kyung] Harvard Univ, Div Cardiol, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Jang, IK (reprint author), Harvard Univ, Div Cardiol, Massachusetts Gen Hosp, Sch Med, Bigelow 800,55 Fruit St, Boston, MA 02114 USA. EM ijang@partners.org NR 4 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-8798 J9 JACC-CARDIOVASC INTE JI JACC-Cardiovasc. Interv. PD FEB PY 2012 VL 5 IS 2 BP E3 EP E4 DI 10.1016/j.jcin.2011.09.026 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 904XO UT WOS:000301232400001 PM 22361615 ER PT J AU Bankova, LG Walter, JE Iyengar, SR Lorenzo, ME Hornick, JL Castells, MC AF Bankova, L. G. Walter, J. E. Iyengar, S. R. Lorenzo, M. E. Hornick, J. L. Castells, M. C. TI Vaccination-induced Severe Bullous Eruption in a Child with Diffuse Cutaneous Mastocytosis SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 02-06, 2012 CL Orlando, FL SP Amer Acad Allergy Asthma & Immunol (AAAAI) C1 [Bankova, L. G.; Castells, M. C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Rheumatol Allergy & Immunol, Boston, MA 02115 USA. [Walter, J. E.; Iyengar, S. R.] Harvard Univ, Sch Med, MassGen Hosp Children, Div Allergy Immunol & Pulmonol, Boston, MA 02115 USA. [Lorenzo, M. E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02115 USA. [Hornick, J. L.] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2012 VL 129 IS 2 SU S BP AB226 EP AB226 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 903QL UT WOS:000301133401020 ER PT J AU Baxi, SN Sheehan, WJ Permaul, P Gaffin, JM Rao, D Fu, C Rogers, C Muilenberg, M Hoffman, EB Gold, DR Phipatanakul, W AF Baxi, S. N. Sheehan, W. J. Permaul, P. Gaffin, J. M. Rao, D. Fu, C. Rogers, C. Muilenberg, M. Hoffman, E. B. Gold, D. R. Phipatanakul, W. TI Airborne Fungus Diversity and Concentrations in Inner City Elementary Schools SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 02-06, 2012 CL Orlando, FL SP Amer Acad Allergy Asthma & Immunol (AAAAI) C1 [Baxi, S. N.; Sheehan, W. J.; Gaffin, J. M.; Rao, D.; Phipatanakul, W.] Childrens Hosp, Boston, MA 02115 USA. [Permaul, P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Fu, C.] Channing Labs, Boston, MA USA. [Rogers, C.; Muilenberg, M.] Univ Massachusetts, Amherst, MA 01003 USA. [Hoffman, E. B.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Gold, D. R.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2012 VL 129 IS 2 SU S BP AB17 EP AB17 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 903QL UT WOS:000301133400068 ER PT J AU Boyle, J Camargo, CA Lieberman, P Sampson, H Schwartz, LB Simons, FER Zitt, M Wilkinson, M Collins, C Tringale, M Wood, R AF Boyle, J. Camargo, C. A. Lieberman, P. Sampson, H. Schwartz, L. B. Simons, F. E. R. Zitt, M. Wilkinson, M. Collins, C. Tringale, M. Wood, R. TI Anaphylaxis in America - Results from a National Telephone Survey SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 02-06, 2012 CL Orlando, FL SP Amer Acad Allergy Asthma & Immunol (AAAAI) C1 [Boyle, J.; Wilkinson, M.] Abt SRBI, Silver Spring, MD USA. [Camargo, C. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lieberman, P.] Univ Tennessee, Coll Med, Germantown, TN USA. [Sampson, H.] Mt Sinai Sch Med, New York, NY USA. [Schwartz, L. B.] Virginia Commonwealth Univ, Richmond, VA USA. [Simons, F. E. R.] Univ Manitoba, Winnipeg, MB, Canada. [Zitt, M.] SUNY Stony Brook, Stony Brook, NY 11794 USA. [Collins, C.; Tringale, M.] Asthma & Allergy Fdn Amer, Landover, MD USA. [Wood, R.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2012 VL 129 IS 2 SU S BP AB132 EP AB132 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 903QL UT WOS:000301133400500 ER PT J AU Gupta, RS Lau, CH Springston, EE Smith, B Warrier, MR Pongracic, J Holl, J AF Gupta, R. S. Lau, C. H. Springston, E. E. Smith, B. Warrier, M. R. Pongracic, J. Holl, J. TI Diagnosis of childhood food allergy in the United States SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 02-06, 2012 CL Orlando, FL SP Amer Acad Allergy Asthma & Immunol (AAAAI) C1 [Gupta, R. S.; Lau, C. H.; Pongracic, J.] Childrens Mem Hosp, Chicago, IL 60614 USA. [Gupta, R. S.; Springston, E. E.; Holl, J.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Smith, B.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Smith, B.] Loyola Univ, Maywood, IL 60153 USA. [Warrier, M. R.] Allergy Asthma & Sinus Care, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2012 VL 129 IS 2 SU S BP AB230 EP AB230 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 903QL UT WOS:000301133401035 ER PT J AU Jones, SM Burks, AW Wood, RA Fleischer, DM Sicherer, SH Lindblad, RW Stablein, D Henning, AK Vickery, BP Liu, AH Scurlock, AM Shreffler, WG Plaut, M Sampson, HA AF Jones, S. M. Burks, A. W. Wood, R. A. Fleischer, D. M. Sicherer, S. H. Lindblad, R. W. Stablein, D. Henning, A. K. Vickery, B. P. Liu, A. H. Scurlock, A. M. Shreffler, W. G. Plaut, M. Sampson, H. A. TI A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Egg Oral Immunotherapy in Children: An Analysis of Clinical Tolerance SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 02-06, 2012 CL Orlando, FL SP Amer Acad Allergy Asthma & Immunol (AAAAI) C1 [Jones, S. M.; Scurlock, A. M.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Jones, S. M.; Scurlock, A. M.] Arkansas Childrens Hosp, Little Rock, AR 72202 USA. [Burks, A. W.; Vickery, B. P.] Duke Univ, Med Ctr, Durham, NC USA. [Wood, R. A.] Johns Hopkins Univ, Med Ctr, Baltimore, MD 21218 USA. [Fleischer, D. M.; Liu, A. H.] Natl Jewish Hlth, Denver, CO USA. [Sicherer, S. H.; Sampson, H. A.] Mt Sinai Sch Med, New York, NY USA. [Lindblad, R. W.; Stablein, D.; Henning, A. K.] EMMES Corp, Rockville, MD USA. [Shreffler, W. G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Plaut, M.] NIAID, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2012 VL 129 IS 2 SU S BP AB65 EP AB65 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 903QL UT WOS:000301133400246 ER PT J AU Kubala, SA Patil, SU Radano, MC Shreffler, WG Hurley, BP AF Kubala, S. A. Patil, S. U. Radano, M. C. Shreffler, W. G. Hurley, B. P. TI Failure Of Hepoxilin A-3 To Chemoattract Eosinophils In An In-vitro Gradient Barrier System SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 02-06, 2012 CL Orlando, FL SP Amer Acad Allergy Asthma & Immunol (AAAAI) C1 [Kubala, S. A.; Patil, S. U.; Radano, M. C.; Shreffler, W. G.; Hurley, B. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2012 VL 129 IS 2 SU S BP AB119 EP AB119 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 903QL UT WOS:000301133400452 ER PT J AU Leung, J Wilson, M AF Leung, J. Wilson, M. TI Amoxicillin-induced Aseptic Meningitis with Neutrophil Predominance SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 02-06, 2012 CL Orlando, FL SP Amer Acad Allergy Asthma & Immunol (AAAAI) C1 [Leung, J.; Wilson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2012 VL 129 IS 2 SU S BP AB236 EP AB236 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 903QL UT WOS:000301133401059 ER PT J AU Ma, A Patil, S Lund, G Lund, K Shreffler, WG AF Ma, A. Patil, S. Lund, G. Lund, K. Shreffler, W. G. TI Antigen-induced Anergy In Human Basophils Is Not Antigen Specific SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 02-06, 2012 CL Orlando, FL SP Amer Acad Allergy Asthma & Immunol (AAAAI) C1 [Ma, A.; Patil, S.; Shreffler, W. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lund, G.; Lund, K.] ALK Abello, Horsholm, Denmark. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2012 VL 129 IS 2 SU S BP AB123 EP AB123 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 903QL UT WOS:000301133400467 ER PT J AU Patil, SU Ma, A Lund, G Lund, K Shreffler, WG AF Patil, S. U. Ma, A. Lund, G. Lund, K. Shreffler, W. G. TI Human Basophil Activation Is Associated With Expression Of Co-stimulatory Molecules And Ige Dependent Antigen Capture SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 02-06, 2012 CL Orlando, FL SP Amer Acad Allergy Asthma & Immunol (AAAAI) C1 [Patil, S. U.; Ma, A.; Shreffler, W. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lund, G.; Lund, K.] ALK Abello, Horsholm, Denmark. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2012 VL 129 IS 2 SU S BP AB123 EP AB123 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 903QL UT WOS:000301133400466 ER PT J AU Permaul, P Hoffman, E Fu, C Sheehan, W Baxi, S Gaffin, J Lane, J Bailey, A Gold, D Phipatanakul, W AF Permaul, P. Hoffman, E. Fu, C. Sheehan, W. Baxi, S. Gaffin, J. Lane, J. Bailey, A. Gold, D. Phipatanakul, W. TI Exposure to Indoor Allergens in Urban Elementary Schools and Homes of Children with Asthma SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 02-06, 2012 CL Orlando, FL SP Amer Acad Allergy Asthma & Immunol (AAAAI) C1 [Permaul, P.] Massachusetts Gen Hosp, Div Pediat Allergy & Immunol, Boston, MA 02114 USA. [Hoffman, E.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Fu, C.; Bailey, A.; Gold, D.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA. [Sheehan, W.; Baxi, S.; Phipatanakul, W.] Childrens Hosp Boston, Div Allergy & Immunol, Boston, MA USA. [Gaffin, J.] Childrens Hosp Boston, Div Pulm, Boston, MA USA. [Lane, J.] Facil Management, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2012 VL 129 IS 2 SU S BP AB63 EP AB63 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 903QL UT WOS:000301133400241 ER PT J AU Ruiter, B Grishina, G Jager, CFD Knol, EF Ozias-Akins, P Sampson, HA Shreffler, WG AF Ruiter, B. Grishina, G. Jager, C. F. den Hartog Knol, E. F. Ozias-Akins, P. Sampson, H. A. Shreffler, W. G. TI Human Dendritic Cells Stimulated with a Novel Peanut Protein Express High Levels of RALDH2 and Induce RA-Sensitive Genes in Naive T Cells SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 02-06, 2012 CL Orlando, FL SP Amer Acad Allergy Asthma & Immunol (AAAAI) C1 [Ruiter, B.; Shreffler, W. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Grishina, G.; Sampson, H. A.] Mt Sinai Sch Med, New York, NY USA. [Jager, C. F. den Hartog; Knol, E. F.] Univ Med Ctr Utrecht, Utrecht, Netherlands. [Ozias-Akins, P.] Univ Georgia, Tifton, GA USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2012 VL 129 IS 2 SU S BP AB243 EP AB243 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 903QL UT WOS:000301133401085 ER PT J AU Sokol, C Bonilla, F Murali, MR Walter, J AF Sokol, C. Bonilla, F. Murali, M. R. Walter, J. TI Combined T and B Cell Defects Presenting in a Previously Healthy Child After Splenectomy for Autoimmune Cytopenias SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 02-06, 2012 CL Orlando, FL SP Amer Acad Allergy Asthma & Immunol (AAAAI) C1 [Sokol, C.; Murali, M. R.; Walter, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bonilla, F.] Childrens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2012 VL 129 IS 2 SU S BP AB87 EP AB87 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 903QL UT WOS:000301133400330 ER PT J AU Thomas, BM Aloe, C Curtin-Brosnan, J Peng, RD Eggleston, PA Shreffler, WG Hagberg, KA Krevans, M Korstanje, R Matsui, EC AF Thomas, B. M. Aloe, C. Curtin-Brosnan, J. Peng, R. D. Eggleston, P. A. Shreffler, W. G. Hagberg, K. A. Krevans, M. Korstanje, R. Matsui, E. C. TI Temporal Changes In Lung Function In A Mouse Worker Population SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 02-06, 2012 CL Orlando, FL SP Amer Acad Allergy Asthma & Immunol (AAAAI) C1 [Thomas, B. M.; Aloe, C.; Curtin-Brosnan, J.; Eggleston, P. A.; Matsui, E. C.] Johns Hopkins Univ, Baltimore, MD USA. [Peng, R. D.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Hagberg, K. A.; Krevans, M.; Korstanje, R.] Jackson Lab, Bar Harbor, ME 04609 USA. [Shreffler, W. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2012 VL 129 IS 2 SU S BP AB58 EP AB58 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 903QL UT WOS:000301133400222 ER PT J AU Buijze, GA Weening, AA Poolman, RW Bhandari, M Ring, D AF Buijze, G. A. Weening, A. A. Poolman, R. W. Bhandari, M. Ring, D. TI Predictors of the accuracy of quotation of references in peer-reviewed orthopaedic literature in relation to publications on the scaphoid SO JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME LA English DT Review ID JOURNAL QUALITY; FRACTURES; SURGERY; RADIUS; BONE AB Using inaccurate quotations can propagate misleading information, which might affect the management of patients. The aim of this study was to determine the predictors of quotation inaccuracy in the peer-reviewed orthopaedic literature related to the scaphoid. We randomly selected 100 papers from ten orthopaedic journals. All references were retrieved in full text when available or otherwise excluded. Two observers independently rated all quotations from the selected papers by comparing the claims made by the authors with the data and expressed opinions of the reference source. A statistical analysis determined which article-related factors were predictors of quotation inaccuracy. The mean total inaccuracy rate of the 3840 verified quotes was 7.6%. There was no correlation between the rate of inaccuracy and the impact factor of the journal. Multivariable analysis identified the journal and the type of study (clinical, biomechanical, methodological, case report or review) as important predictors of the total quotation inaccuracy rate. We concluded that inaccurate quotations in the peer-reviewed orthopaedic literature related to the scaphoid were common and slightly more so for certain journals and certain study types. Authors, reviewers and editorial staff play an important role in reducing this inaccuracy. C1 [Ring, D.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. [Buijze, G. A.; Weening, A. A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Hand & Upper Extrem Serv,Yawkey Ctr, Boston, MA 02114 USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, 55 Fruit St,YAW 2-2C, Boston, MA 02114 USA. EM dring@partners.org NR 17 TC 4 Z9 4 U1 1 U2 3 PU BRITISH EDITORIAL SOC BONE JOINT SURGERY PI LONDON PA 22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND SN 0301-620X J9 J BONE JOINT SURG BR JI J. Bone Joint Surg.-Br. Vol. PD FEB PY 2012 VL 94B IS 2 BP 276 EP 280 DI 10.1302/0301-620X.94B2.27618 PG 5 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 893WF UT WOS:000300387700025 PM 22323700 ER PT J AU Lidz, CW Simon, LJ Seligowski, AV Myers, S Gardner, W Candilis, PJ Arnold, R Appelbaum, PS AF Lidz, Charles W. Simon, Lorna J. Seligowski, Antonia V. Myers, Suzanne Gardner, William Candilis, Philip J. Arnold, Robert Appelbaum, Paul S. TI THE PARTICIPATION OF COMMUNITY MEMBERS ON MEDICAL INSTITUTIONAL REVIEW BOARDS SO JOURNAL OF EMPIRICAL RESEARCH ON HUMAN RESEARCH ETHICS LA English DT Review DE IRB; community member; bioethics; research ethics ID COMMITTEES AB THE GOAL OF THIS STUDY WAS TO describe the contributions of community members (unaffiliated members) who serve on institutional review boards (IRBs) at large medical research centers and to compare their contributions to those of other IRB members. We observed and audiotaped 17 panel meetings attended by community members and interviewed 15 community members, as well as 152 other members and staff. The authors coded transcripts of the panel meetings and reviewed the interviews of the community members. Community members played a lesser role as designated reviewers than other members. They were infrequently primary reviewers and expressed hesitation about the role. As secondary or tertiary reviewers, they were less active participants than other members in those roles. Community members were more likely to focus on issues related to confidentiality when reviewing an application than other reviewers. When they were not designated reviewers, however, they played a markedly greater role and their discussion focused more on consent disclosures than other reviewers. They did not appear to represent the community so much as to provide a nonscientific view of the protocol and the consent form. C1 [Lidz, Charles W.] Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01605 USA. [Seligowski, Antonia V.] VA Boston Healthcare Syst, Natl Ctr PTSD, W Roxbury, MA USA. [Gardner, William] Ohio State Univ, Columbus, OH 43210 USA. [Arnold, Robert] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Appelbaum, Paul S.] Columbia Univ Coll Phys & Surg, New York, NY USA. RP Lidz, CW (reprint author), Univ Massachusetts, Sch Med, Dept Psychiat, 55 Lake Ave N, Worcester, MA 01605 USA. EM Charles.lidz@umassmed.edu FU IRB; National Cancer Institute [5 R01 CA107295] FX The authors gratefully acknowledge the help and assistance of the anonymous IRB staff and members who encouraged and supported our work as well as the PIs at each site. We also appreciate the following individuals who substantially contributed to the study: for data collection Jill Rosenbaum, Christopher Jackson, and Teresa Roach; for data coding John Grillo and Linda Doucette.; This study was funded by a grant from the National Cancer Institute, 5 R01 CA107295. NR 11 TC 7 Z9 8 U1 0 U2 8 PU UNIV CALIFORNIA PRESS PI BERKELEY PA C/O JOURNALS & DIGITAL PUBLISHING DIVISION, 2000 CENTER ST, STE 303, BERKELEY, CA 94704-1223 USA SN 1556-2646 J9 J EMPIR RES HUM RES JI J. Empir. Res. Hum. Res. Ethics PD FEB PY 2012 VL 7 IS 1 BP 1 EP 8 DI 10.1525/jer.2012.7.1.1 PG 8 WC Ethics; Medical Ethics SC Social Sciences - Other Topics; Medical Ethics GA 904OY UT WOS:000301209000001 PM 22378129 ER PT J AU Knafl, KA Deatrick, JA Havill, NL AF Knafl, Kathleen A. Deatrick, Janet A. Havill, Nancy L. TI Continued Development of the Family Management Style Framework SO JOURNAL OF FAMILY NURSING LA English DT Article DE Family Management Style Framework; childhood chronic conditions; research review ID DUCHENNE MUSCULAR-DYSTROPHY; DISABLED-CHILDREN; YOUNG-CHILDREN; PARENTAL EXPERIENCES; DISABILITIES; MOTHERS; PERSPECTIVES; STRESS; ASTHMA; BABIES AB Based on a review of 64 published reports, this article addresses the implications of current research for the further development of the Family Management Style Framework (FMSF). Articles are published in 46 different journals, including 13 in nursing and 12 in interdisciplinary outlets. Most studies are based on samples of less than 50 individuals. The review provides continuing support for the 8 dimensions of the framework, with between 8 and 16 reports supporting the relevance of each. Changes to the sociocultural component of the framework are proposed as well as wording changes to reflect the broader applicability of the framework. The family's social network, health care and education professionals, and resources predominate as key influences on family management. C1 [Knafl, Kathleen A.; Havill, Nancy L.] Univ N Carolina, Sch Nursing, PhD Program, Chapel Hill, NC 27516 USA. [Deatrick, Janet A.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. RP Knafl, KA (reprint author), Univ N Carolina, Sch Nursing, PhD Program, 406 Brookgreen Dr, Chapel Hill, NC 27516 USA. EM kknafl@email.unc.edu FU National Institute of Nursing Research; National Institutes of Health [R01, NR08048]; Donaghue Medical Research Foundation FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors received support for the development of the Family Management Measure from the National Institute of Nursing Research; National Institutes of Health (R01, NR08048) and the Donaghue Medical Research Foundation. NR 71 TC 34 Z9 35 U1 9 U2 20 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1074-8407 J9 J FAM NURS JI J. Fam. Nurs. PD FEB PY 2012 VL 18 IS 1 SI SI BP 11 EP 34 DI 10.1177/1074840711427294 PG 24 WC Family Studies; Nursing SC Family Studies; Nursing GA 894PZ UT WOS:000300440300003 PM 22223495 ER PT J AU Ferreira, GB Kleijwegt, FS Waelkens, E Lage, K Nikolic, T Hansen, DA Workman, CT Roep, BO Overbergh, L Mathieu, C AF Ferreira, Gabriela Bomfim Kleijwegt, Fleur S. Waelkens, Etienne Lage, Kasper Nikolic, Tatjana Hansen, Daniel Aaen Workman, Christopher T. Roep, Bart O. Overbergh, Lut Mathieu, Chantal TI Differential Protein Pathways in 1,25-Dihydroxyvitamin D-3 and Dexamethasone Modulated Tolerogenic Human Dendritic Cells SO JOURNAL OF PROTEOME RESEARCH LA English DT Article DE 2D-DIGE; dendritic cell; dexamethasone; vitamin D; mass spectrometry; pathway analysis; protein interaction networks ID MOLECULAR INTERACTION DATABASE; ANTIGEN-PRESENTING CELLS; AUTOREACTIVE T-CELLS; IN-VIVO; DIHYDROXYVITAMIN D-3; OXIDATIVE STRESS; VITAMIN-D; INDUCTION; ACTIVATION; GENE AB Tolerogenic dendritic cells (DC) that are maturation-resistant and locked in a semimature state are promising tools in clinical applications for tolerance induction. Different immunomodulatory agents have been shown to induce a tolerogenic DC phenotype, such as the biologically active form of vitamin D (1,25(OH)(2)D-3), glucocorticoids, and a synergistic combination of both. In this study, we aimed to characterize the protein profile, function and phenotype of DCs obtained in vitro in the presence of 1,25(OH)(2)D-3, dexamethasone (DEX), and a combination of both compounds (combi). Human CD14(+) monocytes were differentiated toward mature DCs, in the presence or absence of 1,25(OH)(2)D-3 and/or DEX. Cells were prefractionated into cytoplasmic and microsomal fractions and protein samples were separated in two different pH ranges (pH 3-7NL and 6-9), analyzed by 2D-DIGE and differentially expressed spots (p < 0.05) were identified after MALDI-TOF/TOF analysis. In parallel, morphological and phenotypical analyses were performed, revealing that 1,25(OH)(2)D-3- and combi-mDCs are closer related to each other than DEX-mDCs. This was translated in their protein profile, indicating that 1,25(OH)(2)D-3 is more potent than DEX in inducing a tolerogenic profile on human DCs. Moreover, we demonstrate that combining 1,25(OH)(2)D-3 with DEX induces a unique protein expression pattern with major imprinting of the 1,25(OH)(2)D-3 effect. Finally, protein interaction networks and pathway analysis suggest that 1,25(OH)(2)D-3, rather than DEX treatment, has a severe impact on metabolic pathways involving lipids, glucose, and oxidative phosphorylation, which may affect the production of or the response to ROS generation. These findings provide new insights on the molecular basis of DC tolerogenicity induced by 1,25(OH)(2)D-3 and/or DEX, which may lead to the discovery of new pathways involved in DC immunomodulation. C1 [Ferreira, Gabriela Bomfim; Overbergh, Lut; Mathieu, Chantal] Catholic Univ Louvain, Lab Expt Med & Endocrinol LEGENDO, Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium. [Kleijwegt, Fleur S.; Nikolic, Tatjana; Roep, Bart O.] Leiden Univ, Med Ctr, Dept Immunohaematol & Blood Transfus, NL-2300 RC Leiden, Netherlands. [Waelkens, Etienne] Catholic Univ Louvain, Univ Hosp Gasthuisberg, Lab Prot Phosphorylat & Prote, B-3000 Louvain, Belgium. [Lage, Kasper; Hansen, Daniel Aaen; Workman, Christopher T.] Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark. [Lage, Kasper] Massachusetts Gen Hosp, MassGen Hosp Children, Pediat Surg Res Labs, Boston, MA 02114 USA. [Lage, Kasper] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Overbergh, L (reprint author), Univ Hosp Gasthuisberg, LEGENDO, Onderwijs Navorsing 1,Herestr 49,Bus 902, B-3000 Louvain, Belgium. EM lut.overbergh@med.kuleuven.be RI NIkolic, Tatjana/I-2162-2012; Bomfim Ferreira, Gabriela/L-8343-2014; Workman, Christopher/K-1066-2015 OI Workman, Christopher/0000-0002-2210-3743 FU Flemish Research Foundation (Fonds Voor Wetenschappelijk Onderzoek Vlaanderen) [G.0552.06, G.0649.08]; Belgium Program on Interuniversity Poles of Attraction [P6/40]; Catholic University of Leuven; SymBioSys CoE [EF/05/007]; European Union (NAIMIT); Dutch Diabetes Research Foundation (DEN Expert Center Beta Cell Immunoprotection); VICI (ZonMW, Netherlands) FX We thank Eefje Verdrengh, Jos Depovere, Karin Schildermans, Sandra Laban, Sandy Vandoninck and Wim Cockx for their excellent technical assistance. This work was supported by grants from the Flemish Research Foundation (Fonds Voor Wetenschappelijk Onderzoek Vlaanderen G.0552.06 and G.0649.08, a postdoctoral fellowship to G.B.F. and a clinical fellowship to C.M.), the Belgium Program on Interuniversity Poles of Attraction initiated by the Belgian State (P6/40), the Catholic University of Leuven (GOA 2009/10, and SymBioSys CoE EF/05/007), the seventh Framework Program of the European Union (NAIMIT), the Dutch Diabetes Research Foundation (DEN Expert Center Beta Cell Immunoprotection), and a VICI award (ZonMW, Netherlands). NR 63 TC 37 Z9 39 U1 1 U2 7 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1535-3893 J9 J PROTEOME RES JI J. Proteome Res. PD FEB PY 2012 VL 11 IS 2 BP 941 EP 971 DI 10.1021/pr200724e PG 31 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 894WN UT WOS:000300458300037 PM 22103328 ER PT J AU Kantardzhieva, A Peppi, M Lane, WS Sewell, WF AF Kantardzhieva, A. Peppi, M. Lane, W. S. Sewell, W. F. TI Protein Composition of Immunoprecipitated Synaptic Ribbons SO JOURNAL OF PROTEOME RESEARCH LA English DT Article DE synapse; synaptic ribbon; proteomics; vesicle release; active zone; retina; cochlea ID RIM-BINDING-PROTEINS; BOVINE HEART-MITOCHONDRIA; ACTIVE ZONE PROTEIN; NEUROTRANSMITTER RELEASE; PRESYNAPTIC CYTOMATRIX; SPECTRIN-BINDING; BIPOLAR CELLS; ATP SYNTHASE; CA2+ CHANNEL; RAT RETINA AB The synaptic ribbon is an electron-dense structure found in hair cells and photoreceptors. The ribbon is surrounded by neurotransmitter-filled vesicles and considered to play a role in vesicle release. We generated an objective, quantitative analysis of the protein composition of the ribbon complex using a mass spectrometry-based proteomics analysis. Our use of affinity-purified ribbons and control IgG immunoprecipitations ensure that the identified proteins are indeed associated with the ribbon complex. The use of mouse tissue, where the proteome is complete, generated a comprehensive analysis of the candidates. We identified 30 proteins (comprising 56 isoforms and subunits) associated with the ribbon complex. The ribbon complex primarily comprises proteins found in conventional synapses, which we categorized into 6 functional groups: vesicle handling (38.5%), scaffold (7.3%), cytoskeletal molecules (20.6%), phosphorylation enzymes (10.6%), molecular chaperones (8.2%), and transmembrane proteins from the presynaptic membrane firmly attached to the ribbon (11.3%). The 3 CtBP isoforms represent the major protein in the ribbon whether calculated by molar amount (30%) or by mass (20%). The relatively high quantity of phosphorylation enzymes suggests a very active and regulated structure. The ribbon appears to comprise a concentrated cluster of proteins dealing with vesicle creation, retention and distribution, and consequent exocytosis. C1 [Kantardzhieva, A.; Peppi, M.; Sewell, W. F.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Dept Otol & Laryngol, Boston, MA 02114 USA. [Kantardzhieva, A.; Peppi, M.; Sewell, W. F.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Lane, W. S.] Harvard Univ, FAS Ctr Syst Biol, Harvard Mass Spectrometry & Prote Resource Lab, Cambridge, MA 02138 USA. RP Sewell, WF (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Dept Otol & Laryngol, 243 Charles St, Boston, MA 02114 USA. EM wfs@epl.meei.harvard.edu FU NIDCD [DC767, DC9651]; Hearing Health Foundation FX This work was supported by the NIDCD (DC767 and DC9651) and the Hearing Health Foundation (to A.K). We appreciate the contributions of J. Evans of the U. Mass proteomics facility. We thank R. A. Eatock, M. C. Brown, and M. C. Liberman for comments on earlier versions of the manuscript. NR 74 TC 9 Z9 9 U1 0 U2 4 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1535-3893 J9 J PROTEOME RES JI J. Proteome Res. PD FEB PY 2012 VL 11 IS 2 BP 1163 EP 1174 DI 10.1021/pr2008972 PG 12 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 894WN UT WOS:000300458300055 PM 22103298 ER PT J AU Jacobs, PG Konrad-Martin, D Mcmillan, GP McDermott, D Fausti, SA Kagen, D Wan, EA AF Jacobs, Peter G. Konrad-Martin, Dawn Mcmillan, Garnett P. McDermott, Daniel Fausti, Stephen A. Kagen, David Wan, Eric A. TI Influence of acute hyperglycemia on otoacoustic emissions and the medial olivocochlear reflex SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article ID OUTER HAIR-CELLS; COCHLEAR MECHANICS; ADENOSINE 5'-TRIPHOSPHATE; AUDITORY-SYSTEM; NOISE; HEARING; SPEECH; SOUND; ATP; HUMANS AB Stimulus-frequency (SF) otoacoustic emission (OAE) amplitude and the amplitude of medial olivocochlear (MOC) inhibition of SF OAEs for ipsilateral, contralateral and bilateral MOC reflex elicitors were recorded in six subjects with type 2 diabetes during a glucose tolerance test (GTT). Five of the six subjects were tested twice for a total of 11 trials and three subjects were tested in a control experiment. During the GTT experiment, the subjects' blood glucose was elevated from a euglycemic level below 150 mg/dL to a hyperglycemic level above 160 mg/dL following the consumption of a bolus of 80 g of sugar. A subset of three subjects were tested in a control experiment during which SF OAE and MOC reflex measurements were made while blood sugar levels remained constant within the euglycemic region. Mean SF OAE amplitudes were elevated following glucose consumption. A statistically significant increase in MOC inhibition amplitude was observed during elevated sugar levels for the 11 GTT trials. Maximum inhibition occurred about an hour after glucose consumption when blood glucose levels peaked. Results indicate that acute hyperglycemia influences efferent control of the cochlea in people with type 2 diabetes. [DOI: 10.1121/1.3676609] C1 [Jacobs, Peter G.; Konrad-Martin, Dawn; Mcmillan, Garnett P.; McDermott, Daniel; Fausti, Stephen A.] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA. [Kagen, David] Portland VA Med Ctr, Dept Med, Portland, OR 97239 USA. [Wan, Eric A.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA. RP Jacobs, PG (reprint author), Portland VA Med Ctr, VA RR&D Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM peter.jacobs@va.gov FU US National Institute of Diabetes and Digestive and Kidney Diseases [1R21 DK079283-01A1]; VA Rehabilitative Research and Development (RRD) Service [C2759C, C4447K]; VA RR&D National Center for Rehabilitative Auditory Research within Portland VA Medical Center, Portland OR FX This work was funded by the US National Institute of Diabetes and Digestive and Kidney Diseases (1R21 DK079283-01A1), the VA Rehabilitative Research and Development (RR&D) Service (C2759C, C4447K), and the VA RR&D National Center for Rehabilitative Auditory Research within the Portland VA Medical Center, Portland, OR. Thanks to W. Kenneth Ward at Oregon Health & Science University for reviewing an early draft of this paper and providing feedback. NR 56 TC 3 Z9 5 U1 0 U2 1 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD FEB PY 2012 VL 131 IS 2 BP 1296 EP 1306 DI 10.1121/1.3676609 PN 1 PG 11 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA 895ID UT WOS:000300488800048 PM 22352503 ER PT J AU Woodard, LD Landrum, CR Urech, TH Profit, J Virani, SS Petersen, LA AF Woodard, LeChauncy D. Landrum, Cassie R. Urech, Tracy H. Profit, Jochen Virani, Salim S. Petersen, Laura A. TI Treating Chronically Ill People with Diabetes Mellitus with Limited Life Expectancy: Implications for Performance Measurement SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE diabetes mellitus; quality of care; performance measurement; limited life expectancy ID AFFAIRS HEALTH-CARE; QUALITY-OF-CARE; PRACTICE GUIDELINES; GLYCEMIC CONTROL; ELDERLY-PATIENTS; GLUCOSE CONTROL; OLDER PATIENTS; VETERANS; DISEASE; HEART AB OBJECTIVES: To develop an algorithm to identify individuals with limited life expectancy and examine the effect of limited life expectancy on glycemic control and treatment intensification in individuals with diabetes mellitus. DESIGN: Individuals with diabetes mellitus and coexisting congestive heart failure, chronic obstructive pulmonary disease, dementia, end-stage liver disease, and/or primary or metastatic cancer with limited life expectancy were identified. To validate the algorithm, 5-year mortality was assessed in individuals identified as having limited life expectancy. Rates of meeting performance measures for glycemic control between individuals with and without limited life expectancy were compared. In individuals with uncontrolled glycosylated hemoglobin (HbA(1c)) levels, the effect of limited life expectancy on treatment intensification within 90 days was examined. SETTING: One hundred ten Department of Veterans Affairs facilities; October 2006 to September 2007. PARTICIPANTS: Eight hundred eighty-eight thousand six hundred twenty-eight individuals with diabetes mellitus. MEASUREMENTS: HbA(1c); treatment intensification within 90 days of index HbA(1c) reading. RESULTS: Twenty-nine thousand sixteen (3%) participants had limited life expectancy. Adjusting for age, 5-year mortality was five times as high in participants with limited life expectancy than in those without. Participants with limited life expectancy had poorer glycemic control than those without (glycemic control: 77.1% vs 78.1%; odds ratio (OR) = 0.84, 95% confidence interval (CI) = 0.81-0.86) and less-frequent treatment intensification (treatment intensification: 20.9% vs 28.6%; OR = 0.71, 95% CI = 0.67-0.76), even after controlling for patientlevel characteristics. CONCLUSION: Participants with limited life expectancy were less likely than those without to have controlled HbA1c levels and to receive treatment intensification, suggesting that providers treat these individuals less aggressively. Quality measurement and performance-based reimbursement systems should acknowledge the different needs of this population. J Am Geriatr Soc 60: 193-200, 2012. C1 [Woodard, LeChauncy D.; Landrum, Cassie R.; Urech, Tracy H.; Profit, Jochen; Virani, Salim S.; Petersen, Laura A.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Hlth Policy & Qual Program, Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA. [Woodard, LeChauncy D.; Profit, Jochen; Virani, Salim S.; Petersen, Laura A.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Woodard, LD (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Hlth Policy & Qual Program, Hlth Serv Res & Dev Ctr Excellence, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM woodard.lechauncy@va.gov OI Virani, Salim/0000-0001-9541-6954 FU Department of Veterans Affairs (VA) HSRD [PPO 09-316]; VA HSRD [SHP 08-166]; Houston VA HSR&D Center of Excellence [HFP90-020]; Robert Wood Johnson Foundation Generalist Physician Faculty [045444]; National Institute of Child Health and Human Development [K23 HD056298]; VA HSRD Service [CDA-09-028] FX No author has any conflicts of interest to disclose. This work is supported in part by Department of Veterans Affairs (VA) HSR&D PPO 09-316 (PI LeChauncy D. Woodard, MD, MPH), VA HSR&D SHP 08-166 (PI Laura A. Petersen, MD, MPH), and Houston VA HSR&D Center of Excellence HFP90-020 (PI Laura A. Petersen, MD, MPH). Dr. Petersen was a Robert Wood Johnson Foundation Generalist Physician Faculty Scholar (Grant 045444) at the time this work was conducted. Dr. Profit's contribution is supported by National Institute of Child Health and Human Development Grant K23 HD056298 (PI Jochen Profit). Dr. Virani is supported by a VA HSR&D Service Career Development Award (CDA-09-028). Parts of this manuscript were presented at the Department of Veterans Affairs annual Health Services Research and Development National Meeting, February 2009, Washington, DC, and at the Society of General Internal Medicine annual meeting, May 2009, Miami, Florida. NR 37 TC 9 Z9 9 U1 0 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2012 VL 60 IS 2 BP 193 EP 201 DI 10.1111/j.1532-5415.2011.03784.x PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 897ST UT WOS:000300677400001 PM 22260627 ER PT J AU Lee, SJ Boyd, CM AF Lee, Sei J. Boyd, Cynthia M. TI Diabetes Mellitus Performance Measures in Individuals with Limited Life Expectancy SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Editorial Material ID PRACTICE GUIDELINES; QUALITY; INSULIN; SULFONYLUREAS; HYPOGLYCEMIA; PITFALLS; RISK; CARE C1 [Lee, Sei J.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. [Lee, Sei J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Boyd, Cynthia M.] Johns Hopkins Univ, Dept Hlth Policy & Management, Div Geriatr Med & Gerontol, Baltimore, MD 21218 USA. RP Lee, SJ (reprint author), San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. FU NIA NIH HHS [K23AG032910, K23AG040779, K23 AG032910, K23 AG040779-01, K23 AG040779] NR 20 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2012 VL 60 IS 2 BP 361 EP 363 DI 10.1111/j.1532-5415.2011.03783.x PG 3 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 897ST UT WOS:000300677400025 PM 22332676 ER PT J AU Chong, W Li, YQ Liu, BL Liu, ZC Zhao, T Wonsey, DR Chen, CM Velmahos, GC deMoya, MA King, DR Kung, AL Alam, HB AF Chong, Wei Li, Yongqing Liu, Baoling Liu, Zhengcai Zhao, Ting Wonsey, Diane R. Chen, Changmin Velmahos, George C. deMoya, Marc A. King, David R. Kung, Andrew L. Alam, Hasan B. TI Anti-inflammatory properties of histone deacetylase inhibitors: A mechanistic study SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY LA English DT Article; Proceedings Paper CT 70th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery CY SEP 14-17, 2011 CL Chicago, IL SP Amer Assoc Surg Trauma (AAST) DE Hypoxia; macrophages; SAHA; HIF-1 alpha; PHD2 ID NITRIC-OXIDE SYNTHASE; SUBEROYLANILIDE HYDROXAMIC ACID; HYPOXIA-INDUCIBLE FACTOR; HEMORRHAGIC-SHOCK; PROLYL HYDROXYLATION; HEPATIC-INJURY; BLOOD-LOSS; HIF-ALPHA; EXPRESSION; RESUSCITATION AB BACKGROUND: We have demonstrated that postshock administration of suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, can significantly improve early survival in a highly lethal model of hemorrhagic shock. As the primary insult in hemorrhagic shock is cellular hypoxia, and transcription factor hypoxia-inducible factor-1 alpha (HIF-1 alpha) controls proinflammatory gene expression in macrophages, we hypothesized that SAHA would attenuate the HIF-1 alpha associated proinflammatory pathway in a hypoxic macrophage model. METHODS: Mouse macrophages were exposed to hypoxic conditions (0.5% O-2, 10% CO2, and 89.5% N-2) at 37 degrees C in the presence or absence of SAHA (10 mu mol/L). The cells and culture medium were harvested at 1 hour, 4 hours, and 8 hours. Sham (no hypoxia, no SAHA) served as a control. Western blots were performed to assess protein levels of prolyl hydroxylase 2 (PHD2), HIF-1 alpha, and inducible nitric oxide synthase (iNOS) in the cells. Colorimetric biochemical assay and enzyme-linked immunosorbent assay were used to analyze the release of nitric oxide (NO) and secretion of tumor necrosis factor alpha (TNF-alpha), respectively, in the cell culture medium. RESULTS: Hypoxia significantly increased cellular level of HIF-1 alpha (1 hour and 4 hours), gene transcription of iNOS (4 hours and 8 hours), iNOS protein (8 hours), NO production (8 hours), and TNF-alpha secretion (4 hours and 8 hours). SAHA treatment attenuated all of the above hypoxia-induced alterations in the macrophages. In addition, SAHA treatment significantly increased cellular level of PHD2, one of the upstream negative regulators of HIF-1 alpha, at 1 hour. CONCLUSIONS: Treatment with SAHA attenuates hypoxia-HIF-1 alpha-inflammatory pathway in macrophages and suppresses hypoxia-induced release of proinflammatory NO and TNF-alpha. SAHA also causes an early increase in cellular PHD2, which provides, at least in part, a new explanation for the decrease in the HIF-1 alpha protein levels. (J Trauma. 2012; 72: 347-354. Copyright (C) 2012 by Lippincott Williams & Wilkins) C1 [Chong, Wei; Li, Yongqing; Liu, Baoling; Liu, Zhengcai; Zhao, Ting; Velmahos, George C.; deMoya, Marc A.; King, David R.; Alam, Hasan B.] Massachusetts Gen Hosp, Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA. [Wonsey, Diane R.; Chen, Changmin; Kung, Andrew L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Children Hosp, Boston, MA 02115 USA. [Chong, Wei] China Med Univ, Hosp 1, Emergency Dept, Shenyang, Peoples R China. RP Alam, HB (reprint author), Massachusetts Gen Hosp, Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02114 USA. EM hbalam@partners.org OI Kung, Andrew/0000-0002-9091-488X FU NIGMS NIH HHS [R01 GM084127, R01 GM084127-01A1, R01 GM084127-02, R01 GM084127-03, R01 GM084127-04] NR 42 TC 15 Z9 16 U1 2 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 2163-0755 J9 J TRAUMA ACUTE CARE JI J. Trauma Acute Care Surg. PD FEB PY 2012 VL 72 IS 2 BP 347 EP 353 DI 10.1097/TA.0b013e318243d8b2 PG 7 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 898ZN UT WOS:000300781000024 PM 22327976 ER PT J AU Inaba, K Lustenberger, T Recinos, G Georgiou, C Velmahos, GC Brown, C Salim, A Demetriades, D Rhee, P AF Inaba, Kenji Lustenberger, Thomas Recinos, Gustavo Georgiou, Crysanthos Velmahos, George C. Brown, Carlos Salim, Ali Demetriades, Demetrios Rhee, Peter TI Does size matter? A prospective analysis of 28-32 versus 36-40 French chest tube size in trauma SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY LA English DT Article DE Chest tube; thoracostomy tube; size; trauma; complications; retained hemothorax; residual pneumothorax; pain ID MANAGEMENT; CATHETER AB BACKGROUND: The optimal chest tube size for the drainage of traumatic hemothoraces and pneumothoraces is unknown. The purpose of this study was to compare the efficacy of small versus large chest tubes for use in thoracic trauma. Our hypothesis was that (1) there would be no difference in clinically relevant outcomes including retained hemothoraces, the need for additional tube insertion, and invasive procedures and (2) there would be an increase in pain with the insertion of large versus small tubes. METHODS: This is a prospective, institutional review board-approved observational study. All patients requiring open chest tube drainage within 12 hours of admission (January 2007-January 2010) were identified at a Level I trauma center. Clinical demographic data and outcomes including efficacy of drainage, complications, retained hemothoraces, residual pneumothoraces, need for additional tube insertion, video-assisted thoracoscopy, and thoracotomy were collected and analyzed by tube size. Small chest tubes (28-32 Fr) were compared with large (36-40 Fr). RESULTS: During the study period, a total of 353 chest tubes (small: 186; large: 167) were placed in 293 patients. Of the 275 chest tubes inserted for a hemothorax, 144 were small (52.3%) and 131 were large (47.7%). Both groups were similar in age, gender, and mechanism; however, large tubes were placed more frequently in patients with a Glasgow Coma Scale <8, severe head injury, a systolic blood pressure <90 mm Hg, and Injury Severity Score <= 25. The volume of blood drained initially and the total duration of tube placement were similar for both groups (small: 6.3 +/- 3.9 days vs. large: 6.2 +/- 3.6 days; adjusted (adj.) p = 0.427). After adjustment, no statistically significant difference in tube-related complications, including pneumonia (4.9% vs. 4.6%; adj. p = 0.282), empyema (4.2% vs. 4.6%; adj. p = 0.766), or retained hemothorax (11.8% vs. 10.7%; adj. p = 0.981), was found when comparing small versus large chest tubes. The need for tube reinsertion, image-guided drainage, video-assisted thoracoscopy, and thoracotomy was likewise the same (10.4% vs. 10.7%; adj. p = 0.719). For patients with a pneumothorax requiring chest tube drainage (n = 238), there was no difference in the number of patients with an unresolved pneumothorax (14.0% vs. 13.0%; adj. p = 0.620) or those needing reinsertion of a second chest tube. The mean visual analog pain score was similar for small and large tubes (6.0 +/- 3.3 and 6.7 +/- 3.0; p = 0.237). CONCLUSIONS: For injured patients with chest trauma, chest tube size did not impact the clinically relevant outcomes tested. There was no difference in the efficacy of drainage, rate of complications including retained hemothorax, need for additional tube drainage, or invasive procedures. Furthermore, tube size did not affect the pain felt by patients at the site of insertion. (J Trauma. 2012; 72: 422-427. Copyright (C) 2012 by Lippincott Williams & Wilkins) C1 [Inaba, Kenji; Lustenberger, Thomas; Recinos, Gustavo; Georgiou, Crysanthos; Demetriades, Demetrios] Univ So Calif, Keck Sch Med, Los Angeles Cty & Univ So Calif Med Ctr, Div Trauma & Surg Crit Care, Los Angeles, CA 90033 USA. [Velmahos, George C.] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA. [Brown, Carlos] Univ Texas SW Austin, Univ Med Ctr Brackenridge, Dept Surg, Austin, TX USA. [Salim, Ali] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA. [Rhee, Peter] Univ Arizona, Div Trauma Crit Care & Emergency Surg, Tucson, AZ USA. RP Inaba, K (reprint author), Univ So Calif, Keck Sch Med, Los Angeles Cty Univ So Calif Med Ctr, Div Trauma & Surg Crit Care,IPT, 1200 N State St,C5L100, Los Angeles, CA 90033 USA. EM kinaba@surgery.usc.edu NR 10 TC 10 Z9 14 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 2163-0755 J9 J TRAUMA ACUTE CARE JI J. Trauma Acute Care Surg. PD FEB PY 2012 VL 72 IS 2 BP 422 EP 427 DI 10.1097/TA.0b013e3182452444 PG 6 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 898ZN UT WOS:000300781000039 PM 22327984 ER PT J AU Belkora, JK Volz, S Teng, AE Moore, DH Loth, MK Sepucha, KR AF Belkora, Jeffrey K. Volz, Shelley Teng, Alexandra E. Moore, Dan H. Loth, Meredith K. Sepucha, Karen R. TI Impact of decision aids in a sustained implementation at a breast care center SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Breast cancer; Decision aids; Knowledge; Decisional conflict; Implementation; Reach; Effectiveness ID CANCER; METAANALYSIS; KNOWLEDGE; QUALITY AB Objective: We examined the reach and impact of five decision aids (DAs) routinely distributed to breast cancer patients as part of a shared decision making demonstration project. Methods: From 2005 to 2008, we surveyed patients' change in knowledge and decisional conflict (DC) before and after their review of DAs. Using bivariate tests, we identified significant predictors of change in knowledge or decisional conflict and entered significant predictors into a multivariate regression model. Results: We distributed 1553 DAs to 1098 patients and received 549 completed surveys. The DAs were associated with increased knowledge and decreased DC. For knowledge, significant predictors of above-average change included: lower baseline knowledge and viewing the surgery decision aid. For decisional conflict, significant predictors of above-average change included: higher decisional conflict; viewing any of the early-stage cancer DAs; and Hispanic ethnicity. Conclusions: DAs used in routine care were associated with significant knowledge gains and reductions in decisional conflict. Some subsets of patients (those reporting low baseline knowledge, high DC, or Hispanic ethnicity) may benefit more than others. Practice implications: Breast cancer patients benefit overall from routine distribution of DAs. Our exploratory findings may be useful in generating hypotheses to identify target populations who would most benefit from reviewing DAs. (C) 2011 Elsevier Ireland Ltd. All rights reserved. C1 [Belkora, Jeffrey K.; Volz, Shelley] Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA USA. [Teng, Alexandra E.; Loth, Meredith K.] Univ Calif San Francisco, CFB Breast Care Ctr, San Francisco, CA 94143 USA. [Moore, Dan H.] Univ Calif San Francisco, HDF Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Sepucha, Karen R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Belkora, JK (reprint author), 3333 Calif St,Suite 265, San Francisco, CA 94121 USA. EM jeff.belkora@ucsf.edu FU Foundation for Informed Medical Decision Making [0015]; UCSF Breast Care Center FX The Foundation for Informed Medical Decision Making develops the breast cancer decision aids and provides funding for Decision Services' core operations and data collection. The UCSF Breast Care Center funds our field operations. We are also sustained by gifts and donations from individuals and organizations including the Safeway Foundation and Wells Fargo.; The Foundation for Informed Medical Decision Making (grant 0015) provided funding for this study. Authors JB, SV, AT, and ML drew partial salary support from a demonstration project grant provided by the Foundation for Informed Medical Decision Making. Author KS also receives salary support and research funding from the Foundation for other projects. The Foundation is a non-profit corporation that co-develops the breast cancer decision aids described in this report, and supplies them at no charge to the Decision Services unit of the UCSF Breast Care Center as part of the Foundation's research agenda. The decision aids are co-developed and distributed commercially by Health Dialog, a subsidiary of Bupa Health Assurance Limited, a global provider of health services based in the United Kingdom. The funding sources had no involvement in any aspect of this study. NR 21 TC 15 Z9 15 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD FEB PY 2012 VL 86 IS 2 BP 195 EP 204 DI 10.1016/j.pec.2011.05.011 PG 10 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 904QN UT WOS:000301213100010 PM 21665420 ER PT J AU Iwami, S Haeno, H Michor, F AF Iwami, Shingo Haeno, Hiroshi Michor, Franziska TI A Race between Tumor Immunoescape and Genome Maintenance Selects for Optimum Levels of (epi)genetic Instability SO PLOS COMPUTATIONAL BIOLOGY LA English DT Article ID NATURAL-KILLER-CELLS; DELTA-T-CELLS; ERROR CATASTROPHE; IMMUNODEFICIENCY VIRUS; GENETIC INSTABILITY; IMMUNE SURVEILLANCE; MATHEMATICAL-MODEL; COLORECTAL-CANCER; NKT CELLS; ESCAPE AB The human immune system functions to provide continuous body-wide surveillance to detect and eliminate foreign agents such as bacteria and viruses as well as the body's own cells that undergo malignant transformation. To counteract this surveillance, tumor cells evolve mechanisms to evade elimination by the immune system; this tumor immunoescape leads to continuous tumor expansion, albeit potentially with a different composition of the tumor cell population ("immunoediting"). Tumor immunoescape and immunoediting are products of an evolutionary process and are hence driven by mutation and selection. Higher mutation rates allow cells to more rapidly acquire new phenotypes that help evade the immune system, but also harbor the risk of an inability to maintain essential genome structure and functions, thereby leading to an error catastrophe. In this paper, we designed a novel mathematical framework, based upon the quasispecies model, to study the effects of tumor immunoediting and the evolution of (epi)genetic instability on the abundance of tumor and immune system cells. We found that there exists an optimum number of tumor variants and an optimum magnitude of mutation rates that maximize tumor progression despite an active immune response. Our findings provide insights into the dynamics of tumorigenesis during immune system attacks and help guide the choice of treatment strategies that best inhibit diverse tumor cell populations. C1 [Iwami, Shingo] Kyoto Univ, Inst Virus Res, Univ Tokyo, Japan Sci & Technol Agcy,Grad Sch Math Sci,PRESTO, Kyoto 606, Japan. [Haeno, Hiroshi; Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Haeno, Hiroshi; Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Iwami, S (reprint author), Kyoto Univ, Inst Virus Res, Univ Tokyo, Japan Sci & Technol Agcy,Grad Sch Math Sci,PRESTO, Kyoto 606, Japan. EM michor@jimmy.harvard.edu FU JST PRESTO; National Cancer Institute's initiative to found Physical Sciences-Oncology Centers [U54CA143798] FX This work was supported by the JST PRESTO program (S. I.) and the National Cancer Institute's initiative to found Physical Sciences-Oncology Centers (U54CA143798) (H. H., F. M.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 52 TC 6 Z9 6 U1 2 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-734X J9 PLOS COMPUT BIOL JI PLoS Comput. Biol. PD FEB PY 2012 VL 8 IS 2 AR e1002370 DI 10.1371/journal.pcbi.1002370 PG 12 WC Biochemical Research Methods; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Mathematical & Computational Biology GA 898HA UT WOS:000300729900015 PM 22359489 ER PT J AU Pei, L Gaisser, S Schmidt, M AF Pei, Lei Gaisser, Sibylle Schmidt, Markus TI Synthetic biology in the view of European public funding organisations SO PUBLIC UNDERSTANDING OF SCIENCE LA English DT Article DE ELSI; public funding; science funding; science policy; synthetic biology AB We analysed the decisions of major European public funding organisations to fund or not to fund synthetic biology (SB) and related ethical, legal and social implication (ELSI) studies. We investigated the reaction of public organisations in six countries (Austria, France, Germany, the Netherlands, Switzerland and the UK) towards SB that may influence SB's further development in Europe. We examined R&D and ELSI communities and their particular funding situation. Our results show that the funding situation for SB varies considerably among the analysed countries, with the UK as the only country with an established funding scheme for R&D and ELSI that successfully integrates these research communities. Elsewhere, we determined a general lack of funding (France), difficulties in funding ELSI work (Switzerland), lack of an R&D community (Austria), too small ELSI communities (France, Switzerland, Netherlands), or difficulties in linking existing communities with available funding sources (Germany), partly due to an unclear SB definition. C1 [Schmidt, Markus] Org Int Dialogue & Conflict Management, Biosafety Working Grp, A-1070 Vienna, Austria. [Pei, Lei] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis,Dept Med, Boston, MA USA. RP Schmidt, M (reprint author), Org Int Dialogue & Conflict Management, Biosafety Working Grp, Kaiserstr 50-6, A-1070 Vienna, Austria. EM markus.schmidt@idialog.eu NR 14 TC 5 Z9 5 U1 1 U2 11 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0963-6625 J9 PUBLIC UNDERST SCI JI Public Underst. Sci. PD FEB PY 2012 VL 21 IS 2 SI SI BP 149 EP 162 DI 10.1177/0963662510393624 PG 14 WC Communication; History & Philosophy Of Science SC Communication; History & Philosophy of Science GA 904JU UT WOS:000301191900003 PM 22586841 ER PT J AU ElBardissi, AW Sundt, TM AF ElBardissi, Andrew W. Sundt, Thoralf M. TI Human Factors and Operating Room Safety SO SURGICAL CLINICS OF NORTH AMERICA LA English DT Article DE Human factors; Operating room; Safety ID CARDIAC-SURGERY; SURGICAL FLOW; ERRORS; COMMUNICATION; PERFORMANCE; QUALITY; CLASSIFICATION; DISRUPTIONS; TECHNOLOGY; FAILURES AB A human factors model is used to highlight the nature of many systems factors that affect surgical performance, including the OR environment, teamwork and communication, technology and equipment, tasks and workload factors, and organizational variables. If further improvements in the success rate and reliability of cardiac surgery are to be realized, interventions need to be developed to reduce the negative impact that work system failures can have on surgical performance. Some recommendations are proposed here; however, several challenges remain. C1 [ElBardissi, Andrew W.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiac Surg, Boston, MA 02115 USA. [ElBardissi, Andrew W.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [ElBardissi, Andrew W.] Harvard Univ, Sch Med, Ctr Surg & Publ Hlth, Boston, MA 02115 USA. [Sundt, Thoralf M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiac Surg, Boston, MA 02115 USA. RP ElBardissi, AW (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiac Surg, 75 Francis St, Boston, MA 02115 USA. EM aelbardissi@partners.org FU Agency for Health Care Research Quality NRSA [1F32HS019190]; Brigham and Women's Hospital; Center for Surgery and Public Health FX Supported by the Agency for Health Care Research Quality NRSA Grant 1F32HS019190 and the Arthur and Tracy Cabot Fellowship at Brigham and Women's Hospital and the Center for Surgery and Public Health. NR 41 TC 13 Z9 14 U1 2 U2 11 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0039-6109 J9 SURG CLIN N AM JI Surg. Clin.-North Am. PD FEB PY 2012 VL 92 IS 1 BP 21 EP + DI 10.1016/j.suc.2011.11.007 PG 16 WC Surgery SC Surgery GA 903XZ UT WOS:000301157800005 PM 22269258 ER PT J AU Schmader, KE Hanlon, JT AF Schmader, Kenneth E. Hanlon, Joseph T. TI Goodbyes, Hellos, and Changes SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Editorial Material C1 [Schmader, Kenneth E.] Duke Univ, Med Ctr, Geriatr Res Educ & Clin Ctr,Dept Med, Ctr Study Aging & Human Dev,Durham VA Med Ctr, Durham, NC 27706 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Med, Div Pharm & Therapeut,Div Geriatr Med, Pittsburgh, PA 15260 USA. [Hanlon, Joseph T.] VA Pittsburgh Healthcare Syst, Geriatr Res & Educ & Clin Ctr, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. RP Schmader, KE (reprint author), Duke Univ, Med Ctr, Geriatr Res Educ & Clin Ctr,Dept Med, Ctr Study Aging & Human Dev,Durham VA Med Ctr, Durham, NC 27706 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD FEB PY 2012 VL 10 IS 1 BP 1 EP 1 PG 1 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 900CJ UT WOS:000300863900001 ER PT J AU Thorpe, CT Lassila, HC O'Neil, CK Thorpe, JM Hanlon, JT Maher, RL AF Thorpe, Carolyn T. Lassila, Holly C. O'Neil, Christine K. Thorpe, Joshua M. Hanlon, Joseph T. Maher, Robert L. TI Reconsideration of Key Articles Regarding Medication-Related Problems in Older Adults from 2011 SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Editorial Material ID ADVERSE DRUG EVENTS; OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; FLEETWOOD NORTHERN-IRELAND; POPULATION-BASED COHORT; NURSING-HOME RESIDENTS; D PRESCRIPTION BENEFIT; ELDERLY-PATIENTS; PART-D; CARE HOMES C1 [Thorpe, Carolyn T.; Thorpe, Joshua M.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. [Thorpe, Carolyn T.; Thorpe, Joshua M.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Hlth Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Lassila, Holly C.; O'Neil, Christine K.; Maher, Robert L.] Duquesne Univ, Sch Pharm, Div Clin Social & Adm Sci, Pittsburgh, PA 15219 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Hlth Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Hanlon, JT (reprint author), Univ Pittsburgh, Dept Med Geriatr, 3471 5th Ave,Kaufman Bld,Suite 500, Pittsburgh, PA 15213 USA. EM jth14@pitt.edu RI Thorpe, Joshua/C-1188-2013 FU AHRQ HHS [R01 HS018721, K12 HS019461, R01 HS017695]; NIA NIH HHS [K07AG033174, R56 AG027017, R56AG027017, R01AG034056, T32 AG021885, K07 AG033174, P30 AG024827, P30AG024827, R01 AG034056]; NIDDK NIH HHS [R21 DK090634, R21DK090634]; NINR NIH HHS [R01 NR010135, R01NR010135] NR 132 TC 1 Z9 1 U1 3 U2 14 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD FEB PY 2012 VL 10 IS 1 BP 2 EP 13 DI 10.1016/j.amjopharm.2012.01.004 PG 12 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 900CJ UT WOS:000300863900002 PM 22330099 ER PT J AU Chodosh, J Pearson, ML Connor, KI Vassar, SD Kaisey, M Lee, ML Vickrey, BG AF Chodosh, Joshua Pearson, Marjorie L. Connor, Karen I. Vassar, Stefanie D. Kaisey, Marwa Lee, Martin L. Vickrey, Barbara G. TI A Dementia Care Management Intervention: Which Components Improve Quality? SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID MANAGING ALZHEIMERS-DISEASE; RANDOMIZED CONTROLLED-TRIAL; OF-CARE; COORDINATION; CAREGIVERS; PERCEPTIONS; GUIDELINES; OUTCOMES; ILLNESS AB Objectives: To analyze whether types of providers and frequency of encounters are associated with higher quality of care within a coordinated dementia care management (CM) program for patients and caregivers. Design: Secondary analysis of intervention-arm data from a dementia CM cluster-randomized trial, where intervention participants interacted with healthcare organization care managers (HOCMs), community agency care managers (CACMs), and/or healthcare organization primary care providers (HOPCPs) over 18 months. Methods: Encounters of 238 patient/caregivers (dyads) with HOCMs, CACMs, and HOPCPs were abstracted from care management electronic records. The quality domains of assessment, treatment, education/support, and safety were measured from medical record abstractions and caregiver surveys. Mean percentages of met quality indicators associated with exposures to each provider type and frequency were analyzed using multivariable regression, adjusting for participant characteristics and baseline quality. Results: As anticipated, for all 4 domains, the mean percentage of met dementia quality indicators was 15.510 47.2 percentage points higher for dyads with HOCM-only exposure than for dyads with none (all P < .008); not anticipated were higher mean percentages with increasing combinations of provider-type exposure-up to 73.7 percentage points higher for safety (95% confidence interval 65.2%-82.1%) with exposure to all 3 provider types compared with no exposure. While greater frequency of HOCM-dyad encounters was associated with higher quality (P <=.04) this was not so for other provider types. Conclusions: HOCMs' interactions with dyads was essential for dementia care quality improvement. Additional coordinated interactions with primary care and community agency staff yielded even higher quality. (Am J Manag Care. 2012;18(2)85-94) C1 [Chodosh, Joshua] VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Sepulveda, CA USA. [Chodosh, Joshua] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA. [Connor, Karen I.; Vassar, Stefanie D.; Vickrey, Barbara G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. RAND Hlth, Santa Monica, CA USA. [Connor, Karen I.; Vassar, Stefanie D.; Vickrey, Barbara G.] VA Greater Los Angeles Healthcare Syst, Parkinsons Dis Res Educ & Clin Ctr, Los Angeles, CA USA. [Kaisey, Marwa] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Lee, Martin L.] VA Greater Los Angeles Healthcare Syst, Sepulveda Ctr Excellence, Hlth Serv Res & Dev Serv, Sepulveda, CA USA. RP Chodosh, J (reprint author), 11301 Wilshire Blvd 11G, Los Angeles, CA 90073 USA. EM jchodosh@mednet.ucla.edu FU California Department of Public Health [07-65800]; State of California Department of Aging [IG-0001-22]; California HealthCare Foundation [99-3020]; State of California Department of Health Services Alzheimer's Disease Education Initiative; State of California Department of Public Health [06-55314] FX This study was supported by the California Department of Public Health (contract 07-65800). The ACCESS project was funded by the State of California Department of Aging (IG-0001-22); the California HealthCare Foundation (contract 99-3020); the State of California Department of Health Services Alzheimer's Disease Education Initiative; and the State of California Department of Public Health (contract 06-55314) for the University of California, Los Angeles Alzheimer's Disease Research Center. NR 29 TC 13 Z9 13 U1 3 U2 7 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD FEB PY 2012 VL 18 IS 2 BP 85 EP 94 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 903BE UT WOS:000301089200002 PM 22435836 ER PT J AU Kachroo, A Schwarzschild, MA AF Kachroo, Anil Schwarzschild, Michael A. TI Adenosine A2A receptor gene disruption protects in an a-synuclein model of Parkinson's disease SO ANNALS OF NEUROLOGY LA English DT Article ID HUMAN ALPHA-SYNUCLEIN; TRANSGENIC MICE; CAFFEINE; NEUROPROTECTION; PROTEASOME; INSIGHTS AB To investigate the putative interaction between chronic exposure to adenosine receptor antagonist caffeine and genetic influences on Parkinson's disease (PD), we determined whether deletion of the adenosine A2A receptor in knockout (KO) mice protects against dopaminergic neuron degeneration induced by a mutant human a-synuclein (hm2-aSYN) transgene containing both A53T and A30P. The A2A KO completely prevented loss of dopamine and dopaminergic neurons caused by the mutant a-synuclein transgene without altering levels of its expression. The adenosine A2A receptor appears required for neurotoxicity in a mutant a-synuclein model of PD. Together with prior studies the present findings indirectly support the neuroprotective potential of caffeine and more specific A2A antagonists. Ann Neurol 2012;71:278282 C1 Massachusetts Gen Hosp, Dept Neurol, MassGeneral Inst Neurodegenerat Dis, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Kachroo, A (reprint author), Massachusetts Gen Hosp, MassGeneral Inst Neurodegenerat Dis, Dept Neurol, 114 St, Charlestown, MA 02129 USA. EM akachroo@partners.org FU National Institutes of Health [NIEHS R01ES010804, NINDS K24NS060991, R21NS058324, R01ES010804, K24NS060991]; American Federation for Aging Research; Department of Defense [W81XWH-04-1-0881]; DOD [W81XWH-04-1-0881] FX This research was supported by grants (to MAS) from the National Institutes of Health (NIEHS R01ES010804, and NINDS K24NS060991, R21NS058324); the American Federation for Aging Research/Paul Beeson Scholars Program; and the Department of Defense (W81XWH-04-1-0881).; A. K. and M. A. S. have received the following grants: NIH R01ES010804, K24NS060991, R21NS058324, AFAR/Beeson Scholar program, DOD W81XWH-04-1-0881. NR 17 TC 21 Z9 21 U1 0 U2 15 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD FEB PY 2012 VL 71 IS 2 BP 278 EP 282 DI 10.1002/ana.22630 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 898DJ UT WOS:000300715300016 PM 22367999 ER PT J AU Seifarth, H Schlett, CL Truong, QA Hoffmann, U AF Seifarth, Harald Schlett, Christopher L. Truong, Quynh A. Hoffmann, Udo TI Cardiac CT in the Emergency Department SO CARDIOLOGY CLINICS LA English DT Article DE Cardiac computed tomography; Emergency department; Acute coronary syndrome; Triage ID CORONARY-ARTERY-DISEASE; ACUTE CHEST-PAIN; ACUTE MYOCARDIAL-INFARCTION; MULTIDETECTOR COMPUTED-TOMOGRAPHY; LOW-RISK PATIENTS; DUAL-SOURCE CT; INCREMENTAL PROGNOSTIC VALUE; RANDOMIZED CONTROLLED-TRIAL; OPTICAL COHERENCE TOMOGRAPHY; LEFT-VENTRICULAR FUNCTION AB Current triage strategies are not effective in correctly identifying patients suffering from acute coronary syndrome (ACS). The diagnostic workup of patients presenting with acute chest pain continues to represent a major challenge for emergency department (ED) personnel. This statement holds especially true for patients with a low to intermediate likelihood for ACS. Taking current concepts for the diagnosis and management of patients presenting with acute chest pain to the ED into account, this article discusses the evidence and potential role of coronary computed tomography angiography to improve management of patients with possible ACS. C1 [Seifarth, Harald; Schlett, Christopher L.; Truong, Quynh A.; Hoffmann, Udo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac MR PET CT Program, Boston, MA 02114 USA. [Seifarth, Harald] Univ Munster, Dept Clin Radiol, D-48149 Munster, Germany. RP Hoffmann, U (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac MR PET CT Program, 165 Cambridge St, Boston, MA 02114 USA. EM uhoffmann@partners.org NR 123 TC 0 Z9 0 U1 3 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8651 J9 CARDIOL CLIN JI Cardiol. Clin. PD FEB PY 2012 VL 30 IS 1 BP 117 EP + DI 10.1016/j.ccl.2011.12.001 PG 18 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 902ZL UT WOS:000301082600012 PM 22304954 ER PT J AU Wecht, JM Rosado-Rivera, D Jegede, A Cirnigliaro, CM Jensen, MA Kirshblum, S Bauman, WA AF Wecht, Jill M. Rosado-Rivera, Dwindally Jegede, Adejoke Cirnigliaro, Christopher M. Jensen, Marley A. Kirshblum, Steve Bauman, William A. TI Systemic and cerebral hemodynamics during cognitive testing SO CLINICAL AUTONOMIC RESEARCH LA English DT Article DE Paraplegia; Tetraplegia; Blood pressures; Transcranial Doppler ultrasound; Cerebral blood flow; Mental stimulation ID SPINAL-CORD-INJURY; BLOOD-FLOW VELOCITY; WHITE-MATTER HYPERINTENSITIES; CLOSED HEAD-INJURY; TRANSCRANIAL DOPPLER; ORTHOSTATIC HYPOTENSION; ARTERIAL STIFFNESS; MENTAL STRESS; OLDER-ADULTS; PERFORMANCE AB Objective Cognitive deficits are reported in 10-60% of individuals with SCI, the primary etiology of these deficits is believed to be concomitant traumatic brain injury (TBI). We recently documented diminished memory and marginally deficient attention and processing speed in individuals with SCI discordant for hypotension but matched for TBI. Methods Twenty-nine individuals participated: 16 non-SCI controls, 6 paraplegic (T2-T10) and 7 tetraplegic (C4-C8). The Stroop test was used to measure cognitive function and transcranial Doppler ultrasound was used to measure cerebral blood flow (CBF) while resting (5 min) and continuously during cognitive testing. Mean arterial pressure (MAP) was calculated from three brachial blood pressures and cerebral vascular resistance index was calculated as: CVRi = MAP/CBF. Results The paraplegia group (54 +/- 6) was marginally older than the non-SCI (42 +/- 15; p = 0.06) and tetraplegic (42 +/- 11; p = 0.09) groups. Compared to non-SCI group, normalized t-score on the Stroop Color (SC) task was significantly lower in the paraplegic group (p < 0.05). In the tetraplegic group, MAP was significantly lower (p < 0.05) than the non-SCI and paraplegic groups, and related to SC t-score (r(2) = 0.873; p < 0.01). In the paraplegic group, CBF was reduced (p < 0.05) and CVRi increased (p < 0.05) compared to the non-SCI group, and CVRi was increased compared to the tetraplegic group (p < 0.05). A significant inverse relationship was noted between change in CVRi and SC t-score in the non-SCI group. Conclusion Asymptomatic hypotension relates to cognitive performance in persons with tetraplegia; therefore, BP normalization should be considered. The inappropriate cerebral vascular response to cognitive testing and poor test performance should be investigated in persons with paraplegia. C1 [Wecht, Jill M.; Rosado-Rivera, Dwindally; Jegede, Adejoke; Cirnigliaro, Christopher M.; Jensen, Marley A.; Bauman, William A.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA. [Wecht, Jill M.; Bauman, William A.] James J Peters VAMC, Med Serv, Bronx, NY USA. [Wecht, Jill M.; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Wecht, Jill M.; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [Cirnigliaro, Christopher M.; Jensen, Marley A.; Kirshblum, Steve] Kessler Inst Rehabil, W Orange, NJ USA. RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Rm 7A-13,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM jm.wecht@va.gov FU Veterans Affairs Rehabilitation Research and Development Service [A6161W, B3203R, B4162C]; NIH; NHS FX This research was supported by the Veterans Affairs Rehabilitation Research and Development Service (grant no. A6161W, B3203R and B4162C).; We certify that no party having a direct interest in the results of the research supporting this article has or will confer a benefit on us or on any organization with which we are associated AND, if applicable, we certify that all financial and material support for this research (e. g., NIH or NHS grants) and work are clearly identified in the title page of the manuscript. NR 66 TC 9 Z9 9 U1 1 U2 4 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0959-9851 J9 CLIN AUTON RES JI Clin. Auton. Res. PD FEB PY 2012 VL 22 IS 1 BP 25 EP 33 DI 10.1007/s10286-011-0139-1 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 899XE UT WOS:000300849200004 PM 21792728 ER PT J AU Day, KV Kautz, SA Wu, SS Suter, SP Behrman, AL AF Day, Kristin V. Kautz, Steven A. Wu, Samuel S. Suter, Sarah P. Behrman, Andrea L. TI Foot placement variability as a walking balance mechanism post-spinal cord injury SO CLINICAL BIOMECHANICS LA English DT Article DE Spinal cord injury; Walking; Balance; Margin of stability; Variability ID DYNAMIC STABILITY; RECOVERY; RELIABILITY; VALIDITY; FALLS AB Background: Spinal cord injury affects walking balance control, which necessitates methods to quantify balance ability. The purposes of this study were to 1) examine walking balance through foot placement variability post-injury; 2) assess the relationship between measures of variability and clinical balance assessments; and 3) determine if spatial parameter variability might be used as a clinical correlate for more complex balance measurements. Methods: Ten persons with spinal cord injury walked without devices on a split-belt treadmill at self-selected speeds. Ten healthy controls walked at 03 and 0.6 m/s for comparison. Variability of step width and length, anteroposterior and mediolateral foot placements relative to center-of-mass, and margin-of-stability were calculated. Clinical assessments included Berg Balance Scale and Dynamic Gait Index. Findings: Participants with spinal cord injury demonstrated significantly different variability in all biomechanical measures compared to controls (P <= 0.007). Berg Balance Scale scores were significantly inversely associated with step length as well as anteroposterior and mediolateral foot placement variability (P <= 0.05). Dynamic Gait Index scores were significantly inversely associated with mediolateral foot placement variability (P <= 0.05). Participants with spinal cord injury showed significant correlations between spatial parameter variability and all other measures (P <= 0.005), except between step length and margin-of-stability (P=0.068); controls revealed fewer correlations. Interpretation: Persons post-spinal cord injury exhibit an abnormal amount of stepping variability when challenged to walk without devices, yet preserve the ability to avoid falling. When complex laboratory measures of variability are unavailable clinically, spatial parameter variability or standardized balance assessments may be plausible indicators of walking balance control. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Day, Kristin V.] Cardinal Hill Rehabil Hosp, Lexington, KY 40504 USA. [Day, Kristin V.] Univ Kentucky, Dept Rehabil Sci, Lexington, KY USA. [Day, Kristin V.; Suter, Sarah P.; Behrman, Andrea L.] Univ Florida, Dept Phys Therapy, Gainesville, FL USA. [Day, Kristin V.; Kautz, Steven A.; Suter, Sarah P.; Behrman, Andrea L.] Malcom G Randall VA Med Ctr, Brain Rehabil Res Ctr, Gainesville, FL USA. [Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Kautz, Steven A.] Med Univ S Carolina, Div Phys Therapy, Charleston, SC 29425 USA. [Kautz, Steven A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Wu, Samuel S.] Univ Florida, Dept Epidemiol & Hlth Policy Res, Gainesville, FL USA. [Wu, Samuel S.] Malcom G Randall VA Med Ctr, Rehabil Outcomes Res Ctr, Gainesville, FL USA. [Suter, Sarah P.] Univ Florida, Shands Hosp, Dept Rehabil Serv, Gainesville, FL USA. [Behrman, Andrea L.] Univ Florida, McKnight Brain Inst, Gainesville, FL USA. RP Day, KV (reprint author), Cardinal Hill Rehabil Hosp, 2050 Versailles Rd, Lexington, KY 40504 USA. EM kvd2@cardinalhill.org; kautz@musc.edu; samwu@biostat.ufl.edu; spstic@phhp.ufl.edu; abehrman@phhp.ufl.edu OI Kautz, Steven/0000-0003-3151-8235 FU Human Motor Performance Laboratory engineering; VA RRD [B40241]; NIH [R01HD46820, 132 HD043730]; Florida Department of Health Brain and Spinal Cord Injury; Rehabilitation Research & Development Service of the VA FX The authors would like to thank members of the Locomotor Training Research and Recovery Team for assistance with data collection as well as the Human Motor Performance Laboratory engineering support for assistance with data processing. We would also like to acknowledge Yunfeng Dai, MS, for assistance with statistical analysis programming. The following grant funding mechanisms supported production of this work: VA RR&D B40241, NIH R01HD46820, NIH 132 HD043730, the Florida Department of Health Brain and Spinal Cord Injury Program ECRRA, and the Rehabilitation Research & Development Service of the VA. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH, NICHD, Department of VA, or U.S. Government. NR 25 TC 11 Z9 11 U1 3 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0268-0033 J9 CLIN BIOMECH JI Clin. Biomech. PD FEB PY 2012 VL 27 IS 2 BP 145 EP 150 DI 10.1016/j.clinbiomech.2011.09.001 PG 6 WC Engineering, Biomedical; Orthopedics; Sport Sciences SC Engineering; Orthopedics; Sport Sciences GA 899IW UT WOS:000300810600007 PM 22000699 ER PT J AU Dai, TH Vrahas, MS Murray, CK Hamblin, MR AF Dai, Tianhong Vrahas, Mark S. Murray, Clinton K. Hamblin, Michael R. TI Ultraviolet C irradiation: an alternative antimicrobial approach to localized infections? SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY LA English DT Review DE antibiotic resistance; bacteria; DNA repair; fungi; localized infections; mammalian cells; resistance to UVC; ultraviolet C irradiation; wound healing; wound infection ID HUMAN SKIN; ESCHERICHIA-COLI; IN-VIVO; 254 NM; LIGHT; RADIATION; DISINFECTION; INACTIVATION; PHOTOTHERAPY; EXPOSURE AB This review discusses the potential of ultraviolet C (UVC) irradiation as an alternative approach to current methods used to treat localized infections. It has been reported that multidrug-resistant microorganisms are equally sensitive to UVC irradiation as their wild-type counterparts. With appropriate doses, UVC may selectively inactivate microorganisms while preserving viability of mammalian cells and, moreover, is reported to promote wound healing. UVC is also found in animal studies to be less damaging to tissue than UVB. Even though UVC may produce DNA damage in mammalian cells, it can be rapidly repaired by DNA repair enzymes. If UVC irradiation is repeated excessively, resistance of microorganisms to UVC inactivation may develop. In summary, UVC should be investigated as an alternative approach to current methods used to treat localized infections, especially those caused by multidrug-resistant microorganisms. UVC should be used in a manner such that the side effects would be minimized and resistance of microorganisms to UVC would be avoided. C1 [Dai, Tianhong; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Dai, Tianhong; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Vrahas, Mark S.] Massachusetts Gen Hosp, Dept Orthoped Surg, Boston, MA 02114 USA. [Murray, Clinton K.] Brooke Army Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA. [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA. EM hamblin@helix.mgh.harvard.edu OI Hamblin, Michael/0000-0001-6431-4605 FU Airlift Research Foundation [109421]; NIH [RO1AI050875] FX This study was supported in part by an Airlift Research Foundation Extremity Trauma Research Grant (grant #109421 to T Dai) and the NIH (grant RO1AI050875 to MRH). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 48 TC 26 Z9 27 U1 1 U2 12 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1478-7210 J9 EXPERT REV ANTI-INFE JI Expert Rev. Anti-Infect. Ther. PD FEB PY 2012 VL 10 IS 2 BP 185 EP 195 DI 10.1586/ERI.11.166 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 900VN UT WOS:000300919700014 PM 22339192 ER PT J AU Carvajal-Cuenca, A Sua, LF Silva, NM Pittaluga, S Royo, C Song, JY Sargent, RL Espinet, B Climent, F Jacobs, SA Delabie, J Naresh, KN Bagg, A Brousset, P Warnke, RA Serrano, S Harris, NL Swerdlow, SH Jaffe, ES Campo, E AF Carvajal-Cuenca, Alejandra Sua, Luz F. Silva, Nhora M. Pittaluga, Stefania Royo, Cristina Song, Joo Y. Sargent, Rachel L. Espinet, Blanca Climent, Fina Jacobs, Samuel A. Delabie, Jan Naresh, Kikkeri N. Bagg, Adam Brousset, Pierre Warnke, Roger A. Serrano, Sergi Harris, Nancy Lee Swerdlow, Steven H. Jaffe, Elaine S. Campo, Elias TI In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL LA English DT Article DE in situ mantle cell lymphoma; in situ involvement by mantle cell-lymphoma-like cells; indolent behavior ID FOLLICULAR LYMPHOMA; HEALTHY-INDIVIDUALS; NUCLEAR EXPRESSION; INVOLVEMENT; PATTERN; FEATURES; DISEASE; GENES; STAGE; ZONE AB Background Cyclin D1-positive B cells are occasionally found in the mantle zones of reactive lymphoid follicles, a condition that has been called "in situ mantle cell lymphoma". The clinical significance of this lesion remains uncertain. Design and Methods The clinical and pathological characteristics, including SOX11 expression, of 23 cases initially diagnosed as in situ mantle cell lymphoma were studied. Results Seventeen of the 23 cases fulfilled the criteria for in situ mantle cell lymphoma. In most cases, the lesions were incidental findings in reactive lymph nodes. The t(11; 14) was detected in all eight cases examined. SOX11 was positive in seven of 16 cases (44%). Five cases were associated with other small B-cell lymphomas. In two cases, both SOX11-positive, the in situ mantle cell lymphoma lesions were discovered after the diagnosis of overt lymphoma; one 4 years earlier, and one 3 years later. Twelve of the remaining 15 patients had a follow-up of at least 1 year (median 2 years; range, 1-19.5), of whom 11 showed no evidence of progression, including seven who were not treated. Only one of 12 patients with an in situ mantle cell lymphoma lesion and no diagnosis of mantle cell lymphoma at the time developed an overt lymphoma, 4 years later; this case was also SOX11-positive. The six remaining cases were diagnosed as mantle cell lymphoma with a mantle zone pattern. Five were SOX11-positive and four of them were associated with lymphoma without a mantle zone pattern. Conclusions In situ mantle cell lymphoma lesions are usually an incidental finding with a very indolent behavior. These cases must be distinguished from mantle cell lymphoma with a mantle zone pattern and overt mantle cell lymphoma because they may not require therapeutic intervention. C1 [Campo, Elias] Univ Barcelona, Hosp Clin, IDIBAPS, Dept Anat Pathol, E-08036 Barcelona, Spain. [Pittaluga, Stefania; Song, Joo Y.; Jaffe, Elaine S.] NCI, Bethesda, MD 20892 USA. [Sargent, Rachel L.; Jacobs, Samuel A.; Swerdlow, Steven H.] Univ Pittsburgh, Pittsburgh, PA USA. [Espinet, Blanca; Serrano, Sergi] Autonomous Univ Barcelona, Hosp Mar, Barcelona, Spain. [Climent, Fina] Bellvitge Univ Hosp, Barcelona, Spain. [Delabie, Jan] Oslo Univ Hosp, Oslo, Norway. [Naresh, Kikkeri N.] Hammersmith Hosp, London, England. [Bagg, Adam] Hosp Univ Penn, Philadelphia, PA 19104 USA. [Brousset, Pierre] Univ Toulouse, CHU Purpan, Toulouse, France. [Warnke, Roger A.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Harris, Nancy Lee] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Campo, E (reprint author), Univ Barcelona, Hosp Clin, IDIBAPS, Dept Anat Pathol, Villarroel 170, E-08036 Barcelona, Spain. EM ecampo@clinic.ub.es RI Royo, Cristina/H-3193-2015; Song, Joo/E-5356-2016; OI Royo, Cristina/0000-0002-1214-4656; Song, Joo/0000-0003-3497-2513; Delabie, Jan/0000-0001-5023-0689; Sua, Luz F/0000-0001-9574-2370; Jaffe, Elaine/0000-0003-4632-0301; Campo, elias/0000-0001-9850-9793 FU European Regional Development Fund; Comision Interministerial de Ciencia y Tecnologia (CICYT) [SAF08-03630]; Red Tematica de Investigacion Cooperativa en Cancer (RTICC) [RD06/0020/0039]; Instituto de Salud Carlos III (ISCIII); Spanish Ministry of Science and Innovation; Generalitat de Catalunya [2009SGR992]; University of Costa Rica (UCR); Centro de Desarrollo Estrategico e Informacion en Salud y Seguridad Social (CENDEISSS) of Costa Rica FX this work was supported by grants from the European Regional Development Fund; the Comision Interministerial de Ciencia y Tecnologia (CICYT) SAF08-03630; RD06/0020/0039 from Red Tematica de Investigacion Cooperativa en Cancer (RTICC); Instituto de Salud Carlos III (ISCIII); Spanish Ministry of Science and Innovation, and the Generalitat de Catalunya 2009SGR992. AC-C has received a fellowship from the University of Costa Rica (UCR) and the Centro de Desarrollo Estrategico e Informacion en Salud y Seguridad Social (CENDEISSS) of Costa Rica. NR 33 TC 39 Z9 45 U1 1 U2 3 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOL-HEMATOL J JI Haematol-Hematol. J. PD FEB PY 2012 VL 97 IS 2 BP 270 EP 278 DI 10.3324/haematol.2011.052621 PG 9 WC Hematology SC Hematology GA 898UB UT WOS:000300766300024 PM 22058203 ER PT J AU Sostman, HD Jablonski, KA Woodard, PK Stein, PD Naidich, DP Chenevert, TL Weg, JG Hales, CA Hull, RD Goodman, LR Tapson, VF AF Sostman, H. Dirk Jablonski, Kathleen A. Woodard, Pamela K. Stein, Paul D. Naidich, David P. Chenevert, Thomas L. Weg, John G. Hales, Charles A. Hull, Russell D. Goodman, Lawrence R. Tapson, Victor F. TI Factors in the technical quality of gadolinium enhanced magnetic resonance angiography for pulmonary embolism in PIOPED III SO INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING LA English DT Article DE Pulmonary MR angiography; Image quality; Pulmonary embolism; Artifacts ID MR-ANGIOGRAPHY AB In a multi-center trial, gadolinium enhanced magnetic resonance angiography (MRA) for diagnosis of acute pulmonary embolism (PE) had a high rate of technically inadequate images. Accordingly, we evaluated the reasons for poor quality MRA of the pulmonary arteries in these patients. We performed a retrospective analysis of the data collected in the PIOPED III study. We assessed the relationship to the proportion of examinations deemed "uninterpretable" by central readers to the clinical centers, MR equipment platform and vendors, degree of vascular opacification in different orders of pulmonary arteries; type, frequency and severity of image artifacts; patient co-morbidities, symptoms and signs; and reader characteristics. Centers, MR equipment vendor and platform, degree of vascular opacification, and motion artifacts influenced the likelihood of central reader determinations that images were "uninterpretable". Neither the reader nor patient characteristics (age, body mass index, respiratory rate, heart rate) correlated with the likelihood of determining examinations "uninterpretable". Vascular opacification and motion artifact are the principal factors influencing MRA interpretability. Some centers obtain better images more consistently, but the reasons for differences between centers are unclear. C1 [Woodard, Pamela K.] Washington Univ, Sch Med, Dept Radiol, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA. [Sostman, H. Dirk] Weill Cornell Med Coll, Off Dean, Houston, TX USA. [Sostman, H. Dirk] Weill Cornell Med Coll, Dept Radiol, Houston, TX USA. [Sostman, H. Dirk] Methodist Hosp, Houston, TX 77030 USA. [Jablonski, Kathleen A.] George Washington Univ, Ctr Biostat, Rockville, MD USA. [Stein, Paul D.] Michigan State Univ, Coll Osteopath Med, Dept Internal Med, E Lansing, MI 48824 USA. [Naidich, David P.] NYU, Dept Radiol, Med Ctr, New York, NY 10016 USA. [Chenevert, Thomas L.] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA. [Weg, John G.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Hales, Charles A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Hales, Charles A.] Harvard Univ, Sch Med, Boston, MA USA. [Hull, Russell D.] Univ Calgary, Dept Med, Calgary, AB, Canada. [Goodman, Lawrence R.] Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA. [Tapson, Victor F.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. RP Woodard, PK (reprint author), Washington Univ, Sch Med, Dept Radiol, Mallinckrodt Inst Radiol, 510 S Kingshighway Blvd, St Louis, MO 63110 USA. EM woodardp@mir.wustl.edu OI naidich, david/0000-0003-3751-5836 FU U.S. Department of Health and Human Services, Public Health Services, National Heart, Lung, and Blood Institute, Bethesda, Maryland [HL081593, HL177150, HL077149, HL077151, HL077154, HL081594, HL077358, HL077155, HL077153]; GE Healthcare; Siemens Medical Systems FX This study was supported by Grants HL081593, HL177150, HL077149, HL077151, HL077154, HL081594, HL077358, HL077155, and HL077153 from the U.S. Department of Health and Human Services, Public Health Services, National Heart, Lung, and Blood Institute, Bethesda, Maryland.; Dr. Woodard received research support from GE Healthcare and Siemens Medical Systems. NR 16 TC 7 Z9 7 U1 0 U2 6 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1569-5794 J9 INT J CARDIOVAS IMAG JI Int. J. Cardiovasc. Imaging PD FEB PY 2012 VL 28 IS 2 BP 303 EP 312 DI 10.1007/s10554-011-9820-7 PG 10 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 899YU UT WOS:000300853400009 PM 21347594 ER PT J AU Truong, QA Banerji, D Ptaszek, LM Taylor, C Fontes, JD Kriegel, M Irlbeck, T Nagurney, JT Hoffmann, U AF Truong, Quynh A. Banerji, Dahlia Ptaszek, Leon M. Taylor, Carolyn Fontes, Joao D. Kriegel, Matthias Irlbeck, Thomas Nagurney, John T. Hoffmann, Udo TI Utility of nonspecific resting electrocardiographic features for detection of coronary artery stenosis by Computed Tomography in acute chest pain patients: from the ROMICAT trial SO INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING LA English DT Article DE Electrocardiography; Coronary artery stenosis; Computed tomography; Acute chest pain; Emergency department ID ACUTE MYOCARDIAL-INFARCTION; QT-INTERVAL; DIAGNOSTIC PERFORMANCE; HEART-DISEASE; ANGIOGRAPHY; POPULATION; DURATION; ATHEROSCLEROSIS; ABNORMALITIES; DISPERSION AB Twelve-lead surface electrocardiography (ECG) and computed tomography (CT) are used to evaluate for myocardial ischemia and coronary artery disease (CAD), respectively. We aimed to determine features on resting ECG that predict coronary artery stenosis by cardiac CT. In 309 acute chest pain patients, we compared the initial triage resting ECG to contrast-enhanced 64-slice cardiac CT angiography. We assessed for 6 quantitative (QT interval, QTc interval, QTc > 440 ms, gender-specific QTc, QT dispersion and QRS duration) and 4 qualitative ECG parameters (ST depression > 0.05 to a parts per thousand currency sign0.1 mV, T wave inversion a parts per thousand yen0.1 mV, T wave flattening, and any T wave abnormalities) and for the presence of coronary stenosis by CT (> 50% luminal narrowing). Specificities of these ECG parameters were excellent (83.6-97.0%) while sensitivities were poor (12.2-29.3%). For coronary stenosis detection, the ECG features with the greatest performance were the presence of ST depression (positive likelihood ratio [LR+] 4.09) and T wave inversion (LR+ 4.58). In multivariable analyses, the risk for coronary stenosis increased by 33-41% for every 20 ms prolongation of the QTc interval after adjusting for age, gender, and cardiac risk factors or adjustment for Framingham risk score. Similarly, there was an increase of fourfold with the presence of ST depression > 0.05 to a parts per thousand currency sign0.1 mV or T wave inversion a parts per thousand yen0.1 mV. In acute chest pain patients, resting ECG features of QTc interval prolongation, mild ST depression, and T wave inversion are independently associated with the presence of CT coronary stenosis and their presence suggests an increase risk of CAD. C1 [Truong, Quynh A.; Banerji, Dahlia; Taylor, Carolyn; Fontes, Joao D.; Kriegel, Matthias; Irlbeck, Thomas; Hoffmann, Udo] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA. [Truong, Quynh A.; Ptaszek, Leon M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Nagurney, John T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Truong, QA (reprint author), Massachusetts Gen Hosp, Cardiac MR PET CT Program, 165 Cambridge St,Suite 400, Boston, MA 02114 USA. EM qtruong@partners.org FU NIH [R01HL080053, L30HL093896, 1K23HL098370]; Siemens Medical Solutions; General Electrics Healthcare FX This work was supported by the NIH R01HL080053, and in part supported by Siemens Medical Solutions and General Electrics Healthcare. Dr. Truong received support from NIH grants L30HL093896 and 1K23HL098370. NR 26 TC 1 Z9 1 U1 0 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1569-5794 J9 INT J CARDIOVAS IMAG JI Int. J. Cardiovasc. Imaging PD FEB PY 2012 VL 28 IS 2 BP 365 EP 374 DI 10.1007/s10554-011-9823-4 PG 10 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 899YU UT WOS:000300853400016 PM 21287278 ER PT J AU Walcott, BP Coumans, JV AF Walcott, Brian P. Coumans, Jean-Valery TI Postlaminectomy synovial cyst formation: A possible consequence of ligamentum flavum excision SO JOURNAL OF CLINICAL NEUROSCIENCE LA English DT Article DE Synovial Cyst; Laminectomy; Facet Joint; Ligamentum Flavum ID THORACIC SPINE; LUMBAR SPINE; HYPERTROPHY; GANGLION AB Ligamentum flavum is generally resected with impunity when a laminectomy is performed; it is a strong ligament and its removal may not be inconsequential. We sought to examine the consequence of resection of ligamentum flavum as it pertains to the formation of synovial cysts. Following IRB approval, we retrospectively reviewed the charts of consecutive patients who underwent a laminectomy for any diagnosis during the years 2009-2010. Exclusions were made for patients undergoing resection of a synovial cyst, laminectomy done as part of a fusion, and microdiscectomy. A total of 201 laminectomies were performed. 10 instances of post-laminectomy synovial cyst occurred in only the lumbar spine. Synovial cysts occurred exclusively after surgery for stenosis (n = 10). Laminectomy and resection of the ligament flavum is a risk factor for the subsequent formation of a synovial cyst. Secondary synovial cyst formation should be suspected in individuals who develop radiculopathy after laminectomy for stenosis. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Walcott, Brian P.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Walcott, BP (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St,White Bldg,Room 502, Boston, MA 02114 USA. EM walcott.brian@mgh.harvard.edu NR 22 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0967-5868 J9 J CLIN NEUROSCI JI J. Clin. Neurosci. PD FEB PY 2012 VL 19 IS 2 BP 252 EP 254 DI 10.1016/j.jocn.2011.07.007 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 902BB UT WOS:000301012500012 PM 22051031 ER PT J AU Mian, MK Nahed, BV Walcott, BP Coumans, JV AF Mian, Matthew K. Nahed, Brian V. Walcott, Brian P. Coumans, Jean-Valery TI Intraspinal migration of a clavicular Steinmann pin: case report and management strategy SO JOURNAL OF CLINICAL NEUROSCIENCE LA English DT Article DE Spine; Steinmann; Trauma; Hardware; Internal fixation ID SPINAL-CORD-INJURY; KIRSCHNER WIRE; INTRATHORACIC MIGRATION; FIXATION; FRACTURE; TAMPONADE; HEART AB Spine injury resulting from migration of previously implanted appendicular skeleton fixation hardware is rare. We present a 41-year-old man who had Steinmann fixation pins placed for a left clavicular fracture 2 years prior. He presented with a burning sensation over his biceps bilaterally and numbness over the left anterior chest and abdomen following a significant blunt traumatic injury. A CT scan revealed migration of a fractured Steinmann pin entering the left C8 neural foramen, traversing anterior to the spinal cord. The patient underwent a left C7 hemilaminectomy, foraminal decompression, and first rib resection to identify the extraforaminal portion of the pin and remove it under direct vision. He recovered uneventfully. We conclude that a principle of safe surgical removal includes adequate exposure to allow for direct visualization of the pin and neural structures. We review the evaluation and management strategies of this unusual condition. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Mian, Matthew K.; Nahed, Brian V.; Walcott, Brian P.; Coumans, Jean-Valery] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. RP Walcott, BP (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St,White Bldg 502, Boston, MA 02114 USA. EM walcott.brian@mgh.harvard.edu NR 24 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0967-5868 J9 J CLIN NEUROSCI JI J. Clin. Neurosci. PD FEB PY 2012 VL 19 IS 2 BP 310 EP 313 DI 10.1016/j.jocn.2011.05.018 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 902BB UT WOS:000301012500025 PM 22099073 ER PT J AU Gilman, SE Breslau, J Trinh, NH Fava, M Murphy, JM Smoller, JW AF Gilman, Stephen E. Breslau, Joshua Nhi-Ha Trinh Fava, Maurizio Murphy, Jane M. Smoller, Jordan W. TI Bereavement and the Diagnosis of Major Depressive Episode in the National Epidemiologic Survey on Alcohol and Related Conditions SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID CLINICAL-SIGNIFICANCE; COMPLICATED GRIEF; UNITED-STATES; DISORDERS; RELIABILITY; PREVALENCE; VALIDITY; IV; CRITERION; INTERVIEW AB Objective: Bereavement-related depression is excluded from a diagnosis of major depressive episode (MDE) in DSM-IV, unless the syndrome is prolonged or complicated. The objective of this study is to assess the validity of the bereavement exclusion by comparing characteristics of bereavement-related episodes that are excluded from a diagnosis and bereavement-related episodes that qualify for a diagnosis (complicated bereavement) to MDE. Method: We used data from 2 waves of the National Epidemiologic Survey on Alcohol and Related Conditions (n = 43,093) to compare bereavement-excluded depression and complicated bereavement to MDE with respect to indicators of preexisting risk for psychopathology (antecedent indicators) and indicators of disorder severity measured at baseline and at the study's 3-year follow-up interview (consequent indicators). The primary outcome measure was the Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV. Results: Compared to individuals with MDE, individuals with bereavement-excluded depression had lower risks of preexisting psychiatric disorders (eg, 0.44 lower odds of social phobia, P = .006), fewer depressive episodes (recurrence rate 0.37 times lower, P < .001), less psychosocial impairment (P < .001), a 0.18 times lower odds of seeking treatment (P < .001), and a lower risk of psychiatric disorders during a 3-year follow-up period. Unexpectedly, this same pattern of differences was observed between individuals with complicated bereavement and MDE. Conclusions: Despite the presence of a clinically significant depressive episode, bereavement-excluded depression is in many ways less indicative of psychopathology than MDE. However, complicated bereavement was more similar to bereavement-excluded depression than to MDE. We therefore question whether the DSM-IV criteria validly distinguish between nondisordered loss reactions (bereavement-excluded depression), pathological loss reactions (complicated bereavement), and nonloss-related MDE. J Clin Psychiatry 2012;73(2):208-215 (C) Copyright 2011 Physicians Postgraduate Press, Inc. C1 [Gilman, Stephen E.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Gilman, Stephen E.; Murphy, Jane M.; Smoller, Jordan W.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Nhi-Ha Trinh; Fava, Maurizio; Murphy, Jane M.; Smoller, Jordan W.] Harvard Univ, Sch Med, Boston, MA USA. [Nhi-Ha Trinh; Fava, Maurizio; Murphy, Jane M.; Smoller, Jordan W.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Breslau, Joshua] Univ Calif Davis, Dept Internal Med, Davis, CA USA. RP Gilman, SE (reprint author), Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, 677 Huntington Ave, Boston, MA 02115 USA. EM sgilman@hsph.harvard.edu RI Breslau, Joshua/I-6956-2012; Gilman, Stephen/E-7632-2010 OI Gilman, Stephen/0000-0002-8331-6419 FU Abbott; Alkermes; Aspect Medical Systems; AstraZeneca; BioResearch; BrainCells; Bristol-Myers Squibb; Cephalon; CeNeRx BioPharma; Clinical Trials Solutions; Clintara; Covidien; Eli Lilly; EnVivo; Euthymics Bioscience; Forest; Ganeden Biotech; GlaxoSmithKline; Icon Clinical Research; i3 Innovus/Ingenix; Johnson & Johnson Pharmaceutical Research Development; Lichtwer Pharma GmbH; Lorex; National Alliance for Research on Schizophrenia & Depression (NARSAD); National Center for Complementary and Alternative Medicine; National Institute of Drug Abuse; National Institute of Mental Health; Novartis AG; Organon; PamLab; Pfizer; Pharmavite; Photothera; Roche; RCT Logic; Sanofi-Aventis; Shire; Solvay; Synthelabo; Wyeth-Ayerst; Affectis AG; Amarin Pharma; Auspex; Bayer AG; Best Practice Project Management; BioMarin; Biovail; CNS Response; Compellis; Cypress; DiagnoSearch Life Sciences (P); Dainippon Sumitomo Pharma; Dov; Edgemont; Eisai; ePharmaSolutions; EPIX; Fabre-Kramer; GenOmind; Grunenthal GmbH; i3 Innovus/Ingenis; Janssen; Jazz; Knoll; Labopharm; Lundbeck; MedAvante; Merck; MSI Methylation Sciences; Naurex; Neuronetics; Next Wave; Nutrition 21; Orexigen Therapeutics; Organon Otsuka; PharmaStar; PharmoRx Therapeutics; Precision Human Biolaboratory; Prexa Pharmaceuticals; Puretech Ventures; PsychoGenics; Psylin Neurosciences; Rexahn; Ridge Diagnostics; Sepracor; Servier Laboratories; Schering-Plough; Somaxon; Somerset; Sunovion; Supernus; Takeda; Tal Medical; Tetragenex; TransForm; Transcept; Vanda; Adamed; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; Belvoir Media Group; Boehringer Ingelheim GmbH; CME Institute/Physicians Postgraduate Press; Imedex; Massachusetts General Hospital (MGH) Psychiatry Academy/Primedia; MGH Psychiatry Academy/Reed Elsevier; United BioSource; National Institutes of Health [MH087544, DA080887, MH66057] FX Dr Fava has received research support from Abbott, Alkermes, Aspect Medical Systems, AstraZeneca, BioResearch, BrainCells, Bristol-Myers Squibb, Cephalon, CeNeRx BioPharma, Clinical Trials Solutions, Clintara, Covidien, Eli Lilly, EnVivo, Euthymics Bioscience, Forest, Ganeden Biotech, GlaxoSmithKline, Icon Clinical Research, i3 Innovus/Ingenix, Johnson & Johnson Pharmaceutical Research & Development, Lichtwer Pharma GmbH, Lorex, National Alliance for Research on Schizophrenia & Depression (NARSAD), National Center for Complementary and Alternative Medicine, National Institute of Drug Abuse, National Institute of Mental Health, Novartis AG, Organon, PamLab, Pfizer, Pharmavite, Photothera, Roche, RCT Logic, Sanofi-Aventis, Shire, Solvay, Synthelabo, and Wyeth-Ayerst; has received advisory/consulting fees from Abbott, Affectis AG; Alkermes, Amarin Pharma, Aspect Medical Systems, AstraZeneca, Auspex, Bayer AG, Best Practice Project Management, BioMarin, Biovail, BrainCells, Bristol-Myers Squibb, CeNeRx BioPharma, Cephalon, Clinical Trials Solutions, CNS Response, Compellis, Cypress, DiagnoSearch Life Sciences (P), Dainippon Sumitomo Pharma, Dov, Edgemont, Eisai, Eli Lilly, ePharmaSolutions, EPIX, Euthymics Bioscience, Fabre-Kramer, Forest, GenOmind, GlaxoSmithKline, Grunenthal GmbH, i3 Innovus/Ingenis, Janssen, Jazz, Johnson & Johnson Pharmaceutical Research & Development, Knoll, Labopharm, Lorex, Lundbeck, MedAvante, Merck, MSI Methylation Sciences, Naurex, Neuronetics, Next Wave, Novartis AG, Nutrition 21, Orexigen Therapeutics, Organon Otsuka, PamLab, Pfizer, PharmaStar, Pharmavite, PharmoRx Therapeutics, Precision Human Biolaboratory, Prexa Pharmaceuticals, Puretech Ventures, PsychoGenics, Psylin Neurosciences, Rexahn, Ridge Diagnostics, Roche, RCT Logic, Sanofi-Aventis, Sepracor, Servier Laboratories, Schering-Plough, Solvay, Somaxon, Somerset, Sunovion, Supernus, Synthelabo, Takeda, Tal Medical, Tetragenex, TransForm, Transcept, and Vanda; has received speaking/publishing fees from Adamed, Advanced Meeting Partners, American Psychiatric Association, American Society of Clinical Psychopharmacology, AstraZeneca, Belvoir Media Group, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Cephalon, CME Institute/Physicians Postgraduate Press, Eli Lilly, Forest, GlaxoSmithKline, Imedex, Massachusetts General Hospital (MGH) Psychiatry Academy/Primedia, MGH Psychiatry Academy/Reed Elsevier, Novartis AG, Organon, Pfizer, PharmaStar, United BioSource, and Wyeth-Ayerst; has equity holdings in Compel lis; receives copyright royalties for the MGH Cognitive & Physical Functioning Questionnaire, Sexual Functioning Inventory, Antidepressant Treatment Response Questionnaire, Discontinuation-Emergent Signs & Symptoms, and SAFER; and has a patent application for a combination of azapirones and bupropion in major depressive disorder. Dr Fava also has a patent for Sequential Parallel Comparison Design (SPCD) and a patent for research and licensing of SPCD with RCT Logic; Lippincott, Williams & Wilkins; and World Scientific Publishing. In the past 3 years, Dr Smoller has consulted to Eli Lilly, Herman Dana Trust, and RTI International. Drs Gilman, Breslau, Trinh, and Murphy report no financial or other conflicts of interest related to the subject of the article.; This work was supported in part by National Institutes of Health grants MH087544, DA080887, and MH66057. NR 47 TC 25 Z9 25 U1 1 U2 13 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD FEB PY 2012 VL 73 IS 2 BP 208 EP 215 DI 10.4088/JCP.10m06080 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 900TZ UT WOS:000300915100010 PM 21903020 ER PT J AU Blanco, C Vesga-Lopez, O Stewart, JW Liu, SM Grant, BF Hasin, DS AF Blanco, Carlos Vesga-Lopez, Oriana Stewart, Jonathan W. Liu, Shang-Min Grant, Bridget F. Hasin, Deborah S. TI Epidemiology of Major Depression With Atypical Features: Results From the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID INTERVIEW SCHEDULE AUDADIS; GENERAL-POPULATION SAMPLE; COMPREHENSIVE DEVELOPMENTAL MODEL; PSYCHIATRIC DIAGNOSTIC MODULES; AGE-OF-ONSET; USE-DISORDER; BIPOLAR-II; PERSONALITY-DISORDERS; DRUG MODULES; COMORBIDITY SURVEY AB Objective: To examine prevalence, correlates, comorbidity and treatment-seeking among individuals with a lifetime major depressive episode (MDE) with and without atypical features. Method: Data were derived from the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions, a large cross-sectional survey of a representative sample (N = 43,093) of the US population that assessed psychiatric disorders using the Alcohol Use Disorder and Associated Disabilities Interview Schedule-DSM-IVVersion (AUDADIS-IV). Comparison groups were defined based on the presence or absence of hypersomnia or hyperphagia in individuals who met criteria for lifetime DSM-IV MDE. Results: The presence of atypical features during an MDE was associated with greater rates of lifetime psychiatric comorbidity, including alcohol abuse, drug dependence, dysthymia, social anxiety disorder, specific phobia, and any personality disorder (all P values < .05), except antisocial personality disorder, than MDE without atypical features. Compared with the latter group, MDE with atypical features was associated with female gender, younger age at onset, more MDEs, greater episode severity and disability, higher rates of family history of depression, bipolar I disorder, suicide attempts, and larger mental health treatment-seeking rates (all P values < .05). Conclusions: Our data provide further evidence for the clinical significance and validity of this depressive specifier. Based on the presence of any of the 2 reversed vegetative symptoms during an MDE, most of the commonly cited validators of atypical depression were confirmed in our study. Major depressive episode with atypical features may be more common, severe, and impairing than previously documented. J Clin Psychiatry 2012;73(2):224-232 (C) Copyright 2011 Physicians Postgraduate Press, Inc. C1 [Grant, Bridget F.] NIAAA, Lab Epidemiol & Biometry, Div Intramural Clin & Biol Res, NIH, Bethesda, MD 20892 USA. [Blanco, Carlos; Stewart, Jonathan W.; Liu, Shang-Min; Hasin, Deborah S.] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Dept Psychiat, New York, NY 10032 USA. [Hasin, Deborah S.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Vesga-Lopez, Oriana] Harvard Univ, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Grant, BF (reprint author), NIAAA, Lab Epidemiol & Biometry, Div Intramural Clin & Biol Res, NIH, Room 3077,MS 9304,5635 Fishers Lane, Bethesda, MD 20892 USA. EM bgrant@willco.niaaa.nih.gov RI Blanco, Carlos/I-4906-2013 OI Blanco, Carlos/0000-0001-6187-3057 FU Eli Lilly; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Intramural Program; NIAAA; National Institutes of Health (NIH) [DA019606, DA020783, DA023200, DA023973, MH076051, MH082773, R01AA08159, K05AA00161]; American Foundation for Suicide Prevention; New York State Psychiatric Institute FX Dr Stewart has received financial support for his participation in a Continuing Medical Education course funded by Eli Lilly (course content was not screened by Eli Lilly). Drs Blanco, Vesga-Lopez, Grant, and Hasin and Ms Liu report no financial or other conflicts of interest related to the subject of this article.; The National Epidemiologic Survey on Alcohol and Related Conditions was sponsored by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and funded, in part, by the Intramural Program, NIAAA, National Institutes of Health (NIH). This study is supported by NIH grants DA019606, DA020783, DA023200, DA023973, MH076051, and MH082773 (Dr Blanco); R01AA08159 and K05AA00161 (Dr Hasin); the American Foundation for Suicide Prevention (Dr Blanco); and the New York State Psychiatric Institute (Drs Blanco, Hasin, and Stewart). NR 57 TC 25 Z9 27 U1 1 U2 11 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD FEB PY 2012 VL 73 IS 2 BP 224 EP 232 DI 10.4088/JCP.10m06227 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 900TZ UT WOS:000300915100012 PM 21939615 ER PT J AU Newport, DJ Baldessarini, RJ Knight, BT Fernandez, SV Morris, NJ Viguera, AC Stowe, ZN AF Newport, D. Jeffrey Baldessarini, Ross J. Knight, Bettina T. Fernandez, Susana V. Morris, Natalie J. Viguera, Adele C. Stowe, Zachary N. TI Comparison of Women With Confirmed Versus Presumably Misdiagnosed Bipolar Disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID SECONDARY MANIA; DEPRESSION; PREGNANCY; DIAGNOSIS; MEMBERS; ABUSE AB Objective: Because bipolar disorder can be difficult to diagnose, we compared characteristics of women with confirmed versus presumably misdiagnosed bipolar disorder. Method:This cohort study was conducted from July 2005 to January 2010 in the outpatient clinic of the Emory Women's Mental Health Program, Atlanta, Georgia. Young adult women (mean age = 32 years) who were either pregnant or planning to conceive and who reported having previous clinical diagnoses of bipolar disorder completed 2 independent diagnostic assessments: the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID) and an evaluation by a perinatal mood-disorder expert who was masked to the SCID findings. We compared clinical characteristics of women with confirmed versus presumably misdiagnosed bipolar disorder by bivariate testing followed by multivariate logistic regression modeling. Results: Of 199 participants, 141 (70.9%) had confirmed DSM-IV bipolar disorder on the basis of concordant assessments, 23 (11.6%) were considered misdiagnosed, and 35(17.6%) who had discordant diagnostic assessments were excluded from further analysis. Multivariate modeling indicated that confirmed bipolar disorder was associated with a history of antidepressant-associated mania/hypomania (OR = 13.30; 95% CI, 3.32-53.20; P = .0003), psychotic symptoms (OR = 12.40; 95% CI, 2.147-1.10; P = .005), and sustained euthymia during mood-stabilizer treatment (OR = 4.53; 95% CI, 1.32-15.60; P = .02); presumably misdiagnosed bipolar disorder was associated with childhood physical abuse (OR = 8.73; 95% CI, 2.33-32.70; P = .001) and comorbid obsessive-compulsive disorder (OR = 7.26; 95% CI, 1.86-28.30; P = .004). Conclusions: Several clinical factors found to distinguish women with confirmed versus presumably misdiagnosed bipolar disorder may help to refine clinical diagnosis. J Clin Psychiatry 2012;73(2):242-246 (C) Copyright 2011 Physicians Postgraduate Press, Inc. C1 [Newport, D. Jeffrey; Knight, Bettina T.; Fernandez, Susana V.; Morris, Natalie J.; Stowe, Zachary N.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA. [Stowe, Zachary N.] Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA 30322 USA. [Baldessarini, Ross J.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Baldessarini, Ross J.] Massachusetts Gen Hosp, Int Consortium Bipolar Disorder Res, McLean Div, Boston, MA 02114 USA. [Baldessarini, Ross J.; Viguera, Adele C.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Viguera, Adele C.] Cleveland Clin, Dept Psychiat, Cleveland, OH 44106 USA. RP Newport, DJ (reprint author), Emory Univ, Sch Med, Dept Psychiat, 1365 Clifton Rd NE,Ste B6100, Atlanta, GA 30322 USA. EM jeff.newport@emory.edu RI Newport, Donald/H-9846-2013; OI Newport, D. Jeffrey/0000-0003-1695-9710 FU NIH [MH-71531, MH-71762]; Bruce J. Anderson Foundation; McLean Private Donors Bipolar Disorder and Psychopharmacology Research Fund; National Institutes of Health (NIH); NARSAD; Eli Lilly; GlaxoSmithKline; Janssen; Wyeth; Bristol-Myers Squibb; Cyberonics; Forest; Novartis; Epilepsy Foundation; AstraZeneca; Pfizer; Ortho-McNeil-Janssen FX Supported by NIH grants MH-71531 (to Drs Newport and Stowe and Mss Knight, Fernandez, and Morris) and MH-71762 (to Drs Baldessarini and Viguera), a grant from the Bruce J. Anderson Foundation (to Dr Baldessarini), and the McLean Private Donors Bipolar Disorder and Psychopharmacology Research Fund (to Dr Baldessarini).; Dr Newport has received research support from the National Institutes of Health (NIH), NARSAD, Eli Lilly, GlaxoSmithKline, Janssen, and Wyeth and has received speaker honoraria from AstraZeneca, Eli Lilly, GlaxoSmithKline, and Pfizer. Ms Knight has received research support from Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest, Janssen, Novartis, and Wyeth. Dr Viguera has received research support from NIH, the Epilepsy Foundation, AstraZeneca, Bristol-Myers Squibb, Pfizer, and Ortho-McNeil-Janssen. Dr Stowe has received research support from, has been a consultant to, and has received speaker honoraria from GlaxoSmithKline, Pfizer, and Wyeth and has also received speaker honoraria from Eli Lilly and Forest. Dr Baldessarini and Mss Fernandez and Morris have no potential conflicts of interest to report. Additionally, no author or any family member holds equity positions in pharmaceutical or biomedical corporations. NR 24 TC 2 Z9 2 U1 2 U2 4 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD FEB PY 2012 VL 73 IS 2 BP 242 EP 246 DI 10.4088/JCP.11m06936 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 900TZ UT WOS:000300915100015 PM 22225624 ER PT J AU Schenker, Y White, DB Asch, DA Kahn, JM AF Schenker, Yael White, Douglas B. Asch, David A. Kahn, Jeremy M. TI Health-care system distrust in the intensive care unit SO JOURNAL OF CRITICAL CARE LA English DT Article DE Health-care system; Distrust; Critical care; Surrogate ID END-OF-LIFE; RACIAL-DIFFERENCES; TRUST; PHYSICIAN; SCALE; ATTITUDES; FAMILY; STATES AB Purpose: To examine the performance and properties of the Revised Health Care System Distrust Scale among surrogates in the intensive care unit (ICU). Materials and Methods: Pilot, prospective cohort study of 50 surrogates of adult, mechanically ventilated patients surveyed on days 1, 3, and 7 of ICU admission. Results: Responses on the Health Care System Distrust Scale on day 1 ranged from 9 to 34 (possible range 9-45, with higher scores indicating more distrust), with a mean and SD of 20.3 +/- 6.9. Factor analysis demonstrated a 2-factor structure, corresponding to the domains of values and competence. Cronbach alpha for the overall scale was .83, for the competence subscale, .76, and for the values subscale, .74. Health-care system distrust was inversely correlated with trust in ICU physicians (Pearson coefficient - .63). When evaluated over the course of each patient's ICU stay, health-care system distrust ratings decreased by 0.31 per patient-day (95% CI 0.55-0.06, P = .015). Correlation between health-care system distrust and trust in ICU physicians decreased slightly over time. Conclusions: Among surrogates in the ICU, the Health Care System Distrust Scale has high internal consistency and convergent validity. There was substantial variability in surrogates' trust in the healthcare system. (C) 2012 Elsevier Inc. All rights reserved. C1 [Schenker, Yael] Univ Pittsburgh, Div Gen Internal Med, Sect Palliat Care & Med Eth, Pittsburgh, PA 15260 USA. [White, Douglas B.; Kahn, Jeremy M.] Univ Pittsburgh, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness CRI, Pittsburgh, PA 15260 USA. [Asch, David A.] Univ Penn, Ctr Hlth Equity Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Asch, David A.] Univ Pittsburgh, Leonard Davis Inst Hlth Econ, Pittsburgh, PA 15260 USA. RP Schenker, Y (reprint author), Univ Pittsburgh, Div Gen Internal Med, Sect Palliat Care & Med Eth, Pittsburgh, PA 15260 USA. EM schenkery@upmc.edu OI Asch, David/0000-0002-7970-286X FU National Palliative Care Research Center; Greenwall Foundation; National Institutes of Health [AG032875, HL082650] FX Dr Schenker was supported by a Junior Faculty Career Development Award from the National Palliative Care Research Center. Dr White is supported by a Greenwall Foundation Faculty Scholars Award and a Paul Beeson Award in Aging Research from the National Institutes of Health (AG032875). Dr Kahn is supported by a career development award from the National Institutes of Health (HL082650). NR 37 TC 6 Z9 6 U1 5 U2 12 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0883-9441 J9 J CRIT CARE JI J. Crit. Care PD FEB PY 2012 VL 27 IS 1 BP 3 EP 10 DI 10.1016/j.jcrc.2011.04.006 PG 8 WC Critical Care Medicine SC General & Internal Medicine GA 898VX UT WOS:000300771600002 PM 21715134 ER PT J AU Romanus, D Kindler, HL Archer, L Basch, E Niedzwiecki, D Weeks, J Schrag, D AF Romanus, Dorothy Kindler, Hedy L. Archer, Laura Basch, Ethan Niedzwiecki, Donna Weeks, Jane Schrag, Deborah CA Canc Leukemia Grp B TI Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303) SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article; Proceedings Paper CT 43rd Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 01-05, 2007 CL Chicago, IL SP Amer Soc Clin Oncol DE Advanced pancreas cancer; gemcitabine; quality of life ID PLUS GEMCITABINE; CLINICAL BENEFIT; SURVIVAL; ADENOCARCINOMA; INSTITUTE; THERAPY; PLACEBO AB Context. Gemcitabine for advanced pancreatic cancer (APC) is palliative and the prognosis is poor, making health-related quality of life (HRQOL) particularly important. Objectives. We evaluated HRQOL with the EuroQol (EQ-5D(TM)) in patients with APC participating in Cancer and Leukemia Group B 80303, a multicenter, doubleblind, randomized trial comparing overall survival (OS) between two treatment arms: gemcitabine with bevacizumab or gemcitabine with placebo. Methods. A consecutive subsample of patients was invited to complete the EQ-5D surveys. Because neither clinical nor HRQOL outcomes differed based on the study arm, analyses were pooled. Changes in mean scores from baseline to eight weeks and the prognostic value of the EQ-5D were evaluated. Results. Mean index scores remained stable (0.78 at baseline [n = 267], 0.79 at eight weeks [n =186], P = 0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/ depression scores. A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P = 0.026). HRQOL changes within chemotherapy response strata revealed stable index scores but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease. Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P = 0.029). Baseline scores from both EQ-5D scales were significant predictors of OS in Cox proportional hazard models. Conclusion. Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL. Small improvements in pain and mood are observed despite progressive functional decline. Those who respond to gemcitabine may experience a slight slowing of functional deterioration. J Pain Symptom Manage 2012;43:205-217. (C) 2012 U. S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. C1 [Weeks, Jane; Schrag, Deborah] Dana Farber Canc Inst, Boston, MA 02115 USA. [Romanus, Dorothy] Harvard Univ, Sch Publ Hlth, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Kindler, Hedy L.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Archer, Laura; Niedzwiecki, Donna] CALGB Stat Ctr, Durham, NC USA. [Basch, Ethan] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. RP Schrag, D (reprint author), Dana Farber Canc Inst, 44 Binney St,SM 204, Boston, MA 02115 USA. EM deb_schrag@dfci.harvard.edu FU NCI NIH HHS [U10 CA086726, U10 CA032291, CA77597, CA04326, U10 CA003927, CA35421, CA86726, CA08025, CA45418, CA26806, CA164504, CA74811, U10 CA045418, CA32291, U10 CA077658, CA77440, U10 CA021060, CA77658, U10 CA047577, CA41287, U10 CA067663, CA47642, CA45808, CA37135, U10 CA012046, CA77651, U10 CA114558, U10 CA074811, CA04457, U10 CA047559, U10 CA045389, U10 CA077597, CA45564, U10 CA035421, CA12046, U10 CA045808, CA03927, CA114558-02, CA77406, U10 CA037447, U10 CA077651, U10 CA045564, U10 CA016450, CA29165, U10 CA004457, CA47577, CA77298, U10 CA041287, U10 CA059518, CA47559, U10 CA077298, CA45389, CA59518, U10 CA047642, U10 CA011789, U10 CA077440, U10 CA008025, CA21060, CA11789] NR 23 TC 13 Z9 13 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 205 EP 217 DI 10.1016/j.jpainsymman.2011.09.001 PG 13 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900010 PM 22104618 ER PT J AU Ko, D Blatchford, P Kutner, J Abernethy, A AF Ko, Danielle Blatchford, Patrick Kutner, Jean Abernethy, Amy TI Medications for Comorbidities in Hospice and Palliative Cared-Survey of Current Practice Using Statins as a Test Case SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Ko, Danielle] Massachusetts Gen Hosp, Cambridge, MA USA. [Blatchford, Patrick] Univ Colorado, Colorado Sch Publ Hlth, Aurora, CO USA. [Kutner, Jean] Univ Colorado, Sch Med, Aurora, CO USA. [Abernethy, Amy] Duke Univ, Med Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 335 EP 336 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900024 ER PT J AU Taecharvongphairoj, V Goldberg, J Walling, A Rosenfeld, K Lorenz, K AF Taecharvongphairoj, Veeravat Goldberg, Jaime Walling, Anne Rosenfeld, Kenneth Lorenz, Karl TI Prognostic Tools for Congestive Heart Failure SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Taecharvongphairoj, Veeravat; Goldberg, Jaime; Rosenfeld, Kenneth; Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. [Walling, Anne] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 345 EP 345 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900038 ER PT J AU Baggs, J Schmitt, M Prendergast, T Norton, S Sellers, C Quinn, J AF Baggs, Judith Schmitt, Madeline Prendergast, Thomas Norton, Sally Sellers, Craig Quinn, Jill TI Who Is Attending? End-of-Life Decision Making in the ICU SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Baggs, Judith] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Schmitt, Madeline; Norton, Sally; Sellers, Craig; Quinn, Jill] Univ Rochester, Rochester, NY USA. [Prendergast, Thomas] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 352 EP 352 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900048 ER PT J AU Bernacki, R Cooper, Z AF Bernacki, Rachelle Cooper, Zara TI Chronic Critical Illness: Opportunities and Challenges SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Bernacki, Rachelle] Dana Farber Canc Inst, Cambridge, MA USA. [Cooper, Zara] Harvard Univ, Sch Med, Boston, MA USA. [Cooper, Zara] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 355 EP 355 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900053 ER PT J AU Vesel, T Lupu, D Muriel, A AF Vesel, Tamara Lupu, Dale Muriel, Anna TI Nonpharmacological Approaches to Pain, Anxiety, and Dyspnea: Expanding Your Bedside Toolbox SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Vesel, Tamara; Muriel, Anna] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lupu, Dale] George Washington Univ, Silver Spring, MD USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 358 EP 358 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900058 ER PT J AU Bickel, K Rodgers, P Meier, D Arnold, R Loengard, A Jackson, V AF Bickel, Kathleen Rodgers, Phillip Meier, Diane Arnold, Robert Loengard, Anna Jackson, Vicki TI Models and Approaches to Developing Integrated Palliative Care Systems SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Bickel, Kathleen] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Meier, Diane] Mt Sinai Sch Med, Ctr Adv Palliat Care, New York, NY USA. [Meier, Diane] Lilian & Benjamin Hertzberg Palliat Care Inst, New York, NY USA. [Arnold, Robert] Univ Pittsburgh, Pittsburgh, PA USA. [Loengard, Anna] St Francis Healthcare Syst, Honolulu, HI USA. [Jackson, Vicki] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 362 EP 362 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900065 ER PT J AU Schaefer, K Chittenden, E Periyakoil, V Carey, E Morrison, L Reilly, SS Block, S AF Schaefer, Kristen Chittenden, Eva Periyakoil, Vyjeyanthi Carey, Elise Morrison, Laura Reilly, Sandra Sanchez Block, Susan TI Defining and Validating Palliative Care Competencies for Medical Students and Residents: A National Consensus Project SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Schaefer, Kristen; Block, Susan] Dana Farber Canc Inst, Boston, MA 02115 USA. [Schaefer, Kristen; Block, Susan] Brigham & Womens Hosp, Boston, MA 02115 USA. [Chittenden, Eva] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Periyakoil, Vyjeyanthi] Stanford Univ, Palo Alto, CA 94304 USA. [Carey, Elise] Mayo Clin, Rochester, MN USA. [Morrison, Laura] Baylor Coll Med, Pearland, TX USA. [Reilly, Sandra Sanchez] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 363 EP 363 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900067 ER PT J AU Prommer, E Rabow, M Temel, J Bakitas, M Smith, T AF Prommer, Eric Rabow, Michael Temel, Jennifer Bakitas, Marie Smith, Thomas TI Simultaneous Care Studies in Cancer Care: Designing the Best Study SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Prommer, Eric] Mayo Clin, Phoenix, AZ USA. [Rabow, Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Temel, Jennifer] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bakitas, Marie] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. [Smith, Thomas] VCU Massey Canc Ctr, Richmond, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 368 EP 369 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900077 ER PT J AU Gustin, J Wood, G Childers, J Jacobsen, J Thomas, JD AF Gustin, Jillian Wood, Gordon Childers, Julie Jacobsen, Juliet Thomas, Jane DeLima TI Becoming a Clinician Educator in Palliative Care: Finding a Path Early Career SIG SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Gustin, Jillian] Ohio State Univ, Columbus, OH 43210 USA. [Wood, Gordon] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Childers, Julie] Univ Pittsburgh, Pittsburgh, PA USA. [Jacobsen, Juliet] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Jane DeLima] Dana Farber Canc Inst, Boston, MA 02115 USA. [Thomas, Jane DeLima] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 371 EP 372 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900082 ER PT J AU Goebel, J Ahluwalia, S Chong, K Lorenz, KA Walling, A AF Goebel, Joy Ahluwalia, Sangeeta Chong, Kelly Lorenz, Karl A. Walling, Anne TI Why, How, What, and "So What!" Developing Clinical Informatics Tools for Determined Skeptics SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Goebel, Joy] Calif State Univ Long Beach, Long Beach, CA 90840 USA. [Ahluwalia, Sangeeta; Chong, Kelly; Lorenz, Karl A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Walling, Anne] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 403 EP 403 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900131 ER PT J AU Reilly, SS Thomas, JD Morrison, L Kapo, J Bernacki, R AF Reilly, Sandra Sanchez Thomas, Jane DeLima Morrison, Laura Kapo, Jen Bernacki, Rachelle TI Caring for Oneself to Care for Others SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Reilly, Sandra Sanchez] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Thomas, Jane DeLima; Bernacki, Rachelle] Dana Farber Canc Inst, Boston, MA 02115 USA. [Thomas, Jane DeLima] Brigham & Womens Hosp, Boston, MA 02115 USA. [Morrison, Laura] Baylor Coll Med, Pearland, TX USA. [Kapo, Jen] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 403 EP 404 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900133 ER PT J AU Morrison, L Thomas, JD O'Neill, LB Carey, E Jacobsen, J Reilly, SS Kapo, J Bernacki, R Periyakoil, V AF Morrison, Laura Thomas, Jane DeLima O'Neill, Lynn Bunch Carey, Elise Jacobsen, Juliet Reilly, Sandra Sanchez Kapo, Jennifer Bernacki, Rachelle Periyakoil, Vyjevanthi TI Giving Feedback to Palliative Care Learners SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Morrison, Laura] Baylor Coll Med, Pearland, TX USA. [Thomas, Jane DeLima; Bernacki, Rachelle] Dana Farber Canc Inst, Boston, MA 02115 USA. [Thomas, Jane DeLima] Brigham & Womens Hosp, Boston, MA 02115 USA. [O'Neill, Lynn Bunch] Duke Univ, Chapel Hill, NC USA. [Carey, Elise] Mayo Clin, Rochester, MN USA. [Jacobsen, Juliet] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Reilly, Sandra Sanchez] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Kapo, Jennifer] Univ Penn, Philadelphia, PA 19104 USA. [Periyakoil, Vyjevanthi] Stanford Univ, Palo Alto, CA 94304 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 414 EP 414 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900150 ER PT J AU Linebarger, J Clark, J AF Linebarger, Jennifer Clark, Jennifer TI Stick It to Me: Topical and Transdermal Analgesics at End of Life (524) SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Linebarger, Jennifer] Dana Farber Canc Inst, Boston, MA 02115 USA. [Clark, Jennifer] Univ Oklahoma, Tulsa, OK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 415 EP 416 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900153 ER PT J AU Chittenden, E Wilson, E AF Chittenden, Eva Wilson, Erica TI A Case of Dual Diagnosis in Palliative Care: Challenges and Strategies (527) SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Chittenden, Eva; Wilson, Erica] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 416 EP 417 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900155 ER PT J AU Maytal, G Jackson, V AF Maytal, Guy Jackson, Vicki TI Difficult Interactions in End-of-Life Care (526) SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Maytal, Guy; Jackson, Vicki] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 416 EP 416 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900154 ER PT J AU Goodlin, S Schaefer, K Kovner, V Reznickova, N Smusz, T AF Goodlin, Sarah Schaefer, Kristen Kovner, Victor Reznickova, Nora Smusz, Tina TI Referral of Heart Failure Patients to Hospice: Is It Time for New Guidelines? Heart Failure SIG SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Goodlin, Sarah] Portland VA Med Ctr, Portland, OR USA. [Schaefer, Kristen] Dana Farber Canc Inst, Boston, MA 02115 USA. [Schaefer, Kristen] Brigham & Womens Hosp, Boston, MA 02115 USA. [Reznickova, Nora] Colorado Permanente Med Grp, Boulder, CO USA. [Smusz, Tina] Caril Clin, Christiansburg, VA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 417 EP 417 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900156 ER PT J AU Wittich, A Williams, B Woodby, L Bailey, FA Burgio, K AF Wittich, Angelina Williams, Beverly Woodby, Lesa Bailey, F. Amos Burgio, Kathryn TI "He Got His Last Wishes"-Next-of-Kin Ways of Knowing Patient's End of Life Preferences and Affirming Clinical Conformity SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Wittich, Angelina] Birmingham Vet Adm Med Ctr, Birmingham, AL USA. [Williams, Beverly] VA Med Ctr, Birmingham, AL USA. [Woodby, Lesa; Bailey, F. Amos] BHM VAMC, Birmingham, AL USA. [Burgio, Kathryn] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 434 EP 435 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900184 ER PT J AU Matlock, D Sepucha, K Keech, T Masoudi, F Kutner, J AF Matlock, Dan Sepucha, Karen Keech, Tarah Masoudi, Frederick Kutner, Jean TI Do Clinician Opinion Leaders and Patients Agree On the Factors Important in Implantable Cardioverter Defibrillator Decision Making? SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Kutner, Jean] Univ Colorado, Sch Med, Aurora, CO USA. [Sepucha, Karen] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 443 EP 444 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900198 ER PT J AU Goldman, B Sanchez-Reilly, S Ross, J Lee, S AF Goldman, Babak Sanchez-Reilly, Sandra Ross, Jeanette Lee, Shuko TI Evaluating an Interdisciplinary, Multicultural, Innovative, and Required Palliative Care Medical Student Course SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Goldman, Babak; Sanchez-Reilly, Sandra; Ross, Jeanette] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra; Lee, Shuko] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 447 EP 448 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900205 ER PT J AU Healy, J El Ahdab, S Lee, S Ross, J Sanchez-Reilly, S AF Healy, Jennifer El Ahdab, Samih Lee, Shuko Ross, Jeanette Sanchez-Reilly, Sandra TI Bereaved Family Members as Teachers: Educating Medical Students in What Matters Most SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Healy, Jennifer] UTHSCSA, HPM, San Antonio, TX USA. [Lee, Shuko; Sanchez-Reilly, Sandra] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 451 EP 451 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900210 ER PT J AU Alshehabi, M Nguyen, G Lee, S Sanchez-Reilly, S AF Alshehabi, Muna Nguyen, George Lee, Shuko Sanchez-Reilly, Sandra TI Is PEG Tube Really the Way To Go: A Comparison of Symptoms Among Subjects With Head and Neck Cancer SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Alshehabi, Muna; Nguyen, George; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, Shuko; Sanchez-Reilly, Sandra] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 455 EP 456 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900218 ER PT J AU Carleton, J Madhusudanannair, V Lee, S Sanchez-Reilly, S AF Carleton, Johelen Madhusudanannair, Vinu Lee, Shuko Sanchez-Reilly, Sandra TI The Impact of Deferolimus On Survival and Quality of Life in Advanced Cancer Subjects SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Carleton, Johelen] Univ Texas San Antonio, San Antonio, TX USA. [Madhusudanannair, Vinu] UTHSCH San Antonio, San Antonio, TX USA. [Lee, Shuko; Sanchez-Reilly, Sandra] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 463 EP 464 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900230 ER PT J AU Lee, YC Padera, RF Noss, EH Fossel, AH Bienfang, D Liang, MH Docken, WP AF Lee, Yvonne C. Padera, Robert F. Noss, Erika H. Fossel, Anne H. Bienfang, Don Liang, Matthew H. Docken, William P. TI Clinical Course and Management of a Consecutive Series of Patients with "Healed Temporal Arteritis" SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE GIANT CELL ARTERITIS; TEMPORAL ARTERITIS; BIOPSY ID GIANT-CELL ARTERITIS; POLYMYALGIA-RHEUMATICA; RISK-FACTORS; VISUAL-LOSS; CORTICOSTEROID TREATMENT; CRANIAL ARTERITIS; BIOPSY FINDINGS; DISEASE AB Objective. To describe the clinical course and management of patients with a pathologic diagnosis of "healed" giant cell arteritis (GCA), and to determine whether previously published histological descriptions of healed arteritis can identify patients with a greater likelihood of clinically significant arteritis. Methods. All temporal artery biopsy reports between 1994 and 2003 were examined for a diagnosis of "healed arteritis." Two rheumatologists abstracted the medical record for presenting features, physical findings, comorbid conditions, and data on treatment and outcomes. One pathologist, blinded to the clinical data, reviewed all specimens and reinterpreted the biopsies according to published histological descriptions of healed arteritis. Results. Forty-seven patients with an initial pathologic diagnosis of healed arteritis were identified. In 54% of these patients, corticosteroid therapy did not change after the diagnosis of healed arteritis was documented in the pathology report. Seventy percent were ultimately treated with no corticosteroids or low-moderate corticosteroid regimens. Only 32% of the initial cases were confirmed upon review of the biopsies using standardized histological criteria. Patients with confirmed healed arteritis were more likely to have a documented history of polymyalgia rheumatica/GCA and a longer duration of corticosteroid treatment before biopsy. These patients were not more likely to have adverse outcomes. Conclusion. In this case series, the diagnosis of healed arteritis had little effect on treatment decisions. In most cases, the initial pathologic diagnosis of healed arteritis was not confirmed when biopsies were reviewed by a single pathologist using uniform histological criteria. (First Release Dec 1 2011; J Rheumatol 2012;39:295-302; doi:10.3899/jrheum.110317) C1 [Lee, Yvonne C.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Dept Pathol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. VA Boston Healthcare Syst, Rheumatol Sect, Boston, MA USA. Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA. RP Lee, YC (reprint author), Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Dept Pathol, 75 Francis St,PBB B3, Boston, MA 02115 USA. EM ylee9@partners.org FU National Institutes of Health [AR 057578] FX Dr. Lee is supported by National Institutes of Health grant AR 057578. NR 23 TC 5 Z9 5 U1 0 U2 1 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD FEB PY 2012 VL 39 IS 2 BP 295 EP 302 DI 10.3899/jrheum.110317 PG 8 WC Rheumatology SC Rheumatology GA 901ZK UT WOS:000301008200015 PM 22133620 ER PT J AU Beason, DP Connizzo, BK Dourte, LM Mauck, RL Soslowsky, LJ Steinberg, DR Bernstein, J AF Beason, David P. Connizzo, Brianne K. Dourte, LeAnn M. Mauck, Robert L. Soslowsky, Louis J. Steinberg, David R. Bernstein, Joseph TI Fiber-aligned polymer scaffolds for rotator cuff repair in a rat model SO JOURNAL OF SHOULDER AND ELBOW SURGERY LA English DT Article DE Rotator cuff; scaffold; tendon; biomechanics; injury; animal model; tissue engineering; shoulder ID BIOARTIFICIAL TENDONS; OVINE MODEL; AUGMENTATION; SUBMUCOSA; MATRIX AB Background: Repair techniques of rotator cuff tendon tears have improved in recent years; nonetheless, the failure rate remains high. Despite the availability of various graft materials for repair augmentation, there has yet to be a biomechanical study using fiber-aligned scaffolds in vivo. The objective of this study was to evaluate the efficacy of fiber-aligned nanofibrous polymer scaffolds as a potential treatment-delivery vehicle in a rat rotator cuff injury model. Materials and methods: Scaffolds with and without sacrificial fibers were fabricated via electrospinning and implanted to augment supraspinatus repair in rats. Repairs without scaffold augmentation were also performed to serve as controls. Rats were sacrificed at 4 and 8 weeks postoperatively, and repairs were evaluated histologically and biomechanically. Results: Both scaffold formulations remained in place, with more noticeable cellular infiltration and colonization at 4 and 8 weeks after injury and repair for scaffolds lacking sacrificial fibers. Specimens with scaffolds were larger in cross-sectional area compared with controls. Biomechanical testing revealed no significant differences in structural properties between the groups. Some apparent material properties were significantly reduced in the scaffold groups. These reductions were due to increases in cross-sectional area, most likely caused by the extra thickness of the implanted scaffold material. No differences were observed between the 2 scaffold groups. Conclusions: No adverse effect of surgical implantation of overlaid fiber-aligned scaffolds on structural properties of supraspinatus tendons in rat rotator cuff repair was demonstrated, validating this model as a platform for targeted delivery. Level of evidence: Review Article. (C) 2012 Journal of Shoulder and Elbow Surgery Board of Trustees. C1 [Steinberg, David R.; Bernstein, Joseph] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Beason, David P.; Connizzo, Brianne K.; Dourte, LeAnn M.; Mauck, Robert L.; Soslowsky, Louis J.] Univ Penn, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA. RP Bernstein, J (reprint author), Philadelphia Vet Affairs Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM joseph.bernstein@uphs.upenn.edu FU Philadelphia Veterans Affairs Medical Center Institutional Animal Care and Use Committee [01036, 0003]; Veterans Administration MERIT program [RRD 85071R] FX This study was approved by the Philadelphia Veterans Affairs Medical Center Institutional Animal Care and Use Committee (ID#: 01036, Prom#: 0003).; This study was funded by the Veterans Administration MERIT program (Grant VA No. RR&D 85071R), awarded to Dr. Bernstein. These funds were used in the conducting of experiments and collecting of data. NR 23 TC 28 Z9 29 U1 3 U2 38 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1058-2746 J9 J SHOULDER ELB SURG JI J. Shoulder Elbow Surg. PD FEB PY 2012 VL 21 IS 2 BP 245 EP 250 DI 10.1016/j.jse.2011.10.021 PG 6 WC Orthopedics; Sport Sciences; Surgery SC Orthopedics; Sport Sciences; Surgery GA 898WJ UT WOS:000300772800017 PM 22244068 ER PT J AU Pernar, LIM Peyre, SE Smink, DS Block, SD Cooper, ZR AF Pernar, Luise I. M. Peyre, Sarah E. Smink, Douglas S. Block, Susan D. Cooper, Zara R. TI Feasibility and Impact of a Case-Based Palliative Care Workshop for General Surgery Residents SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID OF-LIFE CARE; EDUCATION; CURRICULUM AB BACKGROUND: The American Board of Surgery has emphasized that palliative care education should be included in surgical training. The few formal curricula for teaching palliative care, although effective, are time-intensive and have low longitudinal participation rates. The aim of this project was to design a feasible and effective palliative care intervention for general surgery residency training. STUDY DESIGN: A multidisciplinary group developed a 2-hour case-based palliative care workshop including a brief introductory didactic, 4 case-based scenarios, and role-playing exercises. Program effectiveness was assessed using pre- and 3 weeks post-workshop surveys to measure attitudes toward and knowledge of palliative care. Fisher's exact test was used for data analysis; statistical significance was accepted at p < 0.05. RESULTS: Twenty-two (88%) residents attended the workshop and completed the baseline survey; 16 (72.7%) completed the post-workshop survey. The workshop changed residents' attitudes to be more consistent with accepted palliative care principles. Statistically significant shifts were seen in attitudes about the use of total parenteral nutrition for malignant small bowel obstruction (31.8% disagree with use pre- vs 68.8% post-workshop; p < 0.0001); the use of surgical therapy for malignant small bowel obstruction (45.5% disagree pre- vs 68.8% post-workshop; p = 0.002); and that depression is normal in terminal illness (22.7% disagree pre- vs 43.8% post-workshop; p = 0.002). Residents also performed considerably better on knowledge questions about CPR, patient autonomy, and withdrawal of life-sustaining therapy. CONCLUSIONS: A brief, interactive workshop is effective in changing general surgery residents' attitudes toward and knowledge of palliative care. The results demonstrate that a single teaching session is a useful intervention. (J Am Coll Surg 2012;214:231-236. (C) 2012 by the American College of Surgeons) C1 [Pernar, Luise I. M.; Peyre, Sarah E.; Smink, Douglas S.; Cooper, Zara R.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Pernar, Luise I. M.; Peyre, Sarah E.; Smink, Douglas S.; Cooper, Zara R.] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA. [Block, Susan D.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Cooper, ZR (reprint author), Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA. EM zcooper@partners.org NR 25 TC 7 Z9 7 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD FEB PY 2012 VL 214 IS 2 BP 231 EP 236 DI 10.1016/j.jamcollsurg.2011.11.002 PG 6 WC Surgery SC Surgery GA 891RO UT WOS:000300234500014 PM 22169003 ER PT J AU Skibitsky, M Edelen, MO Martin, JL Harker, J Alessi, C Saliba, D AF Skibitsky, Megan Edelen, Maria Orlando Martin, Jennifer L. Harker, Judith Alessi, Cathy Saliba, Debra TI Can Standardized Sleep Questionnaires be Used to Identify Excessive Daytime Sleeping in Older Post-Acute Rehabilitation Patients? SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE Sleep; postacute care; rehabilitation; screen ID NURSING-HOME RESIDENTS; PRACTICE PARAMETERS; CIRCADIAN-RHYTHMS; WAKEFULNESS TEST; ELDERLY PERSONS; LATENCY TEST; CLINICAL-USE; POPULATION; COMPLAINTS; MORTALITY AB Objectives: Excessive daytime sleeping is associated with poorer functional outcomes in rehabilitation populations and may be improved with targeted interventions. The purpose of this study was to test simple methods of screening for excessive daytime sleeping among older adults admitted for postacute rehabilitation. Design: Secondary analysis of data from 2 clinical samples. Setting: Two postacute rehabilitation (PAR) units in southern California. Participants: Two hundred twenty-six patients older than 65 years with Mini-Mental State Examination (MMSE) score higher than 11 undergoing rehabilitation. Measurements: The primary outcome was excessive daytime sleeping, defined as greater than 15% (1.8 hours) of daytime hours (8 AM to 8 PM) sleeping as measured by actigraphy. Results: Participants spent, on average, 16.2% (SD12.5%) of daytimehours sleeping as measured by actigraphy. Thirty-nine percent of participants had excessive daytime sleeping. The Pittsburgh Sleep Quality Index (PSQI) was significantly associated with actigraphically measured daytime sleeping (P=.0038), but the Epworth Sleepiness Scale (ESS) was not (P=.49). Neither the ESS nor the PSQI achieved sufficient sensitivity and specificity to be used as a screening tool for excessive daytime sleeping. Two additional models using items from these questionnaires were not significantly associated with the outcome. Conclusions: In an older PAR population, self-report items from existing sleep questionnaires do not identify excessive daytime sleeping. Therefore we recommend objective measures for the evaluation of excessive daytime sleeping as well as further research to identify new self-report items that may be more applicable in PAR populations. Copyright (C) 2012 - American Medical Directors Association, Inc. C1 [Edelen, Maria Orlando; Saliba, Debra] RAND Corp, Santa Monica, CA 90401 USA. [Skibitsky, Megan; Martin, Jennifer L.; Alessi, Cathy; Saliba, Debra] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Martin, Jennifer L.; Harker, Judith; Alessi, Cathy; Saliba, Debra] Vet Adm Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Alessi, Cathy; Saliba, Debra] Los Angeles Jewish Homes Borun Ctr Gerontol Res, Los Angeles, CA USA. RP Saliba, D (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA. EM megan.skibitsky@hsc.utah.edu FU Veterans Administration Health Services Research and Development [SDR 03-217, IIR 01-053-1, AIA 03-047]; NIH/NIA [K23 AG028452]; VA Greater Los Angeles Healthcare System Geriatric Research, Education, and Clinical Center (GRECC); AFAR FX Research was supported by the Veterans Administration Health Services Research and Development (SDR 03-217, D.S.; IIR 01-053-1, C.A.; and AIA 03-047, J.L.M.), NIH/NIA K23 AG028452 (J.L.M.), and the VA Greater Los Angeles Healthcare System Geriatric Research, Education, and Clinical Center (GRECC), and the AFAR Medical Student Summer Research Training in Aging Program. NR 33 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD FEB PY 2012 VL 13 IS 2 BP 127 EP 135 DI 10.1016/j.jamda.2010.05.004 PG 9 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 898HX UT WOS:000300733600010 PM 21450184 ER PT J AU van der Steen, JT Lane, P Kowall, NW Knol, DL Volicer, L AF van der Steen, Jenny T. Lane, Patricia Kowall, Neil W. Knol, Dirk L. Volicer, Ladislav TI Antibiotics and Mortality in Patients with Lower Respiratory Infection and Advanced Dementia SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE Palliative care; treatment outcome; nursing homes; dementia; pneumonia; antibiotics ID NURSING-HOME PATIENTS; TRACT INFECTION; CLINICAL JUDGMENT; ILLNESS SEVERITY; ALZHEIMER-TYPE; PNEUMONIA; CANCER; DECISIONS; STRATEGY; SURVIVAL AB Objectives: To describe long-term mortality rate and to assess associations between mortality rate and antibiotic treatment of lower respiratory infection in patients with advanced dementia; antibiotic treatment allocation was independent of mortality risk-leaving less room for biased associations than in previous multicenter observational studies. Design: Prospective study (2004-2009). Multilevel Cox proportional hazard analyses with adjustment for mortality risk were used to assess associations between antibiotics and mortality using time-dependent covariates. Setting: A US Department of Veterans Affairs nursing home. Participants: Ninety-four residents with advanced dementia who developed 109 episodes. Measurements: Survival, treatment, mortality risk, illness severity, fluid intake, and several other patient characteristics. Results: Ten-day mortality was 48%, and 6-month mortality was 74%. Antibiotics were used in 77% of episodes. Overall, antibiotics were not associated with mortality rate (Hazard Ratio [HR] 0.70, Confidence Interval [CI] 0.38-1.30); however, antibiotics were associated with reduced 10-day mortality rate (HR 0.51, CI, 0.30-0.87; rate after 10 days: 1.5, CI 0.42-5.2). Benefit from antibiotics was less likely with inadequate fluid intake, and when experiencing the first episode. Conclusion: In our sample of male nursing home residents with advanced dementia and lower respiratory infection, mortality was substantial despite antibiotic treatment. Antibiotics prolonged life but in many cases only for several days. Treatment decisions should take into account that antibiotics may delay death but may also prolong the dying process, indicating a need for accurate prediction of mortality and study of characteristics that may alter effectiveness of antibiotics. Copyright (C) 2012 - American Medical Directors Association, Inc. C1 [van der Steen, Jenny T.] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Dept Nursing Home Med, NL-1081 BT Amsterdam, Netherlands. [van der Steen, Jenny T.] Vrije Univ Amsterdam Med Ctr, Dept Publ & Occupat Hlth, NL-1081 BT Amsterdam, Netherlands. [Lane, Patricia; Kowall, Neil W.; Volicer, Ladislav] Edith Nourse Rogers Mem Vet Adm Hosp, Geriatr Res Educ Clin Ctr, Bedford, MA USA. [Kowall, Neil W.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Kowall, Neil W.] Boston Univ, Alzheimers Dis Ctr, Boston, MA 02215 USA. [Kowall, Neil W.] VA Boston Healthcare Syst, Neurol Serv, Boston, MA USA. [Knol, Dirk L.] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, NL-1081 BT Amsterdam, Netherlands. [Volicer, Ladislav] Univ S Florida, Sch Aging Studies, Tampa, FL USA. [Volicer, Ladislav] Charles Univ Prague, Sch Med, Prague, Czech Republic. RP van der Steen, JT (reprint author), Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Dept Nursing Home Med, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands. EM j.vandersteen@vumc.nl RI Kowall, Neil/G-6364-2012; OI Kowall, Neil/0000-0002-6624-0213; van der Steen, Jenny/0000-0002-9063-7501 FU Geriatric Research Education and Clinical Center at the Bedford VA Medical Center; National Institute on Aging; Boston University Alzheimer's Disease Center [P30 AG013846]; Netherlands Organisation for Scientific Research (NWO, the Hague) [Veni 916.66.073] FX The study was supported by the Geriatric Research Education and Clinical Center at the Bedford VA Medical Center, and in part by the National Institute on Aging-funded Boston University Alzheimer's Disease Center (P30 AG013846). J.T.S. is supported by a career award of the Netherlands Organisation for Scientific Research (NWO, the Hague; Veni 916.66.073). NWO also provided 2 travel grants. NR 34 TC 17 Z9 17 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 EI 1538-9375 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD FEB PY 2012 VL 13 IS 2 BP 156 EP 161 DI 10.1016/j.jamda.2010.07.001 PG 6 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 898HX UT WOS:000300733600014 PM 21450193 ER PT J AU Haibe-Kains, B Desmedt, C Loi, S Culhane, AC Bontempi, G Quackenbush, J Sotiriou, C AF Haibe-Kains, Benjamin Desmedt, Christine Loi, Sherene Culhane, Aedin C. Bontempi, Gianluca Quackenbush, John Sotiriou, Christos TI A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes SO JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID GENE-EXPRESSION SIGNATURES; ADJUVANT CHEMOTHERAPY; MICROARRAY ANALYSIS; INTRINSIC SUBTYPES; DATA SETS; SURVIVAL; CLASSIFICATION; VALIDATION; PROGNOSIS; METASTASIS AB Background Single sample predictors (SSPs) and Subtype classification models (SCMs) are gene expression-based classifiers used to identify the four primary molecular subtypes of breast cancer (basal-like, HER2-enriched, luminal A, and luminal B). SSPs use hierarchical clustering, followed by nearest centroid classification, based on large sets of tumor-intrinsic genes. SCMs use a mixture of Gaussian distributions based on sets of genes with expression specifically correlated with three key breast cancer genes (estrogen receptor [ER], HER2, and aurora kinase A [AURKA]). The aim of this study was to compare the robustness, classification concordance, and prognostic value of these classifiers with those of a simplified three-gene SCM in a large compendium of microarray datasets. Methods Thirty-six publicly available breast cancer datasets (n = 5715) were subjected to molecular subtyping using five published classifiers (three SSPs and two SCMs) and SCMGENE, the new three-gene (ER, HER2, and AURKA) SCM. We used the prediction strength statistic to estimate robustness of the classification models, defined as the capacity of a classifier to assign the same tumors to the same subtypes independently of the dataset used to fit it. We used Cohen kappa and Cramer V coefficients to assess concordance between the subtype classifiers and association with clinical variables, respectively. We used Kaplan-Meier survival curves and cross-validated partial likelihood to compare prognostic value of the resulting classifications. All statistical tests were two-sided. Results SCMs were statistically significantly more robust than SSPs, with SCMGENE being the most robust because of its simplicity. SCMGENE was statistically significantly concordant with published SCMs (kappa = 0.65-0.70) and SSPs (kappa = 0.34-0.59), statistically significantly associated with ER (V = 0.64), HER2 (V = 0.52) status, and histological grade (V = 0.55), and yielded similar strong prognostic value. Conclusion Our results suggest that adequate classification of the major and clinically relevant molecular subtypes of breast cancer can be robustly achieved with quantitative measurements of three key genes. C1 [Haibe-Kains, Benjamin; Culhane, Aedin C.; Quackenbush, John] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Quackenbush, John] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Haibe-Kains, Benjamin; Culhane, Aedin C.; Quackenbush, John] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Desmedt, Christine; Loi, Sherene; Sotiriou, Christos] Univ Libre Bruxelles, Breast Canc Translat Res Lab JC Heuson, Dept Med Oncol, Inst Jules Bordet, Brussels, Belgium. [Bontempi, Gianluca] Univ Libre Bruxelles, Machine Learning Grp, Dept Comp Sci, Brussels, Belgium. RP Haibe-Kains, B (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, 450 Brookline Ave, Boston, MA 02115 USA. EM bhaibeka@jimmy.harvard.edu RI Haibe-Kains, Benjamin/D-3702-2011; Loi, Sherene/H-1979-2016; OI Haibe-Kains, Benjamin/0000-0002-7684-0079; Loi, Sherene/0000-0001-6137-9171; Desmedt, Christine/0000-0002-5223-5579 FU Fulbright Commission for Educational Exchange for postdoctoral research; National Library of Medicine of the US National Institutes of Health [R01 LM010129-01]; Claudia Adams Barr Program in Innovative Basic Cancer Research; Belgian National Foundation for Research (FNRS); MEDIC Foundation; Breast Cancer Research Foundation (BCRF); Belgian National Foundation for Research (FNRS), Belgium; National Health and Medical Research Council of Australia (NHMRC); European Society of Medical Oncology (ESMO) FX B.H.-K. was supported by a grant in aid from Fulbright Commission for Educational Exchange for postdoctoral research. B.H.-K. and J.Q. were supported by a grant from the National Library of Medicine of the US National Institutes of Health (R01 LM010129-01). A.C.C. and J.Q. were supported by a grant from the Claudia Adams Barr Program in Innovative Basic Cancer Research. C.S. was supported by the Belgian National Foundation for Research (FNRS), the MEDIC Foundation and the Breast Cancer Research Foundation (BCRF). C.D. was supported by the Belgian National Foundation for Research (FNRS), Belgium. S.L. was supported by the National Health and Medical Research Council of Australia (NHMRC) and the European Society of Medical Oncology (ESMO). NR 75 TC 108 Z9 108 U1 1 U2 14 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 J NATL CANCER I JI J. Natl. Cancer Inst. PD FEB PY 2012 VL 104 IS 4 BP 311 EP 325 DI 10.1093/jnci/djr545 PG 15 WC Oncology SC Oncology GA 898FY UT WOS:000300725100012 PM 22262870 ER PT J AU Goss, K Taylor, M Maron, M Maron, B Metterville, D Sweetser, D Sims, K AF Goss, Kendrick Taylor, Matthew Maron, Martin Maron, Barry Metterville, Danielle Sweetser, David Sims, Katherine TI Prevalence of Fabry Disease in a High Risk US Cohort with Hypertophic Cardiomyopathy and Other Cardiac Diagnoses SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 8th Anuual Research Meeting of the WORLD Symposium on Lysosomal Disease Networks CY FEB 07-10, 2012 CL San Diego, CA C1 [Goss, Kendrick; Metterville, Danielle; Sweetser, David; Sims, Katherine] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Taylor, Matthew] Univ Colorado Denver, Aurora, CO USA. [Maron, Martin] Tufts Med Ctr, Boston, MA USA. [Maron, Barry] Minneapolis Heart lnst, Hypertroph Cardiomyopathy Ctr, Minneapolis, MN USA. [Sims, Katherine] Baylor Res Inst, Inst Metab Dis, Dallas, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2012 VL 105 IS 2 BP S32 EP S32 DI 10.1016/j.ymgme.2011.11.065 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 885DI UT WOS:000299758300076 ER PT J AU Hopkin, R Mauer, M Lemay, R Strotmann, J Sims, K AF Hopkin, Robert Mauer, Michael Lemay, Roberta Strotmann, Jorg Sims, Katherine TI Fabry Registry Data Indicate that Early Initiation of Agalsidase Beta Treatment is Associated with Fewer Clinical Events SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 8th Anuual Research Meeting of the WORLD Symposium on Lysosomal Disease Networks CY FEB 07-10, 2012 CL San Diego, CA C1 [Hopkin, Robert] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [Mauer, Michael] Univ Minnesota, Div Pediat Nephrol, Minneapolis, MN USA. [Lemay, Roberta] Genzyme, Biomed Data Sci & Informat, Cambridge, MA USA. [Strotmann, Jorg] Stadt Krankenhaus, Med Klin 1, Kiel, Germany. [Sims, Katherine] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Sims, Katherine] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2012 VL 105 IS 2 BP S36 EP S36 DI 10.1016/j.ymgme.2011.11.079 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 885DI UT WOS:000299758300090 ER PT J AU Mazzulli, J Krainc, D AF Mazzulli, Joseph Krainc, Dimitri TI A Mechanistic Connection Between Gaucher Disease and the Synucleinopathies SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 8th Anuual Research Meeting of the WORLD Symposium on Lysosomal Disease Networks CY FEB 07-10, 2012 CL San Diego, CA C1 [Mazzulli, Joseph; Krainc, Dimitri] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2012 VL 105 IS 2 BP S46 EP S46 DI 10.1016/j.ymgme.2011.11.112 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 885DI UT WOS:000299758300123 ER PT J AU Schiffmann, R Forni, S Swift, C Wu, XY Lockhart, D Pond, S Chee, M Goss, K Sims, K Elfrida, B Sweetman, L AF Schiffmann, Raphael Forni, Sabrina Swift, Caren Wu, Xiaoyang Lockhart, David Pond, Stephanie Chee, Mark Goss, Kendrick Sims, Katherine Elfrida, Benjamin Sweetman, Lawrence TI Increased Urinary Globotriaosylceramide and Previously Undiagnosed Fabry Patients are Found in a Non-Selected Heart Disease Patient Population SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 8th Anuual Research Meeting of the WORLD Symposium on Lysosomal Disease Networks CY FEB 07-10, 2012 CL San Diego, CA C1 [Schiffmann, Raphael; Forni, Sabrina; Swift, Caren; Sweetman, Lawrence] Baylor Res Inst, Dallas, TX USA. [Wu, Xiaoyang; Lockhart, David; Elfrida, Benjamin] Amicus Therapeut, Cranbury, NJ USA. [Pond, Stephanie; Chee, Mark] Prognosys Biosci Inc, La Jolla, CA USA. [Goss, Kendrick; Sims, Katherine] Massachusetts Gen Hosp, Neurogenet DNA Diagnost Lab, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2012 VL 105 IS 2 BP S55 EP S56 DI 10.1016/j.ymgme.2011.11.144 PG 2 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 885DI UT WOS:000299758300155 ER PT J AU Shacka, J Davidson, K Evonuk, K Feng, WG Jaimes, E Warnock, D AF Shacka, John Davidson, Kathryn Evonuk, Kirsten Feng Wenguang Jaimes, Edgar Warnock, David TI CNS Neuropathology in a Mouse Model of Fabry Disease Indicates Alterations in the Autophagy-Lysosome Pathway SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 8th Anuual Research Meeting of the WORLD Symposium on Lysosomal Disease Networks CY FEB 07-10, 2012 CL San Diego, CA C1 [Shacka, John; Davidson, Kathryn; Evonuk, Kirsten] Birmingham VA Med Ctr, UAB Dept Pathol, Birmingham, AL USA. [Feng Wenguang; Jaimes, Edgar; Warnock, David] UAB Dept Med Nephrol, Birmingham, AL USA. OI Evonuk, Kirsten/0000-0002-2750-0289 NR 0 TC 0 Z9 0 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2012 VL 105 IS 2 BP S57 EP S57 DI 10.1016/j.ymgme.2011.11.148 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 885DI UT WOS:000299758300159 ER PT J AU Sims, K Fitzpatrick, K Metterville, D Rost, N AF Sims, Katherine Fitzpatrick, Kaitlin Metterville, Danielle Rost, Natalia TI Neuroimaging Characteristics in Fabry Disease: White Matter Hyperintensity Volume Assessment in Patients with Fabry Disease SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 8th Anuual Research Meeting of the WORLD Symposium on Lysosomal Disease Networks CY FEB 07-10, 2012 CL San Diego, CA C1 [Sims, Katherine; Fitzpatrick, Kaitlin; Metterville, Danielle; Rost, Natalia] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2012 VL 105 IS 2 BP S58 EP S58 DI 10.1016/j.ymgme.2011.11.151 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 885DI UT WOS:000299758300162 ER PT J AU Yerramilli-Rao, P Giannikopoulos, O Kublis, K Pan, J Eichler, F AF Yerramilli-Rao, Padmaja Giannikopoulos, Ourania Kublis, Kim Pan, Jessica Eichler, Florian TI The Natural History of Late Onset Tay-Sachs Disease SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 8th Anuual Research Meeting of the WORLD Symposium on Lysosomal Disease Networks CY FEB 07-10, 2012 CL San Diego, CA C1 [Yerramilli-Rao, Padmaja; Giannikopoulos, Ourania; Pan, Jessica; Eichler, Florian] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kublis, Kim] Natl Tay Sachs & Allied Dis Assoc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2012 VL 105 IS 2 BP S67 EP S67 DI 10.1016/j.ymgme.2011.11.181 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 885DI UT WOS:000299758300192 ER PT J AU Thames, AD Foley, JM Wright, MJ Panos, SE Ettenhofer, M Ramezani, A Streiff, V El-Saden, S Goodwin, S Bookheimer, SY Hinkin, CH AF Thames, April D. Foley, Jessica M. Wright, Matthew J. Panos, Stella E. Ettenhofer, Mark Ramezani, Amir Streiff, Vanessa El-Saden, Suzie Goodwin, Scott Bookheimer, Susan Y. Hinkin, Charles H. TI Basal ganglia structures differentially contribute to verbal fluency: Evidence from Human Immunodeficiency Virus (HIV)-infected adults SO NEUROPSYCHOLOGIA LA English DT Article DE Basal ganglia; Verbal fluency; Magnetic resonance imaging; Human Immunodeficiency Virus; Neuropsychology; Aging ID FRONTAL-SUBCORTICAL CIRCUITS; HUNTINGTONS-DISEASE; PREFRONTAL CORTEX; MATTER VOLUME; HIV DEMENTIA; FMRI; IMPAIRMENT; HETEROGENEITY; METAANALYSIS; PERFORMANCE AB Background: The basal ganglia (BC) are involved in executive language functions (i.e., verbal fluency) through their connections with cortical structures. The caudate and putamen receive separate inputs from prefrontal and premotor cortices, and may differentially contribute to verbal fluency performance. We examined BC integrity in relation to lexico-semantic verbal fluency performance among older HIV infected adults. Method: 20 older (50+ years) HIV+ adults underwent MRI and were administered measures of semantic and phonemic fluency. BC (caudate, putamen) regions of interest were extracted. Results: Performance on phonemic word generation significantly predicted caudate volume, whereas performance on phonemic switching predicted putamen volume. Conclusions: These findings suggest a double dissociation of BC involvement in verbal fluency tasks with the caudate subserving word generation and the putamen associated with switching. As such, verbal fluency tasks appear to be selective to BC function. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Thames, April D.; Panos, Stella E.; Ramezani, Amir; El-Saden, Suzie; Bookheimer, Susan Y.; Hinkin, Charles H.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. [Foley, Jessica M.] Harvard Univ, Sch Med, Boston VA Healthcare Syst, Boston, MA 02130 USA. [Wright, Matthew J.] Harbor UCLA Med Ctr, Dept Psychiat, Psychol Div, Los Angeles, CA USA. [Thames, April D.; Panos, Stella E.; Ramezani, Amir; El-Saden, Suzie; Hinkin, Charles H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Thames, AD (reprint author), Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, 760 Westwood Plaza, Los Angeles, CA 90095 USA. EM athames@mednet.ucla.edu RI Thames, April/K-1964-2014 OI Thames, April/0000-0001-8414-7189 FU UCLA Academic Senate FAU [56199 AQ 19914]; NIH NRSA [T32 (MH19535)]; VA Merit Review; Center for AIDS Research (CFAR) FX The authors would like to acknowledge the following funding sources: UCLA Academic Senate FAU 56199 AQ 19914 (PI: Susan Bookheimer), NIH NRSA T32 (MH19535), VA Merit Review (PI: Charles Hinkin), Center for AIDS Research Grant (CFAR; PI: Jessica Foley). NR 52 TC 13 Z9 16 U1 0 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 EI 1873-3514 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD FEB PY 2012 VL 50 IS 3 BP 390 EP 395 DI 10.1016/j.neuropsychologia.2011.12.010 PG 6 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 899LE UT WOS:000300816600005 PM 22223078 ER PT J AU Demirkan, A van Duijn, CM Ugocsai, P Isaacs, A Pramstaller, PP Liebisch, G Wilson, JF Johansson, A Rudan, I Aulchenko, YS Kirichenko, AV Janssens, ACJW Jansen, RC Gnewuch, C Domingues, FS Pattaro, C Wild, SH Jonasson, I Polasek, O Zorkoltseva, IV Hofman, A Karssen, LC Struchalin, M Floyd, J Igl, W Biloglav, Z Broer, L Pfeufer, A Pichler, I Campbell, S Zaboli, G Kolcic, I Rivadeneira, F Huffman, J Hastie, ND Uitterlinden, A Franke, L Franklin, CS Vitart, V Nelson, CP Preuss, M Bis, JC O'Donnell, CJ Franceschini, N Witteman, JCM Axenovich, T Oostra, BA Meitinger, T Hicks, AA Hayward, C Wright, AF Gyllensten, U Campbell, H Schmitz, G AF Demirkan, Ayse van Duijn, Cornelia M. Ugocsai, Peter Isaacs, Aaron Pramstaller, Peter P. Liebisch, Gerhard Wilson, James F. Johansson, Asa Rudan, Igor Aulchenko, Yurii S. Kirichenko, Anatoly V. Janssens, A. Cecile J. W. Jansen, Ritsert C. Gnewuch, Carsten Domingues, Francisco S. Pattaro, Cristian Wild, Sarah H. Jonasson, Inger Polasek, Ozren Zorkoltseva, Irina V. Hofman, Albert Karssen, Lennart C. Struchalin, Maksim Floyd, James Igl, Wilmar Biloglav, Zrinka Broer, Linda Pfeufer, Arne Pichler, Irene Campbell, Susan Zaboli, Ghazal Kolcic, Ivana Rivadeneira, Fernando Huffman, Jennifer Hastie, Nicholas D. Uitterlinden, Andre Franke, Lude Franklin, Christopher S. Vitart, Veronique Nelson, Christopher P. Preuss, Michael Bis, Joshua C. O'Donnell, Christopher J. Franceschini, Nora Witteman, Jacqueline C. M. Axenovich, Tatiana Oostra, Ben A. Meitinger, Thomas Hicks, Andrew A. Hayward, Caroline Wright, Alan F. Gyllensten, Ulf Campbell, Harry Schmitz, Gerd CA DIAGRAM Consortium CARDIoGRAM Consortium CHARGE Consortium EUROSPAN Consortium TI Genome-Wide Association Study Identifies Novel Loci Associated with Circulating Phospho- and Sphingolipid Concentrations SO PLOS GENETICS LA English DT Article ID TANDEM MASS-SPECTROMETRY; HIGH-THROUGHPUT QUANTIFICATION; FATTY-ACIDS; SUSCEPTIBILITY LOCI; MEMBRANE-LIPIDS; HUMAN PLATELETS; LYSOPHOSPHATIDYLCHOLINE; DISEASE; PHOSPHATIDYLCHOLINE; ATHEROSCLEROSIS AB Phospho- and sphingolipids are crucial cellular and intracellular compounds. These lipids are required for active transport, a number of enzymatic processes, membrane formation, and cell signalling. Disruption of their metabolism leads to several diseases, with diverse neurological, psychiatric, and metabolic consequences. A large number of phospholipid and sphingolipid species can be detected and measured in human plasma. We conducted a meta-analysis of five European family-based genome-wide association studies (N = 4034) on plasma levels of 24 sphingomyelins (SPM), 9 ceramides (CER), 57 phosphatidylcholines (PC), 20 lysophosphatidylcholines (LPC), 27 phosphatidylethanolamines (PE), and 16 PE-based plasmalogens (PLPE), as well as their proportions in each major class. This effort yielded 25 genome-wide significant loci for phospholipids (smallest P-value = 9.88 x 10(-204)) and 10 loci for sphingolipids (smallest P-value = 3.10 x 10(-57)). After a correction for multiple comparisons (P-value, 2.2 x 10(-9)), we observed four novel loci significantly associated with phospholipids (PAQR9, AGPAT1, PKD2L1, PDXDC1) and two with sphingolipids (PLD2 and APOE) explaining up to 3.1% of the variance. Further analysis of the top findings with respect to within class molar proportions uncovered three additional loci for phospholipids (PNLIPRP2, PCDH20, and ABDH3) suggesting their involvement in either fatty acid elongation/saturation processes or fatty acid specific turnover mechanisms. Among those, 14 loci (KCNH7, AGPAT1, PNLIPRP2, SYT9, FADS1-2-3, DLG2, APOA1, ELOVL2, CDK17, LIPC, PDXDC1, PLD2, LASS4, and APOE) mapped into the glycerophospholipid and 12 loci (ILKAP, ITGA9, AGPAT1, FADS1-2-3, APOA1, PCDH20, LIPC, PDXDC1, SGPP1, APOE, LASS4, and PLD2) to the sphingolipid pathways. In large meta-analyses, associations between FADS1-2-3 and carotid intima media thickness, AGPAT1 and type 2 diabetes, and APOA1 and coronary artery disease were observed. In conclusion, our study identified nine novel phospho- and sphingolipid loci, substantially increasing our knowledge of the genetic basis for these traits. C1 [Demirkan, Ayse; van Duijn, Cornelia M.; Isaacs, Aaron; Aulchenko, Yurii S.; Karssen, Lennart C.; Struchalin, Maksim; Broer, Linda] Erasmus Univ, Med Ctr, Dept Epidemiol, Genet Epidemiol Unit, Rotterdam, Netherlands. [Demirkan, Ayse; van Duijn, Cornelia M.; Isaacs, Aaron; Aulchenko, Yurii S.; Karssen, Lennart C.; Struchalin, Maksim; Broer, Linda] Erasmus Univ, Dept Clin Genet, Med Ctr, Genet Epidemiol Unit, NL-3000 DR Rotterdam, Netherlands. [van Duijn, Cornelia M.; Isaacs, Aaron; Oostra, Ben A.] Ctr Med Sytems Biol, Leiden, Netherlands. [van Duijn, Cornelia M.; Hofman, Albert; Rivadeneira, Fernando; Uitterlinden, Andre; Witteman, Jacqueline C. M.] Netherlands Genom Initiat, Netherlands Consortium Hlth Aging, Leiden, Netherlands. [Ugocsai, Peter; Liebisch, Gerhard; Gnewuch, Carsten; Schmitz, Gerd] Univ Hosp Regensburg, Inst Clin Chem & Lab Med, Regensburg, Germany. [Pramstaller, Peter P.; Domingues, Francisco S.; Pattaro, Cristian; Pfeufer, Arne; Pichler, Irene; Hicks, Andrew A.] European Acad Bozen Bolzano EURAC, Ctr Biomed, Bolzano, Italy. [Pramstaller, Peter P.] Gen Cent Hosp, Dept Neurol, Bolzano, Italy. [Pramstaller, Peter P.] Univ Lubeck, Dept Neurol, Lubeck, Germany. [Wilson, James F.; Rudan, Igor; Wild, Sarah H.; Campbell, Susan; Vitart, Veronique; Campbell, Harry] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland. [Johansson, Asa; Jonasson, Inger; Igl, Wilmar; Zaboli, Ghazal; Gyllensten, Ulf] Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, Uppsala, Sweden. [Rudan, Igor] Univ Hosp Sestre Milosrdnice, Inst Clin Med Res, Zagreb, Croatia. [Rudan, Igor; Jonasson, Inger; Polasek, Ozren; Kolcic, Ivana] Univ Split, Fac Med, Croatian Ctr Global Hlth, Split, Croatia. [Kirichenko, Anatoly V.; Zorkoltseva, Irina V.; Axenovich, Tatiana] Russian Acad Sci, Inst Cytol & Genet, Siberian Div, Novosibirsk 630090, Russia. [Jansen, Ritsert C.] Univ Groningen, Groningen Bioinformat Ctr, Groningen Biomol Sci & Biotechnol Inst, Groningen, Netherlands. [Floyd, James; Franklin, Christopher S.] Wellcome Trust Sanger Inst, Hinxton, England. [Biloglav, Zrinka] Univ Zagreb, Fac Med, Andrija Stampar Sch Publ Hlth, Zagreb 41000, Croatia. [Rivadeneira, Fernando; Uitterlinden, Andre] Erasmus Univ, Med Ctr, Dept Internal Med, Rotterdam, Netherlands. [Huffman, Jennifer; Hastie, Nicholas D.; Vitart, Veronique; Hayward, Caroline; Wright, Alan F.] Inst Genet & Mol Med, Med Res Council Human Genet Unit, Edinburgh, Midlothian, Scotland. [Franke, Lude] Univ Med Ctr Groningen, Dept Genet, NL-9713 AV Groningen, Netherlands. [Nelson, Christopher P.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England. [Preuss, Michael] Univ Lubeck, Inst Med Biometrie & Stat, Lubeck, Germany. [Preuss, Michael] Univ Lubeck, Med Klin 2, Lubeck, Germany. [Bis, Joshua C.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Bis, Joshua C.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA USA. [O'Donnell, Christopher J.] Harvard Univ, Sch Med, Dept Med, Cardiol Div,Massachusetts Gen Hosp, Boston, MA USA. [Franceschini, Nora] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Meitinger, Thomas] Helmholtz Zentrum Munchen, Inst Human Genet, Neuherberg, Germany. [Meitinger, Thomas] Tech Univ Munich, Inst Human Genet, Munich, Germany. [Meitinger, Thomas] Munich Heart Alliance, Munich, Germany. RP Demirkan, A (reprint author), Erasmus Univ, Med Ctr, Dept Epidemiol, Genet Epidemiol Unit, Rotterdam, Netherlands. EM a.isaacs@erasmusmc.nl RI Wilson, James F/A-5704-2009; Polasek, Ozren/B-6002-2011; Meitinger, Thomas/O-1318-2015; Rivadeneira, Fernando/O-5385-2015; Prokopenko, Inga/H-3241-2014; Hayward, Caroline/M-8818-2016; Franke, Lude/P-7036-2016; Kolcic, Ivana/E-2713-2017; Hicks, Andrew/E-9518-2017; Liebisch, Gerhard/G-6130-2010; Willenborg, Christina/D-2668-2012; Rudan, Igor/I-1467-2012; Boehm, Bernhard/F-8750-2015; Gudnason, Vilmundur/K-6885-2015; Jansen, Ritsert/C-1160-2013; Elliott, Amanda/G-5120-2012; Pfeufer, Arne/B-6634-2013; Aulchenko, Yurii/M-8270-2013; Pramstaller, Peter/C-2357-2008; Johansson, Asa/G-5270-2011 OI Karssen, Lennart C./0000-0002-1959-342X; Kleber, Marcus/0000-0003-0663-7275; Pichler, Irene/0000-0001-8251-0757; Janssens, A Cecile/0000-0002-6153-4976; van Vliet-Ostaptchouk, Jana/0000-0002-7943-3153; Hide, Winston/0000-0002-8621-3271; Zeggini, Eleftheria/0000-0003-4238-659X; Jorgensen, Torben/0000-0001-9453-2830; Wilson, James F/0000-0001-5751-9178; Polasek, Ozren/0000-0002-5765-1862; Rivadeneira, Fernando/0000-0001-9435-9441; Prokopenko, Inga/0000-0003-1624-7457; Hayward, Caroline/0000-0002-9405-9550; Franke, Lude/0000-0002-5159-8802; Kolcic, Ivana/0000-0001-7918-6052; Hicks, Andrew/0000-0001-6320-0411; Liebisch, Gerhard/0000-0003-4886-0811; Willenborg, Christina/0000-0001-5217-6882; Rudan, Igor/0000-0001-6993-6884; Gudnason, Vilmundur/0000-0001-5696-0084; Jansen, Ritsert/0000-0003-2977-9110; Aulchenko, Yurii/0000-0002-7899-1575; Johansson, Asa/0000-0002-2915-4498 FU European Commission [018947 (LSHG-CT-2006-01947), 2007-202272]; Netherlands Organisation for Scientific Research [NWO-RFBR 047.017.043]; Russian Foundation for Basic Research [NWO-RFBR 047.017.043]; Netherlands Organisation for Scientific Research (Pionier) [047.016.009, 047.017.043]; Centre for Medical Systems Biology (CMSB; National Genomics Initiative); Erasmus MC; Ministry of Health and Department of Educational Assistance, University and Research of the Autonomous Province of Bolzano; South Tyrolean Sparkasse Foundation; Swedish Natural Sciences Research Council; Swedish Medical Research Council; European Commission through EUROSPAN; Foundation for Strategic Research (SSF); Linneaus Centre for Bioinformatics (LCB); Scottish Executive Health Department; Royal Society; Wellcome Trust Clinical Research Facility in Edinburgh; Medical Research Council UK; Ministry of Science, Education, and Sport of the Republic of Croatia [108-1080315-0302] FX EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947). High-throughput genome-wide association analysis of the data was supported by a joint grant from the Netherlands Organisation for Scientific Research and the Russian Foundation for Basic Research (NWO-RFBR 047.017.043). Lipidomic analysis was supported by the European Commission FP7 grant LipidomicNet (2007-202272). The ERF study was supported by grants from the Netherlands Organisation for Scientific Research (Pionier, 047.016.009, 047.017.043), Erasmus MC, and the Centre for Medical Systems Biology (CMSB; National Genomics Initiative). In South Tyrol, the MICROS study was supported by the Ministry of Health and Department of Educational Assistance, University and Research of the Autonomous Province of Bolzano, and the South Tyrolean Sparkasse Foundation. The Northern Swedish Population Health Study (NSPHS) was supported by grants from the Swedish Natural Sciences Research Council, Swedish Medical Research Council, the European Commission through EUROSPAN, the Foundation for Strategic Research (SSF), and the Linneaus Centre for Bioinformatics (LCB). The ORCADES study was supported by the Scottish Executive Health Department, the Royal Society, and the Wellcome Trust Clinical Research Facility in Edinburgh. The CROATIA_Vis study in the Croatian island of Vis was supported through grants from the Medical Research Council UK and Ministry of Science, Education, and Sport of the Republic of Croatia (number 108-1080315-0302). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 39 TC 63 Z9 63 U1 2 U2 22 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD FEB PY 2012 VL 8 IS 2 AR e1002490 DI 10.1371/journal.pgen.1002490 PG 14 WC Genetics & Heredity SC Genetics & Heredity GA 898GA UT WOS:000300725500014 PM 22359512 ER PT J AU McHale, MJ Sarwar, ZU Cardenas, DP Porter, L Salinas, AS Michalek, JE McManus, LM Shireman, PK AF McHale, Matthew J. Sarwar, Zaheer U. Cardenas, Damon P. Porter, Laurel Salinas, Anna S. Michalek, Joel E. McManus, Linda M. Shireman, Paula K. TI Increased fat deposition in injured skeletal muscle is regulated by sex-specific hormones SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE hormones; injury; adipocyte; ovariectomy; castration ID INFLUENCE POSTEXERCISE INDEXES; POINT-COUNTERPOINT ESTROGEN; GENDER DIFFERENCES; TRAUMA-HEMORRHAGE; OXIDATIVE STRESS; MALE RATS; ALTERED INFLAMMATION; SATELLITE CELLS; BONE-DENSITY; CCR2-/-MICE AB McHale MJ, Sarwar ZU, Cardenas DP, Porter L, Salinas AS, Michalek JE, McManus LM, Shireman PK. Increased fat deposition in injured skeletal muscle is regulated by sex-specific hormones. Am J Physiol Regul Integr Comp Physiol 302: R331-R339, 2012. First published November 23, 2011; doi:10.1152/ajpregu.00427.2011.-Sex differences in skeletal muscle regeneration are controversial; comparisons of regenerative events between sexes have not been rigorously defined in severe injury models. We comprehensively quantified inflammation and muscle regeneration between sexes and manipulated sex-specific hormones to determine effects on regeneration. Cardiotoxin injury was induced in intact, castrated and ovariectomized female and male mice; ovariectomized mice were replaced with low-or high-dose 17-beta estradiol (E-2) or progesterone (P4). Extent of injury was comparable between intact mice, but females were more efficient in removal of necrotic debris, despite similar tissue levels of inflammatory cells and chemokines. Myofiber size during regeneration was equivalent between intact mice and after castration or ovariectomy (OVX) but was decreased (P < 0.001) in ovariectomized mice with high-dose E-2 replacement. Intermuscular adipocytes were absent in uninjured muscle, whereas adipocyte area was increased among regenerated myofibers in all groups. Interestingly, intermuscular fat was greater (P = 0.03) in intact females at day 14 compared with intact males. Furthermore, castration increased (P = 0.01) and OVX decreased adipocyte accumulation. After OVX, E-2, but not P4, replacement decreased (P <= 0.03) fat accumulation. In conclusion, sex-dependent differences in regeneration consisted of more efficient removal of necrosis and increased fat deposition in females with similar injury, inflammation, and regenerated myofiber size; high-dose E-2 decreased myofiber size and fat deposition. Adipocyte accumulation in regenerating muscle was influenced by sex-specific hormones. Recovery following muscle injury was different between males and females, and sex-specific hormones contributed to these differences, suggesting that sex-specific treatments could be beneficial after injury. C1 [McHale, Matthew J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, Div Vasc Surg, San Antonio, TX 78229 USA. [Michalek, Joel E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA. [McManus, Linda M.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Shireman, Paula K.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Shireman, PK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, Div Vasc Surg, 7703 Floyd Curl Dr,MSC 7741, San Antonio, TX 78229 USA. EM shireman@uthscsa.edu FU United States Air Force; National Institutes of Health [R01-HL074236]; Veterans Administration; UTHSCSA; NIH-NCI [P30 CA054174] FX These studies were supported, in part, by the United States Air Force and by grants from the National Institutes of Health R01-HL074236 and Veterans Administration Merit Review. Data were generated in the Core Flow Cytometry Facility, which is supported by the UTHSCSA and NIH-NCI P30 CA054174 (Cancer Therapy & Research Center). NR 71 TC 7 Z9 7 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD FEB PY 2012 VL 302 IS 3 BP R331 EP R339 DI 10.1152/ajpregu.00427.2011 PG 9 WC Physiology SC Physiology GA 896ZB UT WOS:000300609000003 PM 22116509 ER PT J AU Gill, RR Richards, WG Yeap, BY Matsuoka, S Wolf, AS Gerbaudo, VH Bueno, R Sugarbaker, DJ Hatabu, H AF Gill, Ritu R. Richards, William G. Yeap, Beow Y. Matsuoka, Shin Wolf, Andrea S. Gerbaudo, Victor H. Bueno, Raphael Sugarbaker, David J. Hatabu, Hiroto TI Epithelial Malignant Pleural Mesothelioma After Extrapleural Pneumonectomy: Stratification of Survival With CT-Derived Tumor Volume SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE CT; imaging biomarkers; mesothelioma; pleura; pneumonectomy; survival; tumor volume ID POSITRON-EMISSION-TOMOGRAPHY; COMPUTED-TOMOGRAPHY; TRIMODALITY THERAPY; PROGNOSTIC-FACTORS; PREDICTION; EXPERIENCE; DISEASE; CANCER AB OBJECTIVE. The purpose of this study was to assess the usefulness of CT-derived tumor volume, with control for other prognostic factors, for stratifying survival after surgery-based multimodality treatment of a large cohort of patients with epithelial malignant pleural mesothelioma. MATERIALS AND METHODS. We retrospectively reviewed 338 patients with mesothelioma who underwent extrapleural pneumonectomy between 2001 and 2007. The study cohort comprised 88 patients with epithelial subtype tumors, DICOM-format CT scans, and data regarding neoadjuvant and adjuvant therapy. Tumor volume was calculated, and Kaplan-Meier survival and Cox regression analyses were performed to compare the estimated survival functions of patient subgroups based on volume and other covariates related to outcome (sex, age, preoperative platelet count, hemoglobin concentration, WBC count, clinical and pathologic TNM category, and administration of neoadjuvant and adjuvant therapy). A multivariate regression model was derived on the basis of the most significant univariate predictors. RESULTS. The median estimated tumor volume was 319 cm(3) (range, 4-3256 cm(3)). In univariate analysis, tumor volume, hemoglobin concentration, platelet count, pathologic TNM category, and administration of adjuvant chemotherapy or radiation therapy met the criteria for inclusion in the reverse stepwise regression analysis. In the final model, tumor volume, hemoglobin concentration, and administration of adjuvant chemotherapy or radiotherapy were identified as independently associated with overall survival. CONCLUSION. With control of prognostic covariates, CT-derived tumor volume can be used to stratify survival of patients with epithelial mesothelioma after extrapleural pneumonectomy and should be included in prognostic evaluation of patients for whom resection is being considered. C1 [Gill, Ritu R.; Matsuoka, Shin; Gerbaudo, Victor H.; Hatabu, Hiroto] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Richards, William G.; Wolf, Andrea S.; Bueno, Raphael; Sugarbaker, David J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Thorac Surg, Boston, MA 02115 USA. [Yeap, Beow Y.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Gill, RR (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, 75 Francis St, Boston, MA 02115 USA. EM rgill@partners.org NR 25 TC 27 Z9 27 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD FEB PY 2012 VL 198 IS 2 BP 359 EP 363 DI 10.2214/AJR.11.7015 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 892OX UT WOS:000300296600031 PM 22268178 ER PT J AU Duigenan, S Oliva, E Lee, SI AF Duigenan, Shauna Oliva, Esther Lee, Susanna I. TI Ovarian Torsion: Diagnostic Features on CT and MRI With Pathologic Correlation SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Review DE CT; MRI; ovarian torsion; ultrasound ID ADNEXAL TORSION; SONOGRAPHIC FINDINGS; DOPPLER SONOGRAPHY; DEPICTION; GIRLS AB OBJECTIVE. The CT and MRI features of ovarian torsion are illustrated with gross pathologic correlation. Ovarian enlargement with or without an underlying mass is the finding most frequently associated with torsion, but it is nonspecific. A twisted pedicle, although not often detected on imaging, is pathognomonic when seen. Subacute ovarian hemorrhage and abnormal enhancement is usually seen, and both features show characteristic patterns on CT and MRI. Ipsilateral uterine deviation can also be seen. CONCLUSION. Diagnostic pitfalls that may mimic ovarian torsion and observations for discriminating them are discussed. C1 [Duigenan, Shauna; Lee, Susanna I.] Massachusetts Gen Hosp, Dept Radiol, Div Abdominal Imaging & Intervent, Boston, MA 02114 USA. [Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Duigenan, S (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Abdominal Imaging & Intervent, Ellison 234,55 Fruit St, Boston, MA 02114 USA. EM sduigenan@toh.on.ca NR 31 TC 22 Z9 23 U1 0 U2 1 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD FEB PY 2012 VL 198 IS 2 BP W122 EP W131 DI 10.2214/AJR.10.7293 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 892OX UT WOS:000300296600003 PM 22268201 ER PT J AU Chung, H Dai, TH Sharma, SK Huang, YY Carroll, JD Hamblin, MR AF Chung, Hoon Dai, Tianhong Sharma, Sulbha K. Huang, Ying-Ying Carroll, James D. Hamblin, Michael R. TI The Nuts and Bolts of Low-level Laser (Light) Therapy SO ANNALS OF BIOMEDICAL ENGINEERING LA English DT Article DE Low level laser therapy; Photobiomodulation; Mitochondria; Tissue optics; Wound healing; Hair regrowth; Laser acupuncture ID HELIUM-NEON LASER; LOW-POWER LASER; NEAR-INFRARED LIGHT; RANDOMIZED-CONTROLLED-TRIAL; TERM NEUROLOGICAL DEFICITS; CYTOCHROME-C-OXIDASE; VENOUS LEG ULCERS; OPEN SKIN WOUNDS; DOUBLE-BLIND; NITRIC-OXIDE AB Soon after the discovery of lasers in the 1960s it was realized that laser therapy had the potential to improve wound healing and reduce pain, inflammation and swelling. In recent years the field sometimes known as photobiomodulation has broadened to include light-emitting diodes and other light sources, and the range of wavelengths used now includes many in the red and near infrared. The term "low level laser therapy" or LLLT has become widely recognized and implies the existence of the biphasic dose response or the Arndt-Schulz curve. This review will cover the mechanisms of action of LLLT at a cellular and at a tissular level and will summarize the various light sources and principles of dosimetry that are employed in clinical practice. The range of diseases, injuries, and conditions that can be benefited by LLLT will be summarized with an emphasis on those that have reported randomized controlled clinical trials. Serious life-threatening diseases such as stroke, heart attack, spinal cord injury, and traumatic brain injury may soon be amenable to LLLT therapy. C1 [Chung, Hoon; Dai, Tianhong; Sharma, Sulbha K.; Huang, Ying-Ying; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Chung, Hoon; Dai, Tianhong; Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China. [Carroll, James D.] Thor Photomed Ltd, Chesham HP5 1HQ, England. [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. EM hamblin@helix.mgh.harvard.edu RI Huang, Ying-ying/G-3153-2011; OI Huang, Ying-ying/0000-0003-3066-6981; Carroll, James/0000-0002-9205-1061; Hamblin, Michael/0000-0001-6431-4605 FU NIH [R01AI050875]; Center for Integration of Medicine and Innovative Technology [DAMD17-02-2-0006]; CDMRP [W81XWH-09-1-0514]; Air Force Office of Scientific Research [FA9950-04-1-0079]; Airlift Research Foundation [109421] FX Funding: Research in the Hamblin laboratory is supported by NIH grant R01AI050875, Center for Integration of Medicine and Innovative Technology (DAMD17-02-2-0006), CDMRP Program in TBI (W81XWH-09-1-0514) and Air Force Office of Scientific Research (FA9950-04-1-0079). Tianhong Dai was supported by an Airlift Research Foundation Extremity Trauma Research Grant (grant 109421). NR 132 TC 190 Z9 193 U1 13 U2 84 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0090-6964 EI 1573-9686 J9 ANN BIOMED ENG JI Ann. Biomed. Eng. PD FEB PY 2012 VL 40 IS 2 BP 516 EP 533 DI 10.1007/s10439-011-0454-7 PG 18 WC Engineering, Biomedical SC Engineering GA 895GV UT WOS:000300485100019 PM 22045511 ER PT J AU Merrill, A Millham, F AF Merrill, Andrea Millham, Frederick TI Increased Risk of Postoperative Deep Vein Thrombosis and Pulmonary Embolism in Patients With Inflammatory Bowel Disease A Study of National Surgical Quality Improvement Program Patients SO ARCHIVES OF SURGERY LA English DT Article ID VENOUS THROMBOEMBOLISM; ULCERATIVE-COLITIS; PREVALENCE; PLATELETS; ARTERIAL; HEPARIN AB Hypothesis: Patients with inflammatory bowel disease (IBD) undergoing surgery are at increased risk for postoperative thromboembolism, including deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke. Design: Retrospective cohort study. Setting: Two hundred eleven hospitals participating in the American College of Surgeons National Surgical Quality Improvement Program. Patients: All 271 368 patients from the National Surgical Quality Improvement Program 2008 Participant Use Data File were examined, and 2249 patients with IBD were compared with 269 119 patients without IBD. Main Outcome Measures: Occurrence of DVT, PE, myocardial infarction, or stroke within 30 days of surgery. Results: Of 268 703 National Surgical Quality Improvement Program patients, 2249 (0.8%) had IBD. There were 2665 cases of DVT or PE (1.0%). Occurrence of DVT or PE was more common in patients with IBD (2.5%) overall (P < .001). Nonintestinal surgical cases had a higher rate of DVT or PE (5.0%; P = .002). Regression analysis, controlling for confounders, confirmed that IBD was associated with increased risk for DVT or PE (odds ratio = 2.03; 95% CI, 1.52-2.70). For nonintestinal surgery, risk of DVT or PE for patients with IBD was increased (odds ratio = 4.45; 95% CI, 1.72-11.49). Inflammatory bowel disease had no effect on risk of postoperative myocardial infarction or stroke. Conclusions: Patients with IBD are at increased risk for developing postoperative DVT or PE. This risk persists when potential confounding variables are controlled for. Risk of DVT or PE appears to be even higher for patients with IBD who are having nonintestinal surgery. Cardiac and stroke risks do not appear to be increased by IBD. Perhaps standards for DVT and PE prophylaxis in these cases should be reconsidered. C1 [Merrill, Andrea] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Millham, Frederick] Newton Wellesley Hosp, Dept Surg, Boston, MA USA. RP Millham, F (reprint author), Newton Wellesley Hosp, Dept Surg, Green MOB, 2000 Washington St,Ste 670, Newton, MA 02462 USA. EM fmillham@partners.org NR 19 TC 30 Z9 31 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD FEB PY 2012 VL 147 IS 2 BP 120 EP 124 DI 10.1001/archsurg.2011.297 PG 5 WC Surgery SC Surgery GA 895VJ UT WOS:000300524500007 PM 22006853 ER PT J AU Lillemoe, KD AF Lillemoe, Keith D. TI Omental Roll-up Technique Decreases Pancreatic Fistula-or Does It? SO ARCHIVES OF SURGERY LA English DT Editorial Material C1 Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Lillemoe, KD (reprint author), Massachusetts Gen Hosp, Dept Surg, 55 Fruit St,Mailbox WHT506, Boston, MA 02114 USA. EM klillemoe@partners.org NR 2 TC 1 Z9 1 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD FEB PY 2012 VL 147 IS 2 BP 150 EP 151 PG 3 WC Surgery SC Surgery GA 895VJ UT WOS:000300524500013 PM 22351909 ER PT J AU Fromson, JA AF Fromson, John A. TI Surgeon, Heal Thyself SO ARCHIVES OF SURGERY LA English DT Editorial Material C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02117 USA. RP Fromson, JA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, 1 Bowdoin Sq,7th Floor, Boston, MA 02117 USA. EM fromson.john@mgh.harvard.edu NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD FEB PY 2012 VL 147 IS 2 BP 174 EP 174 PG 1 WC Surgery SC Surgery GA 895VJ UT WOS:000300524500018 PM 22351914 ER PT J AU Tolliver, BK DeSantis, SM Brown, DG Prisciandaro, JJ Brady, KT AF Tolliver, Bryan K. DeSantis, Stacia M. Brown, Delisa G. Prisciandaro, James J. Brady, Kathleen T. TI A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report SO BIPOLAR DISORDERS LA English DT Article DE acamprosate; addiction; alcohol; bipolar disorder; craving; depression; glutamate; mania ID NATIONAL EPIDEMIOLOGIC SURVEY; SUBSTANCE USE DISORDERS; PSYCHIATRIC-DISORDERS; COMORBIDITY SURVEY; ATTEMPTED-SUICIDE; ACUTE MANIA; DSM-IV; ABUSE; PREVALENCE; NALTREXONE AB Background: Alcohol use disorders commonly co-occur with bipolar disorder and are associated with a more severe course of bipolar illness, yet treatment research in this important clinical population is scarce. The current study assessed the effects of acamprosate on alcohol use and mood symptoms in subjects with co-occurring bipolar disorder and active alcohol dependence. Methods: Thirty-three adults meeting criteria for bipolar I or bipolar II disorder and current alcohol dependence were randomized to receive add-on acamprosate (1998 mg/day) or placebo while concurrently maintained on mood stabilizing medications. Participants were assessed weekly for frequency and quantity of alcohol consumption and general clinical severity for eight weeks. Depressive symptoms, manic symptoms, and alcohol craving were assessed biweekly. Biomarkers of alcohol use were assessed at study baseline and endpoint. Results: Of the 33 subjects randomized, 23 (69.7%) completed all active phase visits. Over the trial as a whole, no statistically significant treatment differences were detected in drinking outcomes. Post-hoc analysis revealed lower Clinical Global Impression scores of substance use severity in acamprosate-treated participants in weeks 7-8 of the trial. No significant differences in depressive symptoms, manic symptoms, or adverse events were observed between groups. Conclusions: Acamprosate was well-tolerated, with no worsening of depressive or manic symptoms, and appeared to confer some clinical benefit in study completers in the last two weeks of the trial. Larger studies of longer duration are required to fully explore the utility of acamprosate in this population. C1 [Tolliver, Bryan K.; Brown, Delisa G.; Prisciandaro, James J.; Brady, Kathleen T.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, Charleston, SC 29425 USA. [DeSantis, Stacia M.] Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC 29425 USA. [Brady, Kathleen T.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Tolliver, BK (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, 67 President St, Charleston, SC 29425 USA. EM tollive@musc.edu FU Forest Laboratories FX This study was supported by an investigator-initiated research grant from Forest Laboratories. The authors report no other commercial associations that might pose a conflict of interest in connection with this manuscript. NR 48 TC 24 Z9 25 U1 6 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-5647 EI 1399-5618 J9 BIPOLAR DISORD JI Bipolar Disord. PD FEB PY 2012 VL 14 IS 1 BP 54 EP 63 DI 10.1111/j.1399-5618.2011.00973.x PG 10 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 894SU UT WOS:000300448000006 PM 22329472 ER PT J AU Mahindra, A Bolwell, BJ Rybicki, L Elder, P Kalaycio, M Dean, R Avalos, B Sobecks, R Tench, S Andresen, S Pohlman, B Sweetenham, J Devine, S Copelan, E AF Mahindra, A. Bolwell, B. J. Rybicki, L. Elder, P. Kalaycio, M. Dean, R. Avalos, B. Sobecks, R. Tench, S. Andresen, S. Pohlman, B. Sweetenham, J. Devine, S. Copelan, E. TI Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia SO BONE MARROW TRANSPLANTATION LA English DT Article DE etoposide; priming; lymphoma; secondary malignancies ID STEM-CELL TRANSPLANTATION; NON-HODGKINS-LYMPHOMA; ACUTE MYELOGENOUS LEUKEMIA; HIGH-DOSE THERAPY; BONE-MARROW TRANSPLANTATION; MYELOID-LEUKEMIA; MALIGNANCIES; AUTOTRANSPLANTATION; DISEASE AB The use of etoposide (VP-16) for stem cell mobilization has been reported as a significant risk factor for the development of therapy-related myelodysplasia/therapy-related AML (tMDS/tAML) after transplantation. We compared the safety and effectiveness of VP-16+G-CSF (VP+G) to G-CSF alone for PBPC mobilization in patients with non-Hodgkin's lymphoma and Hodgkin's lymphoma who underwent autologous transplantation at the Cleveland Clinic and Ohio State University. In the VP+G group, median total CD34+ cells collected were 9.34 x 10(6) per kg (range 0.97-180.89), with 42% of all patients having adequate (2 x 10(6) cells per kg) CD 34+ collection after 2 days of apheresis compared with a median in the G-CSF group of 3.83 x 10(6) per kg (range, 0.72-50.38), with only 16% patients having adequate collection after 2 days (P < 0.001). tMDS/tAML occurred in 15 patients (2.3%) in the VP+G and in 12 patients (3.8%) receiving G-CSF alone. (P = 0.62). Increased number of days of apheresis was associated with the risk of tMDS/tAML (hazard ratio (HR) 1.19, 95% confidence interval (CI) 1.08-1.30, P < 0.001). Priming regimen was not a significant variable for relapse-free survival or OS. The addition of etoposide significantly improves the effectiveness of mobilization at the cost of an increased incidence of neutropenic fever though with no mortalities. There is no evidence of increased incidence of tMDS/tAML in patients receiving VP+G compared with those mobilized with G-CSF alone. Bone Marrow Transplantation (2012) 47, 231-235; doi:10.1038/bmt.2011.73; published online 4 April 2011 C1 [Mahindra, A.] Massachusetts Gen Hosp, Ctr Canc, Div Hematol & Med Oncol, Boston, MA 02114 USA. [Bolwell, B. J.; Kalaycio, M.; Dean, R.; Sobecks, R.; Tench, S.; Andresen, S.; Pohlman, B.; Sweetenham, J.; Copelan, E.] Cleveland Clin, Dept Hematol Oncol & Blood Disorders, Taussig Canc Inst, Cleveland, OH 44106 USA. [Rybicki, L.] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA. [Elder, P.; Avalos, B.; Devine, S.] Ohio State Univ, Div Hematol Oncol, Columbus, OH 43210 USA. RP Mahindra, A (reprint author), Massachusetts Gen Hosp, Ctr Canc, Div Hematol & Med Oncol, 55 Fruit St,POB 236, Boston, MA 02114 USA. EM amahindra@partners.org NR 16 TC 9 Z9 9 U1 1 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD FEB PY 2012 VL 47 IS 2 BP 231 EP 235 DI 10.1038/bmt.2011.73 PG 5 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 894GM UT WOS:000300415100011 PM 21460870 ER PT J AU Caplan, D Gow, D AF Caplan, David Gow, David TI Effects of tasks on BOLD signal responses to sentence contrasts: Review and commentary SO BRAIN AND LANGUAGE LA English DT Review DE Sentence comprehension; Syntactic processing; Functional neuroimaging ID SYNTACTIC AMBIGUITY RESOLUTION; SPOKEN-LANGUAGE COMPREHENSION; CAT VISUAL-CORTEX; E-Z-READER; WORKING-MEMORY; GRANGER CAUSALITY; SPEECH-PERCEPTION; RELATIVE CLAUSES; EYE-MOVEMENTS; BROCAS AREA AB Functional neuroimaging studies of syntactic processing have been interpreted as identifying the neural locations of parsing and interpretive operations. However, current behavioral studies of sentence processing indicate that many operations occur simultaneously with parsing and interpretation. In this review, we point to issues that arise in discriminating the effects of these concurrent processes from those of the parser/interpreter in neural measures and to approaches that may help resolve them. (C) 2010 Elsevier Inc. All rights reserved. C1 [Caplan, David; Gow, David] Massachusetts Gen Hosp, Dept Neurol, Neuropsychol Lab, Boston, MA 02114 USA. RP Caplan, D (reprint author), Massachusetts Gen Hosp, Dept Neurol, Neuropsychol Lab, 175 Cambridge St,Suite 340, Boston, MA 02114 USA. EM dcaplan@partners.org FU NIDCD [DC02146, 013108] FX The research was supported by Grants from NIDCD for David Caplan (DC02146) and to David Gow (013108). NR 118 TC 5 Z9 5 U1 2 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0093-934X J9 BRAIN LANG JI Brain Lang. PD FEB PY 2012 VL 120 IS 2 SI SI BP 174 EP 186 DI 10.1016/j.bandl.2010.08.002 PG 13 WC Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental SC Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology GA 895EI UT WOS:000300478600008 PM 20932562 ER PT J AU Sakamoto, FH Izikson, L Tannous, Z Zurakowski, D Anderson, RR AF Sakamoto, F. H. Izikson, L. Tannous, Z. Zurakowski, D. Anderson, R. Rox TI Surgical scar remodelling after photodynamic therapy using aminolaevulinic acid or its methylester: a retrospective, blinded study of patients with field cancerization SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Article ID BASAL-CELL CARCINOMA; TRANSPLANT RECIPIENTS; SKIN-CANCER; ULTRAVIOLET AB Background Photodynamic therapy (PDT) is a nonsurgical alternative to conventional tumour excision for nonmelanoma skin cancers (NMSCs). Objectives We evaluated whether patients with field cancerization (multiple NMSCs) treated with aminolaevulinic acid (ALA) or its methylester (MAL) for that indication had PDT-induced changes in surgical scars in the treatment field. Methods Six adult patients with multiple NMSCs and a total of 21 scars from previous excisions were studied in a retrospective blinded evaluation from clinical photographs of scar response to ALA/MAL-PDT. After a 3-h application of topical 20% ALA or 16.8% MAL under occlusion, each field was irradiated with 635-nm light-emitting diode light at the fluence of 200 J cm(-2). Patients underwent one to three PDT sessions per field at similar to 1 month intervals, to fields that included scars on the back, thigh, arms and neck. Pre- and post-treatment digital photographs of scars were combined into 92 pairs that were independently and blindly evaluated by three board-certified dermatologists. This study was performed at our academic practice at the Massachusetts General Hospital. Results PDT produced a statistically significant improvement in scar appearance. The degree of improvement correlated with the number of treatment sessions (two or three treatments; P < 0.05). Improvement after a single treatment was not statistically different from baseline ratings (P = 0.99). Conclusions Surgical scar remodelling and clinical improvement may be accomplished via ALA/MAL-PDT, but may require repeated treatment sessions. Larger, prospective studies are necessary to confirm the effectiveness of PDT for this indication. C1 [Sakamoto, F. H.; Izikson, L.; Tannous, Z.; Anderson, R. Rox] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. [Zurakowski, D.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Surg, Boston, MA 02115 USA. RP Anderson, RR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. EM rranderson@partners.org NR 15 TC 12 Z9 13 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0007-0963 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD FEB PY 2012 VL 166 IS 2 BP 413 EP 416 DI 10.1111/j.1365-2133.2011.10576.x PG 4 WC Dermatology SC Dermatology GA 897YN UT WOS:000300699200025 PM 21848691 ER PT J AU Hong, TS Clark, JW Haigis, KM AF Hong, Theodore S. Clark, Jeffrey W. Haigis, Kevin M. TI Cancers of the Colon and Rectum: Identical or Fraternal Twins? SO CANCER DISCOVERY LA English DT Article ID PREOPERATIVE CHEMORADIOTHERAPY; COLORECTAL-CANCER; LOCAL RECURRENCE; SURVIVAL; FLUOROURACIL; TRIAL; RADIOTHERAPY; EXPRESSION; EFFICACY AB Colorectal cancer represents a major cause of cancer morbidity and mortality, with approximately 1.2 million cases and 600,000 deaths worldwide each year. Because of the anatomic continuity of the colon into the rectum, cancers affecting these organs have historically been considered equivalent. In this Prospective, we discuss the clinical and experimental data suggesting that colon cancer and rectal cancer are highly related, but distinct, diseases. Reconsidering the relationship between these cancers has implications for the development of new therapeutic paradigms. Cancer Discovery; 2(2); 117-21. (C) 2012 AACR. C1 [Hong, Theodore S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Clark, Jeffrey W.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Haigis, Kevin M.] Massachusetts Gen Hosp, Mol Pathol Unit, Boston, MA 02114 USA. RP Haigis, KM (reprint author), Mol Pathol Unit, 149 13th St,7-372, Charlestown, MA 02129 USA. EM khaigis@partners.org NR 22 TC 17 Z9 17 U1 0 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2159-8274 EI 2159-8290 J9 CANCER DISCOV JI Cancer Discov. PD FEB PY 2012 VL 2 IS 2 BP 117 EP 121 DI 10.1158/2159-8290.CD-11-0315 PG 5 WC Oncology SC Oncology GA 896UV UT WOS:000300597800021 PM 22585856 ER PT J AU Chatterjee, NA Upadhyay, GA Ellenbogen, KA McAlister, FA Choudhry, NK Singh, JP AF Chatterjee, Neal A. Upadhyay, Gaurav A. Ellenbogen, Kenneth A. McAlister, Finlay A. Choudhry, Niteesh K. Singh, Jagmeet P. TI Atrioventricular Nodal Ablation in Atrial Fibrillation A Meta-Analysis and Systematic Review SO CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY LA English DT Review DE atrioventricular node; ablation; pacing; fibrillation; meta-analysis ID QUALITY-OF-LIFE; RADIOFREQUENCY CATHETER ABLATION; CONGESTIVE-HEART-FAILURE; CARDIAC-RESYNCHRONIZATION THERAPY; PERMANENT PACEMAKER IMPLANTATION; LEFT-VENTRICULAR FUNCTION; LONG-TERM SURVIVAL; JUNCTION ABLATION; PACING THERAPY; HIS-BUNDLE AB Background-In the treatment of patients with refractory atrial fibrillation (AF), the safety and efficacy of atrioventricular nodal ablation (AVNA) versus pharmacotherapy alone remains unclear. Additionally, the impact of AVNA in patients with reduced systolic function is of growing interest. Methods and Results-A total of 5 randomized or prospective trials were included for efficacy review (314 patients), 11 studies for effectiveness review (810 patients), and 47 studies for safety review (5632 patients). All-cause mortality was similar between AVNA and medical therapy (3.1% versus 3.3%; relative risk ratio, 1.05; 95% confidence interval [CI], 0.29-3.85). There was no significant difference in exercise duration or ejection fraction (EF) with AVNA relative to pharmacotherapy. In subgroup analysis, patients with baseline systolic dysfunction (116 patients; mean EF, 44%) showed significant relative improvement in EF after AVNA (+4% greater; 95% CI, 3.11-4.89). In pooled observational analysis, AVNA was also associated with significant improvement in EF only in patients with systolic dysfunction (+7.44%; 95% CI, 5.4-9.5). The incidence of procedure-related mortality (0.27%) and malignant arrhythmia (0.57%) was low. At mean follow-up of 26.5 months, the incidence of sudden cardiac death after AVNA was 2.1%. There was significant heterogeneity in quality-of-life scales used; compared with pharmacotherapy, AVNA was associated with significant improvement in several symptoms (palpitations, dyspnea). Conclusions-In the management of refractory AF, AVNA is associated with improvement in symptoms and quality of life, with a low incidence of procedure morbidity. In patients with reduced systolic function, AVNA demonstrates small but significantly improved echocardiographic outcomes relative to medical therapy alone. (Circ Arrhythm Electrophysiol. 2012;5:68-76.) C1 [Chatterjee, Neal A.; Upadhyay, Gaurav A.; Singh, Jagmeet P.] Massachusetts Gen Hosp, Ctr Heart, Cardiac Arrhythmia Serv, Boston, MA 02411 USA. [Chatterjee, Neal A.; Upadhyay, Gaurav A.; Singh, Jagmeet P.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02411 USA. [Ellenbogen, Kenneth A.] Virginia Commonwealth Univ, Sch Med, Div Cardiol, Richmond, VA USA. [McAlister, Finlay A.] Univ Alberta Hosp, Div Internal Med, Edmonton, AB T6G 2B7, Canada. [Choudhry, Niteesh K.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, Boston, MA 02115 USA. RP Singh, JP (reprint author), Massachusetts Gen Hosp, Ctr Heart, Cardiac Arrhythmia Serv, GRB 109,55 Fruit St, Boston, MA 02411 USA. EM jsingh@partners.org RI McAlister, Finlay/C-4151-2013 FU Medtronic; Boston Science; Biotronik; St Jude Medical; Sorin Group FX Dr Ellenbogen is a consultant for Biotronik, Boston Scientific, Medtronic, Sorin Group, and St Jude Medical and receives research grants from Medtronic, Boston Science, and St Jude and fellowship support form Medtronic, Boston Science, and Biotronik. Dr McAlister receives speaker's fees from St Jude Medical. Dr Singh is a consultant and receives lecture fees from Biotronik, Boston Scientific, Medtronic, Sorin Group, and St Jude Medical and is a consultant for CardioInsight Inc, Thoratec Inc, and Biosense Webster. NR 75 TC 18 Z9 18 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3149 J9 CIRC-ARRHYTHMIA ELEC JI Circ.-Arrhythmia Electrophysiol. PD FEB PY 2012 VL 5 IS 1 BP 68 EP U148 DI 10.1161/CIRCEP.111.967810 PG 13 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 897AM UT WOS:000300613000015 PM 22187425 ER PT J AU Jang, IK AF Jang, Ik-Kyung TI Near Infrared Spectroscopy Another Toy or Indispensible Diagnostic Tool? SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS LA English DT Editorial Material DE Editorials; acute coronary syndrome; angina; coronary artery disease; imaging; plaque ID OPTICAL COHERENCE TOMOGRAPHY; CORONARY ANGIOSCOPY; PLAQUE; CLASSIFICATION; LESIONS C1 [Jang, Ik-Kyung] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Jang, Ik-Kyung] Harvard Univ, Sch Med, Boston, MA USA. RP Jang, IK (reprint author), Massachusetts Gen Hosp, Div Cardiol, Bigelow 8,55 Fruit St, Boston, MA 02114 USA. EM ijang@partners.org NR 10 TC 3 Z9 4 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7640 J9 CIRC-CARDIOVASC INTE JI Circ.-Cardiovasc. Interv. PD FEB PY 2012 VL 5 IS 1 BP 10 EP 11 DI 10.1161/CIRCINTERVENTIONS.111.967935 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 896ZR UT WOS:000300610900007 PM 22338001 ER PT J AU Walker, AK Naar, AM AF Walker, Amy K. Naeaer, Anders M. TI SREBPs: regulators of cholesterol/lipids as therapeutic targets in metabolic disorders, cancers and viral diseases SO CLINICAL LIPIDOLOGY LA English DT Article DE AMPK; cholesterol membrane production; lipid; metabolic syndrome; miR-33a/b; mTOR; SREBP ID ACTIVATED PROTEIN-KINASE; ELEMENT-BINDING PROTEIN-1; HEPATITIS-C PATIENTS; INSULIN-RESISTANCE; FATTY LIVER; TRANSCRIPTION FACTOR; COMBINATION THERAPY; LIPID-METABOLISM; SMALL-MOLECULE; PATHWAY AB SREBPs control genes involved in cholesterol/lipid metabolism, membrane synthesis and fat storage. Aberrant SREBP activities have been linked to conditions associated with metabolic syndrome, including insulin resistance, obesity, elevated circulating LDL-C and triglycerides, and nonalcoholic fatty liver diseases. In addition, SREBPs have been implicated in cancer cell proliferation and enveloped viral replication through regulation of membrane synthesis. Therapeutic approaches to block SREBP functions linked to disease states may act through potentiation of SREBP negative regulators such as AMP-activated kinase or the sirtuin, SIRTI, or by inhibiting the proteolytic maturation into the active transcription factor forms. Additionally, cofunctional miRNAs embedded within the SREBP genomic loci (miR-33a/b) may also serve as novel therapeutic targets to ameliorate cardiometabolic diseases. Taken together, aberrant SREBP-linked activities could represent important targets of therapies to limit lipid/cholesterol synthesis or membrane production in metabolic diseases, cancer progression and viral pathogenesis. C1 [Naeaer, Anders M.] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA. [Walker, Amy K.] Univ Massachusetts, Sch Med, Worcester, MA 01605 USA. [Naeaer, Anders M.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. RP Naar, AM (reprint author), Massachusetts Gen Hosp, Ctr Canc, Room 7407,Bldg 149,13th St, Charlestown, MA 02129 USA. EM naar@helix.mgh.harvard.edu NR 77 TC 5 Z9 6 U1 1 U2 19 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1758-4299 J9 CLIN LIPIDOL JI Clin. Lipidol. PD FEB PY 2012 VL 7 IS 1 BP 27 EP 36 DI 10.2217/CLP.11.67 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 896DV UT WOS:000300546500008 ER PT J AU Cotman, SL Staropoli, JF AF Cotman, Susan L. Staropoli, John F. TI The juvenile Batten disease protein, CLN3, and its role in regulating anterograde and retrograde post-Golgi trafficking SO CLINICAL LIPIDOLOGY LA English DT Review DE autophagy; Batten disease; CLN3; endosome; Golgi; juvenile neuronal; ceroid lipofuscinosis; lysosome; palmitoylation ID NEURONAL CEROID-LIPOFUSCINOSIS; SYNTHASE SUBUNIT-C; KNOCK-IN MICE; YEAST MODEL; GENE CLN3; MICRODELETION SYNDROME; MEMBRANE GLYCOPROTEIN; DELTA-9 DESATURASE; DILEUCINE MOTIF; MOUSE MODELS AB Loss-of-function mutations in CLN3 are responsible for juvenile-onset neuronal ceroid lipofuscinosis (JNCL), or Batten disease, which is an incurable lysosomal disease that manifests with vision loss, followed by seizures and progressive neurodegeneration, robbing children of motor skills, speech and cognition, and eventually leading to death in the second or third decade of life. Emerging clinical evidence points to JNCL pathology outside of the CNS, including the cardiovascular system. The CLN3 gene encodes an unusual transmembrane protein, CLN3 or battenin, whose elusive function has been the subject of intense study for more than 10 years. Owing to the detailed characterization of a large number of disease models, our knowledge of CLN3 protein function is finally coming into focus. This review will describe the most current understanding of CLN3 structure, function and dysfunction in JNCL. C1 [Cotman, Susan L.; Staropoli, John F.] Massachusetts Gen Hosp, Mol Neurogenet Unit, Ctr Human Genet Res, Boston, MA 02114 USA. [Staropoli, John F.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Cotman, SL (reprint author), Massachusetts Gen Hosp, Dept Neurol, 185 Cambridge St, Boston, MA 02114 USA. EM cotman@helix.mgh.harvard.edu FU Batten Disease Support and Research Association; Dubai-Harvard Foundation for Medical Research; National Institute of Neurological Disorders and Stroke at the NIH [NS073813] FX The authors of this review are supported by grants from the Batten Disease Support and Research Association (both authors), the Dubai-Harvard Foundation for Medical Research (SL Cotman) and the National Institute of Neurological Disorders and Stroke at the NIH (NS073813, SL Cotman). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 95 TC 22 Z9 23 U1 3 U2 14 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1758-4299 J9 CLIN LIPIDOL JI Clin. Lipidol. PD FEB PY 2012 VL 7 IS 1 BP 79 EP 91 DI 10.2217/CLP.11.70 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 896DV UT WOS:000300546500012 PM 22545070 ER PT J AU Adler, LA Wilens, T Zhang, SY Dittmann, RW D'Souza, DN Schuh, L Durell, TM AF Adler, Lenard A. Wilens, Timothy Zhang, Shuyu Dittmann, Ralf W. D'Souza, Deborah N. Schuh, Leslie Durell, Todd M. TI Atomoxetine Treatment Outcomes in Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder: Results From a Post Hoc, Pooled Analysis SO CLINICAL THERAPEUTICS LA English DT Article DE ADHD; adolescence; atomoxetine; young adulthood ID DEFICIT HYPERACTIVITY DISORDER; ONCE-DAILY ATOMOXETINE; COMORBIDITY SURVEY REPLICATION; DOUBLE-BLIND; CHILDREN; ADHD; PATTERNS; TRIAL; PREVALENCE; DIVERSION AB Background: Many children with attention-deficit/hyperactivity disorder (ADHD) continue to experience this disorder as adults, which may, in part, be due to the discontinuity of health care that often occurs during the transition period between late adolescence and young adulthood. Although atomoxetine is reported to be efficacious in both adolescents and young adults, no longitudinal studies have been designed to assess directly the effects of atomoxetine treatment during this transition period. As a first step, we present the results of a post hoc, pooled analysis that compared the efficacy and safety profile of atomoxetine in these 2 patient populations. Objective: The aim of the present study was to assess the efficacy and safety profile of atomoxetine treatment in adolescents and young adults with ADHD. Methods: A post hoc, pooled analysis was conducted by combining data from 6 double-blind trials (6-9 weeks in duration) that studied adolescents (12-17 years of age; atomoxetine, n = 154; placebo, n = 88; mean final dose = 1.38 mg/kg) and 3 trials (10 weeks in duration) that studied young adults (18-30 years of age; atomoxetine, n = 117; placebo, n = 125; mean final dose = 1.21 mg/kg). Efficacy measures used in these analyses were ADHD Rating Scale (ADHDRS) for adolescents, Conners' Adult ADHD Rating Scale (CAARS) for young adults, and Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) for both age groups. Treatment response was defined as >= 30 % reduction from baseline in total ADHD symptom score. Results: In adolescents (mean age, 13.4 years), atomoxetine improved ADHD significantly compared with placebo (ADHDRS total score change, -12.9 vs -7.5; P < 0.001). In young adults (mean age, 24.7 years), atomoxetine improved ADHD significantly (CAARS total score change, -13.6 vs -7.7; P < 0.001; CGI-ADHD-S change, -1.1 vs -0.6; P < 0.001). No significant treatment-by-age subgroup interaction was observed. Tolerability was similar for both age subgroups, except for treatment-emergent nausea, which occurred significantly more frequently with aromoxetine than with placebo in young adults (13.7% vs 4.8%, respectively; P = 0.024); in adolescents no statistically significant differences were observed in frequency of nausea between atomoxetine and placebo treatment (4.5% vs 10.2%, respectively; P = 0.108). Conclusions: Results from this post hoc, pooled analysis suggest that acute treatment with atomoxetine was efficacious in both adolescent and young adult patients with ADHD. The safety profile findings from this study were consistent with the previously reported atomoxetine safety and tolerability profiles, suggesting that it may be continued during the transition from adolescence to young adulthood. (Clin Ther. 2012;34: 363-373) (C) 2012 Elsevier HS Journals, Inc. All rights reserved. C1 [Adler, Lenard A.] NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA. [Adler, Lenard A.] New York Vet Hlth Adm Harbor Healthcare Syst, Psychiat Serv, New York, NY USA. [Wilens, Timothy] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Zhang, Shuyu] Lilly Res Labs, Indianapolis, IN USA. [Dittmann, Ralf W.] Univ Heidelberg, Eli Lilly Endowed Chair Pediat Psychopharmacol, Dept Child & Adolescent Psychiat, Cent Inst Mental Hlth, D-6800 Mannheim, Germany. [D'Souza, Deborah N.] InVentiv Hlth Co, PharmaNet i3, Burlington, MA USA. [Schuh, Leslie] St Vincent Bariatr Ctr Excellence, Carmel, IN USA. [Durell, Todd M.] Lilly USA LLC, Indianapolis, IN USA. RP Adler, LA (reprint author), NYU, Sch Med, Dept Psychiat, HCC 5A,530 1st Ave, New York, NY 10016 USA. EM lenard.adler@med.nyu.edu OI Adler, Len/0000-0002-9812-8234 FU Eli Lilly and Company; Abbott Laboratories; Cortex Pharmaceuticals; Bristol-Myers Squibb; Merck Co; Novartis Pharmaceuticals; Pfizer; Shire; Ortho McNeil/Janssen/Johnson and Johnson; New River Pharmaceuticals; Cephalon; National Institute of Drug Abuse (NIDA); Abbott; McNeil; Eli Lilly; Janssen-Cilag; Shire Pharmaceuticals; German Research Foundation; German Ministry of Research; European Union; Allergan; Ethicon FX This research was supported by Eli Lilly and Company.; Dr. Adler has no equity interests or stock ownership; receives grant/research support from Abbott Laboratories, Cortex Pharmaceuticals, Bristol-Myers Squibb, Merck & Co, Novartis Pharmaceuticals, Pfizer, Shire, Eli Lilly and Company, Ortho McNeil/Janssen/Johnson and Johnson, New River Pharmaceuticals, Cephalon, National Institute of Drug Abuse (NIDA); is on the speakers' bureaus of Eli Lilly and Shire; and is on the advisory board and is a consultant for Abbott, AstraZeneca, McNeil, Eli Lilly, NIH, Novartis, Merck, and Shire. Dr. Wilens receives grant support from Abbott, McNeil, Eli Lilly, the NIDA, Merck, and Shire; has been a speaker for McNeil, Novartis, and Shire; and is a consultant for Abbott, AstraZeneca, McNeil, Eli Lilly, NIH, Novartis, Merck, and Shire. Dr. Dittmann is a stockholder and former employee of Eli Lilly (Lilly Deutschland, Germany); is on the advisory board and has been a speaker for Eli Lilly; has received grant support from Janssen-Cilag, Eli Lilly, Shire Pharmaceuticals, the German Research Foundation, the German Ministry of Research, and the European Union. Dr. Schuh is a former employee of Eli Lilly and has received grant/research support from Eli Lilly, Allergan, and Ethicon. Dr. D'Souza is a former employee of Eli Lilly. Dr. Durell and Ms. Zhang are employees of Lilly USA and are minor stockholders in Eli Lilly. The authors have indicated that they have no other conflicts of interest regarding the content of this article. NR 28 TC 7 Z9 7 U1 2 U2 2 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 J9 CLIN THER JI Clin. Ther. PD FEB PY 2012 VL 34 IS 2 BP 363 EP 373 DI 10.1016/j.clinthera.2011.12.015 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 896TZ UT WOS:000300595600010 PM 22285724 ER PT J AU Zhang, G Wang, Y Zhang, Y Wan, X Li, J Liu, K Wang, F Liu, K Liu, Q Yang, C Yu, P Huang, Y Wang, S Jiang, P Qu, Z Luan, J Duan, H Zhang, L Hou, A Jin, S Hsieh, TC Wu, E AF Zhang, G. Wang, Y. Zhang, Y. Wan, X. Li, J. Liu, K. Wang, F. Liu, K. Liu, Q. Yang, C. Yu, P. Huang, Y. Wang, S. Jiang, P. Qu, Z. Luan, J. Duan, H. Zhang, L. Hou, A. Jin, S. Hsieh, T. -C. Wu, E. TI Anti-Cancer Activities of Tea Epigallocatechin-3-Gallate in Breast Cancer Patients under Radiotherapy SO CURRENT MOLECULAR MEDICINE LA English DT Review DE Adjuvant therapy; breast cancer patients; EGCG; gamma-radiation; HGF; MMP9/MMP2; VEGF ID ENDOTHELIAL GROWTH-FACTOR; NF-KAPPA-B; CELL-CYCLE ARREST; GREEN TEA; CARCINOMA-CELLS; TUMOR-GROWTH; IN-VIVO; (-)-EPIGALLOCATECHIN GALLATE; VASCULAR-PERMEABILITY; FACTOR/SCATTER FACTOR AB The purpose of this study was to test the hypothesis that administration of epigallocatechin-3-gallate (EGCG), a polyphenol present in abundance in widely consumed tea, inhibits cell proliferation, invasion, and angiogenesis in breast cancer patients. EGCG in 400 mg capsules was orally administered three times daily to breast cancer patients undergoing treatment with radiotherapy. Parameters related to cell proliferation, invasion, and angiogenesis were analyzed while blood samples were collected at different time points to determine efficacy of the EGCG treatment. Compared to patients who received radiotherapy alone, those given radiotherapy plus EGCG for an extended time period (two to eight weeks) showed significantly lower serum levels of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and reduced activation of metalloproteinase-9 and metalloproteinase-2 (MMP9/MMP2). Addition of sera obtained from patients treated with combination of radiotherapy and EGCG feeding for 2-8 weeks to in vitro cultures of highly-metastatic human MDA-MB-231 breast cancer cells resulted in the following significant changes: (1) suppression of cell proliferation and invasion; (2) arrest of cell cycles at the G0/G1 phase; (3) reduction of activation of MMP9/MMP2, expressions of Bcl-2/Bax, c-Met receptor, NF-kappa B, and the phosphorylation of Akt. MDA-MB-231 cells exposed to 5-10 mu M EGCG also showed significant augmentation of the apoptosis inducing effects of gamma-radiation, concomitant with reduced NF-kappa B protein level and AKT phosphorylation. These results provide hitherto unreported evidence that EGCG potentiated efficacy of radiotherapy in breast cancer patients, and raise the possibility that this tea polyphenol has potential to be a therapeutic adjuvant against human metastatic breast cancer. C1 [Zhang, G.; Liu, K.; Liu, K.; Liu, Q.; Yu, P.; Huang, Y.; Wang, S.; Luan, J.; Duan, H.] Yantai Univ, Sch Pharm, Mol Pharmacol Lab, Yantai 264005, Shandong, Peoples R China. [Wang, Y.; Jiang, P.; Qu, Z.] Chinese PLA 107 Hosp, Ctr Nontraumat Treatment & Diag Tumor, Yantai 264002, Shandong, Peoples R China. [Zhang, Y.] Anhui Med Univ, Clin Coll, Hefei 230601, Anhui, Peoples R China. [Wan, X.] Anhui Agr Univ, Minist Agr, Key Lab Tea Biochem & Biotechnol, Hefei 230036, Anhui, Peoples R China. [Li, J.; Zhang, L.; Jin, S.] Shandong Res Ctr Stem Cell Engn, Yantai 264001, Shandong, Peoples R China. [Li, J.; Zhang, L.; Jin, S.] Yuhuangding Hosp Yantai, Yantai 264001, Shandong, Peoples R China. [Wang, F.; Wu, E.] N Dakota State Univ, Dept Pharmaceut Sci, Fargo, ND 58105 USA. [Yang, C.] Harvard Univ, Massachusetts Gen Hosp, Canc Res Ctr, Ctr Canc, Boston, MA 02114 USA. [Hou, A.] Yantai Hosp Tradit Chinese Med, Yantai 264003, Shandong, Peoples R China. [Hsieh, T. -C.] New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA. RP Zhang, G (reprint author), Yantai Univ, Sch Pharm, Mol Pharmacol Lab, Yantai 264005, Shandong, Peoples R China. EM zhang_zhang6173@yahoo.com.cn; erxi.wu@ndsu.edu FU Ministry of Education of the People's Republic of China; Ministry of Human Resources and Social Security of the People's Republic of China; Department of Science and Technology of Shandong Province [Y2008C71, 2009GG10002087]; Yantai University; National Natural Science Foundation of China [30973553]; PLA [06G034]; NDSU; National Center for Research Resources (NCRR) [NIH P20 RR020151] FX This work is supported by grants from the Ministry of Education of the People's Republic of China to G.Z., from the Ministry of Human Resources and Social Security of the People's Republic of China to G.Z., from the Department of Science and Technology of Shandong Province to G.Z. (Y2008C71; 2009GG10002087), Projects from Yantai University to G.Z., a grant from the National Natural Science Foundation of China to G.Z. (No. 30973553), a grant from the PLA and Research Fund of Medicine and Health to Y.W. (06G034), NDSU Faculty Research Funds (NDSU and ND EPSCoR) (E.W.), and Pilot Project Grant (E.W.) from the Centers of Biomedical Research Excellence (COBRE) grant NIH P20 RR020151 from the National Center for Research Resources (NCRR). NCRR is a component of the National Institutes of Health (NIH). The contents of this report are solely the responsibility of the authors and do not necessarily reflect the official views of the NIH or NCRR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors would like to extend their thanks to Dr. Arthur Pardee (Dana-Farber Cancer Institute) and Dr. CS Yang (The State University of New Jersey) for great help in writing, Dr. Eric T. Wong (Beth Israel Deaconess Medical Center), Dr. Mehdi A. Fini (University of Colorado), Ronald E. Vincent (BIOCON Scientific), and Enrico Sassi (North Dakota State University) for their thoughtful reading. NR 63 TC 38 Z9 53 U1 1 U2 23 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1566-5240 J9 CURR MOL MED JI Curr. Mol. Med. PD FEB PY 2012 VL 12 IS 2 BP 163 EP 176 PG 14 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 897HJ UT WOS:000300638600006 PM 22280355 ER PT J AU Baker, AM Haeri, S Camargo, CA Stuebe, AM Boggess, KA AF Baker, Arthur M. Haeri, Sina Camargo, Carlos A., Jr. Stuebe, Alison M. Boggess, Kim A. TI First-trimester maternal vitamin D status and risk for gestational diabetes (GDM) a nested case-control study SO DIABETES-METABOLISM RESEARCH AND REVIEWS LA English DT Article DE gestational diabetes; pregnancy; vitamin D; 25-hydroxyvitamin D ID INSULIN-RESISTANCE; D DEFICIENCY; MELLITUS; 25-HYDROXYVITAMIN-D; PREVALENCE; HEALTH AB Background Vitamin D deficiency may contribute to impaired glucose metabolism. There are sparse data regarding vitamin D and the development of gestational diabetes (GDM). The objective of this study was to assess if first-trimester vitamin D deficiency is more prevalent in women later diagnosed with GDM compared with women with uncomplicated pregnancies. Methods We conducted a nested case-control study of pregnant women who had previously given blood for routine genetic multiple marker screening and subsequently delivered at a tertiary hospital between November 2004 and July 2009. From an overall cohort of 4225 women, 60 cases of GDM were matched by race/ethnicity with 120 women delivering at term (>= 37 weeks) with uncomplicated pregnancies. Banked maternal serum was used to measure maternal 25-hydroxyvitamin D [25(OH)D]. Results The prevalence of first-trimester maternal vitamin D deficiency (defined as 25(OH)D < 50 nmol/L) was comparable among women with GDM compared with controls (5/60 vs 8/120, p = 0.90). The median 25(OH)D level for all subjects was 89 nmol/L (interquartile range, 73-106 nmol/L). Seventy three percent (117/160) of the cohort had 25(OH)D levels = 75 nmol/L. Conclusions In a cohort of pregnant women with mostly sufficient levels of serum 25(OH)D, vitamin D deficiency was not associated with GDM. Further studies are warranted with larger cohorts, especially in populations with lower levels of vitamin D. Copyright (C) 2011 John Wiley & Sons, Ltd. C1 [Baker, Arthur M.] Mem Hlth Univ Med Ctr, Mercer Sch Med, Savannah, GA 31404 USA. [Haeri, Sina] Baylor Coll Med, Dept Obstet & Gynecol, Div Maternal Fetal Med, Houston, TX 77030 USA. [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Ctr D Receptor Activat Res, Boston, MA 02114 USA. [Stuebe, Alison M.; Boggess, Kim A.] Univ N Carolina, Dept Obstet & Gynecol, Div Maternal Fetal Med, Chapel Hill, NC 27599 USA. [Stuebe, Alison M.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC USA. RP Baker, AM (reprint author), Mem Hlth Univ Med Ctr, Mercer Sch Med, Savannah Campus,4750 Waters Ave,Suite 302, Savannah, GA 31404 USA. EM arthurbaker@memorialhealth.com FU Bowes/Cefalo Young Researcher Award; Massachusetts General Hospital Center for D-receptor Activation Research FX This research was supported, in part, by the Bowes/Cefalo Young Researcher Award (AMB) and the Massachusetts General Hospital Center for D-receptor Activation Research (CAC). The resources of the BHRC research network are gratefully acknowledged (A. M. B. and S. H.). NR 25 TC 36 Z9 42 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1520-7552 J9 DIABETES-METAB RES JI Diabetes-Metab. Res. Rev. PD FEB PY 2012 VL 28 IS 2 BP 164 EP 168 DI 10.1002/dmrr.1282 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 895ND UT WOS:000300502100009 PM 21818838 ER PT J AU Su, KG Savino, C Marracci, G Chaudhary, P Yu, XL Morris, B Galipeau, D Giorgio, M Forte, M Bourdette, D AF Su, Kimmy G. Savino, Costanza Marracci, Gail Chaudhary, Priya Yu, Xiaolin Morris, Brooke Galipeau, Danielle Giorgio, Marco Forte, Michael Bourdette, Dennis TI Genetic inactivation of the p66 isoform of ShcA is neuroprotective in a murine model of multiple sclerosis SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE EAE; mitochondria; multiple sclerosis; neurodegeneration; neuroprotective; p66 isoform of ShcA ID MITOCHONDRIAL PERMEABILITY TRANSITION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CYCLOPHILIN-D; LIFE-SPAN; OXIDATIVE STRESS; SPINAL-CORD; CELL-DEATH; AXONAL DEGENERATION; REDOX ENZYME; ANIMAL-MODEL AB Although multiple sclerosis (MS) has traditionally been considered to be an inflammatory disease, recent evidence has brought neurodegeneration into the spotlight, suggesting that accumulated damage and loss of axons is critical to disease progression and the associated irreversible disability. Proposed mechanisms of axonal degeneration in MS posit cytosolic and subsequent mitochondrial Ca2+ overload, accumulation of pathologic reactive oxygen species (ROS), and mitochondrial dysfunction leading to cell death. In this context, the role of the p66 isoform of ShcA protein (p66) may be significant. The ShcA isoform is uniquely targeted to the mitochondrial intermembrane space in response to elevated oxidative stress, and serves as a redox enzyme amplifying ROS generation in a positive feedforward loop that eventually mediates cell death by activation of the mitochondrial permeability transition pore. Consequently, we tested the hypothesis that genetic inactivation of p66 would reduce axonal injury in a murine model of MS, experimental autoimmune encephalomyelitis (EAE). As predicted, the p66-knockout (p66-KO) mice developed typical signs of EAE, but had less severe clinical impairment and paralysis than wild-type (WT) mice. Histologic examination of spinal cords and optic nerves showed significant axonal protection in the p66-KO tissue, despite similar levels of inflammation. Furthermore, cultured p66-KO neurons treated with agents implicated in MS neurodegenerative pathways showed greater viability than WT neurons. These results confirm the critical role of ROS-mediated mitochondrial dysfunction in the axonal loss that accompanies EAE, and identify p66 as a new pharmacologic target for MS neuroprotective therapeutics. C1 [Su, Kimmy G.; Marracci, Gail; Chaudhary, Priya; Yu, Xiaolin; Morris, Brooke; Galipeau, Danielle; Forte, Michael; Bourdette, Dennis] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [Savino, Costanza; Giorgio, Marco] Portland VA Med Ctr, Portland, OR 97239 USA. [Marracci, Gail; Bourdette, Dennis] European Inst Oncol, I-20141 Milan, Italy. RP Forte, M (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM forte@ohsu.edu; bourdett@ohsu.edu RI Giorgio, Marco/I-9425-2012 OI Giorgio, Marco/0000-0002-5842-6042 FU National Institutes of Health [P30-NS0693464, GM-069883, NS-057433, F30-NS704792]; National MS Society; Tartar Trust; OHSU Brain Institute; Laura Fund for Innovation in Multiple Sclerosis; Department of Veterans Affairs; Veterans Health Administration; Office of Research and Development; Biomedical Laboratory Research and Development FX We thank the members of the Forte and Bourdette laboratories for their excellent technical assistance. This work was supported by grants from the National Institutes of Health (P30-NS0693464, GM-069883, NS-057433, and F30-NS704792), the National MS Society, the Tartar Trust, the OHSU Brain Institute, the Laura Fund for Innovation in Multiple Sclerosis, and the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The contents do not represent the views of the Department of Veterans Affairs or the US government. NR 34 TC 17 Z9 19 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0953-816X J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD FEB PY 2012 VL 35 IS 4 BP 562 EP 571 DI 10.1111/j.1460-9568.2011.07972.x PG 10 WC Neurosciences SC Neurosciences & Neurology GA 895MC UT WOS:000300499300007 PM 22277070 ER PT J AU Smolderen, KG Wang, K de Pouvourville, G Bruggenjurgen, B Rother, J Zeymer, U Parhofer, KG Steg, PG Bhatt, DL Magnuson, EA AF Smolderen, K. G. Wang, K. de Pouvourville, G. Brueggenjuergen, B. Roether, J. Zeymer, U. Parhofer, K. G. Steg, P. G. Bhatt, D. L. Magnuson, E. A. CA REACH Registry Investigators TI Two-year Vascular Hospitalisation Rates and Associated Costs in Patients at Risk of Atherothrombosis in France and Germany: Highest Burden for Peripheral Arterial Disease SO EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY LA English DT Article DE Costs; Cerebrovascular disease; Coronary disease; Peripheral arterial disease; Hospitalisation ID CARDIOVASCULAR-DISEASES; UNITED-STATES; TRENDS; OUTPATIENTS; MANAGEMENT; EUROPE AB Objectives: To obtain Western European perspectives on the economic burden of atherothrombosis in patients with multiple risk factors only (MRF), cerebrovascular disease (CVD), coronary artery disease (CAD), and in the under-evaluated group of patients with peripheral arterial disease (PAD), we examined vascular-related hospitalisation rates and associated costs in France and Germany. Design: The prospective REACH Registry enrolled 4693 patients in France, and 5594 patients in Germany (from December 2003 until June 2004). Methods: For each country, 2-year rates and costs associated with cardiovascular events and vascular-related hospitalisations were examined for patients with MRF, CVD, CAD, and PAD. Results: Two-year hospitalisation costs were highest for patients with PAD (3182.1(sic) for France: 2724.4(sic) for Germany) and lowest for the MRF group (749.1(sic) for France; 503.3(sic) for Germany). Peripheral revascularizations and amputations were the greatest contributors to costs for all risk groups. Across all PAD subgroups, peripheral procedures constituted approximately half of the 2-year costs. Conclusion: Hospitalisation rates and costs associated with atherothrombotic disease in France and Germany are high, especially so for patients with PAD. (C) 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved. C1 [Smolderen, K. G.; Wang, K.; Magnuson, E. A.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA. [Smolderen, K. G.] Tilburg Univ, Ctr Res Psychol Somat Dis, Dept Med Psychol & Neuropsychol, NL-5000 LE Tilburg, Netherlands. [de Pouvourville, G.] ESSEC Chair Hlth Econ, Cergy Pontoise, France. [Brueggenjuergen, B.] Univ Berlin, Chair Inst Hlth Econ, Berlin, Germany. [Brueggenjuergen, B.] Univ Med Berlin, Charite, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany. [Roether, J.] Asklepios Klin Altona, Hamburg, Germany. [Zeymer, U.] Inst Herzinfarktforsch Ludwigshafen, Ludwigshafen, Germany. [Parhofer, K. G.] Univ Munich, Dept Med 2, Munich, Germany. [Steg, P. G.] Hop Bichat Claude Bernard, F-75877 Paris 18, France. [Bhatt, D. L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA. [Bhatt, D. L.] Harvard Univ, Sch Med, Boston, MA USA. RP Magnuson, EA (reprint author), St Lukes Hosp, Mid Amer Heart Inst, 4401 Wornall Rd, Kansas City, MO 64111 USA. EM emagnuson@saint-lukes.org RI Smolderen, Kim/B-8078-2015 FU Bristol-Myers Squibb; sanofi-aventis; American Heart Association Pharmaceutical [0875149N]; Netherlands Organization for Scientific Research [VENI] [916.11.179]; AstraZeneca; Boehringer-Ingelheim; Diamed; Fresenius Medical Care; Genzyme; Kaneka; Merck Sharp Dohme; Novartis; Roche; Sanofi; Servier; Eisai; Medicines Company; Daiichi-Sankyo; Eli Lilly FX The REACH Registry was sponsored by Bristol-Myers Squibb and sanofi-aventis. The REACH Registry is endorsed by the World Heart Federation. A complete list of REACH investigators appears in JAMA 2006;295:180-9. Dr. Smolderen was supported by the Outcomes Research post-doctoral fellowship awarded by the American Heart Association Pharmaceutical Roundtable and David and Stevie Spina [grant number AHA #: 0875149N] and by the Netherlands Organization for Scientific Research [VENI grant no.: 916.11.179]. Dr. Parhofer has received research grants and/or honoraria for consulting or presentations from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Diamed, Fresenius Medical Care, Genzyme, Kaneka, Merck Sharp & Dohme, Novartis, Roche and Sanofi. Dr. Steg has received research grant support from Servier (2009-2014); is a consultant or advisory board member for Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, BMS, Daiichi-Sankyo-Lilly, GlaxoSmithKline, Medtronic, Otsuka, Roche, sanofi-aventis, Servier, and The Medicines Company, and is a stockholder for Aterovax. Dr. Bhatt has received research support from AstraZeneca, Bristol-Myers Squibb, Eisai, Sanofi-Aventis, and The Medicines Company. Dr. Magnuson has received grant support from Sanofi-Aventis, Bristol-Myers Squibb, Daiichi-Sankyo, and Eli Lilly, and has received honoraria from sanofi-aventis and Bristol-Myers Squibb. NR 25 TC 18 Z9 18 U1 0 U2 1 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1078-5884 J9 EUR J VASC ENDOVASC JI Eur. J. Vasc. Endovasc. Surg. PD FEB PY 2012 VL 43 IS 2 BP 198 EP 207 DI 10.1016/j.ejvs.2011.09.016 PG 10 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 892CD UT WOS:000300263400013 PM 22001145 ER PT J AU Sekiyama, E Saint-Geniez, M Yoneda, K Hisatomi, T Nakao, S Walshe, TE Maruyama, K Hafezi-Moghadam, A Miller, JW Kinoshita, S D'Amore, PA AF Sekiyama, Eiichi Saint-Geniez, Magali Yoneda, Kazuhito Hisatomi, Toshio Nakao, Shintaro Walshe, Tony E. Maruyama, Kazuichi Hafezi-Moghadam, Ali Miller, Joan W. Kinoshita, Shigeru D'Amore, Patricia A. TI Heat treatment of retinal pigment epithelium induces production of elastic lamina components and antiangiogenic activity SO FASEB JOURNAL LA English DT Article DE choroidal neovascularization; transpupillary thermotherapy; endostatin; thrombospondin-1; elastin ID CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; BRUCHS MEMBRANE; IN-VIVO; EXPRESSION; ANGIOGENESIS; ENDOSTATIN; CELLS; EYES; CHORIOCAPILLARIS AB Age-related macular degeneration (AMD) is the leading cause of blindness in the Western world. In advanced AMD, new vessels from choriocapillaris (CC) invade through the Bruch's membrane (BrM) into the retina, forming choroidal neovascularization (CNV). BrM, an elastic lamina that is located between the retinal pigment epithelium (RPE) and CC, is thought to act as a physical and functional barrier against CNV. The BrM of patients with early AMD are characterized by decreased levels of antiangiogenic factors, including endostatin, thrombospondin-1 (TSP-1), and pigment epithelium-derived factor (PEDF), as well as by degeneration of the elastic layer. Motivated by a previous report that heat increases elastin expression in human skin, we examined the effect of heat on human ARPE-19 cell production of BrM components. Heat treatment stimulated the production of BrM components, including TSP-1, PEDF, and tropoelastin in vitro and increased the antiangiogenic activity of RPE measured in a mouse corneal pocket assay. The effect of heat on experimental CNV was investigated by pretreating the retina with heat via infrared diode laser prior to the induction of CNV. Heat treatment blocked the development of experimental CNV in vivo. These findings suggest that heat treatment may restore BrM integrity and barrier function against new vessel growth.-Sekiyama, E., Saint-Geniez, M., Yoneda, K., Hisatomi, T., Nakao, S., Walshe, T. E., Maruyama, K., Hafezi-Moghadam, A., Miller, J. W., Kinoshita, S., D'Amore, P. A. Heat treatment of retinal pigment epithelium induces production of elastic lamina components and anti-angiogenic activity. FASEB J. 26, 567-575 (2012). www.fasebj.org C1 [Sekiyama, Eiichi; Saint-Geniez, Magali; Walshe, Tony E.; Maruyama, Kazuichi; D'Amore, Patricia A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA. [Sekiyama, Eiichi; Saint-Geniez, Magali; Walshe, Tony E.; D'Amore, Patricia A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA. [D'Amore, Patricia A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Pathol, Boston, MA 02114 USA. [Hisatomi, Toshio; Nakao, Shintaro; Hafezi-Moghadam, Ali; Miller, Joan W.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Angiogenesis Lab, Boston, MA 02114 USA. [Yoneda, Kazuhito; Maruyama, Kazuichi; Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Ophthalmol, Grad Sch Med, Kyoto, Japan. RP D'Amore, PA (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA. EM patricia.damore@schepens.harvard.edu OI Hisatomi, Toshio/0000-0003-2552-9595; Hafezi-Moghadam, Ali/0000-0002-5336-0697 FU NEI NIH HHS [R01 EY015435] NR 26 TC 4 Z9 4 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD FEB PY 2012 VL 26 IS 2 BP 567 EP 575 DI 10.1096/fj.11-184127 PG 9 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 895HA UT WOS:000300485700010 PM 22067481 ER PT J AU Apidianakis, Y Que, YA Xu, WH Tegos, GP Zimniak, P Hamblin, MR Tompkins, RG Xiao, WZ Rahme, LG AF Apidianakis, Yiorgos Que, Yok-Ai Xu, Weihong Tegos, George P. Zimniak, Piotr Hamblin, Michael R. Tompkins, Ronald G. Xiao, Wenzhong Rahme, Laurence G. TI Down-regulation of glutatione S-transferase alpha 4 (hGSTA4) in the muscle of thermally injured patients is indicative of susceptibility to bacterial infection SO FASEB JOURNAL LA English DT Article DE reactive oxygen species; oxidative stress; 4-hydroxynonenal; lipid peroxidation; trauma; biomarker ID BURN WOUND INFECTIONS; PSEUDOMONAS-AERUGINOSA; LIPID-PEROXIDATION; SKELETAL-MUSCLE; OXIDATIVE STRESS; GENE-EXPRESSION; TRAUMA; CONJUGATION; PRODUCTS; ENZYME AB Patients with severe burns are highly susceptible to bacterial infection. While immunosuppression facilitates infection, the contribution of soft tissues to infection beyond providing a portal for bacterial entry remains unclear. We showed previously that glutathione S-transferase S1 (gstS1), an enzyme with conjugating activity against the lipid peroxidation by-product 4-hydroxynonenal (4HNE), is important for resistance against wound infection in Drosophila muscle. The importance of the mammalian functional counterpart of GstS1 in the context of wounds and infection has not been investigated. Here we demonstrate that the presence of a burn wound dramatically affects expression of both human (hGSTA4) and mouse (mGsta4) 4HNE scavengers. hGSTA4 is down-regulated significantly within 1 wk of thermal burn injury in the muscle and fat tissues of patients from the large-scale collaborative Inflammation and the Host Response to Injury multicentered study. Similarly, mGsta4, the murine GST with the highest catalytic efficiency for 4HNE, is down-regulated to approximately half of normal levels in mouse muscle immediately postburn. Consequently, 4HNE protein adducts are increased 4- to 5-fold in mouse muscle postburn. Using an open wound infection model, we show that deletion of mGsta4 renders mice more susceptible to infection with the prevalent wound pathogen Pseudomonas aeruginosa, while muscle hGSTA4 expression negatively correlates with burn wound infection episodes per patient. Our data suggest that hGSTA4 down-regulation and the concomitant increase in 4HNE adducts in human muscle are indicative of susceptibility to infection in individuals with severely thermal injuries.-Apidianakis, Y., Que, Y.-A., Xu, W., Tegos, G. P., Zimniak, P., Hamblin, M. R., Tompkins, R. G., Xiao, W., Rahme, L. G. Down-regulation of glutatione S-transferase alpha 4 (hGSTA4) in the muscle of thermally injured patients is indicative of susceptibility to bacterial infection. FASEB J. 26, 730-737 (2012). www.fasebj.org C1 [Apidianakis, Yiorgos; Que, Yok-Ai; Tompkins, Ronald G.; Xiao, Wenzhong; Rahme, Laurence G.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Tegos, George P.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Apidianakis, Yiorgos; Que, Yok-Ai; Tompkins, Ronald G.; Xiao, Wenzhong; Rahme, Laurence G.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. [Tegos, George P.; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Rahme, Laurence G.] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA. [Apidianakis, Yiorgos; Que, Yok-Ai; Tompkins, Ronald G.; Rahme, Laurence G.] Shriners Burn Inst, Boston, MA 02114 USA. [Xu, Weihong; Xiao, Wenzhong] Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA. [Zimniak, Piotr] Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA. [Zimniak, Piotr] Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA. [Tegos, George P.] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA. [Tegos, George P.] Univ New Mexico, Ctr Mol Discovery, Albuquerque, NM 87131 USA. RP Rahme, LG (reprint author), Massachusetts Gen Hosp, Dept Surg, Thier 340, Boston, MA 02114 USA. EM rahme@amber.mgh.harvard.edu RI Xu, Weihong/C-4175-2012; OI Apidianakis, Yiorgos/0000-0002-7465-3560; xiao, wenzhong/0000-0003-4944-6380 FU Shriners research grants [87100, 85600]; U.S. National Institutes of Health (NIH) [U54 GM-062119]; Swiss National Science Foundation/Swiss Medical Association [PASMP3-123226]; SICPA Foundation; NIH [AG-032643, AI050875]; U.S. Department of Veterans Affairs FX This work was supported in part by Shriners research grants 87100 and 85600 and by the U.S. National Institutes of Health (NIH) Inflammation and the Host Response to Injury Large Scale Collaborative Project, U54 GM-062119. Y.A.Q. was supported by a Swiss National Science Foundation/Swiss Medical Association grant PASMP3-123226) and a grant from the SICPA Foundation. P.Z. was supported by NIH grant AG-032643 and by a U.S. Department of Veterans Affairs Research Career Scientist Award and M. R. H. by NIH grant AI050875. NR 26 TC 9 Z9 9 U1 0 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD FEB PY 2012 VL 26 IS 2 BP 730 EP 737 DI 10.1096/fj.11-192484 PG 8 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 895HA UT WOS:000300485700024 PM 22038048 ER PT J AU Nakao, S Zandi, S Faez, S Kohno, R Hafezi-Moghadam, A AF Nakao, Shintaro Zandi, Souska Faez, Sepideh Kohno, Ri-ichiro Hafezi-Moghadam, Ali TI Discontinuous LYVE-1 expression in corneal limbal lymphatics: dual function as microvalves and immunological hot spots SO FASEB JOURNAL LA English DT Article DE lymphangiogenesis; VE-cadherin; imaging; leukocyte recruitment ID LYMPHEDEMA-DISTICHIASIS; LYMPHANGIOGENESIS; GROWTH; ANGIOGENESIS; VESSELS; NEOVASCULARIZATION; ENDOTHELIUM; MACROPHAGES; HYALURONAN; INDUCTION AB LYVE-1(+) corneal lymphatics contribute to drainage and immunity. LYVE-1 is widely accepted as the most reliable lymphatic marker because of its continuous expression in lymphatic endothelium. LYVE-1 expression in corneal lymphatics has not been examined. In this study, we report intact CD31(+) corneal lymphatic capillary endothelial cells that do not express LYVE-1. The number of LYVE-1(-) gaps initially increased until 8 wk of age but was significantly reduced in aged mice. C57BL/6 mice showed a notably higher number of the LYVE-1(-)/CD31(+) lymphatic regions than BALB/c mice, which suggests a genetic predisposition for this histological feature. The LYVE-1(-) lymphatic gaps expressed podoplanin and VE-cadherin but not alpha SMA or FOXC2. Interestingly, the number of LYVE-1(-) gaps in FGF-2, but not VEGF-A, implanted corneas was significantly lower than in untreated corneas. Over 70% of the CD45(+) leukocytes were found in the proximity of the LYVE-1(-) gaps. Using a novel in vivo imaging technique for visualization of leukocyte migration into and out of corneal stroma, we showed reentry of extravasated leukocytes from angiogenic vessels into newly grown corneal lymphatics. This process was inhibited by VE-cadherin blockade. To date, existence of lymphatic valves in cornea is unknown. Electron microscopy showed overlapping lymphatic endothelial ends, reminiscent of microvalves in corneal lymphatics. This work introduces a novel corneal endothelial lymphatic phenotype that lacks LYVE-1. LYVE-1(-) lymphatic endothelium could serve as microvalves, supporting unidirectional flow, as well as immunological hot spots that facilitate reentry of stromal macropahges.-Nakao, S., Zandi, S., Faez, S., Kohno, R., Hafezi-Moghadam, A. Discontinuous LYVE-1 expression in corneal limbal lymphatics: dual function as microvalves and immunological hot spots. FASEB J. 26, 808-817 (2012). www.fasebj.org C1 [Nakao, Shintaro; Zandi, Souska; Hafezi-Moghadam, Ali] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Excellence Funct & Mol Imaging, Boston, MA 02115 USA. [Nakao, Shintaro; Zandi, Souska; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Nakao, Shintaro; Zandi, Souska; Faez, Sepideh; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Angiogenesis Lab,Dept Ophthalmol, Boston, MA 02115 USA. [Nakao, Shintaro; Kohno, Ri-ichiro] Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Fukuoka 812, Japan. RP Hafezi-Moghadam, A (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Excellence Funct & Mol Imaging, 221 Longwood Ave,3rd Floor, Boston, MA 02115 USA. EM ahm@bwh.harvard.edu OI Hafezi-Moghadam, Ali/0000-0002-5336-0697 FU U.S. National Institutes of Health NIH [AI050775]; Bausch Lomb; Japan Eye Bank Association; Tear Film and Ocular Surface Society; Young Investigator Fellowship FX This work was supported by U.S. National Institutes of Health NIH grants AI050775 (A.H.-M.), an overseas Research Fellowship Award from Bausch & Lomb, a Fellowship Award from the Japan Eye Bank Association and Tear Film and Ocular Surface Society, and a Young Investigator Fellowship (to S.N. under the mentorship of A.H.-M.). The authors thank the Malaysian Palm Oil Board and the American Health Assistance Foundation. The authors thank Alexander Schering and Rebecca C. Garland for their help with the preparation of the manuscript and Dr. David Jackson and Dr. Takayuki Hattori for helpful suggestions. S.N. and A.H.-M. designed research and organized the experiments; S.N., S.Z., S. F., and R. K. performed research and analyzed data; S.N. and A.H.-M. wrote the paper. The authors declare no conflicts of interest. NR 24 TC 13 Z9 13 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD FEB PY 2012 VL 26 IS 2 BP 808 EP 817 DI 10.1096/fj.11-183897 PG 10 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 895HA UT WOS:000300485700032 PM 22090317 ER PT J AU Gusev, A Shah, MJ Kenny, EE Ramachandran, A Lowe, JK Salit, J Lee, CC Levandowsky, EC Weaver, TN Doan, QC Peckham, HE McLaughlin, SF Lyons, MR Sheth, VN Stoffel, M De La Vega, FM Friedman, JM Breslow, JL Pe'er, I AF Gusev, A. Shah, M. J. Kenny, E. E. Ramachandran, A. Lowe, J. K. Salit, J. Lee, C. C. Levandowsky, E. C. Weaver, T. N. Doan, Q. C. Peckham, H. E. McLaughlin, S. F. Lyons, M. R. Sheth, V. N. Stoffel, M. De La Vega, F. M. Friedman, J. M. Breslow, J. L. Pe'er, I. TI Low-Pass Genome-Wide Sequencing and Variant Inference Using Identity-by-Descent in an Isolated Human Population SO GENETICS LA English DT Article ID GENOTYPE-IMPUTATION; METABOLIC TRAITS; COMPLEX TRAITS; HUMAN EXOMES; ASSOCIATION; DISCOVERY; CAPTURE; DISEASE; MODELS; LOCI AB Whole-genome sequencing in an isolated population with few founders directly ascertains variants from the population bottleneck that may be rare elsewhere. In such populations, shared haplotypes allow imputation of variants in unsequenced samples without resorting to complex statistical methods as in studies of outbred cohorts. We focus on an isolated population cohort from the Pacific Island of Kosrae, Micronesia, where we previously collected SNP array and rich phenotype data for the majority of the population. We report identification of long regions with haplotypes co-inherited between pairs of individuals and methodology to leverage such shared genetic content for imputation. Our estimates show that sequencing as few as 40 personal genomes allows for inference in up to 60% of the 3000-person cohort at the average locus. We ascertained a pilot data set of whole-genome sequences from seven Kosraean individuals, with average 5x coverage. This assay identified 5,735,306 unique sites of which 1,212,831 were previously unknown. Additionally, these variants are unusually enriched for alleles that are rare in other populations when compared to geographic neighbors (published Korean genome SJK). We used the presence of shared haplotypes between the seven Kosraen individuals to estimate expected imputation accuracy of known and novel homozygous variants at 99.6% and 97.3%, respectively. This study presents whole-genome analysis of a homogenous isolate population with emphasis on optimal rare variant inference. C1 [Gusev, A.; Shah, M. J.; Kenny, E. E.; Ramachandran, A.; Pe'er, I.] Columbia Univ, Dept Comp Sci, New York, NY 10027 USA. [Gusev, A.; Ramachandran, A.; Pe'er, I.] Columbia Univ, Ctr Computat Biol & Bioinformat, New York, NY 10027 USA. [Shah, M. J.; Lee, C. C.; Levandowsky, E. C.; Weaver, T. N.; Doan, Q. C.; Peckham, H. E.; McLaughlin, S. F.; Lyons, M. R.; Sheth, V. N.; De La Vega, F. M.] Life Technol, Beverly, MA 01915 USA. [Kenny, E. E.; Lowe, J. K.; Salit, J.; Friedman, J. M.; Breslow, J. L.] Rockefeller Univ, New York, NY 10065 USA. [Lowe, J. K.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Lowe, J. K.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA 02142 USA. [Salit, J.] Cornell Univ, Sch Med, New York, NY 10065 USA. [Stoffel, M.] Swiss Fed Inst Technol, Inst Mol Syst Biol, CH-8092 Zurich, Switzerland. RP Gusev, A (reprint author), Columbia Univ, Dept Comp Sci, 500 W 120th St, New York, NY 10027 USA. EM gusev@cs.columbia.edu OI Friedman, Jan/0000-0002-7482-9570 NR 43 TC 7 Z9 7 U1 1 U2 3 PU GENETICS SOC AM PI BETHESDA PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA SN 0016-6731 J9 GENETICS JI Genetics PD FEB PY 2012 VL 190 IS 2 BP 679 EP U615 DI 10.1534/genetics.111.134874 PG 32 WC Genetics & Heredity SC Genetics & Heredity GA 897CW UT WOS:000300621200030 PM 22135348 ER PT J AU Babadi, B McKinney, SM Tarokh, V Ellenbogen, JM AF Babadi, Behtash McKinney, Scott M. Tarokh, Vahid Ellenbogen, Jeffrey M. TI DiBa: A Data-Driven Bayesian Algorithm for Sleep Spindle Detection SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING LA English DT Article DE Bayesian methods; electroencephalography (EEG); Karhunen-Loeve (KL) transform; medical signal detection; sleep spindles ID EYE-MOVEMENT SLEEP; MEMORY CONSOLIDATION; AUTOMATED DETECTION; HEALTHY-SUBJECTS; EEG; AMPLITUDE; AGE AB Although the spontaneous brain rhythms of sleep have commanded much recent interest, their detection and analysis remains suboptimal. In this paper, we develop a data-driven Bayesian algorithm for sleep spindle detection on the electroencephalography (EEG). The algorithm exploits the Karhunen-Loeve transform and Bayesian hypothesis testing to produce the instantaneous probability of a spindle's presence with maximal resolution. In addition to possessing flexibility, transparency, and scalability, this algorithm could perform at levels superior to standard methods for EEG event detection. C1 [Ellenbogen, Jeffrey M.] Harvard Univ, Sch Med, Div Sleep Med, Boston, MA 02215 USA. [Babadi, Behtash] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Babadi, Behtash] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. [McKinney, Scott M.] Stanford Univ, Inst Computat & Math Engn, Stanford, CA 94305 USA. [Tarokh, Vahid] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA. [Ellenbogen, Jeffrey M.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Ellenbogen, JM (reprint author), Harvard Univ, Sch Med, Div Sleep Med, Boston, MA 02215 USA. EM behtash@nmr.mgh.harvard.edu; scott.mckinney@stanford.edu; vahid@seas.harvard.edu; jeffrey_ellenbogen@hms.harvard.edu NR 47 TC 12 Z9 12 U1 0 U2 7 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 0018-9294 J9 IEEE T BIO-MED ENG JI IEEE Trans. Biomed. Eng. PD FEB PY 2012 VL 59 IS 2 BP 483 EP 493 DI 10.1109/TBME.2011.2175225 PG 11 WC Engineering, Biomedical SC Engineering GA 895PF UT WOS:000300507800022 PM 22084041 ER PT J AU Aubin, PM Whittaker, E Ledoux, WR AF Aubin, Patrick M. Whittaker, Eric Ledoux, William R. TI A Robotic Cadaveric Gait Simulator With Fuzzy Logic Vertical Ground Reaction Force Control SO IEEE TRANSACTIONS ON ROBOTICS LA English DT Article DE Force control; gait simulation; medical robots and systems; neural and fuzzy control; parallel robotics ID IN-VITRO SIMULATION; STANCE PHASE GAIT; MODEL; MUSCLE; WALKING; JOINT AB Lower limb dynamic cadaveric gait simulators are useful to investigate the biomechanics of the foot and ankle, but many systems have several common limitations, which include simplified tendon forces, nonphysiologic tibial kinematics, greatly reduced velocities, scaled body weight (BW), and, most importantly, trial-and-error vertical ground reaction force (vGRF) control. This paper presents the design, development, and validation of the robotic gait simulator (RGS), which addresses these limitations. A 6-degrees-of-freedom (6-DOF) parallel robot was utilized as part of the RGS to recreate the relative tibia to ground motion. A custom-designed nine-axis proportional-integral-derivative (PID) force-control tendon actuation system provided force to the extrinsic tendons of the cadaveric lower limb. A fuzzy logic vGRF controller was developed, which altered tendon forces in real time and iteratively adjusted the robotic trajectory in order to track a target vGRF. The RGS was able to accurately reproduce 6-DOF tibial kinematics, tendon forces, and vGRF with a cadaveric lower limb. The fuzzy logic vGRF controller was able to track the target in vivo vGRF with an average root-mean-square error of only 5.6% BW during a biomechanically realistic 3/4 BW, 2.7-s stance phase simulation. C1 [Aubin, Patrick M.] Univ Washington, Dept Elect Engn, Seattle, WA 98195 USA. [Aubin, Patrick M.; Whittaker, Eric; Ledoux, William R.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Seattle, WA 98108 USA. [Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. RP Aubin, PM (reprint author), Vilnius Gediminas Tech Univ, Dept Biomech, LT-01134 Vilnius, Lithuania. EM patrickmarkaubin@gmail.com; whittaker.eric@gmail.com; wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 FU VA Rehabilitation Research and Development Service [A2661C, A3923R, A4843C, A6669R] FX Manuscript received June 24, 2010; revised May 4, 2011; accepted August 3, 2011. Date of publication September 29, 2011; date of current version February 9, 2012. This paper was recommended for publication by Associate Editor E. Guglielmelli and Editor J.-P. Laumond upon evaluation of the reviewers' comments. This work was supported by the VA Rehabilitation Research and Development Service under Grant A2661C, Grant A3923R, Grant A4843C, and Grant A6669R. NR 26 TC 11 Z9 13 U1 3 U2 23 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1552-3098 J9 IEEE T ROBOT JI IEEE Trans. Robot. PD FEB PY 2012 VL 28 IS 1 BP 246 EP 255 DI 10.1109/TRO.2011.2164958 PG 10 WC Robotics SC Robotics GA 891AJ UT WOS:000300188300020 ER PT J AU Mizukami, Y Sasajima, J Ashida, T Kohgo, Y AF Mizukami, Yusuke Sasajima, Junpei Ashida, Toshifumi Kohgo, Yutaka TI Abnormal tumor vasculatures and bone marrow-derived pro-angiogenic cells in cancer SO INTERNATIONAL JOURNAL OF HEMATOLOGY LA English DT Article DE Angiogenesis; Cancer; Pro-angiogenic cell; Cell therapy ID ENDOTHELIAL GROWTH-FACTOR; STEM-CELLS; PROGENITOR CELLS; ADULT NEOVASCULARIZATION; VESSEL FORMATION; ACCESSORY CELLS; VE-CADHERIN; METASTASIS; RECRUITMENT; THERAPY AB Tumor-derived factors affect the stroma of cancer tissue by activating pro-angiogenic signals. One of the key components of this response is the mobilization of the pro-angiogenic cells from bone marrow (BM), which contribute to the development of abnormal tumor vasculature. Evidence is accumulating that the pro-angiogenic cells derived from BM are involved in the physiological processes of tissue repair and wound healing. However, vascular structure in cancer tissue is impaired, resulting in the formation of chaotic neo-vessels and hypoxic microenvironments. Ultimately, these structural and functional abnormalities result in the limited delivery of chemotherapeutic agents and create regions of metabolic derangement, both of which enhance resistance to chemotherapy. In spite of recent advances in targeted therapy using anti-vascular agents, clinical results from studies using individual agents have unsatisfactory, necessitating the combinatorial use of anti-cancer drugs and a targeting agent. We suggest the possibility of a new therapeutic approach in which aberrant tumor vessels are normalized by BM-derived pro-angiogenic cells, and the delivery of anti-cancer drugs is maximized. In this review, we focus on the current understanding of the structure and function of tumor vessels, and an alternative approach to the repair of abnormal tumor vasculature by the use of BM-derived pro-angiogenic cells. This approach may improve both the delivery and the efficacy of anti-cancer drugs by restoring aberrant tumor vascularization and hypoxia. C1 [Mizukami, Yusuke] Massachusetts Gen Hosp, Ctr Canc Res, Gastrointestinal Unit, Boston, MA 02114 USA. [Mizukami, Yusuke] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Mizukami, Yusuke; Ashida, Toshifumi] Sapporo Higashi Tokushukai Hosp, Cell Therapy & Tissue Engn Ctr, Sapporo, Hokkaido, Japan. [Mizukami, Yusuke; Sasajima, Junpei; Kohgo, Yutaka] Asahikawa Med Univ, Dept Med, Div Gastroenterol & Hematol Oncol, Asahikawa, Hokkaido, Japan. RP Mizukami, Y (reprint author), Massachusetts Gen Hosp, Ctr Canc Res, Gastrointestinal Unit, 55 Fruit St,GRJ 825, Boston, MA 02114 USA. EM ymizukami@partners.org FU New Energy and Industrial Technology Development Organization of Japan [07A05010a]; Ministry of Education, Science, Sports, and Culture of Japan [22590754] FX This study was supported by research funding to Y.M. from New Energy and Industrial Technology Development Organization of Japan (07A05010a) and Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan (22590754). NR 66 TC 4 Z9 4 U1 0 U2 2 PU SPRINGER TOKYO PI TOKYO PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN SN 0925-5710 J9 INT J HEMATOL JI Int. J. Hematol. PD FEB PY 2012 VL 95 IS 2 BP 125 EP 130 DI 10.1007/s12185-012-1017-x PG 6 WC Hematology SC Hematology GA 895PA UT WOS:000300507300003 PM 22311464 ER PT J AU Oberaigner, W Siebert, U Horninger, W Klocker, H Bektic, J Schafer, G Frauscher, F Schennach, H Bartsch, G AF Oberaigner, Willi Siebert, Uwe Horninger, Wolfgang Klocker, Helmut Bektic, Jasmin Schaefer, Georg Frauscher, Ferdinand Schennach, Harald Bartsch, Georg TI Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008 SO INTERNATIONAL JOURNAL OF PUBLIC HEALTH LA English DT Article DE Prostate-specific antigen; Prostate cancer; Mortality; Screening; Early detection ID TEMPORAL VARIATION; SCREENING TRIAL; COHORT MODELS; AGE PERIOD; RATES AB The objective of this study was to update an in-depth analysis of the time trend for prostate cancer (PCA) mortality in the population of Tyrol by 5 years, namely to 2008. In Tyrol, prostate-specific antigen (PSA) tests were introduced in 1988/89; more than three-quarters of all men in the age group 45-74 had at least one PSA test in the past decade. We applied the same model as in a previous publication, i.e., an age-period-cohort model using Poisson regression, to the mortality data covering more than three decades from 1970 to 2008. For Tyrol from 2004 to 2008 in the age group 60+ period terms show a significant reduction in prostate cancer mortality with a risk ratio of 0.70 (95% confidence interval 0.57, 0.87) for Tyrol, and for Austria excluding Tyrol a moderate reduction with a risk ratio of 0.92 (95% confidence interval 0.87, 0.97), each compared to the mortality rate in the period 1989-1993. This update strengthens our previously published results, namely that PSA testing offered to a population at no charge can reduce prostate cancer mortality. The extent of mortality reduction is in line with that reported in the other recent publications. However, our data do not permit us to fully assess the harms associated with PCA screening, and no recommendation for PSA screening can be made without a careful evaluation of overdiagnosis and overtreatment. C1 [Oberaigner, Willi] TILAK GmbH, Canc Registry Tyrol, Innsbruck, Austria. [Oberaigner, Willi; Siebert, Uwe] Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth & Hlth Technol Assessment, Hall In Tirol, Austria. [Oberaigner, Willi; Siebert, Uwe] Oncotyrol Ctr Personalized Canc Med, Oncotyrol Div Publ Hlth Decis Modelling Hlth Tech, Innsbruck, Austria. [Siebert, Uwe] Harvard Univ, Sch Med, Dept Radiol,Cardiovasc Res Program, Inst Technol Assessment,Massachusetts Gen Hosp, Boston, MA 02115 USA. [Siebert, Uwe] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA 02115 USA. [Horninger, Wolfgang; Klocker, Helmut; Bektic, Jasmin; Bartsch, Georg] Innsbruck Med Univ, Dept Urol, Innsbruck, Austria. [Schaefer, Georg] Innsbruck Med Univ, Dept Pathol, Innsbruck, Austria. [Frauscher, Ferdinand] Innsbruck Med Univ, Dept Radiol, Innsbruck, Austria. [Schennach, Harald] Innsbruck Med Univ, Dept Immunol & Transfus Med, Innsbruck, Austria. RP Oberaigner, W (reprint author), TILAK GmbH, Canc Registry Tyrol, Anichstr 35, Innsbruck, Austria. EM willi.oberaigner@iet.at FU Oncotyrol Center for Personal Cancer Medicine; Federal Ministry for Transport Innovation and Technology (BMVIT); Federal Ministry of Economics and Labor (BMWA); Tyrolean Future Foundation (TZS; Land of Styria; UMIT-University for Health Sciences; Medical Informatics and Technology; Innsbruck Medical University; Tyrolean Health Insurance Fund; Tyrolean Health Company FX This work was supported by the Oncotyrol Center for Personal Cancer Medicine. Oncotyrol is a Comet Center funded by the Federal Ministry for Transport Innovation and Technology (BMVIT) and the Federal Ministry of Economics and Labor (BMWA), the Tyrolean Future Foundation (TZS) and the Land of Styria represented by the Styrian Business Promotion Agency (SFG) [and supported by UMIT-University for Health Sciences, Medical Informatics and Technology, Innsbruck Medical University, Tyrolean Health Insurance Fund and Tyrolean Health Company. NR 20 TC 20 Z9 20 U1 0 U2 5 PU SPRINGER BASEL AG PI BASEL PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND SN 1661-8556 J9 INT J PUBLIC HEALTH JI Int. J. Public Health PD FEB PY 2012 VL 57 IS 1 BP 57 EP 62 DI 10.1007/s00038-011-0266-4 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 896FR UT WOS:000300551400012 PM 21681451 ER PT J AU Wolf, EJ Miller, MW Harrington, KM Reardon, A AF Wolf, Erika J. Miller, Mark W. Harrington, Kelly M. Reardon, Annemarie TI Personality-Based Latent Classes of Posttraumatic Psychopathology: Personality Disorders and the Internalizing/Externalizing Model SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE internalizing; externalizing; PTSD; personality disorders; latent profile analysis ID STRESS-DISORDER; INTERNALIZING SUBTYPES; VETERANS; QUESTIONNAIRE; COMORBIDITY; MIXTURE; NUMBER; PTSD AB Prior research using the Brief Form of the Multidimensional Personality Questionnaire (MPQ-BF; Patrick, Curtin, & Tellegen, 2002) has shown evidence of 3 temperament-based subtypes-termed internalizing, externalizing, and simple PTSD-among individuals with symptoms of posttraumatic stress disorder (PTSD; Miller, Greif, & Smith, 2003). This study sought to replicate and extend research in this area by conducting a latent profile analysis of higher order temperament scales from the MPQ-BF using a new sample of 208 veterans with symptoms of PTSD. Results suggest that a 3-class solution reflecting internalizing, externalizing, and simple subtypes of posttraumatic psychopathology provided the best fit to the data. The externalizing subtype was characterized by features of antisocial, borderline, histrionic, and narcissistic personality disorders on the International Personality Disorder Examination (Loranger, 1999) as well as low levels of constraint and high levels of negative emotionality on the MPQ-BF. In contrast, individuals in the internalizing class exhibited features of schizoid and avoidant personality disorders, low levels of positive emotionality, and high levels of negative emotionality. The simple subtype was defined by low levels of comorbid personality disorder features and relatively normal personality profiles. Findings support the reliability of this typology and support the relevance of the internalizing and externalizing model to the structure of personality disorders. C1 [Wolf, Erika J.; Miller, Mark W.; Harrington, Kelly M.; Reardon, Annemarie] VA Natl Ctr PTSD, Boston, MA USA. [Wolf, Erika J.; Miller, Mark W.; Harrington, Kelly M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. RP Miller, MW (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B2, 150 S Huntington Ave, Boston, MA 02130 USA. EM mark.miller5@va.gov RI Schueter, nicos/A-3625-2014; Miller, Mark/G-7322-2011; OI Miller, Mark/0000-0001-6393-8563; Wolf, Erika/0000-0003-2666-2435 FU CSRD VA [I01 CX000431]; Intramural VA [CDA-2-067-10S]; NIMH NIH HHS [R01 MH079806] NR 30 TC 31 Z9 31 U1 1 U2 11 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD FEB PY 2012 VL 121 IS 1 BP 256 EP 262 DI 10.1037/a0023237 PG 7 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA 891DX UT WOS:000300198500026 PM 21574669 ER PT J AU Thompson, GR Patterson, TF AF Thompson, George R., III Patterson, Thomas F. TI Fungal disease of the nose and paranasal sinuses SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Fungal colonization; fungus balls; allergic fungal rhinosinusitis; chronic rhinosinusitis; granulomatous fungal sinusitis; acute fulminant fungal rhinosinusitis ID CHRONIC HYPERTROPHIC RHINOSINUSITIS; FOLLOW-UP; ANTIFUNGAL AGENTS; AMPHOTERICIN-B; DOUBLE-BLIND; SINUSITIS; DIAGNOSIS; IMMUNOTHERAPY; BALLS AB Fungal infections of the nose and paranasal sinuses represent a spectrum of diseases ranging from colonization to invasive rhinosinusitis. Clinical manifestations are largely dependent on the immune status of the host, and given the ubiquitous nature of these organisms, exposure is unavoidable. Noninvasive disease includes asymptomatic fungal colonization, fungus balls, and allergic fungal rhinosinusitis. Invasive disease includes indolent chronic rhinosinusitis, granulomatous fungal sinusitis, and acute fulminant fungal rhinosinusitis. A differentiation of these somewhat overlapping syndromes and the disparate treatment regimens required for effective management are the focus of this review. (J Allergy Clin Immunol 2012;129:321-6.) C1 [Thompson, George R., III] Univ Calif Davis, Dept Internal Med, Div Infect Dis, Coccidioidomycosis Serol Lab,Dept Med Microbiol &, Davis, CA 95616 USA. [Thompson, George R., III] Univ Calif Davis Med Ctr, Dept Internal Med, Div Infect Dis, Sacramento, CA 95817 USA. [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Thompson, GR (reprint author), Univ Calif Davis, Dept Internal Med, Div Infect Dis, Coccidioidomycosis Serol Lab,Dept Med Microbiol &, 1 Shields Ave,Tupper Hall,Rm 3146, Davis, CA 95616 USA. EM grthompson@ucdavis.edu FU Pfizer; Astellas Pharma US; Merck FX G. R. Thompson has received research support from Pfizer. T. F. Patterson has consultant arrangements with Pfizer, Viamet Pharmaceuticals, Toyama, Merck, and Astellas Pharma US and has received research support from Astellas Pharma US, Merck, and Pfizer. NR 39 TC 33 Z9 33 U1 0 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2012 VL 129 IS 2 BP 321 EP 326 DI 10.1016/j.jaci.2011.11.039 PG 6 WC Allergy; Immunology SC Allergy; Immunology GA 887TC UT WOS:000299951700004 PM 22206776 ER PT J AU Patil, SU Long, ADA Ling, M Wilson, MT Hesterberg, P Wong, JT Banerji, A AF Patil, Sarita U. Long, Aidan A. Ling, Morris Wilson, Michael T. Hesterberg, Paul Wong, Johnson T. Banerji, Aleena TI A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Carboplatin; hypersensitivity; skin testing; drug allergy; desensitization ID RAPID DESENSITIZATION; SKIN-TEST; CHEMOTHERAPY; ANAPHYLAXIS; EXPERIENCE; PREDICT AB Background: Management of patients with carboplatin-induced hypersensitivity reactions (HSR) has been complicated by high false-negative rates of carboplatin skin test (ST) results. These patients might be at risk for future carboplatin-induced HSRs. In this article we identify a strategy to improve risk stratification of patients with a history of carboplatin-induced HSRs by using a protocol that includes repeat skin testing and drug desensitization. Objective: We sought to identify a management strategy for patients with a history of carboplatin-induced HSRs with negative carboplatin ST results. Methods: From 2008-2010, patients with carboplatin-induced HSR underwent risk stratification per a protocol using 3 repeat STs with intervening drug desensitizations. Results: Of the 44 patients with carboplatin-induced HSRs, 39 completed the protocol. Patients were classified as having positive ST results (n = 16), having negative ST results (n = 11), or ST converters when the ST result converted to positive after an initial negative result (n = 12). ST converters are more likely to have HSRs during subsequent desensitizations than patients with negative ST results (56.1% vs 4.5%, P < .001). ST converters had a significantly longer time interval between their initial HSR and initial ST evaluation compared with either patients with true-negative ST results (22.1 vs 6.0 months, P = .03) or patients with positive ST results (22.1 vs 1.8 months, P = .001). Conclusion: Our experience suggests that repeat STs are necessary for risk stratification in patients with a remote clinical history of HSR and an initial negative ST result because there is a significant rate of conversion to a positive ST result. ST converters have an increased risk of HSRs during subsequent carboplatin treatment. (J Allergy Clin Immunol 2012;129:443-7.) C1 [Patil, Sarita U.; Long, Aidan A.; Ling, Morris; Wilson, Michael T.; Hesterberg, Paul; Wong, Johnson T.; Banerji, Aleena] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA. RP Patil, SU (reprint author), 55 Fruit St,Cox 201, Boston, MA 02441 USA. EM spatil35@partners.org OI Ling, Morris/0000-0002-9657-8960 NR 14 TC 31 Z9 34 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2012 VL 129 IS 2 BP 443 EP 447 DI 10.1016/j.jaci.2011.10.010 PG 5 WC Allergy; Immunology SC Allergy; Immunology GA 887TC UT WOS:000299951700023 PM 22099941 ER PT J AU Rosendorff, C AF Rosendorff, Clive TI ss-Blockade: Benefits Beyond Blood Pressure Reduction? SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Editorial Material ID BETA-BLOCKERS C1 [Rosendorff, Clive] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Rosendorff, Clive] Mt Sinai Sch Med, New York, NY USA. RP Rosendorff, C (reprint author), James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM clive.rosendorff@va.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD FEB PY 2012 VL 14 IS 2 BP 69 EP 70 DI 10.1111/j.1751-7176.2011.00562.x PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 882FR UT WOS:000299549100001 PM 22277137 ER PT J AU Powell, ES Khare, RK Venkatesh, AK Van Roo, BD Adams, JG Reinhardt, G AF Powell, Emilie S. Khare, Rahul K. Venkatesh, Arjun K. Van Roo, Ben D. Adams, James G. Reinhardt, Gilles TI THE RELATIONSHIP BETWEEN INPATIENT DISCHARGE TIMING AND EMERGENCY DEPARTMENT BOARDING SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article DE boarding; crowding; operations; admitting patients; discharging patients ID ADMITTED PATIENTS; MYOCARDIAL-INFARCTION; OPPORTUNITY LOSS; CHEST-PAIN; ASSOCIATION; MANAGEMENT; CONGESTION; HOSPITALS; CAPACITY; OUTCOMES AB Background: Patient crowding and boarding in Emergency Departments (EDs) impair the quality of care as well as patient safety and satisfaction. Improved timing of inpatient discharges could positively affect ED boarding, and this hypothesis can be tested with computer modeling. Study Objective: Modeling enables analysis of the impact of inpatient discharge timing on ED boarding. Three policies were tested: a sensitivity analysis on shifting the timing of current discharge practices earlier; discharging 75% of inpatients by 12:00 noon; and discharging all inpatients between 8:00 a.m. and 4:00 p.m. Methods: A cross-sectional computer modeling analysis was conducted of inpatient admissions and discharges on weekdays in September 2007. A model of patient flow streams into and out of inpatient beds with an output of ED admitted patient boarding hours was created to analyze the three policies. Results: A mean of 38.8 ED patients, 22.7 surgical patients, and 19.5 intensive care unit transfers were admitted to inpatient beds, and 81.1 inpatients were discharged daily on September 2007 weekdays: 70.5%, 85.6%, 82.8%, and 88.0%, respectively, occurred between noon and midnight. In the model base case, total daily admitted patient boarding hours were 77.0 per day; the sensitivity analysis showed that shifting the peak inpatient discharge time 4 h earlier eliminated ED boarding, and discharging 75% of inpatients by noon and discharging all inpatients between 8:00 a.m. and 4:00 p.m. both decreased boarding hours to 3.0. Conclusion: Timing of inpatient discharges had an impact on the need to board admitted patients. This model demonstrates the potential to reduce or eliminate ED boarding by improving inpatient discharge timing in anticipation of the daily surge in ED demand for inpatient beds. (C) 2012 Elsevier Inc. C1 [Powell, Emilie S.; Khare, Rahul K.; Adams, James G.] Northwestern Univ, Dept Emergency Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Powell, Emilie S.; Khare, Rahul K.] Northwestern Univ, Inst Healthcare Studies, Chicago, IL 60611 USA. [Powell, Emilie S.; Khare, Rahul K.] Northwestern Univ, Div Gen Internal Med, Chicago, IL 60611 USA. [Venkatesh, Arjun K.] Massachusetts Gen Hosp, Brigham & Womens Hosp, Boston, MA 02114 USA. [Van Roo, Ben D.] RAND Corp, Santa Monica, CA USA. [Reinhardt, Gilles] Depaul Univ, Dept Management, Chicago, IL 60604 USA. RP Powell, ES (reprint author), Northwestern Univ, Dept Emergency Med, Feinberg Sch Med, 259 E Erie St,Suite 100, Chicago, IL 60611 USA. FU Institute for Healthcare Studies at Northwestern University under Agency for Healthcare Research and Quality [ESP: T-32 HS 000078, RKK: F-32 HS 17876-01] FX Research for this work was completed in part while ESP and RKK were National Research Service Award postdoctoral fellows at the Institute for Healthcare Studies at Northwestern University under institutional awards from the Agency for Healthcare Research and Quality (ESP: T-32 HS 000078; RKK: F-32 HS 17876-01). NR 31 TC 19 Z9 19 U1 3 U2 26 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD FEB PY 2012 VL 42 IS 2 BP 186 EP 196 DI 10.1016/j.jemermed.2010.06.028 PG 11 WC Emergency Medicine SC Emergency Medicine GA 895ZS UT WOS:000300535800015 PM 20888163 ER PT J AU Raja, AS Sullivan, AF Pallin, DJ Bohan, JS Camargo, CA AF Raja, Ali S. Sullivan, Ashley F. Pallin, Daniel J. Bohan, J. Stephen Camargo, Carlos A., Jr. TI ADOPTION OF VIDEO LARYNGOSCOPY IN MASSACHUSETTS EMERGENCY DEPARTMENTS SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article DE airway management; quality improvement; finance; epidemiology; knowledge translation ID CERVICAL-SPINE-MOTION; TRACHEAL INTUBATION; MACINTOSH-LARYNGOSCOPE; DIFFICULT AIRWAY; MANAGEMENT; GLIDESCOPE; STYLET AB Background: Previous research suggests that video laryngoscopy may be superior to direct laryngoscopy. Objectives: We sought to determine the proportion of Massachusetts emergency departments (EDs) that have adopted video laryngoscopy, the characteristics of user and non-user EDs, the reasons why non-users do not use video laryngoscopy, and how the adoption of video laryngoscopy compares to typical technology adoption life cycles. Methods: Surveys were mailed to directors of all non-federal EDs in Massachusetts (n = 74) in early 2009. Non-responders received repeat mailings and were then contacted via telephone or e-mail. Results: Sixty-three of 74 (85%) EDs responded and 43% had adopted video laryngoscopy. EDs with video laryngoscopy had a higher median annual visit volume than EDs without video laryngoscopy (48,000 vs. 36,500, p = 0.04), but had similar mean intubations per week (4.5 vs. 4.4, p = 0.97) and mean surgical airways per year (0.7 vs. 1.1, p = 0.19). Half of the EDs affiliated with emergency medicine residency programs had video laryngoscopy available. Among EDs with video laryngoscopy, the technology had been available for >5 years in 4% (1/27), 1-5 years in 44% (12/27), and <1 year in 52% (14/27). Although EDs not using video laryngoscopy did not do so primarily because it was too expensive (69% [25/361), video laryngoscopy adoption has still progressed more rapidly than predicted by the typical technology adoption timeline. Conclusion: Video laryngoscopy has been adopted by 43% of Massachusetts EDs; results were similar in academic institutions. Cost is the primary barrier to adoption for non-user EDs, but adoption is progressing more rapidly than expected for a new technology. (C) 2012 Elsevier Inc. C1 [Raja, Ali S.; Pallin, Daniel J.; Bohan, J. Stephen] Harvard Univ, Dept Emergency Med, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Sullivan, Ashley F.; Camargo, Carlos A., Jr.] Harvard Univ, Dept Emergency Med, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. RP Raja, AS (reprint author), Harvard Univ, Dept Emergency Med, Brigham & Womens Hosp, Sch Med, 75 Francis St,Neville House, Boston, MA 02115 USA. RI Pallin, Daniel/H-6382-2013 OI Pallin, Daniel/0000-0002-8517-9702 FU Brigham and Women's Hospital Department of Emergency Medicine FX This research was funded by a Brigham and Women's Hospital Department of Emergency Medicine Seed Grant. NR 15 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD FEB PY 2012 VL 42 IS 2 BP 233 EP 237 DI 10.1016/j.jemermed.2010.10.020 PG 5 WC Emergency Medicine SC Emergency Medicine GA 895ZS UT WOS:000300535800020 PM 21215555 ER PT J AU Sadik, CD Luster, AD AF Sadik, Christian D. Luster, Andrew D. TI Lipid-cytokine-chemokine cascades orchestrate leukocyte recruitment in inflammation SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Review DE mediators; chemotaxis; cell trafficking/adhesion ID LEUKOTRIENE B-4 RECEPTOR; PLATELET-ACTIVATING-FACTOR; T-CELL RECRUITMENT; PROSTAGLANDIN-D SYNTHASE; INFL AMMATORY ARTHRITIS; RHEUMATOID-ARTHRITIS; AIRWAY INFLAMMATION; DENDRITIC CELLS; MAST-CELLS; TH2 CELLS AB Chemoattractants are pivotal mediators of host defense, orchestrating the recruitment of immune cells into sites of infection and inflammation. Chemoattractants display vast chemical diversity and include bioactive lipids, proteolytic fragments of serum proteins, and chemokines (chemotactic cytokines). All chemoattractants induce chemotaxis by activating seven-transmembrane-spanning GPCRs expressed on immune cells, establishing the concept that all chemoattractants are related in function. However, although chemoattractants have overlapping functions in vitro, recent in vivo data have revealed that they function, in many cases, nonredundantly in vivo. The chemically diverse nature of chemoattractants contributes to the fine control of leukocyte trafficking in vivo, with sequential chemoattractant use guiding immune cell recruitment into inflammatory sites. Lipid mediators frequently function as initiators of leukocyte recruitment, attracting the first immune cells into tissues. These initial responding immune cells produce cytokines locally, which in turn, induce the local release of chemokines. Local chemokine production then markedly amplifies subsequent waves of leukocyte recruitment. These new discoveries establish a paradigm for leukocyte recruitment in inflammation-described as lipid-cytokine-chemokine cascades-as a driving force in the effector phase of immune responses. J. Leukoc. Biol. 91: 207-215; 2012. C1 [Sadik, Christian D.; Luster, Andrew D.] Harvard Univ, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Ctr Immunol & Inflammatory Dis,Med Sch, Boston, MA 02114 USA. RP Luster, AD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Ctr Immunol & Inflammatory Dis,Med Sch, Boston, MA 02114 USA. EM aluster@mgh.harvard.edu RI Sadik, Christian/E-8404-2012 FU Deutsche Forschungsgemeinschaft; NIH; Arthritis Foundation FX Support for this work was provided by grants from the Deutsche Forschungsgemeinschaft and the Arthritis Foundation to C.D.S. and from NIH to A.D.L. NR 123 TC 67 Z9 67 U1 2 U2 8 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD FEB PY 2012 VL 91 IS 2 BP 207 EP 215 DI 10.1189/jlb.0811402 PG 9 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 894EA UT WOS:000300408600005 PM 22058421 ER PT J AU Xu, X Zhang, H Song, YL Lynch, SV Lowell, CA Wiener-Kronish, JP Caughey, GH AF Xu, Xiang Zhang, Hong Song, Yuanlin Lynch, Susan V. Lowell, Clifford A. Wiener-Kronish, Jeanine P. Caughey, George H. TI Strain-dependent induction of neutrophil histamine production and cell death by Pseudomonas aeruginosa SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE mast cell; histidine decarboxylase; Toll-like receptor; endotoxin; Myd88; exotoxin ID OBSTRUCTIVE PULMONARY-DISEASE; CYSTIC-FIBROSIS; EXOENZYME-S; MYCOPLASMA-PNEUMONIA; BACTERIAL BIOFILMS; CHRONIC-BRONCHITIS; III SECRETION; INFECTIONS; EXPRESSION; MICE AB Airway diseases often feature persistent neutrophilic inflammation and infection. In cystic fibrosis bronchitis, for example, Pseudomonas aeruginosa is isolated frequently. Previously, this laboratory revealed that neutrophils become major sources of histamine in mice with tracheobronchitis caused by the wall-less bacterium Mycoplasma pulmonis. To test the hypothesis that more-broadly pathogenic P. aeruginosa (which expresses cell wall-associated LPS and novel toxins) has similar effects, we incubated naive mouse neutrophils with two strains of P. aeruginosa. Strain PAO1 greatly increased neutrophil histamine content and secretion, whereas strain PA103 depressed histamine production by killing neutrophils. The histamine-stimulating capacity of PAO1, but not PA103-mediated toxicity, persisted in heat-killed organisms. In PAO1-infected mice, lung and neutrophil histamine content increased. However, PAO1 did not alter production by mast cells (classical histamine reservoirs), which also resisted PA103 toxicity. To explore mechanisms of neutrophil-selective induction, we measured changes in mRNA encoding histidine decarboxylase (rate-limiting for histamine synthesis), probed involvement of endotoxin-TLR pathways in Myd88-deficient neutrophils, and examined contributions of pyocyanin and exotoxins. Results revealed that PAO1 increased histamine production by up-regulating histidine decarboxylase mRNA via pathways largely independent of TLR, pyocyanin, and type III secretion system exotoxins. PAO1 also increased histidine decarboxylase mRNA in neutrophils purified from infected lung. Stimulation required direct contact with neutrophils and was blocked by phagocytosis inhibitor cytochalasin D. In summary, Pseudomonas-augmented histamine production by neutrophils is strain-dependent in vitro and likely mediated by up-regulation of histidine decarboxylase. These findings raise the possibility that Pseudomonas-stimulated neutrophils can enhance airway inflammation by producing histamine. J. Leukoc. Biol. 91: 275-284; 2012. C1 [Caughey, George H.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Xu, Xiang; Lynch, Susan V.; Caughey, George H.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Zhang, Hong; Lowell, Clifford A.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. [Song, Yuanlin] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA. [Caughey, George H.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA. [Wiener-Kronish, Jeanine P.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Caughey, George H.] No Calif Inst Res & Educ, San Francisco, CA USA. RP Caughey, GH (reprint author), Vet Affairs Med Ctr, 111-D,4150 Clement St, San Francisco, CA 94121 USA. EM george.caughey@ucsf.edu FU NIH [PO1 HL024136]; Diamond Family Foundation; Cystic Fibrosis Research FX This work was supported by grant PO1 HL024136 from NIH, by the Diamond Family Foundation, and by Cystic Fibrosis Research. The authors thank Baidong Hou for assistance in obtaining Myd88-/- mice and Drs. Weidong Kong and Ramya Srinivasan for assistance in growing mutant strains of PAO1 and in culturing PAO1 as biofilms. NR 45 TC 6 Z9 7 U1 0 U2 5 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD FEB PY 2012 VL 91 IS 2 BP 275 EP 284 DI 10.1189/jlb.0711356 PG 10 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 894EA UT WOS:000300408600011 PM 22075928 ER PT J AU Ellingson, LD Shields, MR Stegner, AJ Cook, DB AF Ellingson, Laura D. Shields, Morgan R. Stegner, Aaron J. Cook, Dane B. TI Physical Activity, Sustained Sedentary Behavior, and Pain Modulation in Women With Fibromyalgia SO JOURNAL OF PAIN LA English DT Article DE Fibromyalgia; pain modulation; physical activity; fMRI; sedentary behavior ID BRAIN RESPONSES; TEMPORAL SUMMATION; AMERICAN-COLLEGE; HEALTH; PERCEPTION; HUMANS; STIMULATION; MECHANISMS; DEPRESSION; SCIENCE AB Fibromyalgia (FM) has been conceptualized as a disorder of the central nervous system, characterized by augmented sensory processing and an inability to effectively modulate pain. We previously reported that physical activity is related to brain processing of pain, providing evidence for a potential mechanism of pain management. The purpose of this study was to extend our work by manipulating pain modulation and determining relationships to both physical activity and sustained sedentary behavior. Eleven women with FM completed accelerometer measures of physical activity and underwent functional magnetic resonance imaging of painful heat, administered alone and during distracting cognitive tasks. Results showed that physical activity was significantly (P < .005) and positively related to brain responses during distraction from pain in regions implicated in pain modulation including the dorsolateral prefrontal cortex (DLPFC), the dorsal posterior cingulate, and the periaqueductal grey. A significant negative relationship occurred in the left anterior insula. For sedentary time, significant negative relationships were observed in areas involved in both pain modulation and the sensory-discriminative aspects of pain including the DLPFC, thalamus, and superior frontal and pre- and post-central gyri. These results suggest that physical activity and sedentary behaviors are related to central nervous system regulation of pain in FM. Perspective: Our results support a promising benefit of physical activity and highlight the potentially deleterious effects of sustained sedentary behavior for pain regulation in FM. Studies aimed at increasing physical activity or reducing sedentary behavior and determining the impact of these on pain regulation are warranted. Published by Elsevier Inc. on behalf of the American Pain Society C1 [Cook, Dane B.] Univ Wisconsin, Dept Kinesiol, Unit Gymnasium Natatorium 2, Madison, WI 53706 USA. [Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Cook, DB (reprint author), Univ Wisconsin, Dept Kinesiol, Unit Gymnasium Natatorium 2, 2000 Observ Dr, Madison, WI 53706 USA. EM dcook@education.wisc.edu FU National Institutes of Health [ROI 5R01AR050969]; National Institute of Arthritis and Musculoskeletal and Skin Disorders (NIAMS) FX Supported by National Institutes of Health grant ROI 5R01AR050969, and the National Institute of Arthritis and Musculoskeletal and Skin Disorders (NIAMS). NR 47 TC 37 Z9 37 U1 3 U2 18 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD FEB PY 2012 VL 13 IS 2 BP 195 EP 206 DI 10.1016/j.jpain.2011.11.001 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 896TL UT WOS:000300594200011 PM 22245361 ER PT J AU Green, JA Mor, MK Shields, AM Sevik, MA Palevsky, PM Fine, MJ Arnold, RM Weisbord, SD AF Green, Jamie A. Mor, Maria K. Shields, Anne Marie Sevik, Mary Ann Palevsky, Paul M. Fine, Michael J. Arnold, Robert M. Weisbord, Steven D. TI Renal Provider Perceptions and Practice Patterns Regarding the Management of Pain, Sexual Dysfunction, and Depression in Hemodialysis Patients SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID QUALITY-OF-LIFE; CHRONIC DIALYSIS PATIENTS; PRIMARY-CARE PROVIDERS; STAGE KIDNEY-DISEASE; ERECTILE DYSFUNCTION; SYMPTOM BURDEN; HEALTH-CARE; PREVALENCE; NEPHROLOGISTS; SILDENAFIL AB Background: Although pain, sexual dysfunction, and depression are common in patients receiving chronic hemodialysis, these symptoms frequently remain untreated. We sought to characterize renal provider perceptions and practice patterns regarding the treatment of these symptoms. Methods: We surveyed renal providers whose patients were participating in a clinical trial of symptom management at nine hemodialysis units in southwestern Pennsylvania. We used Spearman's correlation to assess the association of provider characteristics with the reported frequency of providing treatment. Results: Overall, 27 of 35 (77%) providers completed the survey. While 21 (78%) believed symptom management to be "very" important and 23 (85%) reported spending a "moderate" to "a lot" of time managing symptoms, <50% reported treating pain and <20% reported treating sexual dysfunction or depression "most" or "all" of the time. Most providers believed it was nonrenal providers' responsibility to treat these symptoms. A greater reported comfort level managing symptoms was associated with a higher reported frequency of treating pain (r = 0.6; p < 0.01), sexual dysfunction (r = 0.67; p < 0.01), and depression (r = 0.43; p < 0.03). Providers who believed it was nonrenal providers' responsibility to treat these symptoms reported treating pain (r = -0.62; p < 0.01) and depression (r = -0.48; p = 0.02) less frequently. Conclusions: Despite reporting considerable importance and substantial time managing symptoms in general, renal providers commonly describe not treating pain, sexual dysfunction, and depression in hemodialysis patients. Given renal providers' beliefs that nonrenal clinicians are primarily responsible for treating these symptoms, multidisciplinary approaches to symptom management in these patients are needed. C1 [Green, Jamie A.; Weisbord, Steven D.] Univ Pittsburgh, Grad Sch Publ Hlth, Renal Electrolyte Div, Pittsburgh, PA 15261 USA. [Sevik, Mary Ann; Fine, Michael J.; Arnold, Robert M.] Univ Pittsburgh, Grad Sch Publ Hlth, Div Gen Internal Med, Pittsburgh, PA 15261 USA. [Arnold, Robert M.] Univ Pittsburgh, Grad Sch Publ Hlth, Sect Palliat Care, Pittsburgh, PA 15261 USA. [Mor, Maria K.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Mor, Maria K.; Shields, Anne Marie; Sevik, Mary Ann; Fine, Michael J.; Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Palevsky, Paul M.; Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. RP Green, JA (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Renal Electrolyte Div, A915 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM greenja@upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 FU Department of Veterans Affairs Health Services Research and Development Service [Weisbord HSRD IIR 07-190]; American Kidney Fund Clinical Scientist in Nephrology Program FX This study was funded by a grant from the Department of Veterans Affairs Health Services Research and Development Service (Weisbord HSR&D IIR 07-190). Dr. Green is supported by a grant from the American Kidney Fund Clinical Scientist in Nephrology Program. NR 29 TC 10 Z9 11 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB PY 2012 VL 15 IS 2 BP 163 EP 167 DI 10.1089/jpm.2011.0284 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 897FL UT WOS:000300631700005 PM 22339326 ER PT J AU Bernacki, RE Ko, DN Higgins, P Whitlock, SN Cullinan, A Wilson, R Jackson, V Dahlin, C Abrahm, J Mort, E Scheer, KN Block, S Billings, JA AF Bernacki, Rachelle E. Ko, Danielle N. Higgins, Philip Whitlock, Sandra N. Cullinan, Amelia Wilson, Robin Jackson, Vicki Dahlin, Constance Abrahm, Janet Mort, Elizabeth Scheer, Kenneth N. Block, Susan Billings, J. Andrew TI Improving Access to Palliative Care through an Innovative Quality Improvement Initiative: An Opportunity for Pay-for-Performance SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID OF-LIFE CARE; FINANCIAL INCENTIVES; CANCER-PATIENTS; HEART-FAILURE; HEALTH-CARE; OUTCOMES; CONSULTATION; DISEASE; TRIAL; COST AB Background: Improving access to palliative care is an important priority for hospitals as they strive to provide the best care and quality of life for their patients. Even in hospitals with longstanding palliative care programs, only a small proportion of patients with life-threatening illnesses receive palliative care services. Our two well-established palliative care programs in large academic hospitals used an innovative quality improvement initiative to broaden access to palliative care services, particularly to noncancer patients. Methods: The initiative utilized a combination of electronic and manual screening of medical records as well as intensive outreach efforts to identify two cohorts of patients with life-threatening illnesses who, according to University HealthSystems Consortium (UHC) benchmarking criteria, would likely benefit from palliative care consultation. Given the differing cultures and structure of the two institutions, each service developed a unique protocol for identifying and consulting on suitable patients. Results: Consultation rates in the target populations tripled following the initiative: from 16% to 46% at one hospital and from 15% to 48% at the other. Although two different screening and identification processes were developed, both successfully increased palliative care consultations in the target cohorts. Conclusion: Quality improvement strategies that incorporate pay-for-performance incentives can be used effectively to expand palliative care services to underserved populations. C1 [Bernacki, Rachelle E.; Higgins, Philip; Abrahm, Janet; Block, Susan] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Div Adult Palliat Care, Boston, MA 02115 USA. [Bernacki, Rachelle E.] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02115 USA. [Block, Susan] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. [Bernacki, Rachelle E.; Ko, Danielle N.; Jackson, Vicki; Dahlin, Constance; Abrahm, Janet; Block, Susan; Billings, J. Andrew] Harvard Univ, Sch Med, Ctr Palliat Care, Boston, MA USA. [Ko, Danielle N.; Jackson, Vicki; Dahlin, Constance] Massachusetts Gen Hosp, Dept Med, Palliat Care Serv, Boston, MA 02114 USA. [Mort, Elizabeth; Scheer, Kenneth N.] Massachusetts Gen Hosp, Edward P Lawrence Ctr Qual & Safety, Boston, MA 02114 USA. [Whitlock, Sandra N.] Four Seasons, Flat Rock, NC USA. [Cullinan, Amelia] NW Mem Hosp, Div Hosp Med, Chicago, IL 60611 USA. [Wilson, Robin] Visiting Nurse Assoc, VNA Hosp Care, Boston, MA USA. RP Bernacki, RE (reprint author), Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Div Adult Palliat Care, 44 Binney St,SW 411, Boston, MA 02115 USA. EM rbernacki@partners.org FU Center of Clinical Excellence FX The MGH team acknowledges the diligent efforts of Mitchell Harris PhD and Michael Zalis MD with QPID. BWH team thanks Suzanne McHale, Susan Wante and the Center of Clinical Excellence staff for their enthusiastic support. NR 29 TC 10 Z9 10 U1 1 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB PY 2012 VL 15 IS 2 BP 192 EP 199 DI 10.1089/jpm.2011.0301 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 897FL UT WOS:000300631700009 PM 22304680 ER PT J AU O'Connor, NR Kumar, P AF O'Connor, Nina R. Kumar, Pallavi TI Conservative Management of End-Stage Renal Disease without Dialysis: A Systematic Review SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Review ID CHRONIC KIDNEY-DISEASE; QUALITY-OF-LIFE; PALLIATIVE CARE; REPLACEMENT THERAPY; CLINICAL-OUTCOMES; STARTING DIALYSIS; ELDERLY-PATIENTS; LAST YEAR; SYMPTOMS; SURVIVAL AB Purpose: To summarize evidence on conservative, nondialytic management of end-stage renal disease regarding 1) prognosis and 2) symptom burden and quality of life (QOL). Methods: Medline, Cinahl, and Cochrane were searched for records indexed prior to March 1, 2011. Bibliographies of articles and abstracts from recent meetings were reviewed. Authors and nephrologists were contacted to identify additional studies. Articles were reviewed by two authors and selected if they described stage 5 chronic kidney disease (CKD) patients managed without dialysis, including one or more of the following outcomes: prognosis, symptoms, or QOL. Levels of evidence ratings were assigned using the SORT (Strength of Recommendation Taxonomy) system. Data was abstracted independently by two authors for descriptive analysis. Results: Thirteen studies were included. In studies of prognosis, conservative management resulted in median survival of at least six months (range 6.3 to 23.4 months). Findings are mixed as to whether dialysis prolongs survival in the elderly versus conservative, nondialytic management. Any survival benefit from dialysis decreases with comorbidities, especially ischemic heart disease. Patients managed conservatively report a high symptom burden, underscoring the need for concurrent palliative care. Additional head-to-head studies are needed to compare the symptoms of age-matched dialysis patients, but preliminary studies suggest that QOL is similar. Conclusions: Conservative management is an important alternative to discuss when counseling patients and families about dialysis. Unlike withdrawal of dialysis in which imminent death is expected, patients who decline dialysis initiation can live for months to years with appropriate supportive care. C1 [O'Connor, Nina R.] Arkansas Hosp, N Little Rock, AR 72116 USA. [Kumar, Pallavi] Dana Farber Harvard Canc Ctr, Boston, MA USA. RP O'Connor, NR (reprint author), Arkansas Hosp, 14 Parkstone Circle, N Little Rock, AR 72116 USA. EM noconnor@arkansashospice.org FU NCRR NIH HHS [5KL2 RR024130-04]; NIA NIH HHS [K23 AG025933] NR 42 TC 51 Z9 56 U1 0 U2 11 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB PY 2012 VL 15 IS 2 BP 228 EP 235 DI 10.1089/jpm.2011.0207 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 897FL UT WOS:000300631700015 PM 22313460 ER PT J AU Anderson, WG Goldstein, NE AF Anderson, Wendy G. Goldstein, Nathan E. TI Update in Hospice and Palliative Care SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; DEMENTIA; CANCER; VIDEO C1 [Anderson, Wendy G.] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA. [Anderson, Wendy G.] Univ Calif San Francisco, Palliat Care Program, San Francisco, CA 94143 USA. [Goldstein, Nathan E.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. [Goldstein, Nathan E.] James J Peters VA Med Ctr, Bronx, NY USA. RP Anderson, WG (reprint author), Univ Calif San Francisco, Div Hosp Med, 521 Parnassus Ave,Box 0903, San Francisco, CA 94143 USA. EM Wendy.Anderson@ucsf.edu FU University of California San Francisco Clinical and Translational Science Institute; National Institutes of Health (NIH) [5KL2 RR024130-04]; National Institute of Aging (NIA) [K23 AG025933] FX Dr. Anderson was supported by the University of California San Francisco Clinical and Translational Science Institute Career Development Program, supported by National Institutes of Health (NIH) grant number 5KL2 RR024130-04. Dr. Goldstein was supported by a Mentored Patient-Oriented Research Career Development Award from the National Institute of Aging (NIA), number K23 AG025933. Drs. Anderson and Goldstein presented these articles for the State of the Science Plenary Session at the Annual Assembly of the American Academy of Hospice and Palliative Medicine and the Hospice and Palliative Nurses Association on February 19, 2011, in Vancouver, British Columbia, Canada. NR 11 TC 1 Z9 1 U1 1 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB PY 2012 VL 15 IS 2 BP 236 EP 241 DI 10.1089/jpm.2011.0449 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 897FL UT WOS:000300631700016 PM 22339328 ER PT J AU Shimizu, A Yamada, K Robson, SC Sachs, DH Colvin, RB AF Shimizu, Akira Yamada, Kazuhiko Robson, Simon C. Sachs, David H. Colvin, Robert B. TI Pathologic Characteristics of Transplanted Kidney Xenografts SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID DECAY-ACCELERATING FACTOR; THYMIC LOBE TRANSPLANTATION; ANTI-PIG ANTIBODIES; TO-BABOON MODEL; MINIATURE SWINE; TOLERANCE INDUCTION; MISMATCHED BARRIERS; NUCLEAR TRANSFER; PORCINE KIDNEY; KNOCKOUT PIGS AB For xenotransplantation to become a clinical reality, we need to better understand the mechanisms of graft rejection or acceptance. We examined pathologic changes in alpha 1,3-galactosyltransferase gene-knockout pig kidneys transplanted into baboons that were treated with a protocol designed to induce immunotolerance through thymic transplantation (n=4) or were treated with long-term immunosuppressants (n=3). Hyperacute rejection did not occur in alpha 1,3-galactosyltransferase gene-knockout kidney xenografts. By 34 days, acute humoral rejection led to xenograft loss in all three xenografts in the long-term immunosuppression group. The failing grafts exhibited thrombotic microangiopathic glomerulopathy with multiple platelet-fibrin microthrombi, focal interstitial hemorrhage, and acute cellular xenograft rejection. Damaged glomeruli showed IgM, IgG, C4d, and C5b-9 deposition. They also demonstrated endothelial cell death, diffuse endothelial procoagulant activation with high expression of tissue factor and vWF, and low expression of the ectonucleotidase CD39. In contrast, in the immunotolerance group, two of four grafts had normal graft function and no pathologic findings of acute or chronic rejection at 56 and 83 days. One of the remaining kidneys had mild but transient graft dysfunction with reversible, mild microangiopathic glomerulopathy, probably associated with preformed antibodies. The other kidney in the immunotolerance group developed unstable graft function at 81 days and developed chronic xenograft glomerulopathy. In summary, the success of pig-to-primate xenotransplantation may necessitate immune tolerance to inhibit acute humoral and cellular xenograft rejection. C1 [Shimizu, Akira; Yamada, Kazuhiko; Sachs, David H.] Harvard Univ, Transplantat Biol Res Ctr, Massachusetts Gen Hosp, Sch Med, Boston, MA 02129 USA. [Shimizu, Akira; Colvin, Robert B.] Harvard Univ, Dept Pathol, Massachusetts Gen Hosp, Sch Med, Boston, MA 02129 USA. [Shimizu, Akira] Nippon Med Sch, Dept Pathol, Tokyo 113, Japan. [Robson, Simon C.] Harvard Univ, Dept Med, Transplant Ctr, Beth Israel Deaconess Med Ctr,Med Sch, Boston, MA 02129 USA. RP Shimizu, A (reprint author), Harvard Univ, Transplantat Biol Res Ctr, Massachusetts Gen Hosp, Sch Med, Bldg 149-9019,13th St, Boston, MA 02129 USA. EM kaz.yamada@tbrc.mgh.harvard.edu FU National Institutes of Health [1PO1 A145897, 5PO1-A145897]; Immerge BioTherapeutics, Inc.; Massachusetts General Hospital; Japanese Society for the Promotion of Science [C20591900] FX This work was supported in part by National Institutes of Health Program Project 1PO1 A145897 and 5PO1-A145897 and by a Sponsored Research Agreement between Immerge BioTherapeutics, Inc. and the Massachusetts General Hospital. A.S. was a recipient of a grant from the Japanese Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C20591900). The authors thank Novartis Pharma AG (Basel, Switzerland) for generously providing anti-CD 154 mAb and Immerge BioTherapeutics Inc. (Cambridge, MA) for providing LoCD2b mAb and cobra venom factor. NR 45 TC 15 Z9 16 U1 0 U2 4 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD FEB PY 2012 VL 23 IS 2 BP 225 EP 235 DI 10.1681/ASN.2011040429 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 895XX UT WOS:000300531100010 PM 22114174 ER PT J AU Tangri, N Inker, LA Tighiouart, H Sorensen, E Menon, V Beck, G Shlipak, M Coresh, J Levey, AS Sarnak, MJ AF Tangri, Navdeep Inker, Lesley A. Tighiouart, Hocine Sorensen, Eric Menon, Vandana Beck, Gerald Shlipak, Michael Coresh, Josef Levey, Andrew S. Sarnak, Mark J. TI Filtration Markers May Have Prognostic Value Independent of Glomerular Filtration Rate SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID BETA-TRACE-PROTEIN; CHRONIC KIDNEY-DISEASE; SERUM CYSTATIN-C; PROSTAGLANDIN-D SYNTHASE; ESTIMATING GFR; RISK-FACTOR; CARDIOVASCULAR EVENTS; HEART-FAILURE; CREATININE; OUTCOMES AB Serum levels of creatinine, cystatin C, or beta trace protein allow estimation of GFR, but whether these markers contribute additional prognostic information beyond that reflected in GFR is unknown. Here, we analyzed data from the Modification of Diet in Renal Disease study, which provided baseline levels of these markers for 816 participants with a median follow-up of 16.6 years. We examined associations between the reciprocals of these filtration markers and I-125 iothalamate GFR, expressed per SD, with kidney failure and mortality. In univariate analysis, lower GFR and higher levels of each filtration marker associated with a higher risk for all outcomes. After adjustment for GFR in a Cox proportional hazards model, higher creatinine associated with a higher risk for kidney failure but a lower risk for all-cause mortality. Higher cystatin C and beta trace protein associated with a higher risk for both kidney failure and all-cause mortality. In models including either cystatin C or beta trace protein, the association of GFR with all-cause mortality was no longer significant after the addition of the filtration marker, suggesting the possibility of multicollinearity. In summary, after adjustment for GFR, levels of creatinine, cystatin C, and beta trace protein, each remained directly associated with kidney failure but differed with respect to their associations with mortality. These differences may be a result of non-GFR related associations of filtration markers, residual confounding by GFR, or collinearity between the filtration markers and GFR. beta trace protein and cystatin C seem to provide more consistent prognostic information than creatinine. C1 [Tangri, Navdeep; Inker, Lesley A.; Sorensen, Eric; Levey, Andrew S.; Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Dept Med, Boston, MA 02111 USA. [Tighiouart, Hocine; Menon, Vandana] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA. [Beck, Gerald] Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA. [Menon, Vandana] Outcome Sci, Cambridge, MA USA. [Shlipak, Michael] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Shlipak, Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Coresh, Josef] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Sarnak, MJ (reprint author), Tufts Med Ctr, Div Nephrol, Dept Med, Box 391, Boston, MA 02111 USA. EM msarnak@tuftsmedicalcenter.org OI Tangri, Navdeep/0000-0002-5075-6370 FU CKD-EPI [UO1 DK 053869, UO1 DK 067651, UO1 DK 35073]; KRESCENT; Kidney Foundation of Canada; Canadian Institute of Health Research; Canadian Society of Nephrology; [K24 DK078204]; [K23DK081017] FX This work was supported by Grants K24 DK078204 (M.J.S.), CKD-EPI UO1 DK 053869, UO1 DK 067651, and UO1 DK 35073 (A.S.L. and L.A.I.), as well as K23DK081017 (L.A.I.). N.T. is supported by a KRESCENT postdoctoral fellowship, a joint initiative of the Kidney Foundation of Canada, the Canadian Institute of Health Research, and the Canadian Society of Nephrology. NR 42 TC 37 Z9 37 U1 0 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD FEB PY 2012 VL 23 IS 2 BP 351 EP 359 DI 10.1681/ASN.2011070663 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 895XX UT WOS:000300531100021 PM 22173699 ER PT J AU Burstein, HJ AF Burstein, Harold J. TI Disclosing Pharma Payments to Oncologists: What Will We Learn? SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Editorial Material C1 [Burstein, Harold J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Burstein, Harold J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Burstein, Harold J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Burstein, Harold J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Burstein, HJ (reprint author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD FEB PY 2012 VL 10 IS 2 BP 133 EP 134 PG 2 WC Oncology SC Oncology GA 889IR UT WOS:000300067400001 PM 22308511 ER PT J AU Hurria, A Browner, IS Cohen, HJ Denlinger, CS deShazo, M Extermann, M Ganti, AKP Holland, JC Holmes, HM Karlekar, MB Keating, NL McKoy, J Medeiros, BC Mrozek, E O'Connor, T Petersdorf, SH Rugo, HS Silliman, RA Tew, WP Walter, LC Weir, AB Wildes, T AF Hurria, Arti Browner, Ilene S. Cohen, Harvey Jay Denlinger, Crystal S. deShazo, Mollie Extermann, Martine Ganti, Apar Kishor P. Holland, Jimmie C. Holmes, Holly M. Karlekar, Mohana B. Keating, Nancy L. McKoy, June Medeiros, Bruno C. Mrozek, Ewa O'Connor, Tracey Petersdorf, Stephen H. Rugo, Hope S. Silliman, Rebecca A. Tew, William P. Walter, Louise C. Weir, Alva B., III Wildes, Tanya TI Senior Adult Oncology SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Review DE NCCN Clinical Practice Guidelines; NCCN Guidelines; senior adult; elderly; advanced age; older patient; comprehensive geriatric assessment; cancer treatment ID CELL-LUNG-CANCER; NON-HODGKINS-LYMPHOMA; METASTATIC COLORECTAL-CANCER; COLONY-STIMULATING FACTOR; COMPREHENSIVE GERIATRIC ASSESSMENT; ACUTE MYELOID-LEUKEMIA; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; INAPPROPRIATE MEDICATION USE; PREDNISONE PLUS THALIDOMIDE C1 [Hurria, Arti] City Hope Comprehens Canc Ctr, Los Angeles, CA USA. [Browner, Ilene S.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Sidney, BC, Canada. [Cohen, Harvey Jay] Duke Canc Inst, Durham, NC USA. [Denlinger, Crystal S.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [deShazo, Mollie] Univ Alabama, Birmingham Comprehens Canc Ctr, Tuscaloosa, AL 35487 USA. [Extermann, Martine] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Ganti, Apar Kishor P.] Nebraska Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE USA. [Holland, Jimmie C.; Tew, William P.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Holmes, Holly M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Karlekar, Mohana B.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Keating, Nancy L.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [McKoy, June] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. [Medeiros, Bruno C.] Stanford Canc Inst, Stanford, CA USA. [Mrozek, Ewa] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA. [Mrozek, Ewa] Solove Res Inst, Columbus, OH USA. [O'Connor, Tracey] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Petersdorf, Stephen H.] Univ Washington Med Ctr Seattle Canc Care Allianc, Seattle, WA 98195 USA. [Rugo, Hope S.] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. [Weir, Alva B., III] Univ Tennessee, Inst Canc, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA. [Wildes, Tanya] Washington Univ, Siteman Canc Ctr, Barnes Jewish Hosp, St Louis, MO 63130 USA. RP Hurria, A (reprint author), City Hope Comprehens Canc Ctr, Los Angeles, CA USA. RI Mrozek, Ewa/E-3708-2011 FU NCATS NIH HHS [UL1 TR000448]; NCI NIH HHS [KM1 CA156708, R01 CA134425]; NIA NIH HHS [K24 AG041180] NR 360 TC 39 Z9 39 U1 8 U2 13 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD FEB PY 2012 VL 10 IS 2 BP 162 EP 209 PG 48 WC Oncology SC Oncology GA 889IR UT WOS:000300067400005 PM 22308515 ER PT J AU Wood, DE Eapen, GA Ettinger, DS Hou, LF Jackman, D Kazerooni, E Klippenstein, D Lackner, RP Leard, L Leung, ANC Massion, PP Meyers, BF Munden, RF Otterson, GA Peairs, K Pipavath, S Pratt-Pozo, C Reddy, C Reid, ME Rotter, AJ Schabath, MB Sequist, LV Tong, BC Travis, WD Unger, M Yang, SC AF Wood, Douglas E. Eapen, George A. Ettinger, David S. Hou, Lifang Jackman, David Kazerooni, Ella Klippenstein, Donald Lackner, Rudy P. Leard, Lorriana Leung, Ann N. C. Massion, Pierre P. Meyers, Bryan F. Munden, Reginald F. Otterson, Gregory A. Peairs, Kimberly Pipavath, Sudhakar Pratt-Pozo, Christie Reddy, Chakravarthy Reid, Mary E. Rotter, Arnold J. Schabath, Matthew B. Sequist, Lecia V. Tong, Betty C. Travis, William D. Unger, Michael Yang, Stephen C. TI Lung Cancer Screening SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Review DE NCCN Clinical Practice Guidelines; NCCN Guidelines; lung cancer; screening; LDCT; smoking; carcinogen; tobacco ID OBSTRUCTIVE PULMONARY-DISEASE; MAXIMUM INTENSITY PROJECTION; SPIRAL COMPUTED-TOMOGRAPHY; LOW-DOSE CT; CRYPTOGENIC FIBROSING ALVEOLITIS; RANDOMIZED CONTROLLED-TRIAL; COST-EFFECTIVENESS ANALYSIS; FORTHCOMING 7TH EDITION; GROUND-GLASS OPACITY; TUMOR DOUBLING TIME C1 [Wood, Douglas E.; Pipavath, Sudhakar] Univ Washington Seattle Canc Care Alliance, Seattle, WA USA. [Eapen, George A.; Munden, Reginald F.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Ettinger, David S.; Peairs, Kimberly; Yang, Stephen C.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. [Hou, Lifang] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. [Jackman, David] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Kazerooni, Ella] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Klippenstein, Donald; Pratt-Pozo, Christie; Schabath, Matthew B.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Lackner, Rudy P.] Nebraska Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE USA. [Leard, Lorriana] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. [Leung, Ann N. C.] Stanford Comprehens Canc Ctr, Stanford, CA USA. [Massion, Pierre P.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Meyers, Bryan F.] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO 63110 USA. [Meyers, Bryan F.] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Otterson, Gregory A.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA. [Otterson, Gregory A.] Solove Res Inst, Columbus, MO USA. [Reddy, Chakravarthy] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA. [Reid, Mary E.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Rotter, Arnold J.] City Hope Comprehens Canc Ctr, Los Angeles, CA USA. [Sequist, Lecia V.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Tong, Betty C.] Duke Canc Inst, Durham, NC USA. [Travis, William D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Unger, Michael] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. RP Wood, DE (reprint author), Univ Washington Seattle Canc Care Alliance, Seattle, WA USA. NR 172 TC 98 Z9 102 U1 1 U2 16 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD FEB PY 2012 VL 10 IS 2 BP 240 EP 265 PG 26 WC Oncology SC Oncology GA 889IR UT WOS:000300067400008 PM 22308518 ER PT J AU Maguen, S Madden, E Lau, KM Seal, K AF Maguen, Shira Madden, Erin Lau, Karen M. Seal, Karen TI The impact of head injury mechanism on mental health symptoms in veterans: Do number and type of exposures matter? SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; ALCOHOL-CONSUMPTION; AUDIT-C; IRAQ; AFGHANISTAN; DEPLOYMENT AB This study examined the association between screening results for mental health problems and the number and type of head injuries in 1,082 Iraq and Afghanistan War veterans who received population-based screening for traumatic brain injury at a Veterans Administration health care facility. Nearly one third of all veterans reported multiple types of head injuries (median = 1 among those with any head injury, range = 16 types of head injury). Veterans reporting multiple head injury mechanisms had 6 times the odds of screening positive for posttraumatic stress disorder (PTSD), adjusted odds ratio (OR) = 6.15, 95% confidence interval (CI) [4.4, 8.7], p < .001, over 4 times the odds of screening positive for depression, adjusted OR = 4.09, 95% CI [2.8, 5.9], p < .001, and about twice the odds of screening positive for alcohol misuse, adjusted OR = 1.64, 95% CI [1.19, 2.3], p = .003, compared to those without head injuries. Veterans reporting a blast plus another head injury mechanism had higher odds of screening positive for all mental health outcomes than any other group (e.g., compared to no head injury group): PTSD, adjusted OR = 6.52, 95% CI [4.6, 9.3], p < .001; depression, adjusted OR = 4.42, 95% CI [3.0, 6.4], p < .001; alcohol misuse, adjusted OR =1.59, 95% CI [1.14, 2.2], p = .006. Given their association with a variety of mental health outcomes, number and type of head injury mechanism should be considered as part of any postdeployment evaluation. C1 [Maguen, Shira; Madden, Erin; Lau, Karen M.; Seal, Karen] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Maguen, Shira] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Seal, Karen] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Maguen, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St 116-P, San Francisco, CA 94121 USA. EM Shira.Maguen@va.gov RI Schueter, nicos/A-3625-2014 NR 19 TC 5 Z9 5 U1 2 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD FEB PY 2012 VL 25 IS 1 BP 3 EP 9 DI 10.1002/jts.21669 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 897VA UT WOS:000300685800002 PM 22354503 ER PT J AU Joseph, AM McFall, M Saxon, AJ Chow, BK Leskela, J Dieperink, ME Carmody, TP Beckham, JC AF Joseph, Anne M. McFall, Miles Saxon, Andrew J. Chow, Bruce K. Leskela, Jennie Dieperink, Michael E. Carmody, Timothy P. Beckham, Jean C. TI Smoking intensity and severity of specific symptom clusters in posttraumatic stress disorder SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID ADMINISTERED PTSD SCALE; RECRUITED DAILY SMOKERS; CIGARETTE CONSUMPTION; NICOTINE DEPENDENCE; VETERANS; AFGHANISTAN; CESSATION; IRAQ AB Smoking prevalence among patients with posttraumatic stress disorder (PTSD) is over 40%. Baseline data from the VA Cooperative Studies Program trial of integrated versus usual care for smoking cessation in veterans with PTSD (N = 863) were used in multivariate analyses of PTSD and depression severity, and 4 measures of smoking intensity: cigarettes per day (CPD), Fagerstrom Test for Nicotine Dependence (FTND), time to first cigarette, and expired carbon monoxide. Multivariate regression analysis showed the following significant associations: CPD with race (B = -7.16), age (B = 0.11), and emotional numbing (B =0 .16); FTND with race (B = -0.94), education (B = -0.34), emotional numbing (B = 0.04), significant distress (B = -0.12), and PHQ-9 (B = 0.04); time to first cigarette with education (B = 0.41), emotional numbing (B = -0.03), significant distress (B = 0.09), and PHQ-9 (B = -0.03); and expired carbon monoxide with race (B = -9.40). Findings suggest that among veterans with PTSD, White race and emotional numbing were most consistently related to increased smoking intensity and had more explanatory power than total PTSD symptom score. Results suggest specific PTSD symptom clusters are important to understanding smoking behavior in patients with PTSD. C1 [Joseph, Anne M.] Univ Minnesota, Dept Med, Minneapolis, MN 55414 USA. [McFall, Miles; Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Chow, Bruce K.] VA Palo Alto Hlth Care Syst, Vet Affairs Cooperat Studies Program, Palo Alto, CA USA. [Leskela, Jennie; Dieperink, Michael E.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55414 USA. [Carmody, Timothy P.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Carmody, Timothy P.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Beckham, Jean C.] Duke Univ, Durham VA Med Ctr, Chapel Hill, NC USA. [Beckham, Jean C.] Duke Univ, Dept Psychiat & Behav Sci, Chapel Hill, NC USA. RP Joseph, AM (reprint author), Univ Minnesota, Dept Med, 717 Delaware St SE,Suite 166, Minneapolis, MN 55414 USA. EM amjoseph@umn.edu RI Schueter, nicos/A-3625-2014 NR 32 TC 11 Z9 11 U1 2 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD FEB PY 2012 VL 25 IS 1 BP 10 EP 16 DI 10.1002/jts.21670 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 897VA UT WOS:000300685800003 PM 22328334 ER PT J AU Griffin, MG Resick, PA Galovski, TE AF Griffin, Michael G. Resick, Patricia A. Galovski, Tara E. TI Does physiologic response to loud tones change following cognitive-behavioral treatment for posttraumatic stress disorder? SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID FEAR-POTENTIATED STARTLE; PROCESSING THERAPY; VIETNAM VETERANS; ASSAULT VICTIMS; PTSD; REACTIVITY; EXPOSURE; IMAGERY; REFLEX; RAPE AB This study examined responses to loud tones before and after cognitivebehavioral treatment for posttraumatic stress disorder (PTSD). Seventy-four women in a PTSD treatment outcome study for rape-related (n = 54) or physical assault-related PTSD (n = 20) were assessed in an auditory loud tone paradigm. Assessments were conducted before and after a 6-week period of cognitivebehavioral therapy. Physiologic responses to loud tones included heart rate (HR), skin conductance (SC), and eye-blink electromyogram (EMG). Groups were formed based upon treatment outcome and included a treatment responder group (no PTSD at posttreatment) and a nonresponder group (PTSD-positive at posttreatment). Treatment was successful for 53 of 74 women (72%) and unsuccessful for 21 women (28%). Responders and nonresponders were not significantly different from each other at pretreatment on the main outcome variables. Treatment responders showed a significant reduction in loud tone-related EMG, HR, and SC responses from pre- to posttreatment (partial ?2 = .24, .31, and .36, respectively; all p < .001) and the EMG and HR responses were significantly smaller than nonresponders at posttreatment (partial ?2 = .11, p = .004 and .19, p < .001, respectively). Successful cognitivebehavioral treatment of PTSD is associated with a quantifiable reduction in physiological responding to loud tones. C1 [Griffin, Michael G.; Galovski, Tara E.] Univ Missouri, Ctr Trauma Recovery, St Louis, MO 63121 USA. [Griffin, Michael G.; Galovski, Tara E.] Univ Missouri, Dept Psychol, St Louis, MO 63121 USA. [Resick, Patricia A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA. [Resick, Patricia A.] Boston Univ, Boston, MA 02215 USA. RP Griffin, MG (reprint author), Univ Missouri, Ctr Trauma Recovery, Kathy J Weinman Bldg,1 Univ Blvd, St Louis, MO 63121 USA. EM michael_griffin@umsl.edu FU NIMH NIH HHS [R01 MH055542-03, MH55542, MH55688, R01 MH055542, R29 MH055688] NR 42 TC 7 Z9 7 U1 3 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD FEB PY 2012 VL 25 IS 1 BP 25 EP 32 DI 10.1002/jts.21667 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 897VA UT WOS:000300685800005 PM 22354505 ER PT J AU Dubosc, A Capitaine, M Franko, DL Bui, E Brunet, A Chabrol, H Rodgers, RF AF Dubosc, Auberi Capitaine, Maud Franko, Debra L. Bui, Eric Brunet, Alain Chabrol, Henri Rodgers, Rachel F. TI Early adult sexual assault and disordered eating: The mediating role of posttraumatic stress symptoms SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID PSYCHIATRIC COMORBIDITY; PSYCHOMETRIC PROPERTIES; OBJECTIFICATION THEORY; BULIMIA-NERVOSA; ABUSE; RAPE; CHILDHOOD; BEHAVIORS; CHECKLIST; WOMENS AB Although adult sexual assault has been suggested to be a risk factor for disordered eating, little is known about the pathways leading to this disorder. This study aimed to examine the mediating effect of depressive symptoms and symptoms of posttraumatic stress disorder (PTSD), in the relationship between sexual assault and disordered eating among female students. A sample of 296 French female students completed a questionnaire assessing experiences of sexual assault from age 15, PTSD symptoms, depressive symptoms, and disordered eating. Results revealed that PTSD symptoms fully mediated the effect of early adult sexual assault on disordered eating (B = 1.10, SE = 1.64), and depressive symptoms were a partial mediator of this relationship (B = 2.64, SE = 1.28). When examining both mediators simultaneously the relationship was fully mediated and neither variable emerged as a significantly stronger mediator. Our findings highlight the complex relationship between PTSD symptoms, depressive symptoms, and disordered eating following sexual assault. Further investigation into the temporal relationships between these variables would contribute to inform prevention interventions for disordered eating. C1 [Dubosc, Auberi; Capitaine, Maud; Chabrol, Henri; Rodgers, Rachel F.] Univ Toulouse Le Mirail, Ctr Etud & Rech Psychopathol, Toulouse, France. [Franko, Debra L.; Rodgers, Rachel F.] Northeastern Univ, Dept Counseling & Appl Educ Psychol, Boston, MA 02115 USA. [Bui, Eric] Univ Toulouse, UPS, Lab Stress Traumat LST EA 4560, Toulouse, France. [Bui, Eric] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Bui, Eric] Harvard Univ, Sch Med, Boston, MA USA. [Brunet, Alain] McGill Univ, Dept Psychiat, Montreal, PQ, Canada. [Brunet, Alain] Douglas Mental Hlth Univ Inst, Montreal, PQ, Canada. RP Rodgers, RF (reprint author), Univ Toulouse 2, CERPP, F-31058 Toulouse 9, France. EM rodgers.rachel@gmail.com RI Bui, Eric/J-8347-2015 OI Bui, Eric/0000-0002-1413-6473 NR 48 TC 6 Z9 6 U1 0 U2 14 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD FEB PY 2012 VL 25 IS 1 BP 50 EP 56 DI 10.1002/jts.21664 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 897VA UT WOS:000300685800008 PM 22354508 ER PT J AU de Andrea, CE Kroon, HM Wolterbeek, R Romeo, S Rosenbeig, AE DeYoung, BR Liegl-Atzwanger, B Inwards, CY Hauben, E McCarthy, E Idoate, M Athanason, NA Jones, KB Hogendoorn, PCW Bovee, JVMG AF de Andrea, C. E. Kroon, H. M. Wolterbeek, R. Romeo, S. Rosenbeig, A. E. DeYoung, B. R. Liegl-Atzwanger, B. Inwards, C. Y. Hauben, E. McCarthy, E. Idoate, M. Athanason, N. A. Jones, K. B. Hogendoorn, P. C. W. Bovee, J. V. M. G. TI Interobserver Reliability in the Histopathological Diagnosis of Peripheral Cartilaginous Tumors in Patients with Multiple Osteochondromas: How Can We Improve Diagnostic Quality? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Leiden Univ, Med Ctr, Leiden, Netherlands. Treviso Reg Hosp, I-31100 Treviso, Italy. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Iowa, Carver Coll Med, Iowa City, IA USA. Med Univ Graz, Graz, Austria. Katholieke Univ Leuven Hosp, Louvain, Belgium. Mayo Clin, Rochester, MN 55905 USA. Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Univ Navarra, E-31080 Pamplona, Spain. Univ Oxford, Nuffield Orthopaed Ctr, Oxford, England. Univ Utah, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 32 BP 11A EP 11A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900033 ER PT J AU Ishak, SEA Nielsen, GP Rosenberg, AE AF Ishak, S. E. A. Nielsen, G. P. Rosenberg, A. E. TI Chordoma Arising in Benign Notochordal Cell Tumor: A Detailed Radiological, Gross and Microscopic Description of Three Cases Involving the Lumbar Spine SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Cairo Univ, Cairo, Egypt. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Miami, Miami, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 46 BP 14A EP 14A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900047 ER PT J AU Kerr, DA Deshpande, V Borger, DR Nielsen, GP AF Kerr, D. A. Deshpande, V. Borger, D. R. Nielsen, G. P. TI Molecular Distinction of Chondrosarcoma from Chondroblastic Osteosarcoma through IDH12 Mutations SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Kerr, D. A.; Deshpande, V.; Borger, D. R.; Nielsen, G. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 50 BP 15A EP 15A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900051 ER PT J AU Lee, YD Le, LP Deshpande, V Iafrates, AJ Rosenberg, AE Nielsen, GP AF Lee, Y. D. Le, L. P. Deshpande, V. Iafrates, A. J. Rosenberg, A. E. Nielsen, G. P. TI The Benign Notochordal Cell Tumor and Ecchordosis Physaliphora Lack the Complex Genomic and Genetic Alterations Commonly Found in the Conventional Chordomas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Miami, Miami, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 54 BP 16A EP 16A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900055 ER PT J AU Lew, M Carruthers, M Khosroshahi, A Hasserjian, R Stone, JH Nielsen, GP Deshpande, V AF Lew, M. Carruthers, M. Khosroshahi, A. Hasserjian, R. Stone, J. H. Nielsen, G. P. Deshpande, V. TI Clinicopathologic Features of IgG4-Associated Retroperitoneal Fibrosis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Lew, M.; Carruthers, M.; Khosroshahi, A.; Hasserjian, R.; Stone, J. H.; Nielsen, G. P.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 55 BP 16A EP 16A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900056 ER PT J AU Sioletic, S Fletcher, CDM Hornick, JL AF Sioletic, S. Fletcher, C. D. M. Hornick, J. L. TI Well-Differentiated and Dedifferentiated Liposarcomas with Prominent Myxoid Stroma: Analysis of 55 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 72 BP 20A EP 20A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900073 ER PT J AU Demski, S Gelber, S Marotti, J Cole, K Kereakoglow, S Ruddy, K Brachtel, E Schapiro, L Come, S Borges, V Schedin, P Warner, E Winer, E Partridge, A Collins, L AF Demski, S. Gelber, S. Marotti, J. Cole, K. Kereakoglow, S. Ruddy, K. Brachtel, E. Schapiro, L. Come, S. Borges, V. Schedin, P. Warner, E. Winer, E. Partridge, A. Collins, L. TI Molecular Phenotype of Pregnancy Associated Breast Cancers (PABC) in a Large Cohort of Young Women SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Colorado, Ctr Canc, Denver, CO 80262 USA. Sunnybrook Odette Canc Ctr, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 129 BP 33A EP 34A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900130 ER PT J AU Fang, Y Xie, Q Wang, H Yang, C Braverman, AS Axiotis, CA AF Fang, Y. Xie, Q. Wang, H. Yang, C. Braverman, A. S. Axiotis, C. A. TI Differential Expression of Milk Fat Globule-EGF Factor 8 (MFG-E8) in Breast Cancers SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Suny Downstate Med Ctr, Kings Cty Hosp, Brooklyn, NY 11203 USA. BIDMC, Boston, MA USA. MGH, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 145 BP 38A EP 38A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900146 ER PT J AU Fernandez, LJ Buckley, JM Aftreth, OP Tang, R Saksena, M Yagi, Y Michaelson, JS Koerner, FC Brachtel, EF Smith, BL AF Fernandez, L. J. Buckley, J. M. Aftreth, O. P. Tang, R. Saksena, M. Yagi, Y. Michaelson, J. S. Koerner, F. C. Brachtel, E. F. Smith, B. L. TI Breast Excision Specimens Evaluated by Micro-Computed Tomography (Micro-CT) with Histopathological Correlations SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Fernandez, L. J.; Buckley, J. M.; Aftreth, O. P.; Tang, R.; Saksena, M.; Yagi, Y.; Michaelson, J. S.; Koerner, F. C.; Brachtel, E. F.; Smith, B. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 149 BP 39A EP 39A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900150 ER PT J AU Shabani, M Mehta, TS Wells, C Kraus, JA Gilmore, H Schnitt, SJ Collins, LC AF Shabani, M. Mehta, T. S. Wells, C. Kraus, J. A. Gilmore, H. Schnitt, S. J. Collins, L. C. TI Upgrade Rates on Surgical Excision for Targeted vs. Incidental Radial Scars/Complex Sclerosing Lesions (RS/CSLs) Identified on Core Needle Biopsy (CNB) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Case Western Reserve Univ, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 264 BP 66A EP 66A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900265 ER PT J AU Bongiovanni, A Spitale, A Faquin, WC Mazzucchelli, L Baloch, ZW AF Bongiovanni, A. Spitale, A. Faquin, W. C. Mazzucchelli, L. Baloch, Z. W. TI The Bethesda System for Reporting Thyroid Cytopathology: A Meta-Analysis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Inst Pathol, Locarno, Switzerland. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Penn, Med Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 337 BP 83A EP 83A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900338 ER PT J AU Chang, S Phan, RT Moatamed, NA Apple, SK AF Chang, S. Phan, R. T. Moatamed, N. A. Apple, S. K. TI Utility of BRAF Gene Testing on Thyroid Nodules Diagnosed as Follicular Lesion of Undetermined Significance (FLUS) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 345 BP 85A EP 85A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900346 ER PT J AU Ly, A Ono, J Hughes, K Pitman, MB Balassanian, R AF Ly, A. Ono, J. Hughes, K. Pitman, M. B. Balassanian, R. TI Fine Needle Aspiration Biopsy of Palpable Breast Masses Is Associated with Shorter Length of Time to First Treatment Compared with Core Biopsy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 397 BP 97A EP 98A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900398 ER PT J AU Nishino, HT Tambouret, RH Qian, X AF Nishino, H. T. Tambouret, R. H. Qian, X. TI Fine Needle Aspiration of Spleen Lesions: Cytopathologic Analysis of 66 Cases with Clinical and Histological Correlation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 410 BP 101A EP 101A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900411 ER PT J AU Pitman, MB Yaeger, KA Brugge, WR Mino-Kenudson, M AF Pitman, M. B. Yaeger, K. A. Brugge, W. R. Mino-Kenudson, M. TI Prospective Analysis of Atypical Epithelial Cells as a High Risk Cytological Feature for Malignancy in Pancreatic Cysts SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Pitman, M. B.; Yaeger, K. A.; Brugge, W. R.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 417 BP 102A EP 103A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900418 ER PT J AU Baker, GM Hoang, MP AF Baker, G. M. Hoang, M. P. TI Vulvar Adnexal Neoplasms: A Thirty-Two Year Single-Institution Review SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Baker, G. M.; Hoang, M. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 466 BP 114A EP 115A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900467 ER PT J AU Harris, AC Iafrate, AJ Kamangar, F Flotte, TJ Sepehr, A AF Harris, A. C. Iafrate, A. J. Kamangar, F. Flotte, T. J. Sepehr, A. TI Presence of K-ras Mutations and Distinct Age-Associated Variations in Pilomatricoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Morgan State Univ, Baltimore, MD 21239 USA. Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 498 BP 121A EP 121A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900499 ER PT J AU Hung, T Piris, A Lobo, A Mihm, MM Sober, AJ Tsao, H Tanabe, KK Duncan, LM AF Hung, T. Piris, A. Lobo, A. Mihm, M. M. Sober, A. J. Tsao, H. Tanabe, K. K. Duncan, L. M. TI Sentinel Lymph Node Metastases in Problematic Spitzoid Melanocytic Tumors: Not a Predictor of Malignancy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Vancouver Gen Hosp, Vancouver, BC, Canada. Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Sao Paulo, Hosp Clin, Sao Paulo, Brazil. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 505 BP 124A EP 124A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900506 ER PT J AU Linskey, K Piris, A Mihm, MC Hoang, M AF Linskey, K. Piris, A. Mihm, M. C. Hoang, M. TI Lentiginous Compound Dysplastic Nevus of the Back - A Mimic of Recurrent Nevus and Malignant Melanoma with Regression SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 517 BP 126A EP 127A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900518 ER PT J AU Tse, JY Le, LP Nguyen, A Wang, G Hoang, MP AF Tse, J. Y. Le, L. P. Nguyen, A. Wang, G. Hoang, M. P. TI Microcystic Adnexal Carcinoma Versus Desmoplastic Trichoepithelioma: A Histologic and Immunohistochemical Comparison SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Tse, J. Y.; Le, L. P.; Nguyen, A.; Wang, G.; Hoang, M. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 555 BP 135A EP 136A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900556 ER PT J AU Kerr, SE Schnabel, CA Sullivan, PS Zhang, Y Singh, V Carey, B Erlander, MG Highsmith, WE Brachtel, EF Dry, SM AF Kerr, S. E. Schnabel, C. A. Sullivan, P. S. Zhang, Y. Singh, V. Carey, B. Erlander, M. G. Highsmith, W. E. Brachtel, E. F. Dry, S. M. TI Use of a 92-Gene Molecular Classifier To Predict the Site of Origin for Primary and Metastatic Tumors with Neuroendocrine Differentiation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Mayo Clin, Rochester, MN USA. BioTheranostics Inc, San Diego, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Massachussetts Gen Hosp, Boston, MA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 604 BP 147A EP 147A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900605 ER PT J AU Kovach, AE Lam, Q Dias-Santagata, D Sadow, PM AF Kovach, A. E. Lam, Q. Dias-Santagata, D. Sadow, P. M. TI Cellular Localization of Beta-Catenin by Immunohistochemistry Is a Sensitive and Specific Surrogate for CTNNB1 Mutational Status in Adrenal Cortical Neoplasms SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 607 BP 147A EP 147A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900608 ER PT J AU Donath, FR Kraft, S Barletta, JA AF Donath, F. Rosenblum Kraft, S. Barletta, J. A. TI Rate of Extrathyroidal Extension and Lymph Node Metastases in Papillary Thyroid Carcinoma with Tall Cell Features SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 618 BP 150A EP 150A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900619 ER PT J AU Vivero, M Kraft, S Barletta, JA AF Vivero, M. Kraft, S. Barletta, J. A. TI Risk Stratification of Follicular Variant of Papillary Thyroid Carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 624 BP 151A EP 151A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900625 ER PT J AU Agoston, AT Odze, RD Lauwers, GY Srivastava, A AF Agoston, A. T. Odze, R. D. Lauwers, G. Y. Srivastava, A. TI Immunohistochemical Features of Intestinal and Foveolar Dysplasia in Barrett's Esophagus SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 630 BP 152A EP 152A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900631 ER PT J AU Han, HS Lauwers, GY AF Han, H. S. Lauwers, G. Y. TI Autoimmune Gastritis Versus Severe Body Predominant H. pylori Gastritis: A Comparative Analysis of 88 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Konkuk Univ, Sch Med, Seoul, South Korea. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 671 BP 162A EP 162A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900672 ER PT J AU Huang, Q Wu, H Sun, Q Ye, Q AF Huang, Q. Wu, H. Sun, Q. Ye, Q. TI Primary High-Grade Neuroendocrine Carcinoma of the Esophagus: A Clinicopathologic Study of 42 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China. VA Boston Healthcare Syst, W Roxbury, MA USA. Harvard Univ, Sch Med, W Roxbury, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 676 BP 163A EP 163A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900677 ER PT J AU Huang, Q Lauwers, GY Shi, J Sun, Q Fan, X Feng, A Wu, H Yu, C Zhou, Q Mashimo, H AF Huang, Q. Lauwers, G. Y. Shi, J. Sun, Q. Fan, X. Feng, A. Wu, H. Yu, C. Zhou, Q. Mashimo, H. TI Carcinomas in the Distal Esophagus of Chinese Patients Are Heterogeneous in Histopathology but Adenocarcinoma Remains Rare SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China. VA Boston Healthcare Syst, W Roxbury, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 675 BP 163A EP 163A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900676 ER PT J AU Khor, TS Lauwers, GY Odze, RD Srivastava, A AF Khor, T. S. Lauwers, G. Y. Odze, R. D. Srivastava, A. TI "Mass-Forming" Ischemic Colitis Is a Distinctive Variant with Predilection for the Proximal Colon: A Clinicopathologic Study of 16 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 682 BP 164A EP 165A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900683 ER PT J AU Khor, TS Badizadegan, K Bellizi, A Brown, I Fujita, H Han, HS Kumarasinghe, P Mattia, A Misdraji, J Park, D Srivastava, A Odze, RD Lauwers, GY AF Khor, T. S. Badizadegan, K. Bellizi, A. Brown, I. Fujita, H. Han, H-S Kumarasinghe, P. Mattia, A. Misdraji, J. Park, D. Srivastava, A. Odze, R. D. Lauwers, G. Y. TI Interobserver Agreement in the Phenotypic Classification of Barrett Dysplasia SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Envoi Pathol, Herston, Qld, Australia. PathW Lab, Nedlands, WA, Australia. N Shore Med Ctr, Salem, MA USA. Pusan Natl Univ Hosp, Pusan, South Korea. RI Brown, Ian/R-7763-2016 OI Brown, Ian/0000-0001-6329-2547 NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 683 BP 165A EP 165A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900684 ER PT J AU Kim, JY Shin, N Lauwers, GY Park, DY AF Kim, J. Y. Shin, N. Lauwers, G. Y. Park, D. Y. TI Method of Measurement of Invasion Depth and Scoring System To Predict LN Metastasis in Submucosal EGC SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Pusan Natl Univ Hosp, Pusan, South Korea. Pusan Natl Univ, Sch Med, Pusan, South Korea. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 684 BP 165A EP 165A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900685 ER PT J AU Kumarasinghe, P de Boer, B Sheng, K Oai, E Jayasinghe, S Fox, S AF Kumarasinghe, P. de Boer, B. Sheng, K. Oai, E. Jayasinghe, S. Fox, S. TI HER2 Copy Number in the Assessment of HER2 Status in Gastric/GOJ Cancers: Does It Matter? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 PathWest, QEII Med Ctr, Perth, WA, Australia. Massachusetts Gen Hosp, Boston, MA 02114 USA. Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. Univ Western Australia, Perth, WA 6009, Australia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 689 BP 166A EP 166A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900690 ER PT J AU Li, Y Chang, X Zhou, W Xiao, Y Chen, J Lauwers, GY AF Li, Y. Chang, X. Zhou, W. Xiao, Y. Chen, J. Lauwers, G. Y. TI Gastric Intestinal Metaplasia with Dysplasia-Like Atypia: A Morphological and Biologic Evaluation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 698 BP 168A EP 168A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900699 ER PT J AU Ogino, S Liao, X Morikawa, T Fuchs, C AF Ogino, S. Liao, X. Morikawa, T. Fuchs, C. TI Concomitant Presence of PIK3CA Mutations in Both Exons 9 and 20 Predicts Aggressive Behavior of Colorectal Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 720 BP 173A EP 174A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900721 ER PT J AU Ogino, S Yamauchi, M Morikawa, T Fuchs, C AF Ogino, S. Yamauchi, M. Morikawa, T. Fuchs, C. TI Do Molecular Features of Colorectal Cancers Change Abruptly at Splenic Flexure? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 718 BP 173A EP 173A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900719 ER PT J AU Rice-Stitt, TL Zen, Y Deshpande, V AF Rice-Stitt, T. L. Zen, Y. Deshpande, V. TI An Interobserver Study on IgG4 Related Disease SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Kings Coll Hosp London, London, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 733 BP 177A EP 177A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901010 ER PT J AU Shen, J Morikawa, T Fuchs, CS Ogino, S AF Shen, J. Morikawa, T. Fuchs, C. S. Ogino, S. TI Prognostic Role of Combined MSI and BRAF Mutation Status in Colorectal Cancer: Toward Routine Clinical Use SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 743 BP 179A EP 179A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901020 ER PT J AU Wang, H Brown, I Kumarasinghe, P Langner, C Lauwers, G Shepherd, N Vieth, M Srivastava, A Odze, R AF Wang, H. Brown, I. Kumarasinghe, P. Langner, C. Lauwers, G. Shepherd, N. Vieth, M. Srivastava, A. Odze, R. TI Poor Agreement for Detection of Goblet Cells in Esophageal and GEJ Biopsies SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Beth Israel Deaconess Med Ctr, Boston, MA USA. Royal Brisbane Hosp, Brisbane, Qld 4029, Australia. PathW QEII UWA, Perth, WA, Australia. Med Univ Graz, Graz, Austria. Massachusetts Gen Hosp, Boston, MA 02114 USA. Cheltenham Gen Hosp, Cheltenham, Glos, England. Inst Pathol, Bayreuth, Germany. Brigham & Womens Hosp, Boston, MA 02115 USA. RI Brown, Ian/R-7763-2016 OI Brown, Ian/0000-0001-6329-2547 NR 0 TC 2 Z9 2 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 764 BP 184A EP 185A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901041 ER PT J AU Yantiss, RK Solit, DB Janakiraman, M Misdraji, J AF Yantiss, R. K. Solit, D. B. Janakiraman, M. Misdraji, J. TI Low-Grade Appendiceal Mucinous Neoplasms Show Activation of the Mitogen Activated Protein (MAP) Kinase Pathway SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Weill Cornell Med Coll, New York, NY USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 773 BP 186A EP 187A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901050 ER PT J AU Dong, F Wang, C Farris, AB Wu, S Lee, H Olumi, AF McDougal, WS Young, RH Wu, CL AF Dong, F. Wang, C. Farris, A. B. Wu, S. Lee, H. Olumi, A. F. McDougal, W. S. Young, R. H. Wu, C-L TI The Impact of the 2005 Modified Gleason Grading System on the Clinical Outcome of Prostate Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Dong, F.; Wang, C.; Farris, A. B.; Wu, S.; Lee, H.; Olumi, A. F.; McDougal, W. S.; Young, R. H.; Wu, C-L] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 834 BP 200A EP 201A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901111 ER PT J AU Gershman, B Dong, F McGovern, FJ Heney, NM McDougal, WS Wu, CL AF Gershman, B. Dong, F. McGovern, F. J. Heney, N. M. McDougal, W. S. Wu, C-L TI Smaller Prostate Size Is Independently Associated with Biochemical Recurrence in Gleason 7 Prostate Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Gershman, B.; Dong, F.; McGovern, F. J.; Heney, N. M.; McDougal, W. S.; Wu, C-L] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 864 BP 207A EP 207A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901141 ER PT J AU Gershman, B Dong, F Dahl, DM McGovern, FJ Heney, NM McDougal, WS Wu, CL AF Gershman, B. Dong, F. Dahl, D. M. McGovern, F. J. Heney, N. M. McDougal, W. S. Wu, C-L TI Smaller Prostate Size Is Associated with Greater Volume of Disease at Prostatectomy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Gershman, B.; Dong, F.; Dahl, D. M.; McGovern, F. J.; Heney, N. M.; McDougal, W. S.; Wu, C-L] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 865 BP 208A EP 208A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901142 ER PT J AU Hipp, JD Monaco, J Kunju, PL Cheng, J Yagi, Y Rodriguez-Canales, J Emmert-Buck, MR Hewitt, S Feldman, MD Tomaszewski, JE Toner, M Tompkins, RG Flotte, T Lucas, D Gilbertson, JR Madabhushi, A Balis, UJ AF Hipp, J. D. Monaco, J. Kunju, P. L. Cheng, J. Yagi, Y. Rodriguez-Canales, J. Emmert-Buck, M. R. Hewitt, S. Feldman, M. D. Tomaszewski, J. E. Toner, M. Tompkins, R. G. Flotte, T. Lucas, D. Gilbertson, J. R. Madabhushi, A. Balis, U. J. TI Integration of Architectural and Cytologic Driven Image Algorithms for Prostate Adenocarcinoma Identification SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Univ Michigan, Ann Arbor, MI 48109 USA. Rutgers State Univ, Piscataway, NJ USA. Harvard Univ, Boston, MA 02115 USA. NCI, NIH, Bethesda, MD 20892 USA. Univ Penn, Perlman Sch Med, Philadelphia, PA 19104 USA. Mayo Clin, Rochester, MN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 890 BP 213A EP 214A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901167 ER PT J AU Kawaguchi, KR Park, K Chinnaiyan, A Loda, M Robinson, BD Lis, R Scherr, DS Rosenberg, JE Rubin, MA Mosquera, JM AF Kawaguchi, K. R. Park, K. Chinnaiyan, A. Loda, M. Robinson, B. D. Lis, R. Scherr, D. S. Rosenberg, J. E. Rubin, M. A. Mosquera, J. M. TI Differential Expression of SPINK1 in Urothelial Neoplasia: Clinical and Pathological Implications SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Weill Cornell Med Coll, New York, NY USA. Univ Michigan, Ann Arbor, MI 48109 USA. Dana Farber Canc Inst, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 907 BP 217A EP 217A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901184 ER PT J AU Miyai, K Yamamoto, S Iwaya, K Matsubara, O Mark, EJ AF Miyai, K. Yamamoto, S. Iwaya, K. Matsubara, O. Mark, E. J. TI Consecutive Progression from Intratubular Germ Cell Neoplasm, Unclassified (IGCNU) to Seminoma and Ultimately to Embryonal Carcinoma of the Adult Testis: An Allelotyping Analysis of Cases with Embryonal Carcinoma Accompanied by Co-Existing Seminoma and/or IGCNU Components SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Natl Def Med Coll, Tokorozawa, Saitama 359, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 952 BP 228A EP 228A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901229 ER PT J AU Wirth, G Lu, J Wu, S Dahl, DM Olumi, AF McDougal, WS Young, RH Wu, CL AF Wirth, G. Lu, J. Wu, S. Dahl, D. M. Olumi, A. F. McDougal, W. S. Young, R. H. Wu, C-L TI Close Surgical Margins after Radical Prostatectomy Are an Independent Predictor of Prostate Cancer Recurrent SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Wirth, G.; Lu, J.; Wu, S.; Dahl, D. M.; Olumi, A. F.; McDougal, W. S.; Young, R. H.; Wu, C-L] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1061 BP 252A EP 252A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901338 ER PT J AU Bandyopadhyay, S Van de Vijver, KK Oliva, E Nucci, MR Shi, D Qureshi, F Hayek, K Alosh, B Feng, Z Jaratli, H Schultz, D Ali-Fehmi, R AF Bandyopadhyay, S. Van de Vijver, K. K. Oliva, E. Nucci, M. R. Shi, D. Qureshi, F. Hayek, K. Alosh, B. Feng, Z. Jaratli, H. Schultz, D. Ali-Fehmi, R. TI Tumor Size as a Prognostic Factor in Uterine Serous Carcinoma: A Large Multi-Institutional Study SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Wayne State Univ, Detroit, MI USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Henry Ford Hlth Syst, Detroit, MI USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1090 BP 259A EP 259A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901367 ER PT J AU Chiang, S Castilla, MA Palacios, J Oliva, E AF Chiang, S. Castilla, M. A. Palacios, J. Oliva, E. TI microRNA Expression Profiling of Low-Grade Endometrial Stromal Sarcomas and Undifferentiated Endometrial Sarcomas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Hosp Univ Virgen del Rocio, Inst Invest Biomed, Seville, Spain. RI Castilla, M Angeles/C-9454-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1106 BP 263A EP 263A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901383 ER PT J AU Chiang, S Van de Vijver, K Loureiro, J Nucci, M Oliva, E AF Chiang, S. Van de Vijver, K. Loureiro, J. Nucci, M. Oliva, E. TI Do Mitotic Index and Tumor Cell Necrosis Predict Patient Outcome in Low-Grade Endometrial Stromal Sarcomas? A Study of 33 Patients SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Maastricht Univ, Med Ctr, Maastricht, Netherlands. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1105 BP 263A EP 263A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901382 ER PT J AU DeLair, D Van de Vijver, K Park, KJ Oliva, E AF DeLair, D. Van de Vijver, K. Park, K. J. Oliva, E. TI Wolffian Tumors of the Female Genital Tract: A Study of 32 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1114 BP 265A EP 265A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901391 ER PT J AU Ip, PP Irving, JA McCluggage, GW Young, RH AF Ip, P. P. Irving, J. A. McCluggage, G. W. Young, R. H. TI Papillary Proliferation of the Endometrium: A Clinicopathologic Study of 56 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Univ Hong Kong, Queen Mary Hosp, Hksar, Hong Kong, Peoples R China. Royal Jubilee Hosp, Victoria, BC, Canada. Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1163 BP 277A EP 278A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901440 ER PT J AU Loureiro, J Borger, D Van de Vijver, K Dias-Santagata, D Penson, R Iafrate, J Oliva, E AF Loureiro, J. Borger, D. Van de Vijver, K. Dias-Santagata, D. Penson, R. Iafrate, J. Oliva, E. TI Utility of the SNaPshot Assay in Ovarian Carcinoma Genotyping SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Loureiro, J.; Borger, D.; Van de Vijver, K.; Dias-Santagata, D.; Penson, R.; Iafrate, J.; Oliva, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1191 BP 284A EP 284A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901468 ER PT J AU Van de Vijver, KK Liu, L Iafrate, AJ Oliva, E AF Van de Vijver, K. K. Liu, L. Iafrate, A. J. Oliva, E. TI Mismatch Repair Protein Expression in Clear Cell Carcinoma of the Endometrium: Frequency and Clinicopathologic Correlation of 41 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Van de Vijver, K. K.; Liu, L.; Iafrate, A. J.; Oliva, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1254 BP 298A EP 299A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901531 ER PT J AU Huck, AE Faquin, WC Stone, JH Nielsen, GP Deshpande, V AF Huck, A. E. Faquin, W. C. Stone, J. H. Nielsen, G. P. Deshpande, V. TI Fibrosing Variant of Hashimoto's Thyroiditis Is an IgG4 Related Disease SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1305 BP 310A EP 310A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901582 ER PT J AU Boyer, DF Attar, E Hasserjian, RP AF Boyer, D. F. Attar, E. Hasserjian, R. P. TI Fli-1 Expression Is Increased in Erythroblasts in MDS with Del(5q) and Correlates with Response to Lenalidomide SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Boyer, D. F.; Attar, E.; Hasserjian, R. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1366 BP 325A EP 325A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901643 ER PT J AU Calvo, KR Wang, W Corrigan-Cummins, M Zingone, A Costello, R Korde, N Ghobrial, I Landgren, O AF Calvo, K. R. Wang, W. Corrigan-Cummins, M. Zingone, A. Costello, R. Korde, N. Ghobrial, I. Landgren, O. TI MicroRNA Profiles of the Bone Marrow Microenvironment and Serum in Multiple Myeloma Reveal Micrornas in the Serum Associated with Myeloma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 NIH, Ctr Clin, Bethesda, MD 20892 USA. NCI, Bethesda, MD 20892 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1369 BP 326A EP 326A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901646 ER PT J AU Carvajal-Cuenca, A Salaverria, I Royo, C Clot, G Navarro, A Hartmann, EM Trim, N Woroniecka, R Erber, W Gaulard, P Wlodarska, I Rymkiewicz, G Ott, G Rosenwald, A Lopez-Guillermo, A Quintanilla-Fend, L Ferry, JA Harris, NL Jaffe, ES Siebert, R Campo, E Bea, S AF Carvajal-Cuenca, A. Salaverria, I. Royo, C. Clot, G. Navarro, A. Hartmann, E. M. Trim, N. Woroniecka, R. Erber, W. Gaulard, P. Wlodarska, I. Rymkiewicz, G. Ott, G. Rosenwald, A. Lopez-Guillermo, A. Quintanilla-Fend, L. Ferry, J. A. Harris, N. L. Jaffe, E. S. Siebert, R. Campo, E. Bea, S. TI Clinicopathologic Characterization of Cyclin D1-Negative Mantle Cell Lymphoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Univ Barcelona, Hosp Clin, Barcelona, Spain. Univ Wurzburg, Inst Pathol, D-8700 Wurzburg, Germany. Addenbrookes Hosp, Cambridge, England. MSCM Canc Ctr & Inst, Warsaw, Poland. Henri Mondor Hosp, Creteil, France. Catholic Univ Louvain, Ctr Human Genet, B-3000 Louvain, Belgium. Robert Bosch Krankenhaus, Stuttgart, Germany. Univ Tubingen, Inst Pathol, D-7400 Tubingen, Germany. Massachusetts Gen Hosp, Boston, MA 02114 USA. NCI, Bethesda, MD 20892 USA. Univ Kiel, Kiel, Germany. NR 0 TC 1 Z9 1 U1 2 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1370 BP 326A EP 327A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901647 ER PT J AU Chen, BJ Ouyang, J Sinha, P Shipp, MA Fletcher, CDM Rodig, SJ AF Chen, B. J. Ouyang, J. Sinha, P. Shipp, M. A. Fletcher, C. D. M. Rodig, S. J. TI Expression of Galectin-1 by EBV-Positive Lymphoproliferative Disorders SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1379 BP 329A EP 329A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901656 ER PT J AU Courville, E Wu, Y Kourda, J Brockmann, J de Leval, L Orazi, A Hasserjian, R AF Courville, E. Wu, Y. Kourda, J. Brockmann, J. de Leval, L. Orazi, A. Hasserjian, R. TI Acute Myeloid Leukemia Arising from Chronic Myelomonocytic Leukemia Has Poor Prognosis and High Incidence of Normal Karyotype and NPM1 Mutation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Weill Cornell Med Coll, New York, NY USA. Inst Univ Pathol, Lausanne, Switzerland. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1387 BP 331A EP 331A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901664 ER PT J AU Hwang, DG Dorfman, DM Briggs, DA Silverio, R Pozdnyakova, O AF Hwang, D. G. Dorfman, D. M. Briggs, D. A. Silverio, R. Pozdnyakova, O. TI Screening for Myelodysplastic Syndromes on Peripheral Blood Using the NEUT-X Parameter on the New Sysmex XE-5000 Analyzer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1436 BP 343A EP 343A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901713 ER PT J AU Kunder, CA Deangelo, DJ Gotlib, JR Gitana, G Atwater, SK George, TI AF Kunder, C. A. Deangelo, D. J. Gotlib, J. R. Gitana, G. Atwater, S. K. George, T. I. TI Loss of CD25 Expression in Advanced Systemic Mastocytosis Patients Treated with Midostaurin (PKC412) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Stanford Univ, Stanford, CA 94305 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1462 BP 349A EP 349A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901739 ER PT J AU Louissaint, A Ackerman, A Ferry, JA Iafrate, AJ Zukerberg, LR Harris, NL Hasserjian, RP AF Louissaint, A. Ackerman, A. Ferry, J. A. Iafrate, A. J. Zukerberg, L. R. Harris, N. L. Hasserjian, R. P. TI Pediatric-Type Follicular Lymphoma Occurs in Both Children and Adults and Is Characterized by a High Proliferation Index and the Absence of a BCL2 Gene Rearrangement SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Louissaint, A.; Ackerman, A.; Ferry, J. A.; Iafrate, A. J.; Zukerberg, L. R.; Harris, N. L.; Hasserjian, R. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1483 BP 353A EP 353A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799901760 ER PT J AU Sohani, AR Mahindra, A Khosroshahi, A Stone, JH Deshpande, V Hasserjian, RP AF Sohani, A. R. Mahindra, A. Khosroshahi, A. Stone, J. H. Deshpande, V. Hasserjian, R. P. TI Bone Marrow Manifestations of IgG4-Related Disease SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Sohani, A. R.; Mahindra, A.; Khosroshahi, A.; Stone, J. H.; Deshpande, V.; Hasserjian, R. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1553 BP 370A EP 371A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902065 ER PT J AU Song, JY Eberle, FC Xi, L Raffeld, M Harris, NL Wilson, WH Pittaluga, S Jaffe, ES AF Song, J. Y. Eberle, F. C. Xi, L. Raffeld, M. Harris, N. L. Wilson, W. H. Pittaluga, S. Jaffe, E. S. TI Nodal Involvement by Transformed Cutaneous CD30-Positive T-Cell Lymphoma Mimicking Classical Hodgkin Lymphoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 NCI, Bethesda, MD 20892 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1556 BP 372A EP 372A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902068 ER PT J AU Tan, KL Scott, DW Hong, F Horning, SJ Fisher, RI Bartlett, NL Shepherd, LE Connors, JM Kahl, BS Gordon, LI Steidl, C Gascoyne, RD AF Tan, K. L. Scott, D. W. Hong, F. Horning, S. J. Fisher, R. I. Bartlett, N. L. Shepherd, L. E. Connors, J. M. Kahl, B. S. Gordon, L. I. Steidl, C. Gascoyne, R. D. TI Tumor-Associated Macrophages Predict Inferior Outcomes in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma - A Correlative Study from the E2496 Intergroup Trial SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. Dana Farber Canc Inst, Boston, MA 02115 USA. Genentech Inc, San Francisco, CA 94080 USA. Univ Rochester, Rochester, NY 14627 USA. Washington Univ, St Louis, MO 63130 USA. NCIC Clin Trials Off, Kingston, ON, Canada. Univ Wisconsin, Madison, WI 53706 USA. Northwestern Univ, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1568 BP 374A EP 375A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902080 ER PT J AU McClintock, DS Bakst, JB Gilbertson, JR AF McClintock, D. S. Bakst, J. B. Gilbertson, J. R. TI Using Computerized Simulations To Measure the Effects of Full Adoption Whole Slide Imaging on Medium and High Volume Clinical Histology Laboratories SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Chicago, Med Ctr, Chicago, IL 60637 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1643 BP 393A EP 393A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902155 ER PT J AU Yagi, Y Bautista, PA AF Yagi, Y. Bautista, P. A. TI Whole Slide Imaging System Resolution Evaluation Slide Set Development: Toward Standardization SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Yagi, Y.; Bautista, P. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1650 BP 394A EP 395A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902162 ER PT J AU Olar, A Stein, TD Davidson, CJ Perry, A Gheorghe, G AF Olar, A. Stein, T. D. Davidson, C. J. Perry, A. Gheorghe, G. TI Central Nervous System Involvement by Myeloid Sarcoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Methodist Hosp, Houston, TX 77030 USA. Boston Univ, Boston VA Med Ctr, Sch Med, Jamaica Plain, NY USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Childrens Hosp Wisconsin, Med Coll Wisconsin, Milwaukee, WI 53201 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1808 BP 434A EP 434A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902320 ER PT J AU Sioletic, S Alexander, B Lauriola, L Balducci, M Ligon, K AF Sioletic, S. Alexander, B. Lauriola, L. Balducci, M. Ligon, K. TI Evaluation of Interactions of PI3K Pathway, IDH1(R132H), and OLIG2 Expression in Newly Diagnosed Glioblastoma Clinical Outcomes SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Gemelli Hosp, Rome, Italy. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1820 BP 436A EP 436A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902332 ER PT J AU Boyer, DF Yang, Y Wright, CVE AF Boyer, D. F. Yang, Y. Wright, C. V. E. TI Multipotent Progenitor Cells in Mouse Fetal Pancreas Are Defined by High Sox9 and Low Ngn3 SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1841 BP 441A EP 441A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902353 ER PT J AU Khor, TS Le, LP Iafrate, AJ Lauwers, GY Deshpande, V AF Khor, T. S. Le, L. P. Iafrate, A. J. Lauwers, G. Y. Deshpande, V. TI Are Pancreatic Endocrine Neoplasms in Tuberous Sclerosis Complex a Syndrome Associated Lesion? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Khor, T. S.; Le, L. P.; Iafrate, A. J.; Lauwers, G. Y.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1856 BP 445A EP 445A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902368 ER PT J AU Lew, M Hong, T Deshpande, V AF Lew, M. Hong, T. Deshpande, V. TI Comparison of Histologic Grading Schemes for Response to Neoadjuvant Therapy in Pancreatic Adenocarcinoma (PDAC) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Lew, M.; Hong, T.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1862 BP 446A EP 446A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902374 ER PT J AU Lew, M Morales-Oyarvide, V Liao, X Ogino, S Chen, JH Pitman, MB Mino-Kenudson, M AF Lew, M. Morales-Oyarvide, V. Liao, X. Ogino, S. Chen, J-H Pitman, M. B. Mino-Kenudson, M. TI Clinicopathologic Characteristics and Biologic Behavior of Concurrent Pancreatic Ductal Adenocarcinoma (PDAC) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Indiana Univ, Indianapolis, IN 46204 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1861 BP 446A EP 446A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902373 ER PT J AU Xiao, HD Pitman, MB Mino-Kenudson, M AF Xiao, H. D. Pitman, M. B. Mino-Kenudson, M. TI Downregulation of PTEN Expression in Intraductal Papillary Mucinous Neoplasm of the Pancreas Is Associated with an Invasive Phenotype SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Xiao, H. D.; Pitman, M. B.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1876 BP 449A EP 450A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902388 ER PT J AU Kerr, SE Schnabel, CA Sullivan, PS Zhang, Y Singh, V Carey, B Erlander, MG Highsmith, WE Dry, SM Brachtel, EF AF Kerr, S. E. Schnabel, C. A. Sullivan, P. S. Zhang, Y. Singh, V. Carey, B. Erlander, M. G. Highsmith, W. E. Dry, S. M. Brachtel, E. F. TI Multisite Analytical Validation of a 92-Gene Molecular Classifier for Cancers of Uncertain Primary SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Mayo Clin, Rochester, MN USA. BioTheranost Inc, San Diego, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1888 BP 453A EP 453A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902400 ER PT J AU Bauer, D Mitchell, C Straight, K Lathan, C Stelow, E Luer, S Muhammed, S Evans, A Sholl, L Rosai, J Giraldi, E Oakley, R Rodriguez-Galindo, C London, W Sallan, S Bradner, J French, C AF Bauer, D. Mitchell, C. Straight, K. Lathan, C. Stelow, E. Luer, S. Muhammed, S. Evans, A. Sholl, L. Rosai, J. Giraldi, E. Oakley, R. Rodriguez-Galindo, C. London, W. Sallan, S. Bradner, J. French, C. TI Clinicopathologic Features and Long-Term Outcomes of NUT Midline Carcinoma: An Index Report of the International NMC Registry SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Div Hematol Oncol, Boston, MA USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. Dana Farber Harvard Canc Care & Childrens Hosp, Boston, MA USA. Univ Virginia, Charlottesville, VA 22903 USA. Univ Bern, Inselspital, Univ Childrens Hosp Bern, CH-3010 Bern, Switzerland. Ctr Diagnost Italiano Int Ctr Oncol Pathol Consul, Milan, Italy. Osped Riuniti Bergamo, I-24100 Bergamo, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 1964 BP 472A EP 472A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902476 ER PT J AU Kovach, AE Klepeis, V Mark, EJ Dias-Santagata, D Iafrate, AJ Mino-Kenudson, M AF Kovach, A. E. Klepeis, V. Mark, E. J. Dias-Santagata, D. Iafrate, A. J. Mino-Kenudson, M. TI C-Kit Expression Is Associated with KRAS Mutation in Lung Adenocarcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Kovach, A. E.; Klepeis, V.; Mark, E. J.; Dias-Santagata, D.; Iafrate, A. J.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 2002 BP 480A EP 480A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902514 ER PT J AU Matsubara, O Miyai, K Kikuchi, R Iwaya, K Nakatani, Y Mark, EJ AF Matsubara, O. Miyai, K. Kikuchi, R. Iwaya, K. Nakatani, Y. Mark, E. J. TI Acute Exacerbations of Interstitial Pneumonias in Amyopathic Dermatomyositis: Different Pathogenesis in Ordinary Dermatomyositis/ Polymyositis When Compared to Amyopathic Dermatomyositis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Natl Def Med Coll, Tokorozawa, Saitama 359, Japan. Chiba Univ, Chiba, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 2014 BP 483A EP 483A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902526 ER PT J AU Nishino, M Klepeis, VE Yeap, B Bergethon, K Mark, MJ Iafrate, AJ Mino-Kenudson, M AF Nishino, M. Klepeis, V. E. Yeap, B. Bergethon, K. Mark, M. J. Iafrate, A. J. Mino-Kenudson, M. TI Histologic Multivariate Model for Predicting Presence of ALK-Rearrangement in Lung Adenocarcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 [Nishino, M.; Klepeis, V. E.; Yeap, B.; Bergethon, K.; Mark, M. J.; Iafrate, A. J.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 2021 BP 485A EP 485A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902533 ER PT J AU Rekhtman, N Paik, PK Arcila, ME Tafe, LJ Oxnard, GR Moreira, AL William, TD Zakowski, MF Mark, KG Ladanyi, M AF Rekhtman, N. Paik, P. K. Arcila, M. E. Tafe, L. J. Oxnard, G. R. Moreira, A. L. William, T. D. Zakowski, M. F. Mark, K. G. Ladanyi, M. TI Resolving the Controversy on EGFR/KRAS Mutations in Pulmonary Squamous Cell Carcinoma Via Comprehensive Pathologic Assessment Incorporating lmmunohistochemistry SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Mem Sloan Kettering Canc Ctr MSKCC, New York, NY USA. Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 2032 BP 487A EP 487A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902544 ER PT J AU Shen, J Taneja, K Zhang, W Dillon, DA Gandhi, L Sholl, LM AF Shen, J. Taneja, K. Zhang, W. Dillon, D. A. Gandhi, L. Sholl, L. M. TI HER2 Mutated Lung Adenocarcinoma Is a Distinct Molecular and Clinicopathologic Entity SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Charlton Mem Hosp, Fall River, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 2044 BP 490A EP 490A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902556 ER PT J AU Sholl, LM Iafrate, AJ Wu, MT Ligon, A Janne, PA Christiani, DC Chirieac, LR AF Sholl, L. M. Iafrate, A. J. Wu, M-T Ligon, A. Janne, P. A. Christiani, D. C. Chirieac, L. R. TI Met Activation Is Associated with Unique Clinicopathologic and Molecular Features in Lung Adenocarcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Kaohsiung Med Univ, Kaohsiung, Taiwan. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 2046 BP 491A EP 491A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902558 ER PT J AU Travis, WD Reklaman, N Shen, R Yi, ES Aubry, MC Cheney, R Dacic, S Flieder, D Funkhouser, W Illei, P Myers, J Tsao, MS Wilkerson, M Hammerman, P Govindan, R Hayes, N Meyerson, M AF Travis, W. D. Reklaman, N. Shen, R. Yi, E. S. Aubry, M. C. Cheney, R. Dacic, S. Flieder, D. Funkhouser, W. Illei, P. Myers, J. Tsao, M. S. Wilkerson, M. Hammerman, P. Govindan, R. Hayes, N. Meyerson, M. TI Molecular Histologic Correlations in the Cancer Genome Atlas (TCGA) Study of Lung Squamous Cell Carcinoma (SQC) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Mem Sloan Kettering, New York, NY USA. Mayo Clin, Rochester, MN USA. Univ Pittsburgh, Pittsburgh, PA USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Univ N Carolina, Chapel Hill, NC USA. Johns Hopkins, Baltimore, MD USA. Penrose St Francis Hlth Serv, Colorado Springs, CO USA. Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. Dana Farber Canc Inst, Boston, MA 02115 USA. Washington Univ, St Louis, MO USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 2049 BP 491A EP 491A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799902561 ER PT J AU Cassani, B Villablanca, EJ De Calisto, J Wang, S Mora, JR AF Cassani, Barbara Villablanca, Eduardo J. De Calisto, Jaime Wang, Sen Mora, J. Rodrigo TI Vitamin A and immune regulation: Role of retinoic acid in gut-associated dendritic cell education, immune protection and tolerance SO MOLECULAR ASPECTS OF MEDICINE LA English DT Review DE Vitamin A; Retinoic acid; Homing; Dendritic cells; Tolerance ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INFLAMMATORY-BOWEL-DISEASE; ANTIGEN-PRESENTING CELLS; DRAINING LYMPH-NODES; GROWTH-FACTOR-BETA; REACTIVE T-CELLS; ORAL TOLERANCE; SMALL-INTESTINE; DEFICIENT RATS; PEYERS-PATCHES AB The vitamin A (VA) metabolite all-trans retinoic acid (RA) plays a key role in mucosal immune responses. RA is produced by gut-associated dendritic cells (DC) and is required for generating gut-tropic lymphocytes and IgA-antibody-secreting cells (IgA-ASC). Moreover, RA modulates Foxp3(+) regulatory T cell (T-REG) and Th17 effector T cell differentiation. Thus, although RA could be used as an effective "mucosal adjuvant" in vaccines, it also appears to be required for establishing intestinal immune tolerance. Here we discuss the roles proposed for RA in shaping intestinal immune responses and tolerance at the gut mucosal interface. We also focus on recent data exploring the mechanisms by which gut-associated DC acquire RA-producing capacity. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Cassani, Barbara; Villablanca, Eduardo J.; De Calisto, Jaime; Wang, Sen; Mora, J. Rodrigo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA. RP Mora, JR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, 55 Fruit St,GRJ 815, Boston, MA 02114 USA. EM j_rodrigo_mora@hms.harvard.edu RI Villablanca, Eduardo/E-1380-2016; Cassani, Barbara/K-3871-2016 OI Villablanca, Eduardo/0000-0001-9522-9729; Cassani, Barbara/0000-0002-4115-8109 FU Ingrid Ramos; EMBO; Crohn's & Colitis Foundation of America (CCFA); Cancer Research Institute (CRI); Massachusetts Life Science Center (MLSC); NIH/NIAMS [P30 AR042689]; NIH [DP2 2009A054301] FX We thank Ms. Allison McNulty for excellent editorial assistance. J.R.M. is indebted to Ingrid Ramos for constant support. B.C. was supported by a postdoctoral fellowship from EMBO. E.J.V. was supported by a postdoctoral fellowship from Crohn's & Colitis Foundation of America (CCFA). J.R.M. was supported by grants from CCFA, Cancer Research Institute (CRI), Massachusetts Life Science Center (MLSC), Pilot Feasibility Grant NIH/NIAMS P30 AR042689 (HSDRC), and NIH New Director's Innovator Award DP2 2009A054301. NR 158 TC 47 Z9 51 U1 1 U2 18 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0098-2997 J9 MOL ASPECTS MED JI Mol. Asp. Med. PD FEB PY 2012 VL 33 IS 1 SI SI BP 63 EP 76 DI 10.1016/j.mam.2011.11.001 PG 14 WC Biochemistry & Molecular Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Research & Experimental Medicine GA 896CJ UT WOS:000300542700008 PM 22120429 ER PT J AU Weintraub, D Mamikonyan, E Papay, K Shea, JA Xie, SX Siderowf, A AF Weintraub, Daniel Mamikonyan, Eugenia Papay, Kimberly Shea, Judith A. Xie, Sharon X. Siderowf, Andrew TI Questionnaire for impulsive-compulsive disorders in Parkinson's Disease-Rating Scale SO MOVEMENT DISORDERS LA English DT Article DE dopamine agonists; impulse control disorder; Parkinson's disease ID BEHAVIORS; DYSREGULATION AB Impulse control disorders and related disorders (hobbyism-punding and dopamine dysregulation syndrome) occur in 15% to 20% of Parkinson's disease (PD) patients. We assessed the validity and reliability of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's DiseaseRating Scale (QUIP-RS), a rating scale designed to measure severity of symptoms and support a diagnosis of impulse control disorders and related disorders in PD. A convenience sample of PD patients at a movement disorders clinic self-completed the QUIP-RS and were administered a semistructured diagnostic interview by a blinded trained rater to assess discriminant validity for impulse control disorders (n = 104) and related disorders (n = 77). Subsets of patients were assessed to determine interrater reliability (n = 104), retest reliability (n = 63), and responsiveness to change (n = 29). Adequate cutoff points (both sensitivity and specificity values >80% plus acceptable likelihood ratios) were established for each impulse control disorder and hobbyism-punding. Interrater and retest reliability (intraclass correlation coefficient r) were >0.60 for all disorders. Participants in an impulse control disorder treatment study who experienced full (t = 3.65, P = .004) or partial (t = 2.98, P = .01) response demonstrated significant improvement on the rating scale over time, while nonresponders did not (t = 0.12, P = .91). The QUIP-RS appears to be valid and reliable as a rating scale for impulse control disorders and related disorders in PD. Preliminary results suggest that it can be used to support a diagnosis of these disorders, as well as to monitor changes in symptom severity over time. (C) 2011 Movement Disorder Society C1 [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel; Siderowf, Andrew] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr MIRECC, Philadelphia, PA USA. [Shea, Judith A.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Shea, Judith A.] Philadelphia Vet Affairs Med Ctr, CHERP, Philadelphia, PA USA. [Xie, Sharon X.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. RP Weintraub, D (reprint author), Univ Penn, Perelman Sch Med, Dept Psychiat, 3615 Chestnut St,330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu FU Michael J. Fox Foundation. FX Michael J. Fox Foundation. NR 20 TC 50 Z9 50 U1 2 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD FEB PY 2012 VL 27 IS 2 BP 242 EP 247 DI 10.1002/mds.24023 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 894LW UT WOS:000300429200014 PM 22134954 ER PT J AU Cristofaro, V Yalla, SV Sullivan, MP AF Cristofaro, Vivian Yalla, Subbarao V. Sullivan, Maryrose P. TI SPATIAL DISTRIBUTION AND MOLECULAR INTERACTION OF CAVEOLIN PROTEINS IN BLADDER SMOOTH MUSCLE SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Annual Winter Meeting of the Society-for-Urodynamics-and-Female-Urology (SUFU) CY FEB 28-MAR 03, 2012 CL New Orleans, LA SP Soc Urodynam & Female Urol (SUFU) C1 [Cristofaro, Vivian; Yalla, Subbarao V.; Sullivan, Maryrose P.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2012 VL 31 IS 2 BP 232 EP 233 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 895NG UT WOS:000300502400051 ER PT J AU Wang, ZW Cheng, ZY Cristofaro, V Gomez, P Sullivan, M Adam, R Olumi, A AF Wang, Zongwei Cheng, Zhiyong Cristofaro, Vivian Gomez, Pablo Sullivan, Maryrose Adam, Rosalyn Olumi, Aria TI INHIBITION OF TNF-alpha IMPROVES THE BLADDER DYSFUNCTION THAT IS ASSOCIATED WITH TYPE 2 DIABETES IN MICE SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Annual Winter Meeting of the Society-for-Urodynamics-and-Female-Urology (SUFU) CY FEB 28-MAR 03, 2012 CL New Orleans, LA SP Soc Urodynam & Female Urol (SUFU) C1 [Wang, Zongwei; Olumi, Aria] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cheng, Zhiyong] Childrens Hosp, Howard Hughes Med Inst, Div Endocrinol, Boston, MA 02115 USA. [Cristofaro, Vivian; Sullivan, Maryrose] VA Boston Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2012 VL 31 IS 2 BP 239 EP 239 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 895NG UT WOS:000300502400067 ER PT J AU Munoz, A Somogyi, G Boone, T Ford, A Smith, C AF Munoz, Alvaro Somogyi, George Boone, Timothy Ford, Anthony Smith, Christopher TI BLADDER SENSORY SIGNALS ARE POSITIVELY MODULATED BY UROTHELIAL P2 X 3 AND P2 X 2/3 PURINERGIC RECEPTORS IN SPINAL CORD INJURED RATS SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Annual Winter Meeting of the Society-for-Urodynamics-and-Female-Urology (SUFU) CY FEB 28-MAR 03, 2012 CL New Orleans, LA SP Soc Urodynam & Female Urol (SUFU) C1 [Munoz, Alvaro; Somogyi, George; Smith, Christopher] Baylor Coll Med, Houston, TX 77030 USA. [Boone, Timothy] Methodist Hosp, Houston, TX 77030 USA. [Boone, Timothy; Smith, Christopher] VA Med Ctr, Houston, TX USA. [Ford, Anthony] Afferent Pharmaceut, San Mateo, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2012 VL 31 IS 2 BP 241 EP 241 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 895NG UT WOS:000300502400072 ER PT J AU Jena, AB Seabury, S Lakdawalla, D Chandra, A AF Jena, Anupam B. Seabury, Seth Lakdawalla, Darius Chandra, Amitabh TI Malpractice Risk According to Physician Specialty EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material C1 [Jena, Anupam B.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Jena, Anupam B.] Harvard Univ, Sch Med, Boston, MA USA. [Seabury, Seth] RAND, Santa Monica, CA USA. [Lakdawalla, Darius] Univ So Calif, Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA. [Lakdawalla, Darius] Univ So Calif, Sch Policy Planning & Dev, Los Angeles, CA USA. [Chandra, Amitabh] Harvard Univ, Kennedy Sch, Cambridge, MA 02138 USA. RP Jena, AB (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD FEB PY 2012 VL 67 IS 2 BP 73 EP 75 DI 10.1097/OGX.0b013e318247c521 PG 4 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 896YK UT WOS:000300607200003 ER PT J AU Chabner, BA Smith, M AF Chabner, Bruce A. Smith, Matthew TI Call It Cancer SO ONCOLOGIST LA English DT Editorial Material ID MORTALITY C1 [Chabner, Bruce A.; Smith, Matthew] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Chabner, BA (reprint author), Massachusetts Gen Hosp, 10 N Grove St,LRH 214, Boston, MA 02114 USA. EM bchabner@partners.org NR 7 TC 5 Z9 5 U1 1 U2 2 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PD FEB PY 2012 VL 17 IS 2 BP 149 EP 150 DI 10.1634/theoncologist.2012-0004 PG 2 WC Oncology SC Oncology GA 898HC UT WOS:000300730200001 PM 22302229 ER PT J AU Saylor, PJ Kozak, KR Smith, MR Ancukiewicz, MA Efstathiou, JA Zietman, AL Jain, RK Duda, DG AF Saylor, Philip J. Kozak, Kevin R. Smith, Matthew R. Ancukiewicz, Marek A. Efstathiou, Jason A. Zietman, Anthony L. Jain, Rakesh K. Duda, Dan G. TI Changes in Biomarkers of Inflammation and Angiogenesis During Androgen Deprivation Therapy for Prostate Cancer SO ONCOLOGIST LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; IN-VITRO EXPRESSION; LEUKEMIA GROUP-B; PROGNOSTIC-SIGNIFICANCE; DISEASE PROGRESSION; CYTOKINE EXPRESSION; DOUBLING TIME; MEN; RECEPTOR; PLASMA AB Introduction. Angiogenesis and inflammation are both important to the pathogenesis of malignancies. Androgen deprivation therapy (ADT) for prostate cancer causes drastic hormonal changes that alter both disease and host factors. We measured inflammatory and angiogenic biomarkers in ADT-treated and control groups of men with prostate cancer. Materials and Methods. Baseline and 12-week plasma samples were collected from 37 ADT-naive men with locally advanced or recurrent prostate cancer. Of those, 23 initiated ADT with a gonadotropin-releasing hormone (GnRH) agonist and 14 served as nontreatment controls. Samples were tested for a panel of angiogenic and inflammatory biomarkers. Results. The treatment group had significantly higher concentrations of the inflammatory biomarkers interleukin (IL)-1 beta, IL-6, IL-8, tumor necrosis factor (TNF)-alpha, and stromal cell-derived factor (SDF)-1 alpha. None of the angiogenic biomarkers were significantly different between the groups at baseline. Among patients with a short prostate-specific antigen (PSA) doubling time (<6 months), the proangiogenic factor basic fibroblast growth factor (bFGF) was lower at baseline. In the treatment group, plasma placental growth factor (PlGF) increased and IL-6 decreased after 12 weeks of ADT. Moreover, the treatment group continued to have significantly higher concentrations of the inflammatory biomarkers IL-1 beta, IL-8, and SDF-1 alpha as well as bFGF than controls. Discussion. These men were characterized by elevations in several traditional markers of aggressive disease and also by higher levels of several inflammatory biomarkers. Although ADT decreased IL-6 levels, IL-1 beta, IL-8, and SDF-1 alpha remained significantly higher than in controls. The role of these biomarkers should be further explored. The Oncologist 2012;17:212-219 C1 [Kozak, Kevin R.; Ancukiewicz, Marek A.; Efstathiou, Jason A.; Zietman, Anthony L.; Jain, Rakesh K.; Duda, Dan G.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Kozak, Kevin R.; Ancukiewicz, Marek A.; Efstathiou, Jason A.; Zietman, Anthony L.; Jain, Rakesh K.; Duda, Dan G.] Harvard Univ, Sch Med, Boston, MA USA. [Saylor, Philip J.; Smith, Matthew R.] Massachusetts Gen Hosp, Ctr Canc, Div Hematol Oncol, Boston, MA 02114 USA. [Kozak, Kevin R.] Univ Wisconsin, Dept Human Oncol, Sch Med & Publ Hlth, Madison, WI USA. RP Jain, RK (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. EM jain@steele.mgh.harvard.edu; duda@steele.mgh.harvard.edu RI Inov Farmaceutica, Inct/K-2313-2013 FU MedImmune; Roche; Dyax; Bertucci Prostate Cancer Research Grant; National Cancer Institute [R01-CA115767, P01-CA080124, R01-CA085140, R01-CA126642, R01-CA159258, K24-CA121990]; Federal Share Proton Beam Program Income Grants; American Cancer Society [120733-RSG-11-073-01-TBG]; Prostate Cancer Foundation; ASCO Cancer Foundation FX Disclosures: Philip J. Saylor: None; Kevin R. Kozak: None; Matthew R. Smith: None; Marek A. Ancukiewicz: None; Jason A. Efstathiou: None; Anthony L. Zietman: Chair American Society for Radiation Oncology (E); Co-chair NCI GU Steering Committee (C/A); Rakesh K. Jain: NoxxonPharma (C/A); MedImmune, Roche (RF); Dyax (C/A, RF); Xtuit Pharmaceuticals, SynDevRx (C/A, OI); Dan G. Duda: None.; This work was supported by a Bertucci Prostate Cancer Research Grant, and in part by National Cancer Institute grants R01-CA115767, P01-CA080124, R01-CA085140, R01-CA126642, R01-CA159258, and K24-CA121990, and Federal Share Proton Beam Program Income Grants as well as by grant 120733-RSG-11-073-01-TBG from the American Cancer Society. P.J. Saylor is supported by Young Investigator Awards from the Prostate Cancer Foundation and ASCO Cancer Foundation. M.R. Smith is supported by awards from the Prostate Cancer Foundation. NR 46 TC 20 Z9 22 U1 1 U2 3 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PD FEB PY 2012 VL 17 IS 2 BP 212 EP 219 DI 10.1634/theoncologist.2011-0321 PG 8 WC Oncology SC Oncology GA 898HC UT WOS:000300730200013 PM 22302227 ER PT J AU Saylor, PJ Michaelson, MD AF Saylor, Philip J. Michaelson, M. Dror TI Should the Denosumab Metastasis Prevention Trial Change Practice for Men with Nonmetastatic Prostate Cancer? SO ONCOLOGIST LA English DT Editorial Material ID PLACEBO-CONTROLLED TRIAL; ZOLEDRONIC ACID; BONE METASTASES; MITOXANTRONE; PREDNISONE; DOCETAXEL; THERAPY C1 [Saylor, Philip J.; Michaelson, M. Dror] Massachusetts Gen Hosp, Div Hematol Oncol, Ctr Canc, Boston, MA USA. RP Saylor, PJ (reprint author), Massachusetts Gen Hosp, Div Hematol Oncol, Ctr Canc, Boston, MA USA. RI Inov Farmaceutica, Inct/K-2313-2013; OI Michaelson, Dror/0000-0001-9249-6338 NR 15 TC 0 Z9 0 U1 0 U2 0 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PD FEB PY 2012 VL 17 IS 2 BP 288 EP 290 DI 10.1634/theoncologist.2011-0433 PG 3 WC Oncology SC Oncology GA 898HC UT WOS:000300730200022 PM 22267850 ER PT J AU Sills, MR Ginde, AA Clark, S Camargo, CA AF Sills, Marion R. Ginde, Adit A. Clark, Sunday Camargo, Carlos A. TI Multicenter Analysis of Quality Indicators for Children Treated in the Emergency Department for Asthma SO PEDIATRICS LA English DT Article DE asthma; outcome and process assessments (health care); quality of health care; Severity of Illness Index; practice guideline; antiasthmatic agents; asthma; preschool child; child; adolescent ID PEDIATRIC ASTHMA; HEALTH-CARE; HOSPITALIZATION; MANAGEMENT; RELAPSE AB OBJECTIVE: To test the hypothesis that an association exists between process and outcome measures of the quality of acute asthma care provided to children in the emergency department. METHODS: Investigators at 14 US sites prospectively enrolled consecutive children 2 to 17 years of age presenting to the emergency department with acute asthma. In models adjusted for variables commonly associated with the quality of acute asthma care, we measured the association between 7 measures of concordance with national asthma guideline-recommended processes and 2 outcomes. Specifically, we modeled the association between 5 receipt/nonreceipt process measures and successful discharge and the association between 2 timeliness measures and admission. RESULTS: In this cohort of 1426 patients, 62% were discharged without relapse or ongoing symptoms (successful discharge), 15% were discharged with relapse or ongoing symptoms, and 24% were admitted. The composite score for receipt of all 5 receipt/nonreceipt process measures was 84%, and for timeliness measures, 57% receive a timely corticosteroid and 92% a timely beta-agonist. Our adjusted models showed no association between process and outcome measures, with 1 exception: timely beta-agonist administration was associated with admission, likely reflecting confounding by severity rather than a true process-outcome association. CONCLUSIONS: We found no clinically significant association between process and outcome quality measures in the delivery of asthma-related care to children in a children in a multicenter study study. Although the quality of emergency department care does not predict successful discharge, other factors, such as outpatient care, may better predict outcomes. Pediatrics 2012;129:e325-e332 C1 [Camargo, Carlos A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Sills, Marion R.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA. [Ginde, Adit A.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA. [Clark, Sunday] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. RP Camargo, CA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, 326 Cambridge St,Suite 410, Boston, MA 02114 USA. EM ccamargo@partners.org RI Siry, Bonnie/D-7189-2017; OI Sills, Marion/0000-0003-1322-0822 FU AstraZeneca; Dey; GlaxoSmithKline; Merck; Novartis; Sanofi-Aventis; National Institutes of Health (NIH) [KL2 RR025779, HL-03533, HL-63253]; American College of Emergency Physicians [1 R03 HS016418-01A1]; Agency for Healthcare Research and Quality; American Lung Association; Children's Hospital Research Institute FX Dr Camargo has received financial support from a variety of groups for participation in conferences, consulting, and investigator-initiated medical research. Recent industry sponsors with an interest in asthma were AstraZeneca, Dey, GlaxoSmithKline, Merck, Novartis, and Sanofi-Aventis. Drs Sills, Ginde, and Clark have indicated they have no financial relationships relevant to this article to disclose.; Funded by the National Institutes of Health (NIH).; Dr Sills was supported by the Riggs Family/Health Policy grant from the American College of Emergency Physicians, grant 1 R03 HS016418-01A1 from the Agency for Healthcare Research and Quality, the Social Behavioral Research grant from the American Lung Association, and by the Children's Hospital Research Institute; Dr Ginde was supported by NIH grant KL2 RR025779. The Multicenter Airway Research Collaboration was supported by NIH grant HL-03533 and HL-63253, and by an unrestricted grant from GlaxoSmithKline (Research Triangle Park, NC). NR 25 TC 10 Z9 10 U1 0 U2 5 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD FEB PY 2012 VL 129 IS 2 BP E325 EP E332 DI 10.1542/peds.2010-3302 PG 8 WC Pediatrics SC Pediatrics GA 893YZ UT WOS:000300395100010 PM 22250025 ER PT J AU Wilmot, B Voruganti, VS Chang, YPC Fu, Y Chen, Z Taylor, HA Wilson, JG Gipson, T Shah, VO Umans, JG Flessner, MF Hitzemann, R Shuldiner, AR Comuzzie, AG McWeeney, S Zager, PG MacCluer, JW Cole, SA Cohen, DM AF Wilmot, Beth Voruganti, V. Saroja Chang, Yen-Pei C. Fu, Yi Chen, Zhan Taylor, Hrman A. Wilson, James G. Gipson, Teresa Shah, Vallabh O. Umans, Jason G. Flessner, Michael F. Hitzemann, Robert Shuldiner, Alan R. Comuzzie, Anthony G. McWeeney, Shannon Zager, Philip G. MacCluer, Jean W. Cole, Shelley A. Cohen, David M. TI Heritability of serum sodium concentration: evidence for sex- and ethnic-specific effects SO PHYSIOLOGICAL GENOMICS LA English DT Article DE hyponatremia; hypernatremia; osmoregulation; water balance ID NEPHROGENIC DIABETES-INSIPIDUS; CORONARY-HEART-DISEASE; INAPPROPRIATE ANTIDIURESIS; INDUCED HYPONATREMIA; RECEPTOR GENE; CARDIOVASCULAR-DISEASE; PROGNOSTIC IMPORTANCE; AMERICAN-INDIANS; LINKAGE ANALYSIS; CHANNEL AB Wilmot B, Voruganti VS, Chang YP, Fu Y, Chen Z, Taylor HA, Wilson JG, Gipson T, Shah VO, Umans JG, Flessner MF, Hitzemann R, Shuldiner AR, Comuzzie AG, McWeeney S, Zager PG, MacCluer JW, Cole SA, Cohen DM. Heritability of serum sodium concentration: evidence for sex- and ethnic-specific effects. Physiol Genomics 44: 220-228, 2012. First published December 20, 2011; doi:10.1152/physiolgenomics.00153.2011.-Serum sodium concentration is the clinical index of systemic water balance. Although disordered water balance is common and morbid, little is known about genetic effects on serum sodium concentration at the population level. Prior studies addressed only participants of European descent and either failed to demonstrate significant heritability or showed only modest effect. We investigated heritability of serum sodium concentration in large cohorts reflecting a range of races/ethnicities, including the Framingham Heart Study (FHS, non-Hispanic Caucasian), the Heredity and Phenotype Intervention Heart Study (HAPI, Amish Caucasian), the Jackson Heart Study (JHS, African American), the Strong Heart Family Study (SHFS, American Indian), and the Genetics of Kidney Disease in Zuni Indians Study (GKDZI, American Indian). Serum sodium was transformed for the osmotic effect of glucose, and participants with markedly elevated glucose or reduced estimated glomerular filtration rate (eGFR) were excluded. Using a standard variance components method, incorporating covariates of age, glucose, and eGFR, we found heritability to be high in African American and American Indian populations and much more modest in non-Hispanic Caucasian populations. Estimates among females increased after stratification on sex and were suggestive among female participants in FHS (0.18 +/- 0.12, P = 0.057) and male participants in JHS (0.24 +/- 0.16, P = 0.067) and statistically significant among female participants in JHS (0.44 +/- 0.09, P = 1 x 10(-7)), SHFS (0.59 +/- 0.05, P = 9.4 x 10(-46)), and GKDZI (0.46 +/- 0.15, P = 1.7 x 10(-4)), and male participants in HAPI (0.18 +/- 0.12, P = 0.03) and SHFS (0.67 +/- 0.07, P = 5.4 x 10(-26)). Exclusion of diuretic users increased heritability among females and was significant in all cohorts where data were available. In aggregate, these data strongly support the heritability of systemic water balance and underscore sex and ethnicity-specific effects. C1 [Fu, Yi; Chen, Zhan; Cohen, David M.] Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97239 USA. [Wilmot, Beth; McWeeney, Shannon] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. [Hitzemann, Robert] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Gipson, Teresa] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97239 USA. [Fu, Yi; Chen, Zhan; Cohen, David M.] Portland VA Med Ctr, Portland, OR USA. [Voruganti, V. Saroja; Comuzzie, Anthony G.; MacCluer, Jean W.; Cole, Shelley A.] SW Fdn Biomed Res, Dept Genet, San Antonio, TX USA. [Taylor, Hrman A.; Wilson, James G.; Flessner, Michael F.] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Taylor, Hrman A.; Wilson, James G.; Flessner, Michael F.] GV Sonny Montgomery Vet Affairs Med Ctr, Jackson, MS USA. [Chang, Yen-Pei C.; Shuldiner, Alan R.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. [Umans, Jason G.] Medstar Res Inst, Washington, DC USA. [Zager, Philip G.] Univ New Mexico, Sch Med, Dept Med, Albuquerque, NM 87131 USA. [Shah, Vallabh O.] Univ New Mexico, Sch Med, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA. RP Cohen, DM (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Mailcode L463V,3314 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM cohend@ohsu.edu FU National Institutes of Health; Department of Veterans Affairs; American Heart Association; National Heart, Lung, and Blood Institute's (NHLBI) FHS [N01-HC-25195]; NHLBI in collaboration with Boston University; NHLBI [U01 HL-041654, U01 HL-041642, U01 HL-041652, U01 HL-065520, U01 HL-065521]; National Institute of Diabetes and Digestive and Kidney Diseases [DK-066660-03, DK-57300-05]; University of New Mexico Clinical Research Center [5M01RR-00997]; National Institute of Environmental Health Sciences [P30 ES-012072]; Dialysis Clinic; National Center on Minority Health and Health Disparities FX This work was supported by grants from the National Institutes of Health, the Department of Veterans Affairs, and the American Heart Association (to D. M. Cohen). A portion of this work was supported by the National Heart, Lung, and Blood Institute's (NHLBI) FHS (contract no. N01-HC-25195). The FHS is conducted and supported by the NHLBI in collaboration with Boston University. The HAPI Heart Study is supported by NHLBI Grant HL-72515-01. The SHS is supported by the following NHLBI grants: U01 HL-041654, U01 HL-041642, U01 HL-041652, U01 HL-065520, and U01 HL-065521. GKDZI receives funding from National Institute of Diabetes and Digestive and Kidney Diseases (DK-066660-03; DK-57300-05), University of New Mexico Clinical Research Center (5M01RR-00997), National Institute of Environmental Health Sciences (P30 ES-012072), and Dialysis Clinic. The JHS is supported by the NHLBI and the National Center on Minority Health and Health Disparities. NR 69 TC 4 Z9 4 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1094-8341 EI 1531-2267 J9 PHYSIOL GENOMICS JI Physiol. Genomics PD FEB PY 2012 VL 44 IS 3 BP 220 EP 228 DI 10.1152/physiolgenomics.00153.2011 PG 9 WC Cell Biology; Genetics & Heredity; Physiology SC Cell Biology; Genetics & Heredity; Physiology GA 896XN UT WOS:000300604800002 PM 22186255 ER PT J AU Desalermos, A Fuchs, BB Mylonakis, E AF Desalermos, Athanasios Fuchs, Beth Burgwyn Mylonakis, Eleftherios TI Selecting an Invertebrate Model Host for the Study of Fungal Pathogenesis SO PLOS PATHOGENS LA English DT Article ID DEFICIENT DROSOPHILA-MELANOGASTER; INNATE IMMUNE-RESPONSE; CRYPTOCOCCUS-NEOFORMANS; GALLERIA-MELLONELLA; CANDIDA-ALBICANS; CAENORHABDITIS-ELEGANS; VIRULENCE; DICTYOSTELIUM; MUTANTS; LARVAE C1 [Desalermos, Athanasios; Fuchs, Beth Burgwyn; Mylonakis, Eleftherios] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02115 USA. RP Desalermos, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02115 USA. EM emylonakis@partners.org FU National Institutes of Health [AI075286, AI070569] FX This work was supported by the National Institutes of Health through an R01 award (AI075286) and an R21 award (AI070569) to EM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 20 TC 25 Z9 25 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7366 J9 PLOS PATHOG JI PLoS Pathog. PD FEB PY 2012 VL 8 IS 2 AR e1002451 DI 10.1371/journal.ppat.1002451 PG 4 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 898GQ UT WOS:000300728100002 PM 22319439 ER PT J AU Yuen, EK Goetter, EM Herbert, JD Forman, EM AF Yuen, Erica K. Goetter, Elizabeth M. Herbert, James D. Forman, Evan M. TI Challenges and Opportunities in Internet-Mediated Telemental Health SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article DE telemental health; remote treatment; distance treatment; technology; Internet ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; POSTTRAUMATIC-STRESS-DISORDER; FACE-TO-FACE; OBSESSIVE-COMPULSIVE DISORDER; SMOKING-CESSATION PROGRAM; PANIC DISORDER; SOCIAL PHOBIA; SELF-HELP; WEIGHT-LOSS AB The use of technology to provide remote psychological assessment and intervention services is growing rapidly. Remote assessment, treatment, training, and consultation options, particularly those provided via the Internet (e.g., videoconferencing, self-help Web sites, handheld devices), have the potential to increase access to high-quality psychological services. Despite the promise of these technologies, a variety of clinical, ethical, and logistical challenges accompany the remote delivery of such services. Among these challenges are issues involving security, competence, the therapeutic alliance, usability, and technical difficulties. We elucidate some of the challenges posed by these technologies and suggest preliminary recommendations for psychologists considering their use. C1 [Herbert, James D.] Drexel Univ, Dept Psychol, Coll Arts & Sci, Philadelphia, PA 19102 USA. [Forman, Evan M.] Drexel Univ, Doctoral Program Clin Psychol, Philadelphia, PA 19102 USA. [Yuen, Erica K.] Med Univ S Carolina, Charleston, SC 29425 USA. [Yuen, Erica K.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Herbert, JD (reprint author), Drexel Univ, Dept Psychol, Coll Arts & Sci, 245 N 15th St,Mail Stop 988, Philadelphia, PA 19102 USA. EM james.herbert@drexel.edu RI Forman, Evan/I-1042-2012 NR 71 TC 24 Z9 24 U1 1 U2 6 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD FEB PY 2012 VL 43 IS 1 BP 1 EP 8 DI 10.1037/a0025524 PG 8 WC Psychology, Multidisciplinary SC Psychology GA 895GE UT WOS:000300483400001 ER PT J AU Meyer, EC Zimering, R Daly, E Knight, J Kamholz, BW Gulliver, SB AF Meyer, Eric C. Zimering, Rose Daly, Erin Knight, Jeffrey Kamholz, Barbara W. Gulliver, Suzy Bird TI Predictors of Posttraumatic Stress Disorder and Other Psychological Symptoms in Trauma-Exposed Firefighters SO PSYCHOLOGICAL SERVICES LA English DT Article DE PTSD; firefighters; depression; alcohol abuse; social support ID ADMINISTERED PTSD SCALE; SOCIAL SUPPORT; PSYCHOMETRIC PROPERTIES; PROFESSIONAL FIREFIGHTERS; VOLUNTEER FIREFIGHTERS; CAGE QUESTIONNAIRE; RESCUE WORKERS; PREVALENCE; INVENTORY; METAANALYSIS AB Firefighters are exposed to a range of potentially traumatic stressors, yet studies examining the impact of this exposure are equivocal. Although some studies suggest increased risk for mental health problems, others suggest unusual resilience. Type of assessment methodology may contribute to the lack of consistent findings. We assessed 142 trauma-exposed, professional firefighters utilizing a standardized clinical interview and self-report measures and found low rates of posttraumatic stress disorder (PTSD) diagnoses (4.2%), and depressive, anxiety, and alcohol-abuse symptoms. Frequency of trauma exposure did not predict psychological symptoms. Perceived social support, occupational stress, coping, as well as the interaction between perceived social support and self-blame were significant predictors of symptoms. Firefighters reporting low-perceived social support and high self-blame demonstrated the highest levels of clinically significant symptoms. These findings may inform education, treatment, and resilience training for emergency personnel. C1 [Meyer, Eric C.; Gulliver, Suzy Bird] Cent Texas Vet Hlth Care Syst 151C, US Dept Vet Affairs, VISN 17, Ctr Excellence Res Returning War Vet, Waco, TX 76711 USA. [Zimering, Rose; Daly, Erin; Knight, Jeffrey; Kamholz, Barbara W.] US Dept Vet Affairs, Boston, MA USA. [Zimering, Rose; Knight, Jeffrey; Kamholz, Barbara W.] Boston Univ, Sch Med, Boston, MA 02215 USA. RP Meyer, EC (reprint author), Cent Texas Vet Hlth Care Syst 151C, US Dept Vet Affairs, VISN 17, Ctr Excellence Res Returning War Vet, 4800 Mem Dr, Waco, TX 76711 USA. EM Eric.Meyer2@va.gov NR 60 TC 26 Z9 31 U1 10 U2 40 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2012 VL 9 IS 1 BP 1 EP 15 DI 10.1037/a0026414 PG 15 WC Psychology, Clinical SC Psychology GA 896BW UT WOS:000300541400001 PM 22449083 ER PT J AU Yoder, M Tuerk, PW Price, M Grubaugh, AL Strachan, M Myrick, H Acierno, R AF Yoder, Matthew Tuerk, Peter W. Price, Matthew Grubaugh, Anouk L. Strachan, Martha Myrick, Hugh Acierno, Ron TI Prolonged Exposure Therapy for Combat-Related Posttraumatic Stress Disorder: Comparing Outcomes for Veterans of Different Wars SO PSYCHOLOGICAL SERVICES LA English DT Article DE posttraumatic stress disorder; veterans; prolonged exposure; treatment effectiveness; exposure therapy ID PTSD; AFGHANISTAN; IRAQ AB There is significant support for exposure therapy as an effective treatment for posttraumatic stress disorder (PTSD) across a variety of populations, including veterans; however, there is little empirical information regarding how veterans of different war theaters respond to exposure therapy. Accordingly, questions remain regarding therapy effectiveness for treatment of PTSD for veterans of different eras. Such questions have important implications for the dissemination of evidence based treatments, treatment development, and policy. The current study compared treatment outcomes across 112 veterans of the Vietnam War, the first Persian Gulf War, and the wars in Afghanistan and Iraq. All subjects were diagnosed with PTSD and enrolled in Prolonged Exposure (PE) treatment. Veterans from all three groups showed significant improvement in PTSD symptoms, with veterans from Vietnam and Afghanistan/Iraq responding similarly to treatment. Persian Gulf veterans did not respond to treatment at the same rate or to the same degree as veterans from the other two eras. Questions and issues regarding the effectiveness of evidence based treatment for veterans from different eras are discussed. C1 [Yoder, Matthew; Tuerk, Peter W.; Price, Matthew; Grubaugh, Anouk L.; Strachan, Martha; Myrick, Hugh; Acierno, Ron] Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Yoder, Matthew; Tuerk, Peter W.; Price, Matthew; Grubaugh, Anouk L.; Strachan, Martha; Myrick, Hugh; Acierno, Ron] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Yoder, M (reprint author), Ralph H Johnson Med Ctr, Dept Vet Affairs, 109 Bee St, Charleston, SC 29401 USA. EM yoderm@musc.edu RI Schueter, nicos/A-3625-2014 FU NIMH NIH HHS [T32 MH018869] NR 25 TC 24 Z9 24 U1 1 U2 4 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2012 VL 9 IS 1 BP 16 EP 25 DI 10.1037/a0026279 PG 10 WC Psychology, Clinical SC Psychology GA 896BW UT WOS:000300541400002 PM 22449084 ER PT J AU Harper, JD Spencer, ES Porter, MP Gore, JL AF Harper, Jonathan D. Spencer, E. Sophie Porter, Michael P. Gore, John L. TI Adoption of Laparoscopic Radical Nephrectomy in the State of Washington SO UROLOGY LA English DT Article ID DONOR NEPHRECTOMY; KIDNEY-CANCER; DIFFUSION; REGIONALIZATION AB OBJECTIVE To examine state-wide trends in adoption of laparoscopic radical nephrectomy (LRN). Open radical nephrectomy and LRN confer equivalent long-term oncological outcomes, yet LRN usage has not increased analogous to diffusion of laparoscopy in other fields. MATERIAL AND METHODS From the Washington State Comprehensive Hospital Abstract Reporting System, we identified patients who underwent ORN and LRN from 1998 to 2007. Number of LRNs was examined for each hospital state-wide. Length of stay outcomes were examined, and multivariate models were created to examine characteristics of LRN patients and of patients who received care at high-volume LRN hospitals (HiLap). RESULTS The proportion of nephrectomies performed laparoscopically increased 27%. In 1998, 7 hospitals (12%) performed >= 1 LRN compared with 36 hospitals (61%) in 2007. Four HiLap hospitals accounted for 61% of the increase in LRN from 1998-2002, and 36% of the increase overall. Women (OR 1.15, 95% CI 1.00-1.33) and healthier patients (OR 1.52, 95% CI 1.28-1.82 for patients with Charlson 0 vs >= 2) were more likely to undergo LRN. Mean length of stay for nephrectomies was shorter at HiLap hospitals (P = .04 for 1998-2002, P < .001 for 2003-2007). CONCLUSIONS Uptake of LRN in Washington state parallels national trends; however, the proportion of LRN is lower than expected. A handful of hospitals account for the majority of the increase in LRN. The quality of nephrectomy care may be better at these centers. Barriers exist that prevent LRN adoption even after a trial case. Dissemination of the processes or personnel associated with use of LRN may increase the proportion of patients undergoing LRN. UROLOGY 79: 326-331, 2012. (C) 2012 Elsevier Inc. All rights reserved. C1 Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Urol Sect, Seattle, WA USA. RP Harper, JD (reprint author), UW Urol, 1959 NE Pacific,Box 356510, Seattle, WA 98195 USA. EM jdharper@uw.edu OI Gore, John/0000-0002-2847-5062 FU VA Puget Sound Health Care System, Seattle, Washington FX This material is the result of work supported in part by resources from the VA Puget Sound Health Care System, Seattle, Washington. NR 18 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD FEB PY 2012 VL 79 IS 2 BP 326 EP 331 DI 10.1016/j.urology.2011.10.029 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 894DM UT WOS:000300407200034 PM 22310748 ER PT J AU Zhuang, LY Duty, BD Conlin, MJ Daneshmand, S AF Zhuang, Liyan Duty, Brian D. Conlin, Michael J. Daneshmand, Siamak TI Colocalycostomy for Repair of Ureterojejunal Fistula SO UROLOGY LA English DT Editorial Material AB Calycostomy is a procedure used for an inaccessible renal pelvis during pyeloplasty. We report the first case of using an anterior calycostomy to repair a ureterojejeunal fistula in a transverse colon conduit in which the ureter and pelvis were not accessible because of intense fibrosis. UROLOGY 79: e12-e14, 2012. (C) 2012 Elsevier Inc. C1 [Daneshmand, Siamak] USC Norris Comprehens Canc Ctr, Inst Urol, USC Keck Sch Med, Los Angeles, CA 90089 USA. Oregon Hlth & Sci Univ, Dept Surg, Div Urol & Renal Transplantat, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. RP Daneshmand, S (reprint author), USC Norris Comprehens Canc Ctr, Inst Urol, USC Keck Sch Med, 1441 Eastlake Ave,Suite 7416, Los Angeles, CA 90089 USA. EM siadaneshmand@yahoo.com OI Conlin, Michael/0000-0002-3128-3731; Daneshmand, Siamak/0000-0001-6224-9598 NR 1 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD FEB PY 2012 VL 79 IS 2 BP E12 EP E14 DI 10.1016/j.urology.2011.04.040 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 894DM UT WOS:000300407200006 PM 21705047 ER PT J AU Grenon, SM Hughes-Fulford, M Rapp, J Conte, MS AF Grenon, S. Marlene Hughes-Fulford, Millie Rapp, Joseph Conte, Michael S. TI Polyunsaturated fatty acids and peripheral artery disease SO VASCULAR MEDICINE LA English DT Review DE lipids; nutrition; peripheral arterial disease; peripheral vascular diseases; review ID CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; FISH-OIL SUPPLEMENTATION; TUMOR-NECROSIS-FACTOR; ALPHA-LINOLENIC ACID; NF-KAPPA-B; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; HUMAN ENDOTHELIAL-CELLS; SMOOTH-MUSCLE-CELLS AB There is substantial evidence that polyunsaturated fatty acids (PUFAs) such as n-3 and n-6 fatty acids (FAs) play an important role in prevention of atherosclerosis. In vitro and in vivo studies focusing on the interactions between monocytes and endothelial cells have explored the molecular effects of FAs on these interactions. Epidemiological surveys, followed by large, randomized, control trials have demonstrated a reduction in major cardiovascular events with supplementation of n-3 FAs in secondary prevention settings. The evidence of beneficial effects specific to patients with peripheral artery disease (PAD) remains elusive, and is the focus of this review. C1 [Grenon, S. Marlene] Univ Calif San Francisco, Div Vasc & Endovasc Surg, San Francisco Vet Affairs Med Ctr, Surg Serv, San Francisco, CA 94121 USA. [Hughes-Fulford, Millie] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. [Hughes-Fulford, Millie] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94121 USA. RP Grenon, SM (reprint author), Univ Calif San Francisco, Div Vasc & Endovasc Surg, San Francisco Vet Affairs Med Ctr, Surg Serv, Mail Code 112 G, San Francisco, CA 94121 USA. EM marlene.grenon@ucsfmedctr.org FU Department of Surgery, University of California, San Francisco; Northern California Institute for Research and Education; National Center for Research Resources [KL2RR024130] FX This work was supported by funds from the Department of Surgery, University of California, San Francisco and the Northern California Institute for Research and Education. The project described was supported by Award Number KL2RR024130 from the National Center for Research Resources. NR 121 TC 13 Z9 13 U1 0 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1358-863X EI 1477-0377 J9 VASC MED JI Vasc. Med. PD FEB PY 2012 VL 17 IS 1 BP 51 EP 63 DI 10.1177/1358863X11429175 PG 13 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 896HY UT WOS:000300557500007 PM 22363018 ER PT J AU Weinberg, I Jaff, MR AF Weinberg, Ido Jaff, Michael R. TI Penile ischemic lesions associated with anti-phospholipid antibody syndrome SO VASCULAR MEDICINE LA English DT Article C1 [Weinberg, Ido; Jaff, Michael R.] Massachusetts Gen Hosp, Vasc Med Sect, Div Cardiol, Vasc Ctr, Boston, MA 02114 USA. RP Weinberg, I (reprint author), Massachusetts Gen Hosp, Vasc Med Sect, Div Cardiol, Vasc Ctr, 55 Fruit St, Boston, MA 02114 USA. EM iweinberg@partners.org NR 5 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1358-863X J9 VASC MED JI Vasc. Med. PD FEB PY 2012 VL 17 IS 1 BP 68 EP 69 DI 10.1177/1358863X11424933 PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 896HY UT WOS:000300557500010 PM 22025525 ER PT J AU Ford, JM Perez, VB Mathalon, DH AF Ford, Judith M. Perez, Veronica B. Mathalon, Daniel H. TI Neurophysiology of a possible fundamental deficit in schizophrenia SO WORLD PSYCHIATRY LA English DT Editorial Material ID COROLLARY DISCHARGE DYSFUNCTION; AUDITORY HALLUCINATIONS; SYNCH C1 [Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA 94121 USA. [Ford, Judith M.; Perez, Veronica B.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. RP Ford, JM (reprint author), San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA 94121 USA. OI Mathalon, Daniel/0000-0001-6090-4974 FU NIMH NIH HHS [R01 MH058262, K02 MH067967, R01 MH076989, T32 MH089920] NR 10 TC 2 Z9 2 U1 0 U2 4 PU ELSEVIER MASSON PI MILANO PA VIA PALEOCAPA 7, 20121 MILANO, ITALY SN 1723-8617 J9 WORLD PSYCHIATRY JI World Psychiatry PD FEB PY 2012 VL 11 IS 1 BP 58 EP 60 PG 3 WC Psychiatry SC Psychiatry GA 894XI UT WOS:000300460400018 PM 22295012 ER PT J AU Huddle, TS AF Huddle, Thomas S. TI Regarding Physician Advocacy Reply SO ACADEMIC MEDICINE LA English DT Letter C1 [Huddle, Thomas S.] Univ Alabama Birmingham Sch Med, Div Gen Internal Med, Dept Med, Birmingham, AL 35294 USA. [Huddle, Thomas S.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Huddle, TS (reprint author), Univ Alabama Birmingham Sch Med, Div Gen Internal Med, Dept Med, Birmingham, AL 35294 USA. EM thuddle@uab.edu NR 0 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD FEB PY 2012 VL 87 IS 2 BP 132 EP 132 DI 10.1097/ACM.0b013e318241ade6 PG 1 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 894BN UT WOS:000300402100003 ER PT J AU Neal-Boylan, L Hopkins, A Skeete, R Hartmann, SB Iezzoni, LI Nunez-Smith, M AF Neal-Boylan, Leslie Hopkins, Amy Skeete, Rachel Hartmann, Sarah B. Iezzoni, Lisa I. Nunez-Smith, Marcella TI The Career Trajectories of Health Care Professionals Practicing With Permanent Disabilities SO ACADEMIC MEDICINE LA English DT Article ID QUALITATIVE RESEARCH; PHYSICIANS; EXPERIENCES; KNOWLEDGE; BLINDNESS; TURNOVER; RNS AB Purpose The authors sought to generate insights and hypotheses about the professional experiences of registered nurses and physicians with self-identified disabilities to inform local and national policy conversations on supporting a diverse health care workforce. Method In 2009-2010, the authors conducted in-depth interviews in person and over the telephone with a sample of licensed registered nurses and physicians across the country who self-identified as having a permanent disability. They coded the interview transcripts to identify key themes across the participants' responses. Results The authors interviewed 10 registered nurses and 10 physicians. Five novel and consistent themes emerged from the data analysis: (1) Living and working with a physical/sensory disability narrows the career choices and trajectories of nurses and physicians, (2) nurses and physicians struggle with decisions regarding whether to disclose and discuss their disabilities at work, (3) nurses and physicians rarely seek legally guaranteed workplace accommodations, instead viewing patient safety as a personal responsibility, (4) interpersonal interactions often reflect the institutional climate and set the tone for how welcome nurses and physicians feel at work, and (5) reactions to workplace disability-related challenges run an emotional spectrum from anger and grief to resilience and optimism. Conclusions The responses revealed several missed opportunities for supporting health care professionals with disabilities in the workplace. These findings should inform the continuing debate regarding what defines "reasonable accommodation" and how to create a workplace that is welcoming for nurses and physicians with disabilities. C1 [Skeete, Rachel; Nunez-Smith, Marcella] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06520 USA. [Nunez-Smith, Marcella] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA. [Neal-Boylan, Leslie] So Connecticut State Univ, Dept Nursing, New Haven, CT 06515 USA. [Hartmann, Sarah B.] Yale Univ, Sch Nursing, New Haven, CT 06536 USA. [Iezzoni, Lisa I.] Harvard Univ, Sch Med, Dept Internal Med, Boston, MA USA. [Iezzoni, Lisa I.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. RP Nunez-Smith, M (reprint author), Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, POB 208088,IE-61 SHM, New Haven, CT 06520 USA. EM marcella.nunez-smith@yale.edu FU Sigma Theta Tau Delta Mu Chapter; Association of American Medical Colleges FX This study was supported by grants from Sigma Theta Tau Delta Mu Chapter (PI: L.N.B.) and from the Association of American Medical Colleges Nickens Faculty Fellowship (PI: M.N.S.). NR 36 TC 6 Z9 6 U1 2 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD FEB PY 2012 VL 87 IS 2 BP 172 EP 178 DI 10.1097/ACM.0b013e31823e1e1c PG 7 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 894BN UT WOS:000300402100013 PM 22189880 ER PT J AU Santagata, S Xu, YM Wijeratne, EMK Kontnik, R Rooney, C Perley, CC Kwon, H Clardy, J Kesari, S Whitesell, L Lindquist, S Gunatilaka, AAL AF Santagata, Sandro Xu, Ya-ming Wijeratne, E. M. Kithsiri Kontnik, Renee Rooney, Christine Perley, Casey C. Kwon, Hyoungtae Clardy, Jon Kesari, Santosh Whitesell, Luke Lindquist, Susan Gunatilaka, A. A. Leslie TI Using the Heat-Shock Response To Discover Anticancer Compounds that Target Protein Homeostasis SO ACS CHEMICAL BIOLOGY LA English DT Article ID GROWN WITHANIA-SOMNIFERA; STRESS-RESPONSE; WITHAFERIN-A; REACTIVE ELECTROPHILES; NATURAL-PRODUCTS; GENE-EXPRESSION; HSP90 INHIBITOR; SONORAN-DESERT; CANCER-CELLS; PLANT AB Unlike normal tissues, cancers experience profound alterations in protein homeostasis. Powerful innate adaptive mechanisms, especially the transcriptional response regulated by Heat Shock Factor 1 (HSF1), are activated in cancers to enable survival under these stressful conditions. Natural products that further tax these stress responses can overwhelm the ability to cope and could provide leads for the development of new, broadly effective anticancer drugs. To identify compounds that drive the HSF1-dependent stress response, we evaluated over 80,000 natural and synthetic compounds as well as partially purified natural product extracts using a reporter cell line optimized for high-throughput screening. Surprisingly, many of the strongly active compounds identified were natural products representing five diverse chemical classes (limonoids, curvularins, withanolides, celastraloids, and colletofragarones). All of these compounds share the same chemical motif, an alpha,beta-unsaturated carbonyl functionality, with strong potential for thiol-reactivity. Despite the lack of a priori mechanistic requirements in our primary phenotypic screen, this motif was found to be necessary albeit not sufficient, for both heat-shock activation and inhibition of glioma tumor cell growth. Within the withanolide class, a promising therapeutic index for the compound withaferin A was demonstrated in vivo using a stringent orthotopic human glioma xenograft model in mice. Our findings reveal that diverse organisms elaborate structurally complex thiol-reactive metabolites that at on the stress responses of heterologous organisms including humans. From a chemical biology perspective, they define a robust approach for discovering candidate compounds that target the malignant phenotype by disrupting protein homeostasis. C1 [Santagata, Sandro; Whitesell, Luke; Lindquist, Susan] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA. [Santagata, Sandro] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Kontnik, Renee; Clardy, Jon] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Xu, Ya-ming; Wijeratne, E. M. Kithsiri; Gunatilaka, A. A. Leslie] Univ Arizona, SW Ctr Nat Prod Res & Commercializat, Sch Nat Resources & Environm, Coll Agr & Life Sci, Tucson, AZ 85706 USA. [Rooney, Christine] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Perley, Casey C.; Kwon, Hyoungtae; Lindquist, Susan] MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02142 USA. [Kesari, Santosh] Univ Calif San Diego, Moores UCSD Canc Ctr, La Jolla, CA 92093 USA. RP Lindquist, S (reprint author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA. EM lindquist.admin@wi.mit.edu; leslieg@cals.arizona.edu RI Kesari, Santosh/E-8461-2013 FU National Cancer Institute [R01 CA90265]; Arizona Biomedical Research Commission [0804]; American Recovery and Reinvestment Act [3P30CA023100-25S8]; NIH [KO8CAI 24804, K08NS064168]; Sontag Foundation; Kenney, Quinn, Ford Brain Tumor Research Foundation; American Brain Tumor Association; Beez Foundation; Marble Fund; Stewart Foundation; V Foundation for Cancer Research FX We thank N. Tolliday, C. McLellan, and the Broad Institute Chemical Biology Platform members for input and assistance with high-throughput screening, G. Tamayo and InBio (Instituto Nacional de Biodiversidad, Costa Rica) members for providing natural product extracts, and members of the Lindquist laboratory for helpful comments on the project. We also thank the National Cancer Institute (Grant R01 CA90265) and Arizona Biomedical Research Commission for Funding (Grant 0804) to A.A.L.G. S.K. was supported in part by grants from American Recovery and Reinvestment Act (3P30CA023100-25S8), NIH (KO8CAI 24804), Sontag Foundation Distinguished Scientist Award, and Kenney, Quinn, Ford Brain Tumor Research Foundation award. S.S. was supported by a Translational Grant in honor of Juliana S. Schafer from the American Brain Tumor Association and by the Beez Foundation, NIH grant K08NS064168, the Marble Fund, the Stewart Foundation, and the V Foundation for Cancer Research. S.L. is a senior investigator of the Howard Hughes Medical Institute. NR 45 TC 49 Z9 49 U1 1 U2 22 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1554-8929 J9 ACS CHEM BIOL JI ACS Chem. Biol. PD FEB PY 2012 VL 7 IS 2 BP 339 EP 348 DI 10.1021/cb200353m PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 893EY UT WOS:000300339600013 PM 22050377 ER PT J AU Neelamegam, R Ricq, EL Malvaez, M Patnaik, D Norton, S Carlin, SM Hill, IT Wood, MA Haggarty, SJ Hooker, JM AF Neelamegam, Ramesh Ricq, Emily L. Malvaez, Melissa Patnaik, Debasis Norton, Stephanie Carlin, Stephen M. Hill, Ian T. Wood, Marcelo A. Haggarty, Stephen J. Hooker, Jacob M. TI Brain-Penetrant LSD1 Inhibitors Can Block Memory Consolidation SO ACS CHEMICAL NEUROSCIENCE LA English DT Article DE LSD1; mechanism-based inhibitors; histone demethylase; epigenetics; brain ID HISTONE DEMETHYLASE LSD1; LYSINE-SPECIFIC DEMETHYLASE-1; LONG-TERM-MEMORY; MECHANISM-BASED INACTIVATOR; STRUCTURAL BASIS; CHROMATIN MODIFICATIONS; SILENCED GENES; TRANS-2-PHENYLCYCLOPROPYLAMINE; RECOGNITION; ANALOGS AB Modulation of histone modifications in the brain may represent a new mechanism for brain disorder therapy. Post-translational modifications of histones regulate gene expression, affecting major cellular processes such as proliferation, differentiation, and function. An important enzyme involved in one of these histone modifications is lysine specific demethylase 1 (LSD1). This enzyme is flavin-dependent and exhibits homology to amine oxidases. Parnate 8 (2-phenylcyclopropylamine (2-PCPA); tranylcypromine) is a potent inhibitor of monoamine oxidases, and derivatives of 2-PCPA have been used for development of selective LSD1 inhibitors based on the ability to form covalent adducts with flavin adenine dinucleotide (FAD). Here we report the synthesis and in vitro characterization of LSD1 inhibitors that bond covalently to FAD. The two most potent and selective inhibitors were used to demonstrate brain penetration when administered systemically to rodents. First, radiosynthesis of a positron-emitting analogue was used to obtain preliminary biodistribution data and whole brain time-activity curves. Second, we demonstrate that this series of LSD1 inhibitors is capable of producing a cognitive effect in a mouse model. By using a memory formation paradigm, novel object recognition, we show that LSD1 inhibition can abolish long-term memory formation without affecting short-term memory, providing further evidence for the importance of reversible histone methylation in the function of the nervous system. C1 [Neelamegam, Ramesh; Ricq, Emily L.; Carlin, Stephen M.; Hill, Ian T.; Hooker, Jacob M.] Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Massachusetts Gen Hosp,Dept Radiol, Charlestown, MA 02129 USA. [Ricq, Emily L.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA. [Ricq, Emily L.; Patnaik, Debasis; Norton, Stephanie; Haggarty, Stephen J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Human Genet Res,Dept Neurol, Boston, MA 02114 USA. [Haggarty, Stephen J.] Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA. [Malvaez, Melissa; Wood, Marcelo A.] Univ Calif Irvine, Dept Neurobiol & Behav, Ctr Neurobiol Learning & Memory, Irvine, CA 92697 USA. [Hooker, Jacob M.] Brookhaven Natl Lab, Upton, NY 11973 USA. RP Hooker, JM (reprint author), Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Massachusetts Gen Hosp,Dept Radiol, Bldg 149,13th St,Suite 2301, Charlestown, MA 02129 USA. EM haggarty@chgr.mgh.harvard.edu; hooker@nmr.mgh.harvard.edu RI Wood, Marcelo/G-9527-2012; Patnaik, Debasis/A-9752-2016; OI Patnaik, Debasis/0000-0002-9829-3352; Hooker, Jacob/0000-0002-9394-7708; Haggarty, Stephen J./0000-0002-7872-168X FU National Institutes of Health [R01DA028301, 1P30DA028800]; National Institute on Drug Abuse [R01DA028301, 1P30DA028800]; Stanley Medical Research Institute FX This research was supported by the National Institutes of Health Grants R01DA028301 and 1P30DA028800. The project described was supported in part by Award Number R01DA028301 (S.J.H.) and 1P30DA028800 (J.M.H.) from the National Institute on Drug Abuse. S.J.H. is also supported by the Stanley Medical Research Institute. NR 56 TC 51 Z9 52 U1 0 U2 15 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1948-7193 J9 ACS CHEM NEUROSCI JI ACS Chem. Neurosci. PD FEB PY 2012 VL 3 IS 2 BP 120 EP 128 DI 10.1021/cn200104y PG 9 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology GA 894YV UT WOS:000300464300006 PM 22754608 ER PT J AU Safren, SA Hendriksen, ES Smeaton, L Celentano, DD Hosseinipour, MC Barnett, R Guanira, J Flanigan, T Kumarasamy, N Klingman, K Campbell, T AF Safren, Steven A. Hendriksen, Ellen S. Smeaton, Laura Celentano, David D. Hosseinipour, Mina C. Barnett, Ronald Guanira, Juan Flanigan, Timothy Kumarasamy, N. Klingman, Karin Campbell, Thomas TI Quality of Life Among Individuals with HIV Starting Antiretroviral Therapy in Diverse Resource-Limited Areas of the World SO AIDS AND BEHAVIOR LA English DT Article DE Quality of life (QOL); Highly active antiretroviral therapy (HAART); HIV ID HUMAN-IMMUNODEFICIENCY-VIRUS; SURVEY MOS-HIV; HEALTH SURVEY; MEDICAL OUTCOMES; INFECTED PATIENTS; HIV/AIDS; RELIABILITY; VALIDITY; HAART; CARE AB As Antiretroviral Therapy (ART) is scaled up in low- and middle-income countries, it is important to understand Quality of Life (QOL) correlates including disease severity and person characteristics and to determine the extent of between-country differences among those with HIV. QOL and medical data were collected from 1,563 of the 1,571 participants at entry into a randomized clinical trial of ART conducted in the U.S. (n = 203) and 8 resource-limited countries (n = 1,360) in the Caribbean, South America, Asia, and Africa. Participants were interviewed prior to initiation of ART using a modified version of the ACTG SF-21, a health-related QOL measure including 8 subscales: general health perception, physical functioning, role functioning, social functioning, cognitive functioning, pain, mental health, and energy/fatigue. Other measures included demographics, CD4+ lymphocyte count, plasma HIV-1 RNA viral load. Higher quality of life in each of the 8 QOL subscales was associated with higher CD4+ lymphocyte category. General health perception, physical functioning, role functioning, and energy/fatigue varied by plasma HIV-1 RNA viral load categories. Each QOL subscale included significant variation by country. Only the social functioning subscale varied by sex, with men having greater impairments than women, and only the physical functioning subscale varied by age category. This was the first large-scale international ART trial to conduct a standardized assessment of QOL in diverse international settings, thus demonstrating that implementation of the behavioral assessment was feasible. QOL indicators at study entry varied with disease severity, demographics, and country. The relationship of these measures to treatment outcomes can and should be examined in clinical trials of ART in resource-limited settings using similar methodologies. C1 [Safren, Steven A.; Hendriksen, Ellen S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02445 USA. [Smeaton, Laura] Harvard Univ, Sch Publ Hlth, Boston, MA 02445 USA. [Celentano, David D.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Hosseinipour, Mina C.] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Barnett, Ronald; Klingman, Karin] NIH, Bethesda, MD 20892 USA. [Guanira, Juan] Invest Med Salud INMENSA, Lima, Peru. [Flanigan, Timothy] Brown Univ, Rhode Isl Hosp, Sch Med, Providence, RI 02903 USA. [Flanigan, Timothy] Brown Univ, Sch Med, Miriam Hosp, Providence, RI 02912 USA. [Kumarasamy, N.] YRG CARE, Chennai, Tamil Nadu, India. [Campbell, Thomas] Univ Colorado, Sch Med, Denver, CO USA. RP Safren, SA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 1 Bowdoin Sq,7th Floor, Boston, MA 02445 USA. EM ssafren@partners.org OI Guanira, Juan/0000-0002-2746-3086 FU NCRR NIH HHS [UL1RR024156, RR00424, RR024996, RR025780, UL1 RR024156, UL1 RR024996, UL1 RR025780, M01 RR000865, UL 1RR 025747]; NIAID NIH HHS [1U01AI069426-01, 1U01AI069518-01, 3U01AI046376-05S4, 5 U01 AI069399-04, AI-069439, AI-69419, AI032782, AI050410, AI069423-03, AI069463, AI069470, AI069472, AI069474, AI25915, AI27661, AI38858-09S1, AI46370, AI69450, P30 AI045008, P30-AI045008-11, U01 AI025915, U01 AI027661, U01 AI027665, U01 AI032782, U01 AI038858, U01 AI046370, U01 AI046376, U01 AI069399, U01 AI069401, U01 AI069421, U01 AI069421-05, U01 AI069423, U01 AI069436, U01 AI069438, U01 AI069450, U01 AI069463, U01 AI069467, U01 AI069470, U01 AI069472, U01 AI069474, U01 AI069476, U01 AI069511, U01 AI069513, U01AI069476, UM1 AI068634, UM1 AI068636, UM1 AI069419, UM1 AI069424, UM1 AI069428, UM1 AI069439, UM1 AI069471, UM1 AI069532, 1U01AI069436-01, 1U01AI069513-01, 5 U01 AI069518-04, 5U01 AI069 484-02, 5U01AI069401, 5U01AI069417-04, 5U01AI069438, AI-27665, AI069424, AI069428, AI069471, AI069532, AI34853, AI68634, AI68636, P30 AI050410, U01 AI034853, U01 AI068634, U01 AI068636, U01 AI068636-03, U01 AI069417, U01 AI069419, U01 AI069424, U01 AI069426, U01 AI069428, U01 AI069439, U01 AI069471, U01 AI069495, U01 AI069518, U01 AI069532, U01AI068636, U01AI069495, U01AI069511-02, U01AI68634, UM1 AI069423, UM1 AI069450, UM1 AI069463, UM1 AI069470, UM1 AI069472, UM1 AI069474]; PHS HHS [MOIRR00865, U01A1069432] NR 29 TC 12 Z9 14 U1 2 U2 11 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD FEB PY 2012 VL 16 IS 2 BP 266 EP 277 DI 10.1007/s10461-011-9947-5 PG 12 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 892HW UT WOS:000300278300003 PM 21499794 ER PT J AU Haberer, JE Robbins, GK Ybarra, M Monk, A Ragland, K Weiser, SD Johnson, MO Bangsberg, DR AF Haberer, Jessica E. Robbins, Gregory K. Ybarra, Michele Monk, Alexandra Ragland, Kathleen Weiser, Sheri D. Johnson, Mallory O. Bangsberg, David R. TI Real-Time Electronic Adherence Monitoring is Feasible, Comparable to Unannounced Pill Counts, and Acceptable SO AIDS AND BEHAVIOR LA English DT Article DE Real-time adherence monitoring; HIV antiretroviral therapy ID ACTIVE ANTIRETROVIRAL THERAPY; MEDICATION ADHERENCE; INTERVENTIONS; POPULATION; INFECTION; OUTCOMES AB Second generation electronic medication adherence monitors provide real-time data on pill bottle opening behavior. Feasibility, validity, and acceptability, however, have not been established. Med-eMonitor is a multi-compartment adherence device with reminder and education capacity that transmits data through a telephone connection. Monthly adherence levels were measured for 52 participants over approximately 3 months using the Med-eMonitor (unadjusted and adjusted for participant confirmed dosing) and unannounced pill counts. HIV RNA was assessed before and after the 3-month period. Acceptability of Med-eMonitor was determined. Over 92% of Med-eMonitor data was transmitted daily. Unannounced pill counts significantly correlated with adjusted Med-eMonitor adherence (r = 0.29, P = 0.04). HIV RNA significantly correlated with unannounced pill counts (r = -0.34, P = 0.02), and trended toward a significant correlation with unadjusted Med-eMonitor adherence (r = -0.26; P = 0.07). Most, but not all, participants liked using the Med-eMonitor. Med-eMonitor allows for real-time adherence monitoring and potentially intervention, which may be critical for prolonging treatment success. C1 [Haberer, Jessica E.; Bangsberg, David R.] Harvard Inst Global Hlth, Cambridge, MA 02138 USA. [Haberer, Jessica E.; Robbins, Gregory K.; Ragland, Kathleen; Bangsberg, David R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Haberer, Jessica E.; Bangsberg, David R.] Massachusetts Gen Hosp, Ragon Inst, Massachusetts Inst Technol & Harvard, Charlestown, MA USA. [Ybarra, Michele] Internet Solut Kids, Santa Ana, CA USA. [Monk, Alexandra; Weiser, Sheri D.; Johnson, Mallory O.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Haberer, JE (reprint author), Harvard Inst Global Hlth, 104 Mt Auburn St,3rd Floor, Cambridge, MA 02138 USA. EM jhaberer@partners.org FU NCRR NIH HHS [UL1 RR024131, UL1RR024131]; NIAID NIH HHS [K01 AI062435, K01AI062435, P30 AI060354]; NIMH NIH HHS [K24MH87227, K23 MH087228, K23 MH087228-02, K23MH087228, K24 MH087220, K24 MH087227, MH077502, R01 MH054907, R01MH54907, R41 MH077502] NR 22 TC 29 Z9 29 U1 0 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD FEB PY 2012 VL 16 IS 2 BP 375 EP 382 DI 10.1007/s10461-011-9933-y PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 892HW UT WOS:000300278300015 PM 21448728 ER PT J AU Ponikowski, P Metra, M Teerlink, JR Unemori, E Felker, GM Voors, AA Filippatos, G Greenberg, B Teichman, SL Severin, T Mueller-Velten, G Cotter, G Davison, BA AF Ponikowski, Piotr Metra, Marco Teerlink, John R. Unemori, Elaine Felker, G. Michael Voors, Adriaan A. Filippatos, Gerasimos Greenberg, Barry Teichman, Sam L. Severin, Thomas Mueller-Velten, Guenther Cotter, Gad Davison, Beth A. TI Design of the RELAXin in Acute Heart Failure Study SO AMERICAN HEART JOURNAL LA English DT Article ID RANDOMIZED CONTROLLED-TRIALS; IN-HOSPITAL MORTALITY; CLINICAL-TRIALS; TASK-FORCE; PHASE-III; NESIRITIDE; ASSOCIATION; ANTAGONIST; OUTCOMES; DYSPNEA AB Background Acute heart failure (AHF) remains a major public health burden with a high prevalence and poor prognosis. Relaxin is a naturally occurring peptide hormone that increases cardiac output, arterial compliance, and renal blood flow during pregnancy. The RELAX-AHF-1 study will evaluate the effect of RLX030 (recombinant form of human relaxin 2) on symptom relief and clinical outcomes in patients with AHF. Methods The protocol includes a completed phase 2 234-patient dose-finding study (Pre-RELAX-AHF) and an ongoing phase 3 1,160-patient trial (RELAX-AHF-1). Patients with AHF and systolic blood pressure >125 mm Hg are randomized within 16 hours of presentation to a 48-hour IV infusion of RLX030 or placebo. The 30 mu g/kg per day dose of RLX030 was chosen for RELAX-AHF-1 based on effects on dyspnea, clinical outcomes, and safety observed in Pre-RELAX-AHF. Primary efficacy end points in RELAX-AHF-1 are (1) the area under the curve of change of the dyspnea Visual Analog Scale from baseline through day 5 and (2) whether the patient reports moderately to markedly better dyspnea at 6, 12, and 24 hours. Secondary efficacy end points include days alive and out of the hospital through day 60 and cardiovascular death or rehospitalization for heart failure or renal failure through day 60. Patients will be followed up through day 180 for mortality. As of September 19, 2011, 978 patients have been enrolled. Conclusions Pre-RELAX-AHF results suggested that infusion of RLX030 may accelerate dyspnea relief and improve prognosis in patients hospitalized with AHF. RELAX-AHF-1 will further evaluate these effects. (Am Heart J 2012;163:149-155.e1.) C1 [Cotter, Gad; Davison, Beth A.] Momentum Res Inc, Durham, NC 27707 USA. [Ponikowski, Piotr] Med Univ, Mil Hosp, Dept Heart Dis, Wroclaw, Poland. [Metra, Marco] Univ Brescia, Dept Expt & Appl Med, Brescia, Italy. [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Sect Cardiol, San Francisco, CA 94143 USA. [Unemori, Elaine; Teichman, Sam L.] Corthera Inc, San Mateo, CA USA. [Felker, G. Michael] Duke Univ, Duke Clin Res Inst, Durham, NC USA. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9713 AV Groningen, Netherlands. [Filippatos, Gerasimos] Athens Univ Hosp Attikon, Heart Failure Unit, Athens, Greece. [Greenberg, Barry] Univ Calif San Diego, Adv Heart Failure Program, San Diego, CA 92103 USA. [Severin, Thomas; Mueller-Velten, Guenther] Novartis Pharma AG, Basel, Switzerland. RP Davison, BA (reprint author), Momentum Res Inc, 3100 Tower Blvd,Suite 802, Durham, NC 27707 USA. EM bethdavison@momentum-research.com RI Teerlink, John/D-2986-2012; Lainscak, Mitja/F-3237-2015; Ponikowski, Piotr/O-6454-2015; OI Ponikowski, Piotr/0000-0002-3391-7064; Metra, Marco/0000-0001-6691-8568; Davison, Beth/0000-0003-2374-6449 NR 40 TC 26 Z9 26 U1 0 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD FEB PY 2012 VL 163 IS 2 BP 149 EP U234 DI 10.1016/j.ahj.2011.10.009 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 891ON UT WOS:000300226600004 PM 22305830 ER PT J AU Steingart, RM Bakris, GL Chen, HX Chen, MH Force, T Ivy, SP Leier, CV Liu, G Lenihan, D Lindenfeld, J Maitland, ML Remick, SC Tang, WHW AF Steingart, Richard M. Bakris, George L. Chen, Helen X. Chen, Ming-Hui Force, Thomas Ivy, S. Percy Leier, Carl V. Liu, Glenn Lenihan, Daniel Lindenfeld, JoAnn Maitland, Michael L. Remick, Scot C. Tang, W. H. Wilson TI Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors SO AMERICAN HEART JOURNAL LA English DT Article ID RENAL-CELL CARCINOMA; TYROSINE KINASE INHIBITOR; METASTATIC BREAST-CANCER; PHASE-III TRIAL; SUNITINIB MALATE; CARDIOTOXICITY; BEVACIZUMAB; MECHANISMS; PAZOPANIB; THERAPEUTICS AB Background Interfering with angiogenesis is an effective, widely used approach to cancer therapy, but antiangiogenic therapies have been associated with important systemic cardiovascular toxicities such as hypertension, left ventricular dysfunction, heart failure, and myocardial ischemia and infarction. As the use of vascular endothelial growth factor signaling pathway (VSP) inhibitors broadens to include older patients and those with existing cardiovascular disease, the adverse effects are likely to be more frequent, and cardiologists will increasingly be enlisted to help oncologists manage patients who develop adverse cardiovascular effects. Methods The Cardiovascular Toxicities Panel of the National Cancer Institute reviewed the published literature and abstracts from major meetings, shared experience gained during clinical development of VSP inhibitors, and contributed extensive clinical experience in evaluating and treating patients with cancer with cardiovascular disease. This report was edited and approved by the National Cancer Institute Investigational Drug Steering Committee. It presents the panel's expert opinion on the current clinical use and future investigation for safer, more expansive use of these drugs. Results and Conclusions The panel recommends that physicians (1) conduct and document a formal risk assessment for existing cardiovascular disease and potential cardiovascular complications before VSP inhibitor treatment recognizing that preexisting hypertension and cardiovascular disease are common in patients with cancer, (2) actively monitor for blood pressure elevations and cardiac toxicity with more frequent assessments during the first treatment cycle, and (3) aggressively manage blood pressure elevations and early symptoms and signs of cardiac toxicity to prevent clinically limiting complications of VSP inhibitor therapy. (Am Heart J 2012;163:156-63.) C1 [Steingart, Richard M.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA. [Bakris, George L.; Maitland, Michael L.] Univ Chicago, Chicago, IL 60637 USA. [Chen, Helen X.; Ivy, S. Percy] NCI, Bethesda, MD 20892 USA. [Chen, Ming-Hui] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Chen, Ming-Hui] Childrens Hosp, Boston, MA 02115 USA. [Force, Thomas] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Leier, Carl V.] Ohio State Univ, Columbus, OH 43210 USA. [Liu, Glenn] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. [Lenihan, Daniel] Vanderbilt Univ, Nashville, TN USA. [Lindenfeld, JoAnn] Univ Colorado, Denver, CO 80202 USA. [Remick, Scot C.] W Virginia Univ, Sch Med, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA. [Tang, W. H. Wilson] NCI, Cleveland Clin, Invest Drug Steering Comm, Cleveland, OH USA. RP Steingart, RM (reprint author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA. EM steingar@mskcc.org RI Tang, Wai Hong/I-1238-2013; OI Force, Thomas/0000-0002-0450-8659 NR 28 TC 44 Z9 45 U1 2 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD FEB PY 2012 VL 163 IS 2 BP 156 EP 163 DI 10.1016/j.ahj.2011.10.018 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 891ON UT WOS:000300226600005 PM 22305831 ER PT J AU White, HD Chew, DP Dauerman, HL Mahaffey, KW Gibson, CM Stone, GW Gruberg, L Harrington, RA Bhatt, DL AF White, Harvey D. Chew, Derek P. Dauerman, Harold L. Mahaffey, Kenneth W. Gibson, C. Michael Stone, Gregg W. Gruberg, Luis Harrington, Robert A. Bhatt, Deepak L. TI Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction SO AMERICAN HEART JOURNAL LA English DT Article ID PERCUTANEOUS CORONARY INTERVENTION; CLOPIDOGREL; INSIGHTS; PRASUGREL; OUTCOMES AB Background There is a clinical need for an intravenous P2Y(12) inhibitor in patients with acute coronary syndromes (ACS) for patients who are unable to take oral medications or might benefit from a rapidly reversible compound. As the time from admission to percutaneous coronary intervention (PCI) shortens, establishing the benefit of novel therapies impacting ischemic events is increasingly challenging. Cangrelor, an intravenous potent rapidly acting P2Y(12) inhibitor, bolus 30 mu g/Kg plus infusion of 4 mu g/Kg/min, was compared to a 600-mg loading dose of clopidogrel either before or early after PCI in patients with ACS undergoing PCI in The CHAMPION (Cangrelor versus standard tHerapy to Achieve optimal Management of Platelet InhibitiON) PLATFORM and PCI studies. Methods As both CHAMPION studies used similar inclusion/exclusion criteria and death, myocardial infarction, or ischemia-driven revascularization (including stent thrombosis) at 48 hours as their primary end points, the studies were pooled. The clinical events committee adjudicated myocardial infarction. The universal definition was used to define myocardial infarction. Results A total of 13 049 patients were included. Cangrelor had no effect on the primary end point with the original MI definition (P = .646). With the use of the universal definition, the primary end point was decreased with cangrelor (odds ratio 0.82, 95% confidence interval 0.68-0.99, P = .037). Stent thrombosis was reduced from 0.4% to 0.2% (odds ratio 0.44, 95% confidence interval 0.22-0.87, P = .018). Thrombolysis in Myocardial Infarction major bleeding and transfusions were not increased with cangrelor. Conclusion With the use of the universal definition of myocardial infarction, cangrelor was associated with a significant reduction in early ischemic events when compared with clopidogrel in patients with non-ST-elevation ACS undergoing PCI. (Am Heart J 2012;163:182-190.e4.) C1 [White, Harvey D.] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand. [Chew, Derek P.] Flinders Univ S Australia, Dept Cardiovasc Med, Adelaide, SA, Australia. [Dauerman, Harold L.] Univ Vermont, Burlington, VT USA. [Mahaffey, Kenneth W.; Harrington, Robert A.] Duke Clin Res Inst, Durham, NC USA. [Gibson, C. Michael] Beth Israel Hosp, Boston, MA USA. [Stone, Gregg W.] Columbia Univ, Med Ctr, New York, NY USA. [Stone, Gregg W.] Cardiovasc Res Fdn, New York, NY USA. [Gruberg, Luis] SUNY Stony Brook, Med Ctr, New York, NY USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Bhatt, Deepak L.] VA Boston Healthcare Syst, Boston, MA USA. RP White, HD (reprint author), Auckland City Hosp, Green Lane Cardiovasc Serv, Private Bag 92024,Victoria St, W Auckland 11421, New Zealand. EM HarveyW@adhb.govt.nz FU Sanofi Aventis; Eli Lilly; Medicines Company; NIH; Pfizer; Roche; Johnson Johnson; Schering Plough; Merck Sharpe Dohme; Astra Zeneca; GlaxoSmithKline; Daiichi Sankyo Pharma Development; Bristol-Myers Squibb; Astra-Zeneca Australia; Sanofi-Aventis Australia; Abbott Vascular; Medtronic; MDS Scientific; Bayer; Daiichi Sankyo; Sanofi-Aventis; Schering-Plough; Boston Scientific; Nycomed; Guidant; Abbott; Lilly-Daiichi Sankyo; BMS; Novartis; Portola; Medicines Company, Parsippany, NJ FX Harvey White - Research grants: Sanofi Aventis; Eli Lilly; Medicines Company; NIH; Pfizer; Roche; Johnson & Johnson; Schering Plough; Merck Sharpe & Dohme; Astra Zeneca; GlaxoSmithKline; Daiichi Sankyo Pharma Development; Bristol-Myers Squibb; Consulting: Regado Biosciences.; Dr Chew - Research grants: Astra-Zeneca Australia, and Sanofi-Aventis Australia.; Dr Dauerman - Research grants: Abbott Vascular, Medtronic, MDS Scientific; Consulting: Abbott Vascular, Medtronic, The Medicines Company, MDS Scientific.; Dr Mahaffey - Consulting: AstraZeneca, Eli Lilly, Johnson & Johnson, and Schering-Plough; Lecture fees: Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Sanofi-Aventis, and Schering-Plough; Travel support: Bayer, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Schering-Plough, and Sanofi-Aventis.; Dr Gibson-Research grant: The Medicines Company; Consulting: The Medicines Company; Speaker: The Medicines Company.; Dr Stone - Lecture fees: The Medicines Company, Boston Scientific, Nycomed, Guidant, Medtronic, and Abbott; Consulting: The Medicines Company, Boston Scientific, Guidant, Abbott, Volcano, St. Jude, and BMS.; Dr Gruberg - Lecture fees: Lilly-Daiichi Sankyo, Abbott; Consulting: Abbott.; Dr Harrington - Research grants: The Medicines Company, BMS, Sanofi-Aventis, AstraZeneca, Eli Lilly, Novartis, Portola, Merck Sharpe & Dohme; Consulting: BMS, AstraZeneca, Novartis, Merck Sharpe & Dohme.; Dr Bhatt - Research grants: Astra Zeneca, Bristol-Myers Squibb, Eisai, Ethicon, Heartscape, Sanofi Aventis, The Medicines Company.; CHAMPION PLATFORM was funded by The Medicines Company, Parsippany, NJ.; CHAMPION PCI was funded by The Medicines Company, Parsippany, NJ.; Funding for MPION PCI and PLATFORM was provided by The Medicines Company, Parsippany, NJ. NR 18 TC 51 Z9 52 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD FEB PY 2012 VL 163 IS 2 BP 182 EP U275 DI 10.1016/j.ahj.2011.11.001 PG 13 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 891ON UT WOS:000300226600009 PM 22305835 ER PT J AU Dubin, R Li, YM Ix, JH Shlipak, MG Whooley, M Peralta, CA AF Dubin, Ruth Li, Yongmei Ix, Joachim H. Shlipak, Michael G. Whooley, Mary Peralta, Carmen A. TI Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: Data from the Heart and Soul Study SO AMERICAN HEART JOURNAL LA English DT Article ID CHRONIC KIDNEY-DISEASE; ACUTE MYOCARDIAL-INFARCTION; SERUM CYSTATIN-C; DEPRESSIVE SYMPTOMS; ELDERLY PERSONS; RENAL-FUNCTION; PTX3; HEALTH; RISK; ATHEROSCLEROSIS AB Background Pentraxin-3 (PTX3) is an inflammatory marker thought to be more specific to vascular inflammation than C-reactive protein (CRP). Whether PTX3 is independently associated with adverse events among persons with stable coronary heart disease (CHD), independently of CRP, and whether kidney dysfunction influences these associations are not known. Methods We evaluated the associations of baseline PTX3 levels with all-cause mortality, cardiovascular (CV) events (myocardial infarction, stroke, or CHD death), and incident heart failure (HF) during 37 months among ambulatory persons with stable CHD participating in the Heart and Soul Study. Cox proportional hazards models were adjusted for age, sex, race, hypertension, diabetes, smoking, and CRP. Results Among 986 persons with stable CHD, each 1 unit increase in log PTX3 at baseline was associated with an 80% increased risk of all-cause mortality (hazard ratio [HR] 1.8, 95% CI 1.5-2.1), a 50% increased risk of CV events (HR 1.5, 95% CI, 1.2-1.9), and an 80% greater risk of incident HF (HR 1.8, 95% CI, 1.3-2.5). Further adjustment for estimated glomerular filtration rate (eGFR) attenuated these associations to 1.6 (1.3-1.9) for mortality, 1.3 (1.0-1.6) for CV events and 1.5 (1.1-2.1) for incident HF. Stratification by eGFR >60 mL/min per 1.73m(2) or <60 mL/min per 1.73m(2) did not affect these associations (P interaction > .3 for all outcomes). Conclusions Among persons with stable CHD, higher PTX3 concentrations were associated with increased risk for all-cause mortality, CV events, and incident HF independently of systemic inflammation. Adjustment for eGFR modestly attenuated these associations, suggesting that future studies of PTX3 should adjust for kidney function. (Am Heart J 2012;163:274-9.) C1 [Dubin, Ruth] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Li, Yongmei; Shlipak, Michael G.; Whooley, Mary; Peralta, Carmen A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ix, Joachim H.] Univ Calif San Diego, La Jolla, CA 92093 USA. RP Dubin, R (reprint author), Univ Calif San Francisco, Div Nephrol, 521 Parnassus Ave,C443, San Francisco, CA 94143 USA. EM ruth.dubin@ucsf.edu FU NHLBI NIH HHS [R01 HL079235]; NIDDK NIH HHS [K23 DK082793, K23 DK082793-01, T32 DK007219] NR 27 TC 44 Z9 45 U1 2 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD FEB PY 2012 VL 163 IS 2 BP 274 EP 279 DI 10.1016/j.ahj.2011.11.007 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 891ON UT WOS:000300226600021 PM 22305847 ER PT J AU Burns, AC Petersen, NJ Garza, A Arya, M Patterson, JE Naik, AD Trautner, BW AF Burns, Allison C. Petersen, Nancy J. Garza, Armandina Arya, Monisha Patterson, Jan E. Naik, Aanand D. Trautner, Barbara W. TI Accuracy of a urinary catheter surveillance protocol SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Catheter-associated urinary tract infection; Infection control; Chart review; Infection; Infection control ID INFECTIOUS-DISEASES-SOCIETY; HOME-ASSOCIATED INFECTIONS; CARE-ASSOCIATED INFECTIONS; TRACT-INFECTION; GUIDELINES; MEDICARE; PREVENTION; DIAGNOSIS; AMERICA; ADULTS AB Background: Many hospitals are increasing surveillance for catheter-associated urinary tract infections, which requires documentation of urinary catheter device-days. However, device-days are usually obtained by chart review or nursing reports. The aim of this study was to demonstrate that chart review can provide accurate urinary catheter data compared with physical inspection of the urinary catheter at the bedside. Methods: We compared 2 methods for collecting urinary catheter data over a 6-month period on 10 wards at our VA hospital. For the chart reviews, we created a daily bed-occupancy roster from the electronic medical record. Catheter data were extracted from the daily progress notes for each patient using a standardized review process. Bedside reviews were conducted by visiting the ward and verifying the presence and type of urinary catheters. Agreement between the 2 methods was calculated. Results: We obtained urinary catheter data by both methods in 621 cases. The presence or type of urinary catheter differed between chart and bedside review in only 10 cases (1.6%). Chart review had a sensitivity of 100%, a specificity of 97.7%, raw agreement of 98.4%, and a kappa value of 0.96. Conclusions: Individual chart review in the electronic medical record provided very accurate data on urinary catheter use. Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Burns, Allison C.; Petersen, Nancy J.; Garza, Armandina; Arya, Monisha; Naik, Aanand D.; Trautner, Barbara W.] Michael E DeBakey VA Med Ctr, VA Hlth Serv Res & Dev Houston Ctr Excellence, Houston, TX USA. [Arya, Monisha; Trautner, Barbara W.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA. [Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Infect Dis, San Antonio, TX 78229 USA. [Patterson, Jan E.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Naik, Aanand D.; Trautner, Barbara W.] Baylor Coll Med, Dept Med, Sect Geriatr, Houston, TX 77030 USA. [Trautner, Barbara W.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. RP Trautner, BW (reprint author), MEDVAMC HSR & D CoE 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM barbara.trautner@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [IIR 09-104]; VA HSR&D Houston Center of Excellence [HFP90-020]; RRD [B4623]; National Institute of Aging [K23AG027144]; Doris Duke Charitable Foundation FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service IIR 09-104. Also partly supported by the VA HSR&D Houston Center of Excellence (HFP90-020). The views expressed are those of the authors and do not necessarily represent those of the Department of Veterans Affairs/Baylor College of Medicine. B.W.T. is a physician investigator at the Michael E. DeBakey VA Medical Center Health Services Research and Development Center of Excellence, Houston, Texas. She is also supported by a VA Career Development Award from RR&D (B4623). A.D.N. is supported by the National Institute of Aging (K23AG027144) and the Doris Duke Charitable Foundation. NR 20 TC 9 Z9 9 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD FEB PY 2012 VL 40 IS 1 BP 55 EP 58 DI 10.1016/j.ajic.2011.04.006 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 891CW UT WOS:000300195000012 PM 21813209 ER PT J AU Vinnard, C Lee, I Linkin, D AF Vinnard, Christopher Lee, Ingi Linkin, Darren TI Successful control of a norovirus outbreak among attendees of a hospital teaching conference SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Infection control; Health care; Gastroenteritis ID VIRUS AB We report an outbreak of norovirus gastroenteritis after a hospital teaching conference, and describe the specific measures instituted by the infection control team. No secondary cases of norovirus infection were identified among hospital staff or patients. In a case-control study, we identified multiple food source contamination as the source of the outbreak. Our report highlights the potential success of a multifaceted infection control strategy in preventing the transmission of norovirus in health care settings. Copyright (C) 2012 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved. C1 [Vinnard, Christopher; Lee, Ingi; Linkin, Darren] Univ Penn, Dept Med, Div Infect Dis, Sch Med, Philadelphia, PA 19104 USA. [Linkin, Darren] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Vinnard, C (reprint author), Univ Penn, Dept Med, Div Infect Dis, Sch Med, 502 Johnson Pavil,3610 Hamilton Walk, Philadelphia, PA 19104 USA. EM christopher.vinnard@uphs.upenn.edu OI Linkin, Darren R./0000-0002-2408-0987 FU National Institutes of Health [T32] FX C.V. received salary support through a National Institutes of Health Institutional Research Training Grant (T32). NR 8 TC 3 Z9 3 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD FEB PY 2012 VL 40 IS 1 BP 73 EP 74 DI 10.1016/j.ajic.2011.03.033 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 891CW UT WOS:000300195000017 PM 21816511 ER PT J AU Kinkel, RP Dontchev, M Kollman, C Skaramagas, TT O'Connor, PW Simon, JH AF Kinkel, R. Philip Dontchev, Mariya Kollman, Craig Skaramagas, Thomai T. O'Connor, Paul W. Simon, Jack H. CA Controlled High-Risk Avonex Multip TI Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes A 10-Year Follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance SO ARCHIVES OF NEUROLOGY LA English DT Article ID DEFINITE MULTIPLE-SCLEROSIS; 1ST DEMYELINATING EVENT; MS; CONVERSION; DISABILITY; THERAPY AB Objective: To determine whether immediate initiation of treatment at the time of a clinically isolated syndrome in patients at high risk for clinically definite multiple sclerosis alters disease course over 10 years. Design: Prospective follow-up study. Setting: Twenty-four Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS) sites in the United States and Canada. Participants: A total of 81 patients originally randomly assigned to receive intramuscular interferon beta-1a (the immediate-treatment group) and 74 patients originally randomly assigned to receive placebo (the delayed-treatment group). All patients were from CHAMPS. Intervention: For the immediate-treatment group, treatment was initiated within a month after the onset of a clinically isolated syndrome, and for the delayed-treatment group, treatment was initiated a median of 30 months (interquartile range, 24-35 months) after CHAMPS randomization. Main Outcome Measures: Rate of developing clinically definite multiple sclerosis, annualized relapse rate, disease course classification, disability measures, and magnetic resonance imaging measures. Results: The immediate-treatment group showed a lower 10-year rate of clinically definite multiple sclerosis (unadjusted hazard ratio, 0.64 [95% CI, 0.48-0.87]; P=.004) and a lower annualized relapse rate between years 5 and 10 (P=.03). There was no differential effect on disability, magnetic resonance imaging T2-weighted lesions, or the proportion of patients developing progressive disease at 10 years. Few patients reached the Expanded Disability Status Scale milestone scores of 4.0 or greater (9% of patients) or 6.0 or greater (6% of patients). Conclusions: Immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome in high-risk patients reduces relapse rates over 10 years but does not improve disability outcomes compared with a control group that also initiated therapy relatively early in the disease course. C1 [Kinkel, R. Philip] Harvard Univ, Beth Israel Deaconess Med Ctr, Multiple Sclerosis Ctr, Sch Med, Boston, MA 02215 USA. [Dontchev, Mariya; Kollman, Craig] Jaeb Ctr Hlth Res, Tampa, FL USA. [Skaramagas, Thomai T.] Cleveland Clin Fdn, Cleveland, OH USA. [O'Connor, Paul W.] St Michaels Hosp, Toronto, ON M5B 1W8, Canada. [Simon, Jack H.] Portland VA Med Ctr, Portland, OR USA. RP Kinkel, RP (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Multiple Sclerosis Ctr, Sch Med, 330 Brookline Ave,KS 211, Boston, MA 02215 USA. EM rkinkel@bidmc.harvard.edu FU National MS Society; MS Society of Canada; Direct-MS FX Dr Kinkel has received either personal compensation or financial support from his institution for activities in collaboration with pharmaceutical companies (including Acorda, Avanir, Biogen Idec, and Teva) that develop products for MS. He has also received grant support from the National MS Society as well as support as section editor of Reviews in Neurological Diseases. Dr O'Connor has received either personal compensation or financial support from his institution for activities in collaboration with pharmaceutical companies (including Actelion, Biogen Idec, Celgene, sanofi-aventis, EMD Serono, Abbott, Teva, Bayer, BioMS Technology Corp, Genentech, Lilly, Roche, and Novartis) that develop products for MS. He has received grant support from the MS Society of Canada and Direct-MS. Dr Simon has received either personal compensation or financial support from his institution for activities related to pharmaceutical companies (including Genzyme, Protein Design Labs, Pfizer, Genentech, Bristol-Myers Squibb, Artielle Immunotherapeutics, BioMS Technology Corp, and Biogen Idec) that develop products for MS. NR 16 TC 42 Z9 42 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD FEB PY 2012 VL 69 IS 2 BP 183 EP 190 DI 10.1001/archneurol.2011.1426 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 891NV UT WOS:000300224800005 PM 21987393 ER PT J AU Oster, JM Igbokwe, E Cosgrove, GR Cole, AJ AF Oster, Joel M. Igbokwe, Eme Cosgrove, G. Rees Cole, Andrew J. TI Identifying Subtle Cortical Gyral Abnormalities as a Predictor of Focal Cortical Dysplasia and a Cure for Epilepsy SO ARCHIVES OF NEUROLOGY LA English DT Article ID PRESURGICAL EVALUATION; EEG AB Objectives: To highlight a case series of 3 cases of focal cortical dysplasia that were unrecognized for many years though the patients were seen by various neurologists and received the appropriate neuroimaging studies, and to retrospectively characterize the clinical elements, neuroimaging, electroencephalography, and pathologic findings in these cases. Design: Retrospective descriptive study. Setting: Tertiary urban and suburban neurology and epilepsy outpatient and inpatient clinic settings and hospitals. Patients: We analyze retrospectively 3 patients in whom magnetic resonance images were previously deemed as normal, who, in fact, exhibited subtle gyral abnormalities and who underwent focal surgical resections of these regions after invasive electroencephalography monitoring or electrocorticography and were cured of their epilepsy. Main Outcome Measures: Clinical semiology and neuroimaging findings. Results: Focal cortical dysplasias may present with subtle gyral abnormalities. These gyral abnormalities may guide invasive electroencephalography or electrocorticography and may delineate seizure onsets with precision. Resection of these areas in 3 such patients resulted in excellent surgical outcomes. Conclusions: Subtle gyral abnormalities may be associated with intractable epilepsy and seizure onsets. Focal resection after appropriate evaluations in selected patients may be curative. The magnetic resonance imaging features of focal cortical dysplasia can be subtle and require a high index of suspicion based on ictal semiology and clinical presentation. C1 [Oster, Joel M.] Tufts Univ, Burlington, MA 01805 USA. [Igbokwe, Eme] Tufts Univ, Sch Med, Dept Neurol, Boston, MA 02111 USA. [Cole, Andrew J.] Harvard Univ, Sch Med, Boston, MA USA. [Cole, Andrew J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cosgrove, G. Rees] Brown Univ, Dept Neurosurg, Warren Alpert Sch Med, Providence, RI 02912 USA. [Oster, Joel M.] Lahey Clin Fdn, Burlington, MA 01805 USA. RP Oster, JM (reprint author), Tufts Univ, 41 Mall Rd, Burlington, MA 01805 USA. EM joel.m.oster@lahey.org NR 13 TC 3 Z9 3 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD FEB PY 2012 VL 69 IS 2 BP 257 EP 261 DI 10.1001/archneurol.2011.1002 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 891NV UT WOS:000300224800014 PM 21987396 ER PT J AU Hameed, F Hunter, DJ Rainville, J Li, L Suri, P AF Hameed, Farah Hunter, David J. Rainville, James Li, Ling Suri, Pradeep TI Prevalence of Anatomic Impediments to Interlaminar Lumbar Epidural Steroid Injection SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Injections, epidural; Low back pain; Pathological conditions, anatomical; Rehabilitation; Spine ID MEDICARE POPULATION; CORONARY-ARTERY; FLUOROSCOPY; DISEASE; GROWTH; DESIGN; COHORT; PAIN AB Hameed F, Hunter DJ, Rainville J, Li L, Suri P. Prevalence of anatomic impediments to interlaminar lumbar epidural steroid injection. Arch Phys. Med Rehabil 2012;93:339-43. Objective: To determine the prevalence of anatomic impediments to interlaminar lumbar epidural steroid injection (LEST) in a community-based population. Design: Cross-sectional observational study. Setting: Community-based. Participants: Older adults (N=333) sampled irrespective of back pain status. Interventions: Not applicable. Main Outcome Measures: Computed tomography evaluation of 5 potential anatomic impediments to interlaminar LEST at the L2-S1 spinal levels, including (1) ligamentum flavum (LF) calcification, (2) interspinous ligament (ISL) calcification, (3) spinous process (SP) contact, (4) the absence of epidural fat in the posterior epidural space, and (5) the presence of fat density superficial to the LF in the midsagittal plane. Independent variables included age, sex, body mass index (BMI), and current smoking. Results: LF and ISL calcifications were prevalent in 3% to 7% and 2% to 3% of spinal levels, respectively, without significant differences by spinal level. SP contact was most common at the L4-5 level (22%). Absence of posterior epidural fat was very common at L5-S1 (65%), but infrequent at other levels. The presence of midline fat density superficial to LF was most common at L5-S1 (55%). The prevalence of LF calcification, ISL calcification, and SP contact increased with age, but the prevalence of absence of posterior epidural fat and the presence of a midline fat density superficial to LF did not. Sex and smoking status were not associated with the prevalence of anatomic impediments, but higher BMI was associated with a lower prevalence of absence of posterior epidural fat. Conclusions: Anatomic impediments to interlaminar LEST were common in this community-based population, particularly at the L5-S1 spinal level. Because of the high overall prevalence of anatomic impediments, and differences in prevalence by spinal level, knowledge of the distribution and frequency of these impediments may aid in aspects of decision-making for the interventional spine physician. C1 [Suri, Pradeep] VA Boston Healthcare Syst, Div PM&R, Boston, MA 02130 USA. [Hameed, Farah; Rainville, James; Suri, Pradeep] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. [Hameed, Farah; Suri, Pradeep] Spaulding Rehabil Hosp, Boston, MA USA. [Hunter, David J.; Rainville, James; Li, Ling; Suri, Pradeep] New England Baptist Hosp, Boston, MA USA. [Hunter, David J.] Univ Sydney, No Clin Sch, Sydney, NSW 2006, Australia. RP Suri, P (reprint author), VA Boston Healthcare Syst, Div PM&R, 150 S Huntington Ave, Boston, MA 02130 USA. EM pradeep.suri@va.gov RI Hunter, David/A-4622-2010 OI Hunter, David/0000-0003-3197-752X FU Framingham Heart Study of the National Heart, Lung, and Blood Institute of the National Institutes of Health [N01-HC-25195]; Boston University School of Medicine; National Institutes of Health [K12 HD001097]; Australian Research Council FX Supported by the Framingham Heart Study of the National Heart, Lung, and Blood Institute of the National Institutes of Health (contract no. N01-HC-25195) and Boston University School of Medicine, which provided for the recruitment, enrollment, and examination of the Offspring and Third Generation Cohorts and the computed tomography scans; Boston University School of Medicine; an Australian Research Council Future Fellowship; and the Rehabilitation Medicine Scientist Training Program and the National Institutes of Health (grant no. K12 HD001097). NR 21 TC 3 Z9 3 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD FEB PY 2012 VL 93 IS 2 BP 339 EP 343 DI 10.1016/j.apmr.2011.08.024 PG 5 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 893ER UT WOS:000300338900024 PM 22289247 ER PT J AU Krause, JS Terza, JV Erten, M Focht, KL Dismuke, CE AF Krause, James S. Terza, Joseph V. Erten, Mujde Focht, Kendrea L. Dismuke, Clara E. TI Prediction of Postinjury Employment and Percentage of Time Worked After Spinal Cord Injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Employment; Occupations; Rehabilitation; Spinal cord injuries; Work ID EARNINGS AB Krause JS, Terza JV, Erten M, Focht KL, Dismuke CE. Prediction of postinjury employment and percentage of time worked after spinal cord injury. Arch Phys Med Rehabil 2012;93:373-5. Objective: To use a 2-part model to identify biographic, injury, educational, and vocational predictors of postinjury employment and the percentage of time employed after spinal cord injury (SCI) onset. Design: Survey. Setting: Data were collected at 3 hospitals in the Southeastern and Midwestern United States. Participants: Participants were adults with traumatic SCI of at least 1 year duration, all under 65 years at the time of SCI onset. A total of 1329 observations were used in the analysis. Interventions: Not applicable. Main Outcome Measures: Postinjury employment, defined by whether the individual had ever been employed after SCI and percentage of time employed after SCI onset. Results: Almost 52% of participants worked at some point in time postinjury. Among those who had worked postinjury, the mean portion of time spent working was 0.56. Several factors were significantly related to postinjury employment and portion of time worked postinjury. The probability of postinjury employment increased with successively less severe injury. However, only ambulatory participants were found to have a significantly greater portion of time postinjury among those who became employed. Having obtained either a 4-year or graduate degree after injury was associated with a greater likelihood of postinjury employment. Conversely, among those who worked postinjury, having obtained those degrees prior to injury was associated with a greater portion of time employed. Being white, a man, having completed a 4-year degree or a graduate degree, and having worked in the service industry prior to SCI onset were all associated with a greater portion of time working among those who had worked. Conclusions: The factors precipitating PE are not identical to those associated with a greater portion of time employed after SCI onset. C1 [Krause, James S.] Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, Charleston, SC 29425 USA. [Terza, Joseph V.] Univ N Carolina, Bryan Sch Business & Econ, Greensboro, NC 27412 USA. [Erten, Mujde] Univ Maryland, Sch Pharm, Pharmaceut Hlth Serv Res, Baltimore, MD 21201 USA. [Dismuke, Clara E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC 29403 USA. RP Krause, JS (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, 77 President St,Suite C101,MSC 700, Charleston, SC 29425 USA. EM krause@musc.edu FU Department of Education, National Institute on Disability and Rehabilitation Research [H133G060126, H133B090005] FX Supported by the Department of Education, National Institute on Disability and Rehabilitation Research (grant nos. H133G060126 and H133B090005). The content of this article does not necessarily represent the policy of the Department of Education, and you should not assume endorsement by the Federal Government. NR 10 TC 8 Z9 9 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD FEB PY 2012 VL 93 IS 2 BP 373 EP 375 DI 10.1016/j.apmr.2011.09.006 PG 3 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 893ER UT WOS:000300338900029 PM 22289252 ER PT J AU Mullen, TD Hannun, YA Obeid, LM AF Mullen, Thomas D. Hannun, Yusuf A. Obeid, Lina M. TI Ceramide synthases at the centre of sphingolipid metabolism and biology SO BIOCHEMICAL JOURNAL LA English DT Review DE ceramide; ceramide synthase (CerS); de novo sphingolipid synthesis; salvage pathway; sphingolipid; sphingosine ID SPHINGANINE N-ACYLTRANSFERASE; RADIATION-INDUCED APOPTOSIS; LONGEVITY ASSURANCE GENE-1; COLON-CANCER CELLS; ACTIVATED PROTEIN-KINASE; MYELOID-LEUKEMIA CELLS; DE-NOVO; SERINE PALMITOYLTRANSFERASE; (DIHYDRO)CERAMIDE SYNTHASE; ENZYMATIC-HYDROLYSIS AB Sphingolipid metabolism in metazoan cells consists of a complex interconnected web of numerous enzymes, metabolites and modes of regulation. At the centre of sphingolipid metabolism reside CerSs (ceramide synthases), a group of enzymes that catalyse the formation of ceramides from sphingoid base and acyl-CoA substrates. From a metabolic perspective, these enzymes occupy a unique niche in that they simultaneously regulate de novo sphingolipid synthesis and the recycling of free sphingosine produced from the degradation of pre-formed sphingolipids (salvage pathway). Six mammalian CerSs (CerS1-CerS6) have been identified. Unique characteristics have been described for each of these enzymes, but perhaps the most notable is the ability of individual CerS isoforms to produce ceramides with characteristic acyl-chain distributions. Through this control of acyl-chain length and perhaps in a compartment-specific manner, CerSs appear to regulate multiple aspects of sphingolipid-mediated cell and organismal biology. In the present review, we discuss the function of CerSs as critical regulators of sphingolipid metabolism, highlight their unique characteristics and explore the emerging roles of CerSs in regulating programmed cell death, cancer and many other aspects of biology. C1 [Hannun, Yusuf A.; Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Mullen, Thomas D.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Obeid, Lina M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Hannun, YA (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. EM hannun@musc.edu; obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847 FU National Institutes of Health (NIH)/National Institute of Environmental Health Sciences (NIEHS) [5T32ES012878]; Ruth L. Kirschstein National Research Service (NIH/NIEHS) [1 F30 ES016975-01]; NIH [R01AG016583, R01GM062887]; Office of Research and Development; Department of Veterans Affairs; Ralph H. Johnson Veterans Affairs Medical Center; NIH/National Cancer Institute (NCI) [P01 CA097132] FX This work is supported by the MUSC Department of Pharmaceutical Sciences Training Program in Environmental Stress Signaling [National Institutes of Health (NIH)/National Institute of Environmental Health Sciences (NIEHS)] [grant number 5T32ES012878] and a Ruth L. Kirschstein National Research Service Award (NIH/NIEHS) [grant number 1 F30 ES016975-01] (to T.D.M.), and was supported in part by the NIH [grant numbers R01AG016583, R01GM062887] and a MERIT Award by the Office of Research and Development, Department of Veterans Affairs, Ralph H. Johnson Veterans Affairs Medical Center (to L.M.O.), and by the NIH/National Cancer Institute (NCI) [grant number P01 CA097132 (to Y.A.H.)). NR 131 TC 117 Z9 121 U1 5 U2 36 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0264-6021 J9 BIOCHEM J JI Biochem. J. PD FEB 1 PY 2012 VL 441 BP 789 EP 802 DI 10.1042/BJ20111626 PN 3 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 886MY UT WOS:000299859700002 PM 22248339 ER PT J AU Ligibel, JA Meyerhardt, J Pierce, JP Najita, J Shockro, L Campbell, N Newman, VA Barbier, L Hacker, E Wood, M Marshall, J Paskett, E Shapiro, C AF Ligibel, Jennifer A. Meyerhardt, Jeffrey Pierce, John P. Najita, Julie Shockro, Laura Campbell, Nancy Newman, Vicky A. Barbier, Leslie Hacker, Eileen Wood, Marie Marshall, James Paskett, Electra Shapiro, Charles TI Impact of a telephone-based physical activity intervention upon exercise behaviors and fitness in cancer survivors enrolled in a cooperative group setting SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Breast cancer; Exercise; Cooperative group; Intervention; Physical functioning ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; BREAST-CANCER; CLINICAL-TRIALS; QUESTIONNAIRE QLQ-C30; WALK DISTANCE; WOMEN; HEALTH; DIAGNOSIS; SCORES AB Observational studies demonstrate an association between physical activity and improved outcomes in breast and colon cancer survivors. To test these observations with a large, randomized clinical trial, an intervention that significantly impacts physical activity in these patients is needed. The Active After Cancer Trial (AACT) was a multicenter pilot study evaluating the feasibility of a telephone-based exercise intervention in a cooperative group setting. Sedentary (engaging in < 60 min of recreational activity/week) breast and colorectal cancer survivors were randomized to a telephone-based exercise intervention or usual care control group. The intervention was delivered through the University of California at San Diego; participants received ten phone calls over the course of the 16-week intervention. All participants underwent assessment of physical activity, fitness, physical functioning, fatigue and exercise self-efficacy at baseline and after the 16-week intervention. One hundred and twenty-one patients were enrolled through ten Cancer and Leukemia Group B (CALGB) institutions; 100 patients had breast cancer and 21 had colorectal cancer. Participants randomized to the exercise group increased physical activity by more than 100 versus 22% in controls (54.5 vs. 14.6 min, P = 0.13), and experienced significant increases in fitness (increased 6-min walk test distance by 186.9 vs. 81.9 feet, P = 0.006) and physical functioning (7.1 vs. 2.6, P = 0.04) as compared to the control group. Breast and colorectal cancer survivors enrolled in a multicenter, telephone-based physical activity intervention increased physical activity and experienced significant improvements in fitness and physical functioning. Lifestyle intervention research is feasible in a cooperative group setting. C1 [Ligibel, Jennifer A.; Meyerhardt, Jeffrey; Najita, Julie; Shockro, Laura; Campbell, Nancy] Dana Farber Canc Inst, Boston, MA 02215 USA. [Pierce, John P.; Newman, Vicky A.; Barbier, Leslie] Moores Univ Calif, San Diego Canc Ctr, San Diego, CA USA. [Hacker, Eileen] Univ Illinois, Chicago, IL USA. [Wood, Marie] Univ Vermont, Burlington, VT USA. [Marshall, James] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Paskett, Electra; Shapiro, Charles] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH 43210 USA. RP Ligibel, JA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave Boston, Boston, MA 02215 USA. EM jligibel@partners.org FU Cancer and Leukemia Group B Pilot Prevention Grant; Dana-Farber Cancer Institute FX This work was supported by a Cancer and Leukemia Group B Pilot Prevention Grant and by the Gloria Spivak Faculty Support Fund at the Dana-Farber Cancer Institute. NR 43 TC 31 Z9 31 U1 2 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD FEB PY 2012 VL 132 IS 1 BP 205 EP 213 DI 10.1007/s10549-011-1882-7 PG 9 WC Oncology SC Oncology GA 892HX UT WOS:000300278400020 PM 22113257 ER PT J AU Kis, B O'Regan, KN Agoston, A Javery, O Jagannathan, J Ramaiya, NH AF Kis, B. O'Regan, K. N. Agoston, A. Javery, O. Jagannathan, J. Ramaiya, N. H. TI Imaging of desmoplastic small round cell tumour in adults SO BRITISH JOURNAL OF RADIOLOGY LA English DT Review ID TOMOGRAPHY; ABDOMEN AB Desmoplastic small round cell tumour (DSRCT) belongs to the histological descriptive category of small round blue cell tumours. DSRCT primarily occurs in adolescents and young adults between the ages of 15 and 25 years and has a male predominance. DSRCT is an aggressive disease with a poor prognosis; timely diagnosis is therefore critical to the management of these patients. Although their radiographic appearances overlap with other aggressive malignancies, there are certain imaging features that can suggest the diagnosis and expedite the initiation of appropriate therapy. The aim of our pictorial review is to describe the imaging findings of primary and metastatic DSRCT in adults. C1 [Kis, B.; Javery, O.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA. [Kis, B.; O'Regan, K. N.; Javery, O.; Jagannathan, J.; Ramaiya, N. H.] Dana Farber Canc Inst, Dept Imaging, Boston, MA USA. [Agoston, A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. RP Kis, B (reprint author), Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA. EM bkis@partners.org NR 12 TC 7 Z9 8 U1 0 U2 1 PU BRITISH INST RADIOLOGY PI LONDON PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND SN 0007-1285 J9 BRIT J RADIOL JI Br. J. Radiol. PD FEB PY 2012 VL 85 IS 1010 BP 187 EP 192 DI 10.1259/bjr/57186741 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 894CS UT WOS:000300405200019 PM 22128126 ER PT J AU Eberlin, LS Norton, I Dill, AL Golby, AJ Ligon, KL Santagata, S Cooks, RG Agar, NYR AF Eberlin, Livia S. Norton, Isaiah Dill, Allison L. Golby, Alexandra J. Ligon, Keith L. Santagata, Sandro Cooks, R. Graham Agar, Nathalie Y. R. TI Classifying Human Brain Tumors by Lipid Imaging with Mass Spectrometry SO CANCER RESEARCH LA English DT Article ID CANCER; TISSUE; ASTROCYTOMA; SURGERY; BREAST AB Brain tissue biopsies are required to histologically diagnose brain tumors, but current approaches are limited by tissue characterization at the time of surgery. Emerging technologies such as mass spectrometry imaging can enable a rapid direct analysis of cancerous tissue based on molecular composition. Here, we illustrate how gliomas can be rapidly classified by desorption electrospray ionization-mass spectrometry (DESI-MS) imaging, multivariate statistical analysis, and machine learning. DESI-MS imaging was carried out on 36 human glioma samples, including oligodendroglioma, astrocytoma, and oligoastrocytoma, all of different histologic grades and varied tumor cell concentration. Gray and white matter from glial tumors were readily discriminated and detailed diagnostic information could be provided. Classifiers for subtype, grade, and concentration features generated with lipidomic data showed high recognition capability with more than 97% cross-validation. Specimen classification in an independent validation set agreed with expert histopathology diagnosis for 79% of tested features. Together, our findings offer proof of concept that intraoperative examination and classification of brain tissue by mass spectrometry can provide surgeons, pathologists, and oncologists with critical and previously unavailable information to rapidly guide surgical resections that can improve management of patients with malignant brain tumors. Cancer Res; 72(3); 645-54. (C) 2011 AACR. C1 [Eberlin, Livia S.; Dill, Allison L.; Cooks, R. Graham] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA. [Eberlin, Livia S.; Dill, Allison L.; Cooks, R. Graham] Purdue Univ, Ctr Analyt Instrumentat Dev, W Lafayette, IN 47907 USA. [Norton, Isaiah; Golby, Alexandra J.; Agar, Nathalie Y. R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA. [Norton, Isaiah; Golby, Alexandra J.; Agar, Nathalie Y. R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Ligon, Keith L.; Santagata, Sandro] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Ligon, Keith L.; Santagata, Sandro] Brigham & Womens Hosp, Dept Med Oncol, Boston, MA 02115 USA. [Ligon, Keith L.; Santagata, Sandro] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Cooks, RG (reprint author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA. EM cooks@purdue.edu; nagar@bwh.harvard.edu RI Cooks, R/G-1051-2015 OI Cooks, R/0000-0002-9581-9603 FU U.S. NIH [1R21EB009459-01]; Brain Science Foundation; Daniel E. Ponton fund for the Neurosciences; NIH [1DP2OD007383-01]; Klarman Family Foundation FX The work received support from the U.S. NIH (grant 1R21EB009459-01 to L. S. Eberlin, A. L. Dill, and R. G. Cooks); Brain Science Foundation and the Daniel E. Ponton fund for the Neurosciences and the NIH Director's New Innovator Award (grant 1DP2OD007383-01 to N.Y.R. Agar); the Klarman Family Foundation (A. J. Golby). NR 30 TC 88 Z9 90 U1 8 U2 93 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD FEB 1 PY 2012 VL 72 IS 3 BP 645 EP 654 DI 10.1158/0008-5472.CAN-11-2465 PG 10 WC Oncology SC Oncology GA 894CZ UT WOS:000300405900009 PM 22139378 ER PT J AU Chen, DY Lee, Y Van Tine, BA Searleman, AC Westergard, TD Liu, H Tu, HC Takeda, S Dong, YY Piwnica-Worms, DR Oh, KJ Korsmeyer, SJ Hermone, A Gussio, R Shoemaker, RH Cheng, EHY Hsieh, JJD AF Chen, David Y. Lee, Yishan Van Tine, Brian A. Searleman, Adam C. Westergard, Todd D. Liu, Han Tu, Ho-Chou Takeda, Shugaku Dong, Yiyu Piwnica-Worms, David R. Oh, Kyoung J. Korsmeyer, Stanley J. Hermone, Ann Gussio, Richard Shoemaker, Robert H. Cheng, Emily H. -Y. Hsieh, James J. -D. TI A Pharmacologic Inhibitor of the Protease Taspase1 Effectively Inhibits Breast and Brain Tumor Growth SO CANCER RESEARCH LA English DT Article ID NON-ONCOGENE ADDICTION; GENE-EXPRESSION; TRANSGENIC MICE; CELL-GROWTH; MLL; PROTEOLYSIS; ACTIVATION; PHOSPHORYLATION; IDENTIFICATION; FRAGMENTS AB The threonine endopeptidase Taspase1 has a critical role in cancer cell proliferation and apoptosis. In this study, we developed and evaluated small molecule inhibitors of Taspase1 as a new candidate class of therapeutic modalities. Genetic deletion of Taspase1 in the mouse produced no overt deficiencies, suggesting the possibility of a wide therapeutic index for use of Taspase1 inhibitors in cancers. We defined the peptidyl motifs recognized by Taspase1 and conducted a cell-based dual-fluorescent proteolytic screen of the National Cancer Institute diversity library to identify Taspase1 inhibitors (TASPIN). On the basis of secondary and tertiary screens the 4-[(4-arsonophenyl) methyl] phenyl] arsonic acid NSC48300 was determined to be the most specific active compound. Structure-activity relationship studies indicated a crucial role for the arsenic acid moiety in mediating Taspase1 inhibition. Additional fluorescence resonance energy transfer-based kinetic analysis characterized NSC48300 as a reversible, noncompetitive inhibitor of Taspase1 (Ki 4.22 mmol/ L). In the MMTV-neu mouse model of breast cancer and the U251 xenograft model of brain cancer, NSC48300 produced effective tumor growth inhibition. Our results offer an initial preclinical proof-of-concept to develop TASPINs for cancer therapy. Cancer Res; 72(3); 736-46. (C) 2011 AACR. C1 [Liu, Han; Tu, Ho-Chou; Takeda, Shugaku; Dong, Yiyu; Cheng, Emily H. -Y.; Hsieh, James J. -D.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA. [Cheng, Emily H. -Y.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA. [Hsieh, James J. -D.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA. [Chen, David Y.; Lee, Yishan; Van Tine, Brian A.; Searleman, Adam C.; Westergard, Todd D.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA. [Piwnica-Worms, David R.] Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, BRIGHT Inst,Mol Imaging Ctr, St Louis, MO 63110 USA. [Oh, Kyoung J.] Rosalind Franklin Univ, Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL USA. [Korsmeyer, Stanley J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hermone, Ann; Gussio, Richard] NCI, Informat Technol Branch, Dev Therapeut Program, Frederick, MD 21701 USA. [Shoemaker, Robert H.] NCI, Screening Technol Branch, Dev Therapeut Program, Frederick, MD 21701 USA. RP Hsieh, JJD (reprint author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, Z801,415 E 68th St, New York, NY 10065 USA. EM hsiehj@mskcc.org OI Searleman, Adam/0000-0003-1084-2415; Takeda, Shugaku/0000-0003-4730-9390 FU NIH CA [R01-119008]; American Cancer Society FX This study is supported by NIH CA R01-119008 and the American Cancer Society. NR 43 TC 14 Z9 14 U1 1 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD FEB 1 PY 2012 VL 72 IS 3 BP 736 EP 746 DI 10.1158/0008-5472.CAN-11-2584 PG 11 WC Oncology SC Oncology GA 894CZ UT WOS:000300405900018 PM 22166309 ER PT J AU Sher, L Braquehais, MD Casas, M AF Sher, Leo Dolores Braquehais, Maria Casas, Miquel TI Posttraumatic stress disorder, depression, and suicide in veterans SO CLEVELAND CLINIC JOURNAL OF MEDICINE LA English DT Review ID NATIONAL COMORBIDITY SURVEY; AFGHANISTAN WAR VETERANS; VIETNAM COMBAT VETERANS; RISK-FACTORS; PSYCHIATRIC OUTPATIENTS; EVENTUAL SUICIDE; IDEATION; BEHAVIOR; HOPELESSNESS; PREVALENCE AB Suicidal behavior is a critical problem in war veterans. Combat veterans are not only more likely to have suicidal ideation, often associated with posttraumatic stress disorder (PTSD) and depression, but they are more likely to act on a suicidal plan. Especially since veterans may be less likely to seek help from a mental health professional, non-mental-health physicians are in a key position to screen for PTSD, depression, and suicidal ideation in these patients. The authors discuss the association of PTSD, depression, and suicide in veterans, keys to assessment of suicide risk, and interventions. C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. [Sher, Leo] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Dolores Braquehais, Maria; Casas, Miquel] Univ Autonoma Barcelona, Dept Psychiat & Legal Med, Vall dHebron Univ Hosp, CIBERSAM, Barcelona, Spain. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Leo.Sher@mssm.edu RI Schueter, nicos/A-3625-2014 NR 67 TC 11 Z9 11 U1 2 U2 15 PU CLEVELAND CLINIC PI CLEVELAND PA 9500 EUCLID AVE, CLEVELAND, OH 44106 USA SN 0891-1150 J9 CLEV CLIN J MED JI Clevel. Clin. J. Med. PD FEB PY 2012 VL 79 IS 2 BP 92 EP 97 DI 10.3949/ccjm.79a.11069 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 893CB UT WOS:000300332100002 PM 22301558 ER PT J AU Anderson, KC DuBois, RN AF Anderson, Kenneth C. DuBois, Raymond N. TI Overview of the AACR Clinical and Translational Cancer Research Think Tank Meeting SO CLINICAL CANCER RESEARCH LA English DT Editorial Material C1 [Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Neoplasia, Boston, MA 02115 USA. [DuBois, Raymond N.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA. [DuBois, Raymond N.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA. RP Anderson, KC (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Neoplasia, 44 Binney St, Boston, MA 02115 USA. EM kenneth_anderson@dfci.harvard.edu NR 0 TC 2 Z9 2 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD FEB 1 PY 2012 VL 18 IS 3 BP 607 EP 611 DI 10.1158/1078-0432.CCR-11-3228 PG 5 WC Oncology SC Oncology GA 889ZN UT WOS:000300115000004 PM 22298892 ER PT J AU Arteaga, CL Baselga, J AF Arteaga, Carlos L. Baselga, Jose TI Impact of Genomics on Personalized Cancer Medicine SO CLINICAL CANCER RESEARCH LA English DT Article ID CELL LUNG-CANCER; METASTATIC COLORECTAL-CANCER; POSITIVE BREAST-CANCER; EGFR KINASE INHIBITORS; MET AMPLIFICATION; MUTATIONS; RESISTANCE; GEFITINIB; PIK3CA; GENE AB Recent advances in tumor genetics and drug development have led to the generation of a wealth of anticancer targeted therapies. A few recent examples indicate that these drugs are mainly, if not exclusively, active against tumors of a particular genotype that can be identified by a diagnostic test, usually by detecting a somatic alteration in the tumor DNA. However, for the majority of targeted therapies in development, there are still no clinical tools to determine which patients are most likely to benefit or, alternatively, be resistant de novo to these novel agents or drug combinations. Clin Cancer Res; 18(3); 612-8. (C)2012 AACR. C1 [Arteaga, Carlos L.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA. [Baselga, Jose] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA. RP Arteaga, CL (reprint author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, 2200 Pierce Ave,777 PRB, Nashville, TN 37232 USA. EM carlos.arteaga@vanderbilt.edu NR 50 TC 28 Z9 28 U1 0 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD FEB 1 PY 2012 VL 18 IS 3 BP 612 EP 618 DI 10.1158/1078-0432.CCR-11-2019 PG 7 WC Oncology SC Oncology GA 889ZN UT WOS:000300115000005 PM 22298893 ER PT J AU Parkinson, DR Johnson, BE Sledge, GW AF Parkinson, David R. Johnson, Bruce E. Sledge, George W. TI Making Personalized Cancer Medicine a Reality: Challenges and Opportunities in the Development of Biomarkers and Companion Diagnostics SO CLINICAL CANCER RESEARCH LA English DT Article ID ONCOLOGY AB The origins of this article stem from discussions at the American Association for Cancer Research Clinical and Translational Cancer Research Think Tank meeting held in San Francisco in early 2010. This article synthesizes the opinions and issues considered at that meeting, and discusses many of the important events that have since occurred in the field of personalized cancer medicine. Although investigators continue to make progress in better linking individual patient biology with risk determination, diagnosis, prognosis, and treatment selection, the pace of this progress continues to be limited by many of the issues identified in the meeting. Clin Cancer Res; 18(3); 619-24. (C)2012 AACR. C1 [Parkinson, David R.] Nodality Inc, San Francisco, CA 94080 USA. [Johnson, Bruce E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sledge, George W.] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA. RP Parkinson, DR (reprint author), Nodality Inc, 170 Harbor Way, San Francisco, CA 94080 USA. EM david.parkinson@nodality.com NR 12 TC 38 Z9 40 U1 2 U2 13 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD FEB 1 PY 2012 VL 18 IS 3 BP 619 EP 624 DI 10.1158/1078-0432.CCR-11-2017 PG 6 WC Oncology SC Oncology GA 889ZN UT WOS:000300115000006 PM 22298894 ER PT J AU Ogino, S Shima, K Meyerhardt, JA McCleary, NJ Ng, K Hollis, D Saltz, LB Mayer, RJ Schaefer, P Whittom, R Hantel, A Benson, AB Spiegelman, D Goldberg, RM Bertagnolli, MM Fuchs, CS AF Ogino, Shuji Shima, Kaori Meyerhardt, Jeffrey A. McCleary, Nadine J. Ng, Kimmie Hollis, Donna Saltz, Leonard B. Mayer, Robert J. Schaefer, Paul Whittom, Renaud Hantel, Alexander Benson, Al B., III Spiegelman, Donna Goldberg, Richard M. Bertagnolli, Monica M. Fuchs, Charles S. TI Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803 SO CLINICAL CANCER RESEARCH LA English DT Article ID ISLAND METHYLATOR PHENOTYPE; METASTATIC COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; V600E MUTATION; ADJUVANT THERAPY; MISMATCH REPAIR; KRAS MUTATION; IRINOTECAN; SURVIVAL; CAMPTOTHECIN AB Purpose: Alterations in the RAS-RAF-MAP2K (MEK)-MAPK signaling pathway are major drivers in colorectal carcinogenesis. In colorectal cancer, BRAF mutation is associated with microsatellite instability (MSI), and typically predicts inferior prognosis. We examined the effect of BRAF mutation on survival and treatment efficacy in patients with stage III colon cancer. Methods: We assessed status of BRAF c.1799T>A (p.V600E) mutation and MSI in 506 stage III colon cancer patients enrolled in a randomized adjuvant chemotherapy trial [5-fluorouracil and leucovorin (FU/LV) vs. irinotecan (CPT11), FU and LV (IFL); CALGB 89803]. Cox proportional hazards model was used to assess the prognostic role of BRAF mutation, adjusting for clinical features, adjuvant chemotherapy arm, and MSI status. Results: Compared with 431 BRAF wild-type patients, 75 BRAF-mutated patients experienced significantly worse overall survival [OS; log-rank P = 0.015; multivariate HR = 1.66; 95% Cl: 1.05-2.63]. By assessing combined status of BRAF and MSI, it seemed that BRAF-mutated MSS (microsatellite stable) tumor was an unfavorable subtype, whereas BRAF wild-type MSI-high tumor was a favorable subtype, and BRAF-mutated MSI-high tumor and BRAF wild-type MSS tumor were intermediate subtypes. Among patients with BRAF-mutated tumors, a nonsignificant trend toward improved OS was observed for IFL versus FU/LV arm (multivariate HR = 0.52; 95% Cl: 0.25-1.10). Among patients with BRAF wild-type cancer, IFL conferred no suggestion of benefit beyond FU/LV alone (multivariate HR = 1.02; 95% Cl: 0.72-1.46). Conclusions: BRAF mutation is associated with inferior survival in stage III colon cancer. Additional studies are necessary to assess whether there is any predictive role of BRAF mutation for irinotecan-based therapy. Clin Cancer Res; 18(3); 890-900. (C) 2011 AACR. C1 [Ogino, Shuji] Harvard Univ, Dana Farber Canc Inst, Brigham & Womens Hosp, Ctr Mol Oncol Pathol,Med Sch,Dept Pathol, Boston, MA 02215 USA. [Ogino, Shuji; Shima, Kaori; Meyerhardt, Jeffrey A.; McCleary, Nadine J.; Ng, Kimmie; Mayer, Robert J.; Fuchs, Charles S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Ogino, Shuji; Shima, Kaori; Meyerhardt, Jeffrey A.; McCleary, Nadine J.; Ng, Kimmie; Mayer, Robert J.; Fuchs, Charles S.] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Spiegelman, Donna; Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Bertagnolli, Monica M.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Spiegelman, Donna] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA. [Spiegelman, Donna] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA. [Hollis, Donna] Duke Univ, Med Ctr, CALGB Stat Ctr, Durham, NC USA. [Saltz, Leonard B.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Schaefer, Paul] Toledo Community Hosp Oncol Program, NCCTG, Toledo, OH USA. [Whittom, Renaud] Hop Sacre Coeur, NCIC, Montreal, PQ H4J 1C5, Canada. [Hantel, Alexander] Loyola Univ, Stritch Sch Med, SWOG, Maywood, IL 60153 USA. [Benson, Al B., III] Northwestern Univ, Chicago, IL 60611 USA. [Goldberg, Richard M.] Univ N Carolina, Chapel Hill, NC USA. RP Ogino, S (reprint author), Harvard Univ, Dana Farber Canc Inst, Brigham & Womens Hosp, Ctr Mol Oncol Pathol,Med Sch,Dept Pathol, 450 Brookline Ave,Room JF-215C, Boston, MA 02215 USA. EM shuji_ogino@dfci.harvard.edu RI Goldberg , Richard/M-1311-2013; OI Saltz, Leonard/0000-0001-8353-4670 FU National Cancer Institute [CA31946, CA33601, R01 CA151993, R01 CA149222, R01 CA118553, K07 CA148894]; Pfizer Oncology; SPORE grant [P50 CA127003]; [CA77651]; [CA35415]; [CO15]; [CA38926]; [CA32101]; [CA46282]; [CA23318]; [CA47559] FX The research for CALGB 89803 was supported, in part, by grants from the National Cancer Institute (CA31946) to the Cancer and Leukemia Croup B (currently, Alliance for Clinical Trials in Oncology; Monica M. Bertagnolli) and to the CALGB Statistical Center (Stephen George, PhD, CA33601), and support from Pharmacia & Upjohn Company, now Pfizer Oncology. S. Ogino, J.A. Meyerhardt, and CS. Fuchs were supported in part by R01 awards from the National Cancer Institute (R01 CA151993 to S. Ogino; R01 CA149222 to J.A. Meyerhardt; R01 CA118553 to CS. Fuchs), and K. Ng was supported in part by K07 award from the National Cancer Institute (K07 CA148894). S. Ogino, J.A. Meyerhardt, K. Ng, and C.S. Fuchs were supported in part by the SPORE grant (P50 CA127003 to C.S. Fuchs). The study was also supported by the following grants: CA33601 (D. Hollis); CA77651 (L.B. Saltz); CA35415 (P. Schaefer); CO15 (R. Whittom); CA38926, CA32101, CA46282 (A. Hamel); CA23318 (Al B. Benson III); and CA47559 (R.M. Goldberg). NR 50 TC 120 Z9 122 U1 1 U2 9 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD FEB 1 PY 2012 VL 18 IS 3 BP 890 EP 900 DI 10.1158/1078-0432.CCR-11-2246 PG 11 WC Oncology SC Oncology GA 889ZN UT WOS:000300115000032 PM 22147942 ER PT J AU Sylvia, LG Reilly-Harrington, NA Leon, AC Kansky, CI Ketter, TA Calabrese, JR Thase, ME Bowden, CL Friedman, ES Ostacher, MJ Iosifescu, DV Severe, J Keyes, M Nierenberg, AA AF Sylvia, Louisa G. Reilly-Harrington, Noreen A. Leon, Andrew C. Kansky, Christine I. Ketter, Terence A. Calabrese, Joseph R. Thase, Michael E. Bowden, Charles L. Friedman, Edward S. Ostacher, Michael J. Iosifescu, Dan V. Severe, Joanne Keyes, Michelle Nierenberg, Andrew A. TI Methods to limit attrition in longitudinal comparative effectiveness trials: lessons from the Lithium Treatment - Moderate dose Use Study (LiTMUS) for bipolar disorder SO CLINICAL TRIALS LA English DT Article; Proceedings Paper CT University-of-Pennsylvania Annual Conference on Statistical Issues in Clinical Trials CY APR 13-13, 2011 CL Philadelphia, PA ID CONTROLLED CLINICAL-TRIAL; TREATMENT ADHERENCE; INTERVENTIONS; INDIVIDUALS; DESIGN AB Background High attrition rates, which occur frequently in longitudinal clinical trials of interventions for bipolar disorder, limit the interpretation of results. Purpose The aim of this article is to present design approaches that limited attrition in the Lithium Treatment - Moderate dose Use Study (LiTMUS) for bipolar disorder. Methods LiTMUS was a 6-month randomized, longitudinal multisite comparative effectiveness trial that enrolled bipolar participants who were at least mildly ill. Participants were randomized to either low to moderate doses of lithium or no lithium; other treatments needed for mood stabilization were administered in a guideline-informed, empirically supported, and personalized fashion to participants in both treatment arms. Results Components of the study design that may have contributed to low attrition (16%) among 283 participants randomized included the use of (1) an intent-to-treat design, (2) a randomized adjunctive single-blind design, (3) participant reimbursement, (4) assessment of intent to attend the next study visit (included a discussion of attendance obstacles when intention was low), (5) quality care with limited participant burden, and (6) target windows for study visits. Limitations The relationships between attrition and effectiveness and tolerability of treatment have not been analyzed yet. Conclusions These components of the LiTMUS design may have limited attrition and may inform the design of future randomized comparative effectiveness trials among similar patients and those from other difficult-to-follow populations. Clinical Trials 2012; 9: 94-101. http://ctj.sagepub.com C1 [Sylvia, Louisa G.; Reilly-Harrington, Noreen A.; Kansky, Christine I.; Nierenberg, Andrew A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Leon, Andrew C.] Weill Cornell Med Coll, New York, NY USA. [Ketter, Terence A.; Ostacher, Michael J.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Calabrese, Joseph R.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Thase, Michael E.] Univ Penn, Philadelphia, PA 19104 USA. [Bowden, Charles L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Friedman, Edward S.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Iosifescu, Dan V.] Mt Sinai Med Ctr, New York, NY 10029 USA. [Severe, Joanne] NIMH, Bethesda, MD 20892 USA. [Keyes, Michelle] Harvard Clin Res Inst, Boston, MA USA. RP Sylvia, LG (reprint author), Massachusetts Gen Hosp, 50 Staniford St, Boston, MA 02114 USA. EM Lsylvia2@partners.org OI Ostacher, Michael/0000-0003-0353-7535 FU National Institute of Mental Health [NO1MH80001] FX LiTMUS was sponsored by National Institute of Mental Health (Contract # NO1MH80001) and is registered with the National Library of Medicine's ClinicalTrials.gov website (record number: NCT00667745). NR 20 TC 5 Z9 5 U1 3 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1740-7745 EI 1740-7753 J9 CLIN TRIALS JI Clin. Trials PD FEB PY 2012 VL 9 IS 1 BP 94 EP 101 DI 10.1177/1740774511427324 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 893UA UT WOS:000300380200013 PM 22076437 ER PT J AU Brancati, FL Evans, M Furberg, CD Geller, N Haffner, S Kahn, SE Kaufmann, PG Lewis, CE Nathan, DM Pitt, B Safford, MM AF Brancati, Frederick L. Evans, Mary Furberg, Curt D. Geller, Nancy Haffner, Steven Kahn, Steven E. Kaufmann, Peter G. Lewis, Cora E. Nathan, David M. Pitt, Bertram Safford, Monika M. CA Look AHEAD Study Grp TI Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study SO CLINICAL TRIALS LA English DT Article; Proceedings Paper CT University-of-Pennsylvania Annual Conference on Statistical Issues in Clinical Trials CY APR 13-13, 2011 CL Philadelphia, PA ID CORONARY-HEART-DISEASE; RANDOMIZED CONTROLLED-TRIAL; CARDIOVASCULAR EVENTS; ATHEROSCLEROSIS RISK; MACROVASCULAR EVENTS; ARTERY-DISEASE; OUTCOMES; PREVENTION; COMMUNITIES; NATEGLINIDE AB The Look AHEAD (Action for Health in Diabetes) Study is a long-term clinical trial that aims to determine the cardiovascular disease (CVD) benefits of an intensive lifestyle intervention (ILI) in obese adults with type 2 diabetes. The study was designed to have 90% statistical power to detect an 18% reduction in the CVD event rate in the ILI Group compared to the Diabetes Support and Education (DSE) Group over 10.5 years of follow-up. The original power calculations were based on an expected CVD rate of 3.125% per year in the DSE group; however, a much lower-than-expected rate in the first 2 years of follow-up prompted the Data and Safety Monitoring Board (DSMB) to recommend that the Steering Committee undertake a formal blinded evaluation of these design considerations. The Steering Committee created an Endpoint Working Group (EPWG) that consisted of individuals masked to study data to examine relevant issues. The EPWG considered two primary options: (1) expanding the definition of the primary endpoint and (2) extending follow-up of participants. Ultimately, the EPWG recommended that the Look AHEAD Steering Committee approve both strategies. The DSMB accepted these modifications, rather than recommending that the trial continue with inadequate statistical power. Trialists sometimes need to modify endpoints after launch. This decision should be well justified and should be made by individuals who are fully masked to interim results that could introduce bias. This article describes this process in the Look AHEAD study and places it in the context of recent articles on endpoint modification and recent trials that reported endpoint modification. Clinical Trials 2012; 9: 113-124. http://ctj.sagepub.com C1 [Brancati, Frederick L.] Johns Hopkins Univ, Baltimore, MD 21205 USA. [Evans, Mary] NIDDK, Bethesda, MD USA. [Furberg, Curt D.] Wake Forest Univ, Winston Salem, NC 27109 USA. [Geller, Nancy; Kaufmann, Peter G.] NHLBI, Bethesda, MD 20892 USA. [Kahn, Steven E.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Lewis, Cora E.; Safford, Monika M.] Univ Alabama Birmingham, Birmingham, AL USA. [Nathan, David M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Pitt, Bertram] Univ Michigan, Ann Arbor, MI 48109 USA. RP Brancati, FL (reprint author), Johns Hopkins Univ, 2024 E Monument St,2-619, Baltimore, MD 21205 USA. EM fbrancat@jhmi.edu OI Kahn, Steven/0000-0001-7307-9002 FU Department of Health and Human Services from the National Institutes of Health [DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, DK56992]; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; Office of Research on Women's Health; Centers for Disease Control and Prevention; Department of Veterans Affairs FX This study is supported by the Department of Health and Human Services through the following cooperative agreements from the National Institutes of Health: DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, and DK56992. The following federal agencies have contributed support: National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; Office of Research on Women's Health; the Centers for Disease Control and Prevention; and the Department of Veterans Affairs. This research was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. The Indian Health Service (IHS) provided personnel, medical oversight, and use of facilities. The opinions expressed in this article are those of the authors and do not necessarily reflect the views of the IHS or other funding sources.; Additional support was received from The Johns Hopkins Medical Institutions Bayview General Clinical Research Center (M01RR02719) and the Prevention & Control Core of the Baltimore Diabetes Research & Training Center (P60KD079637); the Massachusetts General Hospital Mallinckrodt General Clinical Research Center and the Massachusetts Institute of Technology General Clinical Research Center (M01RR01066); the University of Colorado Health Sciences Center General Clinical Research Center (M01RR00051) and Clinical Nutrition Research Unit (P30 DK48520); the University of Tennessee at Memphis General Clinical Research Center (M01RR0021140); the University of Pittsburgh General Clinical Research Center (GCRC) (M01RR000056), the Clinical Translational Research Center (CTRC) funded by the Clinical & Translational Science Award (UL1 RR 024153) and NIH grant (DK 046204); and the Frederic C. Bartter General Clinical Research Center (M01RR01346) NR 29 TC 13 Z9 13 U1 0 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1740-7745 EI 1740-7753 J9 CLIN TRIALS JI Clin. Trials PD FEB PY 2012 VL 9 IS 1 BP 113 EP 124 DI 10.1177/1740774511432726 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 893UA UT WOS:000300380200015 PM 22334468 ER PT J AU Khan, R Jang, IK AF Khan, Razi Jang, Ik-Kyung TI Evaluation of coronary allograft vasculopathy using multi-detector row computed tomography: a systematic review SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Review DE Coronary allograft vasculopathy; Multi-detector row computed tomography; Catheter-based coronary angiography; Intravascular ultrasound ID CARDIAC-TRANSPLANT RECIPIENTS; LEFT-VENTRICULAR FUNCTION; ARTERY-DISEASE; INTRAVASCULAR ULTRASOUND; INTRACORONARY ULTRASOUND; ANGIOGRAPHY; HEART; ATHEROSCLEROSIS; STENOSIS; RISK AB Coronary allograft vasculopathy (CAV) is a significant cause of morbidity and mortality after cardiac transplantation and requires frequent surveillance with catheter-based coronary angiography (CCA). Multi-detector row computed tomography (MDCT) has been shown to be effective in assessing atherosclerosis in native coronary arteries. This article systematically reviews the literature to determine the accuracy of MDCT in CAV assessment. An English-language literature search was performed using EMBASE, OVID, PubMed, and Cochrane Library databases. Studies that directly compared MDCT with CCA and/or IVUS for the detection of coronary artery stenosis or significant intimal thickening in cardiac transplant patients were analyzed. Data were pooled to obtain weighted sensitivities, specificities, and diagnostic accuracies. Negative and positive predictive values (NPV/PPV) were calculated. A total of seven studies with a sum of 272 patients were included in this review. There were three studies examining 16-slice MDCTand four studies looking at 64-slice MDCT in CAV. Using per-segment analysis, MDCTassessed between 91% and 96% of all coronary segments when evaluating for stenosis. Pooled estimates for sensitivity and specificity for MDCT ranged from 82% to 89% and 89% to 99%, respectively, while NPV was 99%. Per-patient analysis revealed a sensitivity of 87-100% and NPV of 96-100%. PPV was less than 50% for 64-slice MDCT in both per-segment and per-patient analysis. When compared with IVUS, MDCT had a sensitivity of 74-96% and specificity of 88-92% in assessment of intimal thickening. NPV and PPV were 80-81% and 84-98%, respectively. The high sensitivity and NPV of MDCTsuggest that it may be a useful, noninvasive screening tool to rule out CAV. C1 [Khan, Razi] Univ Western Ontario, Dept Med, Div Cardiol, London, ON, Canada. [Jang, Ik-Kyung] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. [Jang, Ik-Kyung] Harvard Univ, Sch Med, Boston, MA USA. RP Khan, R (reprint author), 363 Colborne St,Apartment 2503, London, ON N6B 3N3, Canada. EM razi.khan@gmail.com NR 40 TC 5 Z9 5 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1010-7940 J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD FEB PY 2012 VL 41 IS 2 BP 415 EP 422 DI 10.1016/j.ejcts.2011.06.033 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 891ST UT WOS:000300237600037 PM 21820912 ER PT J AU Schmedt, T Silva, MM Ziaei, A Jurkunas, U AF Schmedt, Thore Silva, Mariana Mazzini Ziaei, Alireza Jurkunas, Ula TI Molecular bases of corneal endothelial dystrophies SO EXPERIMENTAL EYE RESEARCH LA English DT Article DE apoptosis; congenital hereditary endothelial dystrophy (CHED); fuchs endothelial corneal dystrophy (FECD); genetics; guttae; oxidative stress; posterior polymorphous corneal dystrophy (PPCP); sodium biocarbonate transporter-like protein 11 (SLC4A11) ID POSTERIOR POLYMORPHOUS DYSTROPHY; UNFOLDED PROTEIN RESPONSE; FUCHS COMBINED DYSTROPHY; OXIDATIVE STRESS; MISSENSE MUTATIONS; CELL-DEATH; CLUSTERIN EXPRESSION; CONFOCAL MICROSCOPY; SLC4A11 MUTATIONS; GENE-EXPRESSION AB The phrase "corneal endothelial dystrophies" embraces a group of bilateral corneal conditions that are characterized by a non-inflammatory and progressive degradation of corneal endothelium. Corneal endothelial cells exhibit a high pump site density and, along with barrier function, are responsible for maintaining the cornea in its natural state of relative dehydration. Gradual loss of endothelial cells leads to an insufficient water outflow, resulting in corneal edema and loss of vision. Since the pathologic mechanisms remain largely unknown, the only current treatment option is surgical transplantation when vision is severely impaired. In the past decade, important steps have been taken to understand how endothelial degeneration progresses on the molecular level. Studies of affected multigenerational families and sporadic cases identified genes and chromosomal loci, and revealed either Mendelian or complex disorder inheritance patterns. Mutations have been detected in genes that carry important structural, metabolic, cytoprotective, and regulatory functions in corneal endothelium. In addition to genetic predisposition, environmental factors like oxidative stress were found to be involved in the pathogenesis of endotheliopathies. This review summarizes and crosslinks the recent progress on deciphering the molecular bases of corneal endothelial dystrophies. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Schmedt, Thore; Ziaei, Alireza; Jurkunas, Ula] Schepens Eye Res Inst, Boston, MA 02114 USA. [Schmedt, Thore; Ziaei, Alireza; Jurkunas, Ula] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Silva, Mariana Mazzini] Tadeu Cvintal Ophthalmol Inst, Sao Paulo, Brazil. [Jurkunas, Ula] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Jurkunas, U (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA. EM ula.jurkunas@schepens.harvard.edu FU NIH/NEI [R01-EY020581]; Research to Prevent Blindness FX Supported by Grants: NIH/NEI R01-EY020581 and Research to Prevent Blindness (UVJ). NR 125 TC 37 Z9 37 U1 0 U2 10 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0014-4835 J9 EXP EYE RES JI Exp. Eye Res. PD FEB PY 2012 VL 95 IS 1 SI SI BP 24 EP 34 DI 10.1016/j.exer.2011.08.002 PG 11 WC Ophthalmology SC Ophthalmology GA 893WT UT WOS:000300389100005 PM 21855542 ER PT J AU Gaballa, MR Laubach, JP Schlossman, RL Redman, K Noonan, K Mitsiades, CS Ghobrial, IM Munshi, N Anderson, KC Richardson, PG AF Gaballa, Mahmoud R. Laubach, Jacob P. Schlossman, Robert L. Redman, Katherine Noonan, Kimberly Mitsiades, Constantine S. Ghobrial, Irene M. Munshi, Nikhil Anderson, Kenneth C. Richardson, Paul G. TI Management of myeloma-associated renal dysfunction in the era of novel therapies SO EXPERT REVIEW OF HEMATOLOGY LA English DT Review DE bortezomib; dexamethasone; lenalidomide; multiple myeloma; renal dysfunction; thalidomide ID REFRACTORY MULTIPLE-MYELOMA; LENALIDOMIDE PLUS DEXAMETHASONE; BORTEZOMIB-BASED REGIMENS; PLASMA-CELL DYSCRASIAS; FREE LIGHT-CHAINS; HIGH-DOSE DEXAMETHASONE; PROXIMAL TUBULE CELLS; MONOCLONAL GAMMOPATHIES; IMMUNOPATHOLOGY GROUP; HISTOLOGICAL LESIONS AB Multiple myeloma (MM) is a plasma cell neoplasm often associated with renal impairment (RI), with myeloma cast nephropathy recognized as the most common cause. While RI is present in over 50% of MM patients at some point in their disease course, it is associated with higher tumor burden, more aggressive disease, diminished quality of life, development of complications and increased mortality. The introduction of novel therapies, including bortezomib, lenalidomide and thalidomide, has revolutionized the management of MM. They are now considered first-line therapies in induction, maintenance and salvage therapy for MM. In addition to their anti-MM effect, they can improve outcome in patients with RI, especially when combined, and bortezomib with dexamethasone may have a renal protective effect. This review focuses on the use of these agents in patients with MM and RI, and evaluates their efficacy, safety, need for dose adjustment and impact on RI. C1 [Laubach, Jacob P.; Schlossman, Robert L.; Redman, Katherine; Noonan, Kimberly; Mitsiades, Constantine S.; Ghobrial, Irene M.; Munshi, Nikhil; Anderson, Kenneth C.; Richardson, Paul G.] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancy, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Gaballa, Mahmoud R.] Thomas Jefferson Univ, Dept Internal Med, Philadelphia, PA 19107 USA. RP Richardson, PG (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancy, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. EM paul_richardson@dfci.harvard.edu NR 130 TC 14 Z9 19 U1 1 U2 3 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1747-4086 EI 1747-4094 J9 EXPERT REV HEMATOL JI Expert Rev. Hematol. PD FEB PY 2012 VL 5 IS 1 BP 51 EP 68 DI 10.1586/EHM.11.72 PG 18 WC Hematology SC Hematology GA 892DH UT WOS:000300266400014 PM 22272706 ER PT J AU Kim, JY Jo, MW Brauner, SC Ferrufino-Ponce, Z Ali, R Cremers, SL Henderson, BA AF Kim, J. Y. Jo, M-W Brauner, S. C. Ferrufino-Ponce, Z. Ali, R. Cremers, S. L. Henderson, B. A. TI Comment to 'Increased intraocular pressure on the first post-operative day following sutureless extracapsular cataract surgery in Africa' SO EYE LA English DT Letter C1 [Kim, J. Y.] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, Seoul, South Korea. [Kim, J. Y.] Univ Ulsan, Coll Med, Asan Med Ctr, Res Inst Biomacromol, Seoul, South Korea. [Kim, J. Y.; Brauner, S. C.; Cremers, S. L.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA. [Jo, M-W] Univ Ulsan, Coll Med, Dept Prevent Med, Seoul, South Korea. [Ferrufino-Ponce, Z.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Ali, R.] Univ Texas Med Branch, Dept Ophthalmol & Visual Sci, Galveston, TX USA. RP Kim, JY (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, Seoul, South Korea. EM jykim2311@amc.seoul.kr NR 2 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-222X J9 EYE JI Eye PD FEB PY 2012 VL 26 IS 2 BP 332 EP 333 DI 10.1038/eye.2011.274 PG 3 WC Ophthalmology SC Ophthalmology GA 892UX UT WOS:000300312200026 ER PT J AU Campos, F Sobrino, T Ramos-Cabrer, P Castillo, J AF Campos, Francisco Sobrino, Tomas Ramos-Cabrer, Pedro Castillo, Jose TI Oxaloacetate: A novel neuroprotective for acute ischemic stroke SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY LA English DT Article DE Oxaloacetate; Ischemic stroke; Glutamate; GOT ID BLOOD GLUTAMATE; BRAIN; TRANSAMINASE; PYRUVATE; RELEASE; NEURONS; CELLS; ACID AB It is well established that glutamate acts as an important mediator of neuronal degeneration during cerebral ischemia. Different kind of glutamate antagonists have been used to reduce the deleterious effects of glutamate. However, their preclinical success failed to translate into practical treatments. Far from the classical use of glutamate antagonists employed so far, the systemic administration of oxaloacetate represents a novel neuroprotective strategy to minimize the deleterious effect of glutamate in the brain tissue after ischemic stroke. The neuroprotective effect of oxaloacetate is based on the capacity of this molecule to reduce the brain and blood glutamate levels as a result of the activation of the blood-resident enzyme glutamate-oxaloacetate transaminase. Here we review the recent experimental and clinical results where it is demonstrated the potential applicability of oxaloacetate as a novel and powerful neuroprotective treatment against ischemic stroke. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Campos, Francisco; Sobrino, Tomas; Ramos-Cabrer, Pedro; Castillo, Jose] Univ Santiago de Compostela, Clin Neurosci Res Lab, Dept Neurol, Hosp Clin Univ,IDIS, Santiago De Compostela 15706, Spain. RP Campos, F (reprint author), Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA. EM francampos@linc-stg.eu RI Ramos-Cabrer, Pedro/J-5306-2014; Sobrino, Tomas/D-2498-2017; OI Ramos-Cabrer, Pedro/0000-0003-0368-7031; Sobrino, Tomas/0000-0002-9760-8690; Castillo, Jose/0000-0002-6685-3001 NR 22 TC 20 Z9 22 U1 1 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1357-2725 J9 INT J BIOCHEM CELL B JI Int. J. Biochem. Cell Biol. PD FEB PY 2012 VL 44 IS 2 BP 262 EP 265 DI 10.1016/j.biocel.2011.11.003 PG 4 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 889JC UT WOS:000300069000002 PM 22085530 ER PT J AU Sanoff, HK Carpenter, WR Martin, CF Sargent, DJ Meyerhardt, JA Sturmer, T Fine, JP Weeks, J Niland, J Kahn, KL Schymura, MJ Schrag, D AF Sanoff, Hanna K. Carpenter, William R. Martin, Christopher F. Sargent, Daniel J. Meyerhardt, Jeffrey A. Stuermer, Til Fine, Jason P. Weeks, Jane Niland, Joyce Kahn, Katherine L. Schymura, Maria J. Schrag, Deborah TI Comparative Effectiveness of Oxaliplatin vs Non-Oxaliplatin-containing Adjuvant Chemotherapy for Stage III Colon Cancer SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID COLORECTAL-CANCER; ELDERLY-PATIENTS; POOLED ANALYSIS; COMORBIDITY INDEX; OLDER PATIENTS; FLUOROURACIL; LEUCOVORIN; IRINOTECAN; SURVIVAL; TRIAL AB The addition of oxaliplatin to adjuvant 5-fluorouracil (5-FU) improves survival of patients with stage III colon cancer in randomized clinical trials (RCTs). However, RCT participants are younger, healthier, and less racially diverse than the general cancer population. Thus, the benefit of oxaliplatin outside RCTs is uncertain. Patients younger than 75 years with stage III colon cancer who received chemotherapy within 120 days of surgical resection were identified from five observational data sources-the Surveillance, Epidemiology, and End Results registry linked to Medicare claims (SEER-Medicare), the New York State Cancer Registry (NYSCR) linked to Medicaid and Medicare claims, the National Comprehensive Cancer Network (NCCN) Outcomes Database, and the Cancer Care Outcomes Research & Surveillance Consortium (CanCORS). Overall survival (OS) was compared among patients treated with oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy. Overall survival for 4060 patients diagnosed during 2004-2009 was compared with pooled data from five RCTs (the Adjuvant Colon Cancer ENdpoinTs [ACCENT] group, n = 8292). Datasets were juxtaposed but not combined using Kaplan-Meier curves. Covariate and propensity score adjusted proportional hazards models were used to calculate adjusted survival hazard ratios (HR). Stratified analyses examined effect modifiers. All statistical tests were two-sided. The survival advantage associated with the addition of oxaliplatin to adjuvant 5-FU was evident across diverse practice settings (3-year OS: RCTs, 86% [n = 1273]; SEER-Medicare, 80% [n = 1152]; CanCORS, 88% [n = 129]; NYSCR-Medicaid, 82% [n = 54]; NYSCR-Medicare, 79% [n = 180]; and NCCN, 86% [n = 438]). A statistically significant improvement in 3-year overall survival was seen in the largest cohort, SEER-Medicare, and in the NYSCR-Medicare cohort (non-oxaliplatin-containing vs oxaliplatin-containing adjuvant therapy, adjusted HR of death: pooled RCTs: HR = 0.80, 95% CI = 0.70 to 0.92, P = .002; SEER-Medicare: HR = 0.70, 95% CI = 0.60 to 0.82, P < .001; NYSCR-Medicare patients aged >= 65 years: HR = 0.58, 95% CI = 0.38 to 0.90, P = .02). The association between oxaliplatin treatment and better survival was maintained in older and minority group patients, as well as those with higher comorbidity. The addition of oxaliplatin to 5-FU appears to be associated with better survival among patients receiving adjuvant colon cancer treatment in the community. C1 [Meyerhardt, Jeffrey A.; Weeks, Jane; Schrag, Deborah] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Sanoff, Hanna K.] Univ Virginia, Dept Med, Div Hematol & Oncol, Charlottesville, VA USA. [Carpenter, William R.] Univ N Carolina, Dept Hlth Policy & Management, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Stuermer, Til] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Fine, Jason P.] Univ N Carolina, Dept Biostat, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Martin, Christopher F.] Univ N Carolina, Dept Med, Div Gastroenterol & Hepatol, Chapel Hill, NC USA. [Sargent, Daniel J.] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA. [Kahn, Katherine L.] RAND Corp, Santa Monica, CA USA. [Kahn, Katherine L.] Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Schymura, Maria J.] New York State Dept Hlth, New York State Canc Registry, Albany, NY USA. [Niland, Joyce] City Hope Canc Ctr, Dept Informat Sci, Duarte, CA USA. [Niland, Joyce] Natl Comprehens Canc Ctr, Data Coordinating Ctr, Duarte, CA USA. RP Schrag, D (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,Smith 270, Boston, MA 02115 USA. EM deb_schrag@dfci.harvard.edu RI Carpenter, William/E-5125-2013; OI Sargent, Daniel/0000-0002-2684-4741 FU Agency for Healthcare Research and Quality (AHRQ); US Department of Health and Human Services (HHS) [HSA290-2005-0016-I-TO7-WA1, 36-BWH-1, HHSA290-2005-0040-I-TO4-WA1, 36-UNC]; National Cancer Institute [R01CA131847]; National Cancer Institute; Primary Data Collection and Research Centers [U01 CA093344, U01 CA093332, U01 CA093324, U01 CA093348, U01 CA093329, U01 CA01013, U01 CA093326]; Department of Veteran's Affairs [CRS 02-164, HARO 03-438MO-03]; Centers for Disease Control and Prevention (CDC) through the Association of Schools of Public Health (ASPH) [U01 CA25224] FX The Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services (HHS) as part of the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program (Contract No. HSA290-2005-0016-I-TO7-WA1, 36-BWH-1 and HHSA290-2005-0040-I-TO4-WA1, 36-UNC). The authors of the report are responsible for its content. Statements in the report should not be construed as endorsement by the AHRQ or the US Department of HHS. The National Cancer Institute (R01CA131847 to D. Schrag, Principle Investigator) funded work on the Medicaid and SEER-Medicare data. The CanCORS study was supported by grants from the National Cancer Institute to the CanCORS Statistical Coordinating Center and Primary Data Collection and Research Centers (U01 CA093344, U01 CA093332, U01 CA093324, U01 CA093348, U01 CA093329, U01 CA01013, U01 CA093326), and by a grant from the Department of Veteran's Affairs to the Durham VA Medical Center (CRS 02-164) and (HARO 03-438MO-03). The National Institute on Aging (R01AG023178, T. Sturmer, PI), The National Institute of Diabetes and Digestive and Kidney Diseases (2P30DK034987, Robert Sandler, PI), The ACCENT collaboration is funded by (U01 CA25224) The Centers for Disease Control and Prevention (CDC) through the Association of Schools of Public Health (ASPH), (S3888, M. J. Schymura, PI). NR 42 TC 50 Z9 51 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD FEB PY 2012 VL 104 IS 3 BP 211 EP 227 DI 10.1093/jnci/djr524 PG 17 WC Oncology SC Oncology GA 893GA UT WOS:000300343000010 PM 22266473 ER PT J AU Borus, J Blood, E Volkening, L Laffel, LM Shrier, LA AF Borus, Joshua Blood, Emily Volkening, Lisa Laffel, Lori M. Shrier, Lydia A. TI MOMENTARY ASSESSMENT OF SOCIAL CONTEXT AND ADHERENCE IN ADOLESCENTS WITH TYPE 1 DIABETES SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Borus, Joshua; Blood, Emily; Shrier, Lydia A.] Childrens Hosp Boston, Boston, MA USA. [Volkening, Lisa; Laffel, Lori M.] Joslin Diabet Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2012 VL 50 IS 2 SU S BP S1 EP S2 PG 2 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 891UV UT WOS:000300243000003 ER PT J AU Primack, BA Kim, KH Shensa, AS Sidani, J Barnett, T Switzer, GE AF Primack, Brian A. Kim, Kevin H. Shensa, Ariel S. Sidani, Jaime Barnett, Tracey Switzer, Galen E. TI TOBACCO, MARIJUANA, AND ALCOHOL USE IN UNIVERSITY STUDENTS: A CLUSTER ANALYSIS SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Primack, Brian A.; Kim, Kevin H.; Shensa, Ariel S.; Sidani, Jaime] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Barnett, Tracey] Univ Florida, Gainesville, FL 32611 USA. [Switzer, Galen E.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2012 VL 50 IS 2 SU S BP S74 EP S75 PG 2 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 891UV UT WOS:000300243000156 ER PT J AU Walls, CE Richmond, TK Blood, EA Austin, SB Greaney, ML Spadano-Gasbarro, J Wang, ML Mezgebu, S Peterson, KE AF Walls, Courtney E. Richmond, Tracy K. Blood, Emily A. Austin, S. Bryn Greaney, Mary L. Spadano-Gasbarro, Jennifer Wang, Monica L. Mezgebu, Solomon Peterson, Karen E. TI THE INFLUENCE OF SCHOOL NEIGHBORHOOD SAFETY AND PARKS AND RECREATION RESOURCES ON MIDDLE SCHOOL STUDENTS' PHYSICAL ACTIVITY LEVELS SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Richmond, Tracy K.; Blood, Emily A.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Austin, S. Bryn; Spadano-Gasbarro, Jennifer] Harvard Univ, Sch Publ Hlth, Childrens Hosp Boston, Cambridge, MA 02138 USA. [Greaney, Mary L.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Cambridge, MA 02138 USA. [Mezgebu, Solomon] Massachusetts Dept Publ Hlth, Boston, MA 02111 USA. [Peterson, Karen E.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2012 VL 50 IS 2 SU S BP S37 EP S37 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 891UV UT WOS:000300243000076 ER PT J AU Friedman, N Sadhu, J Jellinek, M AF Friedman, Nora Sadhu, Julie Jellinek, Michael TI DSM-5: Implications for Pediatric Mental Health Care SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS LA English DT Review ID OF-ONSET CRITERION; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; NONSUICIDAL SELF-INJURY; BIPOLAR DISORDER; ADOLESCENT VERSION; CLINICAL-PRACTICE; BEHAVIOR PROBLEMS; EATING-DISORDER; SLEEP DISORDERS C1 [Friedman, Nora; Sadhu, Julie; Jellinek, Michael] Massachusetts Gen Hosp, Child Psychiat Serv, Boston, MA 02114 USA. [Jellinek, Michael] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Jellinek, Michael] Newton Wellesley Hosp, Newton, MA USA. [Jellinek, Michael] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. RP Jellinek, M (reprint author), Massachusetts Gen Hosp, Child Psychiat Serv, 55 Fruit St,Bulfinch Room 351, Boston, MA 02114 USA. EM Mjellinek@partners.org NR 118 TC 0 Z9 0 U1 2 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0196-206X J9 J DEV BEHAV PEDIATR JI J. Dev. Behav. Pediatr. PD FEB-MAR PY 2012 VL 33 IS 2 BP 163 EP 178 DI 10.1097/DBP.0b013e3182435c5a PG 16 WC Behavioral Sciences; Psychology, Developmental; Pediatrics SC Behavioral Sciences; Psychology; Pediatrics GA 894AR UT WOS:000300399700009 PM 22198548 ER PT J AU Jea, SY Mosaed, S Vold, SD Rhee, DJ AF Jea, Seung Youn Mosaed, Sameh Vold, Steven D. Rhee, Douglas J. TI Effect of a Failed Trabectome on Subsequent Trabeculectomy SO JOURNAL OF GLAUCOMA LA English DT Article DE intraocular pressure; open-angle glaucoma; success; trabectome; trabeculectomy ID TOPICAL ANTIGLAUCOMA MEDICATION; GLAUCOMA TRIPLE PROCEDURE; OPEN-ANGLE GLAUCOMA; FOLLOW-UP; ADJUNCTIVE MITOMYCIN; FILTRATION SURGERY; RISK-FACTORS; FAILURE; PSEUDOPHAKIA; APHAKIA AB Purpose: To determine the effect of a failed trabectome on the outcomes of a subsequent trabeculectomy. Patients and Methods: A cohort study of eyes that underwent trabeculectomy after a failed trabectome procedure (study) compared with eyes that underwent trabeculectomy as an initial surgical procedure (control). Inclusion criteria were open-angle glaucoma, age >= 18 years, and uncontrolled glaucoma with maximally tolerated medical therapy. Exclusion criteria were concurrent surgery and follow-up less than 6 months. Outcome measures were intraocular pressure (IOP), success rate, and occurrence of complications. Failure was the occurrence of additional glaucoma surgery, loss of light perception vision, or IOP > 21mm Hg, <= 5 mm Hg, or < 20% reduction below baseline on 2 consecutive follow-up visits after 1 month. Results: Mean follow-up was 15.4 months and 18.6 months for study (n = 34) and control (n = 42) groups, respectively. IOP decreased from 27.6 +/- 11.8 mm Hg at baseline to 10.6 +/- 2.6 mm Hg at 2 years in study group, and 29.2 +/- 11.4 mm Hg to 11.0 +/- 5.4 mm Hg in the control group. The success rates at 2 years were 60.2% and 55.5% in the study and control groups, respectively (P = 0.895). Systemic hypertension [P = 0.009; adjusted hazard ratio, 4.03; 95% confidence interval, 1.41-11.53] and number of the preoperative antiglaucoma medications (P = 0.005; 2.29; 1.28 to 4.11) were significant risk factors for failure in the multivariate analysis. Failed trabectome was not associated with trabeculectomy failure (P = 0.899). Postoperative complications were similar. Conclusions: A failed trabectome did not affect the success rate of a subsequent trabeculectomy. C1 [Rhee, Douglas J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Glaucoma Serv, Boston, MA 02114 USA. [Mosaed, Sameh] Univ Calif Irvine, Irvine, CA USA. [Vold, Steven D.] Boozman Hof Eye Clin PA, Rogers, AR USA. RP Rhee, DJ (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Glaucoma Serv, 243 Charles St, Boston, MA 02114 USA. EM dougrhee@aol.com NR 22 TC 25 Z9 27 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1057-0829 J9 J GLAUCOMA JI J. Glaucoma PD FEB PY 2012 VL 21 IS 2 BP 71 EP 75 DI 10.1097/IJG.0b013e31820bcfda PG 5 WC Ophthalmology SC Ophthalmology GA 894BY UT WOS:000300403200001 PM 21336149 ER PT J AU Zhao, H Lin, WY Kumthip, K Cheng, D Fusco, DN Hofmann, O Jilg, N Tai, AW Goto, K Zhang, LL Hide, W Jang, JY Peng, LF Chung, RT AF Zhao, Hong Lin, Wenyu Kumthip, Kattareeya Cheng, Du Fusco, Dahlene N. Hofmann, Oliver Jilg, Nikolaus Tai, Andrew W. Goto, Kaku Zhang, Leiliang Hide, Winston Jang, Jae Young Peng, Lee F. Chung, Raymond T. TI A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus SO JOURNAL OF HEPATOLOGY LA English DT Article DE HCV; IFN-alpha; siRNA; SART1; U4/U6.U5tri-snRNP ID KINASE PATHWAY; TRI-SNRNP; REPLICATION; EXPRESSION; RIBAVIRIN; NETWORK; CULTURE AB Background & Aims: The precise mechanisms by which IFN exerts its antiviral effect against HCV have not yet been elucidated. We sought to identify host genes that mediate the antiviral effect of IFN-alpha by conducting a whole-genome siRNA library screen. Methods: High throughput screening was performed using an HCV genotype 1b replicon, pRep-Feo. Those pools with replicate robust Z scores >= 2.0 entered secondary validation in full-length OR6 replicon cells. Huh7.5.1 cells infected with JFH1 were then used to validate the rescue efficacy of selected genes for HCV replication under IFN-alpha treatment. Results: We identified and confirmed 93 human genes involved in the IFN-alpha anti-HCV effect using a whole-genome siRNA library. Gene ontology analysis revealed that mRNA processing (23 genes, p = 2.756e-22), translation initiation (nine genes, p = 2.42e-6), and IFN signaling (five genes, p = 1.00e-3) were the most enriched functional groups. Nine genes were components of U4/U6.U5 tri-snRNP. We confirmed that silencing squamous cell carcinoma antigen recognized by T cells (SART1), a specific factor of tri-snRNP, abrogates IFN-alpha's suppressive effects against HCV in both replicon cells and JFH1 infectious cells. We further found that SART1 was not IFN-alpha inducible, and its anti-HCV effector in the JFH1 infectious model was through regulation of interferon stimulated genes (ISGs) with or without IFN-alpha. Conclusions: We identified 93 genes that mediate the anti-HCV effect of IFN-alpha through genome-wide siRNA screening; 23 and nine genes were involved in mRNA processing and translation initiation, respectively. These findings reveal an unexpected role for mRNA processing in generation of the antiviral state, and suggest a new avenue for therapeutic development in HCV. (C) 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. C1 [Zhao, Hong; Lin, Wenyu; Kumthip, Kattareeya; Cheng, Du; Fusco, Dahlene N.; Jilg, Nikolaus; Goto, Kaku; Zhang, Leiliang; Jang, Jae Young; Peng, Lee F.; Chung, Raymond T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Gastrointestinal Unit, Boston, MA 02114 USA. [Zhao, Hong] Peking Univ, Hosp 1, Dept Infect Dis, Beijing 100034, Peoples R China. [Tai, Andrew W.] Univ Michigan Hlth Syst Ann Arbor, Dept Med, Ann Arbor, MI 48105 USA. [Hide, Winston] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Chung, RT (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Gastrointestinal Unit, Warren 1007, Boston, MA 02114 USA. EM rtchung@partners.org RI Hofmann, Oliver/F-1800-2013; OI Hofmann, Oliver/0000-0002-7738-1513; Hide, Winston/0000-0002-8621-3271; Tai, Andrew/0000-0002-6877-450X FU National Natural Science Foundation of China [81170386]; research foundation of Peking University First Hospital; Chinese Scholarship Council; NIH-MGH Center for Human Immunology Pilot/Feasibility Study; National Institutes of Health [A1082630, DK078772, DK088951, UL1 RR 025758]; NERCE [U54 A1057159]; Harvard Clinical and Translational Science Center FX This work was supported by grants from The National Natural Science Foundation of China (81170386), research foundation of Peking University First Hospital, and the Chinese Scholarship Council (to H.Z.), NIH-MGH Center for Human Immunology Pilot/Feasibility Study Grant (to W.L.), Grants A1082630, and DK078772 (to R.T.C.) from the National Institutes of Health, and U54 A1057159 from NERCE (to R.T.C.), Grant UL1 RR 025758 (to O.H.), and Grant DK088951 from the National Institutes of Health (to L.F.P.).; We thank Drs. Nobuyuki Kato and Masanori Ikeda for the gift of the OR6 cell line; Dr. Francis Chisari for the Huh7.5.1 cell line; Dr. Takaji Wakita for the infectious HCV virus JFH1 DNA construct. The SART1 overexpression plasmid was obtained from Prof. Mei Yee Koh (Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, Texas). We would like to acknowledge the superb technical assistance provided by Dr. Caroline Shamu, Su Chiang, Tao Ren, Sean Johnston, Stewart Rudnicki, David Wrobel, and Jen Nale at the ICCB-Longwood screening facility at the Harvard Medical School. The project described was conducted with the support of Harvard Catalyst (The Harvard Clinical and Translational Science Center) (NIH award #UL1 RR 025758 and financial contributions from participating institutions). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. NR 29 TC 36 Z9 37 U1 0 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PD FEB PY 2012 VL 56 IS 2 BP 326 EP 333 DI 10.1016/j.jhep.2011.07.026 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 890JI UT WOS:000300140500007 PM 21888876 ER PT J AU Winne, M Cashavelly, B Annese, C Nagle, B Shiga, T Chisari, RG Lee, S AF Winne, Maria Cashavelly, Barbara Annese, Christine Nagle, Beth Shiga, Takashi Chisari, Roger Gino Lee, Susan TI Implementation of 2 Nurse Practitioner Inpatient Models SO JOURNAL OF NURSING ADMINISTRATION LA English DT Article ID INTENSIVE-CARE-UNIT AB Opportunities for nurse practitioners in acute care settings are expanding owing to the restricted hours for medical residents. This is coupled with national initiatives to improve the quality of care driven by patients, insurers, and national healthcare organizations that wish to enhance access to healthcare for all Americans. The authors discuss 2 care delivery models that were designed and implemented at Massachusetts General Hospital with nurses acting as full partners in the redesign. C1 [Winne, Maria] Massachusetts Gen Hosp, Patient Care Serv, Knight Simulat Program, Boston, MA 02114 USA. [Shiga, Takashi] Harvard Univ, Sch Med, Boston, MA USA. [Chisari, Roger Gino] Massachusetts Gen Hosp, Norman Knight Nursing Ctr Clin & Profess Dev, Boston, MA 02114 USA. [Lee, Susan] Massachusetts Gen Hosp, Yvonne L Munn Ctr Nursing Res, Age WISE Project, Boston, MA 02114 USA. [Shiga, Takashi] Massachusetts Gen Hosp, Emergency Serv, Boston, MA 02114 USA. RP Winne, M (reprint author), Massachusetts Gen Hosp, Patient Care Serv, Knight Simulat Program, 50 Fruit St, Boston, MA 02114 USA. EM mwinne@partners.org NR 12 TC 1 Z9 1 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-0443 J9 J NURS ADMIN JI J. Nurs. Adm. PD FEB PY 2012 VL 42 IS 2 BP 110 EP 116 DI 10.1097/NNA.0b013e3182433831 PG 7 WC Nursing SC Nursing GA 892HZ UT WOS:000300278600011 PM 25734934 ER PT J AU Jiang, H Erickson, JI Ditomassi, M Adams, JM AF Jiang, Hong Erickson, Jeanette Ives Ditomassi, Marianne Adams, Jeffrey M. TI Promoting a Culture of International Professional Practice for Nursing Through a Twinning Relationship SO JOURNAL OF NURSING ADMINISTRATION LA English DT Article AB This article illustrates the impact of a twinning relationship between the nursing services of Huashan Hospital, Fudan University (HH), in Shanghai, China, and of Massachusetts General Hospital (MGH) in Boston, Massachusetts. Through twinning, the healthcare leaders and nursing staff at HH learned key concepts, skills, and methods from their MGH colleagues, enhancing the role, presence, and overall impact of nursing in their organization. Strategies to advance a nursing leadership development agenda included establishing twinning relationships and immersing nurse leaders into each other's practice arena via nurse visitation exchanges. This collaborative effort, although only 3 years old, begins the process of modeling twinning for replication among nurses and across organizations internationally. Improvements in nursing care delivery and patient care at both organizations are attributed to this project. C1 [Ditomassi, Marianne] Massachusetts Gen Hosp, Yvonne L Munn Ctr Nursing Res, Boston, MA 02114 USA. [Jiang, Hong] Fudan Univ, Huashan Hosp, Shanghai 200433, Peoples R China. RP Ditomassi, M (reprint author), Massachusetts Gen Hosp, Yvonne L Munn Ctr Nursing Res, 55 Fruit St,Bulfinch 230, Boston, MA 02114 USA. EM mditomassi@partners.org NR 7 TC 4 Z9 4 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-0443 J9 J NURS ADMIN JI J. Nurs. Adm. PD FEB PY 2012 VL 42 IS 2 BP 117 EP 122 DI 10.1097/NNA.0b013e318243384e PG 6 WC Nursing SC Nursing GA 892HZ UT WOS:000300278600012 PM 25734935 ER PT J AU Perkins, AC Maglione, J Hillebrand, GG Miyamoto, K Kimball, AB AF Perkins, Alexis C. Maglione, Jessica Hillebrand, Greg G. Miyamoto, Kukizo Kimball, Alexa B. TI Acne Vulgaris in Women: Prevalence Across the Life Span SO JOURNAL OF WOMENS HEALTH LA English DT Article ID SEBUM EXCRETION; FACIAL ACNE; SMOKING; ADULTS; SKIN; AGE; ADOLESCENCE; POPULATION; RISK AB Background: Acne vulgaris is a common skin disease with a large quality of life impact, characterized by comedones, inflammatory lesions, secondary dyspigmentation, and scarring. Although traditionally considered a disease of adolescence, reports suggest it is also a disease of adults, especially adult women. Our objectives were to determine acne prevalence in a large, diverse group of women and to examine acne by subtype and in relation to other skin findings, measurements, and lifestyle factors. Methods: We recruited 2895 women aged 10-70 from the general population. Photographs were graded for acne lesions, scars, and dyspigmentation. Measurements were taken of sebum excretion and pore size, and survey data were collected. Results: Of the women studied, 55% had some form of acne: 28% had mild acne, and 27% had clinical acne, 14% of which was primarily inflammatory and 13% of which was primarily comedonal. Acne peaked in the teenage years, but 45% of women aged 21-30, 26% aged 31-40, and 12% aged 41-50 had clinical acne. Women with inflammatory acne were younger than those with comedonal acne (p <= 0.001), and postmenopausal women had less acne than age-matched peers (p < 0.0001). Acne was associated with facial hirsutism (p = 0.001), large pores (p = 0.001), and sebum excretion (p = 0.002). Smokers had more, primarily comedonal, acne than nonsmokers. Conclusions: The cross-sectional design precludes conclusions about progression of acne with age. Participation was restricted to women. The photographic nature of the study imposes general limitations. Techniques used in this study were not sufficiently sensitive to identify cases of subclinical acne. More than a quarter of women studied had acne, which peaked in the teens but continued to be prevalent through the fifth decade. C1 [Perkins, Alexis C.; Maglione, Jessica; Kimball, Alexa B.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Hillebrand, Greg G.; Miyamoto, Kukizo] Procter & Gamble Co, Cincinnati, OH USA. RP Kimball, AB (reprint author), Massachusetts Gen Hosp, Clin Unit Res Trials Skin, Dept Dermatol, 50 Staniford St,Suite 240, Boston, MA 02114 USA. EM harvardskinstudies@partners.org FU Proctor Gamble; Doris Duke Clinical Research Foundation FX This study was funded in part by an unrestricted grant from Proctor & Gamble. A. C. P. received fellowship funding from the Doris Duke Clinical Research Foundation. A. B. K. became an investigator for Proctor & Gamble in May 2011. NR 27 TC 23 Z9 25 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD FEB PY 2012 VL 21 IS 2 BP 223 EP 230 DI 10.1089/jwh.2010.2722 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 891TV UT WOS:000300240400016 PM 22171979 ER PT J AU D'Amico, AV Chen, MH de Castro, M Loffredo, M Lamb, DS Steigler, A Kantoff, PW Denham, JW AF D'Amico, Anthony V. Chen, Ming-Hui de Castro, Mario Loffredo, Marian Lamb, David S. Steigler, Allison Kantoff, Philip W. Denham, James W. TI Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials SO LANCET ONCOLOGY LA English DT Article ID RADICAL PROSTATECTOMY; RADIATION-THERAPY; MITOXANTRONE; DEPRIVATION; PREDNISONE; DOCETAXEL; SURVIVAL; FAILURE AB Background Androgen suppression therapy and radiotherapy are used to treat locally advanced prostate cancer. 3 years of androgen suppression confers a small survival benefit compared with 6 months of therapy in this setting, but is associated with more toxic effects. Early identification of men in whom radiotherapy and 6 months of androgen suppression is insufficient for cure is important. Thus, we assessed whether prostate-specific antigen (PSA) values can act as an early surrogate for prostate cancer-specific mortality (PCSM). Methods We systematically reviewed randomised controlled trials that showed improved overall and prostate cancer-specific survival with radiotherapy and 6 months of androgen suppression compared with radio therapy alone and measured lowest PSA concentrations (PSA nadir) and those immediately after treatment (PSA end). We assessed a cohort of 734 men with localised or locally advanced prostate cancer from two eligible trials in the USA and Australasia that randomly allocated participants between Feb 2, 1996, and Dec 27, 2001. We used Prentice criteria to assess whether reported PSA nadir or PSA end concentrations of more than 0.5 ng/mL were surrogates for PCSM. Findings Men treated with radiotherapy and 6 months of androgen suppression in both trials were significantly less likely to have PSA end and PSA nadir values of more than 0.5 ng/mL than were those treated with radiotherapy alone (p<0.0001). Presence of candidate surrogates (ie, PSA end and PSA nadir values >0.5 ng/mL) alone and when assessed in conjunction with the randomised treatment group increased risk of PCSM in the US trial (PSA nadir p=0.0016; PSA end p=0.017) and Australasian trial (PSA nadir p<0.0001; PSA end p=0.0012). In both trials, the randomised treatment group was no longer associated with PCSM (p >= 0.20) when the candidate surrogates were included in the model. Therefore, both PSA metrics satisfied Prentice criteria for surrogacy. Interpretation After radiotherapy and 6 months of androgen suppression, men with PSA end values exceeding 0.5 ng/mL should be considered for long-term androgen suppression and those with localised or locally advanced prostate cancer with PSA nadir values exceeding 0.5 ng/mL should be considered for inclusion in randomised trials investigating the use of drugs that have extended survival in castration-resistant metastatic prostate cancer. C1 [D'Amico, Anthony V.; Loffredo, Marian] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Kantoff, Philip W.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. [Chen, Ming-Hui; de Castro, Mario] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA. [de Castro, Mario] Univ Sao Paulo, Dept Appl Math & Stat, Sao Paulo, Brazil. [Lamb, David S.] Univ Otago, Dept Radiat Oncol, Wellington, New Zealand. [Steigler, Allison] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2300, Australia. [Denham, James W.] Newcastle Mater Hosp, Dept Radiat Oncol, Newcastle, NSW, Australia. RP D'Amico, AV (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA. EM adamico@partners.org RI DENHAM, JAMES/G-7505-2013 OI DENHAM, JAMES/0000-0002-4177-9503 FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) in Brazil FX MdC acknowledges partial salary support from the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) in Brazil for his postdoctoral position with M-HC but the funding source had no role in the study. NR 26 TC 22 Z9 22 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 EI 1474-5488 J9 LANCET ONCOL JI Lancet Oncol. PD FEB PY 2012 VL 13 IS 2 BP 189 EP 195 DI 10.1016/S1470-2045(11)70295-9 PG 7 WC Oncology SC Oncology GA 891DT UT WOS:000300197400044 PM 22112793 ER PT J AU Walcott, BP Nahed, BV Mohyeldin, A Coumans, JV Kahle, KT Ferreira, MJ AF Walcott, Brian P. Nahed, Brian V. Mohyeldin, Ahmed Coumans, Jean-Valery Kahle, Kristopher T. Ferreira, Manuel J. TI Chordoma: current concepts, management, and future directions SO LANCET ONCOLOGY LA English DT Review ID PROTON RADIATION-THERAPY; CARBON ION RADIOTHERAPY; SKULL BASE CHORDOMAS; TERM-FOLLOW-UP; SACROCOCCYGEAL CHORDOMA; CERVICAL-SPINE; SACRAL CHORDOMA; CLIVAL CHORDOMA; PHOTON IRRADIATION; PROGNOSTIC-FACTORS AB Chordoma is a rare bone cancer that is aggressive, locally invasive, and has a poor prognosis. Chordomas are thought to arise from transformed remnants of notochord and have a predilection for the axial skeleton, with the most common sites being the sacrum, skull base, and spine. The gold standard treatment for chordomas of the mobile spine and sacrum is en-bloc excision with wide margins and postoperative external-beam radiation therapy. Treatment of clival chordomas is unique from other locations with an enhanced emphasis on preservation of neurological function, typified by a general paradigm of maximally safe cytoreductive surgery and advanced radiation delivery techniques. In this Review, we highlight current standards in diagnosis, clinical management, and molecular characterisation of chordomas, and discuss current research. C1 [Walcott, Brian P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA 02114 USA. [Walcott, Brian P.; Nahed, Brian V.; Coumans, Jean-Valery; Kahle, Kristopher T.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Mohyeldin, Ahmed] Ohio State Univ, Coll Med, Dept Neurosurg, Columbus, OH 43210 USA. [Ferreira, Manuel J.] Univ Washington, Sch Med, Dept Neurosurg, Seattle, WA USA. RP Walcott, BP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, White Bldg Room 502,55 Fruit St, Boston, MA 02114 USA. EM walcott.brian@mgh.harvard.edu NR 99 TC 105 Z9 113 U1 0 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 EI 1474-5488 J9 LANCET ONCOL JI Lancet Oncol. PD FEB PY 2012 VL 13 IS 2 BP E69 EP E76 PG 8 WC Oncology SC Oncology GA 891DT UT WOS:000300197400018 PM 22300861 ER PT J AU Stapleton, AE Dziura, J Hooton, TM Cox, ME Yarova-Yarovaya, Y Chen, S Gupta, K AF Stapleton, Ann E. Dziura, James Hooton, Thomas M. Cox, Marsha E. Yarova-Yarovaya, Yuliya Chen, Shu Gupta, Kalpana TI Recurrent Urinary Tract Infection and Urinary Escherichia coli in Women Ingesting Cranberry Juice Daily: A Randomized Controlled Trial SO MAYO CLINIC PROCEEDINGS LA English DT Article ID NEUROGENIC BLADDER; PREVENTION; BACTERIURIA; CONSUMPTION; ADHERENCE; VIRULENCE; CYSTITIS; DISEASES; AMERICA; VIVO AB Objective: To compare the time to urinary tract infection (UTI) and the rates of asymptomatic bacteriuria and urinary P-fimbriated Escherichia coli during a 6-month period in women ingesting cranberry vs placebo juice daily. Patients and Methods: Premenopausal women with a history of recent UTI were enrolled from November 16, 2005, through December 31, 2008, at 2 centers and randomized to 1 of 3 arms: 4 oz of cranberry juice daily, 8 oz of cranberry juice daily, or placebo juice. Time to UTI (symptoms plus pyuria) was the main outcome. Asymptomatic bacteriuria, adherence, and adverse effects were assessed at monthly visits. Results: A total of 176 participants were randomized (120 to cranberry juice and 56 to placebo) and followed up for a median of 168 days. The cumulative rate of UTI was 0.29 in the cranberry juice group and 0.37 in the placebo group (P=.82). The adjusted hazard ratio for UTI in the cranberry juice group vs the placebo group was 0.68(95% confidence interval, 0.33-1.39; P=.29). The proportion of women with P-fimbriated urinary E coli isolates during the intervention phase was 10 of 23 (43.5%) in the cranberry juice group and 8 of 10 (80.0%) in the placebo group (P=.07). The mean dose adherence was 91.8% and 90.3% in the cranberry juice group vs the placebo group. Minor adverse effects were reported by 24.2% of those in the cranberry juice group and 12.5% in the placebo group (P=.07). Conclusion: Cranberry juice did not significantly reduce UTI risk compared with placebo. The potential protective effect we observed is consistent with previous studies and warrants confirmation in larger, well-powered studies of women with recurrent UTI. The concurrent reduction in urinary P-fimbriated 8 coli strains supports the biological plausibility of cranberry activity. Trial Registration: clinicaltrials.gov Identifier: NCT00128128 (C) 2012 Mayo Foundation for Medical Education and Research square Mayo Clin Proc. 201287(2)143-150 C1 [Stapleton, Ann E.; Cox, Marsha E.; Yarova-Yarovaya, Yuliya] Univ Washington, Dept Med, Seattle, WA USA. [Dziura, James; Chen, Shu] Yale Univ, Sch Med, Dept Biostat, New Haven, CT USA. [Hooton, Thomas M.] Univ Miami, Sch Med, Dept Med, Miami, FL USA. [Gupta, Kalpana] VA Boston Healthcare Syst, Dept Med, Boston, MA USA. [Gupta, Kalpana] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Gupta, K (reprint author), VA Boston Healthcare Syst, 1400 VFW Pkwy,3 Med, W Roxbury, MA 02132 USA. EM kalpana.gupta@va.gov RI Stapleton, Ann/N-2428-2015 OI Stapleton, Ann/0000-0003-0130-8659 FU National Center for Complementary and Altemative Medicine [RO1 AT002105]; National Center for Research Resources, a component of the National Institutes of Health [ULI RR024139]; National Institutes of Health Roadmap for Medical Research FX This work was funded by grant RO1 AT002105 (K.G.) from the National Center for Complementary and Altemative Medicine, and this publication was made possible by a Clinical and Translational, Science Award grant ULI RR024139 from the National Center for Research Resources, a component of the National Institutes of Health, and the National Institutes of Health Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the National Center for Research Resources or the National Institutes of Health. NR 29 TC 32 Z9 34 U1 3 U2 38 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD FEB PY 2012 VL 87 IS 2 BP 143 EP 150 DI 10.1016/j.mayocp.2011.10.006 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 891ZQ UT WOS:000300256100007 PM 22305026 ER PT J AU Shampo, MA Kyle, RA Steensma, DP AF Shampo, Marc A. Kyle, Robert A. Steensma, David P. TI Isidor Rabi-1944 Nobel Laureate in Physics SO MAYO CLINIC PROCEEDINGS LA English DT Biographical-Item C1 [Shampo, Marc A.; Kyle, Robert A.] Mayo Clin, Rochester, MN 55905 USA. [Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Shampo, MA (reprint author), Mayo Clin, Rochester, MN 55905 USA. OI Steensma, David/0000-0001-5130-9284 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD FEB PY 2012 VL 87 IS 2 BP E11 EP E11 DI 10.1016/j.mayocp.2011.11.012 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 891ZQ UT WOS:000300256100019 PM 22305037 ER PT J AU de Andrea, CE Kroon, HM Wolterbeck, R Romeo, S Rosenberg, AE DeYoung, BR Liegl-Alzwanger, B Inwards, CY Hauben, E McCarthy, EF Idoate, M Athanasou, NA Jones, KB Hogendoorn, PCW Bovee, JVMG AF de Andrea, C. E. Kroon, H. M. Wolterbeck, R. Romeo, S. Rosenberg, A. E. DeYoung, B. R. Liegl-Alzwanger, B. Inwards, C. Y. Hauben, E. McCarthy, E. F. Idoate, M. Athanasou, N. A. Jones, K. B. Hogendoorn, P. C. W. Bovee, J. V. M. G. TI Interobserver Reliability in the Histopathological Diagnosis of Peripheral Cartilaginous Tumors in Patients with Multiple Osteochondromas: How Can We Improve Diagnostic Quality? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Leiden Univ, Med Ctr, Leiden, Netherlands. Treviso Reg Hosp, I-31100 Treviso, Italy. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Iowa, Carver Coll Med, Iowa City, IA USA. Med Univ Graz, Graz, Austria. Mayo Clin, Rochester, MN USA. Univ Hosp Leuven, Louvain, Belgium. Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Univ Navarra, E-31080 Pamplona, Spain. Univ Oxford, Nuffield Orthopaed Ctr, Oxford, England. Univ Utah, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 32 BP 11A EP 11A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900033 ER PT J AU Ishak, SEA Nielsen, GP Rosenberg, AE AF Ishak, S. E. A. Nielsen, G. P. Rosenberg, A. E. TI Chordoma Arising in Benign Notochordal Cell Tumor: A Detailed Radiological, Gross and Microscopic Description of Three Cases Involving the Lumbar Spine SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Cairo Univ, Cairo, Egypt. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Miami, Miami, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 46 BP 14A EP 14A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900047 ER PT J AU Kerr, DA Deshpande, V Borger, DR Nielsen, GP AF Kerr, D. A. Deshpande, V. Borger, D. R. Nielsen, G. P. TI Molecular Distinction of Chondrosarcoma from Chondroblastic Osteosarcoma through IDH12 Mutations SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 [Kerr, D. A.; Deshpande, V.; Borger, D. R.; Nielsen, G. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 50 BP 15A EP 15A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900051 ER PT J AU Lee, YD Le, LP Deshpande, V Iafrates, AJ Rosenberg, AE Nielsen, GP AF Lee, Y. D. Le, L. P. Deshpande, V. Iafrates, A. J. Rosenberg, A. E. Nielsen, G. P. TI The Benign Notochordal Cell Tumor and Ecchordosis Physaliphora Lack the Complex Genomic and Genetic Alterations Commonly Found in the Conventional Chordomas SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Miami, Miami, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 54 BP 16A EP 16A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900055 ER PT J AU Lew, M Carruthers, M Khosroshahi, A Hasserjian, R Stone, JH Nielsen, GP Deshpande, V AF Lew, M. Carruthers, M. Khosroshahi, A. Hasserjian, R. Stone, J. H. Nielsen, G. P. Deshpande, V. TI Clinicopathologic Features of IgG4-Associated Retroperitoneal Fibrosis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 [Lew, M.; Carruthers, M.; Khosroshahi, A.; Hasserjian, R.; Stone, J. H.; Nielsen, G. P.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 55 BP 16A EP 16A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900056 ER PT J AU Sioletic, S Fletcher, CDM Hornick, JL AF Sioletic, S. Fletcher, C. D. M. Hornick, J. L. TI Well-Differentiated and Dedifferentiated Liposarcomas with Prominent Myxoid Stroma: Analysis of 55 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 72 BP 20A EP 20A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900073 ER PT J AU Demski, S Gelber, S Marotti, J Cole, K Kereakoglow, S Ruddy, K Brachtel, E Schapira, L Come, S Borges, V Schedin, P Warner, E Winer, E Partridge, A Collins, L AF Demski, S. Gelber, S. Marotti, J. Cole, K. Kereakoglow, S. Ruddy, K. Brachtel, E. Schapira, L. Come, S. Borges, V. Schedin, P. Warner, E. Winer, E. Partridge, A. Collins, L. TI Molecular Phenotype of Pregnancy Associated Breast Cancers (PABC) in a Large Cohort of Young Women SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Colorado, Ctr Canc, Denver, CO 80262 USA. Sunnybrook Odette Canc Ctr, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 129 BP 33A EP 34A PG 2 WC Pathology SC Pathology GA 888EP UT WOS:000299986900130 ER PT J AU Fang, Y Xie, Q Wang, H Yang, C Braverman, AS Axiotis, CA AF Fang, Y. Xie, Q. Wang, H. Yang, C. Braverman, A. S. Axiotis, C. A. TI Differential Expression of Milk Fat Globule-EGF Factor 8 (MFG-E8) in Breast Cancers SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Kings Cty Hosp, Suny Downstate Med Ctr, Brooklyn, NY USA. BIDMC, Boston, MA USA. MGH, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 145 BP 38A EP 38A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900146 ER PT J AU Fernandez, LJ Buckley, JM Aftreth, OP Tang, R Saksena, M Yagi, Y Michaelson, JS Koerner, FC Brachtel, EF Smith, BL AF Fernandez, L. J. Buckley, J. M. Aftreth, O. P. Tang, R. Saksena, M. Yagi, Y. Michaelson, J. S. Koerner, F. C. Brachtel, E. F. Smith, B. L. TI Breast Excision Specimens Evaluated by Micro-Computed Tomography (Micro-CT) with Histopathological Correlations SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 [Fernandez, L. J.; Buckley, J. M.; Aftreth, O. P.; Tang, R.; Saksena, M.; Yagi, Y.; Michaelson, J. S.; Koerner, F. C.; Brachtel, E. F.; Smith, B. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 149 BP 39A EP 39A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900150 ER PT J AU Shabani, M Mehta, TS Wells, C Kraus, JA Gilmore, H Schnitt, SJ Collins, LC AF Shabani, M. Mehta, T. S. Wells, C. Kraus, J. A. Gilmore, H. Schnitt, S. J. Collins, L. C. TI Upgrade Rates on Surgical Excision for Targeted vs. Incidental Radial Scars/Complex Sclerosing Lesions (RS/CSLs) Identified on Core Needle Biopsy (CNB) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Case Western Reserve Univ, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 264 BP 66A EP 66A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900265 ER PT J AU Bongiovanni, M Spitale, A Faquin, WC Mazzucchelli, L Baloch, ZW AF Bongiovanni, M. Spitale, A. Faquin, W. C. Mazzucchelli, L. Baloch, Z. W. TI The Bethesda System for Reporting Thyroid Cytopathology: A Meta-Analysis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Inst Pathol, Locarno, Switzerland. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Penn, Med Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 337 BP 83A EP 83A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900338 ER PT J AU Chang, S Phan, RT Moatamed, NA Apple, SK AF Chang, S. Phan, R. T. Moatamed, N. A. Apple, S. K. TI Utility of BRAF Gene Testing on Thyroid Nodules Diagnosed as Follicular Lesion of Undetermined Significance (FLUS) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 345 BP 85A EP 85A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900346 ER PT J AU Ly, A Ono, J Hughes, K Pitman, MB Balassanian, R AF Ly, A. Ono, J. Hughes, K. Pitman, M. B. Balassanian, R. TI Fine Needle Aspiration Biopsy of Palpable Breast Masses Is Associated with Shorter Length of Time to First Treatment Compared with Core Biopsy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 397 BP 97A EP 98A PG 2 WC Pathology SC Pathology GA 888EP UT WOS:000299986900398 ER PT J AU Nishino, HT Tambouret, RH Qian, X AF Nishino, H. T. Tambouret, R. H. Qian, X. TI Fine Needle Aspiration of Spleen Lesions: Cytopathologic Analysis of 66 Cases with Clinical and Histological Correlation SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 410 BP 101A EP 101A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900411 ER PT J AU Pitman, MB Yaeger, KA Brugge, WR Mino-Kenudson, M AF Pitman, M. B. Yaeger, K. A. Brugge, W. R. Mino-Kenudson, M. TI Prospective Analysis of Atypical Epithelial Cells as a High Risk Cytological Feature for Malignancy in Pancreatic Cysts SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 [Pitman, M. B.; Yaeger, K. A.; Brugge, W. R.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 417 BP 102A EP 103A PG 2 WC Pathology SC Pathology GA 888EP UT WOS:000299986900418 ER PT J AU Baker, GM Hoang, MP AF Baker, G. M. Hoang, M. P. TI Vulvar Adnexal Neoplasms: A Thirty-Two Year Single-Institution Review SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 [Baker, G. M.; Hoang, M. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 466 BP 114A EP 115A PG 2 WC Pathology SC Pathology GA 888EP UT WOS:000299986900467 ER PT J AU Gimbel, DC Linskey, KR Zukerberg, L Duncan, LM Sadow, PM Nazarian, RM AF Gimbel, D. C. Linskey, K. R. Zukerberg, L. Duncan, L. M. Sadow, P. M. Nazarian, R. M. TI BerEp4, Cytokeratin 17, and Cytokeratin 14 Immunohistochemical Staining Aid in Differentiatation of Basaloid Squamous Cell Carcinoma from Basal Cell Carcinoma with Squamous Features SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 [Gimbel, D. C.; Linskey, K. R.; Zukerberg, L.; Duncan, L. M.; Sadow, P. M.; Nazarian, R. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 494 BP 120A EP 121A PG 2 WC Pathology SC Pathology GA 888EP UT WOS:000299986900495 ER PT J AU Harris, AC Iafrate, AJ Kamangar, F Flotte, TJ Sepehr, A AF Harris, A. C. Iafrate, A. J. Kamangar, F. Flotte, T. J. Sepehr, A. TI Presence of K-ras Mutations and Distinct Age-Associated Variations in Pilomatricoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Morgan State Univ, Baltimore, MD 21239 USA. Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 498 BP 121A EP 121A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900499 ER PT J AU Hung, T Piris, A Lobo, A Mihm, MM Sober, AJ Tsao, H Tanabe, KK Duncan, LM AF Hung, T. Piris, A. Lobo, A. Mihm, M. M. Sober, A. J. Tsao, H. Tanabe, K. K. Duncan, L. M. TI Sentinel Lymph Node Metastases in Problematic Spitzoid Melanocytic Tumors: Not a Predictor of Malignancy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Vancouver Gen Hosp, Vancouver, BC, Canada. Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Sao Paulo, Hosp Clin, Sao Paulo, Brazil. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 505 BP 124A EP 124A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900506 ER PT J AU Linskey, K Piris, A Mihm, MC Hoang, M AF Linskey, K. Piris, A. Mihm, M. C. Hoang, M. TI Lentiginous Compound Dysplastic Nevus of the Back - A Mimic of Recurrent Nevus and Malignant Melanoma with Regression SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 517 BP 126A EP 127A PG 2 WC Pathology SC Pathology GA 888EP UT WOS:000299986900518 ER PT J AU Tse, JY Le, LP Nguyen, A Wang, G Hoang, MP AF Tse, J. Y. Le, L. P. Nguyen, A. Wang, G. Hoang, M. P. TI Microcystic Adnexal Carcinoma Versus Desmoplastic Trichoepithelioma: A Histologic and Immunohistochemical Comparison SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 [Tse, J. Y.; Le, L. P.; Nguyen, A.; Wang, G.; Hoang, M. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 555 BP 135A EP 136A PG 2 WC Pathology SC Pathology GA 888EP UT WOS:000299986900556 ER PT J AU Kerr, SE Schnabel, CA Sullivan, PS Zhang, Y Singh, V Carey, B Erlander, MG Highsmith, WE Brachtel, EP Dry, SM AF Kerr, S. E. Schnabel, C. A. Sullivan, P. S. Zhang, Y. Singh, V. Carey, B. Erlander, M. G. Highsmith, W. E. Brachtel, E. P. Dry, S. M. TI Use of a 92-Gene Molecular Classifier To Predict the Site of Origin for Primary and Metastatic Tumors with Neuroendocrine Differentiation SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Mayo Clin, Rochester, MN USA. BioTheranostics Inc, San Diego, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 604 BP 147A EP 147A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900605 ER PT J AU Kovach, AE Lam, Q Dias-Santagata, D Sadow, PM AF Kovach, A. E. Lam, Q. Dias-Santagata, D. Sadow, P. M. TI Cellular Localization of Beta-Catenin by Immunohistochemistry Is a Sensitive and Specific Surrogate for CTNNB1 Mutational Status in Adrenal Cortical Neoplasms SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 607 BP 147A EP 147A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900608 ER PT J AU Donath, FR Kraft, S Barletta, JA AF Donath, F. Rosenblum Kraft, S. Barletta, J. A. TI Rate of Extrathyroidal Extension and Lymph Node Metastases in Papillary Thyroid Carcinoma with Tall Cell Features SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 618 BP 150A EP 150A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900619 ER PT J AU Vivero, M Kraft, S Barletta, JA AF Vivero, M. Kraft, S. Barletta, J. A. TI Risk Stratification of Follicular Variant of Papillary Thyroid Carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 624 BP 151A EP 151A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900625 ER PT J AU Agoston, AT Odze, RD Lauwers, GY Srivastava, A AF Agoston, A. T. Odze, R. D. Lauwers, G. Y. Srivastava, A. TI Immunohistochemical Features of Intestinal and Foveolar Dysplasia in Barrett's Esophagus SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 630 BP 152A EP 152A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900631 ER PT J AU Han, HS Lauwers, GY AF Han, H. S. Lauwers, G. Y. TI Autoimmune Gastritis Versus Severe Body Predominant H. pylori Gastritis: A Comparative Analysis of 88 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Konkuk Univ, Sch Med, Seoul, South Korea. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 671 BP 162A EP 162A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900672 ER PT J AU Huang, Q Wu, H Sun, Q Ye, Q AF Huang, Q. Wu, H. Sun, Q. Ye, Q. TI Primary High-Grade Neuroendocrine Carcinoma of the Esophagus: A Clinicopathologic Study of 42 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China. VA Boston Healthcare Syst, W Roxbury, MA USA. Harvard Univ, Sch Med, W Roxbury, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 676 BP 163A EP 163A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900677 ER PT J AU Huang, Q Lauwers, GY Shi, J Sun, Q Fan, X Feng, A Wu, H Yu, C Zhou, Q Mashimo, H AF Huang, Q. Lauwers, G. Y. Shi, J. Sun, Q. Fan, X. Feng, A. Wu, H. Yu, C. Zhou, Q. Mashimo, H. TI Carcinomas in the Distal Esophagus of Chinese Patients Are Heterogeneous in Histopathology but Adenocarcinoma Remains Rare SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China. VA Boston Healthcare Syst, W Roxbury, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 675 BP 163A EP 163A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900676 ER PT J AU Khor, TS Lauwers, GY Odze, RD Srivastava, A AF Khor, T. S. Lauwers, G. Y. Odze, R. D. Srivastava, A. TI "Mass-Forming" Ischemic Colitis Is a Distinctive Variant with Predilection for the Proximal Colon: A Clinicopathologic Study of 16 Cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 682 BP 164A EP 165A PG 2 WC Pathology SC Pathology GA 888EP UT WOS:000299986900683 ER PT J AU Khor, TS Badizadegan, K Bellizi, A Brown, I Fujita, H Han, HS Kumarasinghe, P Mattia, A Misdraji, J Park, D Srivastava, A Odze, RD Lauwers, GY AF Khor, T. S. Badizadegan, K. Bellizi, A. Brown, I. Fujita, H. Han, H-S Kumarasinghe, P. Mattia, A. Misdraji, J. Park, D. Srivastava, A. Odze, R. D. Lauwers, G. Y. TI Interobserver Agreement in the Phenotypic Classification of Barrett Dysplasia SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Envoi Pathol, Herston, Qld, Australia. PathW Lab, Nedlands, WA, Australia. N Shore Med Ctr, Salem, MA USA. Pusan Natl Univ Hosp, Pusan, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 683 BP 165A EP 165A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900684 ER PT J AU Kim, JY Shin, N Lauwers, GY Park, DY AF Kim, J. Y. Shin, N. Lauwers, G. Y. Park, D. Y. TI Method of Measurement of Invasion Depth and Scoring System To Predict LN Metastasis in Submucosal EGC SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Pusan Natl Univ Hosp, Pusan, South Korea. Pusan Natl Univ, Sch Med, Pusan, South Korea. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 684 BP 165A EP 165A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900685 ER PT J AU Kumarasinghe, P de Boer, B Sheng, K Ooi, E Jayasinghe, S Fox, S AF Kumarasinghe, P. de Boer, B. Sheng, K. Ooi, E. Jayasinghe, S. Fox, S. TI HER2 Copy Number in the Assessment of HER2 Status in Gastric/GOJ Cancers: Does It Matter? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 QEII Med Ctr, Perth, WA, Australia. Massachusetts Gen Hosp, Boston, MA 02114 USA. Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. Univ Western Australia, Perth, WA 6009, Australia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 689 BP 166A EP 166A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900690 ER PT J AU Li, Y Chang, X Zhou, W Xiao, Y Chen, J Lauwers, GY AF Li, Y. Chang, X. Zhou, W. Xiao, Y. Chen, J. Lauwers, G. Y. TI Gastric Intestinal Metaplasia with Dysplasia-Like Atypia: A Morphological and Biologic Evaluation SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 698 BP 168A EP 168A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900699 ER PT J AU Ogino, S Liao, X Morikawa, T Fuchs, C AF Ogino, S. Liao, X. Morikawa, T. Fuchs, C. TI Concomitant Presence of PIK3CA Mutations in Both Exons 9 and 20 Predicts Aggressive Behavior of Colorectal Cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 720 BP 173A EP 174A PG 2 WC Pathology SC Pathology GA 888EP UT WOS:000299986900721 ER PT J AU Ogino, S Yamauchi, M Morikawa, T Fuchs, C AF Ogino, S. Yamauchi, M. Morikawa, T. Fuchs, C. TI Do Molecular Features of Colorectal Cancers Change Abruptly at Splenic Flexure? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 718 BP 173A EP 173A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900719 ER PT J AU Rice-Stitt, TL Zen, Y Deshpande, V AF Rice-Stitt, T. L. Zen, Y. Deshpande, V. TI An Interobserver Study on IgG4 Related Disease SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Kings Coll Hosp London, London, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 733 BP 177A EP 177A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986901010 ER PT J AU Shen, J Morikawa, J Fuchs, CS Ogino, S AF Shen, J. Morikawa, J. Fuchs, C. S. Ogino, S. TI Prognostic Role of Combined MSI and BRAF Mutation Status in Colorectal Cancer: Toward Routine Clinical Use SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 743 BP 179A EP 179A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986901020 ER PT J AU Wang, H Brown, I Kumarasinghe, P Langner, C Lauwers, G Shepherd, N Vieth, M Srivastava, A Odze, R AF Wang, H. Brown, I. Kumarasinghe, P. Langner, C. Lauwers, G. Shepherd, N. Vieth, M. Srivastava, A. Odze, R. TI Poor Agreement for Detection of Goblet Cells in Esophageal and GEJ Biopsies SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA USA. Royal Brisbane Hosp, Brisbane, Qld 4029, Australia. PathW QEII UWA, Perth, WA, Australia. Med Univ Graz, Graz, Austria. Massachusetts Gen Hosp, Boston, MA 02114 USA. Cheltenham Gen Hosp, Cheltenham, Glos, England. Inst Pathol, Bayreuth, Germany. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 764 BP 184A EP 185A PG 2 WC Pathology SC Pathology GA 888EP UT WOS:000299986901041 ER PT J AU Yantiss, RK Solit, DB Janakiraman, M Misdraji, J AF Yantiss, R. K. Solit, D. B. Janakiraman, M. Misdraji, J. TI Low-Grade Appendiceal Mucinous Neoplasms Show Activation of the Mitogen Activated Protein (MAP) Kinase Pathway SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Weill Cornell Med Coll, New York, NY USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 773 BP 186A EP 187A PG 2 WC Pathology SC Pathology GA 888EP UT WOS:000299986901050 ER PT J AU Dang, F Wang, C Farris, AB Wu, S Lee, H Olumi, AF McDougal, WS Young, RH Wu, CL AF Dang, F. Wang, C. Farris, A. B. Wu, S. Lee, H. Olumi, A. F. McDougal, W. S. Young, R. H. Wu, C-L TI The Impact of the 2005 Modified Gleason Grading System on the Clinical Outcome of Prostate Cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 [Dang, F.; Wang, C.; Farris, A. B.; Wu, S.; Lee, H.; Olumi, A. F.; McDougal, W. S.; Young, R. H.; Wu, C-L] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 834 BP 200A EP 201A PG 2 WC Pathology SC Pathology GA 888EP UT WOS:000299986901111 ER PT J AU Gershman, B Dong, F McGovern, FJ Heney, NM McDougal, WS Wu, CL AF Gershman, B. Dong, F. McGovern, F. J. Heney, N. M. McDougal, W. S. Wu, C-L TI Smaller Prostate Size Is Independently Associated with Biochemical Recurrence in Gleason 7 Prostate Cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 [Gershman, B.; Dong, F.; McGovern, F. J.; Heney, N. M.; McDougal, W. S.; Wu, C-L] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 864 BP 207A EP 207A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986901141 ER PT J AU Gershman, B Dong, F Dahl, DM McGovern, FJ Heney, NM McDougal, WS Wu, CL AF Gershman, B. Dong, F. Dahl, D. M. McGovern, F. J. Heney, N. M. McDougal, W. S. Wu, C-L TI Smaller Prostate Size Is Associated with Greater Volume of Disease at Prostatectomy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 [Gershman, B.; Dong, F.; Dahl, D. M.; McGovern, F. J.; Heney, N. M.; McDougal, W. S.; Wu, C-L] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 865 BP 208A EP 208A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986901142 ER PT J AU Hipp, JD Monaco, J Kunju, PL Cheng, J Yagi, Y Rodriguez-Canales, J Emmert-Buck, MR Hewitt, S Feldman, MD Tomaszewski, JE Toner, M Tompkins, RG Flotte, T Lucas, D Gilbertson, JR Madabhushi, A Balis, UJ AF Hipp, J. D. Monaco, J. Kunju, P. L. Cheng, J. Yagi, Y. Rodriguez-Canales, J. Emmert-Buck, M. R. Hewitt, S. Feldman, M. D. Tomaszewski, J. E. Toner, M. Tompkins, R. G. Flotte, T. Lucas, D. Gilbertson, J. R. Madabhushi, A. Balis, U. J. TI Integration of Architectural and Cytologic Driven Image Algorithms for Prostate Adenocarcinoma Identification SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Univ Michigan, Ann Arbor, MI 48109 USA. Rutgers State Univ, Piscataway, NJ USA. Harvard, Boston, MA USA. NCI, NIH, Bethesda, MD 20892 USA. Univ Penn, Perlman Sch Med, Philadelphia, PA 19104 USA. Mayo Clin, Rochester, MN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 890 BP 213A EP 214A PG 2 WC Pathology SC Pathology GA 888EP UT WOS:000299986901167 ER EF